<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>320684</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publichealth/Flu/Swineflu/DH_103068]]&gt;</url>
    <title>20 July 2009: Chef Medical Officer's advice to pregnant women</title>
    <publicationDate>2009-07-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ GOOD PRACTICE,INFECTIOUS DISEASES,INFLUENZA,COMPLICATED PREGNANCY,NORMAL PREGNANCY,WOMEN'S HEALTH,PROVISION OF CARE,CO-EXISTING DISEASE,PROVISION OF CARE,INFECTIONS,STANDARDS OF PRACTICE,PREGNANT WOMEN,ADULTS,POPULATION GROUPS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Some pregnant women who catch the H1N1 (swine) ‘flu virus will develop complications of the infection (including pneumonia) that could put their own and their baby’s health at risk.&amp;nbsp; The risks are greatest in the second and third trimesters of pregnancy.&amp;nbsp; It is too early in the pandemic of influenza to be able to quantify these risks for the individual but most pregnant women who catch the disease are likely to make an uncomplicated recovery.]]&gt;</body>
  </document>
  <document>
    <id>299205</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299205]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Commentaries</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,NOV 08,ADULTS,PREGNANT WOMEN,POPULATION GROUPS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS,HIV]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Commentaries from experts for the Annual Evidence Update on Diagnosing HIV 2008</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentaries&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=176 alt="Image of a hand holding a pen and writing" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID299205/nelhImp_0000_shutterstock_20704411%5B1%5D.JPG" width=163 align=right border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The following&amp;nbsp;&lt;A href="nelh:299203:1" name=internalLink&gt;experts &lt;/A&gt;have written commentaries&amp;nbsp;about an aspect of diagnosing HIV within their field. Click on the links below to read these. These are also provided alongside the relevant evidence on the &lt;A href="nelh:299385:0" name=internalLink&gt;homepage&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299205:2" name=internalLink&gt;&lt;STRONG&gt;Virological Methods&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; by&amp;nbsp;&lt;EM&gt;&lt;A href="nelh:299203:3" name=internalLink&gt;&lt;EM&gt;Professor Deenan Pillay&lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299205:3" name=internalLink&gt;&lt;STRONG&gt;Mother to Child Transmission&lt;/STRONG&gt; &lt;/A&gt;&lt;/STRONG&gt;by &lt;EM&gt;&lt;A href="nelh:299203:5" name=internalLink&gt;&lt;EM&gt;Dr. Jennifer Tosswill&lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299205:4" name=internalLink&gt;&lt;STRONG&gt;Serological Testing Algorithm for Recent HIV Seroconversion (STARHS)&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; by &lt;EM&gt;&lt;A href="nelh:299203:4" name=internalLink&gt;&lt;EM&gt;Dr. Gary Murphy&lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;EM&gt;&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299205:5" name=internalLink&gt;&lt;STRONG&gt;Public Health: Settings of HIV Testing&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; by &lt;EM&gt;&lt;A href="nelh:299203:2" name=internalLink&gt;&lt;EM&gt;Dr. Anthony Nardone&lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Virological Methods&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 175px; HEIGHT: 160px" height=188 alt="HIV viruses surrounded by red blood cells" hspace=10 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0002_shutterstock_2578409%5B1%5Dhiv2.jpg" width=250 align=right vspace=10 border=1 name=nelh_tempImage0&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Commentary&amp;nbsp;by Professor Deenan Pillay&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Viral Load&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In the mid 1990s the quantification of viral genome in plasma of HIV infected individuals was demonstrated to correlate with clinical prognosis, independent of CD4 cell count. Such viral load levels may reach many millions of RNA copies/ml in an untreated individual. Laboratory methods were rapidly developed in order to provide such testing, which became central to management. In particular, HIV viral load testing is used to monitor the effectiveness of antiretroviral therapy. In general, viral load levels are expected to reach undetectable levels (currently &amp;lt;50 copies viral RNA/ml of plasma) within 12 weeks of initiating treatment. Should viral load rise during treatment on at least two occasions, the patient has undergone virological failure. At this time, resistance testing is undertaken on plasma virus (generally undertaken by nucleic acid sequencing of the virus) to guide next therapy. The meaning of very low level viraemia (typically remaining at &amp;lt;500 c/ml) has been the subject of considerable research. Some feel that these “blips” may predict future failure, whereas others feel they are more a function of laboratory assay variability. A single blip is generally felt to be insignificant. The efficacy of treatment is now very good, due to better formulations of drugs, and good adherence support, and within the UK, reaches around 90% after one year of those starting therapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In the developing world, the lack of laboratory infrastructure limits the degree to which viral load monitoring can be undertaken. This means that 1st to 2nd line treatment switch is guided by clinical progression (e.g. new AIDS defining events) rather than viral rebound. Whilst not negating the very significant benefits of antiretroviral rollout, this may increase the degree of drug resistance emerging on 1st line therapy. The degree to which this compromises the response to 2nd line therapy in this setting remains a research priority. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Viral load testing has also been proposed as a method for detecting early HIV infection, prior to the development of antibodies- the period of days to weeks immediately after infection, known as the window period, when virus is present in the blood. Thus, some investigators propose pooling plasma samples from high risk individuals (to reduce the cost) without antibodies, and then test pools for viral load. This method identifies such infections in comparison to older generation antibody tests. However, the potential for improved diagnosis over the 4th generation assays widely used in the UK (assays which detect antibody and/or virus antigen) is limited. The recent UK guidelines for expansion of HIV testing suggest that 4th generation tests should be the standard of care. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Phylogenetic analysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This is a method by which HIV-1 genetic sequences can be utilised to identify relatedness between viruses. As such, it takes advantage of the capacity for HIV-1 to rapidly evolve (mutate). This method has been useful to identify the likelihood that individuals are linked regarding infection, and also how transmission clusters within the population develop. Finally, this method of analysis is central to our ideas of the origin of HIV within the human population, and the time of entry into the population from chimpanzees. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;HIV Drug Resistance&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;HIV-1 rapidly mutates and selection of viruses is according to the principles of evolution. Some mutants confer resistance to antiretroviral drugs. Treatment whilst virus replication continues selects for ever increasing resistance. Such resistance not only compromises the efficacy of therapy but can also be transmitted to others. The rate of transmission reaches 10% in some populations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Mother to Child Transmission&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 134px; HEIGHT: 193px" height=200 alt="Mother and baby" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0004_shutterstock_19889032%5B1%5D4.jpg" width=134 align=right border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;Commentary&amp;nbsp;by Dr. Jennifer Tosswill&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;An estimated 530,000 children under 15 were newly infected with HIV in 2006, mainly through &lt;B&gt;mother-to-child transmission&lt;/B&gt; (MTCT). MTCT may occur in utero, intra-partum and post-partum via breast feeding. Factors associated with increased transmission risk include elevated maternal HIV-1 viral load and low CD4 count at delivery, duration and complications of labour and breastfeeding. In the absence of any intervention, MTCT occurs in 15-30% of non breast fed infants. However, transmission can be reduced to less than 2% by the use of antiretroviral (ARV) therapy for both the mother and newborn child, by elective caesarean section and by avoiding breastfeeding. Global variations in the reported rates of MTCT and in differential estimates of the timing of infection can be attributed to differences in intervention strategies, to the lack of standardised protocols for diagnosis in exposed infants and to differences in the availability of suitable molecular based diagnostic tests. Within the UK, the reported number of HIV-1 pregnant women has risen to over 1,300 in 2006, with a MTCT rate of around 1% (&lt;A href="nelh:298231:0" name=internalLink&gt;Townsend, BJOG&lt;/A&gt;). Early diagnosis and treatment is of particular importance in infants since plasma HIV-1 RNA virus levels decline only very gradually following acute infection, leading to potential rapid disease progression in untreated infants.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Early diagnosis of HIV infection in infants relies on laboratory methods, since clinical symptoms may not be apparent in early infection. In infants under two years old, nucleic acid amplification techniques such as the polymerase chain reaction (PCR) are recommended. At present, HIV DNA or RNA detection by PCR is the test used most widely for the diagnosis of HIV infection in infancy in industrialised countries, and is recommended by the &lt;A href="http://www.who.int/hiv/topics/paediatric/en/index.html" target="_blank"&gt;WHO&lt;/A&gt;, the American Academy of Pediatrics (Read) and by the British HIV Association (&lt;A href="nelh:298231:0" name=internalLink&gt;de Ruiter&lt;/A&gt;). Antibody tests have little role in early diagnosis, as maternal antibody can persist even beyond 18 months of age.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;STARHS&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;IMG id=nelh_tempImage1 height=150 alt="Pipetting into wells for an ELISA" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0005_shutterstock_3032853%5B1%5D3.jpg" width=200 align=right border=0 name=nelh_tempImage1&gt;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Commentary&amp;nbsp;by Dr. Gary Murphy&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The typically rapid immunological response to HIV infection means that within less than a month of anti-HIV seroconversion commencing, standard HIV test kits are unable to distinguish recent from long-standing infections.&amp;nbsp; However a number of adapted or novel techniques have been developed that are able to identify recent infection over a longer time frame, typically 3-6 months, than those achievable through the use of conventional assays.&amp;nbsp; These methods are intended to be applied to individual specimens in which the presence of anti-HIV-1 antibody has already been confirmed, and the approach is known generically as the &lt;STRONG&gt;Serological Testing Algorithm for Recent HIV Seroconversion (STARHS&lt;/STRONG&gt;). A number of different assays can be used within a STARHS programme and they work on many principles.&amp;nbsp; Some assays such as the detuned and BED ELISAs rely&amp;nbsp; primarily on antibody titre to differentiate recent from long-standing infection whereas others rely on the strength of the antibody/antigen bounding (avidity assays) or the relationship between reacitivities to different viral antigens or the presence/absence of antibodies to particular antigens.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are a number of limitations to STARHS assays. For example, none are licensed for clinical use and only one (The BED-CEIA) is commercially available.&amp;nbsp; It is recommended that the assays are only used on a population basis.&amp;nbsp; Furthermore, factors such as AIDS, treatment with antiretroviral drugs and infection with rare subtypes may lead to inaccurate results. However, the STARHS approach offers a number of important advantages over other methods for determining HIV incidence.&amp;nbsp; Unlike cohort studies which require repeated testing of individuals, and where results may be biased by people leaving the study, STARHS testing can be carried out retrospectively on stored single specimens from cross-sectional serosurveys.&amp;nbsp; In comparison with cohort studies, applying the STARHS approach is cheaper, quicker and simpler to perform. Furthermore, STARHS testing can be performed in real time thus allowing a measure of recent infection at the time of a study as opposed to incidence derived from a cohort study which cannot be ascertained until after the follow-up sample has been collected and tested. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Public Health: Settings of HIV Testing&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;IMG id=nelh_tempImage0 height=180 alt="Crowd of people at a Pride event" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID299202/nelhImp_0001_shutterstock_1693342%5B1%5D2.jpg" width=240 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Summary of the evidence by &lt;A href="nelh:299203:2" name=internalLink&gt;&lt;EM&gt;Dr. Anthony Nardone&lt;/EM&gt; &lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The new &lt;A href="nelh:294604:0" name=internalLink&gt;United Kingdom guidelines for HIV testing &lt;/A&gt;were recently released by the &lt;A href="http://www.bhiva.org/" target="_blank"&gt;British HIV Association (BHIVA)&lt;/A&gt;, &lt;A href="http://www.bashh.org/" target="_blank"&gt;The British Association of Sexual Health and HIV (BASHH) &lt;/A&gt;and the &lt;A href="http://www.britishinfectionsociety.org/" target="_blank"&gt;British Infection Society (BIS&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines recommend the wider testing for HIV in order to reduce the number of undiagnosed infections. An awareness of an HIV positive status will have benefits for both the individual, with a much-improved prognosis, and for the community with reduced levels of HIV transmission.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines recommend that universal HIV testing should be offered in settings such as GUM and sexual health clinics, antenatal services, termination of pregnancy services as well as those healthcare services for those diagnosed with tuberculosis, hepatitis B, hepatitis C and lymphoma. The guidelines, along with the booklet “&lt;A href="nelh:296294:0" name=internalLink&gt;HIV for non-HIV specialists: diagnosing the undiagnosed&lt;/A&gt;” recommend the diagnostic testing of individuals presenting with indicator diseases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In addition, HIV should also be offered in general practice and in general medical admissions where the reported prevalence of diagnosed infection in the local population is &amp;gt;2/1,000 15-59 year olds. The list of Primary Care Organisations and Local Authorities where prevalence exceeds this threshold has been published.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Point of care testing has been recommended in this and previous guidance in a number of settings and including community settings, although with a number of important caveats around quality assurance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299203</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299203]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Contributors</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INFECTIONS,NOV 08,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS,HIV]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Contributors to the Annual Evidence Update on Diagnosing HIV</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The Infections Specialist Library would like to thank the following contributors&amp;nbsp;for their commentaries and evidence.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299203:2" name=internalLink&gt;&lt;STRONG&gt;Dr. Anthony Nardone&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299203:3" name=internalLink&gt;&lt;STRONG&gt;Professor Deenan Pillay&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299203:4" name=internalLink&gt;&lt;STRONG&gt;Dr. Gary Murphy&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:299203:5" name=internalLink&gt;&lt;STRONG&gt;Dr. Jennifer&amp;nbsp;Tosswill&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-layout-grid-align: none"&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Anthony Nardone&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr. Anthony Nardone has nearly 15 years experience in infectious disease epidemiology, of which seven years have been in the area of HIV and sexual health. He currently leads the newly established Sexual Health Promotion &amp;amp; Evaluation unit within the Health Protection Agency’s Centre for Infections, a post taken up in the last year after leading the EuroHIV programme, a European Commission funded project to monitor HIV/AIDS in Europe.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Professor Deenan Pillay&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Deenan Pillay is Professor of Virology at UCL and Honorary Consultant Virologist at UCLH. He also is Consultant Virologist at Centre for Infections, HPA, Colindale. After training in Biochemistry and Medicine, he undertook training in Medical Virology at St Thomas' Hospital, and the Royal Free Hospital, in London before taking up a Fellowship at University of California, San Diego. In 1994 he was appointed to his first Consultant Virologist post in Birmingham, where he became Head of the PHLS Antiviral Susceptibility Reference Unit. In 2003, he moved to UCL, and has clinical and research interests in HIV therapy, drug resistance and diversity.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Gary Murphy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr. Gary Murphy is the Manager of the Seromolecular Services Laboratory in the Virus Reference Department of the HPA.&amp;nbsp; He has a keen research interest in the development and use of STARHS technology for identifying recent HIV Infection, an area in which he gained his PhD.&amp;nbsp; He is a member of the WHO HIV Incidence assay working group.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Jennifer Tosswill&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr. Jennifer Tosswill is a Senior Clinical Scientist and is the HIV clinical co-ordinator in the Virus Reference Department (VRD), CfI. She has a particular interest in HIV diagnosis in infants, about ¾ of the infants born to HIV positive mothers in England are tested at VRD. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299385</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299385]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Homepage</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS &amp; INVESTIGATION,HIV &amp; AIDS,DIAGNOSIS,PROFESSIONS &amp; SPECIALTIES,GENITOURINARY MEDICINE,INFECTIONS,SKIN DISORDERS,MICROORGANISM,INFECTIONS,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,INFECTIOUS DISEASES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,DISORDERS,HIV &amp; AIDS,SEXUALLY TRANSMITTED,VIRAL INFECTIONS,NOV 08,POPULATION GROUPS,ADULTS,PREGNANT WOMEN,HIV,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS,ADDED 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on diagnosing HIV</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 Annual Evidence Update: Diagnosing HIV - Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=center&gt;&lt;IMG alt="World AIDS Day red ribbon" hspace=0 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID299385/nelhImp_0000_44_7D8B13F3A_shutterstock_19421743%5B1%5D3.jpg" align=baseline border=0&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;Welcome to the first &lt;B&gt;Annual Evidence Update on Diagnosing HIV&lt;/B&gt; by the &lt;A href="http://www.library.nhs.uk/Infections/" target="_blank"&gt;Infections Specialist Library &lt;/A&gt;in collaboration with the Health Protection Agency's &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200660065903" target="_blank"&gt;Sexual Health Programme Board &lt;/A&gt;and&amp;nbsp;the &lt;A href="http://www.library.nhs.uk/publichealth/" target="_blank"&gt;National Library of Public Health&lt;/A&gt;.&amp;nbsp;This Annual Evidence Update (AEU)&amp;nbsp;will run from &lt;B&gt;24th November to 7th December 2008&lt;/B&gt;, and has been timed to coincide with &lt;A href="http://www.worldaidscampaign.org/en/Key-events/World-AIDS-Day" target="_blank"&gt;World AIDS Day&lt;/A&gt; on 1st December 2008. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In this first Annual Evidence Update, we have chosen to focus on diagnosing HIV, as early diagnosis&amp;nbsp;of HIV benefits both the individual, with a much improved prognosis, as well as the community, with reduced onward transmission of HIV. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In the United Kingdom, it is estimated that a third of HIV infections remain undiagnosed and over a third of new HIV cases are diagnosed late after a point at which treatment should have commenced. The high priority afforded to improving the testing for HIV is demonstrated by the recently published &lt;A href="nelh:294604:0" name=internalLink&gt;national guidelines for HIV testing&lt;/A&gt;. To support these guidelines we have provided resources and evidence for the implementation of public health interventions to increase HIV testing in health services and in the community.&amp;nbsp; Furthermore, we have provided a comprehensive guide to important laboratory techniques in the diagnosis of HIV and monitoring the course of HIV infection.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:299203:1" name=internalLink&gt;Experts &lt;/A&gt;in the field have written &lt;A href="nelh:299205:1" name=internalLink&gt;commentaries&lt;/A&gt;, highlighted the &lt;EM&gt;best evidence on various aspects of HIV diagnosis&lt;/EM&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;and&amp;nbsp;&lt;A href="nelh:299204:1" name=internalLink&gt;links to useful websites&lt;/A&gt; are also provided.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;1. Commentaries in this AEU include the following:&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;B&gt;&lt;A href="nelh:299170:1" name=internalLink&gt;&lt;B&gt;&lt;A href="nelh:299170:0" name=internalLink&gt;&lt;B&gt;Virological Methods&lt;/B&gt;&lt;/A&gt;&lt;A href="nelh:299170:0" name=internalLink&gt;&lt;/B&gt; &lt;/A&gt;&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;by &lt;EM&gt;&lt;EM&gt;&lt;A href="nelh:299203:3" name=internalLink&gt;&lt;EM&gt;&lt;EM&gt;Professor Deenan Pillay&lt;/EM&gt;&lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="nelh:299199:1" name=internalLink&gt;&lt;B&gt;Mother to Child Transmission&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; by &lt;EM&gt;&lt;EM&gt;&lt;A href="nelh:299203:5" name=internalLink&gt;&lt;EM&gt;&lt;EM&gt;Dr. Jennifer To&lt;/EM&gt;sswill &lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="nelh:299200:1" name=internalLink&gt;&lt;B&gt;Serological Testing Algorithm for Recent HIV Seroconversion (STAHRS)&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; by&amp;nbsp; &lt;EM&gt;&lt;EM&gt;&lt;A href="nelh:299203:4" name=internalLink&gt;&lt;EM&gt;&lt;EM&gt;Dr. Gary Murphy&lt;/EM&gt;&lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:299202:1" name=internalLink&gt;&lt;STRONG&gt;&lt;A href="nelh:299202:0" name=internalLink&gt;&lt;STRONG&gt;Public Health – settings for HIV testing&lt;/STRONG&gt;&lt;/A&gt;&lt;A href="nelh:299202:0" name=internalLink&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;: by &lt;EM&gt;&lt;A href="nelh:299203:2" name=internalLink&gt;&lt;EM&gt;Dr. Anthony Nardone&lt;/EM&gt; &lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. The best evidence on various aspects of HIV diagnosis is provided for the following topics:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;A href="nelh:299170:0" name=internalLink&gt;Virological Methods&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299170:2" name=internalLink&gt;Molecular Epidemiology and Transmission&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299170:3" name=internalLink&gt;Antiretroviral resistance&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299170:4" name=internalLink&gt;Viral testing&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299199:1" name=internalLink&gt;Mother to Child Transmission&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299200:1" name=internalLink&gt;Serological Testing Algorithm for Recent HIV Seroconversion (STARHS)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="nelh:299200:3" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;- &lt;A href="nelh:299201:0" name=internalLink&gt;Points of care for HIV testing&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:299200:3" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:299202:0" name=internalLink&gt;&lt;STRONG&gt;Public Health – settings for HIV testing&lt;/STRONG&gt;&lt;/A&gt;&lt;A href="nelh:299202:0" name=internalLink&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;A href="nelh:299202:0" name=internalLink&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;A href="nelh:299202:1" name=internalLink&gt; &lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299202:2" name=internalLink&gt;Health Services &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299202:3" name=internalLink&gt;Antenatal settings &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299202:4" name=internalLink&gt;Drug treatment&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&lt;A href="nelh:299202:5" name=internalLink&gt;Genito-urinary medicine &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; - &lt;A href="nelh:299202:6" name=internalLink&gt;Respiratory medicine &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&lt;A href="nelh:299202:7" name=internalLink&gt;Emergency departments&amp;nbsp;&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&lt;A href="nelh:299202:8" name=internalLink&gt;Community Settings &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&lt;A href="nelh:299202:9" name=internalLink&gt;Cost effectiveness of HIV testing &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; - &lt;EM&gt;&lt;A href="nelh:298857:0" name=internalLink&gt;&lt;EM&gt;Behavior Change in High Risk Populations&lt;/EM&gt;&amp;nbsp; &lt;/A&gt;&lt;/EM&gt;- available from The &lt;A href="http://www.library.nhs.uk/publichealth/" target="_blank"&gt;National Library for Public Health &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. &lt;A href="nelh:299204:0" name=internalLink&gt;Links to useful websites for HIV&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. A list of all the &lt;A href="nelh:299203:1" name=internalLink&gt;contributors &lt;/A&gt;to this AEU&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/infections/viewResource.aspx?resid=299205&amp;amp;code=5cd65d3a041e2ce338b3307c3ebd0510" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;We welcome &lt;A href="http://www.library.nhs.uk/Infections/ContactUs.aspx" target="_blank"&gt;feedback &lt;/A&gt;about the resources included in this update - please &lt;A href="http://www.library.nhs.uk/Infections/ContactUs.aspx" target="_blank"&gt;contact us &lt;/A&gt;if you would like to send us comments.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299199</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299199]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Mother to Child Transmission</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,NOV 08,PREGNANT WOMEN,ADULTS,POPULATION GROUPS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV)]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on mother to child transmission for the Annual Evidence Update on Diagnosing HIV 2008</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Mother to Child Transmission&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 style="WIDTH: 134px; HEIGHT: 193px" height=200 alt="Mother and baby" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0004_shutterstock_19889032%5B1%5D4.jpg" width=134 align=right border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;EM&gt;Summary of the evidence by &lt;A href="nelh:299203:5" name=internalLink&gt;&lt;EM&gt;Dr. Jennifer Tosswill&lt;/EM&gt; &lt;/A&gt;&lt;/EM&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;An estimated 530,000 children under 15 were newly infected with HIV in 2006, mainly through &lt;B&gt;mother-to-child transmission&lt;/B&gt; (MTCT). MTCT may occur in utero, intra-partum and post-partum via breast feeding. Factors associated with increased transmission risk include elevated maternal HIV-1 viral load and low CD4 count at delivery, duration and complications of labour and breastfeeding. In the absence of any intervention, MTCT occurs in 15-30% of non breast fed infants. However, transmission can be reduced to less than 2% by the use of antiretroviral (ARV) therapy for both the mother and newborn child, by elective caesarean section and by avoiding breastfeeding. Global variations in the reported rates of MTCT and in differential estimates of the timing of infection can be attributed to differences in intervention strategies, to the lack of standardised protocols for diagnosis in exposed infants and to differences in the availability of suitable molecular based diagnostic tests. Within the UK, the reported number of HIV-1 pregnant women has risen to over 1,300 in 2006, with a MTCT rate of around 1% (&lt;A href="nelh:298231:0" name=internalLink&gt;Townsend, BJOG&lt;/A&gt;). Early diagnosis and treatment is of particular importance in infants since plasma HIV-1 RNA virus levels decline only very gradually following acute infection, leading to potential rapid disease progression in untreated infants.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Early diagnosis of HIV infection in infants relies on laboratory methods, since clinical symptoms may not be apparent in early infection. In infants under two years old, nucleic acid amplification techniques such as the polymerase chain reaction (PCR) are recommended. At present, HIV DNA or RNA detection by PCR is the test used most widely for the diagnosis of HIV infection in infancy in industrialised countries, and is recommended by the &lt;A href="http://www.who.int/hiv/topics/paediatric/en/index.html" target="_blank"&gt;WHO&lt;/A&gt;, the American Academy of Pediatrics (Read) and by the British HIV Association (&lt;A href="nelh:298231:0" name=internalLink&gt;de Ruiter&lt;/A&gt;). Antibody tests have little role in early diagnosis, as maternal antibody can persist even beyond 18 months of age.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Mother to Child Transmission&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Summary of the evidence by Dr. Jennifer Tosswill&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;1. Giaquinto C, Morelli E, Fregonese F, Rampon O, Penazzato M, de Rossi A, D'Elia R. &lt;A href="nelh:297228:0" name=internalLink&gt;Current and future antiretroviral treatment options in paediatric HIV infection&lt;/A&gt;. Clin Drug Investig. 2008;28(6):375-97.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Suksomboon N, Poolsup N, Ket-Aim S. &lt;A href="nelh:295864:0" name=internalLink&gt;Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection&lt;/A&gt;. J Clin Pharm Ther. 2007 Jun;32(3):293-311. Review. PMID: 17489882 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. Read JS, Newell ML. &lt;A href="nelh:239135:0" name=internalLink&gt;Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1&lt;/A&gt;. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD005479. DOI: 10.1002/14651858.CD005479.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. Wiysonge CSU, Shey M, Kongnyuy EJ, Sterne JAC, Brocklehurst P. &lt;A href="nelh:238000:0" name=internalLink&gt;Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection&lt;/A&gt;. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003648. DOI: 10.1002/14651858.CD003648.pub2.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. Wiysonge CS, Shey MS, Shang JD, Sterne JAC, Brocklehurst P. &lt;A href="nelh:238002:0" name=internalLink&gt;Vaginal disinfection for preventing mother-to-child transmission of HIV infection&lt;/A&gt;. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003651. DOI: 0.1002/14651858.CD003651.pub2.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;6. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. &lt;A href="nelh:238183:0" name=internalLink&gt;Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection&lt;/A&gt;. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD003510. DOI: 10.1002/14651858.CD003510.pub2. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;8. Breastfeeding and HIV International Transmission Study Group, Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR, Jackson JB, Leroy V, Meda N, Msellati P, Newell ML, Nsuati R, Read JS, Wiktor S. &lt;A href="nelh:297862:0" name=internalLink&gt;Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis&lt;/A&gt;. J Infect Dis. 2004 Jun 15;189(12):2154-66. Epub 2004 May 26.&amp;nbsp; PMID: 15181561 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Chigwedere P, Seage GR, Lee TH, Essex M. &lt;A href="nelh:297863:0" name=internalLink&gt;Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials&lt;/A&gt;. AIDS Res Hum Retroviruses. 2008 Jun;24(6):827-37.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Goetghebuer T, Haelterman E, Marvillet I, Barlow P, Hainaut M, Salameh A, Ciardelli R, Gerard M, Levy J. &lt;A href="nelh:297895:0" name=internalLink&gt;Vertical transmission of HIV in Belgium: a 1986-2002 retrospective analysis&lt;/A&gt;. Eur J Pediatr. 2008 Apr 5. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;11. Leroy V, Ekouevi DK, Becquet R, Viho I, Dequae-Merchadou L, Tonwe-Gold B, Rouet F, Sakarovitch C, Horo A, Timité-Konan M, Rouzioux C, Dabis F; ANRS 1201/1202 DITRAME PLUS Study Group.&lt;BR&gt;&lt;A href="nelh:298222:0" name=internalLink&gt;18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission&lt;/A&gt;. PLoS ONE. 2008 Feb 20;3(2):e1645.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;12. Madeddu G, Calia GM, Campus ML, Lovigu C, Mannazzu M, Olmeo P, Mela MG, Mura MS. &lt;A href="nelh:298225:0" name=internalLink&gt;Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy&lt;/A&gt;. Int J STD AIDS. 2008 Sep;19(9):644-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp; Thorsen VC, Sundby J, Martinson F. &lt;A href="nelh:298227:0" name=internalLink&gt;Potential initiators of HIV-related stigmatization: ethical and programmatic challenges for PMTCT programs&lt;/A&gt;. Dev World Bioeth. 2008 Apr;8(1):43-50.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;14. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. &lt;A href="nelh:298231:0" name=internalLink&gt;Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006&lt;/A&gt;. AIDS. 2008 May 11;22(8):973-81. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;15. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, Faye A, Burgard M, Rouzioux C, Mandelbrot L; ANRS French Perinatal Cohort. &lt;A href="nelh:298233:0" name=internalLink&gt;Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort&lt;/A&gt;. AIDS. 2008 Jan 11;22(2):289-99.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;16. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. &lt;A href="nelh:298241:0" name=internalLink&gt;Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006&lt;/A&gt;. BJOG 2008 August;115(9):1078-86.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;17. Read JS. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18055670?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Diagnosis of HIV-1 infection in children younger than 18 months in the United States&lt;/A&gt;. Pediatrics 2007 December;120(6):e1547-e1562.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;de RA, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G et al. &lt;A href="nelh:292207:0" name=internalLink&gt;British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008&lt;/A&gt;. HIV Med 2008 August;9(7):452-502.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Coutsoudis A, Coovadia HM, Wilfert CM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18368208?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV, infant feeding and more perils for poor people: new WHO guidelines encourage review of formula milk policies&lt;/A&gt;. Bull World Health Organ 2008 March;86(3):210-4.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;20. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA; CHER Study Team. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19020325?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Early antiretroviral therapy and mortality among HIV-infected infants&lt;/A&gt;. N Engl J Med. 2008 Nov 20;359(21):2233-44.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299201</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299201]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Points of care for HIV testing</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,NOV 08,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS,HIV]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on Points of care testing for the Annual Evidence Update on Diagnosing HIV 2008</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Points of care for HIV testing - Technology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;IMG id=nelh_tempImage0 height=150 alt="Nurse talking to patient in bed" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0008_shutterstock_17777329%5B1%5D2.jpg" width=219 align=right border=0 name=nelh_tempImage0&gt;&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Summary of the evidence by &lt;A href="nelh:299203:4" name=internalLink&gt;Dr. Gary Murphy&amp;nbsp;&lt;/A&gt;&amp;amp;&amp;nbsp;&lt;A href="nelh:299203:2" name=internalLink&gt;Dr. Anthony Nardone&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;BR&gt;1. Bateganya MH, Abdulwadud OA, Kiene SM. &lt;A href="nelh:270957:0" name=internalLink&gt;Home-based HIV voluntary counseling and testing in developing countries&lt;/A&gt;. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006493. DOI: 10.1002/14651858.CD006493.pub2 
&lt;H2&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Bogart LM, Howerton D, Lange J, Becker K, Setodji CM, Asch SM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18763412?ordinalpos=6&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Scope of rapid HIV testing in urban U.S. hospitals&lt;/A&gt;. Public Health Rep. 2008 Jul-Aug;123(4):494-503. PMID: 18763412 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Branson BM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18190290?ordinalpos=11&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;State of the art for diagnosis of HIV infection&lt;/A&gt;. Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S221-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Brown P, Merline JR, Levine D, Minces LR. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18591648?ordinalpos=16&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Repeatedly false-negative rapid HIV test results in a patient with undiagnosed advanced AIDS&lt;/A&gt;. Ann Intern Med. 2008 Jul 1;149(1):71-2. No abstract available. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Chou R, Smits AK, Huffman LH, Fu R, Korthuis PT; US Preventive Services Task Force. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15998754?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Prenatal screening for HIV: A review of the evidence for the U.S. Preventive Services Task Force&lt;/A&gt;. Ann Intern Med. 2005 Jul 5;143(1):38-54. Review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Dougan S, Elford J, Chadborn TR, Brown AE, Roy K, Murphy G, Gill ON; Group Investigating Rising HIV Diagnoses Among MSM in UK. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17090569?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Does the recent increase in HIV diagnoses among men who have sex with men in the UK reflect a rise in HIV incidence or increased uptake of HIV testing?&lt;/A&gt;Sex Transm Infect. 2007 Apr;83(2):120-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Hutchinson AB, Branson BM, Kim A, Farnham PG. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16868440?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status&lt;/A&gt;. AIDS. 2006 Aug 1;20(12):1597-604.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Perry KR, Ramskill S, Eglin RP, Barbara JA, Parry JV. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18783582?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Improvement in the performance of HIV screening kits&lt;/A&gt;. Transfus Med. 2008 Aug;18(4):228-40.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;9. Ren A, Louie B, Rauch L, Castro L, Liska S, Klausner JD, Pandori MW. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18809550?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Screening and confirmation of human immunodeficiency virus type 1 infection solely by detection of RNA&lt;/A&gt;. J Med Microbiol. 2008 Oct;57(Pt 10):1228-33.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. J Vidanapathirana, MJ Abramson, A Forbes, C Fairley. &lt;A href="nelh:238849:1" name=internalLink&gt;Mass media interventions for promoting HIV testing&lt;/A&gt;.&lt;A href="nelh:238849:0" name=internalLink&gt;&lt;/A&gt; Cochrane Database of Systematic Reviews 2008 Issue 4 (Status: Unchanged) &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. [No authors listed] &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16749249?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid HIV test kits&lt;/A&gt;. Health Devices. 2006 May;35(5):157-77.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Points of care for HIV testing - Application&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Summary of the evidence by &lt;A href="nelh:299203:4" name=internalLink&gt;Dr. Gary Murphy&lt;/A&gt;&amp;nbsp;&amp;amp; &lt;A href="nelh:299203:2" name=internalLink&gt;Dr. Anthony Nardone&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Centers for Disease Control and Prevention (CDC). &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18566566?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;False-positive oral fluid rapid HIV tests--New York City, 2005-2008&lt;/A&gt;. MMWR Morb Mortal Wkly Rep. 2008 Jun 20;57(24):660-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Doumit G, Gattellari M, Grimshaw J, O'Brien MA. &lt;A href="nelh:236403:0" name=internalLink&gt;Local opinion leaders: effects on professional practice and health care outcomes&lt;/A&gt;. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000125. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Forsyth SF, Agogo EA, Lau L, Jungmann E, Man S, Edwards SG, Robinson AJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18663043?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Would offering rapid point-of-care testing or non-invasive methods improve uptake of HIV testing among high-risk genitourinary medicine clinic attendees? A patient perspective&lt;/A&gt;. Int J STD AIDS. 2008 Aug;19(8):550-2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Goetz MB, Bowman C, Hoang T, Anaya H, Osborn T, Gifford AL, Asch SM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18353185?ordinalpos=36&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Implementing and evaluating a regional strategy to improve testing rates in VA patients at risk for HIV, utilizing the QUERI process as a guiding framework: QUERI Series&lt;/A&gt;. Implement Sci. 2008 Mar 19;3:16.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Guenter D, Greer J, Barbara A, Robinson G, Roberts J, Browne G. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18290752?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid point-of-care HIV testing in community-based anonymous testing program: a valuable alternative to conventional testing. Public health? &lt;/A&gt;AIDS Patient Care STDS. 2008 Mar;22(3):195-204.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Knapp H, Anaya HD, Feld JE. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18725556?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Expanding HIV rapid testing via point-of-care paraprofessionals&lt;/A&gt;. Int J STD AIDS. 2008 Sep;19(9):629-32.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp; Pai NP, Tulsky JP, Cohan D, Colford JM Jr, Reingold AL. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17300622?ordinalpos=25&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid point-of-care HIV testing in pregnant women: a systematic review and meta-analysis&lt;/A&gt;. Trop Med Int Health. 2007 Feb;12(2):162-73. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Prod'hom G, Bille J. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18578431?ordinalpos=17&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Use of POCT (point of care tests) in the diagnosis of infectious diseases&lt;/A&gt;] Rev Med Suisse. 2008 Apr 9;4(152):908-13. &lt;EM&gt;French&lt;/EM&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Souteyrand YP, Collard V, Moatti JP, Grubb I, Guerma T. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18664948?ordinalpos=11&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries.&lt;/A&gt; AIDS. 2008 Jul;22 Suppl 1:S161-8.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp; Winter AJ, Sulaiman Z, Hawkins D; British Association for Sexual Health and HIV Clinical Governance Committee. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17212854?ordinalpos=26&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;BASHH Clinical Governance Committee guidance on the appropriate use of HIV point of care tests&lt;/A&gt;. Int J STD AIDS. 2006 Dec;17(12):802-5. No abstract available.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299202</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299202]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Public Health: Settings for HIV testing</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,NOV 08,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,HIV,MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence in public health settings for the Annual Evidence Update on Diagnosing HIV 2008</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Public Health - Settings for HIV Testing&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=193 alt="Crowd of people at a Pride event" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID299202/nelhImp_0001_shutterstock_1693342%5B1%5D2.jpg" width=278 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Summary of the evidence by &lt;A href="nelh:299203:2" name=internalLink&gt;&lt;EM&gt;Dr. Anthony Nardone&lt;/EM&gt; &lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The new &lt;A href="nelh:294604:0" name=internalLink&gt;United Kingdom guidelines for HIV testing &lt;/A&gt;were recently released by the &lt;A href="http://www.bhiva.org/" target="_blank"&gt;British HIV Association (BHIVA)&lt;/A&gt;, &lt;A href="http://www.bashh.org/" target="_blank"&gt;The British Association of Sexual Health and HIV (BASHH) &lt;/A&gt;and the &lt;A href="http://www.britishinfectionsociety.org/" target="_blank"&gt;British Infection Society (BIS&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines recommend the wider testing for HIV in order to reduce the number of undiagnosed infections. An awareness of an HIV positive status will have benefits for both the individual, with a much-improved prognosis, and for the community with reduced levels of HIV transmission.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines recommend that universal HIV testing should be offered in settings such as GUM and sexual health clinics, antenatal services, termination of pregnancy services as well as those healthcare services for those diagnosed with tuberculosis, hepatitis B, hepatitis C and lymphoma. The guidelines, along with the booklet “&lt;A href="nelh:296294:0" name=internalLink&gt;HIV for non-HIV specialists: diagnosing the undiagnosed&lt;/A&gt;” recommend the diagnostic testing of individuals presenting with indicator diseases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In addition, HIV should also be offered in general practice and in general medical admissions where the reported prevalence of diagnosed infection in the local population is &amp;gt;2/1,000 15-59 year olds. The list of Primary Care Organisations and Local Authorities where prevalence exceeds this threshold has been published.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Point of care testing has been recommended in this and previous guidance in a number of settings and including community settings, although with a number of important caveats around quality assurance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Health Services&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. British HIV Association/British Association for Sexual Health and HIV/British Infection Society. &lt;A href="nelh:294604:0" name=internalLink&gt;UK national guidelines for HIV testing 2008 &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Medical Foundation for AIDS and Sexual Health. &lt;A href="nelh:296294:0" name=internalLink&gt;HIV for non-HIV speacialists: Diagnosing the undiagnosed&lt;/A&gt;. 2008. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Health Protection Report. &lt;A href="http://www.hpa.org.uk/hpr/archives/2008/news3808.htm#sophid" target="_blank"&gt;New guidelines of HIV testing in high prevalence areas&lt;/A&gt;. Volume 2 No 38; 19 September 2008. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. British Association for Sexual Health and HIV (BASHH)&amp;nbsp;Clinical Governance Committee. &lt;A href="http://www.bashh.org/documents/1176/1176.pdf" target="_blank"&gt;Guidance on the appropriate use of HIV Point of Care Tests&lt;/A&gt;. June 2006.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE; Centers for Disease Control and Prevention (CDC). &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16988643?ordinalpos=10&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings&lt;/A&gt;. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Lyons MS, Lindsell CJ, R N DA, Rn DL, Trott AT, Fichtenbaum CJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18578881?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Contributions to early HIV diagnosis among patients linked to care vary by testing venue&lt;/A&gt;. BMC Public Health. 2008 Jun 25;8:220.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Burke RC, Sepkowitz KA, Bernstein KT, Karpati AM, Myers JE, Tsoi BW, Begier EM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17630557?ordinalpos=35&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Why don't physicians test for HIV? A review of the US literature&lt;/A&gt;. AIDS. 2007 Jul 31;21(12):1617-24. Review. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Burns FM, Johnson AM, Nazroo J, Ainsworth J, Anderson J, Fakoya A, Fakoya I, Hughes A, Jungmann E, Sadiq ST, Sullivan AK, Fenton KA; SONHIA Collaboration Group. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18090399?ordinalpos=28&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK&lt;/A&gt;.&lt;BR&gt;AIDS. 2008 Jan 2;22(1):115-22.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Bogart LM, Howerton D, Lange J, Becker K, Setodji CM, Asch SM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18763412?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Scope of rapid HIV testing in urban U.S. hospitals&lt;/A&gt;. Public Health Rep. 2008 Jul-Aug;123(4):494-503.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Knapp H, Anaya HD, Feld JE. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18725556?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Expanding HIV rapid testing via point-of-care paraprofessionals&lt;/A&gt;. Int J STD AIDS. 2008 Sep;19(9):629-32.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;11. McGarrigle CA, Mercer CH, Fenton KA, Copas AJ, Wellings K, Erens B, Johnson AM.&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15627036?ordinalpos=23&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Investigating the relationship between HIV testing and risk behaviour in Britain: National Survey of Sexual Attitudes and Lifestyles 2000&lt;/A&gt;. AIDS. 2005 Jan 3;19(1):77-84. PMID: 15627036 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, Osborn T, Owens DK, Sanders GD, Asch SM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18421508?ordinalpos=13&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing&lt;/A&gt;. J Gen Intern Med. 2008 Jun;23(6):800-7. Epub 2008 Apr 18. PMID: 18421508 [PubMed - indexed for MEDLINE&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Branson B. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17874432?ordinalpos=29&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Current HIV epidemiology and revised&amp;nbsp; recommendations for HIV testing in health-care settings&lt;/A&gt;. J Med Virol. 2007;79 Suppl 1:S6-10.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14. Mehta SD, Hall J, Greenwald JL, Cranston K, Skolnik PR. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18828416?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Patient risks, outcomes, and costs of voluntary HIV testing at five testing sites within a medical center&lt;/A&gt;. Public Health Rep. 2008 Sep-Oct;123(5):608-17.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Whittet S, Trail P, de Ruiter A, O'Sullivan D, Jones R.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11030683?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;General practitioners' attitudes and beliefs on antenatal testing for HIV: postal questionnaire survey&lt;/A&gt;. BMJ. 2000 Oct 14;321(7266):934. No abstract available. PMID: 11030683 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Antenatal Settings&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. &lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/www.rcpch.ac.uk/doc.aspx?id_Resource=1917" target="_blank"&gt;Reducing Mother to Child Transmission of HIV Infection in the United Kingdom.&amp;nbsp; Update Report of an Intercollegiate Working Party July 2006&lt;/A&gt;.&amp;nbsp; Royal College of Paediatrics and Child health &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Simpson WM, Johnstone FD, Boyd FM, Goldberg DJ, Hart GJ, Prescott RJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9472506?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Uptake and acceptability of antenatal HIV testing: randomised controlled trial of different methods of offering the test&lt;/A&gt;. BMJ. 1998 Jan 24;316(7127):262-7.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; Duffy TA, Wolfe CD, Varden C, Kennedy J, Chrystie IL, Banatvala JE.&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9472508?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Antenatal HIV testing: current problems, future solutions. Survey of uptake in one London hospital&lt;/A&gt;. BMJ. 1998 Jan 24;316(7127):270-1. No abstract available. PMID: 9472508 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Sherr L, Fox Z, Lipton M, Whyte P, Jones P, Harrison U; Camden and Islington Steering Group.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16615201?ordinalpos=10&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Sustaining HIV testing in pregnancy- evaluation of routine offer of HIV testing in three London hospitals over 2 years&lt;/A&gt;. AIDS Care. 2006 Apr;18(3):183-8. PMID: 16615201 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Pérez K, Blanch C, Casabona J, Almeda J, Coll O; COBEMB. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15369031?ordinalpos=18&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Coverage of HIV testing among pregnant women in Catalonia, Spain: a comparison of self-reporting with medical records&lt;/A&gt;. Eur J Public Health. 2004 Sep;14(3):261-6. PMID: 15369031 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Brook MG, Taylor GP, Dale A, Lyall EG, Tomlinson D.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11737341?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Management of HIV and pregnancy in England's North Thames Region 1999: a survey of practice in 21 hospitals&lt;/A&gt;. HIV Med. 2000 Jul;1(3):143-7; discussion 148. PMID: 11737341 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp; Foley E, Barton SE, Harindra V, Hamer G, Mandalia S.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11589812?ordinalpos=13&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Midwives and HIV antibody testing: identifying the key factors for achieving the targets.&lt;/A&gt; Int J STD AIDS. 2001 Nov;12(11):730-2. PMID: 11589812 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Drug treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp; Pugatch DL, Levesque BG, Lally MA, Reinert SE, Filippone WJ, Combs CM, Flanigan TP, Brown LK. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11404535?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment&lt;/A&gt;. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):135-42.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Weightman R, Walton R, Bury J.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=15779794&amp;amp;log$=activity" target="_blank"&gt;Audit of bloodborne virus prevention activity with drug users seen in primary care&lt;/A&gt;. Commun Dis Public Health. 2004 Dec;7(4):301-5. PMID: 15779794 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Edeh J, Spalding P.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11192282?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England&lt;/A&gt;. J Public Health Med. 2000 Dec;22(4):531-9. PMID: 11192282 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Genito-urinary medicine &lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Munro HL, Lowndes CM, Daniels DG, Sullivan AK, Robinson AJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18096649?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;National study of HIV testing in men who have sex with men attending genitourinary clinics in the United Kingdom&lt;/A&gt;. Sex Transm Infect. 2008 Aug;84(4):265-70. Epub 2007 Dec 20.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Forsyth SF, Agogo EA, Lau L, Jungmann E, Man S, Edwards SG, Robinson AJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18663043?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Would offering rapid point-of-care testing or non-invasive methods improve uptake of HIV testing among high-risk genitourinary medicine clinic attendees? A patient perspective&lt;/A&gt;. Int J STD AIDS. 2008 Aug;19(8):550-2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Jones KE, Beeching BA, Roberts P, Devine M, Davies J, Bates CM, Jones C. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16877583?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Success of a nurse led community based genitourinary medicine clinic for young people in Liverpool: review of the first year&lt;/A&gt;.&amp;nbsp; Sex Transm Infect. 2006 Aug;82(4):318-20.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Mehta SD, Ghanem KG, Rompalo AM, Erbelding EJ.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16763500?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV seroconversion among public sexually transmitted disease clinic patients: analysis of risks to facilitate early identification.&lt;/A&gt; J Acquir Immune Defic Syndr. 2006 May;42(1):116-22. PMID: 16763500 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;7&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Respiratory medicine&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Melzer M, Warley A, Milburn H, O'Sullivan D, Barker RD, Hutchinson D, Shelton D, Drobniewski F, French G.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12587968?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVLinkOut" target="_blank"&gt;Tuberculosis and HIV seroprevalence in Lambeth, Southwark and Lewisham, an area of South London&lt;/A&gt;. Respir Med. 2003 Feb;97(2):167-72. PMID: 12587968 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Dart S, Alder D, Mamdani M, Solamalai A, Evans A, Johnson N, Cropley I, Lipman M.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16517587?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVLinkOut" target="_blank"&gt;HIV testing in TB clinics: a problem in practice? &lt;/A&gt;Thorax. 2006 Mar;61(3):271-2. No abstract available. PMID: 16517587 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11081535?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVLinkOut" target="_blank"&gt;HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts&lt;/A&gt;. Lancet. 2000 Oct 28;356(9240):1488-9. PMID: 11081535 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;8&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Emergency departments &lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Coil CJ, Haukoos JS, Witt MD, Wallace RC, Lewis RJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14707792?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Evaluation of an emergency department referral system for outpatient HIV testing&lt;/A&gt;. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):52-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Haukoos JS, Witt MD, Coil CJ, Lewis RJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15995093?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;The effect of financial incentives on adherence with outpatient human immunodeficiency virus testing referrals from the emergency department&lt;/A&gt;. Acad Emerg Med. 2005 Jul;12(7):617-21.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Haukoos JS, Hopkins E, Byyny RL; Denver Emergency Department HIV Testing Study Group. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18191295?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Patient acceptance of rapid HIV testing practices in an urban emergency department: assessment of the 2006 CDC recommendations for HIV screening in health care settings&lt;/A&gt;. Ann Emerg Med. 2008 Mar;51(3):303-9, 309.e1. Epub 2008 Jan 11. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Haukoos JS, Hopkins E, Eliopoulos VT, Byyny RL, Laperriere KA, Mendoza MX, Thrun MW; Denver Emergency Department Rapid HIV Testing Study Group. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18045889?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Development and implementation of a model to improve identification of patients infected with HIV using diagnostic rapid testing in the emergency department&lt;/A&gt;. Acad Emerg Med. 2007 Dec;14(12):1149-57.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Hardwicke R, Malecha A, Lewis ST, Grimes RM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18457762?ordinalpos=12&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV testing in emergency departments: a recommendation with missed opportunities&lt;/A&gt;. J Assoc Nurses AIDS Care. 2008 May-Jun;19(3):211-8.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Lyons MS, Raab DL, Lindsell CJ, Trott AT, Fichtenbaum CJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17937817?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences&lt;/A&gt;. BMC Health Serv Res. 2007 Oct 15;7:164.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Rothman RE, Lyons MS, Haukoos JS. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17538079?ordinalpos=12&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Uncovering HIV infection in the emergency department: a broader perspective&lt;/A&gt;. Acad Emerg Med. 2007 Jul;14(7):653-7. Epub 2007 May 30. No abstract available.&amp;nbsp; PMID: 17538079 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Kelen GD, Shahan JB, Quinn TC.&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9922409?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVLinkOut" target="_blank"&gt;Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing&lt;/A&gt;. Ann Emerg Med. 1999 Feb;33(2):147-55. PMID: 9922409 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Landau R, Coker R, Vermeulen E, Touquet R, Fothergill J, Poznansky MC. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9315932?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVLinkOut" target="_blank"&gt;Patients unaware of their HIV status present to inner city accident and emergency department with respiratory&amp;nbsp; complications&lt;/A&gt;. J Accid Emerg Med. 1997 Sep;14(5):304-6.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp; Poznansky MC, Walters J, Cruikshank A, Pollock R, Dendrowskyj P, Lewis K, Parry JV, Fothergill J, Weber J.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8947806?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVLinkOut" target="_blank"&gt;The rising prevalence of HIV-1 infection in patients attending an inner city accident and emergency department&lt;/A&gt;. J Accid Emerg Med. 1996 Nov;13(6):424-5.&lt;BR&gt;PMID: 8947806 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;8&lt;/pageID&gt;&lt;pageSequence&gt;9&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Community Settings &lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Buchér JB, Thomas KM, Guzman D, Riley E, Dela Cruz N, Bangsberg DR. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17305929?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Community-based rapid HIV testing in homeless and marginally housed adults in San Francisco&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Centers for Disease Control and Prevention (CDC). &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18046300?ordinalpos=62&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid HIV testing in outreach and other community settings--United States, 2004-2006&lt;/A&gt;. MMWR Morb Mortal Wkly Rep. 2007 Nov 30;56(47):1233-7&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. Guenter D, Greer J, Barbara A, Robinson G, Roberts J, Browne G. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18290752?ordinalpos=35&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid point-of-care HIV testing in community-based anonymous testing program: a valuable alternative to conventional testing&lt;/A&gt;.&lt;BR&gt;AIDS Patient Care STDS. 2008 Mar;22(3):195-204.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Liang TS, Erbelding E, Jacob CA, Wicker H, Christmyer C, Brunson S, Richardson D, Ellen JM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15857197?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid HIV testing of clients of a mobile STD/HIV clinic&lt;/A&gt;. AIDS Patient Care STDS. 2005 Apr;19(4):253-7.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Macgowan R, Margolis A, Richardson-Moore A, Wang T, Lalota M, French PT, Stodola J, McKeever J, Carrel J, Mullins J, Llanas M, Griffiths SD; for the Rapid Testing in Corrections (RTIC) Team. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17724428?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Voluntary Rapid Human Immunodeficiency Virus (HIV) Testing in Jails&lt;/A&gt;. Sex Transm Dis. 2007 Aug 23. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Mill JE, Jackson RC, Worthington CA, Archibald CP, Wong T, Myers T, Prentice T, Sommerfeldt S. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18840292?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV Testing and Care in Canadian Aboriginal Youth: A community based mixed methods study&lt;/A&gt;. BMC Infect Dis. 2008 Oct 7;8(1):132. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Prost A, Sseruma WS, Fakoya I, Arthur G, Taegtmeyer M, Njeri A, Fakoya A, Imrie J. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17911136?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV voluntary counselling and testing for African communities in London: learning from experiences in Kenya&lt;/A&gt;. Sex Transm Infect. 2007 Dec;83(7):547-51. Epub 2007 Oct 2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Prost A, Elford J, Imrie J, Petticrew M, Hart GJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17497218?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Social, behavioural, and intervention research among people of Sub-Saharan African origin living with HIV in the UK and Europe: literature review and recommendations for intervention&lt;/A&gt;. AIDS Behav. 2008 Mar;12(2):170-94. Epub 2007 May 12. Review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Prost A, Chopin M, McOwan A, Elam G, Dodds J, Macdonald N, Imrie J. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17229791?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;"There is such a thing as asking for trouble": taking rapid HIV testing to gay venues is fraught with challenges&lt;/A&gt;. Sex Transm Infect 2007 Jun;83(3):185-8. Epub 2007 Jan 17.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Rusch ML, Shoveller JA, Burgess S, Stancer K, Patrick DM, Tyndall MW. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18767266?ordinalpos=6&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Demographics, sexual risk behaviours and uptake of screening for sexually transmitted infections among attendees of a weekly women-only community clinic program&lt;/A&gt;. Can J Public Health. 2008 Jul-Aug;99(4):257-61.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. San Antonio-Gaddy M, Richardson-Moore A, Burstein GR, Newman DR, Branson BM, Birkhead GS. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16980908?ordinalpos=20&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid HIV antibody testing in the New York State Anonymous HIV Counseling and Testing Program: experience from the field&lt;/A&gt;. J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):446-50.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12.Smith LV, Rudy ET, Javanbakht M, Uniyal A, Sy LS, Horton&amp;nbsp;T, Kerndt PR. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17052139?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Client satisfaction with rapid HIV testing: comparison between an urban sexually transmitted disease clinic and a community-based testing center&lt;/A&gt;. AIDS Patient Care STDS. 2006 Oct;20(10):693-700.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13. Spielberg F, Branson BM, Goldbaum GM, Lockhart D, Kurth A, Rossini A, Wood RW. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15735456?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Choosing HIV Counseling and Testing Strategies for Outreach Settings: A Randomized Trial&lt;/A&gt;. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):348-55.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14. Walensky RP, Paltiel AD. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16983134?ordinalpos=13&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Rapid HIV testing at home: does it solve a problem or create one?&lt;/A&gt; Ann Intern Med. 2006 Sep 19;145(6):459-62. Review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;15. Jones KE, Beeching BA, Roberts P, Devine M, Davies J, Bates CM, Jones C. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16877583?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Success of a nurse led community based genitourinary medicine clinic for young people in Liverpool: review of the first year&lt;/A&gt;. Sex Transm Infect. 2006 Aug;82(4):318-20.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;16. Weatherburn P, Hickson F, Reid D, Hammond G &amp;amp; the fasTest study group. &lt;A href="http://www.sigmaresearch.org.uk/files/report2006f.pdf" target="_blank"&gt;evaluation of the Department of Health funded fasTest HIV testing in the community pilot&lt;/A&gt;. May 2006.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;17. Weatherburn P, Hickson F, Reid D, Hammond G &amp;amp; the fasTest study group. &lt;A href="http://www.sigmaresearch.org.uk/files/report2006g.pdf" target="_blank"&gt;evaluation of the gsk funded fasTest HIV testing in the community pilot&lt;/A&gt;. November 2006.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;9&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Cost effectiveness of HIV testing&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17133193?ordinalpos=11&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients&lt;/A&gt;.&amp;nbsp; J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S113-8.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Krentz H, Gill M. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18643856?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006&lt;/A&gt;. HIV Med. 2008 Jul 17. [Epub ahead of print] PMID: 18643856 [PubMed - as supplied by publisher&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Krentz HB, Auld MC, Gill MJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15012648?ordinalpos=12&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;The high cost of medical care for patients who present late (CD4 &amp;lt;200 cells/microL) with HIV infection&lt;/A&gt;. HIV Med. 2004 Mar;5(2):93-8.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Tempio P, Holodniy M, Sanders GD, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Chavis D, Borowsky LH, Yano EM, Jensen P, Simberkoff MS, Bozzette SA. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17356961?ordinalpos=13&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV testing of at risk patients in a large integrated health care system&lt;/A&gt;. J Gen Intern Med 2007 Mar; 22(3):315-20.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, Freedberg KA. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17146064?ordinalpos=33&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs&lt;/A&gt;. Ann Intern Med. 2006 Dec 5;145(11):797-806. Summary for patients in: Ann Intern Med. 2006 Dec 5;145(11):I30.&amp;nbsp; PMID: 17146064 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18559840?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Cost-effectiveness of HIV screening in patients older than 55 years of age&lt;/A&gt;. Ann Intern Med. 2008 Jun 17;148(12):889-903&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15703422?ordinalpos=21&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy&lt;/A&gt;. N Engl J Med. 2005 Feb 10;352(6):570-85. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18784465?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV&lt;/A&gt;. AIDS. 2008 Oct 1;22(15):2025-33.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17063130?ordinalpos=21&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;The lifetime cost of current human immunodeficiency virus care in the United States&lt;/A&gt;. Med Care. 2006 Nov;44(11):990-7. Review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17288069?ordinalpos=16&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment&lt;/A&gt;. Health Care Financ Rev. 2005 Summer;26(4):67-80.&lt;BR&gt;PMID: 17288069 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Shrestha RK, Sansom SL, Richardson-Moore A, French PT, Scalco B, Lalota M, Llanas M, Stodola J, Mac Gowan R, Margolis A. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17704724?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Costs of Voluntary Rapid HIV Testing and Counseling in Jails in 4 States-Advancing HIV Prevention Demonstration Project, 2003-2006&lt;/A&gt;. Sex Transm Dis. 2007 Aug 16;Publish Ahead of Print. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Stone PW, Schackman BR, Neukermans CP, Olchanski N, Greenberg D, Rosen AB, Neumann PJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15919624?ordinalpos=29&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;A synthesis of cost-utility analysis literature in infectious disease&lt;/A&gt;. Lancet Infect Dis. 2005 Jun;5(6):383-91. Review. PMID: 15919624 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18190295?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Cost-effectiveness of HIV testing and treatment in the United States&lt;/A&gt;. Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S248-54.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14. Worthington C, Krentz HB. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16176627?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Socio-economic factors and health-related quality of life in adults living with HIV&lt;/A&gt;. Int J STD AIDS. 2005 Sep;16(9):608-14.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299200</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299200]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Serological Testing Algorithm for Recent HIV Seroconversion (STARHS)</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,NOV 08,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,HIV,MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on STAHRS for the Annual Evidence Update on Diagnosing HIV 2008</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Serological Testing Algorithm for Recent HIV Seroconversion (STARHS)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 height=150 alt="Pipetting into wells for an ELISA" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0005_shutterstock_3032853%5B1%5D3.jpg" width=200 align=right border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Summary of the evidence by &lt;A href="nelh:299203:4" name=internalLink&gt;Dr. Gary Murphy&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;H3&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The typically rapid immunological response to HIV infection means that within less than a month of anti-HIV seroconversion commencing, standard HIV test kits are unable to distinguish recent from long-standing infections.&amp;nbsp; However a number of adapted or novel techniques have been developed that are able to identify recent infection over a longer time frame, typically 3-6 months, than those achievable through the use of conventional assays.&amp;nbsp; These methods are intended to be applied to individual specimens in which the presence of anti-HIV-1 antibody has already been confirmed, and the approach is known generically as the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS). A number of different assays can be used within a STARHS programme and they work on many principles.&amp;nbsp; Some assays such as the detuned and BED ELISAs rely&amp;nbsp; primarily on antibody titre to differentiate recent from long-standing infection whereas others rely on the strength of the antibody/antigen bounding (avidity assays) or the relationship between reacitivities to different viral antigens or the presence/absence of antibodies to particular antigens.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are a number of limitations to STARHS assays. For example, none are licensed for clinical use and only one (The BED-CEIA) is commercially available.&amp;nbsp; It is recommended that the assays are only used on a population basis.&amp;nbsp; Furthermore, factors such as AIDS, treatment with antiretroviral drugs and infection with rare subtypes may lead to inaccurate results. However, the STARHS approach offers a number of important advantages over other methods for determining HIV incidence.&amp;nbsp; Unlike cohort studies which require repeated testing of individuals, and where results may be biased by people leaving the study, STARHS testing can be carried out retrospectively on stored single specimens from cross-sectional serosurveys.&amp;nbsp; In comparison with cohort studies, applying the STARHS approach is cheaper, quicker and simpler to perform. Furthermore, STARHS testing can be performed in real time thus allowing a measure of recent infection at the time of a study as opposed to incidence derived from a cohort study which cannot be ascertained until after the follow-up sample has been collected and tested. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence:  Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) - Technology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18594040?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Changes in the risk of death after HIV seroconversion compared with mortality in the general population&lt;/A&gt;. JAMA. 2008 Jul 2;300(1):51-9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Fisher M, Pao D, Murphy G, Dean G, McElborough D, Homer G, Parry JV. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18090279?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application&lt;/A&gt;. AIDS. 2007 Nov 12;21(17):2309-14.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18663213?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women&lt;/A&gt;. Am J Epidemiol. 2008 Sep 1;168(5):532-40. Epub 2008 Jul 28.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Kshatriya R, Cachafeiro AA, Kerr RJ, Nelson JA, Fiscus SA. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18685013?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Comparison of Two Rapid HIV Assays, Determine HIV-1/2 and OraQuick ADVANCE Rapid HIV-1/2 for Detecting Recent HIV Seroconversion&lt;/A&gt;. J Clin Microbiol. 2008 Aug 6. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Murphy G, Parry JV. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18775293?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Assays for the detection of recent infections with human immunodeficiency virus type 1&lt;/A&gt;. Euro Surveill. 2008 Sep 4;13(36). pii: 18966.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Semaille C, Barin F, Cazein F, Pillonel J, Lot F, Brand D, Plantier JC, Bernillon P, Le Vu S, Pinget R, Desenclos JC. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17597452?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France&lt;/A&gt;. J Infect Dis. 2007 Aug 1;196(3):377-83. Epub 2007 Jun 19.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. &lt;A href="http://www.eurosurveillance.org/Public/PressReleases/ViewPressRelease.aspx?PressReleaseId=9" target="_blank"&gt;STARHS (Serological Testing Algorithms for Recent (HIV Seroconversion) - progress towards estimating new HIV infections in Europe&lt;/A&gt;. 04 September 2008 Eurosurveillance (Vol 13, issue 36, 4/9/8)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence:  Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) - Application&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Barin F, Nardone A. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18775294?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Monitoring HIV epidemiology using assays for recent infection: where are we?&lt;/A&gt; Euro Surveill. 2008 Sep 4;13(36). pii: 18967. No abstract available. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18594040?ordinalpos=24&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Changes in the risk of death after HIV seroconversion compared with mortality in the general population&lt;/A&gt;. JAMA. 2008 Jul 2;300(1):51-9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Fisher M, Pao D, Murphy G, Dean G, McElborough D, Homer G, Parry JV. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18090279?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application&lt;/A&gt;. AIDS. 2007 Nov 12;21(17):2309-14.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, Gezahegne S, van 't Wout AB, Jacobson LP, Margolick JB, Mullins JI. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18419538?ordinalpos=96&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study&lt;/A&gt;. J Infect Dis. 2008 Apr 1;197(7):1011-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan EH, McKenna MT, Janssen RS; HIV Incidence Surveillance Group. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18677024?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Estimation of HIV incidence in the United States&lt;/A&gt;. JAMA. 2008 Aug 6;300(5):520-9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Hollingsworth TD, Anderson RM, Fraser C. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18662132?ordinalpos=10&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV-1 Transmission, by Stage of Infection&lt;/A&gt;. J Infect Dis. 2008 Jul 28. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Pillonel J, Barin F, Laperche S, Bernillon P, Le Vu S, Brunet S, Thierry D, Desenclos JC; Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18482193?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections&lt;/A&gt;. Transfusion. 2008 Aug;48(8):1567-75. Epub 2008 May 14.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Rice B, Nardone A, Gill N, Delpech V. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18445455?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Continuing high levels of HIV diagnoses in men who have sex with men in the United Kingdom&lt;/A&gt;. Euro Surveill. 2008 Apr 3;13(14). pii: 8085. No abstract available. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Sudarshi D, Pao D, Murphy G, Parry J, Dean G, Fisher M. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17971369?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Missed &lt;/A&gt;9: Sudarshi D, Pao D, Murphy G, Parry J, Dean G, Fisher M. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17971369?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Missed opportunities for diagnosing primary HIV infection&lt;/A&gt;. Sex Transm Infect. 2008 Feb;84(1):14-6. Epub 2007 Oct 30.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299204</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299204]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Useful Websites</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,NOV 08,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV,MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A list of useful websites for the Annual Evidence Update on Diagnosing HIV 2008</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2008 Annual Evidence Update: Diagnosing HIV - Useful Websites&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage2 style="WIDTH: 228px; HEIGHT: 167px" height=334 alt="Woman sitting at a laptop" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0010_shutterstock_4474720%5B1%5D.JPG" width=500 align=right border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.worldaidsday.org/" target="_blank"&gt;World AIDS Day 2008&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.bhiva.org/" target="_blank"&gt;The British HIV Association&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.bashh.org/" target="_blank"&gt;The British Association for Sexual Health and HIV&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.britishinfectionsociety.org/" target="_blank"&gt;The British Infection Society&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.who.int/hiv/en/" target="_blank"&gt;World Health Organization pages on HIV/AIDS&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.medfash.org.uk/" target="_blank"&gt;Medical Foundation for AIDS &amp;amp; Sexual Health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.hpa.org.uk/webw/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1191942172118?p=1191942172118" target="_blank"&gt;The Health Protection Agency: HIV and STIs&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.hpa.org.uk/webw/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200660065903?p=1200660065903" target="_blank"&gt;The Health Protection Agency: HIV &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:299385:0" name=internalLink&gt;&lt;EM&gt;Return to the AEU homepage&lt;/EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299170</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=299170]]&gt;</url>
    <title>2008 Annual Evidence Update: Diagnosing HIV - Virological Methods</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,NOV 08,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS,HIV]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on virological methods for the Annual Evidence Update on Diagnosing HIV 2008</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Virological Methods&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage0 style="WIDTH: 175px; HEIGHT: 160px" height=188 alt="HIV viruses surrounded by red blood cells" hspace=10 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID298149/nelhImp_0002_shutterstock_2578409%5B1%5Dhiv2.jpg" width=250 align=right vspace=10 border=1 name=nelh_tempImage0&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Summary of the evidence by &lt;A href="nelh:299203:3" name=internalLink&gt;&lt;EM&gt;Professor Deenan Pillay&lt;/EM&gt;&amp;nbsp;&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Viral Load&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In the mid 1990s the quantification of viral genome in plasma of HIV infected individuals was demonstrated to correlate with clinical prognosis, independent of CD4 cell count. Such viral load levels may reach many millions of RNA copies/ml in an untreated individual. Laboratory methods were rapidly developed in order to provide such testing, which became central to management. In particular, HIV viral load testing is used to monitor the effectiveness of antiretroviral therapy. In general, viral load levels are expected to reach undetectable levels (currently &amp;lt;50 copies viral RNA/ml of plasma) within 12 weeks of initiating treatment. Should viral load rise during treatment on at least two occasions, the patient has undergone virological failure. At this time, resistance testing is undertaken on plasma virus (generally undertaken by nucleic acid sequencing of the virus) to guide next therapy. The meaning of very low level viraemia (typically remaining at &amp;lt;500 c/ml) has been the subject of considerable research. Some feel that these “blips” may predict future failure, whereas others feel they are more a function of laboratory assay variability. A single blip is generally felt to be insignificant. The efficacy of treatment is now very good, due to better formulations of drugs, and good adherence support, and within the UK, reaches around 90% after one year of those starting therapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In the developing world, the lack of laboratory infrastructure limits the degree to which viral load monitoring can be undertaken. This means that 1st to 2nd line treatment switch is guided by clinical progression (e.g. new AIDS defining events) rather than viral rebound. Whilst not negating the very significant benefits of antiretroviral rollout, this may increase the degree of drug resistance emerging on 1st line therapy. The degree to which this compromises the response to 2nd line therapy in this setting remains a research priority. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Viral load testing has also been proposed as a method for detecting early HIV infection, prior to the development of antibodies- the period of days to weeks immediately after infection, known as the window period, when virus is present in the blood. Thus, some investigators propose pooling plasma samples from high risk individuals (to reduce the cost) without antibodies, and then test pools for viral load. This method identifies such infections in comparison to older generation antibody tests. However, the potential for improved diagnosis over the 4th generation assays widely used in the UK (assays which detect antibody and/or virus antigen) is limited. The recent UK guidelines for expansion of HIV testing suggest that 4th generation tests should be the standard of care. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Phylogenetic analysis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This is a method by which HIV-1 genetic sequences can be utilised to identify relatedness between viruses. As such, it takes advantage of the capacity for HIV-1 to rapidly evolve (mutate). This method has been useful to identify the likelihood that individuals are linked regarding infection, and also how transmission clusters within the population develop. Finally, this method of analysis is central to our ideas of the origin of HIV within the human population, and the time of entry into the population from chimpanzees. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;HIV Drug Resistance&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;HIV-1 rapidly mutates and selection of viruses is according to the principles of evolution. Some mutants confer resistance to antiretroviral drugs. Treatment whilst virus replication continues selects for ever increasing resistance. Such resistance not only compromises the efficacy of therapy but can also be transmitted to others. The rate of transmission reaches 10% in some populations.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Epidemiology and Transmission&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Archer J, Robertson DL.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17690566?ordinalpos=10&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Understanding the diversification of HIV-1 groups M and O&lt;/A&gt;.&amp;nbsp; AIDS. 2007 Aug 20;21(13):1693-700.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Bailey JR, O'Connell K, Yang HC, Han Y, Xu J, Jilek B, Williams TM, Ray SC, Siliciano RF, Blankson JN. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18495769?ordinalpos=13&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor&lt;/A&gt;. J Virol. 2008 Aug;82(15):7395-410. Epub 2008 May 21.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Brumme CJ, Harrigan PR, Preston EC, Dong WW, Wynhoven B, Murphy C, Montaner JS. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18018773?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Transmission of drug-resistant HIV-1 from an infected individual to a caregiver&lt;/A&gt;. Antivir Ther. 2007;12(7):1139-44.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Katzenstein TL, Petersen AB, Jørgensen LB, Strand TJ, Madsen TV, Gerstoft J. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18671456?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Seventeen-Year-Old Mother-to-Child HIV Type 1 Transmission Identified by Phylogeny and Signature Patterns&lt;/A&gt;. AIDS Res Hum Retroviruses. 2008 Jul 31. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Kaye M, Chibo D, Birch C. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18667928?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Phylogenetic Investigation of Transmission Pathways of Drug-Resistant HIV-1 Utilizing Pol Sequences Derived From Resistance Genotyping&lt;/A&gt;. J Acquir Immune Defic Syndr. 2008 Jul 23. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;de Oliveira T, Rambaut A, Pybus OG, Dunn D, Vandamme AM, Kellam P, Pillay D. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17898057?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Phylogenetic Surveillance of Viral Genetic Diversity and the Evolving Molecular Epidemiology of HIV-1&lt;/A&gt;.&amp;nbsp; J Virol 2007 81(23):13050-6&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/infections/Page.aspx?prv=y&amp;amp;pagename=HIVAEU" target="_blank"&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Antiretroviral resistance&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, Schuurman R, Pillay D, Morris L, Tanuri A, Gershy-Damet GM, Nkengasong J, Gilks CF, Sutherland D, Sandstrom P.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18575191?ordinalpos=69&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;World Health Organization/HIVResNet Drug Resistance Laboratory Strategy&lt;/A&gt;. Antivir Ther. 2008;13 Suppl 2:49-57.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Cane P, Kaye S, Smit E, Tilston P, Kirk S, Shepherd J, Hopkins M, Zhang H, Geretti A. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18557948?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Genotypic antiretroviral drug resistance testing at low viral loads in the UK&lt;/A&gt;. HIV Med. 2008 Jun 16. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Chen TK, Aldrovandi GM. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18664987?ordinalpos=18&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Review of HIV antiretroviral drug resistance&lt;/A&gt;. Pediatr Infect Dis J. 2008 Aug;27(8):749-52. No abstract available.&amp;nbsp;PMID: 18664987 [PubMed - in process]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18650513?ordinalpos=24&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection&lt;/A&gt;. N Engl J Med. 2008 Jul 24;359(4):355-65. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD; EuroSIDA Study Group. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832882?ordinalpos=6&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study&lt;/A&gt;. AIDS. 2008 Oct 18;22(16):2187-98.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study Steering Committee. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18199172?ordinalpos=16&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK&lt;/A&gt;.&lt;BR&gt;HIV Med. 2008 Jan;9(1):47-56&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832245?ordinalpos=10&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection&lt;/A&gt;. N Engl J Med. 2008 Oct 2;359(14):1442-55. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT; on behalf of the UK Collaborative Group on HIV Drug Resistance1. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18769348?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;The Impact of Different Definitions on the Estimated Rate of Transmitted HIV Drug Resistance in the United Kingdom&lt;/A&gt;. J Acquir Immune Defic Syndr. 2008 Sep 2. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, Phillips A, Allen E, Pillay D; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC).&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222956?ordinalpos=48&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;What is the risk of mortality following diagnosis of multidrug-resistant HIV-1&lt;/A&gt;?&amp;nbsp; J Antimicrob Chemother. 2008 Mar;61(3):705-13. Epub 2008 Jan 25.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Gupta R, Hill A, Sawyer AW, Pillay D. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18662137?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials&lt;/A&gt;. Clin Infect Dis. 2008 Sep 1;47(5):712-22.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18549313?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel&lt;/A&gt;. Clin Infect Dis. 2008 Jul 15;47(2):266-85.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18650512?ordinalpos=60&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Raltegravir with optimized background therapy for resistant HIV-1 infection&lt;/A&gt;. N Engl J Med. 2008 Jul 24;359(4):339-54. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832873?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen&amp;nbsp; modification&lt;/A&gt;. AIDS. 2008 Oct 18;22(16):2097-106.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;15. Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B; ANRS CO3 Aquitaine Cohort. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18614864?ordinalpos=41&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy&lt;/A&gt;. AIDS. 2008 Jul 31;22(12):1417-23.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA; CEPAC International Investigators. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17457091?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;HIV drug resistance surveillance for prioritizing treatment in resource-limited settings&lt;/A&gt;. AIDS. 2007 May 11;21(8):973-82&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;17. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18666824?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment – Naïve Populations and Associate with Reduced Treatment Efficacy&lt;/A&gt;. PLoS Med 2008 Jul 29;5(7):e158&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Viral Testing&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Technology&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Baggaley, R. &lt;A href="http://www.medfash.org.uk/publications/documents/HIV_for_non_HIV_specialists.pdf" target="_blank"&gt;HIV for non-HIV specialists- Diagnosing the undiagnosed&lt;/A&gt;. Medical Foundation for AIDS and Sexual Health 2008 Sept 17.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;2. Dodds C, Hickson F, Weatherburn P, Reid D, Hammond G, Jessup K, Adegbite G. &lt;A href="http://www.sigmaresearch.org.uk/files/report2008b.pdf" target="_blank"&gt;BASS Line 2007: Assessing the sexual HIV prevention needs of African people in England&lt;/A&gt;. Original report, July 2008. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Pereira RS. &lt;A href="http://www.medicine.ox.ac.uk/bandolier/bandopubs/bandocon5/Pereira.html" target="_blank"&gt;Viral load testing: which test for what?&lt;/A&gt; Bandolier, January 2004&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. Klausner JD, Grant RM, Kent CK, Turner VF, Pilcher CD, Leone PA. &lt;A href="http://content.nejm.org/cgi/content/short/353/6/631" target="_blank"&gt;Detection of acute HIV infections&lt;/A&gt;. New England Journal of Medicine, 11 August 2005, vol./is. 353/6(631-633)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Mylonakis E, Paliou M, Rich JD. &lt;A href="http://www.aafp.org/afp/20010201/483.pdf" target="_blank"&gt;Plasma viral load testing in the management of HIV infection&lt;/A&gt;. American Family Physician, February 2001, vol./is. 63/3(483-90, 495-6), 0002-838X.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Application&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18440426?ordinalpos=19&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model&lt;/A&gt;. Lancet. 2008 Apr 26;371(9622):1443-51. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Boily MC, Abu-Raddad L, Desai K, Masse B, Self S, Anderson R. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18291341?ordinalpos=39&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Measuring the public-health impact of candidate HIV vaccines as part of the licensing process&lt;/A&gt;. Lancet Infect Dis. 2008 Mar;8(3):200-7.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Langford SE, Ananworanich J, Cooper DA. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17502001?ordinalpos=10&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Predictors of disease progression in HIV infection: a review&lt;/A&gt;. AIDS Res Ther. 2007 May 14;4:11. PMID: 17502001 [PubMed]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Jones LE, Perelson AS. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17496565?ordinalpos=11&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy&lt;/A&gt;. J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):483-93.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18190257?ordinalpos=6&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia&lt;/A&gt;.&lt;BR&gt;J Infect Dis. 2007 Dec 15;196(12):1773-8. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.Gallant JE. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18190251?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Making sense of blips&lt;/A&gt;. J Infect Dis. 2007 Dec 15;196(12):1729-31. No abstract available. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. García-Gascó P, Maida I, Blanco F, Barreiro P, Martín-Carbonero L, Vispo E, González-Lahoz J, Soriano V. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18192682?ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome&lt;/A&gt;. J Antimicrob Chemother. 2008 Mar;61(3):699-704. Epub 2008 Jan 12.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;Return to the AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330997</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=330997]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - Commentaries</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,CHILDREN,POPULATION GROUPS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,NOV 09,ADOLESCENTS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Expert commentaries for the Annual Evidence Update on HIV in children and adolescents</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: HIV in children and adolescents - Commentaries&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0007_44_7D9B19F33_HIVAEU09-MainTitle600.jpg" width=600&gt;&lt;/P&gt;
&lt;P&gt;The following &lt;A href="nelh:331000:1" name=internalLink&gt;experts &lt;/A&gt;have written commentaries about aspects of&amp;nbsp;HIV in children and adolescents. These are also provided alongside the relevant subtopic on the &lt;A href="nelh:330262:1" name=internalLink&gt;Annual Evidence Update homepage&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330997:2" name=internalLink&gt;Introduction &lt;/A&gt;by &lt;A href="nelh:331000:2" name=internalLink&gt;Dr. Valerie Delpech&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330326:1" name=internalLink&gt;Management of HIV&lt;/A&gt; by &lt;A href="nelh:331000:3" name=internalLink&gt;Dr. Caroline Foster&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330316:1" name=internalLink&gt;HIV Testing and Prevention Interventions&lt;/A&gt; by &lt;A href="nelh:331000:4" name=internalLink&gt;Dr. Paddy McMaster&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330323:0" name=internalLink&gt;Mother to Child Transmission&lt;/A&gt; by &lt;A href="nelh:331000:5" name=internalLink&gt;Dr. Pat Tookey&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330997:7" name=internalLink&gt;HIV and AIDS in Children in Continental Europe&lt;/A&gt; by &lt;A href="nelh:331000:6" name=internalLink&gt;Prof. Angus Nicoll&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331000:2" name=internalLink&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0007_44_7D9B19F33_HIVAEU09-MainTitle600.jpg" width=600&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt; by &lt;A href="nelh:331000:2" name=internalLink&gt;&lt;STRONG&gt;Dr. Valerie Delpech&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=justify&gt;This Annual Evidence Update (AEU)&amp;nbsp;provides a collection of evidence that has emerged over the last twelve months on HIV in children and adolescents&amp;nbsp;accompanied by &lt;A href="nelh:330997:1" name=internalLink&gt;commentaries &lt;/A&gt;from &lt;A href="nelh:331000:1" name=internalLink&gt;experts&lt;/A&gt;. The launch of this AEU coincides with this week’s release of the&amp;nbsp;&lt;A href="nelh:331155:1" name=internalLink&gt;AIDS epidemic update 2009 &lt;/A&gt;by UNAIDS and the WHO&amp;nbsp;and the &lt;A href="nelh:331512:1" name=internalLink&gt;Health Protection Agency’s latest report on the UK’s HIV epidemic&lt;/A&gt;&amp;nbsp;– in time for &lt;A href="http://www.worldaidsday.org/" target="_blank"&gt;World AIDS day &lt;/A&gt;on the 1st of December. Links to &lt;A href="nelh:330322:1" name=internalLink&gt;useful websites&lt;/A&gt; are also provided.&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=justify&gt;In 2008 an estimated 33.4 million, [31.1 million–35.8 million] people were living with HIV, a figure higher than ever before as people are living longer due to the beneficial effects of antiretroviral therapy and population growth. There is however some good news with an apparent 10% decline in AIDS-related deaths over the past five years achieved primarily through better access to antiretroviral therapy. UNAIDS and WHO estimate that since the availability of effective treatment in 1996, some 2.9 million lives have been saved. Nevertheless there were a staggering 2.7 million new infections of HIV in 2008 globally, and almost half a million of these were among children under 15. Without treatment, approximately half of the children infected through mother to child transmission (MTCT) will die by the age of 2 (1).&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=justify&gt;Importantly, antiretroviral therapy has also made a significant impact in preventing new infections in children as more HIV-positive mothers gain access to treatment preventing them from transmitting the virus to their children. An estimated 200,000 new infections among children have been prevented since 2001. For example, in Botswana – one of the countries most hit by the epidemic – efforts to accelerate antiretroviral coverage (now estimated at 80%) has resulted in a 50% decrease in AIDS-related deaths in the past five years and the number of children newly orphaned is also coming down as parents are living longer. The UNAIDS report also highlights the significant impact of HIV on maternal mortality with an estimated 50,000 maternal deaths in South Africa alone directly related to HIV infection in 2008. The report calls for "a unified health approach bringing maternal and child health and HIV programmes as well as tuberculosis programmes together to work to achieve their common goal."&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=justify&gt;The situation in the United Kingdom is clearly very different and underscores the successes of antenatal screening of pregnant women and good access to antiretroviral therapy for those diagnosed with HIV. The &lt;A href="nelh:331512:1" name=internalLink&gt;latest HPA report on the UK’s HIV epidemic &lt;/A&gt;shows that the uptake of HIV screening in the antenatal setting has reached over 95% resulting in very low MTCT transmission in the UK. &lt;A href="nelh:331000:5" name=internalLink&gt;Dr. Pat Tookey &lt;/A&gt;from the Institute of Child Health provides us with further insight into our successes in preventing MTCT in the United Kingdom.&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=justify&gt;As a result of effective treatment, many of the children infected through MTCT are now entering adolescence and are therefore transitioning from paediatric to adult services. &lt;A href="nelh:331000:3" name=internalLink&gt;Dr. Caroline Foster &lt;/A&gt;from Imperial College Healthcare NHS Trust provides us with an insight into the complexities of managing HIV in children and adolescents. This transitional period not only offers clinical but also important psychosocial challenges such as the fear of disclosure and the right to a healthy sexual and reproductive life.&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=justify&gt;Finally, whilst there have been real successes in tackling the HIV epidemic in the UK, challenges remain. An estimated one third of the 7,298 people diagnosed in 2008 presented late in the course of their illness. These individuals contributed to half of all deaths in HIV infected individuals in 2008. Furthermore over a quarter of the estimated 83,000 people living with HIV in the UK are unaware of their infection (HPA report). There is therefore a need to maintain high levels of testing in the antenatal and STI clinic settings as well as expand the offer of HIV testing in other clinical and non-clinical setting. The &lt;A href="http://www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf" target="_blank"&gt;Guidelines for HIV Testing 2008 &lt;/A&gt;produced by the British Association for Sexual Health and HIV (BASHH), the British HIV Association (BHIVA) and the British Infection Society (BIS) which recommend testing in a range of settings and most at risk populations were therefore a very welcome addition. &lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=justify&gt;&lt;A href="nelh:331000:4" name=internalLink&gt;Dr. Paddy McMaster&lt;/A&gt; from The University Hospital of North Staffordshire builds on this momentum and highlights that "the future of HIV testing is in the acceptance of it as a routine screen rather than the remit of the specialist." To this end, health professionals are likely to find the Medical Foundation for AIDS &amp;amp; Sexual Health (MedFASH) report ‘&lt;A href="nelh:296294:1" name=internalLink&gt;HIV for non-HIV specialists: diagnosing the undiagnosed&lt;/A&gt;’ helpful in offering a HIV test as part of routine screening when diagnosing their patients. &lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;UNAIDS, &lt;A href="nelh:331155:1" name=internalLink&gt;AIDS epidemic update 2009&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Health Protection Agency, &lt;A href="nelh:331512:0" name=internalLink&gt;HIV in the United Kingdom: 2009 Report&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;MedFASH, &lt;A href="nelh:296294:1" name=internalLink&gt;HIV for non-HIV specialists: diagnosing the undiagnosed &lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331000:2" name=internalLink&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Management of HIV&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330326/nelhImp_0000_44_7D9B19F37_HIVAEU09-PT-M.jpg" width=620&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Commentary &lt;/STRONG&gt;by &lt;A href="nelh:331000:3" name=internalLink&gt;&lt;STRONG&gt;Dr. Caroline Foster&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;World wide, over 2 million of the estimated 33 million people living with HIV are children, the vast majority living in sub-Saharan Africa. In addition there are an estimated 15 million children orphaned due to the AIDS epidemic and over half of all new HIV infections are in young people aged 15 to 24 years. In well resourced setting with access to antiretroviral therapy (ART), the introduction of Highly Active Antiretroviral therapy (HAART) has substantially reduced HIV- associated morbidity and mortality in children and hence perinatally acquired HIV-1 infection has become a chronic disease of childhood. In Europe, prior to the introduction of HAART, half of HIV-infected children died before their tenth birthday. Currently, due to high uptake of antenatal testing, reduced transmission rates in diagnosed women and improved survival following HAART, the average age of perinatally infected children living in the UK is now over 10. Consequently increasing numbers of perinatally infected children are entering adolescence and transitioning from paediatric to adult services. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Adolescence and the period of transition can be complex for many young people living with a chronic disease of childhood, with suboptimal attendance and adherence to therapy resulting in an increase in disease related morbidity and mortality. Poor adherence to antiretroviral therapy leads to virological failure, immunosuppression and the risk of development of virological resistance. The balance between maintaining current immunological function and clinical well being against the risk of acquiring further resistance mutations on failing regimens that will limit future treatment options is complex. Many young people with perinatally acquired HIV have extensive treatment histories and often do not have once daily low pill burden options, that are easier to adhere to, available. A small proportion have multidrug resistance and require new drugs in development, highlighting the need for equal access and adequate pharmacokinetic data in paediatric and adolescent populations. Although prognosis is vastly improved in the HAART era, holistic palliative care is required for young people with endstage HIV disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Whilst the enormous benefits of HAART should not be underestimated, the medium-term side effects of exposure to antiretrovirals are progressively apparent in a population who, following recent evidence to support the earlier initiation of HAART in both infants and adults, are increasingly exposed to antiretrovirals throughout postnatal growth and development. Dyslipidaemia, lipodystrophy and mitochondrial toxicity are reported, however their longer term impact is unknown, although concern exists particularly around future cardiovascular health and highlights the importance of health promotion, particularly the avoidance of smoking and obesity in this group. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;HIV is associated with delayed growth and puberty, and reduced bone mineralization, raising the concern of osteoporosis in later life. The impact of HIV on the developing brain is of continuing concern with recent reports of increased rates of neurocognitive impairment, psychiatric illness and behavioural disorders in adolescents with HIV requiring further elucidation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;HIV adds its own complexities to living with a chronic disease, that of stigma and secrecy, the majority of young people having never disclosed their status beyond their immediate family. In addition some adolescents will have lost one or both parents, siblings and other family members to HIV- related disease. Many have been born abroad and most come from diverse ethnic minority backgrounds. Being born with a sexually transmissible disease before one has ever had sex and the psychological issues around onward transmission and partner disclosure can be challenging for young people to manage and requires comprehensive ongoing multidisciplinary education and support. The potential impact of life long HIV infection with prolonged exposure to antiretroviral therapy on fertility is uncertain, however young adults themselves born with HIV are beginning to have children of their own, the vast majority of whom are healthy infants uninfected with HIV. The long-term follow up of this unique cohort is required if we are able to improve outcomes for children living with HIV, particularly as the role out of ART in sub-Saharan Africa continues to grow giving more children the opportunity of a future.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;HIV Testing and Prevention Interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330316/nelhImp_0000_44_7D9B19F39_HIVAEU09-PT-TaPI.jpg" width=620&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary &lt;/STRONG&gt;by &lt;A href="nelh:331000:4" name=internalLink&gt;&lt;STRONG&gt;Dr. Paddy McMaster&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There have been great advances in HIV but these depend upon the diagnosis having been made first. With antiretrovirals we now expect a long healthy life. Women with HIV can now have babies, confident that there are minimal risks of HIV transmission to their babies with appropriate management in pregnancy. Without knowing the diagnosis, children are presenting with life threatening opportunistic infections and babies are being avoidably infected. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Antenatal testing has resulted in one of the most satisfying advances in HIV medicine. From about ¼ of babies born to mothers with HIV becoming infected, it is now less than 1%. Antenatal testing has been well accepted and in most areas in UK it is over 95% coverage. However there are still babies being born to mothers with HIV. The NSHPC audit on Perinatal Transmission of HIV 2002-2005 gives recommendations for antenatal, perinatal and postnatal care to prevent further infections occurring. The British HIV Association lays out clear guidelines for the management of the mother and infant. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;On the basis of universal antenatal testing being recommended, those who have missed that opportunity in the past should be offered testing now. This can be achieved by enquiring about antenatal screening at any encounter with health professionals. Children are often diagnosed after several events have already been missed which could have triggered testing. Opportunistic infections with unusual organisms and frequent or severe infections with common organisms should stimulate testing. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The future of HIV testing is in the acceptance of it as a routine screen rather than the remit of the specialist. Prevention of sexual transmission is becoming relevant at ever younger ages and this needs to be addressed by health professionals seeing adolescents. &lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Mother to Child Transmission&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330323/nelhImp_0002_44_7D9B19F39_HIVAEU09-PT-MtCT600.jpg" width=620&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary &lt;/STRONG&gt;by &lt;A href="nelh:331000:5" name=internalLink&gt;&lt;STRONG&gt;Dr. Pat Tookey&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Worldwide an estimated 1200 children acquire HIV every day (420,000 new infections per year), the vast majority of them as a result of mother to child transmission (MTCT) of infection.&amp;nbsp; MTCT is now relatively uncommon in high-income settings, where antenatal screening is widely offered and antiretroviral drugs (ART) and safe alternatives to breast feeding are generally available. However, over 90% of the 1.4 million pregnant women living with HIV who gave birth in 2008 live in low and middle income countries, according to the 2009 ‘&lt;A href="nelh:331377:1" name=internalLink&gt;Towards universal access progress report’&lt;/A&gt;, published by WHO, UNICEF and UNAIDS. In these settings, although there has been a moderate increase in the proportion of women tested in pregnancy, it is still only a minority: 28% of pregnant women in Sub-Saharan Africa, where the vast majority of infected women live, are thought to have been tested in 2008. Less than half (45%) of HIV-infected pregnant women in low and middle income countries received ART to reduce the risk of MTCT, and in about 30% of cases this was only a single-dose regimen. Early testing of infants to establish infection status and provide treatment where required remains the exception rather than the rule. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Transmission through breastfeeding contributes substantially to MTCT in countries where avoidance of breastfeeding is unsafe or unaffordable (1, 2). Exclusive breastfeeding during the first few months of life, ART prophylaxis for breast fed infants for the duration of breastfeeding, and ART for breastfeeding women themselves are all effective interventions for reducing the risk of late postnatal MTCT in these circumstances; nevertheless, substantial support for exclusive breastfeeding is necessary, and there are concerns about nevirapine resistance among infants who become infected despite extended prophylaxis. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In the UK, thanks to high uptake of antenatal HIV screening (accepted by over 90% of pregnant women since 2006) at least 90% of women living with HIV infection are currently diagnosed prior to delivery. Over 1300 births to diagnosed infected women in 2008 have been reported through the routine surveillance systems by the &lt;A href="http://www.nshpc.ucl.ac.uk/" target="_blank"&gt;National Study of HIV in Pregnancy and Childhood (NSHPC)&lt;/A&gt; with an MTCT rate of about 1% overall (3). About two-thirds of those women were already aware of their HIV status before conception, with many diagnosed in a previous pregnancy. HIV infected women are living in all regions and countries of the UK, and most NHS Trusts offering maternity care now manage HIV infected pregnant women. Comprehensive guidelines on &lt;A href="http://www.bhiva.org/documents/Guidelines/Pregnancy/2008/PregnancyPub.pdf" target="_blank"&gt;management of HIV in pregnancy &lt;/A&gt;were updated in 2008 (4). Although monotherapy remains an option for pregnant women who do not yet require ART for their own health, and are willing to have a caesarean section delivery, 95% of women take combination therapy, and an increasing proportion of those who achieve viral suppression opt for a planned vaginal delivery. This does present challenges however as the actual timing and duration of labour is unpredictable, there is uncertainty about whether prolonged rupture of membranes presents a risk in these circumstances, and this and other obstetric complications can lead to an increased proportion of emergency caesarean sections. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In addition to the few infants who are infected despite maternal diagnosis prior to delivery, a small number of UK-born children whose mothers were not previously known to be infected are diagnosed with vertically acquired infection each year. These children do not all present in infancy – recent data suggests those who do are likely to represent only a third to a half of the total number.&amp;nbsp; Although some women remain undiagnosed because they decline antenatal testing, or are not tested for some other reason, some mothers of infected children have had a negative test result antenatally. They must have seroconverted during pregnancy, or indeed acquired infection after their baby’s birth while they were still breastfeeding. The relative contribution of undiagnosed maternal infection acquired before pregnancy, seroconversion in pregnancy, and seroconversion in the postnatal period, to infant infections in the UK is currently unclear. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Further reductions in the overall rate of MTCT in the UK are likely to be achieved by facilitating earlier diagnosis of HIV-infected women (preferably prior to conception), maximising antenatal test uptake rates, optimising clinical management, and identifying women who seroconvert in pregnancy or in the early months of motherhood in order to prevent transmissions through breastfeeding. Women with resistant virus, concurrent infections, and difficult family circumstances are in particular need of tailored support and management, as are the small but increasing number of vertically infected young women who are becoming pregnant, or looking forward to doing so. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;:&lt;/P&gt;
&lt;P&gt;1. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. &lt;A href="nelh:304933:1" name=internalLink&gt;Interventions for preventing late postnatal mother-to-child transmission of HIV&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006734. DOI: 10.1002/14651858.CD006734.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Coovadia H. &lt;A href="nelh:330559:1" name=internalLink&gt;Current issues in prevention of mother-to-child transmission of HIV-1&lt;/A&gt;. Current Opinion in HIV and AIDS, July 2009, vol./is. 4/4(319-324), 1746-630X;1746-6318&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. &lt;A href="nelh:330463:1" name=internalLink&gt;Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007&lt;/A&gt;. AIDS. 2009 Feb 20;23(4):519-24.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp;de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, Gilling-Smith C, Hawkins D, Low-Beer N, Lyall H, O'Shea S, Penn Z, Short J, Smith R, Sonecha S, Tookey P, Wood C, Taylor G. &lt;A href="http://www3.interscience.wiley.com/journal/121377309/abstract" target="_blank"&gt;British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008&lt;/A&gt;. HIV Med. 2008 Aug;9(7):452-502.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;HIV and AIDS in Children in Continental Europe&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330997/nelhImp_0000_44_7D9B1B117_HIVAEU09-PT4.jpg" width=620&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary &lt;/STRONG&gt;by &lt;A href="nelh:331000:6" name=internalLink&gt;&lt;STRONG&gt;Prof. Angus Nicoll&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The European Centre for Disease Prevention and Control (ECDC) and WHO’s Regional Office for Europe have recently published their &lt;A href="nelh:331570:1" name=internalLink&gt;annual review of the epidemiology of HIV and AIDS &lt;/A&gt;across WHO’s European Region, a vast area which runs from the Atlantic to the Pacific.+ (1)&amp;nbsp; While there is little&amp;nbsp; consideration of children in the text report&amp;nbsp; (overall reports of HIV and AIDS in children (persons under age 16) or acquired through mother to child transmission (MTCT) represent a very small proportion of the totals of both conditions) there are some telling statistics in the final tables. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The geographical distribution of infection in children remains highly heterogeneous.&amp;nbsp; In the European Union countries a handful of countries (France, German, Ireland, Latvia, the Netherlands and the UK account for the majority of cases through MTCT).&amp;nbsp; Such varying distribution is also the case in the rest of the WHO European Region with most of the cases of paediatric AIDS diagnosed in only a few countries:&amp;nbsp; Belarus, Georgia, Kazakhstan, Kyrgyzstan, Uzbekistan and especially the Ukraine (data are lacking for the most populous country Russia). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ukraine has by far the highest estimated prevalence if HIV infection in Europe.(2) There have been&amp;nbsp; noticeable rises in the incidence of AIDS attributed to MTCT in Europe’s Central and Eastern Areas+ where those countries are. The forces driving the infections in the children are distinct. In the European Union countries, notably in France and the UK these are predominately infections in populations that come from or have spent time in sub-Saharan Africa.&amp;nbsp; In Latvia and Ireland the association is more with groups of parents that have injected drugs. In the Central and Eastern Areas of Europe the infections in children are mostly associated with injecting drug use by mothers or through heterosexual transmission to them from drug injecting male partners.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Considering the Central and Eastern Area of the WHO Region there have been strenuous efforts in recent years to diagnose HIV infection and get adults and children onto treatment, much of this supported by external funding (the Global Fund to Fight AIDS, Tuberculosis and Malaria and the US President’s Emergency Plan for AIDS Relief – PEPFAR).&amp;nbsp; Impressive statistics are quoted in this year's progress reports from WHO, UNAIDS and UNICEF with rising percentages of those children and adults infected being on regular treatment in the middle and low resource countries (see Figure 1), (3,4). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Some caution should be expressed in these figures but progress has certainly been made.&amp;nbsp; The particular importance of diagnosing and treating women and especially pregnant women being that this will prevent subsequent paediatric infections. The difficulties come though for the infected children and adults with what is then a lifelong infection.(5) Externally supported funding will eventually cease and their care will depend on the health care system's ability to support chronic conditions. Here the prospects are less clear across the region given very mixed results of health service delivery and funding reform. (6)&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Figure 1: Statistics quoted in reference 4&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;In 2008, 85,000 people were receiving ART in Europe and Central Asia, compared to 54 000 in 2007, an increase of 57%.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Antiretroviral treatment (ART) coverage among low- and middle income countries in the region was 23% in 2008, up from 16% in 2007.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;An estimated 94% of HIV-positive pregnant women in this region received antiretroviral drugs to prevent mother-to-child HIV transmission, up from 74% in 2007.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;The number of children receiving ART rose from 3000 in 2007 to 4200, representing approximately 85% of those in need.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;At the end of 2008, the following low or middle income countries in the WHO European region are estimated to have reached the United Nations General Assembly Special Session on HIV/AIDS target for preventing mother to-child transmission of HIV by ensuring that at least 80% of pregnant women living with HIV were on ART therapy Belarus,&amp;nbsp; Georgia, Kazakhstan, Latvia, Lithuania, Republic of Moldova, Russian Federation and the Ukraine.&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;+ WHO divides its European Region into three; Eastern Countries those that were in the former USSR including Russia, Central&amp;nbsp; Europe broadly corresponding to the countries that were under Soviet influence prior to 1990 plus Turkey and Cyprus and Western Europe .&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;1.&amp;nbsp;European Centre for Disease Prevention and Control/WHO Regional Office for Europe. &lt;A href="nelh:331570:1" name=internalLink&gt;HIV/AIDS surveillance in Europe 2008&lt;/A&gt;. Stockholm: European Centre for Disease Prevention and Control; 2009.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Kruglov YV Kobyshcha YV, Salyuk T et al. (2008). &lt;A href="http://sti.bmj.com/content/84/Suppl_1/i37.full.pdf" target="_blank"&gt;The most severe HIV epidemic in Europe: Ukraine’s national HIV prevalence estimates for 2007&lt;/A&gt;. Sexually Transmitted Infections, 84:i37–i41.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. The Joint United Nations Programme on HIV/AIDS and the World Health Organisation.&amp;nbsp;&lt;A href="nelh:331155:1" name=internalLink&gt;AIDS Epidemic Update 2009&amp;nbsp; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. The World Health Organisation, UNAIDS The Joint United Nations Programme on HIV/AIDS &amp;amp; The United Nations Children's Fund. &lt;A href="nelh:331377:1" name=internalLink&gt;Scaling up priority HIV/AIDS interventions in the health sector&lt;/A&gt;. Progress Report 2009 &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. Atun RA, Gurol-Urganci I, McKee M. &lt;A href="http://www.bmj.com/cgi/content/extract/338/jun18_1/b2165" target="_blank"&gt;Health systems and increased longevity in people with HIV and AIDS&lt;/A&gt;. BMJ 2009;338:b2165, doi: 10.1136/bmj.b2165&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;6. Coker R, Atun R, McKee M. Health systems and the challenge of communicable diseases: experiences from Europe and Latin America. Maidenhead: Open University Press; 2008. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>331000</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=331000]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - Contributors</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,CHILDREN,POPULATION GROUPS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADOLESCENTS,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Contributors to the HIV Annual Evidence Update</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: HIV in children and adolescents - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0007_44_7D9B19F33_HIVAEU09-MainTitle600.jpg" width=600&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence-infections would like to thank the following contributors for their commentaries and evidence.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331000:2" name=internalLink&gt;Dr. Valerie Delpech&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331000:3" name=internalLink&gt;Dr. Caroline Foster&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331000:4" name=internalLink&gt;Dr. Paddy McMaster&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331000:5" name=internalLink&gt;Dr. Pat Tookey&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331000:6" name=internalLink&gt;Prof. Angus Nicoll&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Valerie Delpech&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr. Valerie Delpech is a public health consultant epidemiologist at the Health Protection Agency and has lead on the national surveillance of HIV infections for the United Kingdom for the past 5 years. She trained in medicine and public health in Australia and the UK and has extensive experience in communicable disease control and public health, with a particular interest in sexual health. Valerie serves on a number of national and international committees in relation to HIV surveillance, prevention and policy development. She provides scientific support to the English Expert Advisory Group on AIDS (EAGA) and was a member of the writing committee of the UK National Guidelines for HIV Testing 2008. Valerie is an executive trustee for the National AIDS Trust.&amp;nbsp; Valerie’s research interests and publications have focused on better understanding changes in the epidemiology of HIV, STIs and HIV co-infections, and tracking efforts to curb these epidemics in vulnerable populations.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Caroline Foster&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr. Caroline Foster is a Consultant in Paediatric and Adolescent Infectious Diseases and HIV at Imperial College Healthcare NHS trust, with a special interest in the transitional care and longterm follow up of young adults with perinatally acquired HIV infection. She is the current chair of HYPNET (HIV Young Persons Network) a multidisciplinary forum advising on care of adolescents living with HIV in the UK (&lt;A href="http://www.hypnet.org.uk/" target="_blank"&gt;www.hypnet.org.uk&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Paddy McMaster&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr. Paddy McMaster is a Consultant Paediatrician at University Hospital of North Staffordshire in Stoke on Trent. He is based in the Paediatric Intensive Care Unit with a specialist interest in Paediatric Infectious Diseases. He is also chair of CHIVA.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Pat Tookey&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr. Pat Tookey is Senior Lecturer in Paediatric Epidemiology at the MRC Centre of Epidemiology for Child Health, Institute of Child Health, University College London. She is a non-clinical epidemiologist with a special interest in infections affecting pregnant women and their children, screening and immunisation. Since 1996 she has been responsible for the National Study of HIV in Pregnancy and Childhood (&lt;A href="http://www.nshpc.ucl.ac.uk/" target="_blank"&gt;www.nshpc.ucl.ac.uk&lt;/A&gt; ), and associated research on obstetric and paediatric HIV infection. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Prof. Angus Nicoll&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Professor Angus Nicoll CBE is employed by the Health Protection Agency but is a seconded National Expert at the European Centre for Disease Prevention and control where he corrdinates its influenza activities. He retains a long interest in HIV. AIDS and STIs having previously been Director of the then HIV &amp;amp; STI Division in what is now the HPA Centre for Infections. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&amp;nbsp;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330316</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=330316]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - HIV testing and prevention interventions</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,OUTCOMES,MANAGEMENT &amp; INTERVENTIONS,GROUPS,POPULATIONS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MONTHLY ADDITIONS,PREVENTION,HIV INFECTION,COMMUNICABLE DISEASES,CHILDREN,NEONATE,AGE GROUPS,WOMEN,PEOPLE WITH HIV OR AIDS,SERVICES,POPULATION BASED &amp; PREVENTATIVE SERVICES,SCREENING,POPULATION GROUPS,CHILDREN,DIAGNOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 09,ADOLESCENTS,2009 NOVEMBER,ADDED 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on HIV testing and prevention interventions in children and adolescents</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary - HIV testing and prevention interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330316/nelhImp_0000_44_7D9B19F39_HIVAEU09-PT-TaPI.jpg" width=620&gt;&lt;/P&gt;
&lt;P&gt;Commentary by &lt;A href="nelh:331000:4" name=internalLink&gt;Dr. Paddy McMaster&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There have been great advances in HIV but these depend upon the diagnosis having been made first. With antiretrovirals we now expect a long healthy life. Women with HIV can now have babies, confident that there are minimal risks of HIV transmission to their babies with appropriate management in pregnancy. Without knowing the diagnosis, children are presenting with life threatening opportunistic infections and babies are being avoidably infected. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Antenatal testing has resulted in one of the most satisfying advances in HIV medicine. From about ¼ of babies born to mothers with HIV becoming infected, it is now less than 1%. Antenatal testing has been well accepted and in most areas in UK it is over 95% coverage. However there are still babies being born to mothers with HIV. The NSHPC audit on Perinatal Transmission of HIV 2002-2005 gives recommendations for antenatal, perinatal and postnatal care to prevent further infections occurring. The British HIV Association lays out clear guidelines for the management of the mother and infant. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;On the basis of universal antenatal testing being recommended, those who have missed that opportunity in the past should be offered testing now. This can be achieved by enquiring about antenatal screening at any encounter with health professionals. Children are often diagnosed after several events have already been missed which could have triggered testing. Opportunistic infections with unusual organisms and frequent or severe infections with common organisms should stimulate testing. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The future of HIV testing is in the acceptance of it as a routine screen rather than the remit of the specialist. Prevention of sexual transmission is becoming relevant at ever younger ages and this needs to be addressed by health professionals seeing adolescents. &lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: HIV testing and prevention interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. &lt;A href="nelh:323135:1" name=internalLink&gt;Don’t forget the children: guidance for the HIV testing of children with HIV-positive parents&lt;/A&gt;. BHIVA, CHIVA and BASHH&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. &lt;A href="nelh:327298:1" name=internalLink&gt;HIV testing guidelines for children of confirmed or suspected HIV positive parents&lt;/A&gt;. CHIVA&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Geretti A.M. &lt;A href="nelh:330296:1" name=internalLink&gt;HIV testing and monitoring&lt;/A&gt;. Medicine, July 2009, vol./is. 37/7(326-329), 1357-3039&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Paul-Ebhohimhen V A, Poobalan A, van Teijlingen E R. &lt;A href="nelh:314223:1" name=internalLink&gt;A systematic review of school-based sexual health interventions to prevent STI/HIV in sub-Saharan Africa&lt;/A&gt;. BMC Public Health 2008; 8:4&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. &lt;A href="nelh:304933:1" name=internalLink&gt;Interventions for preventing late postnatal mother-to-child transmission of HIV&lt;/A&gt;. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006734.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. UNICEF, &lt;A href="nelh:314731:1" name=internalLink&gt;HIV prevention with young people: The key to tackling the epidemic&lt;/A&gt;, 06 May 2009&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Medley A, Kennedy C, O'Reilly K, Sweat M. &lt;A href="nelh:330304:1" name=internalLink&gt;Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis&lt;/A&gt;. AIDS Educ Prev. 2009 Jun;21(3):181-206. Review. PMID: 19519235 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Yankah E, Aggleton P. &lt;A href="nelh:330306:1" name=internalLink&gt;Effects and effectiveness of life skills education for HIV prevention in young people&lt;/A&gt;. AIDS Education &amp;amp; Prevention, 01 December 2008, vol./is. 20/6(465-485), 08999546&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Spiegel H.M.L., Futterman D.C. &lt;A href="nelh:330312:1" name=internalLink&gt;Adolescents and HIV: Prevention and clinical care&lt;/A&gt;. Current HIV/AIDS Reports, May 2009, vol./is. 6/2(100-107), 1548-3568;1548-3576&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330262</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=330262]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - Homepage</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,PREVENTION,ANTIVIRALS,ANTIMICROBIALS,POPULATION GROUPS,CHILDREN,TREATMENT,DIAGNOSIS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on HIV in children and adolescents</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: HIV in children and adolescents - Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0007_44_7D9B19F33_HIVAEU09-MainTitle600.jpg" width=600&gt;&lt;/P&gt;
&lt;P align='Â”"justify"Â”'&gt;Welcome to the &lt;B&gt;2009 Annual Evidence Update: HIV in children and adolescents&lt;/B&gt; by &lt;A href="http://www.library.nhs.uk/Infections/" target="_blank"&gt;NHS Evidence-infections&lt;/A&gt;. This Annual Evidence Update will run from &lt;B&gt;30th November to 6th December 2009&lt;/B&gt;, and has been timed to coincide with &lt;A href="http://www.worldaidsday.org/" target="_blank"&gt;World AIDS day &lt;/A&gt;on 1st December.&lt;/P&gt;
&lt;P align=right&gt;Link to &lt;A href="nelh:331184:0" name=internalLink&gt;methodology&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://isc.anthropith.com/Assets/HIVAEU09Flyer.pdf" target="_blank"&gt;Download Flyers (pdf)&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;
&lt;P align=center&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=620 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:330326:1" name=internalLink&gt;&lt;IMG height=129 alt="Management of HIV" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0023_44_7D9B191219_HIVAEU09MenuUp1.jpg" width=620 border=0&gt;&lt;/A&gt; &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:330316:0" name=internalLink&gt;&lt;IMG height=115 alt="Testing and Prevention Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0024_44_7D9B19121A_HIVAEU09MenuUp2.jpg" width=620 border=0&gt;&lt;/A&gt; &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:330323:1" name=internalLink&gt;&lt;IMG height=115 alt="Mother to Child Transmission" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0025_44_7D9B1B116_HIVAEU09MenuUp3.jpg" width=620 border=0&gt;&lt;/A&gt; &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:330997:7" name=internalLink&gt;&lt;IMG height=148 alt="HIV and AIDS in Children in Continental Europe" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0026_44_7D9B1B115_HIVAEU09MenuUp4.jpg" width=620 border=0&gt;&lt;/A&gt; &lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P align=center&gt;You may also wish to see the National Library for Public Health's Annual Evidence Update on &lt;A href="http://www.library.nhs.uk/publichealth/viewResource.aspx?resid=328610" target="_blank"&gt;HIV/AIDS - Behaviour change in high-risk populations&lt;/A&gt;.&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=left&gt;&lt;B&gt;Introduction&lt;/B&gt; by &lt;A href="nelh:331000:2" name=internalLink&gt;&lt;B&gt;Dr. Valerie Delpech&lt;/B&gt;&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;This Annual Evidence Update (AEU) provides a collection of evidence that has emerged over the last twelve months on HIV in children and adolescents accompanied by &lt;A href="nelh:330997:1" name=internalLink&gt;commentaries &lt;/A&gt;from &lt;A href="nelh:331000:1" name=internalLink&gt;experts&lt;/A&gt;. The launch of this AEU coincides with this weekÂ’s release of the &lt;A href="nelh:331155:1" name=internalLink&gt;AIDS epidemic update 2009 &lt;/A&gt;by UNAIDS and the WHO and the &lt;A href="nelh:331512:1" name=internalLink&gt;Health Protection AgencyÂ’s latest report on the UKÂ’s HIV epidemic&lt;/A&gt; Â– in time for &lt;A href="http://www.worldaidsday.org/" target="_blank"&gt;World AIDS day &lt;/A&gt;on the 1st of December. Links to &lt;A href="nelh:330322:1" name=internalLink&gt;useful websites&lt;/A&gt; are also provided.&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;In 2008 an estimated 33.4 million, [31.1 millionÂ–35.8 million] people were living with HIV, a figure higher than ever before as people are living longer due to the beneficial effects of antiretroviral therapy and population growth. There is however some good news with an apparent 10% decline in AIDS-related deaths over the past five years achieved primarily through better access to antiretroviral therapy. UNAIDS and WHO estimate that since the availability of effective treatment in 1996, some 2.9 million lives have been saved. Nevertheless there were a staggering 2.7 million new infections of HIV in 2008 globally, and almost half a million of these were among children under 15. Without treatment, approximately half of the children infected through mother to child transmission (MTCT) will die by the age of 2 (1).&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;Importantly, antiretroviral therapy has also made a significant impact in preventing new infections in children as more HIV-positive mothers gain access to treatment preventing them from transmitting the virus to their children. An estimated 200,000 new infections among children have been prevented since 2001. For example, in Botswana Â– one of the countries most hit by the epidemic Â– efforts to accelerate antiretroviral coverage (now estimated at 80%) has resulted in a 50% decrease in AIDS-related deaths in the past five years and the number of children newly orphaned is also coming down as parents are living longer. The UNAIDS report also highlights the significant impact of HIV on maternal mortality with an estimated 50,000 maternal deaths in South Africa alone directly related to HIV infection in 2008. The report calls for "a unified health approach bringing maternal and child health and HIV programmes as well as tuberculosis programmes together to work to achieve their common goal."&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;The situation in the United Kingdom is clearly very different and underscores the successes of antenatal screening of pregnant women and good access to antiretroviral therapy for those diagnosed with HIV. The &lt;A href="nelh:331512:1" name=internalLink&gt;latest HPA report on the UKÂ’s HIV epidemic &lt;/A&gt;shows that the uptake of HIV screening in the antenatal setting has reached over 95% resulting in very low MTCT transmission in the UK. &lt;A href="nelh:331000:5" name=internalLink&gt;Dr. Pat Tookey &lt;/A&gt;from the Institute of Child Health provides us with further insight into our successes in preventing MTCT in the United Kingdom.&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;As a result of effective treatment, many of the children infected through MTCT are now entering adolescence and are therefore transitioning from paediatric to adult services. &lt;A href="nelh:331000:3" name=internalLink&gt;Dr. Caroline Foster &lt;/A&gt;from Imperial College Healthcare NHS Trust provides us with an insight into the complexities of managing HIV in children and adolescents. This transitional period not only offers clinical but also important psychosocial challenges such as the fear of disclosure and the right to a healthy sexual and reproductive life.&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;Finally, whilst there have been real successes in tackling the HIV epidemic in the UK, challenges remain. An estimated one third of the 7,298 people diagnosed in 2008 presented late in the course of their illness. These individuals contributed to half of all deaths in HIV infected individuals in 2008. Furthermore over a quarter of the estimated 83,000 people living with HIV in the UK are unaware of their infection (HPA report). There is therefore a need to maintain high levels of testing in the antenatal and STI clinic settings as well as expand the offer of HIV testing in other clinical and non-clinical setting. The &lt;A href="http://www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf" target="_blank"&gt;Guidelines for HIV Testing 2008 &lt;/A&gt;produced by the British Association for Sexual Health and HIV (BASHH), the British HIV Association (BHIVA) and the British Infection Society (BIS) which recommend testing in a range of settings and most at risk populations were therefore a very welcome addition.&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;&lt;A href="nelh:331000:4" name=internalLink&gt;Dr. Paddy McMaster&lt;/A&gt; from The University Hospital of North Staffordshire builds on this momentum and highlights that "the future of HIV testing is in the acceptance of it as a routine screen rather than the remit of the specialist." To this end, health professionals are likely to find the Medical Foundation for AIDS &amp;amp; Sexual Health (MedFASH) report Â‘&lt;A href="nelh:296294:1" name=internalLink&gt;HIV for non-HIV specialists: diagnosing the undiagnosed&lt;/A&gt;Â’ helpful in offering a HIV test as part of routine screening when diagnosing their patients.&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=left&gt;&lt;B&gt;References&lt;/B&gt;:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;UNAIDS, &lt;A href="nelh:331155:1" name=internalLink&gt;AIDS epidemic update 2009&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Health Protection Agency, &lt;A href="nelh:331512:0" name=internalLink&gt;HIV in the United Kingdom: 2009 Report&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;MedFASH, &lt;A href="nelh:296294:1" name=internalLink&gt;HIV for non-HIV specialists: diagnosing the undiagnosed &lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=center&gt;_____________________&lt;/P&gt;
&lt;P align='Â”"justifyÂ”"'&gt;We welcome feedback about all aspects of NHS Evidence-infections, including the resources that make up this Annual Evidence Update. Please &lt;A href="http://www.library.nhs.uk/Infections/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you would like to comment, or take part in our &lt;A href="http://www.library.nhs.uk/infections/Page.aspx?pagename=SMHIV09" target="_blank"&gt;two minute survey&lt;/A&gt;. Thank you.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330326</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=330326]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - Management of HIV</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ POPULATIONS,GROUPS,MANAGEMENT &amp; INTERVENTIONS,OUTCOMES,PUBLIC HEALTH,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MONTHLY ADDITIONS,ANTIVIRALS,ANTIMICROBIALS,MANAGEMENT,MANAGEMENT &amp; POLICY,AGE GROUPS,CHILDREN,YOUNG PEOPLE,COMMUNICABLE DISEASES,HIV INFECTION,CHILDREN,POPULATION GROUPS,OTHER TREATMENT METHODS,TREATMENT,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2009,ADOLESCENTS,NOV 09,2009 NOVEMBER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on the management of HIV in children and adolescents</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Management of HIV&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330326/nelhImp_0000_44_7D9B19F37_HIVAEU09-PT-M.jpg" width=620&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;Commentary by &lt;A href="nelh:331000:3" name=internalLink&gt;Dr. Caroline Foster&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;World wide, over 2 million of the estimated 33 million people living with HIV are children, the vast majority living in sub-Saharan Africa. In addition there are an estimated 15 million children orphaned due to the AIDS epidemic and over half of all new HIV infections are in young people aged 15 to 24 years. In well resourced setting with access to antiretroviral therapy (ART), the introduction of Highly Active Antiretroviral therapy (HAART) has substantially reduced HIV- associated morbidity and mortality in children and hence perinatally acquired HIV-1 infection has become a chronic disease of childhood. In Europe, prior to the introduction of HAART, half of HIV-infected children died before their tenth birthday. Currently, due to high uptake of antenatal testing, reduced transmission rates in diagnosed women and improved survival following HAART, the average age of perinatally infected children living in the UK is now over 10. Consequently increasing numbers of perinatally infected children are entering adolescence and transitioning from paediatric to adult services. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Adolescence and the period of transition can be complex for many young people living with a chronic disease of childhood, with suboptimal attendance and adherence to therapy resulting in an increase in disease related morbidity and mortality. Poor adherence to antiretroviral therapy leads to virological failure, immunosuppression and the risk of development of virological resistance. The balance between maintaining current immunological function and clinical well being against the risk of acquiring further resistance mutations on failing regimens that will limit future treatment options is complex. Many young people with perinatally acquired HIV have extensive treatment histories and often do not have once daily low pill burden options, that are easier to adhere to, available. A small proportion have multidrug resistance and require new drugs in development, highlighting the need for equal access and adequate pharmacokinetic data in paediatric and adolescent populations. Although prognosis is vastly improved in the HAART era, holistic palliative care is required for young people with endstage HIV disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Whilst the enormous benefits of HAART should not be underestimated, the medium-term side effects of exposure to antiretrovirals are progressively apparent in a population who, following recent evidence to support the earlier initiation of HAART in both infants and adults, are increasingly exposed to antiretrovirals throughout postnatal growth and development. Dyslipidaemia, lipodystrophy and mitochondrial toxicity are reported, however their longer term impact is unknown, although concern exists particularly around future cardiovascular health and highlights the importance of health promotion, particularly the avoidance of smoking and obesity in this group. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;HIV is associated with delayed growth and puberty, and reduced bone mineralization, raising the concern of osteoporosis in later life. The impact of HIV on the developing brain is of continuing concern with recent reports of increased rates of neurocognitive impairment, psychiatric illness and behavioural disorders in adolescents with HIV requiring further elucidation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;HIV adds its own complexities to living with a chronic disease, that of stigma and secrecy, the majority of young people having never disclosed their status beyond their immediate family. In addition some adolescents will have lost one or both parents, siblings and other family members to HIV- related disease. Many have been born abroad and most come from diverse ethnic minority backgrounds. Being born with a sexually transmissible disease before one has ever had sex and the psychological issues around onward transmission and partner disclosure can be challenging for young people to manage and requires comprehensive ongoing multidisciplinary education and support. The potential impact of life long HIV infection with prolonged exposure to antiretroviral therapy on fertility is uncertain, however young adults themselves born with HIV are beginning to have children of their own, the vast majority of whom are healthy infants uninfected with HIV. The long-term follow up of this unique cohort is required if we are able to improve outcomes for children living with HIV, particularly as the role out of ART in sub-Saharan Africa continues to grow giving more children the opportunity of a future.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Management of HIV&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. &lt;A href="nelh:325322:0" name=internalLink&gt;United Kingdom national guideline on the management of sexually transmitted infections and related conditions in children and young people&lt;/A&gt; (2009)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. PENTA Steering Committee. &lt;A href="nelh:330904:1" name=internalLink&gt;2009 PENTA Guidelines for the use of antiretroviral therapy in paediatric HIV infection&lt;/A&gt;. HIV Medicine, 27 Oct 2009, vol 10, issue 10, 591-613.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Spiegel H.M.L., Futterman D.C. &lt;A href="nelh:330312:1" name=internalLink&gt;Adolescents and HIV: Prevention and clinical care&lt;/A&gt;. Current HIV/AIDS Reports, May 2009, vol./is. 6/2(100-107), 1548-3568;1548-3576&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Brichard B., Van Der Linden D. &lt;A href="nelh:330527:1" name=internalLink&gt;Clinical practice treatment of HIV infection in children&lt;/A&gt;. European Journal of Pediatrics, April 2009, vol./is. 168/4(387-392), 0340-6199&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Van Der Linden D., Callens S., Brichard B., Colebunders R. &lt;A href="nelh:330486:1" name=internalLink&gt;Pediatric HIV: New opportunities to treat children&lt;/A&gt;. Expert Opinion on Pharmacotherapy, August 2009, vol./is. 10/11(1783-1791), 1465-6566&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Giaquinto C, Morelli E, Fregonese F, Rampon O, Penazzato M, de Rossi A, D'Elia R. &lt;A href="nelh:330341:1" name=internalLink&gt;Current and future antiretroviral treatment options in paediatric HIV infection&lt;/A&gt;. Clin Drug Investig. 2008;28(6):375-97. Review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Kitahata MM, et al. &lt;A href="nelh:330427:1" name=internalLink&gt;Effect of early versus deferred antiretroviral therapy for HIV on survival&lt;/A&gt;. N Engl J Med. 2009 Apr 30;360(18):1815-26&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Ramos J. &lt;A href="nelh:330367:1" name=internalLink&gt;Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children&lt;/A&gt;. HIV Med. 2009 Oct;10(9):536-47.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Cowan F., Pettifor A. &lt;A href="nelh:330519:0" name=internalLink&gt;HIV in adolescents in sub-Saharan Africa&lt;/A&gt;. Current Opinion in HIV and AIDS, July 2009, vol./is. 4/4(288-293), 1746-630X;1746-6318&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. &lt;A href="nelh:330335:1" name=internalLink&gt;Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa&lt;/A&gt;. Lancet Infect Dis. 2008 Aug;8(8):477-89. Review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Havens PL, Mofenson LM; American Academy of Pediatrics Committee on Pediatric AIDS. Collaborators (8) Havens PL, Chakraborty R, Cooper ER, Emmanuel PJ, Flynn PM, Hoyt LG, Martinez J, Van Dyke R. &lt;A href="nelh:330460:1" name=internalLink&gt;Evaluation and management of the infant exposed to HIV-1 in the United States&lt;/A&gt;. Pediatrics. 2009 Jan;123(1):175-87.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Arpadi SM, McMahon D, Abrams EJ, Bamji M, Purswani M, Engelson ES, Horlick M, Shane E. &lt;A href="nelh:330462:1" name=internalLink&gt;Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents&lt;/A&gt;. Pediatrics. 2009 Jan;123(1):e121-6. Erratum in: Pediatrics. 2009 May;123(5):1437.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13. Adetifa I, Okomo U. &lt;A href="nelh:304922:1" name=internalLink&gt;Iron supplementation for reducing morbidity and mortality in children with HIV&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006736. DOI: 10.1002/14651858.CD006736.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14. Gupta RK, Gibb DM, Pillay D. &lt;A href="nelh:330330:1" name=internalLink&gt;&lt;A href="nelh:304922:1" name=internalLink&gt;Management of paediatric HIV-1 resistance&lt;/A&gt;&lt;/A&gt;. Curr Opin Infect Dis. 2009 Jun;22(3):256-63. Review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;15. Ryan M, Griffin S, Chitah B, Walker A S, Mulenga V, Kalolo D, Hawkins N, Merry C, Barry M G, Chintu C, Sculpher M J, Gibb D M. &lt;A href="nelh:324087:1" name=internalLink&gt;The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia&lt;/A&gt;.&amp;nbsp; AIDS 2008; 22(6): 749-757&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;16. Garvie P.A., Lawford J., Banet M.S., West R.L. &lt;A href="nelh:330476:1" name=internalLink&gt;Quality of life measurement in paediatric and adolescent populations with HIV: A review of the literature&lt;/A&gt;. Child: Care, Health and Development, 2009, vol./is. 35/4(440-453), 0305-1862;1365-2214&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;17. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. &lt;A href="nelh:304933:1" name=internalLink&gt;Interventions for preventing late postnatal mother-to-child transmission of HIV&lt;/A&gt;. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006734.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;18. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. &lt;A href="nelh:330463:1" name=internalLink&gt;Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007&lt;/A&gt;. AIDS. 2009 Feb 20;23(4):519-24.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;19. Bannister C., Bennett L., Carville A., Azzopardi P. &lt;A href="nelh:330479:1" name=internalLink&gt;Evidence behind the WHO guidelines: Hospital care for children: What is the evidence that BCG vaccination should not be used in HIV-infected children?&lt;/A&gt; Journal of Tropical Pediatrics, 2009, vol./is. 55/2(78-82), 0142-6338;1465-3664&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;20. Thurey J., Molyneux E. &lt;A href="nelh:330493:1" name=internalLink&gt;Evidence behind the WHO guidelines: Hospital care for children: The usefulness of azole prophylaxis against cryptococcal meningitis in HIV-positive children&lt;/A&gt;. Journal of Tropical Pediatrics, 2008, vol./is. 54/6(361-363), 0142-6338;1465-3664&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;21. Davies MA, Connell T, Johannisen C, Wood K, Pienaar S, Wilkinson KA, Wilkinson RJ, Zar HJ, Eley B, Beatty D, Curtis N, Nicol MP. &lt;A href="nelh:330430:1" name=internalLink&gt;Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay&lt;/A&gt;. AIDS. 2009 May 15;23(8):961-9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;22. Gray DM, Young T, Cotton M, Zar H. &lt;A href="nelh:304939:1" name=internalLink&gt;Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006418. DOI: 10.1002/14651858.CD006418.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;23. England K., Thorne C., Castelli-Gattinara G., Vigano A., El Mehabresh M.I., Newell M.-L. &lt;A href="nelh:330529:1" name=internalLink&gt;HIV and HCV progression in parenterally coinfected children&lt;/A&gt;. Current HIV Research, 2009, vol./is. 7/3(346-353), 1570-162X&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;24. Mekmullica J, Brouwers P, Charurat M, Paul M, Shearer W, Mendez H, Diaz C, Read JS, Mondal P, Smith R, McIntosh K. &lt;A href="nelh:330445:1" name=internalLink&gt;Early immunological predictors of neurodevelopmental outcomes in HIV-infected children&lt;/A&gt;. Clin Infect Dis. 2009 Feb 1;48(3):338-46. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;25. Butler AM, Williams PL, Howland LC, Storm D, Hutton N, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219C Study Team. &lt;A href="nelh:330441:1" name=internalLink&gt;Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection&lt;/A&gt;. Pediatrics. 2009 Mar;123(3):935-43.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;26. King E, De Silva M, Stein A, Patel V. &lt;A href="nelh:312191:1" name=internalLink&gt;Interventions for improving the psychosocial well-being of children affected by HIV and AIDS&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006733. DOI: 10.1002/14651858.CD006733.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;27. Lyon ME, Garvie PA, McCarter R, Briggs L, He J, D’Angelo LJ. &lt;A href="nelh:330444:1" name=internalLink&gt;Who will speak for me? Improving end-of-life decision-making for adolescents with HIV and their families&lt;/A&gt;. Pediatrics. 2009 Feb;123(2):e199-206.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;28. Sherr L, Mueller J. &lt;A href="nelh:330512:1" name=internalLink&gt;Where is the evidence base? Mental health issues surrounding bereavement and HIV in children&lt;/A&gt;. Journal of Public Mental Health, 01 December 2008, vol./is. 7/4(31-39), 17465729&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;29. Johnston E.R. &lt;A href="nelh:330489:1" name=internalLink&gt;Personality disturbance in adolescents living with HIV/AIDS: A review&lt;/A&gt;. Journal of Child and Adolescent Mental Health, December 2008, vol./is. 20/2(83-93), 1728-0583;1728-0591&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/ODLI&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>331184</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=331184]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - Methodology</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the methodology used to search for the best new evidence on HIV in children and adolescents</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: HIV in children and adolescents - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0007_44_7D9B19F33_HIVAEU09-MainTitle600.jpg" width=600&gt;&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Identifying the topic and a starting document&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;New guidelines focussing on testing and managing HIV in children and adolescents were launched in 2009 by the Children’s HIV Association (CHIVA), The British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH):&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:323135:1" name=internalLink&gt;Don’t forget the children: guidance for the HIV testing of children with HIV-positive parents&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:325322:1" name=internalLink&gt;United Kingdom national guideline on the management of sexually transmitted infections and related conditions in children and young people&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:327298:1" name=internalLink&gt;HIV testing guidelines for children of confirmed or suspected HIV positive parents &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These guidelines were used as the basis for the Annual Evidence Update.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Search strategy&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Date of last search: &lt;/STRONG&gt;Searches were conducted on resources published between October 2008 and October 2009. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Databases searched: &lt;/STRONG&gt;CINAHL, EMBASE, MEDLINE and HMIC&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Terms used: &lt;/STRONG&gt;The terms "HIV" OR "human immunodeficiency virus" OR "AIDS" OR "acquired immunodefiency syndrome" were combined with either "children" OR "adolescents" OR "young people"; or "testing" OR "diagnosis" OR "diagnosing” and then these terms were searched for in the title fields. Thesaurus terms (subheadings, exploded terms and major descriptor terms) for each of these were also used in the searches.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Inclusion and exclusion criteria&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The publication type was not restricted to systematic reviews as not many of these have been published in the last year&lt;/LI&gt;
&lt;LI&gt;Guidelines, reviews, reports and some primary evidence have also been included&lt;/LI&gt;
&lt;LI&gt;Articles were included if they had an abstract&lt;/LI&gt;
&lt;LI&gt;If the article was not published in English, it was still included if an English abstract was available&lt;/LI&gt;
&lt;LI&gt;The searches from the databases were combined, duplicates were removed, and the results were sifted through based on the relevance of the title or abstract&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330323</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=330323]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - Mother to Child Transmission</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,POPULATION GROUPS,PREGNANT WOMEN,CHILDREN,ADULTS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 09,ADOLESCENTS,ADDED 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on mother to child transmission of HIV</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Mother to Child Transmission&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330323/nelhImp_0002_44_7D9B19F39_HIVAEU09-PT-MtCT600.jpg" width=620&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary&lt;/STRONG&gt; by &lt;A href="nelh:331000:5" name=internalLink&gt;&lt;STRONG&gt;Dr. Pat Tookey&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Worldwide an estimated 1200 children acquire HIV every day (420,000 new infections per year), the vast majority of them as a result of mother to child transmission (MTCT) of infection.&amp;nbsp; MTCT is now relatively uncommon in high-income settings, where antenatal screening is widely offered and antiretroviral drugs (ART) and safe alternatives to breast feeding are generally available. However, over 90% of the 1.4 million pregnant women living with HIV who gave birth in 2008 live in low and middle income countries, according to the 2009 ‘&lt;A href="nelh:331377:1" name=internalLink&gt;Towards universal access progress report’&lt;/A&gt;, published by WHO, UNICEF and UNAIDS. In these settings, although there has been a moderate increase in the proportion of women tested in pregnancy, it is still only a minority: 28% of pregnant women in Sub-Saharan Africa, where the vast majority of infected women live, are thought to have been tested in 2008. Less than half (45%) of HIV-infected pregnant women in low and middle income countries received ART to reduce the risk of MTCT, and in about 30% of cases this was only a single-dose regimen. Early testing of infants to establish infection status and provide treatment where required remains the exception rather than the rule. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Transmission through breastfeeding contributes substantially to MTCT in countries where avoidance of breastfeeding is unsafe or unaffordable (1, 2). Exclusive breastfeeding during the first few months of life, ART prophylaxis for breast fed infants for the duration of breastfeeding, and ART for breastfeeding women themselves are all effective interventions for reducing the risk of late postnatal MTCT in these circumstances; nevertheless, substantial support for exclusive breastfeeding is necessary, and there are concerns about nevirapine resistance among infants who become infected despite extended prophylaxis. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In the UK, thanks to high uptake of antenatal HIV screening (accepted by over 90% of pregnant women since 2006) at least 90% of women living with HIV infection are currently diagnosed prior to delivery. Over 1300 births to diagnosed infected women in 2008 have been reported through the routine surveillance systems by the &lt;A href="http://www.nshpc.ucl.ac.uk/" target="_blank"&gt;National Study of HIV in Pregnancy and Childhood (NSHPC)&lt;/A&gt; with an MTCT rate of about 1% overall (3). About two-thirds of those women were already aware of their HIV status before conception, with many diagnosed in a previous pregnancy. HIV infected women are living in all regions and countries of the UK, and most NHS Trusts offering maternity care now manage HIV infected pregnant women. Comprehensive guidelines on &lt;A href="http://www.bhiva.org/documents/Guidelines/Pregnancy/2008/PregnancyPub.pdf" target="_blank"&gt;management of HIV in pregnancy &lt;/A&gt;were updated in 2008 (4). Although monotherapy remains an option for pregnant women who do not yet require ART for their own health, and are willing to have a caesarean section delivery, 95% of women take combination therapy, and an increasing proportion of those who achieve viral suppression opt for a planned vaginal delivery. This does present challenges however as the actual timing and duration of labour is unpredictable, there is uncertainty about whether prolonged rupture of membranes presents a risk in these circumstances, and this and other obstetric complications can lead to an increased proportion of emergency caesarean sections. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In addition to the few infants who are infected despite maternal diagnosis prior to delivery, a small number of UK-born children whose mothers were not previously known to be infected are diagnosed with vertically acquired infection each year. These children do not all present in infancy – recent data suggests those who do are likely to represent only a third to a half of the total number.&amp;nbsp; Although some women remain undiagnosed because they decline antenatal testing, or are not tested for some other reason, some mothers of infected children have had a negative test result antenatally. They must have seroconverted during pregnancy, or indeed acquired infection after their baby’s birth while they were still breastfeeding. The relative contribution of undiagnosed maternal infection acquired before pregnancy, seroconversion in pregnancy, and seroconversion in the postnatal period, to infant infections in the UK is currently unclear. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Further reductions in the overall rate of MTCT in the UK are likely to be achieved by facilitating earlier diagnosis of HIV-infected women (preferably prior to conception), maximising antenatal test uptake rates, optimising clinical management, and identifying women who seroconvert in pregnancy or in the early months of motherhood in order to prevent transmissions through breastfeeding. Women with resistant virus, concurrent infections, and difficult family circumstances are in particular need of tailored support and management, as are the small but increasing number of vertically infected young women who are becoming pregnant, or looking forward to doing so. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;:&lt;/P&gt;
&lt;P&gt;1. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. &lt;A href="nelh:304933:1" name=internalLink&gt;Interventions for preventing late postnatal mother-to-child transmission of HIV&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006734. DOI: 10.1002/14651858.CD006734.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Coovadia H. &lt;A href="nelh:330559:1" name=internalLink&gt;Current issues in prevention of mother-to-child transmission of HIV-1&lt;/A&gt;. Current Opinion in HIV and AIDS, July 2009, vol./is. 4/4(319-324), 1746-630X;1746-6318&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. &lt;A href="nelh:330463:1" name=internalLink&gt;Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007&lt;/A&gt;. AIDS. 2009 Feb 20;23(4):519-24.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp;de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, Gilling-Smith C, Hawkins D, Low-Beer N, Lyall H, O'Shea S, Penn Z, Short J, Smith R, Sonecha S, Tookey P, Wood C, Taylor G. &lt;A href="http://www3.interscience.wiley.com/journal/121377309/abstract" target="_blank"&gt;British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008&lt;/A&gt;. HIV Med. 2008 Aug;9(7):452-502.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Mother to Child Transmission&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. &lt;A href="nelh:304933:1" name=internalLink&gt;Interventions for preventing late postnatal mother-to-child transmission of HIV&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006734. DOI: 10.1002/14651858.CD006734.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. MacCarthy S, Laher F, Nduna M, Farlane L, Kaida A. &lt;A href="nelh:330530:1" name=internalLink&gt;Responding to her question: a review of the influence of pregnancy on HIV disease progression in the context of expanded access to HAART in sub-Saharan Africa&lt;/A&gt;. AIDS Behav. 2009 Jun;13 Suppl 1:66-71. Epub 2009 Mar 20. Review. PMID: 19301115 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Kongnyuy EJ, Wiysonge CS, Shey MS. &lt;A href="nelh:330540:1" name=internalLink&gt;A systematic review of randomized controlled trials of prenatal and postnatal vitamin A supplementation of HIV-infected women&lt;/A&gt;. Int J Gynaecol Obstet. 2009 Jan;104(1):5-8. Epub 2008 Oct 15. Review. PMID: 18926534 [PubMed - indexed for MEDLINE]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Singh K.K., Spector S.A. &lt;A href="nelh:330543:1" name=internalLink&gt;Host genetic determinants of human immunodeficiency virus infection and disease progression in children&lt;/A&gt;. Pediatric Research, May 2009, vol./is. 65/SUPPL. 5(55R-63R), 0031-3998;1530-0447.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Al-Husaini A.M. &lt;A href="nelh:330544:1" name=internalLink&gt;Role of placenta in the vertical transmission of human immunodeficiency virus&lt;/A&gt;. Journal of Perinatology, 2009, vol./is. 29/5(331-336), 0743-8346;1476-5543&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Paintsil E., Andiman W.A. &lt;A href="nelh:330547:1" name=internalLink&gt;Update on successes and challenges regarding mother-to-child transmission of HIV&lt;/A&gt;. Current Opinion in Pediatrics, February 2009, vol./is. 21/1(94-101), 1040-8703&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Foster C., Lyall H., Olmscheid B., Pearce G., Zhang S., Gibb D.M. &lt;A href="nelh:330554:1" name=internalLink&gt;Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: Is it time to move on from zidovudine?&lt;/A&gt; HIV Medicine, 2009, vol./is. 10/7(397-406), 1464-2662;1468-1293&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Coovadia H. &lt;A href="nelh:330559:1" name=internalLink&gt;Current issues in prevention of mother-to-child transmission of HIV-1&lt;/A&gt;. Current Opinion in HIV and AIDS, July 2009, vol./is. 4/4(319-324), 1746-630X;1746-6318&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Pai NP, Klein MB. &lt;A href="nelh:330574:1" name=internalLink&gt;Rapid testing at labor and delivery to prevent mother-to-child HIV transmission in developing settings: issues and challenges&lt;/A&gt;. Women's health, January 2009, vol./is. 5/1(55-62), 1745-5065&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. &lt;A href="nelh:330463:1" name=internalLink&gt;Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007&lt;/A&gt;. AIDS. 2009 Feb 20;23(4):519-24.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330322</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=330322]]&gt;</url>
    <title>2009 Annual Evidence Update: HIV in children and adolescents - Useful Websites</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,CHILDREN,POPULATION GROUPS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2009,ADOLESCENTS,NOV 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A list of useful websites to accompany the Annual Evidence Update on HIV in children and adolescents</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: HIV in children and adolescents - Useful Websites&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID330262/nelhImp_0007_44_7D9B19F33_HIVAEU09-MainTitle600.jpg" width=600&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.worldaidsday.org/" target="_blank"&gt;&lt;STRONG&gt;World AIDS Day 2009&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;World AIDS Day is the 1st of December. The National AIDS Trust uses this website to encourage support so they can continue their work.&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;A href="http://www.hpa.org.uk/webw/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200660065903?p=1200660065903" target="_blank"&gt;&lt;STRONG&gt;The Health Protection Agency: HIV &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;The Health Protection Agency's page on HIV contains prevalence data, geographical data, information about surveillance systems and much more.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.chiva.org.uk/" target="_blank"&gt;&lt;STRONG&gt;Children's HIV Association of UK and Ireland (CHIVA)&lt;/STRONG&gt;&lt;/A&gt; &lt;/P&gt;
&lt;P align=left&gt;CHIVA represents professionals who are committed to providing excellence in the care of children infected or affected by HIV and their families. CHIVA provides a resource for guidelines for HIV in children, hosts a national conference in London every autumn and a regional conference every May, local regional meetings, network contacts and information for families and children.&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;A href="http://www.bhiva.org/" target="_blank"&gt;&lt;STRONG&gt;The British HIV Association (BHIVA)&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;BHIVA has become the leading UK professional association representing professionals in HIV care. Now 15 years old, it is a well-established and highly respected organisation with national influence committed to providing excellence in the care of those living with and affected by HIV.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;A href="http://www.bashh.org/" target="_blank"&gt;&lt;STRONG&gt;The British Association for Sexual Health and HIV (BASHH)&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;BASHH aims to be the lead professional representative body for those practicing sexual health including the management of STIs and HIV in the UK&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;SPAN class=style2&gt;&lt;STRONG&gt;&lt;A href="http://www.nshpc.ucl.ac.uk/" target="_blank"&gt;The National Study of HIV in Pregnancy and Childhood (NSHPC)&lt;/A&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;The National Study of HIV in Pregnancy and Childhood (NSHPC) is the confidential national (UK and Ireland) active reporting scheme for pregnancies in HIV-infected women, babies born to HIV-infected women and other children with HIV infection and AIDS.&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.who.int/hiv/en/" target="_blank"&gt;&lt;STRONG&gt;World Health Organization pages on HIV/AIDS&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;As the directing and coordinating authority on international health, the World Health Organization (WHO) takes the lead within the UN system in the global health sector response to HIV/AIDS.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;A href="http://www.medfash.org.uk/" target="_blank"&gt;&lt;STRONG&gt;Medical Foundation for AIDS &amp;amp; Sexual Health (MedFASH)&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;The Medical Foundation for AIDS &amp;amp; Sexual Health is a charity set up by the British Medical Association to promote excellence in the field of sexual health and HIV.&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;A href="http://www.aidsmap.com/cms1038153.aspx" target="_blank"&gt;&lt;STRONG&gt;AIDS Map&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;NAM is an award-winning community based HIV information provider.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.tht.org.uk/" target="_blank"&gt;&lt;STRONG&gt;Terrence Higgins Trust&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;Terrence Higgins Trust is the leading and largest HIV and sexual health charity in the UK.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.pentatrials.org/network.htm" target="_blank"&gt;&lt;STRONG&gt;Paediatric European Network for Treatment of AIDS (PENTA)&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;The Paediatric European Network for the treatment of AIDS (PENTA) was established in 1991 as a collaboration between paediatric HIV centres in Europe.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;A href="http://www.unaids.org/en/" target="_blank"&gt;&lt;STRONG&gt;Joint United Nations Programme on HIV/AIDS (UNAIDS)&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;UNAIDS, the Joint United Nations Programme on HIV/AIDS, is an innovative joint venture of the United Nations family, bringing together the efforts and resources of ten UN system organizations in the AIDS response to help the world prevent new HIV infections, care for people living with HIV, and mitigate the impact of the epidemic.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308484</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=308484]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Commentaries</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,TUBERCULOSIS,PREVENTION,ANTIBIOTICS,ANTIMICROBIALS,INFECTIONS,VACCINES / IMMUNISATION,MARCH 09,DIAGNOSIS,TREATMENT,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,TUBERCULOSIS,MICROORGANISM,BCG,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Commentaries from experts in TB</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: Stopping TB - Commentaries&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The following experts have written commentaries about aspects of stopping TB.&amp;nbsp;These are also provided alongside the relevant subtopic on the AEU homepage. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:308484:6" name=internalLink&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt; &lt;/A&gt;by &lt;A href="nelh:308485:8" name=internalLink&gt;&lt;STRONG&gt;Dr Ibrahim Abubakar&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:308484:2" name=internalLink&gt;&lt;STRONG&gt;TB Vaccine Development&lt;/STRONG&gt;&lt;/A&gt;&amp;nbsp;by &lt;STRONG&gt;&lt;A href="nelh:308485:2" name=internalLink&gt;&lt;STRONG&gt;Professor Philip Marsh&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308484:3" name=internalLink&gt;&lt;STRONG&gt;Treatment Completion&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; by &lt;STRONG&gt;&lt;A href="nelh:308485:3" name=internalLink&gt;&lt;STRONG&gt;Dr. Marc Lipman&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308484:4" name=internalLink&gt;&lt;STRONG&gt;Line probe assays&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; by &lt;STRONG&gt;&lt;A href="nelh:308485:4" name=internalLink&gt;&lt;STRONG&gt;Professor Francis Drobniewski&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308484:5" name=internalLink&gt;&lt;STRONG&gt;HIV testing in TB clinics&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; by &lt;STRONG&gt;&lt;A href="nelh:308485:5" name=internalLink&gt;&lt;STRONG&gt;Dr. Ann Chapman&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;Introduction &lt;/EM&gt;&lt;EM&gt;by &lt;/EM&gt;&lt;EM&gt;Dr Ibrahim Abubakar&lt;/EM&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;This Annual Evidence Update provides a collection of evidence that has emerged over the last twelve months on tuberculosis accompanied by &lt;A href="nelh:308484:0" name=internalLink&gt;commentaries &lt;/A&gt;from &lt;A href="nelh:308485:0" name=internalLink&gt;experts&lt;/A&gt;. This year’s topic is in keeping with the World Health Organization’s focus; “I am stopping TB”. The evidence provided here include guidelines, systematic reviews, articles, reports and &lt;A href="nelh:308486:0" name=internalLink&gt;useful websites&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=”justify”&gt;Tuberculosis is an infectious disease caused by the bacterium &lt;EM&gt;Mycobacterium tuberculosis&lt;/EM&gt;. It remains the leading cause of death due to a single infectious agent globally with about 1.5 million deaths annually. Over 8000 new cases of tuberculosis are currently reported each year in the United Kingdom highlighting the importance and relevance of this week.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=”justify”&gt;Tuberculosis is usually curable provided the full course of treatment is taken. Appropriate use of TB medication also substantially reduces the risk of transmission, but failure to complete the course of treatment could result in the development of multi drug resistant (MDR) tuberculosis. When the bacteria develop the ability to withstand antibiotics, the outcome of care is poor and the strain can be spread from one person to another. &lt;A href="nelh:308477:1" name=internalLink&gt;Treatment completion&lt;/A&gt;, which is key to controlling TB, and particularly drug resistant TB, is discussed by &lt;A href="nelh:308485:3" name=internalLink&gt;Dr. Marc Lipman&lt;/A&gt;, a consultant physician at the Royal Free Hospital NHS Trust. Early diagnosis drug resistance can help clinicians to prescribe the correct medication and stop the spread of the drug resistant TB. New molecular tests such as &lt;A href="nelh:308479:0" name=internalLink&gt;line probe assays &lt;/A&gt;for the early diagnosis of drug resistance have recently been developed and approved by the World Health Organization for use globally. &lt;A href="nelh:308485:4" name=internalLink&gt;Professor Francis Drobniewski&lt;/A&gt;, the Director of the National Mycobacterium Reference Unit and WHO Supranational Reference Laboratory has provided a commentary on these&amp;nbsp;assays.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=”justify”&gt;Many initiatives are underway to develop vaccines with improved protection against tuberculosis. These &lt;A href="nelh:308476:0" name=internalLink&gt;new TB vaccines &lt;/A&gt;are either based on improving the Bacille Calmette-Guérin (BCG) vaccine using defined molecules to boost the protection already provided by a previous dose of BCG vaccine, or developing an attenuated strain of &lt;EM&gt;M. tuberculosis&lt;/EM&gt;. &lt;A href="nelh:308485:2" name=internalLink&gt;Professor Phil Marsh&lt;/A&gt;, the Health Protection Agency’s lead on tuberculosis vaccines, has provided a commentary on this.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P text-align:justify&gt;Human immunodeficiency virus (HIV) infection poses one of the greatest challenges to tuberculosis control with recent UK data suggesting an increase in the proportion of tuberculosis cases co-infected with HIV. New &lt;A href="nelh:294604:0" name=internalLink&gt;United Kingdom guidelines for HIV testing &lt;/A&gt;were recently published by the British HIV Association, the British Association for Sexual Health and HIV and the British Infection Society, in September 2008. These guidelines recommend more widespread HIV testing in clinical services such as TB clinics. This subject is discussed by &lt;A href="nelh:308485:5" name=internalLink&gt;Dr. Ann Chapman&lt;/A&gt;, a consultant infectious disease physician at the Royal Hallamshire Hospital, Sheffield.&amp;nbsp;&lt;/P&gt;
&lt;P text-align:justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P text-align:justify&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;TB Vaccine Development&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308476/nelhImp_0001_44_7d9311E38_TPVaccines.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary by Professor Philip Marsh&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The development of a more effective vaccine would have a major impact on reducing the global incidence of tuberculosis (TB). Currently, the only available vaccine against TB is bacille Calmette-Guérin (BCG), which has been received by over three billion people, making it the most widely used in the world.&amp;nbsp; BCG was developed in the early 1920’s, and is based on a live but attenuated strain of &lt;EM&gt;Mycobacterium bovis&lt;/EM&gt;. Although BCG is safe and protects children from the disease, it is less effective in adults, its efficacy varies globally, and it is not recommended for those who are immunocompromised.&amp;nbsp; Therefore, the development of a new vaccine is essential if tuberculosis is to be controlled and eradicated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The past two decades have seen a significant increase in the pace of development of potential new vaccines for tuberculosis.&amp;nbsp; This is due to advances in the discovery and characterisation of &lt;EM&gt;Mycobacterium tuberculosis&lt;/EM&gt; virulence factors, aided by the publication of the TB genome, and a greater knowledge of the type of immune response required. Current vaccine approaches include:&lt;/P&gt;
&lt;P&gt;(a) replacement of the current BCG vaccine with an improved version, either by introducing genes (e.g. recombinant BCG30 which expresses and secretes the &lt;EM&gt;M. tuberculosis&lt;/EM&gt;&amp;nbsp; Ag85B protein), or by delivering BCG by a mucosal (e.g. oral) route&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;(b) boosting the immunity provided by existing strains of BCG at a later time point with a sub-unit (i.e. a specific protein or DNA) vaccine (a prime-boost strategy). Several candidates for vaccine boosting are in early clinical trials, including hybrid 1 protein (Ag85B-ESAT6), and a viral vector (Modified Vaccinia virus Ankara, MVA) expressing Ag85A. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;(c) developing an attenuated strain of &lt;EM&gt;M. tuberculosis&lt;/EM&gt;.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The development of new TB vaccines would be accelerated if a correlate of protection was available.&amp;nbsp; Although it is known that cell mediated immunity is required, and that interferon gamma (IFN-gamma) production is essential, levels of this cytokine following vaccination do not correlate with protection. This means that new vaccines have to be assessed in long-term efficacy studies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Although the development of an improved TB vaccine is a lengthy process, there is a strong commitment from numerous international health organisations and funding bodies to evaluate a small number of novel formulations and delivery systems in clinical trials over the next 5-10 years. One of the aims of the WHO Global Plan to Stop TB (2006-2015) is to have a safe, affordable, licensed new TB vaccine available by 2015.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Treatment Completion&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308477/nelhImp_0000_44_7d9311FA_TBcompletion.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary&amp;nbsp;by Dr. Marc Lipman &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;When effective anti-tuberculosis agents were first used sixty years ago, treatment was directed at individuals with severe symptomatic (active) tuberculosis disease. It quickly became apparent that lifelong cure was not possible using monotherapy; and that patients relapsed. The addition of further potent drugs led to an acceptable genuine cure rate achieved with a much shorter treatment duration. However in 2009, therapy for drug-sensitive tuberculosis still needs to be taken for a recommended minimum of six months – far longer than pretty much any other “bacterial” infection. Given that current drugs have significant adverse effects, may interact with other prescribed or illicit medication and can be costly if not funded through a free healthcare service, there is great potential for non-adherence to therapy and unsuccessful treatment. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The impact of this can be considerable for both the individual and the general public. The disease may not be controlled in the short term, and it can relapse in either its original form or as a mutated drug-resistant strain. The latter is usually considerably harder to treat and so requires more prolonged therapy with other agents which are likely to have significant adverse effects. Overall outcome (as shown in particular with extensively drug resistant TB, where the organism is resistant to at least isoniazid, rifampicin, a fluoroquinolone and a second line injectable agent such as amikacin, kanamycin or capreomycin) is often poor.&amp;nbsp; If the affected individual has pulmonary TB, they are also at risk of being infectious for longer – leading to increased transmission to their close contacts.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Issues such as this, plus the increasing numbers of HIV co-infected individuals developing accelerated TB disease, have prompted a re-think of how treatment completion may be best achieved. The ultimate aims are to clear the infection and stop its recurrence (which also needs to be distinguished if at all possible from re-infection with another strain in TB endemic areas). Successful strategies have included the use of Directly Observed Therapy programmes, patient reminders and incentives as well as tracer systems in those missing appointments. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are ongoing studies investigating the use of treatment-shortening regimens (eg four months of standard agents where the quinolone, moxifloxacin, is substituted for either isoniazid or ethambutol); as well as a search for possible individual bio-markers (both microbial and related to host immunity) which will predict treatment response and long term non-relapse. The results of these are eagerly awaited as evidence suggests that most subjects who default from treatment can be identified at an early stage (possibly prior to significant non-adherence); and then have tailored treatment programmes based on extent of disease and drug sensitivity (determining regimen composition and duration) as well as social and psychological need. Whilst this may sound an expensive option, it is clear that this approach is likely to be much less than the costs associated with the management of non-adherence and subsequent drug resistant disease.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Unlike sixty years ago, there is now also an increased focus on the detection of asymptomatic individuals with latent TB infection who are likely to progress to active disease. Drug therapy is effective in reducing this risk, though again can be associated with poor rates of treatment completion. Here too, new drug regimens are being trialled for efficacy as well as adverse effect profile (especially important as the individuals are, by definition, symptom-free pre-treatment). Whatever drugs are used, regular contact by the TB service or nominated “peer representatives”, such as family members of individuals on therapy, leads to a greater chance of treatment completion – so avoiding the problems associated with the development of active TB.&amp;nbsp; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Line probe assays&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308479/nelhImp_0000_44_7d9311E3A_TPlpa.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary by Professor Francis Drobniewski&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The annual global multidrug resistant tuberculosis (MDR-TB burden) is estimated at approximately 490 000 cases (Wright et al 2009) with the majority of cases occurring in Russia and the countries of the former Soviet Union, China and India; however, a global lack of laboratory infrastructure has meant that only a small proportion of these cases could be diagnosed, mainly in industrialized countries. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Worrying increases in MDR-TB cases, the emergence of extensively drug resistant TB (XDR-TB i.e MDRTB cases additionally resistant to any fluroquinolone and to either amikacin, kanamycin or capreomycin), potential institutional transmission, and the rapid mortality of MDR-TB and XDR-TB patient with HIV co-infection, have highlighted the urgency for novel rapid screening methods for MDRTB.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Conventional methods for mycobacteriological culture and drug susceptibility testing (DST) are slow, requiring sequential procedures for isolation of mycobacteria from clinical specimens, identification of Mycobacterium tuberculosis complex (MTBC) organisms, and in vitro testing of strain susceptibility to anti-TB drugs. Automated rapid liquid culture techniques have reduced the overall time, but the analysis would still take 3-4 weeks and during this period patients may be inappropriately treated, drug resistant strains may continue to spread, and amplification of resistance may occur.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Novel technologies for rapid detection of anti-TB drug resistance have therefore become a priority in TB research and development and several in house and commercial systems have been developed.&amp;nbsp; Molecular line probe assays focused on rapid detection of rifampicin resistance (alone or in combination with isoniazid)&amp;nbsp; involve the following steps: first, DNA is extracted from M. tuberculosis isolates or directly from clinical specimens. Next, polymerase chain reaction (PCR) amplification of the resistance-determining region of the gene under question is performed using biotinylated primers. Following amplification, labeled PCR products are hybridized with specific oligonucleotide probes immobilized on a strip. Captured labeled hybrids are detected by colorimetric development, enabling detection of the presence of M. tuberculosis complex, as well as the presence of wild-type and mutation probes for resistance. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A limited number of commercial assays for testing clinical specimens (sputum) is currently available on the market, including INNO-LiPA Rif.TB (Innogenetics N.V, Ghent, Belgium) and GenoType® MTBDR (HAIN Lifesciences GmbH, Nehren, Germany). The new version of&amp;nbsp; the latter&amp;nbsp; assay&amp;nbsp; (GenoType® MTBDRplus),&amp;nbsp; targeting&amp;nbsp; the&amp;nbsp; rpoB&amp;nbsp; gene&amp;nbsp; associated&amp;nbsp; with&amp;nbsp; the resistance to RIF and both genes (katG and inhA) associated with the resistance to INH has been evaluated on clinical&amp;nbsp; specimens.&amp;nbsp;&amp;nbsp; Systematic reviews of the performance of the two types of assays have confirmed excellent specificity&amp;nbsp; and good concordance with culture-based DST&amp;nbsp; results.&amp;nbsp; For example, Morgan et al, 2005 reviewed four small studies that applied LiPA directly to clinical specimens showing 100% specificity, and sensitivity that ranged between 80% and 100% and other small studies have found similar results (Traore et al, 2005; Quezada CM et al 2007; Tortoli et al, 2007). In the largest study published to date, Sam et al. (2006) analyzed the results in a nontrial context of nearly 2000 patients and the overall adjusted concordance, sensitivity, specificity, positive predictive value, and negative predictive value for detecting MTBC were 91.2%, 85.2%, 96.2%, 95.7%, and 86.7%, respectively; the parameters for detecting rifampicin resistance were 99.1%, 95.0%, 99.6%, 92.7%, and 99.7%, respectively.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Several small studies of the GenoType® MTBDRplus system in low TB incidence&amp;nbsp; settings, (eg Hilleman et al, 2006; Makinen et al, 2006; Miotto et al 2008) and a&amp;nbsp; meta-analysis (Ling DI et al 2008), have demonstrated excellent&amp;nbsp; specificity&amp;nbsp; and good concordance with culture-based DST&amp;nbsp; results. This system has been evaluated in other settings: a&amp;nbsp; recent&amp;nbsp; study&amp;nbsp; demonstrated&amp;nbsp; the&amp;nbsp; feasibility&amp;nbsp; of&amp;nbsp; this&amp;nbsp; assay&amp;nbsp; as&amp;nbsp; a&amp;nbsp; screening&amp;nbsp; tool&amp;nbsp; when applied&amp;nbsp; in&amp;nbsp; a&amp;nbsp; high-volume&amp;nbsp; public&amp;nbsp; health&amp;nbsp; laboratory&amp;nbsp; in&amp;nbsp; a&amp;nbsp; high&amp;nbsp; TB&amp;nbsp; and&amp;nbsp; HIV,&amp;nbsp; but&amp;nbsp; low&amp;nbsp; drug resistance, incidence area in South Africa. Barnard et al performed the assay directly on 536 consecutive smear-positive sputum specimens with a sensitivity, specificity, and positive and negative predictive values were 98.9, 99.4, 97.9, and 99.7%, respectively, for detection of rifampicin resistance; 94.2, 99.7, 99.1, and 97.9%, respectively, for detection of isoniazid resistance; and 98.8, 100, 100, and 99.7%, respectively, for detection of multidrug resistance compared with conventional DST. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In a high MDR-TB area (Russia) Nikolayevskyy et al (2009), demonstrated a sensitivity of the assay for detection of RIF, INH and MDR-TB resistance of 96.2%, 97.4% and 97.1% and a specificity of 90.7%, 83.3% and 88.9% respectively.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The WHO considered all the above evidence in 2008, and recommended that line probe-type assays have been adequately validated in direct testing of sputum smear-positive specimens and on isolates of M. tuberculosis complex grown from smear-negative and smear-positive specimens. The use of commercial line probe assays rather than in-house assays was recommended to ensure reliability and reproducibility of results.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Line probe assays would not be a complete replacement for conventional culture and DST, as mycobacteriological culture is still required for smear-negative specimens while conventional DST is still necessary to confirm XDR-TB and to analyse other drug resistance for clinical management and surveillance.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;HIV testing in TB clinics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308481/nelhImp_0000_44_7d9311E3B_TPhiv.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary&amp;nbsp;by Ann Chapman&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Over the past 20 years the spectrum of human immunodeficiency virus (HIV) disease in the United Kingdom has shifted from an untreatable, stigmatised infection to a treatable chronic disease with, as far as we know, a normal or near normal life expectancy. With this change have been parallel changes in perceptions of HIV both in the medical profession and the general public. In testing for HIV infection there has been a transition from ‘counselling’ by highly trained staff to ‘informed consent’ by any doctor, nurse or midwife, as with other chronic infections.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The recent guidelines on testing for HIV published by the British HIV Association, British Infection Society and British Association for Sexual Health and HIV (1) recommend increasing the breadth of testing across a wide range of clinical areas. This is advocated on the grounds that up to a third of HIV infections in the UK occur in individuals who are unaware of their status, and that late HIV diagnosis is associated with increased morbidity and mortality (2). Earlier diagnosis allows the patient to be referred to specialist HIV services with timely administration of antimicrobial prophylaxis against opportunistic infections and antiretroviral therapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines recommend testing patients with ‘indicator diseases’ that are more common in HIV-infected individuals; tuberculosis (TB) is one of these. In the United Kingdom in 2006, 3.6% of new TB cases were co-infected with HIV (3): this overall figure is likely to have risen further with the increasing proportion of TB cases from countries of high TB and HIV prevalence, and there are also wide regional variations. Co-infection rates in many other parts of the world are, however, much higher, for example 40-60% of TB patients in Tanzania and Rwanda (4,5), and globally the World Health Organisation has been advocating HIV screening for newly diagnosed TB patients for a number of years (6). Although earlier HIV diagnosis enables patients to receive early antiretroviral therapy if indicated for their stage of HIV disease, provision of antiretroviral therapy is still patchy in many parts of the world, and perhaps a more important immediate intervention is the administration of co-trimoxazole, a cheap and highly effective agent to reduce mortality and morbidity due to opportunistic infection (7). Furthermore, knowledge of one’s HIV status may also lead to risk reduction behaviour and contribute to reduced HIV transmission (8).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;So, what are the barriers to testing for HIV in the UK and beyond? Where concerted efforts are made, high rates of testing can be achieved (4), but in the UK currently it is likely that only a small proportion of newly diagnosed TB patients are tested (9). Clearly many doctors still do not test as a routine, perhaps due to unfamiliarity with obtaining informed consent, or discomfort in broaching the subject, especially with particular patient groups, although the success of the antenatal screening programme suggests that high uptake can be achieved in the UK if the test is presented as a routine element of care. Perhaps one of the main barriers to routine testing of TB patients for HIV infection remains the lack of awareness of the value of this measure both to the individual and to public health more generally, and it is to be hoped that recent initiatives highlighting this, such as the recent guidelines and the National Knowledge Service TB Pilot (1,9), may improve uptake.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. The British HIV Association, the British Association of Sexual Health and HIV, and the British Infection Society. &lt;A href="nelh:294604:0" name=internalLink&gt;UK National Guidelines for HIV testing 2008&lt;/A&gt;. September 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Health Protection Agency. &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;HPAwebStandard/HPAweb_C/1203084355941" target="_blank"&gt;Testing Times. HIV and other sexually transmitted infections in the United Kingdom: 2007&lt;/A&gt;. November 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. World Health Organization. &lt;A href="http://www.who.int/GlobalAtlas/predefinedReports/TB/PDF_Files/gbr.pdf" target="_blank"&gt;TB country profile: United Kingdom&amp;nbsp;2003-2006&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Gasana M, Vandebriel G, Kabanda G, et al. &lt;A href="nelh:308960:0" name=internalLink&gt;Integrating TB and HIV care in rural Rwanda&lt;/A&gt;. Int J Tuberc Lung Dis 2008;12(3 suppl 1):39-43.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Range N, Magnussen P, Mugomela A, et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17524249" target="_blank"&gt;HIV and parasitic co-infections in tuberculosis patients: a cross-sectional study in Mwanza, Tanzania&lt;/A&gt;. Ann Trop Med Parasitol 2007;101:343-351.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. World Health Organization. &lt;A href="http://whqlibdoc.who.int/hq/2004/WHO_HTM_TB_2004.339.pdf" target="_blank"&gt;Guidelines for HIV surveillance among tuberculosis patients&lt;/A&gt;. Geneva,&amp;nbsp;2004.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Harries AD, Zachariah R, Lawn SD. &lt;A href="nelh:308961:0" name=internalLink&gt;Providing HIV care for co-infected TB patients: a perspective from sub-Saharan Africa&lt;/A&gt;. Int J Tuberc Lung Dis 2009;13:6-16.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Deribe K, Woldemichael K, Wondafrash M, et al. &lt;A href="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2275263&amp;amp;blobtype=pdf" target="_blank"&gt;Disclosure experience and associated factors among HIV-positive men and women clinical service users in Southwest Ethiopia&lt;/A&gt;. BMC Public Health 2008;8:81.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. &lt;A href="http://www.bhiva.org/files/file1001377.pdf" target="_blank"&gt;BHIVA Survey of management of TB and HIV co-infection 2004-5&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200055718370" target="_blank"&gt;The National Knowledge Service TB Pilot&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308485</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=308485]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Contributors</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MARCH 09,ADDED 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Contributors to the AEU</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;7&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: Stopping TB - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The Infections Specialist Library would like to thank the following contributors for their commentaries and evidence.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308485:2" name=internalLink&gt;&lt;STRONG&gt;Professor Philip Marsh&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308485:3" name=internalLink&gt;&lt;STRONG&gt;Dr. Marc Lipman&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308485:4" name=internalLink&gt;&lt;STRONG&gt;Professor Francis Drobniewski&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308485:5" name=internalLink&gt;&lt;STRONG&gt;Dr. Ann Chapman&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:308485:8" name=internalLink&gt;&lt;STRONG&gt;Dr. Ibrahim Abubakar&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Professor Philip Marsh&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=628 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;IMG height=120 src="/libraryImages/infections/contentID308485/nelhImp_0008_44_7D9312F3A_pm.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;Professor Marsh is Programme Leader for the TB group at the HPA Centre for Emergency Preparedness and Response, Salisbury. The work of this group is focussed on understanding more about how pathogenic mycobacteria cause active and latent disease, and on developing and evaluating new vaccines against tuberculosis. &lt;/P&gt;
&lt;P&gt;He is a member of the HPA TB Programme Board, and is a Work-package co-ordinator for the EU-funded programme MUVAPRED (Mucosal Vaccines against Poverty Related Diseases). &lt;/P&gt;
&lt;P&gt;Professor Marsh is a regular invited speaker at international conferences, and has published over 200 research papers and reviews on various infectious diseases.&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Marc Lipman&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;TABLE cellSpacing=0 cellPadding=0 width=628 align=center border=0&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD&gt;&lt;IMG height=120 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308485/nelhImp_0009_44_7D9312105_mc.jpg"&gt;&lt;/TD&gt; &lt;TD&gt;&amp;nbsp;&lt;/TD&gt; &lt;TD&gt; &lt;P&gt;Marc Lipman is a Senior Lecturer and Consultant in Respiratory and HIV Medicine at the Royal Free Hospital, London. He is chair of the BTS TB Specialist Advisory Group and a member of the HPA TB Programme Board. His research interests focus on tuberculosis, respiratory infection and HIV. &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Professor Francis Drobniewski&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;BR&gt;&lt;/P&gt; &lt;TABLE cellSpacing=0 cellPadding=0 width=628 align=center border=0&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD&gt;&lt;IMG height=120 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308485/nelhImp_0013_44_7D9313FA_pfd.jpg"&gt;&lt;/TD&gt; &lt;TD&gt;&amp;nbsp;&lt;/TD&gt; &lt;TD&gt; &lt;P&gt;Prof. Francis Drobniewski is the Director of the Health Protection Agency National Mycobacterium Reference Unit (MRU), Consultant Microbiologist and TB Physician, and Professor of Tuberculosis and Mycobacterial Diseases at King's and Queen Mary Colleges, the University of London and Visiting Professor in Infectious Diseases, Imperial College, London. He heads the Clinical TB and HIV group within the Center for Infectious Diseases at Queen Mary College, London.&lt;/P&gt; &lt;P&gt;He received his PhD from University of Cambridge; Diploma of Tropical Medicine and Hygiene, London School Hygiene; MB BS from the University of London; Diploma of Tropical Medicine and Hygiene from the London School Hygiene and Topical Medicine/Royal College of Physicians; and MSc in Medical Microbiology from the University of London. He is a Fellow of the Royal College of Pathologists, and a member of the WHO Strategic and Technical Advisory Group (determines global WHO policy) and chairs the WHO European Laboratory Task force.&lt;/P&gt; &lt;P&gt;His interests relate to all aspects of tuberculosis, AIDS and respiratory infections especially molecular epidemiology and drug resistance, international public health, pathogenesis and opportunistic diseases in the immunocompromised.&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt; &lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Ann Chapman&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;TABLE cellSpacing=0 cellPadding=0 width=628 align=center border=0&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD&gt;&lt;IMG height=120 src="/libraryImages/infections/contentID308485/nelhImp_0011_44_7D9312F3B_alc.jpg"&gt; &lt;/TD&gt; &lt;TD&gt;&amp;nbsp;&lt;/TD&gt; &lt;TD&gt; &lt;P&gt;Dr. Ann Chapman studied Medicine in Cambridge and then Oxford, and then specialised in Infectious Diseases and General Internal Medicine. She completed a PhD in the Immunology of Epstein-Barr virus in 2000. She developed an interest in tuberculosis during her specialist clinical training in Birmingham, and decided therefore to apply her previous research experience to this field, conducting a study of the ELIspot assay for diagnosing active and latent tuberculosis in Zambia, a country of high HIV and TB prevalence. She now works as a Consultant in Infectious Diseases in the Department of Infection and Tropical Medicine in Sheffield, UK, where, among other things, she runs the tuberculosis service and continues to undertake clinical research into tuberculosis.&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;8&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Ibrahim Abubakar&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;TABLE cellSpacing=0 cellPadding=0 width=628 align=center border=0&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD&gt;&lt;IMG height=120 src="/libraryImages/infections/contentID308485/nelhImp_0014_44_7D9313F9_ia.jpg"&gt;&lt;/TD&gt; &lt;TD&gt;&lt;/TD&gt; &lt;TD&gt; &lt;P&gt;Dr. Ibrahim Abubakar heads the TB Section at the HPA's Centre for Infections. He holds a Clinical Senior Lecturer post at the University of East Anglia and is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine and at University College London. Ibrahim runs the national enhanced TB surveillance system and a national clinical/public health advisory service on TB incident/outbreak management. He is a member of the WHO Global Task Force on TB Impact Measurement. His current research interests include various aspects of the epidemiology and control of mycobacterial infections. &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308481</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=308481]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - HIV testing in TB clinics</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,PUBLIC HEALTH,POPULATIONS,GROUPS,MANAGEMENT &amp; INTERVENTIONS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TUBERCULOSIS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,HEALTHCARE &amp; HEALTH SERVICES,SERVICES,PEOPLE WITH HIV OR AIDS,COMMUNICABLE DISEASES,TUBERCULOSIS,HIV INFECTION,HEALTH SERVICES,POPULATION BASED &amp; PREVENTATIVE SERVICES,INFECTION CONTROL,MONTHLY ADDITIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,DIAGNOSIS,MARCH 09,2009 MARCH,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,MALE UROGENITAL DISORDERS,HIV]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on HIV testing in TB clinics</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: HIV testing in TB clinics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308481/nelhImp_0000_44_7d9311E3B_TPhiv.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary by &lt;A href="nelh:308485:5" name=internalLink&gt;Dr. Ann Chapman&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Over the past 20 years the spectrum of human immunodeficiency virus (HIV) disease in the United Kingdom has shifted from an untreatable, stigmatised infection to a treatable chronic disease with, as far as we know, a normal or near normal life expectancy. With this change have been parallel changes in perceptions of HIV both in the medical profession and the general public. In testing for HIV infection there has been a transition from ‘counselling’ by highly trained staff to ‘informed consent’ by any doctor, nurse or midwife, as with other chronic infections.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The recent guidelines on testing for HIV published by the British HIV Association, British Infection Society and British Association for Sexual Health and HIV (1) recommend increasing the breadth of testing across a wide range of clinical areas. This is advocated on the grounds that up to a third of HIV infections in the UK occur in individuals who are unaware of their status, and that late HIV diagnosis is associated with increased morbidity and mortality (2). Earlier diagnosis allows the patient to be referred to specialist HIV services with timely administration of antimicrobial prophylaxis against opportunistic infections and antiretroviral therapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The guidelines recommend testing patients with ‘indicator diseases’ that are more common in HIV-infected individuals; tuberculosis (TB) is one of these. In the United Kingdom in 2006, 3.6% of new TB cases were co-infected with HIV (3): this overall figure is likely to have risen further with the increasing proportion of TB cases from countries of high TB and HIV prevalence, and there are also wide regional variations. Co-infection rates in many other parts of the world are, however, much higher, for example 40-60% of TB patients in Tanzania and Rwanda (4,5), and globally the World Health Organisation has been advocating HIV screening for newly diagnosed TB patients for a number of years (6). Although earlier HIV diagnosis enables patients to receive early antiretroviral therapy if indicated for their stage of HIV disease, provision of antiretroviral therapy is still patchy in many parts of the world, and perhaps a more important immediate intervention is the administration of co-trimoxazole, a cheap and highly effective agent to reduce mortality and morbidity due to opportunistic infection (7). Furthermore, knowledge of one’s HIV status may also lead to risk reduction behaviour and contribute to reduced HIV transmission (8).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;So, what are the barriers to testing for HIV in the UK and beyond? Where concerted efforts are made, high rates of testing can be achieved (4), but in the UK currently it is likely that only a small proportion of newly diagnosed TB patients are tested (9). Clearly many doctors still do not test as a routine, perhaps due to unfamiliarity with obtaining informed consent, or discomfort in broaching the subject, especially with particular patient groups, although the success of the antenatal screening programme suggests that high uptake can be achieved in the UK if the test is presented as a routine element of care. Perhaps one of the main barriers to routine testing of TB patients for HIV infection remains the lack of awareness of the value of this measure both to the individual and to public health more generally, and it is to be hoped that recent initiatives highlighting this, such as the recent guidelines and the National Knowledge Service TB Pilot (1,9), may improve uptake.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. The British HIV Association, the British Association of Sexual Health and HIV, and the British Infection Society. &lt;A href="nelh:294604:0" name=internalLink&gt;UK National Guidelines for HIV testing 2008&lt;/A&gt;. September 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Health Protection Agency. &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;HPAwebStandard/HPAweb_C/1203084355941" target="_blank"&gt;Testing Times. HIV and other sexually transmitted infections in the United Kingdom: 2007&lt;/A&gt;. November 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. World Health Organization. &lt;A href="http://www.who.int/GlobalAtlas/predefinedReports/TB/PDF_Files/gbr.pdf" target="_blank"&gt;TB country profile: United Kingdom&amp;nbsp;2003-2006&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Gasana M, Vandebriel G, Kabanda G, et al. &lt;A href="nelh:308960:0" name=internalLink&gt;Integrating TB and HIV care in rural Rwanda&lt;/A&gt;. Int J Tuberc Lung Dis 2008;12(3 suppl 1):39-43.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Range N, Magnussen P, Mugomela A, et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17524249" target="_blank"&gt;HIV and parasitic co-infections in tuberculosis patients: a cross-sectional study in Mwanza, Tanzania&lt;/A&gt;. Ann Trop Med Parasitol 2007;101:343-351.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. World Health Organization. &lt;A href="http://whqlibdoc.who.int/hq/2004/WHO_HTM_TB_2004.339.pdf" target="_blank"&gt;Guidelines for HIV surveillance among tuberculosis patients&lt;/A&gt;. Geneva,&amp;nbsp;2004.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Harries AD, Zachariah R, Lawn SD. &lt;A href="nelh:308961:0" name=internalLink&gt;Providing HIV care for co-infected TB patients: a perspective from sub-Saharan Africa&lt;/A&gt;. Int J Tuberc Lung Dis 2009;13:6-16.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Deribe K, Woldemichael K, Wondafrash M, et al. &lt;A href="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2275263&amp;amp;blobtype=pdf" target="_blank"&gt;Disclosure experience and associated factors among HIV-positive men and women clinical service users in Southwest Ethiopia&lt;/A&gt;. BMC Public Health 2008;8:81.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. &lt;A href="http://www.bhiva.org/files/file1001377.pdf" target="_blank"&gt;BHIVA Survey of management of TB and HIV co-infection 2004-5&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200055718370" target="_blank"&gt;The National Knowledge Service TB Pilot&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: HIV testing in TB clinics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. The British HIV Association, the British Association of Sexual Health and HIV, and the British Infection Society. &lt;A href="nelh:294604:0" name=internalLink&gt;UK National Guidelines for HIV testing 2008&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Gray DM, Zar H, Cotton M. &lt;A href="nelh:304939:0" name=internalLink&gt;Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children&lt;/A&gt;. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006418. DOI: 10.1002/14651858.CD006418.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Barth RE, Mudrikova T, Hoepelman AIM. &lt;A href="nelh:308667:0" name=internalLink&gt;Interferon-gamma release assays (IGRAs) in high-endemic settings: could they play a role in optimizing global TB diagnostics? Evaluating the possibilities of using IGRAs to diagnose active TB in a rural African setting. &lt;/A&gt;International Journal of Infectious Diseases, November 2008, vol./is. 12/6(e1-e6), 1201-9712.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. El-Sadr WM, Tsiouris SJ. &lt;A href="nelh:308905:0" name=internalLink&gt;HIV-associated Tuberculosis: Diagnostic and treatment challenges&lt;/A&gt;. Seminars in Respiratory and Critical Care Medicine, October 2008, vol./is. 29/5(525-531), 1069-3424;1098-9048.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Lalloo UG, Pillay S. &lt;A href="nelh:308911:0" name=internalLink&gt;Managing tuberculosis and HIV in sub-Sahara Africa&lt;/A&gt;. Current HIV/AIDS Reports, August 2008, vol./is. 5/3(132-9), 1548-3576.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Havlir DV, Getahun H, Sanne I, Nunn P. &lt;A href="nelh:308920:0" name=internalLink&gt;Opportunities and challenges for HIV care in overlapping HIV and TB epidemics&lt;/A&gt;. JAMA - Journal of the American Medical Association, July 2008, vol./is. 300/4(423-430), 0098-7484;1538-3598.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Murphy RA. &lt;A href="nelh:308926:0" name=internalLink&gt;The emerging crisis of drug-resistant tuberculosis in South Africa: Lessons from New York City&lt;/A&gt;. Clinical Infectious Diseases, June 2008, vol./is. 46/11(1729-1732), 1058-4838.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Elston JW, Thaker HK. &lt;A href="nelh:308929:0" name=internalLink&gt;Co-infection with human immunodeficiency virus and tuberculosis&lt;/A&gt;. Indian Journal of Dermatology, Venereology &amp;amp; Leprology, May 2008, vol./is. 74/3(194-9), 0973-3922.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Gunneberg C, Reid A, Williams BG, Floyd K, Nunn P. &lt;A href="nelh:308931:0" name=internalLink&gt;Global monitoring of collaborative TB-HIV activities&lt;/A&gt;. International Journal of Tuberculosis and Lung Disease, March 2008, vol./is. 12/3 SUPPL. 1(S2-S7), 1027-3719.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Harries AD. &lt;A href="nelh:308935:0" name=internalLink&gt;Robert Koch and the discovery of the tubercle bacillus: The challenge of HIV and tuberculosis 125 years later&lt;/A&gt;. International Journal of Tuberculosis and Lung Disease, March 2008, vol./is. 12/3(241-249), 1027-3719.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Lazarus JV, Olsen M, Ditiu L, Matic S. &lt;A href="nelh:308936:0" name=internalLink&gt;Tuberculosis-HIV co-infection: policy and epidemiology in 25 countries in the WHO European region&lt;/A&gt;. HIV Med 2008;9:406-414.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Harris JB, Hatwiinda SM, Randels KM et al. &lt;A href="nelh:308939:0" name=internalLink&gt;Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia&lt;/A&gt;. Int J Tuberc Lung Dis 2008;12:773-9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13. Scano F, Vitoria M, Burman W, et al. &lt;A href="nelh:308945:0" name=internalLink&gt;Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings&lt;/A&gt;. Int J Tuberc Lung Dis 2008;12:1370-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14. Williams G, Alarcon E, Jittimanee S, et al. &lt;A href="nelh:308946:0" name=internalLink&gt;HIV testing and care of the patient co-infected with tuberculosis and HIV&lt;/A&gt;. Int J Tuberc Lung Dis 2008;12:889-94.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;15. &lt;A href="nelh:308952:0" name=internalLink&gt;Provider-initiated HIV testing and counselling of TB patients – Livingstone District, Zambia, September 2004-December 2006&lt;/A&gt;. MMWR Morb Mortal Wkly Rep 2008;57:285-9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;16. Mahendradhata Y, Ahmad RA, Lefevre P, et al. &lt;A href="nelh:308956:0" name=internalLink&gt;Barriers for introducing HIV testing among tuberculosis patients in Jogjakarta, Indonesia: a qualitative study&lt;/A&gt;. BMC Public Health 2008;8:385.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;17. Nunn AJ, Mwaba P, Chintu C, et al. &lt;A href="nelh:308958:0" name=internalLink&gt;Role of co-trimoxazole prophylaxis in reducing mortality in HIV-infected adults being treated for tuberculosis: randomised clinical trial&lt;/A&gt;. BMJ 2008;337:a257.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;18. Gasana M, Vandebriel G, Kabanda G, et al. &lt;A href="nelh:308960:0" name=internalLink&gt;Integrating TB and HIV care in rural Rwanda&lt;/A&gt;. Int J Tuberc Lung Dis 2008;12(3 suppl 1):39-43.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;19. Harries AD, Zachariah R, Lawn SD. &lt;A href="nelh:308961:0" name=internalLink&gt;Providing HIV care for co-infected TB patients: a perspective from sub-Saharan Africa&lt;/A&gt;. Int J Tuberc Lung Dis 2009;13:6-16.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>307020</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=307020]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Homepage</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,INFECTIOUS DISEASES,TUBERCULOSIS,INFORMATION,MANAGEMENT &amp; POLICY,COMMUNICABLE DISEASES,TUBERCULOSIS,INFECTIONS,MONTHLY ADDITIONS,PREVENTION,2009 MARCH,TUBERCULOSIS,MYCOBACTERIUM,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM TUBERCULOSIS,BCG,VACCINES / IMMUNISATION,BACTERIA,MICROORGANISM,MARCH 09,ADDED 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best new evidence on stopping TB</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: Stopping TB - Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=0 cellPadding=0 width=630 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0010_44_7D939D7_TBhead.jpg"&gt; &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=”justify”&gt;Welcome to the &lt;STRONG&gt;2009 Annual Evidence Update: Stopping TB &lt;/STRONG&gt;by the &lt;A href="http://www.library.nhs.uk/Infections/" target="_blank"&gt;Infections Specialist Library &lt;/A&gt;in collaboration with the &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200055718370" target="_blank"&gt;National Knowledge Service - TB&lt;/A&gt;. This Annual Evidence Update will run from &lt;STRONG&gt;23rd to 30th March 2009&lt;/STRONG&gt;, and has been timed to coincide with &lt;A href="http://www.stoptb.org/events/world_tb_day/2009/" target="_blank"&gt;World TB day &lt;/A&gt;on 24th March.&lt;/P&gt;
&lt;P align=right&gt;Link to &lt;A href="nelh:309189:0" name=internalLink&gt;methodology&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;Download flyers in &lt;A href="http://www.onlinecpd.org/ISL/TBAEU-Flyer.pdf" target="_blank"&gt;portrait&lt;/A&gt; or &lt;A href="http://www.onlinecpd.org/ISL/TBAEU-FlyerLS.pdf" target="_blank"&gt;landscape&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=628 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD align=right&gt;&lt;A href="nelh:308476:0" name=internalLink&gt;&lt;IMG height=198 alt="Vaccines to prevent TB" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0011_44_7D939A38_aeub.1.jpg" width=216 border=0&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/infections/viewResource.aspx?resid=308476&amp;amp;code=314fb9232db44cbd622702c822b7072b" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG height=1 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0012_44_7D939B3_blank.jpg" width=68&gt;&lt;/TD&gt;
&lt;TD align=left&gt;&lt;A href="nelh:308477:0" name=internalLink&gt;&lt;A href="nelh:308477:0" name=internalLink&gt;&lt;IMG height=198 alt="Treatment Completion" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0013_44_7D939A3A_aeub.2.jpg" width=216 border=0&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/infections/viewResource.aspx?resid=308477&amp;amp;code=3c85249cde0ce2ac6774b4c2d69207b8" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG height=14 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0014_blank.jpg" width=1&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right&gt;&lt;A href="nelh:308479:0" name=internalLink&gt;&lt;IMG height=198 alt="Line Probe Assays in Diagnosis of TB" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0015_44_7D939B0_aeub.3.jpg" width=216 border=0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG height=1 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0016_blank.jpg" width=68&gt;&lt;/TD&gt;
&lt;TD align=left&gt;&lt;A href="nelh:308481:0" name=internalLink&gt;&lt;IMG height=198 alt="HIV testing in TB clinics" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID307020/nelhImp_0017_44_7D939B2_aeub.4.jpg" width=216 border=0&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=”left”&gt;&lt;BR&gt;Introduction by &lt;A href="nelh:308485:8" name=internalLink&gt;&lt;STRONG&gt;Dr Ibrahim Abubakar&lt;BR&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;Head of TB Section&lt;/STRONG&gt;, Centre for Infections, Health Protection Agency&lt;/P&gt;
&lt;P align=”left”&gt;&lt;/P&gt;
&lt;P align=left&gt;This Annual Evidence Update provides a collection of evidence that has emerged over the last twelve months on tuberculosis accompanied by &lt;A href="nelh:308484:0" name=internalLink&gt;commentaries &lt;/A&gt;from &lt;A href="nelh:308485:0" name=internalLink&gt;experts&lt;/A&gt;. This year’s topic is in keeping with the World Health Organization’s focus; “I am stopping TB”. The evidence provided here include guidelines, systematic reviews, articles, reports and &lt;A href="nelh:308486:0" name=internalLink&gt;useful websites&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=”justify”&gt;Tuberculosis is an infectious disease caused by the bacterium &lt;EM&gt;Mycobacterium tuberculosis&lt;/EM&gt;. It remains the leading cause of death due to a single infectious agent globally with about 1.5 million deaths annually. Over 8000 new cases of tuberculosis are currently reported each year in the United Kingdom highlighting the importance and relevance of this week.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=”justify”&gt;Tuberculosis is usually curable provided the full course of treatment is taken. Appropriate use of TB medication also substantially reduces the risk of transmission, but failure to complete the course of treatment could result in the development of multi drug resistant (MDR) tuberculosis. When the bacteria develop the ability to withstand antibiotics, the outcome of care is poor and the strain can be spread from one person to another. &lt;A href="nelh:308477:1" name=internalLink&gt;Treatment completion&lt;/A&gt;, which is key to controlling TB, and particularly drug resistant TB, is discussed by &lt;A href="nelh:308485:3" name=internalLink&gt;Dr. Marc Lipman&lt;/A&gt;, a consultant physician at the Royal Free Hospital NHS Trust. Early diagnosis drug resistance can help clinicians to prescribe the correct medication and stop the spread of the drug resistant TB. New molecular tests such as &lt;A href="nelh:308479:0" name=internalLink&gt;line probe assays &lt;/A&gt;for the early diagnosis of drug resistance have recently been developed and approved by the World Health Organization for use globally. &lt;A href="nelh:308485:4" name=internalLink&gt;Professor Francis Drobniewski&lt;/A&gt;, the Director of the National Mycobacterium Reference Unit and WHO Supranational Reference Laboratory has provided a commentary on these&amp;nbsp;assays.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=”justify”&gt;Many initiatives are underway to develop vaccines with improved protection against tuberculosis. These &lt;A href="nelh:308476:0" name=internalLink&gt;new TB vaccines &lt;/A&gt;are either based on improving the Bacille Calmette-Guérin (BCG) vaccine using defined molecules to boost the protection already provided by a previous dose of BCG vaccine, or developing an attenuated strain of &lt;EM&gt;M. tuberculosis&lt;/EM&gt;. &lt;A href="nelh:308485:2" name=internalLink&gt;Professor Phil Marsh&lt;/A&gt;, the Health Protection Agency’s lead on tuberculosis vaccines, has provided a commentary on this.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P text-align:justify&gt;Human immunodeficiency virus (HIV) infection poses one of the greatest challenges to tuberculosis control with recent UK data suggesting an increase in the proportion of tuberculosis cases co-infected with HIV. New &lt;A href="nelh:294604:0" name=internalLink&gt;United Kingdom guidelines for HIV testing &lt;/A&gt;were recently published by the British HIV Association, the British Association for Sexual Health and HIV and the British Infection Society, in September 2008. These guidelines recommend more widespread HIV testing in clinical services such as TB clinics. This subject is discussed by &lt;A href="nelh:308485:5" name=internalLink&gt;Dr. Ann Chapman&lt;/A&gt;, a consultant infectious disease physician at the Royal Hallamshire Hospital, Sheffield.&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=center&gt;_____________________&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308479</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=308479]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Line probe assays</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,EMERGENCY CARE,TB,CLINICAL LIBRARY,INFECTIOUS DISEASES,INFECTIONS,MARCH 09,DIAGNOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best evidence on line probe assays for diagnosing TB</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Line probe assays&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308479/nelhImp_0000_44_7d9311E3A_TPlpa.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary by &lt;A href="nelh:308485:4" name=internalLink&gt;Professor Francis Drobniewski&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The annual global multidrug resistant tuberculosis (MDR-TB burden) is estimated at approximately 490 000 cases (Wright et al 2009) with the majority of cases occurring in Russia and the countries of the former Soviet Union, China and India; however, a global lack of laboratory infrastructure has meant that only a small proportion of these cases could be diagnosed, mainly in industrialized countries. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Worrying increases in MDR-TB cases, the emergence of extensively drug resistant TB (XDR-TB i.e MDRTB cases additionally resistant to any fluroquinolone and to either amikacin, kanamycin or capreomycin), potential institutional transmission, and the rapid mortality of MDR-TB and XDR-TB patient with HIV co-infection, have highlighted the urgency for novel rapid screening methods for MDRTB.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Conventional methods for mycobacteriological culture and drug susceptibility testing (DST) are slow, requiring sequential procedures for isolation of mycobacteria from clinical specimens, identification of Mycobacterium tuberculosis complex (MTBC) organisms, and in vitro testing of strain susceptibility to anti-TB drugs. Automated rapid liquid culture techniques have reduced the overall time, but the analysis would still take 3-4 weeks and during this period patients may be inappropriately treated, drug resistant strains may continue to spread, and amplification of resistance may occur.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Novel technologies for rapid detection of anti-TB drug resistance have therefore become a priority in TB research and development and several in house and commercial systems have been developed.&amp;nbsp; Molecular line probe assays focused on rapid detection of rifampicin resistance (alone or in combination with isoniazid)&amp;nbsp; involve the following steps: first, DNA is extracted from M. tuberculosis isolates or directly from clinical specimens. Next, polymerase chain reaction (PCR) amplification of the resistance-determining region of the gene under question is performed using biotinylated primers. Following amplification, labeled PCR products are hybridized with specific oligonucleotide probes immobilized on a strip. Captured labeled hybrids are detected by colorimetric development, enabling detection of the presence of M. tuberculosis complex, as well as the presence of wild-type and mutation probes for resistance. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A limited number of commercial assays for testing clinical specimens (sputum) is currently available on the market, including INNO-LiPA Rif.TB (Innogenetics N.V, Ghent, Belgium) and GenoType® MTBDR (HAIN Lifesciences GmbH, Nehren, Germany). The new version of&amp;nbsp; the latter&amp;nbsp; assay&amp;nbsp; (GenoType® MTBDRplus),&amp;nbsp; targeting&amp;nbsp; the&amp;nbsp; rpoB&amp;nbsp; gene&amp;nbsp; associated&amp;nbsp; with&amp;nbsp; the resistance to RIF and both genes (katG and inhA) associated with the resistance to INH has been evaluated on clinical&amp;nbsp; specimens.&amp;nbsp;&amp;nbsp; Systematic reviews of the performance of the two types of assays have confirmed excellent specificity&amp;nbsp; and good concordance with culture-based DST&amp;nbsp; results.&amp;nbsp; For example, Morgan et al, 2005 reviewed four small studies that applied LiPA directly to clinical specimens showing 100% specificity, and sensitivity that ranged between 80% and 100% and other small studies have found similar results (Traore et al, 2005; Quezada CM et al 2007; Tortoli et al, 2007). In the largest study published to date, Sam et al. (2006) analyzed the results in a nontrial context of nearly 2000 patients and the overall adjusted concordance, sensitivity, specificity, positive predictive value, and negative predictive value for detecting MTBC were 91.2%, 85.2%, 96.2%, 95.7%, and 86.7%, respectively; the parameters for detecting rifampicin resistance were 99.1%, 95.0%, 99.6%, 92.7%, and 99.7%, respectively.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Several small studies of the GenoType® MTBDRplus system in low TB incidence&amp;nbsp; settings, (eg Hilleman et al, 2006; Makinen et al, 2006; Miotto et al 2008) and a&amp;nbsp; meta-analysis (Ling DI et al 2008), have demonstrated excellent&amp;nbsp; specificity&amp;nbsp; and good concordance with culture-based DST&amp;nbsp; results. This system has been evaluated in other settings: a&amp;nbsp; recent&amp;nbsp; study&amp;nbsp; demonstrated&amp;nbsp; the&amp;nbsp; feasibility&amp;nbsp; of&amp;nbsp; this&amp;nbsp; assay&amp;nbsp; as&amp;nbsp; a&amp;nbsp; screening&amp;nbsp; tool&amp;nbsp; when applied&amp;nbsp; in&amp;nbsp; a&amp;nbsp; high-volume&amp;nbsp; public&amp;nbsp; health&amp;nbsp; laboratory&amp;nbsp; in&amp;nbsp; a&amp;nbsp; high&amp;nbsp; TB&amp;nbsp; and&amp;nbsp; HIV,&amp;nbsp; but&amp;nbsp; low&amp;nbsp; drug resistance, incidence area in South Africa. Barnard et al performed the assay directly on 536 consecutive smear-positive sputum specimens with a sensitivity, specificity, and positive and negative predictive values were 98.9, 99.4, 97.9, and 99.7%, respectively, for detection of rifampicin resistance; 94.2, 99.7, 99.1, and 97.9%, respectively, for detection of isoniazid resistance; and 98.8, 100, 100, and 99.7%, respectively, for detection of multidrug resistance compared with conventional DST. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In a high MDR-TB area (Russia) Nikolayevskyy et al (2009), demonstrated a sensitivity of the assay for detection of RIF, INH and MDR-TB resistance of 96.2%, 97.4% and 97.1% and a specificity of 90.7%, 83.3% and 88.9% respectively.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The WHO considered all the above evidence in 2008, and recommended that line probe-type assays have been adequately validated in direct testing of sputum smear-positive specimens and on isolates of M. tuberculosis complex grown from smear-negative and smear-positive specimens. The use of commercial line probe assays rather than in-house assays was recommended to ensure reliability and reproducibility of results.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Line probe assays would not be a complete replacement for conventional culture and DST, as mycobacteriological culture is still required for smear-negative specimens while conventional DST is still necessary to confirm XDR-TB and to analyse other drug resistance for clinical management and surveillance.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Line probe assays&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. I-Ching S, Francis D, Philip M, Melanie K and Timothy B. &lt;A href="nelh:308617:0" name=internalLink&gt;Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom&lt;/A&gt;. Emerging Infectious Diseases 2006; 12:752-759.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Barnard M, Albert H, Coetzee G, O’Brien R and Bosman ME.&amp;nbsp; &lt;A href="nelh:308623:0" name=internalLink&gt;Rapid Molecular Screening for Multidrug-Resistant Tuberculosis in a High-Volume Public Health Laboratory in South Africa&lt;/A&gt;. Am J Respir Crit Care Med. 2008; 177, 787–792. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Hillemann D, Rusch-Gerdes S, Richter E. &lt;A href="nelh:308627:0" name=internalLink&gt;Application of the Genotype MTBDR assay directly on sputum specimens&lt;/A&gt;. Int J Tuberc Lung Dis 2006, 10(9):1057-1059.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Makinen J, Marttila HJ, Marjamaki M, Viljanen MK, Soini H. &lt;A href="nelh:308630:0" name=internalLink&gt;Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis&lt;/A&gt;. J Clin Microbiol 2006, 44(2):350-352.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Miotto P, Piana F, Cirillo DM, Migliori GB. &lt;A href="nelh:308632:0" name=internalLink&gt;Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis&lt;/A&gt;. J Clin Microbiol 2008, 46(1):393-394.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Ling DI, Zwerling AA, Pai M. &lt;A href="nelh:308634:0" name=internalLink&gt;GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis&lt;/A&gt;. Eur Respir J. 2008 Nov;32(5):1165-74. Epub 2008 Jul 9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Shah NS, Lan NT, Huyen MN, Laserson K, Iademarco MF, Binkin N, Wells C, Varma JK. &lt;A href="nelh:308648:0" name=internalLink&gt;Validation of the line-probe assay for rapid detection of rifampicin-resistant Mycobacterium tuberculosis in Vietnam&lt;/A&gt;. Int J Tuberc Lung Dis. 2009 Feb;13(2):247-252.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. World Health Organization. &lt;A href="nelh:308652:0" name=internalLink&gt;Molecular Line Probe Assays for rapid screening of patients at risk of multi drug-resistant tuberculosis (MDR – TB): Policy statement&amp;nbsp; &lt;/A&gt;July 2008 &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Quezada CM, Kamanzi E, Mukamutara J, De Rijk P, Rigouts L, Portaels F, Ben Amor Y. &lt;A href="nelh:308653:0" name=internalLink&gt;Implementation validation performed in Rwanda to determine whether the INNO-LiPA Rif.TB line probe assay can be used for detection of multidrug-resistant Mycobacterium tuberculosis in low-resource countries&lt;/A&gt;. J Clin Microbiol. 2007 Sep;45(9):3111-4. Epub 2007 Jul 11.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Tortoli E, Marcelli F.&amp;nbsp; &lt;A href="nelh:308658:0" name=internalLink&gt;Use of the INNO LiPA Rif.TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility&lt;/A&gt;. Eur J Clin Microbiol Infect Dis. 2007 Jan;26(1):51-5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Traore H, van Deun A, Shamputa IC, Rigouts L, Portaels F.&amp;nbsp;&amp;nbsp; &lt;A href="nelh:308661:0" name=internalLink&gt;Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay&lt;/A&gt;. J Clin Microbiol 2006 Dec;44(12):4384-8. Epub 2006 Oct 11.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Morgan M, Kalantri S, Flores L, Pai M. &lt;A href="nelh:243882:0" name=internalLink&gt;A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis&lt;/A&gt;. BMC Infect Dis. 2005 Jul 28;5:62. Review. PMID &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;-------------------&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Articles in press:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;1. Abigail Wright, Matteo Zignol, Armand Van Deun, Dennis Falzon, Sabine Ruesch Gerdes, Knut Feldman, Sven Hoffner, Francis Drobniewski, Lucia Barrera,&amp;nbsp; Dick van Soolingen, Fadila Boulabhal, C. N. Paramasivan, Kai Man Kam, Satoshi Mitarai, Ernesto Jaramillo, Paul Nunn, Mario Raviglione, for The Global Project on Anti-Tuberculosis Drug Resistance Surveillance.&amp;nbsp; &lt;STRONG&gt;Anti-tuberculosis drug resistance in the world, 2002-2007&lt;/STRONG&gt;.&amp;nbsp; Lancet 2009 (in press). &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Vladyslav Nikolayevskyy, Yanina Balabanova, Tatyana Simak, Nadezhda Malomanova, Ivan Fedorin and Francis Drobniewski.&amp;nbsp; &lt;STRONG&gt;Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation&lt;/STRONG&gt;.&amp;nbsp;&amp;nbsp; BMC Clinical Pathology 2009 (in press).&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>309189</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=309189]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Methodology</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MARCH 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A short summary of the methods used to find the evidence for this AEU</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: Stopping TB - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Identifying the&amp;nbsp;topic and a starting document&lt;/H2&gt;
&lt;P&gt;The last National Institute of Clinical Excellence (NICE) guidelines on TB were published in 2006 and no other suitable guidelines were found to base this Annual Evidence Update on, so this year’s topic was derived from the focus of this year’s campaign by the Stop TB partnership and the World Health Organization which is “I am stopping TB”. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Infections Specialist Library team and the National Knowledge Service-TB were responsible for &lt;A href="http://www.neli.org.uk/IntegratedCRD.nsf/TBNKW_2008?OpenForm" target="_blank"&gt;National Knowledge Weeks on TB &lt;/A&gt;in 2007 and 2008, which are available on the &lt;A href="http://www.neli.org.uk/" target="_blank"&gt;National electronic Library of Infection&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Search strategy&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Date of last search&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;• Searches were conducted on resources published between February 2008 and February 2009. &lt;BR&gt;• The exception to this was the section for line probe assays as they are a new diagnostic method and hence not many papers have been published on them yet. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched&lt;/STRONG&gt;&lt;BR&gt;• CINAHL&lt;BR&gt;• EMBASE&lt;BR&gt;• MEDLINE&lt;BR&gt;• HMIC&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Terms used&lt;/STRONG&gt;&lt;BR&gt;• The search terms “&lt;EM&gt;tuberculosis&lt;/EM&gt;”, “&lt;EM&gt;tb&lt;/EM&gt;” and “&lt;EM&gt;mycobacterium tuberculosis&lt;/EM&gt;” were searched for in the title fields. &lt;BR&gt;• Thesaurus terms (subheadings, exploded terms and major descriptor terms) for each of these were also used in the searches to encompass diagnosis, treatment and drug resistance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion and exclusion criteria&lt;/STRONG&gt;&lt;BR&gt;• The publication type was not restricted to systematic reviews as not many of these have been published in the last year. &lt;BR&gt;• Guidelines, reviews, reports and some primary evidence have also been included. &lt;BR&gt;• Articles were included if they had an abstract&lt;BR&gt;•&amp;nbsp;If the article was not published in English, it was still included if an English abstract was available. &lt;BR&gt;• The searches from the databases were combined, duplicates were removed, and the results were sifted through based on the relevance of the title or abstract. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308477</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=308477]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Treatment Completion</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ MANAGEMENT &amp; INTERVENTIONS,ANALYSIS &amp; RESEARCH,PUBLIC HEALTH,OUTCOMES,TUBERCULOSIS,INFECTIOUS DISEASES,VACCINES / IMMUNISATION,MEDICAL TREATMENT,TUBERCULOSIS,COMMUNICABLE DISEASES,HEALTHCARE &amp; HEALTH SERVICES,METHODS,ANALYSIS,INFECTIONS,MONTHLY ADDITIONS,PREVENTION,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MYCOBACTERIUM,MARCH 09,2009 MARCH,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,BCG,MICROORGANISM]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best evidence on the role of treatment completion in treating TB</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Treatment Completion&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308477/nelhImp_0001_44_7d9311FA_TBcompletion.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary by &lt;A href="nelh:308485:3" name=internalLink&gt;Dr. Marc Lipman&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;When effective anti-tuberculosis agents were first used sixty years ago, treatment was directed at individuals with severe symptomatic (active) tuberculosis disease. It quickly became apparent that lifelong cure was not possible using monotherapy; and that patients relapsed. The addition of further potent drugs led to an acceptable genuine cure rate achieved with a much shorter treatment duration. However in 2009, therapy for drug-sensitive tuberculosis still needs to be taken for a recommended minimum of six months – far longer than pretty much any other “bacterial” infection. Given that current drugs have significant adverse effects, may interact with other prescribed or illicit medication and can be costly if not funded through a free healthcare service, there is great potential for non-adherence to therapy and unsuccessful treatment. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The impact of this can be considerable for both the individual and the general public. The disease may not be controlled in the short term, and it can relapse in either its original form or as a mutated drug-resistant strain. The latter is usually considerably harder to treat and so requires more prolonged therapy with other agents which are likely to have significant adverse effects. Overall outcome (as shown in particular with extensively drug resistant TB, where the organism is resistant to at least isoniazid, rifampicin, a fluoroquinolone and a second line injectable agent such as amikacin, kanamycin or capreomycin) is often poor.&amp;nbsp; If the affected individual has pulmonary TB, they are also at risk of being infectious for longer – leading to increased transmission to their close contacts.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Issues such as this, plus the increasing numbers of HIV co-infected individuals developing accelerated TB disease, have prompted a re-think of how treatment completion may be best achieved. The ultimate aims are to clear the infection and stop its recurrence (which also needs to be distinguished if at all possible from re-infection with another strain in TB endemic areas). Successful strategies have included the use of Directly Observed Therapy programmes, patient reminders and incentives as well as tracer systems in those missing appointments. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There are ongoing studies investigating the use of treatment-shortening regimens (eg four months of standard agents where the quinolone, moxifloxacin, is substituted for either isoniazid or ethambutol); as well as a search for possible individual bio-markers (both microbial and related to host immunity) which will predict treatment response and long term non-relapse. The results of these are eagerly awaited as evidence suggests that most subjects who default from treatment can be identified at an early stage (possibly prior to significant non-adherence); and then have tailored treatment programmes based on extent of disease and drug sensitivity (determining regimen composition and duration) as well as social and psychological need. Whilst this may sound an expensive option, it is clear that this approach is likely to be much less than the costs associated with the management of non-adherence and subsequent drug resistant disease.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Unlike sixty years ago, there is now also an increased focus on the detection of asymptomatic individuals with latent TB infection who are likely to progress to active disease. Drug therapy is effective in reducing this risk, though again can be associated with poor rates of treatment completion. Here too, new drug regimens are being trialled for efficacy as well as adverse effect profile (especially important as the individuals are, by definition, symptom-free pre-treatment). Whatever drugs are used, regular contact by the TB service or nominated “peer representatives”, such as family members of individuals on therapy, leads to a greater chance of treatment completion – so avoiding the problems associated with the development of active TB.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Treatment Completion&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment completion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Kruk ME, Schwalbe NR, Aguiar CA. &lt;A href="nelh:307655:0" name=internalLink&gt;Timing of default from tuberculosis treatment: A systematic review&lt;/A&gt;. Tropical Medicine and International Health, May 2008, vol./is. 13/5(703-712), 1360-2276;1365-3156.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. &lt;A href="nelh:307665:0" name=internalLink&gt;Adherence to treatment for latent tuberculosis infection: Systematic review of studies in the US and Canada&lt;/A&gt;. International Journal of Tuberculosis and Lung Disease, November 2008, vol./is. 12/11(1235-1254), 1027-3719.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM. &lt;A href="nelh:307683:0" name=internalLink&gt;Biomarkers for TB treatment response: Challenges and future strategies&lt;/A&gt;. Journal of Infection, August 2008, vol./is. 57/2(103-109), 0163-4453.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Cox H S, Morrow M, Deutschmann P W.&amp;nbsp; &lt;A href="nelh:297386:0" name=internalLink&gt;Long term efficacy of DOTS regimens for tuberculosis: systematic review&lt;/A&gt;. BMJ 2008; 336: 484&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Storla DG, Yimer S, Bjune GA. &lt;A href="nelh:307685:0" name=internalLink&gt;A systematic review of delay in the diagnosis and treatment of tuberculosis&lt;/A&gt;. BMC Public Health, 2008, vol./is. 8/, 1471-2458.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Kittikraisak W, Burapat C, Kaewsa-ard S, Watthanaamornkiet W, Sirinak C, Sattayawuthipong W, Jittimanee S, Pobkeeree V, Varma JK. &lt;A href="nelh:308521:0" name=internalLink&gt;Factors associated with tuberculosis treatment default among HIV-infected tuberculosis patients in Thailand&lt;/A&gt;. Trans R Soc Trop Med Hyg. 2009 Jan;103(1):59-66. Epub 2008 Oct 19.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Liu Q, Abba K, Alejandria MM, Balanag VM, Berba RP, Lansang MA. &lt;A href="nelh:295737:0" name=internalLink&gt;Reminder systems and late patient tracers in the diagnosis and management of tuberculosis&lt;/A&gt;. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006594.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Krapp F, Véliz JC, Cornejo E, Gotuzzo E, Seas C. &lt;A href="nelh:308532:0" name=internalLink&gt;Bodyweight gain to predict treatment outcome in patients with pulmonary tuberculosis in Peru&lt;/A&gt;. Int J Tuberc Lung Dis. 2008 Oct;12(10):1153-9.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. &lt;A href="nelh:308533:0" name=internalLink&gt;Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment&lt;/A&gt;. J Infect. 2008 Oct 10. [Epub ahead of print].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C. &lt;A href="nelh:308571:0" name=internalLink&gt;Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania&lt;/A&gt;. Int J Tuberc Lung Dis. 2008 Sep;12(9):1037-41.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Abba K, Sudarsanam TD, Grobler L, Volmink J. &lt;A href="nelh:295724:0" name=internalLink&gt;Nutritional supplements for people being treated for active tuberculosis&lt;/A&gt;. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD006086. DOI: 10.1002/14651858.CD006086.pub2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Lew W, Pai M, Oxlade O, Martin D. &lt;A href="nelh:307688:0" name=internalLink&gt;Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis&lt;/A&gt;. Annals of Internal Medicine, 15 July 2008, vol./is. 149/2(123-134), 00034819, 15 July 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Cox HS, Morrow M, Deutschmann PW. &lt;A href="nelh:297386:0" name=internalLink&gt;Long term efficacy of DOTS regimens for tuberculosis: systematic review&lt;/A&gt;. BMJ: British Medical Journal, 01 March 2008, vol./is. 336/7642(484-487), 09598146, 01 March 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Ahmad Z, Khuller GK. &lt;A href="nelh:307706:0" name=internalLink&gt;Alginate-based sustained release drug delivery systems for tuberculosis&lt;/A&gt;. Expert Opinion on Drug Delivery, December 2008, vol./is. 5/12(1323-1334), 1742-5247.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Grant A, Gothard P, Thwaites G. &lt;A href="nelh:307708:0" name=internalLink&gt;Managing drug resistant tuberculosis&lt;/A&gt;. BMJ, September 2008, vol./is. 337/7669(564-569), 0959-8146.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Donald PR, Diacon AH. &lt;A href="nelh:307710:0" name=internalLink&gt;The early bactericidal activity of anti-tuberculosis drugs: a literature review&lt;/A&gt;. Tuberculosis, August 2008, vol./is. 88 Suppl 1/(S75-83), 1873-281X.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Evans DJ. &lt;A href="nelh:307711:0" name=internalLink&gt;The use of adjunctive corticosteroids in the treatment of pericardial, pleural and meningeal tuberculosis: Do they improve outcome?&lt;/A&gt; Respiratory Medicine, June 2008, vol./is. 102/6(793-800), 0954-6111.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Williams G, Alarcon E, Jittimanee S, Walusimbi M, Sebek M, Berga E, Villa TS. &lt;A href="nelh:307712:0" name=internalLink&gt;Guidance for the implementation of best practice for the care of patients with tuberculosis&lt;/A&gt;. International Journal of Tuberculosis and Lung Disease, March 2008, vol./is. 12/3(236-240), 1027-3719.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K. &lt;A href="nelh:308574:0" name=internalLink&gt;Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial&lt;/A&gt;. Ann Intern Med. 2008 Nov 18;149(10):689-97.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Atwood S, Mukherjee JS, Rich ML, Furin JJ, Nardell EA, Kim JY, Shin SS. &lt;A href="nelh:308578:0" name=internalLink&gt;Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. &lt;/A&gt;Lancet. 2008 Oct 18;372(9647):1403-9. Epub 2008 Aug 22.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A, Abubakar I. &lt;A href="nelh:308589:0" name=internalLink&gt;Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data&lt;/A&gt;. BMJ. 2008 May 31;336(7655):1231-4. Epub 2008 May 1.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;12. Chiang CY, Enarson DA, Bai KJ, Suo J, Wu YC, Lin TP, Luh KT. &lt;A href="nelh:308610:0" name=internalLink&gt;Factors associated with a clinician's decision to stop anti-tuberculosis treatment before completion&lt;/A&gt;. Int J Tuberc Lung Dis. 2008 Apr;12(4):441-6.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308486</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=308486]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Useful Websites</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MARCH 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A list of useful websites in the field of TB</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update: Stopping TB - Useful Websites&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;&lt;A href="http://www.stoptb.org/" target="_blank"&gt;Stop TB Partnership&lt;/A&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200055718370" target="_blank"&gt;National Knowledge Service-TB Pilot&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="http://www.hpa.org.uk/webw/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1191942150134?p" target="_blank"&gt;Health Protection Agency -&amp;nbsp;TB&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="http://www.who.int/topics/tuberculosis/en/" target="_blank"&gt;World Health Organization -&amp;nbsp;TB&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.who.int/hiv/topics/tb/en/index.html" target="_blank"&gt;&lt;STRONG&gt;World Health Organization -&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt;TB and HIV&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="http://www.theunion.org/" target="_blank"&gt;The International Union Against Tuberculosis and Lung Disease&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.cdc.gov/tb/default.htm" target="_blank"&gt;&lt;STRONG&gt;Centers for Disease Control and Prevention - Division of Tuberculosis Elimination&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.tbalert.org/" target="_blank"&gt;&lt;STRONG&gt;TB Alert - The UK's National Tuberculosis Charity&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308476</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=308476]]&gt;</url>
    <title>2009 Annual Evidence Update: Stopping TB - Vaccine Development</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Infections Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,PUBLIC HEALTH,ANALYSIS &amp; RESEARCH,MANAGEMENT &amp; INTERVENTIONS,INFECTIOUS DISEASES,TUBERCULOSIS,PREVENTION,MONTHLY ADDITIONS,INFECTIONS,ANALYSIS,METHODS,SERVICES,COMMUNICABLE DISEASES,TUBERCULOSIS,POPULATION BASED &amp; PREVENTATIVE SERVICES,INFECTION CONTROL,VACCINES / IMMUNISATION,2009 MARCH,MARCH 09,MYCOBACTERIUM,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BCG,BACTERIA,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best evidence on the development of new vaccines</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Commentary: Vaccine Development&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID308476/nelhImp_0001_44_7d9311E38_TPVaccines.jpg"&gt;&lt;BR&gt;&lt;EM&gt;Commentary by &lt;A href="nelh:308485:2" name=internalLink&gt;Professor Philip Marsh&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The development of a more effective vaccine would have a major impact on reducing the global incidence of tuberculosis (TB). Currently, the only available vaccine against TB is bacille Calmette-Guérin (BCG), which has been received by over three billion people, making it the most widely used in the world.&amp;nbsp; BCG was developed in the early 1920’s, and is based on a live but attenuated strain of &lt;EM&gt;Mycobacterium bovis&lt;/EM&gt;. Although BCG is safe and protects children from the disease, it is less effective in adults, its efficacy varies globally, and it is not recommended for those who are immunocompromised.&amp;nbsp; Therefore, the development of a new vaccine is essential if tuberculosis is to be controlled and eradicated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The past two decades have seen a significant increase in the pace of development of potential new vaccines for tuberculosis.&amp;nbsp; This is due to advances in the discovery and characterisation of &lt;EM&gt;Mycobacterium tuberculosis&lt;/EM&gt; virulence factors, aided by the publication of the TB genome, and a greater knowledge of the type of immune response required. Current vaccine approaches include:&lt;/P&gt;
&lt;P&gt;(a) replacement of the current BCG vaccine with an improved version, either by introducing genes (e.g. recombinant BCG30 which expresses and secretes the &lt;EM&gt;M. tuberculosis&lt;/EM&gt;&amp;nbsp; Ag85B protein), or by delivering BCG by a mucosal (e.g. oral) route&lt;/P&gt;
&lt;P&gt;(b) boosting the immunity provided by existing strains of BCG at a later time point with a sub-unit (i.e. a specific protein or DNA) vaccine (a prime-boost strategy). Several candidates for vaccine boosting are in early clinical trials, including hybrid 1 protein (Ag85B-ESAT6), and a viral vector (Modified Vaccinia virus Ankara, MVA) expressing Ag85A. &lt;/P&gt;
&lt;P&gt;(c) developing an attenuated strain of &lt;EM&gt;M. tuberculosis&lt;/EM&gt;.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The development of new TB vaccines would be accelerated if a correlate of protection was available.&amp;nbsp; Although it is known that cell mediated immunity is required, and that interferon gamma (IFN-gamma) production is essential, levels of this cytokine following vaccination do not correlate with protection. This means that new vaccines have to be assessed in long-term efficacy studies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Although the development of an improved TB vaccine is a lengthy process, there is a strong commitment from numerous international health organisations and funding bodies to evaluate a small number of novel formulations and delivery systems in clinical trials over the next 5-10 years. One of the aims of the WHO Global Plan to Stop TB (2006-2015) is to have a safe, affordable, licensed new TB vaccine available by 2015.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence: Vaccine Development&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Hoft DF. &lt;A href="nelh:308964:0" name=internalLink&gt;Tuberculosis vaccine development: goals, immunological design, and evaluation.&lt;/A&gt; The Lancet, 2008, vol./is. 372/9633(164-175), 0140-6736.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Gupta UD, Katoch VM, McMurray DN. &lt;A href="nelh:308970:0" name=internalLink&gt;Current status of TB vaccines&lt;/A&gt;. Vaccine (2007) 25: 3742-3751.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Dietrich J, Lundberg CV, Andersen P. &lt;A href="nelh:308972:0" name=internalLink&gt;TB vaccine strategies – What is needed to solve a complex problem?&lt;/A&gt; Tuberculosis (2006) 86: 163-168.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Skeiky YAW, Sadoff JC. &lt;A href="nelh:308973:0" name=internalLink&gt;Advances in tuberculosis vaccine strategies&lt;/A&gt;. Nature Reviews Microbiology (2006) 4: 469-476.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Young DB, Perkins MD, Duncan K, Barry III CE. &lt;A href="nelh:308975:0" name=internalLink&gt;Confronting the scientific obstacles to global control of tuberculosis&lt;/A&gt;. Journal of Clinical Investigation (2008) 118: 1255-1265.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Doherty TM, Dietrich J, Billeskov R. &lt;A href="nelh:308977:0" name=internalLink&gt;Tuberculosis subunit vaccines: from basic science to clinical testing&lt;/A&gt;. Expert Opin. Biol. Ther. (2007) 7: 1539-1549.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Dockrell HM. &lt;A href="nelh:308978:0" name=internalLink&gt;Real vaccines in the real world: tuberculosis vaccines move south&lt;/A&gt;. Expert Review of Vaccines, August 2008, vol./is. 7/6(703-7), 1744-8395.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. &lt;A href="nelh:308979:0" name=internalLink&gt;Influence of BCG vaccine strain on the immune response and protection against tuberculosis.&lt;/A&gt; FEMS Microbiology Reviews, August 2008, vol./is. 32/5(821-841), 0168-6445;1574-6976.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Antas PR, Castello-Branco LR. &lt;A href="nelh:308980:0" name=internalLink&gt;New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil&lt;/A&gt;. Transactions of the Royal Society of Tropical Medicine &amp;amp; Hygiene, July 2008, vol./is. 102/7(628-30), 0035-9203.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;10. Ly LH, McMurray DN. &lt;A href="nelh:308981:0" name=internalLink&gt;Tuberculosis: Vaccines in the pipeline&lt;/A&gt;. Expert Review of Vaccines, July 2008, vol./is. 7/5(635-650), 1476-0584;1744-8395.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Beverley PC, Tchilian EZ. &lt;A href="nelh:308983:0" name=internalLink&gt;Lessons for tuberculosis vaccines from respiratory virus infection&lt;/A&gt;. Expert Review of Vaccines, October 2008, vol./is. 7/8(1165-72), 1744-8395.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Ulrichs T. &lt;A href="nelh:308984:0" name=internalLink&gt;Immunology of tuberculosis and current status of vaccine development&lt;/A&gt;. Pneumologie, March 2008, vol./is. 62/3(143-148), 0934-8387.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;13. Gonzalo Asensio JA, Arbues A, Perez E, Gicquel B, Martin C. &lt;A href="nelh:308985:0" name=internalLink&gt;Live tuberculosis vaccines based on phoP mutants: A step towards clinical trials&lt;/A&gt;. Expert Opinion on Biological Therapy, February 2008, vol./is. 8/2(201-211), 1471-2598.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14. Kaufmann S. &lt;A href="nelh:308986:0" name=internalLink&gt;Rational design of novel antibacterial vaccines with an emphasis on tuberculosis&lt;/A&gt;. Scandinavian Journal of Infectious Diseases, 2008, vol./is. 40/8(595-600), 0036-5548;1651-1980.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;15. Reece ST, Kaufmann SH. &lt;A href="nelh:308987:0" name=internalLink&gt;Rational design of vaccines against tuberculosis directed by basic immunology&lt;/A&gt;. International Journal of Medical Microbiology, January 2008, vol./is. 298/1-2(143-50), 1618-0607.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;16. Giri PK, Khuller GK. &lt;A href="nelh:308988:0" name=internalLink&gt;Is intranasal vaccination a feasible solution for tuberculosis?&lt;/A&gt; Expert Review of Vaccines, November 2008, vol./is. 7/9(1341-1356), 1476-0584;1744-8395.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:307020:0" name=internalLink&gt;Return to AEU homepage&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>390082</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=390082]]&gt;</url>
    <title>2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Commentaries</title>
    <publicationDate>2010-11-29T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,TUBERCULOSIS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MYCOBACTERIUM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,NOV 10,ADDED 2010,WHAT'S NEW]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Expert commentaries for the Annual Evidence Update on HIV</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Commentaries&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=center&gt; &lt;TABLE cellSpacing=0 cellPadding=0 width=450 align=center border=0&gt; &lt;TBODY&gt; &lt;TR align=middle&gt; &lt;TD align=middle&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0001_titlebg01.jpg" name=nelh_tempImage1&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=middle&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="The Global overview of TB and HIV co-infection" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0002_titlebg02.jpg" border=0 name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=middle&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="An overview of the BHIVA guidelines for treatment of TB and HIV co-infection" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0003_titlebg03.jpg" border=0 name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=middle&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Clinical implications of TB and HIV co-infection" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0004_titlebg04.jpg" border=0 name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=middle&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt="An overview of TB and HIV co-infection in the UK" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0005_titlebg05.jpg" border=0 name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=middle&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt="HIV testing: when and how" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0006_titlebg06.jpg" border=0 name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt; &lt;P align=center&gt;&lt;/P&gt; &lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print.&lt;/P&gt; &lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt; &lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt; &lt;TBODY&gt; &lt;TR vAlign=top&gt; &lt;TD width=205&gt; &lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt; &lt;TD width=20&gt;&lt;/TD&gt; &lt;TD width=130&gt; &lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt; &lt;TD width=20&gt;&lt;/TD&gt; &lt;TD width=205&gt; &lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;A global overview of HIV and TB co-infection&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390082/nelhImp_0001_titles.002.jpg" height="100" width="400" alt="A global overview of TB and HIV co-infection"&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:390083:2" name=internalLink&gt;Dr. Jeffrey Lazarus&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="justify"&gt;In 2008, there were an estimated 9.4 million new cases of tuberculosis (TB) in the world [1]. Out of these, around 1.4 million, or 15%, were HIV positive [1]. That same year, TB accounted for 26% of AIDS-related deaths [2].&lt;/p&gt; &lt;p align="justify"&gt;TB incidence is to a large extent driven by the HIV epidemic; the risk of developing TB is 20 to 37 times higher among persons infected with HIV [2]. Africa accounts for most of the overlap between the two diseases, and in some countries in sub-Saharan Africa, up to 80% of patients with TB have HIV [2]. In China, 1.9% of TB patients are estimated to also be co-infected with HIV, compared with 73% in South Africa [3]. However, even where the prevalence of HIV among people with active TB is low, in most parts of the world, TB is a leading cause of morbidity and mortality among people living with HIV [4].&lt;/p&gt; &lt;p align="justify"&gt;HIV and TB infections have a synergistic effect on each other: HIV infection makes TB harder to control and people with HIV who have active TB are much more likely to die during the course of their TB treatment [4].&lt;/p&gt; &lt;p align="justify"&gt;WHO treatment guidelines for TB and HIV state that all patients with active TB who also have an HIV infection are recommended to start antiretroviral therapy (ART) as soon as possible, irrespective of their CD4 cell count. TB treatment should be started first, followed by ART [5]. In a recent study, initiation of ART during TB therapy reduced mortality by 56% and thereby significantly improved survival [6].&lt;/p&gt; &lt;p align="justify"&gt;However, in the majority of HIV-positive TB cases, the individuals do not know their HIV status and are thus not yet accessing ART [3].&lt;/p&gt; &lt;p align="justify"&gt;Integration of TB and HIV services is crucial in order to decrease the burden of TB in HIV infected populations and thus improve survival [4]. A very important factor in this respect is universal coverage with HIV testing at TB services and vice versa [4]. Managers of HIV programs should work closely with their colleagues in the TB field to ensure that persons infected with HIV have access to high-quality comprehensive prevention, care and treatment of HIV and TB.&lt;/p&gt;&lt;br /&gt; &lt;p align="left"&gt;&lt;b&gt;References&lt;/b&gt; &lt;ol&gt; &lt;li&gt;World Health Organization. &lt;a href="http://whqlibdoc.who.int/publications/2009/9789241598866_eng.pdf" target="_blank"&gt;Global tuberculosis control: a short update to the 2009 report. Geneva: World Health Organization, 2009&lt;/a&gt;&lt;/li&gt;&lt;br&gt; &lt;li&gt;Getahun H, Gunneberg C, Granich R, Nunn P. &lt;a href="http://www.journals.uchicago.edu/doi/pdf/10.1086/651492" target="_blank"&gt;HIV infection-associated tuberculosis: the epidemiology and the response.&lt;/a&gt; Clinical Infectious Diseases, 2010; 50(Suppl 3): S201-S207&lt;/li&gt;&lt;br&gt; &lt;li&gt;World Health Organization. &lt;a href="http://whqlibdoc.who.int/publications/2009/9789241563802_eng.pdf" target="_blank"&gt;Global tuberculosis control 2009. Geneva: World Health Organization, 2009&lt;/a&gt;&lt;/li&gt;&lt;br&gt; &lt;li&gt;Legido-Quigley H, Montgomery C, Fakoya A, Grant A. Integrating tuberculosis and HIV services in low and middle-income countries: a systematic review. Clinical Research Unit, London School of Hygiene and Tropical Medicine and Evidence for Action Consortium, 2009&lt;/li&gt;&lt;br&gt; &lt;li&gt;World Health Organization. &lt;a href="http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf" target="_blank"&gt;Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents.&lt;/a&gt; Geneva: World Health Organization; 2009&lt;/li&gt;&lt;br&gt; &lt;li&gt;Karim SSA, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M,Pienaar J, El-Sadr W, Friedland G, Karim QA. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=394469&amp;amp;tabID=289" target="_blank"&gt;Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy.&lt;/a&gt; The New England Journal of Medicine, 2010; 362: 697-706&lt;/li&gt;&lt;/ol&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br /&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;An overview of the BHIVA guidelines for treatment of HIV and TB co-infection&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390082/nelhImp_0002_titles.003.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:390083:3" name=internalLink&gt;Dr. Anton Pozniak&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="justify"&gt; The British HIV Association (BHIVA) guidelines for the treatment of HIV and TB co-infection were drawn up to help physicians manage adults with HIV and TB co-infection as this problem is of significance in the UK. An estimated 6-8% of adults with TB are also HIV positive and the proportion in London is higher, with co-infection rates of between 17 and 25%. [1,2]&lt;/p&gt; &lt;p align="justify"&gt;Although many aspects of the guidelines are applicable to both HIV infected and uninfected persons with tuberculosis there are clinical situations specific to the HIV group. The key areas of guidance cover latent TB, when to start antiretroviral therapy (ART), which drugs to use and the Immune Reconstitution Inflammatory Syndrome (IRIS).&lt;/p&gt; &lt;p align="justify"&gt;The most difficult piece of guidance to develop was that of how to diagnose latent tuberculosis in HIV patients and whom to offer chemoprophylaxis to. This is a really important area as HIV-infected individuals with latent TB infection are much more likely to progress to active TB than HIV-uninfected people. There is therefore an opportunity to try and prevent HIV patients developing active TB by using chemoprophylaxis with isoniazid. The problem is that the current screening test lacks specificity and more importantly, sensitivity, in HIV patients with severe immunosuppression and low CD4 counts.&lt;/p&gt; &lt;p align="justify"&gt;Recent draft NICE guidelines suggest using the Interferon Gamma Release Assay (IGRA) blood test to screen for latent TB in those patients with a CD4 count over 200cells/microlitre and both an IGRA and tuberculin test in those with CD4 counts below this threshold. It was felt that this strategy would add complexity, cost and difficulties in interpretation and so BHIVA only recommend an IGRA test at every CD4 count stratum. Chemopreventative therapy would then be given to those in high risk groups dependent on country of origin, level of immunosuppression (as judged by current CD4 count), and how long the person had received antiviral treatment for, as this helps restore immune responses to TB. [3,4,5]&lt;/p&gt; &lt;p align="justify"&gt;When to start HIV treatment in someone with TB has been an area of controversy as starting ART during TB treatment is complicated by overlapping toxicities, drug interactions, immune reconstitution disease, and high pill burdens which may reduce adherence. Delaying ART for more than a few weeks may lead to prolonged or worsening immune suppression and progression to AIDS and death. Cohort data from the UK in 2002 suggested starting ART early was beneficial and recent data from controlled trials also show that early ART reduces morbidity and mortality especially in those with severe immunosuppression. [6,7]&lt;/p&gt; &lt;p align="justify"&gt;The choice of which antiretrovirals to use in someone already on TB treatment is a pharmacological minefield. Rifampicin and rifabutin induce the cytochrome family of liver enzymes which metabolise HIV drugs. Some of the HIV drugs induce and/or inhibit the same enzymes with a consequent problem of two way drug interactions and having to put together adequate regimens of these drugs effectively and without side effects. The guidelines have given recommendations on what is and what is not recommended including guidance for the use of recently developed HIV drugs. Although there are no definitive data, HIV positive patients should receive the same length of treatment as the HIV negative population. [8]&lt;/p&gt; &lt;p align="justify"&gt;When some patients with opportunistic infections improve their immunity by starting ART they can develop the Immune Reconstitution Inflammatory Syndrome (IRIS). These patients typically develop an exacerbation of symptoms, signs or radiological manifestations of TB with enlargement of lymph nodes or worsening effusions for example. It can lead to sinus formation and other complications and can last months but is rarely fatal. Its aetiology is unknown but may be related to the inability to remove dead bacilli and an abnormal immune response to residual TB antigens. Treatment is symptomatic, usually with a tapering dose of steroids. [9,10]&lt;/p&gt; &lt;p align="justify"&gt;Overall, although these guidelines are very much focused on the difficulties of the medical management of HIV and TB co-infected patients, they are a valuable resource and have relevance beyond the UK.&lt;/p&gt;&lt;br&gt; &lt;p align="left"&gt;&lt;b&gt;References&lt;/b&gt; &lt;ol&gt;&lt;li&gt;Ahmed AB, Abubakar I, Velpech V et al. &lt;a href="http://www.library.nhs.uk/infections/viewResource.aspx?resid=286469&amp;amp;code=db20909abc2342d125e90538300d5116" target="_blank"&gt;The growing impact of HIV infection on the epidemic of tuberculosis in England and Wales.&lt;/a&gt; Thorax 2007; 62: 672-676.&lt;/li&gt;&lt;br&gt; &lt;li&gt;Anderson SA, Maguire H, Carless J. &lt;a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2111261/pdf/162.pdf" target="_blank"&gt;Tuberculosis in London: a decade and a half of no decline.&lt;/a&gt; Thorax 2007; 62; 162-167.&lt;/li&gt;&lt;br&gt; &lt;li&gt;Akolo C, Adetifa I, Shepperd S, Volmink J. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=236448&amp;amp;amp;tabID=289&amp;amp;amp;catID=13837" target="_blank"&gt;Treatment of latent tuberculosis infection in HIV infected persons&lt;/a&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD000171. DOI: 10.1002/14651858.CD000171.pub3.&lt;/li&gt;&lt;br&gt; &lt;li&gt;Matthias Hoffmann and Pernille Ravn &lt;a href="http://www.touchbriefings.com/ebooks/A1noil/euinfect41/resources/25.htm" target="_blank"&gt;The Use of Interferon-gamma Release Assays in HIV-positive Individuals&lt;/a&gt;. European Infectious Disease, 2010;4(1):23-9&lt;/li&gt;&lt;br&gt; &lt;li&gt;Grant AD, Bansi L, Ainsworth J et al. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=394464&amp;amp;tabID=289" target="_blank"&gt;Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?&lt;/a&gt; AIDS 2009; 23: 2507-2515.&lt;/li&gt;&lt;br&gt; &lt;li&gt;Dean GL, Edwards SG, Ives NJ et al. &lt;a href="http://journals.lww.com/aidsonline/pages/articleviewer.aspx?year=2002&amp;amp;issue=01040&amp;amp;article=00010&amp;amp;type=abstract" target="_blank"&gt;Treatment of tuberculosis in HIV-1 infected persons in the era of highly active antiretroviral therapy.&lt;/a&gt; AIDS 2002; 16: 75-83.&lt;/li&gt;&lt;br&gt; &lt;li&gt;Blanc FX, Sok T, Laureillard D et al. &lt;a href="http://www.natap.org/2010/IAS/IAS_91.htm" target="_blank"&gt;Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis.&lt;/a&gt; XVIII International AIDS Conference, Vienna, July 2010 [Abstract THLBB106].&lt;/li&gt;&lt;br&gt; &lt;li&gt;El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. &lt;a href="http://www.journals.uchicago.edu/doi/pdf/10.1086/318706" target="_blank"&gt;A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.&lt;/a&gt; Clin Infect Dis 2001; 32: 623-632.&lt;/li&gt;&lt;br&gt; &lt;li&gt;Price P, Mathiot N, Krueger R, Stere S, Keane NB, French MA. &lt;a href="http://www.sciencedirect.com/science?_ob=MImg&amp;amp;_imagekey=B6VJV-43YR0F4-9-1&amp;amp;_cdi=6104&amp;amp;_user=8810565&amp;amp;_pii=S1386653201002001&amp;amp;_origin=search&amp;amp;_coverDate=10%2F31%2F2001&amp;amp;_sk=999779996&amp;amp;view=c&amp;amp;wchp=dGLzVzz-zSkzk&amp;amp;md5=10a2918888d81a9294b152d71f55b624&amp;amp;ie=/sdarticle.pdf" target="_blank"&gt;Immune restoration disease in HIV patients given highly active antiretroviral therapy.&lt;/a&gt; J Clin Virol 2001; 22: 279-287.&lt;/li&gt;&lt;br&gt; &lt;li&gt;Burman W, Weis S, Vernon A et al. &lt;a href="http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/59858162.1/iuatld/ijtld/2007/00000011/00000012/art00004/434AF19A4F5A690812904432578776C8376C7372DA.pdf?link=http://www.ingentaconnect.com/error/delivery&amp;amp;format=pdf" target="_blank"&gt;Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.&lt;/a&gt; Int J Tuberc Lung Dis 2007; 11: 1282-1289&lt;/li&gt;&lt;/ol&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br /&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Clinical implications of HIV and TB co-infection&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390082/nelhImp_0003_titles.004.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:390083:4" name=internalLink&gt;Dr. Mark Lipman&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="justify"&gt; The social and ethnic diversity found in many parts of England and Wales means that GPs always need to consider infections such as tuberculosis (TB) in individuals presenting with what are usually fairly prolonged respiratory or extra-pulmonary symptoms. Globally, many countries with endemic tuberculosis such as Sub-Saharan Africa now also have very high rates of HIV infection. The immune changes associated with this virus increase the risk of an individual with latent TB infection, i.e. who is carrying the bug but has no clinical symptoms progressing to active disease by around forty fold when compared to HIV uninfected individuals. Globally it is estimated that around fifteen percent of all new cases of active (symptomatic) TB each year occur in HIV co-infected people. Depressingly one quarter of all HIV-related deaths are due to tuberculosis (which overall kills almost two million people worldwide per year).&lt;/p&gt; &lt;p align="justify"&gt;Tuberculosis is often the first serious manifestation of advancing HIV infection. In subjects with reasonably preserved immunity, it will present in a very similar manner to non HIV-related disease. However, with failing immunity, patients can have atypical presentations (for example pulmonary disease may occur despite normal or near normal chest x-rays). The GP therefore needs to think not only of possible HIV co-infection in their patients who present with features compatible with tuberculosis, but also needs to consider the possibility of HIV and TB co-infection in those with unexplained prolonged infection.&lt;/p&gt; &lt;p align="justify"&gt;It cannot be stressed strongly enough that all individuals with suspected tuberculosis should be offered an HIV test. This does not require counselling or a risk assessment, though verbal informed consent is vital. The current recommendation is to offer this in the form of "universal testing" or a risk assessment as part of a care package associated with the clinical condition for which the patient is being investigated.&lt;/p&gt; &lt;p align="justify"&gt;Recent surveys in England and Wales suggest that about ten per cent of all tuberculosis occurring in non-UK born individuals is HIV related. This is about five times the rate seen in subjects with tuberculosis born in the UK. Dismayingly, to date all surveys of HIV testing within TB clinics, suggest that only around two-thirds of patients are offered HIV tests - though the great majority agree to have one, if the subject is raised.&lt;/p&gt; &lt;p align="justify"&gt;Screening for latent and even active TB in HIV positive individuals is not straightforward, as many of the standard tests are not reliable indicators of either TB infection or disease. For example, sputum microscopy for acid and alcohol fast bacilli is less likely to be positive in this setting. Thus if a GP has concerns about possible TB/HIV infection it is important that they seek specialist advice from clinicians with appropriate experience. Recent data from a European survey which included the United Kingdom, indicated that specialist care for complex conditions such as HIV and tuberculosis lead to better outcomes, though often fragmentation of care between HIV and tuberculosis teams was noted. This is an area that is now receiving much attention from professional bodies such as the British HIV Association, British Infection Society and British Thoracic Society.&lt;/p&gt; &lt;p align="justify"&gt;Once the diagnosis of TB and/or HIV has been established, treatment generally needs to be managed within secondary or tertiary care, though the G.P. plays a key role in a treatment journey which lasts months and subsequently years when long term HIV therapy is factored in.&lt;/p&gt; &lt;p align="justify"&gt;There are numerous issues regarding the use of anti-HIV and anti-TB therapies. The drugs interact, reducing the efficacy of either or both treatments; they all have similar adverse effects; and historically concomitant therapy meant an individual had to take a very large number of medicines all at the same time - leading to potential issues of poor adherence, and an increased risk of drug failure and subsequent resistance to previously effective therapies.&lt;/p&gt; &lt;p align="justify"&gt;Balanced against this are the data which indicate that the use of antiretroviral therapy directed against HIV greatly improves the long term outcome for patients also being treated for active tuberculosis. Starting anti-HIV and anti-TB together at the same time greatly increases the risk of immune reconstitution disease (IRD). In essence this is a heightened tissue inflammatory response to mycobacteria that have not yet been cleared by the anti-TB therapy. Although usually self-limiting, if a patient has tuberculosis involving the brain, IRD may result in rapid increases in intracranial pressure and high morbidity and mortality. Thus the decision when to start antiretroviral therapy in a patient with active tuberculosis requires careful assessment.&lt;/p&gt; &lt;p align="justify"&gt;The benefits of anti-HIV treatments also extend to preventing the development of active tuberculosis. Studies from around the world have shown that sustained anti retroviral therapy reduces the risk of developing TB disease by between 70 and 90%. This is a similar benefit to that seen with BCG vaccination in the United Kingdom; and hence widespread antiretroviral therapy is a key component of effective global tuberculosis control.&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br /&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;An overview of HIV and TB co-infection in the UK&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390082/nelhImp_0004_titles.005.jpg" height="100" width="400"&gt;&lt;/p&gt;

&lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;/b&gt;&lt;/p&gt;&lt;br&gt;

&lt;p align="center"&gt;&lt;b&gt;HIV in 2009&lt;/b&gt;&lt;/p&gt;

&lt;p align="justify"&gt;The number of people living with HIV in the UK reached an estimated 85,000 in 2009. Alarmingly, a quarter of persons infected remain unaware of their infection. A total of 6,630 people were newly diagnosed as HIV-infected in 2009 (representing a rate of 11 per 100,000). This represents a fourth year-on-year decline, largely due to fewer diagnoses among people infected heterosexually (from a peak of 7,982 in 2005 to 3,560 in 2009). Six in every ten persons with HIV acquired through heterosexual contact were infected abroad, mostly in Sub-Saharan Africa. The number of new diagnoses among men who have sex with men (MSM) remained high (2,760) in 2009 and most infections (83%) were likely to have been acquired within the UK. More than 1,000 of the people diagnosed probably acquired their infection heterosexually within the UK, accounting for a third of heterosexuals diagnosed.&lt;/p&gt;

&lt;p align="justify"&gt;Importantly half (52%) of all patients with HIV were diagnosed with a late stage of infection in 2009 (CD4 counts of less than 350 per cubic mm within three months of diagnosis), the stage at which treatment is recommended to begin. This proportion was higher among heterosexual men (66%) and heterosexual women (59%) compared to MSM (39%). The number of deaths among HIV-infected people has remained stable over the past decade, and the number of AIDS diagnoses has continued to decline. In 2009, there were 547 individuals reported with a first AIDS diagnosis. Of the 516 reported deaths in 2009 73% were among late presenters (CD4 counts of less than 350). The data highlight the importance of expanding testing to ensure earlier diagnosis in high prevalence areas and specific clinical settings including TB clinics.&lt;/p&gt;

&lt;p align="center"&gt;&lt;b&gt;TB in 2009&lt;/b&gt;&lt;/p&gt;

&lt;p align="justify"&gt;The number of new cases of tuberculosis reported annually has been high in recent years and increased slightly in 2009 with 9,040 cases of tuberculosis reported (a 5% increase on 2008), representing a rate of 15 cases per 100,000. London accounts for the majority of cases (38%) - a rate of 44 cases per 100,000 with other urban areas also showing higher rates. Similar to HIV diagnoses, most diagnoses were among adults aged 15-44 years and new diagnoses reported in London exceed all other regions. Almost three quarters (73%) of all TB cases were born abroad, of whom 28% (1615) were born in India, 17% in Pakistan and 10% in Somalia. Those born in Sub-saharan Africa accounted for about 7% of TB cases born abroad. &lt;/p&gt;&lt;br&gt;

&lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p align="justify"&gt;Globally [1] as well as in the UK [2], the number of people living with HIV continues to grow and had reached an estimated 83,000 persons in the UK by the end of 2008 [2]. The global burden of disease of HIV and TB co-infection is substantial [3], and especially in Sub-Saharan Africa [4].&lt;/p&gt;

&lt;p align="justify"&gt;A national surveillance study examining HIV-TB co-infections in England and Wales found  a co-infection rate of 5.7% (n=1,743) among TB patients diagnosed 1999 and 2003 [5]. During this period, a year on year increase of HIV infection in TB patients was observed, reaching 8.3% of TB cases in 2003. More recent linkage of national database show similar high rates of co-infections [6]. The majority of co-infected cases were born abroad [5], mostly in sub-Saharan Africa and were diagnosed with HIV at the time of their TB infection. Single-centre data suggests that the proportion of co-infection in London may be higher (17-25%) than outside London and this is reflected in national data [7].&lt;/p&gt;

&lt;p align="justify"&gt;A large cohort study found that 741 (2.7%) of 27,868 individuals attending one of the major UK HIV clinics between 1996 and 2006 had active TB during their follow up time (median follow up 4.2 years) [8]. The authors estimated an overall TB incidence rate of 3.28 per 1000 person years amongst HIV positive clinic attendees (this rate excludes patients who presented with TB at HIV diagnosis). However, the rate was substantially larger amongst Black African individuals (8.45 per 1000 person years) [8]. There is evidence that incidence rates elsewhere in Europe are in the same region. In France an overall TB incidence of 4.0 per 1000 person years was found among HIV positive hospital patients, with much higher rates in migrant populations (10.3 per 1000 person years) [9].&lt;/p&gt;

&lt;p align="justify"&gt;These findings indicate that HIV and TB co-infection is a substantial and growing problem in the UK, with migrant populations from high prevalence countries more likely to be affected by dual infections [8].&lt;/p&gt;

&lt;p align="justify"&gt;People with impaired immune responses are at particular risk of developing TB infection and TB is one of the most important AIDS defining illnesses. TB is also associated with a delayed diagnosis of HIV.  In 2008, the proportion of people with late diagnosis of HIV, defined as a CD4 count of &lt;200 per mm3 within three months of diagnosis, was about 32% in the over 15 year olds in the UK [2]. Many of these people are from high prevalence countries, and may have been at risk of TB exposure in the past. They tend not to be well embedded in the healthcare system of their host country; which may explain some of the late presentations [10].&lt;/p&gt;

&lt;p align="justify"&gt;Recent moves to offer universal HIV screening to all individuals resident in parts of the UK with moderately high prevalence for HIV (&gt;2/1000)and in specific risk groups [11] may help to decrease the proportion of late diagnosis [12] and in turn optimise their clinical management and prevent TB infection. All patients attending TB clinics should be offered and recommended an HIV test as per BHIVA guidelines  [11] and a high index of TB suspicion should be maintained for all symptomatic HIV positive individuals, because TB presentations are often atypical [13].&lt;/p&gt;

&lt;p align="justify"&gt;Overall, people with HIV and TB co-infection have higher mortalities compared to  TB in an HIV-free population [14]; however early diagnosis and treatment dramatically improve outcomes, emphasising the urgent need for decreasing the proportion of late diagnosis.&lt;/p&gt;

&lt;p align="left"&gt;&lt;b&gt;References&lt;/b&gt;&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;	UNAIDS and WHO, &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=331155&amp;amp;amp;tabID=290&amp;amp;amp;catID=13837" target="_blank"&gt;AIDS epidemic update 2009&lt;/a&gt;, 02 Nov 2009&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;	Health Protection Agency, &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=331512&amp;amp;amp;tabID=290&amp;amp;amp;catID=13837" target="_blank"&gt;HIV in the United Kingdom&lt;/a&gt;: 2009 Report, 30 Nov 2009&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC et al. &lt;a href="http://archinte.ama-assn.org/cgi/reprint/163/9/1009" target="_blank"&gt;The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.&lt;/a&gt; Arch Intern.Med. 2003;163:1009-21.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Lawn SD,.Churchyard G. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/19532072" target="_blank"&gt;Epidemiology of HIV-associated tuberculosis.&lt;/a&gt; Curr.Opin.HIV.AIDS 2009;4:325-33.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Ahmed AB, Abubakar I, Delpech V, Lipman M, Boccia D, Forde J et al. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=286469&amp;amp;tabID=290" target="_blank"&gt;The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999 2003.&lt;/a&gt; Thorax 2007;62:672-6.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Health Protection Agency. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=332634&amp;amp;tabID=290" target="_blank"&gt;Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2010.&lt;/a&gt;  2010.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Anderson SR, Maguire H, Carless J. &lt;a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2111261/pdf/162.pdf" target="_blank"&gt;Tuberculosis in London: a decade and a half of no decline [corrected]&lt;/a&gt;. Thorax 2007;62:162-7.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;	Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=394464&amp;amp;amp;tabID=289" target="_blank"&gt;Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?&lt;/a&gt; AIDS. 2009 Nov 27;23(18):2507-15&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Abgrall S, Del Giudice P, Melica G, Costagliola D. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/20087155" target="_blank"&gt;HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years.&lt;/a&gt; AIDS 2010;24:763-71.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Johnson M, Sabin C, Girardi E. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/20442455" target="_blank"&gt;Definition and epidemiology of late presentation in Europe.&lt;/a&gt; Antivir.Ther. 2010;15 Suppl 1:3-8.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;British HIV Association, British Association of Sexual Health and HIV, and British Infection Society. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=294604&amp;amp;tabID=288" target="_blank"&gt;UK National Guidelines for HIV Testing 2008.&lt;/a&gt;  1-9-2008.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Tweed E, Hale A, Hurrelle M, Smith R, Delpech V, Ruf M et al. &lt;a href="http://sti.bmj.com/content/early/2010/04/28/sti.2009.041293.full.pdf" target="_blank"&gt;Monitoring HIV testing in diverse healthcare settings: results from a sentinel surveillance pilot study.&lt;/a&gt; Sex Transm.Infect. 2010;86:360-4.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;Pozniak A.L., Collins, S., Coyne, K. M., Freedman, A. R., Johnson, M. A., Lipman, M., Lucas, S. B., Miller, R. F., and Ormerod, L. P. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=66647&amp;amp;tabID=288&amp;amp;catID=13851" target="_blank"&gt;British HIV Association guidelines for the treatment of TB/ HIV co-infection 2009.&lt;/a&gt;  2010.&lt;/li&gt;&lt;br&gt;

  &lt;li&gt;World Health Organisation. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=345526&amp;amp;tabID=290" target="_blank"&gt;Global Tuberculosis Control 2009. Epidemiology Strategy Financing.&lt;/a&gt;  2009. Geneva.&lt;/li&gt;
&lt;/ol&gt; 

&lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br /&gt;
&lt;a href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt;

&lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; 

&lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt;
&lt;tr valign="top"&gt;

&lt;td width="205"&gt;
&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:5" name=internalLink&gt;Epidemiology and overview&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; 

&lt;td width="20"&gt;
&lt;/td&gt;

&lt;td width="130"&gt; 
&lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; 
&lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; 

&lt;td width="20"&gt;
&lt;/td&gt;

&lt;td width="205"&gt; 
&lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; 
&lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; 

&lt;/tr&gt;
&lt;/table&gt; 

&lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt;
&lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;HIV testing: when and how&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390082/nelhImp_0006_titles.05.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="justify"&gt;The 2008 British HIV Association (BHIVA) guidelines on testing for HIV infection marked a sea-change in perception of HIV as an incurable infection of individuals in a few high risk groups to a treatable chronic medical condition with potentially near normal life expectancy [1]. The guidelines advocated testing in a much wider range of settings than previously, facilitated by the change from 'pre-test counselling' to 'informed consent': this change was aimed at 'normalising' HIV testing, such that all doctors, nurses and midwives can request a test, rather than restricting testing to a small number of highly trained doctors and nurses who have had the appropriate training, for example staff in genito-urinary clinics. Three main testing strategies were outlined. Firstly, targeted testing of at-risk individuals was recommended, for example intravenous drug users, men who have sex with men, partners of HIV-positive individuals and people from countries with a high HIV prevalence. Secondly, it was further recommended that opportunistic testing of all individuals in areas/populations where diagnosed HIV prevalence was above 2 cases per 1000 population should be undertaken, through, and in particular testing all patients registering in General Practice, or all general medical admissions. Thirdly, the guidelines outlined a list of specific 'indicator conditions', that is, conditions more likely to occur in the setting of HIV infection, and recommended that individuals presenting with these should be offered testing. Some of these conditions were already widely recognised as being HIV-associated, for example tuberculosis, Kaposi's sarcoma and pneumocystis pneumonia, but others perhaps less so, for example bacterial pneumonia, aseptic meningitis, non-Hodgkin's lymphoma and cervical cancer.&lt;/p&gt; &lt;p align="justify"&gt;The guidelines, however, highlighted barriers to testing. These can be psychological or practical, and may relate to either the individual being tested, for example anxiety regarding the stigma of HIV, costs of transport or inconvenient location or opening hours of the testing centre; or the health care professional, for example low perception of risk, or reluctance to discuss HIV testing [3,4]. As regards health care professionals' attitudes to offering testing, a recent study in the US looked at implementation of guidelines on testing women for HIV in labour where HIV status was undetermined, and found that frequency of testing was affected by preconceived ideas of level of risk, in that white women who had received private antenatal care were less likely to have been tested than other groups [5]. There is clearly further work to be done to optimise testing opportunities and to change perceptions and attitudes.&lt;/p&gt; &lt;p align="justify"&gt;As regards the 'how' of testing, there have been advances in two main areas. The first is the use of near-patient rapid tests in a range of clinical settings, such as in the community and for women in labour [6,7]. However, concerns have been raised over the sensitivity of such tests, particularly in a field environment [8,9]. The second is the use of novel tests to identify recent infection, a useful piece of information both epidemiologically and for contact tracing [10]. The UK Health Protection Agency is rolling out use of RITA (Recent Infection Testing Algorhithm) previously known as STARHS (Serological Testing Algorithm for Recent HIV Seroconversion) testing to all patients newly diagnosed with HIV in an attempt to distinguish recently acquired infection (within 6 months) from recently diagnosed, more chronic infection. This information will help to identify groups at particular risk as well as serving as a measure of the success of public health initiatives, in addition to the potential direct clinical uses.&lt;/p&gt; &lt;p align="justify"&gt;It is hoped that 'normalisation' of HIV testing, together with these recent developments, will lead to a greater understanding of HIV epidemiology in the UK and beyond, as well as contributing to earlier diagnosis, and hence to reduced morbidity, mortality and transmission.&lt;/p&gt; &lt;p align="left"&gt;&lt;b&gt;References&lt;/b&gt; &lt;ol&gt; &lt;li&gt; &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=294604&amp;amp;tabID=288" target="_blank"&gt;UK National Guidelines for HIV Testing 2008&lt;/a&gt;.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. &lt;a href="http://www.library.nhs.uk/INFECTIONS/ViewResource.aspx?resID=365154&amp;amp;amp;tabID=289&amp;amp;amp;catID=13837" target="_blank"&gt; Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model&lt;/a&gt;. Lancet 2009;373:48-57.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Deblonde J, De Koker P, Hamers FF, et al. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=392301&amp;amp;tabID=289" target="_blank"&gt;Barriers to HIV testing in Europe: a systematic review&lt;/a&gt;. Eur J Public Health 2010;20:422-32.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Bateganya M, Abdulwadud OA, Kiene SM. &lt;a href="http://www.library.nhs.uk/INFECTIONS/ViewResource.aspx?resID=270957&amp;amp;amp;tabID=289&amp;amp;amp;catID=13837" target="_blank"&gt;Home-based HIV voluntary counselling and testing (VCT) for improving uptake of HIV testing&lt;/a&gt;. Cochrane Database of Systematic Reviews 2010; Issue 7. Art. No.: CD006493. DOI: 10.1002/14651858.pub4.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Gaur S, Whitley-Williams P, Flash C, Jiminez E, Petrova A. &lt;a href="http://www.library.nhs.uk/Infections/ViewResource.aspx?resID=392303&amp;amp;tabID=289" target="_blank"&gt;Disparity in hospital utilization of rapid HIV-1 testing for women in labor with undocumented HIV status.&lt;/a&gt;. Matern Child Health J 2010;14:268-73.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Torres M. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/20413019" target="_blank"&gt;Rapid HIV screening in the emergency department.&lt;/a&gt; Emerg Med Clin North Am 2010;28:369-80.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Veloso VG, Bastos FI, Portela MC et al. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/20835495" target="_blank"&gt; HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil.&lt;/a&gt; Rev Saude Publica 2010;44:803-11.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Wolpaw BJ, Mathews C, Chopra M et al. &lt;a href="http://www.biomedcentral.com/content/pdf/1472-6963-10-73.pdf" target="_blank"&gt;The failure of routine rapid HIV testing: a case study of improving low sensitivity in the field.&lt;/a&gt; BMC Health Services Research 2010;10:73.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Campbell S, Fedoriw Y. &lt;a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B75HR-4XGB984-9&amp;amp;_user=8810565&amp;amp;_coverDate=09%2F30%2F2009&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_origin=search&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_searchStrId=1557069470&amp;amp;_rerunOrigin=google&amp;amp;_acct=C000046143&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=8810565&amp;amp;md5=d2988b96a598323e5a9bf230ac6a0f9e&amp;amp;searchtype=a" target="_blank"&gt;HIV testing near the patient: changing the face of HIV testing.&lt;/a&gt; Clin Lab Med 2009;29:491-501.&lt;/li&gt;&lt;br&gt; &lt;li&gt; Murphy G, Parry JV. &lt;a href="http://www.eurosurveillance.org/images/dynamic/EE/V13N36/art18966.pdf" target="_blank"&gt;Assays for the detection of recent infections with human immunodeficiency virus type 1.&lt;/a&gt; Euro Surveill 2008;13. pii: 18966&lt;/li&gt; &lt;/ol&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br /&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>390083</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=390083]]&gt;</url>
    <title>2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Contributors</title>
    <publicationDate>2010-11-29T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,TUBERCULOSIS,HIV/AIDS,INFECTIONS,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),WHAT'S NEW,ADDED 2010,NOV 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Short biographies of the contributors to this Annual Evidence Update</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p align="justify" valign="top"&gt;NHS Evidence - infections would like to thank the following contributors for their commentaries and evidence:&lt;/p&gt;

&lt;p align="left" valign="top"&gt;
&lt;a href="nelh:390063:0" name=internalLink&gt;Introduction&lt;/a&gt; by &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:2" name=internalLink&gt;A Global overview of HIV and TB co-infection&lt;/a&gt; by &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:3" name=internalLink&gt;An overview of the BHIVA guidelines for treatment of HIV and TB co-infection&lt;/a&gt; by &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications of HIV and TB co-infection&lt;/a&gt; by &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:5" name=internalLink&gt;An overview of HIV and TB co-infection in the UK&lt;/a&gt; by &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt; and &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt; by &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;
&lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt;
&lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; 

&lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt;
&lt;tr valign="top"&gt;

&lt;td width="205"&gt;
&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; 

&lt;td width="20"&gt;
&lt;/td&gt;

&lt;td width="130"&gt; 
&lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; 
&lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td width="20"&gt;
&lt;/td&gt;

&lt;td width="205"&gt; 
&lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt; 

&lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt;
&lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr Jeffrey Lazarus&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390083/nelhImp_0000_titles.e1.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="justify"&gt;Dr Jeffrey Victor Lazarus, PhD MIH, MA, is the Team leader of Technical Publications and Learning, at the Global Fund to Fight AIDS, Tuberculosis and Malaria. Until September 2009 he was the advocacy and community relations adviser at the Communicable Diseases Unit, WHO/Europe. Prior to that he was the editor of Entre Nous, the European Magazine for Sexual and Reproductive Health, and from 2001 to 2004, he worked as the publication manager for the European Observatory on Health Systems and Policies. He also holds positions as Affiliated Professor at the Medical School in Porto University and External Lecturer in international health at Copenhagen University. Dr Lazarus is the author of more than 80 publications including 40 in peer-reviewed journals.&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary: &lt;a href="nelh:390082:2" name=internalLink&gt;A Global overview of HIV and TB co-infection&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr Anton Pozniak&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390083/nelhImp_0006_titles.e2.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="justify"&gt;Dr Anton Pozniak studied medicine at the University of Bristol and qualified as MBChB in 1979. He trained in GUM and HIV at the Middlesex Hospital, London, UK. He worked as a Consultant Physician in Zimbabwe where he conducted research for his doctorate in TB/HIV and moved back to the UK in 1991. He ran the HIV research unit at King's College, London before moving to his current position as Consultant Physician/Senior Lecturer at the Chelsea and Westminster Hospital, London in 1998, and is now Director of HIV Services. He became a fellow of the Royal College of Physicians in 1996.&lt;/p&gt; &lt;p align="justify"&gt;He is a lifetime member of the British HIV Association (BHIVA) where he has helped co-ordinate and write the BHIVA anti-viral HIV guidelines and is chair of the TB/HIV guidelines committee. He was an advisor on HIV and AIDS to the UK Government Health Select Committee. He is a member of the UK Government's Expert Advisory Group on AIDS on the executive of the European AIDS Clinical Society and on the Governing Council of the International AIDS Society.&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary: &lt;a href="nelh:390082:3" name=internalLink&gt;An overview of the BHIVA guidelines for treatment of HIV and TB co-infection&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr Marc Lipman&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390083/nelhImp_0007_titles.e3.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="justify"&gt;Dr Marc Lipman is an HEFCE-NHS Clinical Senior Lecturer and Consultant in Respiratory and HIV Medicine at the Royal Free Hospital, London. He a member of the London TB Clinical Working Group, Chair of the British Thoracic Society (BTS) TB Specialist Advisory Group, advisor to the Department of Health, a member of the National Knowledge Service TB Programme Board and the National MDRTB advisory service. His research interests focus on tuberculosis, respiratory infections and HIV.&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary: &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications of HIV and TB co-infection&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr Dominik Zenner&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390083/nelhImp_0008_titles.e4.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="justify"&gt;Dr Dominik Zenner MD MA MSc MFPH, is a Public Health Registrar at the Centre for Infection, Health Protection Agency, Medical Advisor to the British Paediatric Surveillance Unit (BPSU) and Honorary Research Fellow at the London School of Hygiene and Tropical Medicine (LSHTM). He is also a practicing General Practitioner. His special interests are in the surveillance of TB and HIV and he has published on HIV and STI epidemiology both internationally and in the UK. He is currently involved in two large TB studies, including a major project on HIV-TB co-infections in the UK.&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary: &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of HIV and TB co-infection in the UK&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;7&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr Valerie Delpech&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390083/nelhImp_0011_titles.e5.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="justify"&gt;Dr. Valerie Delpech is a public health consultant epidemiologist at the Health Protection Agency and has led on the national surveillance of HIV infections for the United Kingdom for the past 6 years. She trained in medicine and public health in Australia and the UK and has extensive experience in communicable disease control and public health, with a particular interest in sexual health.&lt;/p&gt; &lt;p align="justify"&gt;Valerie serves on a number of national and international committees in relation to HIV surveillance, prevention and policy development including the Expert Advisory Group on AIDS (EAGA). She was on the writing committee of the UK National Guidelines for HIV Testing and is leading on a project on developing testing HIV guidelines for European countries. She is also an executive trustee for the National AIDS Trust.&lt;/p&gt; &lt;p align="justify"&gt;Valerie's research interests and publications have focused on better understanding changes in the epidemiology of HIV, STIs and HIV co-infections, and tracking efforts to curb these epidemics in vulnerable populations.&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary: &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of HIV and TB co-infection in the UK&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr Anne Chapman&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390083/nelhImp_0012_titles.e6.jpg" height="100" width="400"&gt;&lt;/p&gt; &lt;p align="justify"&gt;Dr Ann Chapman studied medicine in Cambridge and then Oxford, and then specialised in infectious diseases and General Internal Medicine. Following her PhD, she conducted research into the use of T cell-based assays for diagnosing active and latent tuberculosis in Zambia, a country of high HIV and TB prevalence. Her involvement in this area has continued subsequently, both clinically and through her contribution to the recent NICE guidelines on TB diagnosis. She now works as a Consultant in Infectious Diseases in the Department of Infection and Tropical Medicine in Sheffield, UK, where, among other things, she runs the tuberculosis service and continues to undertake clinical research into tuberculosis.&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary: &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br /&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>390085</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=390085]]&gt;</url>
    <title>2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Evidence</title>
    <publicationDate>2010-11-29T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,TUBERCULOSIS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MYCOBACTERIUM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,NOV 10,ADDED 2010,WHAT'S NEW]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best evidence in HIV over the last 12 months</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This Annual Evidence Update provides a collection of evidence that has emerged over the last twelve months on HIV accompanied by commentaries from experts in the field. The evidence provided here include guidelines, policy, systematic reviews, articles, reports and useful websites.&lt;/P&gt;
&lt;P&gt;You may also wish to review previous Annual Evidence Updates:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;2009 Annual Evidence Update: HIV in children and adolescents&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:299385:1" name=internalLink&gt;2008 Annual Evidence Update: Diagnosing HIV&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Subtopics:&lt;/B&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis B or Hepatitis C co-infection&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Diagnosis and Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bateganya M, Abdulwadud OA, Kiene SM. &lt;A href="nelh:270957:1" name=internalLink&gt;Home-based HIV voluntary counselling and testing (VCT) for improving uptake of HIV testing&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD006493. DOI: 10.1002/14651858.CD006493.pub4.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:374677:1" name=internalLink&gt;Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review&lt;/A&gt;, 30 Jun 2010&lt;/LI&gt;
&lt;LI&gt;Guy R, Gold J, Calleja JM, Kim AA, Parekh B, Busch M, Rehle T, Hargrove J, Remis RS, Kaldor JM; WHO Working Group on HIV Incidence Assays. &lt;A href="nelh:392300:1" name=internalLink&gt;Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review&lt;/A&gt;. Lancet Infect Dis. 2009 Dec;9(12):747-59. Review. Erratum in: Lancet Infect Dis. 2010 Feb;10(2):82.&lt;/LI&gt;
&lt;LI&gt;CRD Health Technology Assessment Database, &lt;A href="nelh:376871:1" name=internalLink&gt;Rapid antibody testing for HIV&lt;/A&gt;, 12 May 2010&lt;/LI&gt;
&lt;LI&gt;World Health Organization, Delivering HIV test results and messages for re-testing and counselling in adults, 9 June 2010&lt;/LI&gt;
&lt;LI&gt;Deblonde J, De Koker P, Hamers FF, Fontaine J, Luchters S, Temmerman M. &lt;A href="nelh:392301:1" name=internalLink&gt;Barriers to HIV testing in Europe: a systematic review&lt;/A&gt;. Eur J Public Health. 2010 Aug;20(4):422-32. Epub 2010 Feb 1.&lt;/LI&gt;
&lt;LI&gt;Fontela PS, Pant Pai N, Schiller I, Dendukuri N, Ramsay A, Pai M. &lt;A href="nelh:345446:1" name=internalLink&gt;Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards&lt;/A&gt;. PLoS One. 2009 Nov 13;4(11):e7753.&lt;/LI&gt;
&lt;LI&gt;Gaur S, Whitley-Williams P, Flash C, Jimenez E, Petrova A. &lt;A href="nelh:392303:1" name=internalLink&gt;Disparity in hospital utilization of rapid HIV-1 testing for women in labor with undocumented HIV status&lt;/A&gt;. Matern Child Health J. 2010 Mar;14(2):268-73. Epub 2009 Mar 4.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:365154:1" name=internalLink&gt;Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model&lt;/A&gt;, 03 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:343069:1" name=internalLink&gt;Cost-effectiveness estimates for antenatal HIV testing in the Netherlands&lt;/A&gt;. 13 Jan 2010.&lt;/LI&gt;
&lt;LI&gt;Dibosa-Osadolor O, Roberts T. &lt;A href="nelh:392306:1" name=internalLink&gt;Economic evaluation, human immunodeficiency virus infection and screening: a review and critical appraisal of economic studies&lt;/A&gt;. Int J Technol Assess Health Care. 2010 Jul;26(3):301-8.&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Lazarus JV, Sihvonen-Riemenschneider H, Laukamm-Josten U, Wong F, Liljestrand J. &lt;A href="nelh:392342:1" name=internalLink&gt;Systematic review of interventions to prevent the spread of sexually transmitted infections, including HIV, among young people in Europe&lt;/A&gt;. Croat Med J. 2010 Feb;51(1):74-84.&lt;/LI&gt;
&lt;LI&gt;Padian NS, McCoy SI, Balkus JE, Wasserheit JN. &lt;A href="nelh:392345:1" name=internalLink&gt;Weighing the gold in the gold standard: challenges in HIV prevention research&lt;/A&gt;. AIDS. 2010 Mar 13;24(5):621-35.&lt;/LI&gt;
&lt;LI&gt;Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA; 2009 Reference Group to the UN on HIV and Injecting Drug Use. &lt;A href="nelh:345023:1" name=internalLink&gt;HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage&lt;/A&gt;. Lancet 2010 Mar 20;375(9719):1014-28. Epub 2010 Feb 26.&lt;/LI&gt;
&lt;LI&gt;Meader N, Li R, Des Jarlais DC, Pilling S. &lt;A href="nelh:341762:1" name=internalLink&gt;Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007192. DOI: 10.1002/14651858.CD007192.pub2.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:392346:1" name=internalLink&gt;Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review&lt;/A&gt;, 23 Jun 2010&lt;/LI&gt;
&lt;LI&gt;Larney S. &lt;A href="nelh:392346:1" name=internalLink&gt;Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review&lt;/A&gt;. Addiction. 2010 Feb;105(2):216-23.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:382282:1" name=internalLink&gt;Cost-effectiveness of newborn circumcision in reducing lifetime HIV risk among U.S. males&lt;/A&gt;, 21 Jul 2010&lt;/LI&gt;
&lt;LI&gt;Weiss HA, Hankins CA, Dickson K. &lt;A href="nelh:392359:1" name=internalLink&gt;Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis&lt;/A&gt;. Lancet Infect Dis. 2009 Nov;9(11):669-77.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:374803:1" name=internalLink&gt;Male circumcision at different ages in Rwanda: a cost-effectiveness study&lt;/A&gt;, 21 Apr 2010&lt;/LI&gt;
&lt;LI&gt;Uthman OA, Popoola TA, Uthman MM, Aremu O. &lt;A href="nelh:392391:1" name=internalLink&gt;Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review&lt;/A&gt;. PLoS One. 2010 Mar 10;5(3):e9628.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:363941:1" name=internalLink&gt;Cost-effectiveness of adult circumcision in a resource-rich setting for HIV prevention among men who have sex with men&lt;/A&gt;, 19 May 2010&lt;/LI&gt;
&lt;LI&gt;Berg R. &lt;A href="nelh:394111:1" name=internalLink&gt;The effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe: A systematic review&lt;/A&gt;. Euro Surveill. 2009 Dec 3;14(48). pii: 19430.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:367749:1" name=internalLink&gt;Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness&lt;/A&gt;, 24 Feb 2010&lt;/LI&gt;
&lt;LI&gt;Baggaley RF, White RG, Boily MC. &lt;A href="nelh:392762:1" name=internalLink&gt;HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention&lt;/A&gt;. Int J Epidemiol. 2010 Aug;39(4):1048-63. Epub 2010 Apr 20. &lt;/LI&gt;
&lt;LI&gt;Burton J, Darbes LA, Operario D. &lt;A href="nelh:392792:1" name=internalLink&gt;Couples-focused behavioral interventions for prevention of HIV: systematic review of the state of evidence.&lt;/A&gt; AIDS Behav. 2010 Feb;14(1):1-10.&lt;/LI&gt;
&lt;LI&gt;Kennedy CE, Medley AM, Sweat MD, O'Reilly KR. &lt;A href="nelh:392798:1" name=internalLink&gt;Behavioural interventions for HIV positive prevention in developing countries: a systematic review and meta-analysis&lt;/A&gt;. Bull World Health Organ. 2010 Aug 1;88(8):615-23. Epub 2010 May 28.&lt;/LI&gt;
&lt;LI&gt;McCoy SI, Kangwende RA, Padian NS. &lt;A href="nelh:392804:1" name=internalLink&gt;Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review&lt;/A&gt;. AIDS Behav. 2010 Jun;14(3):469-82.&lt;/LI&gt;
&lt;LI&gt;Young T, Busgeeth K. &lt;A href="nelh:341716:1" name=internalLink&gt;Home-based care for reducing morbidity and mortality in people infected with HIV/AIDS&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD005417. DOI: 10.1002/14651858.CD005417.pub2.&lt;/LI&gt;
&lt;LI&gt;Kang M, Skinner R, Usherwood T. &lt;A href="nelh:393363:1" name=internalLink&gt;Interventions for young people in Australia to reduce HIV and sexually transmissible infections: a systematic review&lt;/A&gt;. Sex Health. 2010 Jun;7(2):107-28.&lt;/LI&gt;
&lt;LI&gt;Michielsen K, Chersich MF, Luchters S, De Koker P, Van Rossem R, Temmerman M. &lt;A href="nelh:393369:1" name=internalLink&gt;Effectiveness of HIV prevention for youth in sub-Saharan Africa: systematic review and meta-analysis of randomized and nonrandomized trials&lt;/A&gt;. AIDS. 2010 May 15;24(8):1193-202.&lt;/LI&gt;
&lt;LI&gt;Harrison A, Newell ML, Imrie J, Hoddinott G. &lt;A href="nelh:372517:1" name=internalLink&gt;HIV prevention for South African youth: which interventions work? A systematic review of current evidence&lt;/A&gt;. BMC Public Health. 2010 Feb 26;10:102.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:342843:1" name=internalLink&gt;Effectiveness of interventions for the prevention of HIV and other sexually transmitted infections in female sex workers in resource poor setting: a systematic review.&lt;/A&gt; 13 Jan 2010.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:334114:1" name=internalLink&gt;Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials&lt;/A&gt;. 23 Dec 2009.&lt;/LI&gt;
&lt;LI&gt;Galarraga O, Colchero MA, Wamai RG, Bertozzi SM. &lt;A href="nelh:393372:1" name=internalLink&gt;HIV prevention cost-effectiveness: a systematic review&lt;/A&gt;. BMC Public Health. 2009 Nov 18;9 Suppl 1:S5.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:364198:1" name=internalLink&gt;Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia&lt;/A&gt;, 11 Aug 2010&lt;/LI&gt;
&lt;LI&gt;Pattanaphesaj J, Teerawattananon Y. &lt;A href="nelh:393374:1" name=internalLink&gt;Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand&lt;/A&gt;. BMC Public Health. 2010 Jul 7;10(1):401. [Epub ahead of print]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Spaulding A, Rutherford GW, Siegfried N. &lt;A href="nelh:383177:1" name=internalLink&gt;Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naive individuals&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD008651. DOI: 10.1002/14651858.CD008651.&lt;/LI&gt;
&lt;LI&gt;O'Brien K, Nixon S, Tynan AM, Glazier R. &lt;A href="nelh:237097:1" name=internalLink&gt;Aerobic exercise interventions for adults living with HIV/AIDS&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001796. DOI: 10.1002/14651858.CD001796.pub3.&lt;/LI&gt;
&lt;LI&gt;CRD Health Technology Assessment Database, &lt;A href="nelh:376718:1" name=internalLink&gt;Intravenous immunoglobulin for acquired immune deficiency syndrome (AIDS) in adults&lt;/A&gt;, 12 May 2010&lt;/LI&gt;
&lt;LI&gt;CRD Health Technology Assessment Database, &lt;A href="nelh:376429:1" name=internalLink&gt;A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination regimen&lt;/A&gt;, 28 Apr 2010&lt;/LI&gt;
&lt;LI&gt;Malta M, Magnanini MM, Strathdee SA, Bastos FI. &lt;A href="nelh:393380:1" name=internalLink&gt;Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis&lt;/A&gt;. AIDS Behav. 2010 Aug;14(4):731-47. Epub 2008 Nov 20.&lt;/LI&gt;
&lt;LI&gt;Chowers M, Gottesman BS, Leibovici L, Schapiro JM, Paul M. &lt;A href="nelh:393383:1" name=internalLink&gt;Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis&lt;/A&gt;. Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):779-86. Epub 2010 May 7.&lt;/LI&gt;
&lt;LI&gt;Leeper SC, Montague BT, Friedman JF, Flanigan TP. &lt;A href="nelh:393386:1" name=internalLink&gt;Lessons learned from family-centred models of treatment for children living with HIV: current approaches and future directions&lt;/A&gt;. J Int AIDS Soc. 2010 Jun 23;13 Suppl 2:S3.&lt;/LI&gt;
&lt;LI&gt;Humphreys EH, Chang LW, Harris J. &lt;A href="nelh:270958:1" name=internalLink&gt;Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy&lt;/A&gt;. Cochrane Database Syst Rev. 2010 Jun 16;6:CD006517.&lt;/LI&gt;
&lt;LI&gt;Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC, Shin SS. &lt;A href="nelh:393391:1" name=internalLink&gt;Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review&lt;/A&gt;. J Acquir Immune Defic Syndr. 2010 Jun;54(2):167-79.&lt;/LI&gt;
&lt;LI&gt;Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern and Central Africa. &lt;A href="nelh:393394:1" name=internalLink&gt;Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis&lt;/A&gt;. Lancet Infect Dis. 2010 Apr;10(4):251-61. &lt;/LI&gt;
&lt;LI&gt;Sturt AS, Dokubo EK, Sint TT. &lt;A href="nelh:346320:1" name=internalLink&gt;Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women&lt;/A&gt;. Cochrane Database Syst Rev. 2010 Mar 17;3:CD008440.&lt;/LI&gt;
&lt;LI&gt;Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. &lt;A href="nelh:393401:1" name=internalLink&gt;Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review&lt;/A&gt;. Lancet Infect Dis. 2010 Mar;10(3):155-66.&lt;/LI&gt;
&lt;LI&gt;Ford N, Nachega JB, Engel ME, Mills EJ. &lt;A href="nelh:393677:1" name=internalLink&gt;Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials&lt;/A&gt;. Lancet. 2009 Dec 19;374(9707):2064-71. Epub 2009 Nov 30.&lt;/LI&gt;
&lt;LI&gt;Ciaranello AL, Chang Y, Margulis AV, Bernstein A, Bassett IV, Losina E, Walensky RP. &lt;A href="nelh:393679:1" name=internalLink&gt;Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis&lt;/A&gt;. Clin Infect Dis. 2009 Dec 15;49(12):1915-27.&lt;/LI&gt;
&lt;LI&gt;CRD Health Technology Assessment Database, &lt;A href="nelh:376408:1" name=internalLink&gt;Paediatric European Network for the Treatment of AIDS (PENTA) PENTA 16 Trial: Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV-infection&lt;/A&gt;, 21 Apr 2010&lt;/LI&gt;
&lt;LI&gt;Chang LW, Harris J, Humphreys E. &lt;A href="nelh:372002:1" name=internalLink&gt;Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD008494. DOI: 10.1002/14651858.CD008494.&lt;/LI&gt;
&lt;LI&gt;Siegfried N, Uthman OA, Rutherford GW. &lt;A href="nelh:346315:1" name=internalLink&gt;Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD008272. DOI: 10.1002/14651858.CD008272.pub2.&lt;/LI&gt;
&lt;LI&gt;Fox MP, Rosen S. &lt;A href="nelh:393928:1" name=internalLink&gt;Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review&lt;/A&gt;. Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15.&lt;/LI&gt;
&lt;LI&gt;Callaghan M, Ford N, Schneider H. &lt;A href="nelh:393930:1" name=internalLink&gt;A systematic review of task- shifting for HIV treatment and care in Africa&lt;/A&gt;. Hum Resour Health. 2010 Mar 31;8:8.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:385835:1" name=internalLink&gt;Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland&lt;/A&gt;, 04 Aug 2010&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:385999:1" name=internalLink&gt;The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi&lt;/A&gt;, 04 Aug 2010&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:343078:1" name=internalLink&gt;Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure&lt;/A&gt;, 27 Jan 2010&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:365512:1" name=internalLink&gt;The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand&lt;/A&gt;, 30 Jun 2010&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:367756:1" name=internalLink&gt;Assessing efficiency and costs of scaling up HIV treatment&lt;/A&gt;, 17 Feb 2010&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;European Centre for Disease Prevention and Control, &lt;A href="nelh:331570:1" name=internalLink&gt;HIV/AIDS surveillance in Europe 2008&lt;/A&gt;, 01 Dec 2009&lt;/LI&gt;
&lt;LI&gt;Health Protection Agency, &lt;A href="nelh:331512:1" name=internalLink&gt;HIV in the United Kingdom: 2009 Report&lt;/A&gt;, 30 Nov 2009&lt;/LI&gt;
&lt;LI&gt;UNAIDS and WHO, &lt;A href="nelh:331155:1" name=internalLink&gt;AIDS epidemic update 2009&lt;/A&gt;, 02 Nov 2009&lt;/LI&gt;
&lt;LI&gt;Barnighausen T, McWalter TA, Rosner Z, Newell ML, Welte A. &lt;A href="nelh:393931:1" name=internalLink&gt;HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis&lt;/A&gt;. Epidemiology. 2010 Sep;21(5):685-97.&lt;/LI&gt;
&lt;LI&gt;Horyniak D, Guy R, Prybylski D, Hellard M, Kaldor J. &lt;A href="nelh:393933:1" name=internalLink&gt;The utility of voluntary counselling and testing data as a source of information on HIV prevalence: a systematic review&lt;/A&gt;. Int J STD AIDS. 2010 May;21(5):305-11.&lt;/LI&gt;
&lt;LI&gt;Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. &lt;A href="nelh:393958:1" name=internalLink&gt;Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis&lt;/A&gt;. Addiction. 2010 Feb;105(2):311-8. Epub 2009 Nov 16.&lt;/LI&gt;
&lt;LI&gt;Graham SM, Shah PS, Aesch ZC, Beyene J, Bayoumi AM. &lt;A href="nelh:394181:1" name=internalLink&gt;A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power&lt;/A&gt;. HIV Clin Trials. 2009 Nov-Dec;10(6):413-31.&lt;/LI&gt;
&lt;LI&gt;Sawers L, Stillwaggon E. &lt;A href="nelh:394183:1" name=internalLink&gt;Concurrent sexual partnerships do not explain the HIV epidemics in Africa: a systematic review of the evidence&lt;/A&gt;. J Int AIDS Soc. 2010 Sep 13;13(1):34. [Epub ahead of print]&lt;/LI&gt;
&lt;LI&gt;Abu-Raddad LJ, Hilmi N, Mumtaz G, Benkirane M, Akala FA, Riedner G, Tawil O, Wilson D. &lt;A href="nelh:394185:1" name=internalLink&gt;Epidemiology of HIV infection in the Middle East and North Africa&lt;/A&gt;. AIDS. 2010 Jul;24 Suppl 2:S5-23.&lt;/LI&gt;
&lt;LI&gt;Malta M, Magnanini MM, Mello MB, Pascom AR, Linhares Y, Bastos FI. &lt;A href="nelh:394191:1" name=internalLink&gt;HIV prevalence among female sex workers, drug users and men who have sex with men in Brazil: a systematic review and meta-analysis&lt;/A&gt;. BMC Public Health. 2010 Jun 7;10:317.&lt;/LI&gt;
&lt;LI&gt;Beyrer C, Baral SD, Walker D, Wirtz AL, Johns B, Sifakis F. &lt;A href="nelh:394194:1" name=internalLink&gt;The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency&lt;/A&gt;. Epidemiol Rev. 2010 Apr;32(1):137-51. Epub 2010 Jun 23.&lt;/LI&gt;
&lt;LI&gt;Oramasionwu CU, Brown CM, Lawson KA, Ryan L, Frei CR. &lt;A href="nelh:394195:1" name=internalLink&gt;Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies&lt;/A&gt;. J Natl Med Assoc. 2009 Dec;101(12):1221-9.&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;7&lt;/pageSequence&gt;&lt;pageTitle&gt;HIV and TB co-infection&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;British HIV Association,&lt;A href="nelh:66647:1" name=internalLink&gt;British HIV Association guidelines for the treatment of TB/HIV co-infection 2009&lt;/A&gt;, 01 Jan 2010&lt;/LI&gt;
&lt;LI&gt;Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. &lt;A href="nelh:394199:1" name=internalLink&gt;Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis&lt;/A&gt;. Clin Infect Dis. 2010 May 1;50(9):1288-99.&lt;/LI&gt;
&lt;LI&gt;Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. &lt;A href="nelh:345489:1" name=internalLink&gt;Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis&lt;/A&gt;. Lancet Infect Dis. 2010 Feb;10(2):93-102.&lt;/LI&gt;
&lt;LI&gt;Azzopardi P, Bennett CM, Graham SM, Duke T. &lt;A href="nelh:345032:1" name=internalLink&gt;Bacille Calmette-Guerin vaccine-related disease in HIV-infected children: a systematic review&lt;/A&gt;. Int J Tuberc Lung Dis. 2009 Nov;13(11):1331-44.&lt;/LI&gt;
&lt;LI&gt;Akolo C, Adetifa I, Shepperd S, Volmink J. &lt;A href="nelh:236448:1" name=internalLink&gt;Treatment of latent tuberculosis infection in HIV infected persons&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD000171. DOI: 10.1002/14651858.CD000171.pub3.&lt;/LI&gt;
&lt;LI&gt;Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA. &lt;A href="nelh:394200:1" name=internalLink&gt;Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa&lt;/A&gt;. Clin Infect Dis. 2010 Oct 1;51(7):823-9.&lt;/LI&gt;
&lt;LI&gt;Gao L, Zhou F, Li X, Jin Q. &lt;A href="nelh:394203:1" name=internalLink&gt;HIV/TB co-infection in mainland China: a meta-analysis&lt;/A&gt;. PLoS One. 2010 May 20;5(5):e10736.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:371107:1" name=internalLink&gt;Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults&lt;/A&gt;, 07 Jul 2010&lt;/LI&gt;
&lt;LI&gt;Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. &lt;A href="nelh:394464:1" name=internalLink&gt;Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?&lt;/A&gt; AIDS. 2009 Nov 27;23(18):2507-15&lt;/LI&gt;
&lt;LI&gt;Rodger AJ, Story A, Fox Z, Hayward A; London Tuberculosis Nurses Network. &lt;A href="nelh:394465:1" name=internalLink&gt;HIV prevalence and testing practices among tuberculosis cases in London: a missed opportunity for HIV diagnosis?&lt;/A&gt; Thorax. 2010 Jan;65(1):63-9. Epub 2009 Dec 8.&lt;/LI&gt;
&lt;LI&gt;Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. &lt;A href="nelh:394467:1" name=internalLink&gt;Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy&lt;/A&gt;. AIDS. 2010 Jun 1;24(9):1323-8.&lt;/LI&gt;
&lt;LI&gt;Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, Metcalf JA, Masur H, Hassim S. &lt;A href="nelh:394468:1" name=internalLink&gt;Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.&lt;/A&gt; AIDS. 2010 Jul 31;24(12):1849-55.&lt;/LI&gt;
&lt;LI&gt;Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. &lt;A href="nelh:394469:1" name=internalLink&gt;Timing of initiation of antiretroviral drugs during tuberculosis therapy&lt;/A&gt;. N Engl J Med. 2010 Feb 25;362(8):697-706.&lt;/LI&gt;
&lt;LI&gt;Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, Phanuphak P, Teeratakulpisarn N, Phanuphak N, Nguyen HD, Hoang TQ, Le HT, Varma JK. &lt;A href="nelh:394470:1" name=internalLink&gt;An algorithm for tuberculosis screening and diagnosis in people with HIV&lt;/A&gt;. N Engl J Med. 2010 Feb 25;362(8):707-16.&lt;/LI&gt;
&lt;LI&gt;Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G. &lt;A href="nelh:394471:1" name=internalLink&gt;Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome&lt;/A&gt;. AIDS. 2010 Sep 24;24(15):2381-90.&lt;/LI&gt;
&lt;LI&gt;Ha DT, Lan NT, Kiet VS, Wolbers M, Hang HT, Day J, Hien NQ, Tien NA, An PT, Anh TT, Oanh DT, Hoa CL, Chau NT, Hai NN, Binh NT, Ngoc LH, Phuong DT, Quyet TV, Tuyen NT, Ha VT, Nho NT, Hoa DV, Anh PT, Dung NH, Farrar J, Caws M. &lt;A href="nelh:394472:1" name=internalLink&gt;Diagnosis of pulmonary tuberculosis by microscopic observation drug susceptibility assay in hiv-positive patients&lt;/A&gt;. J Clin Microbiol. 2010 Oct 6. [Epub ahead of print]&lt;/LI&gt;
&lt;LI&gt;Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick RM, Johnson WD Jr, Pape JW, Fitzgerald DW. &lt;A href="nelh:394473:1" name=internalLink&gt;Early versus standard antiretroviral therapy for HIV-infected adults in Haiti&lt;/A&gt;. N Engl J Med. 2010 Jul 15;363(3):257-65.&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;8&lt;/pageSequence&gt;&lt;pageTitle&gt;HIV and Hepatitis B or Hepatitis C co-infection&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;British HIV Association, &lt;A href="nelh:343359:1" name=internalLink&gt;British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010&lt;/A&gt;, 27 Jan 2010&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:352352:1" name=internalLink&gt;Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection&lt;/A&gt;, 23 Jun 2010&lt;/LI&gt;
&lt;LI&gt;Iorio A, Marchesini E, Awad T, Gluud LL. &lt;A href="nelh:341713:1" name=internalLink&gt;Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD004888. DOI: 10.1002/14651858.CD004888.pub2.&lt;/LI&gt;
&lt;LI&gt;Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. &lt;A href="nelh:394224:1" name=internalLink&gt;Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients&lt;/A&gt;. Clin Infect Dis. 2010 Sep 1;51(5):496-505.&lt;/LI&gt;
&lt;LI&gt;Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. &lt;A href="nelh:394225:1" name=internalLink&gt;Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis&lt;/A&gt;. Int J Infect Dis. 2010 Sep 24. [Epub ahead of print] &lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;8&lt;/pageID&gt;&lt;pageSequence&gt;9&lt;/pageSequence&gt;&lt;pageTitle&gt;Miscellaneous&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kennedy CE, Spaulding AB, Brickley DB, Almers L, Mirjahangir J, Packel L, Kennedy GE, Mbizvo M, Collins L, Osborne K. &lt;A href="nelh:394229:1" name=internalLink&gt;Linking sexual and reproductive health and HIV interventions: a systematic review&lt;/A&gt;. J Int AIDS Soc. 2010 Jul 19;13:26.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:374691:1" name=internalLink&gt;Linking family planning with HIV/AIDS interventions: a systematic review of the evidence&lt;/A&gt;, 14 Apr 2010&lt;/LI&gt;
&lt;LI&gt;Spaulding AB, Brickley DB, Kennedy C, Almers L, Packel L, Mirjahangir J, Kennedy G, Collins L, Osborne K, Mbizvo M. &lt;A href="nelh:394231:1" name=internalLink&gt;Linking family planning with HIV/AIDS interventions: a systematic review of the evidence&lt;/A&gt;. AIDS. 2009 Nov;23 Suppl 1:S79-88.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:374693:1" name=internalLink&gt;Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review&lt;/A&gt;, 14 Apr 2010&lt;/LI&gt;
&lt;LI&gt;Curtis KM, Nanda K, Kapp N. &lt;A href="nelh:394233:1" name=internalLink&gt;Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review&lt;/A&gt;. AIDS. 2009 Nov;23 Suppl 1:S55-67.&lt;/LI&gt;
&lt;LI&gt;Hilber AM, Francis SC, Chersich M, Scott P, Redmond S, Bender N, Miotti P, Temmerman M, Low N. &lt;A href="nelh:394235:1" name=internalLink&gt;Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis&lt;/A&gt;. PLoS One. 2010 Feb 9;5(2):e9119.&lt;/LI&gt;
&lt;LI&gt;Azar MM, Springer SA, Meyer JP, Altice FL. &lt;A href="nelh:394238:1" name=internalLink&gt;A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization&lt;/A&gt;. Drug Alcohol Depend. 2010 Aug 10. [Epub ahead of print]&lt;/LI&gt;
&lt;LI&gt;Modjarrad K, Vermund SH. &lt;A href="nelh:394241:1" name=internalLink&gt;Effect of treating co-infections on HIV-1 viral load: a systematic review&lt;/A&gt;. Lancet Infect Dis. 2010 Jul;10(7):455-63.&lt;/LI&gt;
&lt;LI&gt;Pomarico L, de Souza IP, Castro GF, Teles RP, Luiz RR, Maia LC. &lt;A href="nelh:394243:1" name=internalLink&gt;Levels of salivary IgA antibodies to Candida spp. in HIV-infected adult patients: a systematic review&lt;/A&gt;. J Dent. 2010 Jan;38(1):10-5. Epub .&lt;/LI&gt;
&lt;LI&gt;Humphreys EH, Smith NM, Azman H, McLeod D, Rutherford GW. &lt;A href="nelh:378151:1" name=internalLink&gt;Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD008563. DOI: 10.1002/14651858.CD008563.&lt;/LI&gt;
&lt;LI&gt;Yanagisawa S, Poudel KC, Jimba M. &lt;A href="nelh:394415:1" name=internalLink&gt;Sibling caregiving among children orphaned by AIDS: Synthesis of recent studies for policy implications&lt;/A&gt;. Health Policy. 2010 Jun 28. [Epub ahead of print]&lt;/LI&gt;
&lt;LI&gt;Sherr L. &lt;A href="nelh:394427:1" name=internalLink&gt;Fathers and HIV: considerations for families&lt;/A&gt;. J Int AIDS Soc. 2010 Jun 23;13 Suppl 2:S4.&lt;/LI&gt;
&lt;LI&gt;CRD Health Technology Assessment Database, &lt;A href="nelh:377061:1" name=internalLink&gt;Solid Organ Transplantation for End Stage Organ Failure (ESOF) in persons with HIV&lt;/A&gt;, 24 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Hillier SL, Louw Q, Morris L, Uwimana J, Statham S. &lt;A href="nelh:341793:1" name=internalLink&gt;Massage therapy for people with HIV/AIDS&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007502. DOI: 10.1002/14651858.CD007502.pub2.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:334103:1" name=internalLink&gt;Cognitive-behavioral stress management interventions for persons living with HIV: a review and critique of the literature&lt;/A&gt;. 16 Dec 2009.&lt;/LI&gt;
&lt;LI&gt;Centre for Reviews and Dissemination, &lt;A href="nelh:334139:1" name=internalLink&gt;Effects and effectiveness of life skills education for HIV prevention in young people&lt;/A&gt;. 9 Dec 2009.&lt;/LI&gt;
&lt;LI&gt;Upreti D, Regmi P, Pant P, Simkhada P. &lt;A href="nelh:394428:1" name=internalLink&gt;Young people's knowledge, attitude, and behaviour on STI/HIV/AIDS in the context of Nepal: a systematic review&lt;/A&gt;. Kathmandu Univ Med J (KUMJ). 2009 Oct-Dec;7(28):383-91.&lt;/LI&gt;
&lt;LI&gt;Phillips AE, Gomez GB, Boily MC, Garnett GP. &lt;A href="nelh:394431:1" name=internalLink&gt;A systematic review and meta-analysis of quantitative interviewing tools to investigate self-reported HIV and STI associated behaviours in low- and middle-income countries&lt;/A&gt;. Int J Epidemiol. 2010 Jul 14. [Epub ahead of print]&lt;/LI&gt;
&lt;LI&gt;Robberstad B, Olsen JA. &lt;A href="nelh:394449:1" name=internalLink&gt;The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study&lt;/A&gt;. Cost Eff Resour Alloc. 2010 Apr 16;8:5.&lt;/LI&gt;
&lt;LI&gt;Hanass-Hancock J. &lt;A href="nelh:394450:1" name=internalLink&gt;Disability and HIV/AIDS - a systematic review of literature on Africa&lt;/A&gt;. J Int AIDS Soc. 2009 Nov 13;2(1):9.&lt;/LI&gt;
&lt;LI&gt;Yin X, Wu T, Yan Y, Zhang H, Bu H. &lt;A href="nelh:374534:1" name=internalLink&gt;Treatment for leiomyosarcoma and leiomyoma in children with HIV infection&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No.: CD007665. DOI: 10.1002/14651858.CD007665.pub2.&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;9&lt;/pageID&gt;&lt;pageSequence&gt;10&lt;/pageSequence&gt;&lt;pageTitle&gt;Guidelines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Clinical Knowledge Summaries, &lt;A href="nelh:347168:1" name=internalLink&gt;HIV infection and AIDS&lt;/A&gt;, 22 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Clinical Knowledge Summaries, &lt;A href="nelh:347173:1" name=internalLink&gt;HIV infection and AIDS: Antiretroviral treatment for HIV&lt;/A&gt;, 22 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Clinical Knowledge Summaries, &lt;A href="nelh:347170:1" name=internalLink&gt;HIV infection and AIDS: HIV detection in asymptomatic people with an epidemiological risk of unsuspected HIV &lt;/A&gt;, 22 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Clinical Knowledge Summaries, &lt;A href="nelh:347169:1" name=internalLink&gt;HIV infection and AIDS: HIV diagnosis in people with symptoms&lt;/A&gt;, 22 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Clinical Knowledge Summaries, &lt;A href="nelh:347171:1" name=internalLink&gt;HIV infection and AIDS: Living with HIV/AIDS and coping with associated problems&lt;/A&gt;, 22 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Clinical Knowledge Summaries, &lt;A href="nelh:347172:1" name=internalLink&gt;HIV infection and AIDS: Post-exposure prophylaxis for HIV&lt;/A&gt;, 22 Mar 2010&lt;/LI&gt;
&lt;LI&gt;Medical Foundation for AIDS and Sexual Health, &lt;A href="nelh:126572:1" name=internalLink&gt;Standards for the management of sexually transmitted infections (STIs&lt;/A&gt;), 21 Jan 2010&lt;/LI&gt;
&lt;LI&gt;Royal College of Obstetricians and Gynaecologists, &lt;A href="nelh:36835:1" name=internalLink&gt;Management of HIV in pregnancy&lt;/A&gt;, 08 Jun 2010&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;10&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Reports&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;World Health Organization, &lt;A href="nelh:394455:1" name=internalLink&gt;Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector&lt;/A&gt;, 28 September 2010&lt;/LI&gt;
&lt;LI&gt;World Health Organization, &lt;A href="nelh:394456:1" name=internalLink&gt;HIV/AIDS programme highlights 2008-2009&lt;/A&gt;, May 2010&lt;/LI&gt;
&lt;LI&gt;World Health Organization, &lt;A href="nelh:371778:1" name=internalLink&gt;Making the case for interventions linking sexual and reproductive health and HIV in proposals to the Global Fund to Fight AIDS, Tuberculosis and Malaria&lt;/A&gt;, 18 Feb 2010.&lt;/LI&gt;
&lt;LI&gt;World Health Organization, &lt;A href="nelh:394462:1" name=internalLink&gt;The Global Plan to Stop TB: 2011-2015&lt;/A&gt;. November 2010.&lt;/LI&gt;
&lt;LI&gt;European Centre for Disease Prevention and Control, &lt;A href="nelh:394458:1" name=internalLink&gt;Implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2010 Progress Report&lt;/A&gt;, 28 Sept 2010&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print. 
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>390063</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=390063]]&gt;</url>
    <title>2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Homepage</title>
    <publicationDate>2010-11-29T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,TUBERCULOSIS,HIV/AIDS,INFECTIONS,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),WHAT'S NEW,ADDED 2010,NOV 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best evidence in HIV over the last 12 months</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0000_pdfpresentation.jpg" id=nelh_tempImage0 name=nelh_tempImage0 height="200" width="550" border="0"&gt;&lt;/p&gt; &lt;p align="justify"&gt;Welcome to the &lt;b&gt;2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture&lt;/b&gt; from &lt;a href="http://www.library.nhs.uk/Infections/" target="_blank"&gt;NHS Evidence-infections&lt;/a&gt;. This Annual Evidence Update will run from &lt;b&gt;29th November to 5th December 2010&lt;/b&gt;, and has been timed to coincide with &lt;a href="http://www.worldaidsday.org/" target="_blank"&gt;World AIDS day&lt;/a&gt; on 1st December.&lt;/p&gt; &lt;p align="center"&gt;&lt;br&gt;&lt;b&gt;Introduction by &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;/b&gt;&lt;br&gt;&lt;/p&gt; &lt;p align="justify"&gt;This Annual Evidence Update (AEU) provides up to date &lt;a href="nelh:390085:1" name=internalLink&gt;evidence&lt;/a&gt; and &lt;a href="nelh:390082:1" name=internalLink&gt;commentaries&lt;/a&gt; from &lt;a href="nelh:390083:1" name=internalLink&gt;experts&lt;/a&gt; related to the epidemiology and management of persons co-infected with HIV and tuberculosis (TB). The launch of this AEU coincides with this week's release of the Health Protection Agency's &lt;a href="http://www.library.nhs.uk/INFECTIONS/ViewResource.aspx?resID=331512&amp;amp;tabID=290" target="_blank"&gt;latest report on the UK's HIV epidemic&lt;/a&gt; - in time for World AIDS day on December 1st. The AEU includes a &lt;a href="http://isc.anthropith.com/NHS_Evidence-Dr_A_Pozniak.mp3" target="_blank"&gt;podcast&lt;/a&gt; with &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;, who discusses new guidance on the treatment of HIV and TB co-infection, and links to useful websites are also provided.&lt;/p&gt; &lt;p align="justify"&gt;In this year's update &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt; from the Global Fund to Fight AIDS, Tuberculosis and Malaria provides &lt;a href="nelh:390082:2" name=internalLink&gt;a global picture of the overlap of HIV and TB infections&lt;/a&gt; and argues that TB incidence is to a large extent driven by the HIV epidemic. It is encouraging that according to new statistics from the UN's programme on HIV/AIDS and the WHO that the number of new HIV infections and deaths from AIDS are falling globally. However, stigma and the number of people living with HIV remains unacceptably high at an estimated total of 33 million in 2009 with over 2.6million of these being newly diagnosed HIV infections. Tuberculosis is a common AIDS defining illness and the condition results in about 1.5 million deaths annually (with or without HIV infection). In 2009, 1.8 million died from AIDS-related illnesses, down from 2.1 million in 2004. Dr. Lazarus calls for better integration of HIV and TB services to ensure improved survival of patients affected by dual infections.&lt;/p&gt; &lt;p align="justify"&gt;Focusing on the UK, &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt; from the Chelsea and Westminster Hospital, takes us through an overview of the &lt;a href="nelh:390082:3" name=internalLink&gt;British HIV Association (BHIVA) guidelines for the treatment of HIV and TB co-infections&lt;/a&gt;, and highlights challenges and difficulties in diagnosing and managing dual infections, including screening for latent TB in HIV infected individuals and when to initiate HIV treatment. The &lt;a href="nelh:390082:4" name=internalLink&gt;clinical implications of dual infections&lt;/a&gt; are further explored by &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;, a consultant physician at the Royal Free Hospital NHS Trust.&lt;/p&gt; &lt;p align="justify"&gt;In the final section of the AEU we provide an &lt;a href="nelh:390082:5" name=internalLink&gt;overview of the HIV and TB epidemics in the UK&lt;/a&gt;, and &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;, Public Health Registrar at the Health Protection Agency, reviews the overlap of these infections. Testing of HIV is paramount to reducing the number of undiagnosed infections in the UK, and guidelines for HIV testing recently published by the British HIV Association, the British Association for Sexual Health and HIV and the British Infection Society advocate for expanding the offer and &lt;a href="nelh:390082:6" name=internalLink&gt;recommend HIV testing in a wider variety of settings including TB clinics&lt;/a&gt;. This subject is discussed by &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;, a consultant infectious disease physician at the Royal Hallamshire Hospital, Sheffield.&lt;/p&gt; &lt;p align="right"&gt;Link to &lt;a href="http://www.library.nhs.uk/INFECTIONS/ViewResource.aspx?resID=390086" target="_blank"&gt;methodology&lt;/a&gt;&lt;br /&gt; &lt;a href="http://isc.anthropith.com/HIV_AEU_2010_Flyer.pdf" target="_blank"&gt;Download Flyers (pdf)&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt; &lt;table align="center" width="450" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr align="center"&gt;&lt;td align="center"&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0001_titlebg01.jpg" name=nelh_tempImage1&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="center"&gt;&lt;a href="nelh:390082:2" name=internalLink&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0002_titlebg02.jpg" border="0" alt="The Global overview of TB and HIV co-infection" id=nelh_tempImage2 name=nelh_tempImage2&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="center"&gt;&lt;a href="nelh:390082:3" name=internalLink&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0003_titlebg03.jpg" border="0" alt="An overview of the BHIVA guidelines for treatment of TB and HIV co-infection" id=nelh_tempImage3 name=nelh_tempImage3&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="center"&gt;&lt;a href="nelh:390082:4" name=internalLink&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0004_titlebg04.jpg" border="0" alt="Clinical implications of TB and HIV co-infection" id=nelh_tempImage4 name=nelh_tempImage4&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="center"&gt;&lt;a href="nelh:390082:5" name=internalLink&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0005_titlebg05.jpg" border="0" alt="An overview of TB and HIV co-infection in the UK" id=nelh_tempImage5 name=nelh_tempImage5&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt;&lt;td align="center"&gt;&lt;a href="nelh:390082:6" name=internalLink&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID390063/nelhImp_0006_titlebg06.jpg" border="0" alt="HIV testing: when and how" id=nelh_tempImage6 name=nelh_tempImage6&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;/p&gt; &lt;p align="justify"&gt;You may also be interested in the National Library for Public Health's AEU on HIV/AIDS: &lt;a href="http://bit.ly/eKZwoT" target="_blank"&gt;Behaviour change in high-risk populations&lt;/a&gt;&lt;/p&gt; &lt;p align="justify"&gt;Our previous Annual Evidence Updates are available to review:&lt;br&gt; &lt;ul&gt;&lt;li&gt; &lt;a href="http://www.library.nhs.uk/INFECTIONS/ViewResource.aspx?resID=330262&amp;amp;pgID=1" target="_blank"&gt;2009: HIV in children and adolescents&lt;/a&gt;&lt;/li&gt; &lt;li&gt;&lt;a href="http://www.library.nhs.uk/INFECTIONS/ViewResource.aspx?resID=299385&amp;amp;pgID=1" target="_blank"&gt;2008: Diagnosing HIV&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt; &lt;table align="center" width="580" cellSpacing="0" cellPadding="0" border="0"&gt; &lt;tr valign="top"&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:5" name=internalLink&gt;Epidemiology and overview&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="130"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390083:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width="20"&gt; &lt;/td&gt; &lt;td width="205"&gt; &lt;p align="left" valign="top"&gt;&lt;b&gt;Evidence&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:390085:10" name=internalLink&gt;Reports&lt;/a&gt;&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;This AEU is also &lt;a href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/a&gt; to download and print.&lt;p&gt; &lt;p align="center"&gt;__________________________________________________________________________&lt;/p&gt;&lt;br&gt; &lt;p align="center"&gt;We welcome feedback about all aspects of NHS Evidence-infections, including the resources that make up this Annual Evidence Update. Please &lt;a href="http://www.library.nhs.uk/Infections/ContactUs.aspx" target="_blank"&gt;contact us&lt;/a&gt; if you would like to comment, or take part in our &lt;a href="http://www.library.nhs.uk/infections/Page.aspx?pagename=SMHIV2010" target="_blank"&gt;two minute survey&lt;/a&gt;. Thank you.&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>390086</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=390086]]&gt;</url>
    <title>2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Methodology</title>
    <publicationDate>2010-11-29T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,TUBERCULOSIS,HIV/AIDS,INFECTIONS,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),WHAT'S NEW,ADDED 2010,NOV 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A short summary of the methods used to find the evidence for this Annual Evidence Update</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B&gt;Search strategy&lt;/B&gt;&lt;/P&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Date of last search&lt;/B&gt;&lt;BR&gt;Searches were conducted on resources published between November 2009 and October 2010.&lt;BR&gt;&lt;BR&gt;&lt;B&gt;Sources used&lt;/B&gt;&lt;/P&gt;
&lt;P align=left valign="top"&gt;Databases:&lt;BR&gt;
&lt;UL&gt;
&lt;LI&gt;CINAHL&lt;/LI&gt;
&lt;LI&gt;EMBASE&lt;/LI&gt;
&lt;LI&gt;PubMED&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left valign="top"&gt;Other sources:&lt;BR&gt;
&lt;UL&gt;
&lt;LI&gt;WHO website&lt;/LI&gt;
&lt;LI&gt;BASHH website&lt;/LI&gt;
&lt;LI&gt;BHIVA website&lt;/LI&gt;
&lt;LI&gt;ECDC website&lt;/LI&gt;
&lt;LI&gt;HPA website&lt;/LI&gt;
&lt;LI&gt;National Library of Guidelines&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Terms used&lt;/B&gt;&lt;BR&gt;
&lt;UL&gt;
&lt;LI&gt;The MeSH terms "HIV" OR "AIDS" were used&lt;/LI&gt;
&lt;LI&gt;Thesaurus terms (subheadings, exploded terms and major descriptor terms) for each of these were also used in the searches.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Inclusion and exclusion criteria&lt;/B&gt;&lt;BR&gt;
&lt;UL&gt;
&lt;LI&gt;Only systematic reviews from the databases were included&lt;/LI&gt;
&lt;LI&gt;Articles were included if they had an abstract&lt;/LI&gt;
&lt;LI&gt;If the article was not published in English, it was still included if an English abstract was available&lt;/LI&gt;
&lt;LI&gt;The websites listed were searched for all new content, and relevant reports were included&lt;/LI&gt;
&lt;LI&gt;The searches from the databases were combined, duplicates were removed, and the results were sifted through based on the relevance of the title or abstract&lt;/LI&gt;
&lt;LI&gt;The expert lead and expert panel assessed the quality and relevance of the articles&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print.
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>390087</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=390087]]&gt;</url>
    <title>2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Useful Websites</title>
    <publicationDate>2010-11-29T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,TUBERCULOSIS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MYCOBACTERIUM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,NOV 10,ADDED 2010,WHAT'S NEW]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A list of useful websites in the field of HIV</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: HIV and TB co-infection: seeing the whole picture - Useful Websites&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="http://www.worldaidsday.org/" target="_blank"&gt;World AIDS Day 2010&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;World AIDS Day is the 1st of December. The National AIDS Trust uses this website to encourage support so they can continue their work.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.hpa.org.uk/webw/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200660065903?p=1200660065903" target="_blank"&gt;&lt;B&gt;The Health Protection Agency: HIV&lt;/B&gt; &lt;/A&gt;&lt;BR&gt;The Health Protection Agency's page on HIV contains prevalence data, geographical data, information about surveillance systems and much more.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="http://www.bhiva.org/" target="_blank"&gt;The British HIV Association (BHIVA)&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;BHIVA has become the leading UK professional association representing professionals in HIV care. Now 15 years old, it is a well-established and highly respected organisation with national influence committed to providing excellence in the care of those living with and affected by HIV.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.bashh.org/" target="_blank"&gt;&lt;B&gt;The British Association for Sexual Health and HIV (BASHH)&lt;/B&gt;&lt;BR&gt;&lt;/A&gt;BASHH aims to be the lead professional representative body for those practicing sexual health including the management of STIs and HIV in the UK.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="http://www.unaids.org/en/" target="_blank"&gt;Joint United Nations Programme on HIV/AIDS (UNAIDS)&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;UNAIDS, the Joint United Nations Programme on HIV/AIDS, is an innovative joint venture of the United Nations family, bringing together the efforts and resources of ten UN system organizations in the AIDS response to help the world prevent new HIV infections, care for people living with HIV, and mitigate the impact of the epidemic.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="http://www.who.int/hiv/en/" target="_blank"&gt;World Health Organization pages on HIV/AIDS&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;As the directing and coordinating authority on international health, the World Health Organization (WHO) takes the lead within the UN system in the global health sector response to HIV/AIDS.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="http://www.medfash.org.uk/" target="_blank"&gt;Medical Foundation for AIDS &amp;amp; Sexual Health (MedFASH)&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;The Medical Foundation for AIDS &amp;amp; Sexual Health is a charity set up by the British Medical Association to promote excellence in the field of sexual health and HIV.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="http://www.aidsmap.com/" target="_blank"&gt;AIDS Map&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;NAM is an award-winning community based HIV information provider.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="http://www.tht.org.uk/" target="_blank"&gt;Terrence Higgins Trust&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;Terrence Higgins Trust is the leading and largest HIV and sexual health charity in the UK. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:390063:0" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Return to Commentaries page&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390082:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:2" name=internalLink&gt;A global overview&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:3" name=internalLink&gt;BHIVA guidelines for treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:4" name=internalLink&gt;Clinical implications&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:7" name=internalLink&gt;Epidemiology in the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:5" name=internalLink&gt;An overview of the UK&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390082:6" name=internalLink&gt;HIV testing: when and how&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=130&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390083:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:2" name=internalLink&gt;Dr Jeffrey Lazarus&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:3" name=internalLink&gt;Dr Anton Pozniak&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:4" name=internalLink&gt;Dr Marc Lipman&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:5" name=internalLink&gt;Dr Dominik Zenner&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:6" name=internalLink&gt;Dr Valerie Delpech&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390083:7" name=internalLink&gt;Dr Anne Chapman&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=20&gt;&lt;/TD&gt;
&lt;TD width=205&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Evidence&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:390085:2" name=internalLink&gt;Diagnosis and Screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:3" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:4" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:5" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:6" name=internalLink&gt;HIV and TB co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:7" name=internalLink&gt;HIV and Hepatitis co-infection&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:8" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:9" name=internalLink&gt;Guidelines&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:390085:10" name=internalLink&gt;Reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;This AEU is also &lt;A href="http://isc.anthropith.com/HIV_AEU_2010.pdf" target="_blank"&gt;available as a PDF document&lt;/A&gt; to download and print.
&lt;P&gt;
&lt;P align=center&gt;__________________________________________________________________________&lt;/P&gt;&lt;BR&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344184</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=344184]]&gt;</url>
    <title>2010 Annual Evidence Update: On The Move Against TB - Commentaries</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Expert commentaries for the Annual Evidence Update on tuberculosis</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: On The Move Against TB - Commentaries&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0000_tb2010title.jpg" alt="2010 Annual Evidence Update: On the move against TB" width="580" height="222" /&gt;&lt;/p&gt;

&lt;p&gt;The following &lt;a href="nelh:344191:1" name=internalLink&gt;experts&lt;/a&gt; have written &lt;a href="nelh:344184:1" name=internalLink&gt;commentaries&lt;/a&gt; about aspects of tuberculosis.&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;a href="nelh:344184:2" name=internalLink&gt;Introduction&lt;/a&gt; by &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt; by &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach groups&lt;/a&gt; by &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt; Update by &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt; of &lt;a href="nelh:308476:1" name=internalLink&gt;last year's commentary&lt;/a&gt; by &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br&gt;
&lt;br&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;b&gt;&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/b&gt;&lt;/a&gt;&lt;/p&gt; &lt;p align="justify"&gt;This year the fight against tuberculosis continues. Tuberculosis remains a major killer globally and the cause of considerable suffering in individuals and families with nearly 2 million deaths and 9 million new cases occurring annually. In the UK, the rise observed over the last two decades continues with provisional data released by the Health Protection Agency showing a further rise of 5.5% between 2008 and 2009 and the total number of cases now exceeding 9000.&lt;/p&gt; &lt;p align="justify"&gt;This year the fight against tuberculosis continues. Tuberculosis remains a major killer globally and the cause of considerable suffering in individuals and families with nearly 2 million deaths and 9 million new cases occurring annually. In the UK, the rise observed over the last two decades continues with provisional data released by the &lt;a href="http://www.hpa.org.uk/" target="_blank"&gt;Health Protection Agency&lt;/a&gt; showing a further rise of 5.5% between 2008 and 2009 and the total number of cases now exceeding 9000.&lt;/p&gt; &lt;p align="justify"&gt;The theme for this year's &lt;a href="http://www.stoptb.org/" target="_blank"&gt;World TB Day&lt;/a&gt;, identifies the need for innovation. In keeping with this message, we have identified three &lt;a href="nelh:344191:1" name=internalLink&gt;experts&lt;/a&gt; to review &lt;a href="nelh:344192:1" name=internalLink&gt;new evidence&lt;/a&gt; and provide &lt;a href="nelh:344184:1" name=internalLink&gt;commentaries&lt;/a&gt;. &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;, chest physician at St Mary's hospital provides a review of &lt;a href="nelh:344184:3" name=internalLink&gt;multi-drug resistant tuberculosis&lt;/a&gt; from the perspective of a clinician. Drug resistance against anti tuberculosis drugs is a key challenge faced by tuberculosis control programmes. This short overview highlights the challenges in tackling drug resistance and opportunities arising from new research.&lt;/p&gt; &lt;p align="justify"&gt;For high income, low incidence countries such as the UK, the burden of tuberculosis is concentrated in &lt;a href="nelh:344184:4" name=internalLink&gt;hard to reach populations&lt;/a&gt;. The public health effort to control tuberculosis therefore has to target effective interventions at this population. &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;, consultant in communicable disease control and the HPA's tuberculosis lead for Yorkshire and the Humber, provides a commentary on the control of tuberculosis in these populations.&lt;/p&gt; &lt;p align="justify"&gt;Tuberculosis is an infectious disease, and as is the case with other infections, an effective &lt;a href="nelh:344184:5" name=internalLink&gt;vaccine&lt;/a&gt; will determine whether we are able to eliminate this scourge. The global effort to identify a new &lt;a href="nelh:344184:5" name=internalLink&gt;vaccine&lt;/a&gt; for tuberculosis has intensified in recent years. The UK is a major player in this effort. &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;, from the University of Oxford, and &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt; from the &lt;a href="http://www.hpa.org.uk/" target="_blank"&gt;Health Protection Agency&lt;/a&gt; provide an update on ongoing research to find a new tuberculosis &lt;a href="nelh:344184:5" name=internalLink&gt;vaccine&lt;/a&gt;.&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;br&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Multi-drug resistant tuberculosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0009_tb2010mdrtb.jpg" width="340" height="115" /&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="justify"&gt;The latest estimates based on survey data reported that 1.6% of new cases and 11.7% of previously treated cases met the definition of multi-drug resistant tuberculosis (MDR-TB), this being resistance to rifampicin and isoniazid, the two most potent first-line anti-tuberculosis drugs. Much of this burden is carried by Eastern Europe, where 45.5% of previously treated tuberculosis cases meet the definition for MDR-TB. Outcomes in MDR-TB are worse than for non MDR-TB. A recent review has identified that several factors predict a worse outcome: being male, alcohol abuse, a low BMI, smear positivity and fluoroquinolone resistance. More recently, attention has been drawn to the emergence of a form of MDR-TB which has a more extensive pattern of resistance, including resistance to the second line agents conventionally used in MDR-TB cases. This extensively drug-resistant tuberculosis (XDR-TB) is currently defined by resistance to rifampicin and isoniazid plus resistance to any fluoroquinolone and at least one second line injectable drug (these being amikacin, kanamycin and capreomycin). Attention was initially drawn to the potential implications of the emergence of XDR-TB by an outbreak in KwaZulu Natal, South Africa, when almost all the patients died with a median survival of only 16 days from the time of sputum. Subsequent studies confirmed that XDR-TB had been isolated from all geographic regions and is thus a global problem. Further studies confirmed that XDR-TB has a worse outcome than other MDR-TB, but reassuringly no study to date has identified high rates of mortality like those seen in KwaZulu Natal. These other studies have also challenged the misconception that XDR-TB is predominantly a disease of HIV infected patients. In fact the majority of these studies have a typical HIV prevalence in the studied population of &lt; 5%.&lt;/p&gt; &lt;p align="justify"&gt;A Russian study confirmed that treatment failure was more common in XDR-TB than MDR-TB, but still suceeded in curing 45% of XDR-TB patients. A similar study in Peru utilizing a co-ordinated outpatient service found no difference in key outcomes between XDR-TB and MDR-TB patients, with impressive cure rates of 60.4% and 65.6% respectively and mortality of 22.9% and 20.4% respectively. Both studies used prolonged individualized treatment regimes based upon drug-sensitivity testing results. Fluoroquinolones and injectables were cornerstones of these treatment regimes, with a prolonged parenteral phase of therapy (median 10.9 months for the Russian study and 15.4 months in the Peruvian study). A recent meta-analysis of outcomes in MDR-TB found that combining a treatment duration longer than 18 months and DOT (directly observed therapy) achieved a significantly greater proportion of treatment success (69% versus 58%, P&lt;0.001).&lt;/p&gt; &lt;p align="justify"&gt;A key to the construction of the best regime is the knowledge of the sensitivity pattern of the isolate. Standard methods of drug sensitivity testing are limited by the turnaround time of between 1 -2 months depending on whether solid or liquid media systems are used. These methods are further complicated by potentially poor correlation between the tested MIC in vitro and the levels of drug available in vivo at the site of disease. In response to these problems, particularly the turnaround time, a variety of novel diagnostic approaches have been employed such as molecular techniques. All of these offer high sensitivity and specificity with improved speed compared with conventional approaches.&lt;/p&gt; &lt;p align="justify"&gt;The relative shortage of new effective drugs has focused attention on non-pharmacological therapies such as vitamin D, interferon-gamma or other immunotherapies, but thus far these have been trialled in only very small numbers of patients. The role of surgery, a mainstay of therapy in the pre-antibiotic era, has also been revisited for the treatment of MDR/XDR-TB.&lt;/p&gt; &lt;p align="justify"&gt;Our understanding of the different factors influencing outcome and determining optimal management in MDR- and XDR-TB is currently limited by significant gaps in the evidence base. However a reasonable consensus has emerged that the treatment of these difficult patients should be individualized, guided by available drug sensitivity testing, aiming to incorporate injectable agents, fluoroquinolones and utilising any available first, second and third line agents to make up a 5 drug regime and that this treatment should be continued for at least 18 months post culture conversion. This management should be supported by drug sensitivity testing, close monitoring and support of patients. Ideally such patients should be managed by physicians with MDR-TB expertise.&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;br&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Hard to reach groups&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0008_tb2010htrg.jpg" width="341" height="115" /&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Commentary by &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align="justify"&gt;Hard to reach groups may include the homeless (rough sleepers, 'sofa surfers', those in temporary accommodation, hostel residents), prisoners, problem drug and alcohol users, itinerant people (mobile communities, travellers), migrants, and those with low educational or income levels. Hard to reach groups are disproportionately affected in high income countries with a low burden of tuberculosis. Unlike the general population who can readily access health services and complete treatment successfully with minimal supervision from health professionals; hard to reach groups experience delayed diagnosis, poor adherence to treatment, and loss to follow-up. These factors result in increased risk of disease transmission, more frequent treatment interruption and failure, and thus higher risk of developing drug-resistant tuberculosis. In addition, some of these groups are also at increased risk of co-infection with HIV.&lt;/p&gt; &lt;p align="justify"&gt;The challenges of managing tuberculosis in hard-to-reach groups are compounded by our limited information about them. Until recently, our surveillance system did not include information on these risk factors; we therefore do not have a clear understanding of the contribution of these groups to the burden of tuberculosis in this country. A survey in London in 2004 estimated that these groups formed 17% of the total TB case load in London, but made up half of all drug resistant infectious cases and half of those who did not complete treatment. Recent improvements to the Enhanced TB Surveillance system for England, Wales and Northern Ireland to include risk factor information such as homelessness, problem alcohol and drug use and history of imprisonment are welcome improvements to aid our assessment of the problem.&lt;/p&gt; &lt;p align="justify"&gt;The control of TB is dependent on early identification of cases and completion of treatment. Traditional approaches based on passive case finding (self-presentation of symptomatic people) and contact tracing, are not effective in hard to reach groups whose social circumstances including reduced access to health services; lack of trust in and understanding of the health system; and high-risk lifestyles may inhibit self presentation to health services and make traditional contact tracing approaches difficult. Therefore alternative strategies are required to overcome these barriers.&lt;/p&gt; &lt;p align="justify"&gt;The evidence to date suggests that combined social and biomedical models are required to control TB in hard to reach groups. Active case finding strategies such as mobile digital x-ray units visiting prisons and homeless shelters and directly observed therapy for cases, should be combined with drug and alcohol treatment services and social support (e.g. supervised housing, educational programmes and assisted access to employment) in order to optimise the chances of treatment completion. The Department of Health funded 'Find and Treat' initiative in London is an example of a step in the right direction.&lt;/p&gt; &lt;p align="justify"&gt;Mandatory screening in hostels, homeless shelters and prisons, combined with incentives to support treatment adherence have been found to be cost effective in some hard to reach populations and should be considered. Strategies to stimulate treatment adherence in problem drug users should be available. These include co-location of TB and drug treatment services, and psychological support through adherence support groups.&lt;/p&gt; &lt;p align="justify"&gt;The development in the last decade of new tests for the diagnosis of latent tuberculosis infection provides an opportunity to further explore the feasibility of detecting and treating latent TB infection in these hard to reach groups. Research into the use of these new technologies in these groups should be encouraged.&lt;/p&gt; &lt;p align="justify"&gt;The knowledge base on effective strategies for the prevention, management and control of TB in hard to reach groups needs to be developed. The many studies and pilot programmes in different regions and subpopulations needs to be collated, evaluated and translated into policy. The development of evidence-based guidelines on the prevention and management of tuberculosis in hard to reach groups started this year by the National Institute for Clinical Excellence (NICE) is most welcome and their recommendations eagerly anticipated.&lt;/p&gt; &lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt; &lt;br&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Vaccines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0007_tb2010vax.jpg" width="313" height="115" /&gt;&lt;/p&gt;
&lt;p align="center"&gt;&lt;b&gt;Update by &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt; of &lt;a href="nelh:308476:1" name=internalLink&gt;last year's commentary&lt;/a&gt; by &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify"&gt;The development of an effective vaccination strategy would have a major impact on reducing the global incidence of tuberculosis (TB). Currently, the only licensed vaccine against TB is bacille Calmette-Guerin (BCG), which has been administered to over three billion people, making it the most widely used vaccine throughout the world. BCG was developed in the early 1920's, and is based on a live but attenuated strain of &lt;i&gt;Mycobacterium bovis&lt;/i&gt;. BCG is safe, at least in an HIV-negative population, and protects against disseminated disease in the first 10 years of life. However BCG does not protect against pulmonary disease at any age but particularly in adolescents and early adulthood. In addition, the efficacy of BCG varies widely by geographical latitude. Recent evidence has demonstrated that HIV-infected infants, who were routinely vaccinated with BCG at birth when asymptomatic, are at high risk of developing disseminated BCG disease (estimated incidence 407-1,300 per 100,000). WHO guindance has since been revised to recommend a selective delayed BCG vaccination policy in HIV-exposed infants. The development of a new, safe vaccine is essential if tuberculosis is to be controlled and eradicated.&lt;/p&gt;
&lt;p align="justify"&gt;The past two decades have seen a significant increase in the pace of development of potential new TB vaccines. This is due in part to advances in the discovery and characterisation of &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; virulence factors, aided by the publication of the TB genome, and a greater understanding of the type of cellular immune response necessary for protection.&lt;/p&gt;
&lt;p align="justify"&gt;Current vaccine approaches include:&lt;br&gt;
&lt;ol&gt;
  &lt;li&gt;Replacement of the current BCG vaccine with an improved version, either by introducing genes (e.g. recombinant BCG expressing listeriolysin which improves induction of a CD8+ T cell response) or by developing an attenuated strain of M. tuberculosis.&lt;/li&gt;
  &lt;li&gt;Enhancing the immunity provided by existing strains of BCG at a later time point with a sub-unit (i.e. a protein or virally vectored) vaccine. &lt;/li&gt;
&lt;/ol&gt;
&lt;p align="justify"&gt;Several such candidate vaccines are now being evaluated in clinical trials, including Modified Vaccinia virus Ankara (MVA) expressing Ag85A (MVA85A); Adenovirus expressing antigen 85A, B and TB10.4; and a fusion protein of two antigens, M72 with adjuvant.&lt;/p&gt;
&lt;p align="justify"&gt;One of the factors most hampering TB vaccine development is the lack of a validated immunological correlate of protection. A strong cell mediated immune response is required for protection, and certain cytokines such as interferon gamma and tumour necrosis factor alpha are essential. However simple measurement of the levels of these cytokines has not been found to correlate with protection. At present the only way the efficacy of the new generation of TB vaccines can be evaluated is in large, expensive and time consuming Phase Iib/ Phase III efficacy trials in high incidence populations within TB endemic countries.&lt;/p&gt;
&lt;p align="justify"&gt;The first of these new generation vaccines has now entered into efficacy testing, and although there are many challenges in the development of a new TB vaccine, there is optimism within the field that considerable progress has been made over the last 10-15 years.&lt;/p&gt;

&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Return to Commentaries page&lt;/a&gt;&lt;/p&gt;
&lt;br&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344191</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=344191]]&gt;</url>
    <title>2010 Annual Evidence Update: On The Move Against TB - Contributors</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,ADDED 2010,WHAT'S NEW,MARCH 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Short biographies of the contributors to this Annual Evidence Update</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: On The Move Against TB - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P align=justify&gt;NHS Evidence-infections would like to thank the following contributors for their commentaries and evidence.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:344184:2" name=internalLink&gt;Introduction&lt;/A&gt; by &lt;A href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/A&gt; by &lt;A href="nelh:344191:4" name=internalLink&gt;Dr. Onn min Kon&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344184:4" name=internalLink&gt;Hard to reach groups&lt;/A&gt; by &lt;A href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/A&gt; Updated by&lt;A href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/A&gt; of &lt;A href="nelh:308476:1"&gt;last year's commentary&lt;/A&gt; by &lt;B&gt;&lt;A href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;P align=right&gt;&lt;A href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;BR&gt;
&lt;P align=center&gt;___________________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=190&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=190&gt;
&lt;P align=left&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:344191:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=190&gt;
&lt;P align=left&gt;&lt;B&gt;Content&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;___________________________________________________________________________________&lt;/P&gt;&lt;/B&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Ibrahim Abubakar&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;table width="580" border="0" align="center"&gt;
  &lt;tr&gt;
    &lt;td width="160" valign="top"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344191/nelhImp_0005_IbrahimAbubaker.jpg" width="160"&gt;&lt;/td&gt;
    &lt;td width="320" valign="top"&gt;&lt;p align="justify"&gt;&lt;b&gt;Dr. Ibrahim Abubakar&lt;/b&gt;&lt;/p&gt;
 							     &lt;p align="justify"&gt;Dr. Ibrahim Abubakar heads the TB Section at the HPA's Centre for Infections. He holds a Clinical Senior Lecturer post at the University of East Anglia and is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine and at University College London. Ibrahim runs the national enhanced TB surveillance system and a national clinical/public health advisory service on TB incident/outbreak management. He is a member of the WHO Global Task Force on TB impact measurement. His current research interests include various aspects of the epidemiology and control of mycobacterial infections.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;br&gt;&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;
&lt;br&gt;&lt;a href="nelh:344191:1" name=internalLink&gt;Return to Contributors page&lt;/a&gt;&lt;/p&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Onn Min Kon&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;table width="580" border="0" align="center"&gt;
  &lt;tr&gt;
    &lt;td width="160" valign="top"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344191/nelhImp_0007_OnnMinKon.jpg" width="160" height="195"&gt;&lt;/td&gt;
    &lt;td width="420" valign="top"&gt;&lt;p align="justify"&gt;&lt;b&gt;Dr. Onn Min Kon&lt;/b&gt;&lt;/p&gt;
 							     &lt;p align="justify"&gt;Dr Onn Min Kon is the Lead Clinician for the tuberculosis service at Imperial College NHS Trust and Consultant Respiratory Physician. He is the Lead Clinician for the North West London TB sector and organises the Advanced London TB Course. He is an Honorary Senior Lecturer at Imperial College and has interests in the diagnosis and management of TB. &lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
&lt;br&gt;&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;br&gt;&lt;a href="nelh:344191:1" name=internalLink&gt;Return to Contributors page&lt;/a&gt;&lt;/p&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Ebere Okereke&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;table width="580" border="0" align="center"&gt;
  &lt;tr&gt;
    &lt;td width="160" valign="top"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344191/nelhImp_0006_EbereOkereke.jpg" width="160" height="200"&gt;&lt;/td&gt;
    &lt;td width="320" valign="top"&gt;&lt;p align="justify"&gt;&lt;b&gt;Dr Ebere Okereke&lt;/b&gt;&lt;/p&gt;
 							     &lt;p align="justify"&gt;Dr. Ebere Okereke is a consultant in communicable disease control at the Health Protection Agency, based in the West Yorkshire Health Protection Unit. She is the HPA Yorkshire and Humber Regional lead for Tuberculosis and New and Emerging Infections (Zoonoses).&lt;/p&gt;
&lt;p align="justify"&gt;Ebere has had a life long interest in tuberculosis following an early experience of TB screening as a contact of a case at age 8. Her particular interest is in improving TB management in high risk populations.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
&lt;br&gt;&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;
&lt;br&gt;&lt;a href="nelh:344191:1" name=internalLink&gt;Return to Contributors page&lt;/a&gt;&lt;/p&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Dr. Helen McShane&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;table width="580" border="0" align="center"&gt;
  &lt;tr&gt;
    &lt;td width="160" valign="top"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344191/nelhImp_0008_HelenMcShane.jpg" width="160" height="196"&gt;&lt;/td&gt;
    &lt;td width="320" valign="top"&gt;&lt;p align="justify"&gt;&lt;b&gt;Dr. Helen McShane&lt;/b&gt;&lt;/p&gt;
 							     &lt;p align="justify"&gt;Dr. Helen McShane is a Reader in Vaccinology and Wellcome Trust Senior Clinical Research Fellow at the Jenner Institute at the University of Oxford. She is also an honorary consultant physician in HIV/GU Medicine and a Fellow of the Royal College of Physicians. She has led the TB vaccine group at Oxford University since 2001. The group focuses on the development of new TB vaccines and evaluation in both preclinical models and in clinical trials, both in the UK, and in South Africa, Senegal and The Gambia. One vaccine developed by the group, MVA85A, is currently the most clinically advanced new TB vaccine. The group also works on the development of cellular immunological assays and in vitro and in vivo models for the evaluation of new TB vaccines. &lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
&lt;br&gt;&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;
&lt;br&gt;&lt;a href="nelh:344191:1" name=internalLink&gt;Return to Contributors page&lt;/a&gt;&lt;/p&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Professor Philip Marsh&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;table width="580" border="0" align="center"&gt;
  &lt;tr&gt;
    &lt;td width="160" valign="top"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344191/nelhImp_0009_PhilMarsh.jpg" width="160" height="200"&gt;&lt;/td&gt;
    &lt;td width="320" valign="top"&gt;&lt;p align="justify"&gt;&lt;b&gt;Professor Philip Marsh&lt;/b&gt;&lt;/p&gt;
 							     &lt;p align="justify"&gt;Professor Marsh is Programme Leader for the TB group at the HPA Centre for Emergency Preparedness and Response, Salisbury. The work of this group is focussed on understanding more about how pathogenic mycobacteria cause active and latent disease, and on developing and evaluating new vaccines against tuberculosis.&lt;/p&gt;
&lt;p align="justify"&gt;He is a member of the HPA TB Programme Board, and is a Work-package co-ordinator for the EU-funded programme MUVAPRED (Mucosal Vaccines against Poverty Related Diseases).&lt;/p&gt;
&lt;p align="justify"&gt;Professor Marsh is a regular invited speaker at international conferences, and has published over 200 research papers and reviews on various infectious diseases.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
&lt;br&gt;&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;
&lt;br&gt;&lt;a href="nelh:344191:1" name=internalLink&gt;Return to Contributors page&lt;/a&gt;&lt;/p&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344192</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=344192]]&gt;</url>
    <title>2010 Annual Evidence Update: On The Move Against TB - Evidence</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,EMERGENCY CARE,CLINICAL LIBRARY,INFECTIOUS DISEASES,TB,INFECTIONS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best evidence in tuberculosis over the last 12 months</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: On The Move Against TB - Evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p&gt;This Annual Evidence Update provides a collection of evidence that has emerged over the last twelve months on tuberculosis accompanied by &lt;a href="nelh:344184:1" name=internalLink&gt;commentaries&lt;/a&gt; from &lt;a href="nelh:344191:1" name=internalLink&gt;experts&lt;/a&gt; in the field. This year's topic is in keeping with Stop TB's focus for 2010: On The Move Against TB.  The evidence provided here include guidelines, policy, systematic reviews, articles, reports and useful websites. You may also wish to review last year's Annual Evidence Update: &lt;a href="nelh:307020:1" name=internalLink&gt;Stopping TB.&lt;/a&gt;&lt;p&gt;
&lt;br&gt;&lt;br&gt;&lt;br&gt;
&lt;p&gt;&lt;b&gt;Subtopics&lt;/b&gt;:&lt;/p&gt; 
&lt;ul&gt;
  &lt;li&gt;&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt;
&lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Diagnosis and Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;
&lt;ol&gt;
  &lt;li&gt;van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. &lt;a href="nelh:345426:1" name=internalLink&gt;Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review&lt;/a&gt;. PLoS One. 2009 Dec 30;4(12):e8517.&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;Tuon FF, Higashino HR, Lopes MI, Litvoc MN, Atomiya AN, Antonangelo L, Leite OM. &lt;a href="nelh:345429:0" name=internalLink&gt;Adenosine deaminase and tuberculous meningitis-A systematic review with meta-analysis&lt;/a&gt;. Scand J Infect Dis. March 2010, Vol. 42, No. 3, Pages 198-207. &lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Arshad S, Bavan L, Gajari K, Paget SN, Baussano I. &lt;a href="nelh:345430:0" name=internalLink&gt;Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis&lt;/a&gt;. Eur Respir J. 2009 Oct 19. [Epub ahead of print]&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. &lt;a href="nelh:345431:0" name=internalLink&gt;Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature&lt;/a&gt;. BMC Infect Dis. 2009 Jun 11;9:91.&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Greco S, Rulli M, Girardi E, Piersimoni C, Saltini C. &lt;a href="nelh:345442:0" name=internalLink&gt;Diagnostic accuracy of in-house PCR for pulmonary tuberculosis in smear-positive patients: meta-analysis and metaregression&lt;/a&gt;. J Clin Microbiol. 2009 Mar;47(3):569-76. Epub 2009 Jan 14.&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Fontela PS, Pant Pai N, Schiller I, Dendukuri N, Ramsay A, Pai M. &lt;a href="nelh:345446:0" name=internalLink&gt;Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards&lt;/a&gt;. PLoS One. 2009 Nov 13;4(11):e7753. &lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Greveson K. &lt;a href="nelh:345449:0" name=internalLink&gt;Can ELISpot replace the tuberculin skin test for latent tuberculosis?&lt;/a&gt; British Journal of Nursing (BJN), 12 November 2009, vol./is. 18/20(1248-1254), 09660461&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Chang K.-C., Yew W.-W., Zhang Y. &lt;a href="nelh:345451:0" name=internalLink&gt;A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate&lt;/a&gt;. Expert Opinion on Medical Diagnostics, March 2009, vol./is. 3/2(99-122), 1753-0059;1753-0067.&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Centre for Reviews and Dissemination. &lt;a href="nelh:334110:0" name=internalLink&gt;Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression&lt;/a&gt;. 16 Dec 2009. &lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Centre for Reviews and Dissemination. &lt;a href="nelh:345442:0" name=internalLink&gt;Diagnostic accuracy of in-house PCR for pulmonary tuberculosis in smear-positive patients: meta-analysis and metaregression&lt;/a&gt;. 25 Nov 2009.&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Centre for Reviews and Dissemination. &lt;a href="nelh:308634:0" name=internalLink&gt;GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis&lt;/a&gt;. 24 Jun 2009.&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Centre for Reviews and Dissemination. &lt;a href="nelh:319451:0" name=internalLink&gt;Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis&lt;/a&gt;. 10 Jun 2009.&lt;br&gt;&lt;/li&gt;
  &lt;li&gt; Davies MA, Connell T, Johannisen C, Wood K, Pienaar S, Wilkinson KA, Wilkinson RJ, Zar HJ, Eley B, Beatty D, Curtis N, Nicol MP.  &lt;a href="nelh:330430:0" name=internalLink&gt;Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay&lt;/a&gt;. AIDS:15 May 2009 - Volume 23 - Issue 8 - p 961-969.&lt;br&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;p align="right"&gt;&lt;a href="nelh:344192:1" name=internalLink&gt;Return to subtopics menu&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt;
&lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;b&gt;Treatment&lt;/b&gt;&lt;/p&gt; &lt;ol&gt;&lt;li&gt;&lt;a href="nelh:66647:0" name=internalLink&gt;BHIVA treatment guidelines for TB/HIV infection&lt;/a&gt;, BHIVA 2010 (updated from 2005).&lt;br&gt;&lt;/li&gt; &lt;li&gt; Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. &lt;a href="nelh:345458:0" name=internalLink&gt;Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis&lt;/a&gt;. PLoS One. 2009 Sep 9;4(9):e6914.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. &lt;a href="nelh:345459:0" name=internalLink&gt;Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis&lt;/a&gt;. PLoS Med. 2009 Sep;6(9):e1000146. Epub 2009 Sep 15.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Gao XF, Li J, Yang ZW, Li YP. &lt;a href="nelh:345461:0" name=internalLink&gt;Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review&lt;/a&gt;. Int J Tuberc Lung Dis. 2009 Jul;13(7):810-9.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. &lt;a href="nelh:345469:0" name=internalLink&gt;Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis&lt;/a&gt;. Lancet Infect Dis. 2009 Mar;9(3):153-61.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Kangovi S, Mukherjee J, Bohmer R, Fitzmaurice G. &lt;a href="nelh:345470:0" name=internalLink&gt;A classification and meta-analysis of community-based Directly Observed Therapy programs for tuberculosis treatment in developing countries&lt;/a&gt;. Journal of Community Health, 01 December 2009, vol./is. 34/6(506-513), 00945145.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Centre for Reviews and Dissemination. &lt;a href="nelh:326957:0" name=internalLink&gt;Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies&lt;/a&gt;. 23 Sep 2009.&lt;br&gt;&lt;/li&gt; &lt;li&gt; World Health Organization. &lt;a href="nelh:345574:0" name=internalLink&gt;Guidelines for surveillance of drug resistance in tuberculosis: fourth edition&lt;/a&gt;&lt;/a&gt;.&lt;br&gt;&lt;/li&gt; &lt;li&gt; World Health Organization. &lt;a href="nelh:345565:0" name=internalLink&gt;Treatment of tuberculosis - guidelines 4th edition.&lt;/a&gt; &lt;/li&gt; &lt;/ol&gt; &lt;p align="right"&gt;&lt;a href="nelh:344192:1" name=internalLink&gt;Return to subtopics menu&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;TB and HIV&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;b&gt;TB and HIV&lt;/b&gt;&lt;/p&gt; &lt;ol&gt; &lt;li&gt;&lt;a href="nelh:66647:0" name=internalLink&gt;BHIVA treatment guidelines for TB/HIV infection&lt;/a&gt;, BHIVA 2010 (updated from 2005).&lt;br&gt;&lt;/li&gt; &lt;li&gt; Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. &lt;a href="nelh:345489:0" name=internalLink&gt;Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis&lt;/a&gt;. Lancet Infect Dis. 2010 Feb;10(2):93-102.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Suchindran S, Brouwer ES, Van Rie A. &lt;a href="nelh:345491:0" name=internalLink&gt;Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review&lt;/a&gt;. PLoS One. 2009;4(5):e5561. Epub 2009 May 15.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Fontela PS, Pant Pai N, Schiller I, Dendukuri N, Ramsay A, Pai M. &lt;a href="nelh:345446:0" name=internalLink&gt;Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards&lt;/a&gt;. PLoS One. 2009 Nov 13;4(11):e7753. &lt;br&gt;&lt;/li&gt; &lt;li&gt; World Health Organization: Regional Office for Europe. &lt;a href="nelh:328506:0" name=internalLink&gt;Prison health - HIV, drugs and TB&lt;/a&gt;. 27 Oct 2009.&lt;br&gt;&lt;/li&gt; &lt;/ol&gt; &lt;p align="right"&gt;&lt;a href="nelh:344192:1" name=internalLink&gt;Return to subtopics menu&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;b&gt;Prevention&lt;/b&gt;&lt;/p&gt; &lt;ol&gt; &lt;li&gt;Azzopardi P, Bennett CM, Graham SM, Duke T. &lt;a href="nelh:345032:0" name=internalLink&gt;Bacille Calmette-Guerin vaccine-related disease in HIV-infected children: a systematic review.&lt;/a&gt; Int J Tuberc Lung Dis. 2009 Nov;13(11):1331-44.&lt;br&gt;&lt;/li&gt; &lt;li&gt;Ziganshina LE, Garner P. &lt;a href="nelh:345034:0" name=internalLink&gt;Tuberculosis (HIV-negative people)&lt;/a&gt;. Clin Evid (Online). 2009 Apr 14;2009. pii: 0904.&lt;br&gt;&lt;/li&gt; &lt;li&gt;World Health Organization. &lt;a href="nelh:325125:0" name=internalLink&gt;Stop TB Partnership Annual Report 2008&lt;/a&gt;. 01 Sep 2009&lt;br&gt;&lt;/li&gt; &lt;li&gt; Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. &lt;a href="nelh:345579:0" name=internalLink&gt;Tuberculosis vaccine research: the impact of immunology&lt;/a&gt;. Curr Opin Immunol. 2009 Jun;21(3):331-8. Epub 2009 Jun 7. &lt;br&gt;&lt;/li&gt; &lt;li&gt;Hawkridge A. &lt;a href="nelh:345036:0" name=internalLink&gt;Clinical studies of TB vaccines&lt;/a&gt;. Hum Vaccin. 2009 Nov;5(11):773-6. Epub 2009 Nov 22.&lt;br&gt; &lt;/li&gt; &lt;/ol&gt; &lt;p align="right"&gt;&lt;a href="nelh:344192:1" name=internalLink&gt;Return to subtopics menu&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;7&lt;/pageSequence&gt;&lt;pageTitle&gt;Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;b&gt;Epidemiology&lt;/b&gt;&lt;/p&gt; &lt;ol&gt; &lt;li&gt;Houben RM, Glynn JR. &lt;a href="nelh:345499:0" name=internalLink&gt;A systematic review and meta-analysis of molecular epidemiological studies of tuberculosis: development of a new tool to aid interpretation&lt;/a&gt;. Trop Med Int Health. 2009 Aug;14(8):892-909.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, Toungoussova O, Zellweger JP, Spanevello A, Cirillo D, Lange C, Migliori GB. &lt;a href="nelh:345502:0" name=internalLink&gt;Epidemiology and clinical management of XDR-TB: a systematic review by TBNET&lt;/a&gt;. Eur Respir J. 2009 Apr;33(4):871-81. Epub 2009 Feb 27.&lt;br&gt;&lt;/li&gt; &lt;li&gt; The International Journal of Tuberculosis and Lung Disease. &lt;a href="nelh:345505:0" name=internalLink&gt;The impact of immigration on tuberculosis rates in the United Kingdom compared with other European countries&lt;/a&gt;. 1 May 2009.&lt;br&gt;&lt;/li&gt; &lt;li&gt; Health Protection Agency. &lt;a href="nelh:332634:0" name=internalLink&gt;Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2009&lt;/a&gt;. 02 Dec 2009.&lt;br&gt;&lt;/li&gt; &lt;li&gt; World Health Organization. &lt;a href="nelh:345522:0" name=internalLink&gt;A guide to monitoring and evaluation for collaborative TB/HIV activities&lt;/a&gt;.&lt;br&gt;&lt;/li&gt; &lt;li&gt; World Health Organization. &lt;a href="nelh:345526:0" name=internalLink&gt;Global tuberculosis control - epidemiology, strategy, financing&lt;/a&gt;.&lt;br&gt;&lt;/li&gt; &lt;/ol&gt; &lt;p align="right"&gt;&lt;a href="nelh:344192:1" name=internalLink&gt;Return to subtopics menu&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;8&lt;/pageSequence&gt;&lt;pageTitle&gt;Miscellaneous&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;b&gt;Miscelleneous&lt;/b&gt;&lt;/p&gt; &lt;ol&gt; &lt;li&gt;Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QC, Zhou BS. &lt;a href="nelh:345540:0" name=internalLink&gt;Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review&lt;/a&gt;. Int J Cancer. 2009 Dec 15;125(12):2936-44.&lt;br&gt;&lt;/li&gt; &lt;li&gt;Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, LÃƒÂ¶nnroth K, Patra J, Poznyak V, Popova S. &lt;a href="nelh:345542:0" name=internalLink&gt;The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review&lt;/a&gt;. BMC Public Health. 2009 Dec 5;9:450.&lt;br&gt;&lt;/li&gt; &lt;li&gt;Lonnroth K, Williams BG, Cegielski P, Dye C. &lt;a href="nelh:345544:0" name=internalLink&gt;A consistent log-linear relationship between tuberculosis incidence and body mass index&lt;/a&gt;. Int J Epidemiol. 2009 Oct 9. [Epub ahead of print].&lt;br&gt;&lt;/li&gt; &lt;li&gt;Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. &lt;a href="nelh:345547:0" name=internalLink&gt;Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data&lt;/a&gt;. Liver Transpl. 2009 Aug;15(8):894-906.&lt;br&gt;&lt;/li&gt; &lt;li&gt;Guo N, Marra F, Marra CA. &lt;a href="nelh:345550:0" name=internalLink&gt;Measuring health-related quality of life in tuberculosis: a systematic review&lt;/a&gt;. Health Qual Life Outcomes. 2009 Feb 18;7:14.&lt;br&gt;&lt;/li&gt; &lt;li&gt;Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA. &lt;a href="nelh:345551:0" name=internalLink&gt;Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections&lt;/a&gt;. Journal of Rheumatology, 01 May 2009, vol./is. 36/5.&lt;br&gt;&lt;/li&gt;&lt;/ol&gt; &lt;p align="right"&gt;&lt;a href="nelh:344192:1" name=internalLink&gt;Return to subtopics menu&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt; &lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;8&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;TB reports&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;
&lt;ol&gt;
  &lt;li&gt;NHS Choices &lt;a href="nelh:286506:0" name=internalLink&gt;page on TB (patient info)&lt;/a&gt;&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;APPG on Global TB Annual Report (June 2009): &lt;a href="nelh:345651:0" name=internalLink&gt;Turning UK TB Policy into Action: The view from the frontline (July 2009)&lt;/a&gt;&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;British Thoracic Society: &lt;a href="nelh:345653:0" name=internalLink&gt;Tackling tuberculosis in England: the PCT response to the challenge (December 2009)&lt;/a&gt;&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;World Health Organization: &lt;a href="nelh:345526:0" name=internalLink&gt;Global tuberculosis control - epidemiology, strategy, financing&lt;/a&gt; 2009&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;World Health Organization: &lt;a href="nelh:345655:0" name=internalLink&gt;The Global Plan to Stop TB, 2006-2015&lt;/a&gt;&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;World Health Organization and Centers for Disease Control &amp;amp; Prevention: &lt;a href="nelh:345657:0" name=internalLink&gt;Planning the development of human resources for health for implementation of the Stop TB Strategy - A handbook&lt;/a&gt; 2009&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;Stop TB Department, Epidemic and Pandemic Alert and Response Department, HIV/AIDS Department, Patient Safety Programme, World Health Organization. &lt;a href="nelh:345659:0" name=internalLink&gt;WHO policy on TB infection control in health-care facilities, congregate settings and households&lt;/a&gt; 2009&lt;br&gt;&lt;/li&gt;
  &lt;li&gt;World Health Organization. &lt;a href="http://www.who.int/entity/tb/publications/2009/airborne/en/index.html" target="_blank"&gt;AIRBORNE. A journey into the challenges and solutions to stopping MDR-TB and XDR-TB.&lt;/a&gt; Who, 2009&lt;br&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;p align="right"&gt;&lt;a href="nelh:344192:1" name=internalLink&gt;Return to subtopics menu&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt;
&lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344178</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=344178]]&gt;</url>
    <title>2010 Annual Evidence Update: On The Move Against TB - Homepage</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,ADDED 2010,MARCH 10,WHAT'S NEW]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A summary of the best evidence in tuberculosis over the last 12 months</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: On The Move Against TB - Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="center"&gt;&lt;img src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0000_tb2010title.jpg" alt="2010 Annual Evidence Update: On the move against TB" width="580" height="222" /&gt;&lt;/p&gt; &lt;p&gt;Welcome to the &lt;b&gt;2010 Annual Evidence Update: One The Move Against TB&lt;/b&gt; by &lt;a href="http://www.library.nhs.uk/infections/" target="_blank"&gt;NHS Evidence-infections&lt;/a&gt; in collaboration with the &lt;a href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200055718370" target="_blank"&gt;National Knowledge Service - TB&lt;/a&gt;. This Annual Evidence Update will run from &lt;b&gt;22nd to 29th March 2010&lt;/b&gt;, and has been timed to coincide with &lt;a href="http://www.stoptb.org/" target="_blank"&gt;&lt;b&gt;&lt;a href="http://www.stoptb.org/" target="_blank"&gt;World TB Day&lt;/a&gt;&lt;/b&gt;&lt;/a&gt; on 24th March 2010.&lt;/p&gt; &lt;p align="right"&gt;Link to &lt;a href="nelh:344189:0" name=internalLink&gt;methodology&lt;/a&gt;&lt;/p&gt; &lt;p align="right"&gt;Download &lt;a href="http://isc.anthropith.com/Assets/tb2010flyer.pdf" target="_blank"&gt;flyers&lt;/a&gt;&lt;/p&gt; &lt;p align="center"&gt;&lt;b&gt;Introduction&lt;/b&gt; by &lt;b&gt;&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt; &lt;/b&gt;&lt;/p&gt; &lt;p align="justify"&gt;This year the fight against tuberculosis continues. Tuberculosis remains a major killer globally and the cause of considerable suffering in individuals and families with nearly 2 million deaths and 9 million new cases occurring annually. In the UK, the rise observed over the last two decades continues with provisional data released by the &lt;a href="http://www.hpa.org.uk/" target="_blank"&gt;Health Protection Agency&lt;/a&gt; showing a further rise of 5.5% between 2008 and 2009 and the total number of cases now exceeding 9000.&lt;/p&gt; &lt;p align="justify"&gt;The theme for this year's &lt;a href="http://www.stoptb.org/" target="_blank"&gt;World TB Day&lt;/a&gt;, identifies the need for innovation. In keeping with this message, we have identified three &lt;a href="nelh:344191:1" name=internalLink&gt;experts&lt;/a&gt; to review &lt;a href="nelh:344192:1" name=internalLink&gt;new evidence&lt;/a&gt; and provide &lt;a href="nelh:344184:1" name=internalLink&gt;commentaries&lt;/a&gt;. &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;, chest physician at St Mary's hospital provides a review of &lt;a href="nelh:344184:3" name=internalLink&gt;multi-drug resistant tuberculosis&lt;/a&gt; from the perspective of a clinician. Drug resistance against anti tuberculosis drugs is a key challenge faced by tuberculosis control programmes. This short overview highlights the challenges in tackling drug resistance and opportunities arising from new research.&lt;/p&gt; &lt;p align="justify"&gt;For high income, low incidence countries such as the UK, the burden of tuberculosis is concentrated in &lt;a href="nelh:344184:4" name=internalLink&gt;hard to reach populations&lt;/a&gt;. The public health effort to control tuberculosis therefore has to target effective interventions at this population. &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;, consultant in communicable disease control and the HPA's tuberculosis lead for Yorkshire and the Humber, provides a commentary on the control of tuberculosis in these populations.&lt;/p&gt; &lt;p align="justify"&gt;Tuberculosis is an infectious disease, and as is the case with other infections, an effective &lt;a href="nelh:344184:5" name=internalLink&gt;vaccine&lt;/a&gt; will determine whether we are able to eliminate this scourge. The global effort to identify a new &lt;a href="nelh:344184:5" name=internalLink&gt;vaccine&lt;/a&gt; for tuberculosis has intensified in recent years. The UK is a major player in this effort. &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;, from the University of Oxford, and &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt; from the &lt;a href="http://www.hpa.org.uk/" target="_blank"&gt;Health Protection Agency&lt;/a&gt; provide an update on ongoing research to find a new tuberculosis &lt;a href="nelh:344184:5" name=internalLink&gt;vaccine&lt;/a&gt;.&lt;/p&gt;&lt;br&gt; &lt;table width="488" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr&gt; &lt;td width="244"&gt;&lt;img border="0" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0001_tb2010menu0l.jpg" width="244" height="41" alt="On the move"&gt;&lt;/td&gt; &lt;td width="244"&gt;&lt;img border="0" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0002_tb2010menu0r.jpg" width="244" height="41" alt="against TB"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&lt;a href="nelh:344184:3" name=internalLink&gt;&lt;img border="0" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0003_tb2010menu1.jpg" width="244" height="160" alt="Multi-drug resistant TB"&gt;&lt;/a&gt;&lt;/td&gt; &lt;td&gt;&lt;a href="nelh:344184:5" name=internalLink&gt;&lt;img border="0" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0004_tb2010menu2.jpg" width="244" height="160" alt="Vaccines"&gt;&lt;/a&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&lt;a href="http://www.library.nhs.uk/infections" target="_blank"&gt;&lt;img border="0" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0005_tb2010menu3.jpg" width="244" height="160" alt="NHS Evidence-infections homepage"&gt;&lt;/a&gt;&lt;/td&gt; &lt;td&gt;&lt;a href="nelh:344184:4" name=internalLink&gt;&lt;img border="0" src="https://rmsadmin.library.nhs.uk/libraryImages/infections/contentID344178/nelhImp_0006_tb2010menu4.jpg" width="244" height="160" alt="Hard to reach groups"&gt;&lt;/a&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;br&gt; &lt;p align="justify"&gt;You may also be interested in the &lt;a href="nelh:307020:1" name=internalLink&gt;2009 Annual Evidence Update: Stopping TB.&lt;/a&gt;&lt;/p&gt; &lt;p align="justify"&gt;We welcome feedback about all aspects of NHS Evidence-infections, including the resources that make up this Annual Evidence Update. Please &lt;a href="mailto:isc@hpa.org.uk?subject=Feedback" target="_blank"&gt;contact us&lt;/a&gt; if you would like to comment, or take part in our &lt;a href="http://www.library.nhs.uk/infections/page.aspx?pagename=SMTB2010" target="_blank"&gt;two minute survey&lt;/a&gt;. Thank you.&lt;/p&gt; &lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt; &lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt; &lt;tr valign="top"&gt; &lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;br&gt;&lt;br&gt; &lt;a href="nelh:344186:1" name=internalLink&gt;Useful Websites&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt; &lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt; &lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344189</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=344189]]&gt;</url>
    <title>2010 Annual Evidence Update: On The Move Against TB - Methodology</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A short summary of the methods used to find the evidence for this Annual Evidence Update</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: On The Move Against TB - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;p align="justify"&gt;Searches were conducted on resources published between February 2009 and February 2010.&lt;/p&gt;
&lt;p align="justify"&gt;&lt;b&gt;Sources Used&lt;/b&gt;:
&lt;ul&gt;
  &lt;li&gt;CINAHL database&lt;/li&gt;
  &lt;li&gt;EMBASE database&lt;/li&gt;
  &lt;li&gt;PubMED database&lt;/li&gt;
  &lt;li&gt;The World Health Organization website&lt;/li&gt;
&lt;/ul&gt;
&lt;p align="justify"&gt;&lt;b&gt;Terms Used&lt;/b&gt;
&lt;ul&gt;
  &lt;li&gt;The MeSH terms &lt;i&gt;tuberculosis&lt;/i&gt; OR &lt;i&gt;tb&lt;/i&gt; were used&lt;/li&gt;
  &lt;li&gt;Thesaurus terms (subheadings, exploded terms and major descriptor terms) for each of these were also used in the searches.
  &lt;/li&gt;
&lt;/ul&gt;
&lt;p align="justify"&gt;&lt;b&gt;Publication Types&lt;/b&gt;: 
&lt;ul&gt;
  &lt;li&gt;Only systematic reviews from the databases&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;b&gt;Inclusion and exclusion criteria&lt;/b&gt;&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;Articles were included if they had an abstract&lt;/li&gt;
  &lt;li&gt;If the article was not published in English, it was still included if an English abstract was available&lt;/li&gt;
  &lt;li&gt;The searches from the databases were combined, duplicates were removed, and the results were sifted through based on the relevance of the title or abstract&lt;/li&gt;
  &lt;li&gt;The expert lead and expert panel assessed the quality and relevance of the articles &lt;/li&gt;
&lt;/ul&gt;
&lt;p align="right"&gt;&lt;a href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/a&gt;&lt;/p&gt;
&lt;br&gt;&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;
&lt;table width="580" border="0" align="center" cellpadding="0" cellspacing="0"&gt;
&lt;tr valign="top"&gt;
&lt;td width="190"&gt;&lt;p align="left" valign="top"&gt;&lt;b&gt;Pages&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;People&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344191:1" name=internalLink&gt;Experts&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="190"&gt;&lt;p align="left"&gt;&lt;b&gt;Content&lt;/b&gt;&lt;br&gt;
&lt;a href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/a&gt;&lt;br&gt;
&lt;a href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/a&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="center"&gt;___________________________________________________________________________________&lt;/p&gt;&lt;br&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344186</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=344186]]&gt;</url>
    <title>2010 Annual Evidence Update: On The Move Against TB - Useful Websites</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>Infections Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,ADDED 2010,WHAT'S NEW,MARCH 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A list of useful websites in the field of tuberculosis</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update: On The Move Against TB - Useful Websites&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BR&gt;
&lt;P align=right&gt;&lt;A href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.stoptb.org/" target="_blank"&gt;The Stop TB Partnership&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.tbalert.org/" target="_blank"&gt;TB Alert - The UK's National Tuberculosis Charity&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1200055718370" target="_blank"&gt;National Knowledge Service-TB Pilot&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.hpa.org.uk/webw/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1191942150134?p" target="_blank"&gt;Health Protection Agency - TB&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.who.int/topics/tuberculosis/en/" target="_blank"&gt;World Health Organization - TB&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.who.int/hiv/topics/tb/en/index.html" target="_blank"&gt;World Health Organization - TB and HIV&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.theunion.org/" target="_blank"&gt;The International Union Against Tuberculosis and Lung Disease&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.cdc.gov/tb/default.htm" target="_blank"&gt;Centers for Disease Control and Prevention - Division of Tuberculosis Elimination&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.theglobalfund.org/en/" target="_blank"&gt;The Global Fund to Fight AIDS, TB and Malaria&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;The British Thoracic Society&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.lunguk.org/" target="_blank"&gt;The British Lung Foundation &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.stoptb.org/" target="_blank"&gt;World TB Day&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.hpa.org.uk/" target="_blank"&gt;Health Protection Agency&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/infections/" target="_blank"&gt;NHS Evidence-infections Homepage&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:330262:1" name=internalLink&gt;2009 Annual Evidence Update: Stopping TB.&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:344178:1" name=internalLink&gt;Return to AEU homepage&lt;/A&gt;&lt;BR&gt;
&lt;P align=center&gt;___________________________________________________________________________________&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=580 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width=190&gt;
&lt;P align=left valign="top"&gt;&lt;B&gt;Pages&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:344184:1" name=internalLink&gt;Commentaries&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344184:3" name=internalLink&gt;Multi-drug resistant tuberculosis&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344184:4" name=internalLink&gt;Hard to reach populations&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344184:5" name=internalLink&gt;Vaccines&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=190&gt;
&lt;P align=left&gt;&lt;B&gt;People&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:344191:1" name=internalLink&gt;Experts&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:2" name=internalLink&gt;Dr. Ibrahim Abubakar&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:4" name=internalLink&gt;Dr. Onn Min Kon&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:5" name=internalLink&gt;Dr. Ebere Okereke&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:6" name=internalLink&gt;Dr. Helen McShane&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344191:3" name=internalLink&gt;Professor Phil Marsh&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width=190&gt;
&lt;P align=left&gt;&lt;B&gt;Content&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:344192:1" name=internalLink&gt;Evidence resources&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:2" name=internalLink&gt;Diagnosis and screening&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:3" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:4" name=internalLink&gt;TB and HIV&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:5" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:6" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:7" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:344192:8" name=internalLink&gt;TB reports&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=center&gt;___________________________________________________________________________________&lt;/P&gt;&lt;BR&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>320834</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_102919]]&gt;</url>
    <title>A (H1N1) Swine Influenza: Standing up the National Pandemic Flu Service</title>
    <publicationDate>2009-07-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Letter from Ian Dalton, National Director of NHS Flu Resilience to all NHS Chief Executives, NHS Trust Chairs, SHA Flu Lead Directors, Local Authority Chief Executives in England and Monitor and Care Quality Commission on the National Pandemic Flu Service.]]&gt;</body>
  </document>
  <document>
    <id>345470</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/c73j0v5x6033w02p/]]&gt;</url>
    <title>A classification and meta-analysis of community-based Directly Observed Therapy programs for tuberculosis treatment in developing countries</title>
    <publicationDate>2009-09-04T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,TREATMENT,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In many developing countries, Directly Observed Therapy (DOT) for tuberculosis has been undertaken mainly in the clinic setting. However, clinicbased DOT may create a high patient load in already overburdened health facilities and increase barriers to care by requiring patients to travel to clinic frequently for therapy. Community-based DOT (CBDOT) may overcome some of these problems. This aims of this review are (a) to describe the main features of CBDOT programs, and (b) to compare features and outcomes of CBDOT programs that do and do not offer financial reward for CBDOT providers. Ten major features define CBDOT program structure and function. Programs that paid their CBDOT providers tended to differ from unpaid programs based on all of these features. CBDOT programs in which providers received financial reward had success rates of 85.7 versus 77.6% in programs without financial reward for providers. This difference was not statistically significant. CBDOT programs fall into two major archetypes, which differ in their structure and possibly in their outcomes.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>308665</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-2334-5-62.pdf]]&gt;</url>
    <title>A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.</title>
    <publicationDate>2005-07-28T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,DIAGNOSIS,MARCH 09,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Mycobacterium tuberculosis is a leading cause of death worldwide. In multi-drug resistant tuberculosis (MDR-TB) infectiousness is frequently prolonged, jeopardizing efforts to control TB. The conventional tuberculosis drug susceptibility tests are sensitive and specific, but they are not rapid. The INNO-LiPA Rif. TB ® (LiPA) is a commercial line probe assay designed to rapidly detect rifampicin resistance, a marker of MDR-TB. Although LiPA has shown promising results, its overall accuracy has not been systematically evaluated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: We did a systematic review and meta-analysis to evaluate the accuracy of LiPA for the detection of rifampicin-resistant tuberculosis among culture isolates and clinical specimens. We searched Medline, Embase, Web of Science, BIOSIS, and Google Scholar, and contacted authors, experts and the manufacturer. Fifteen studies met our inclusion criteria. Of these, 11 studies used culture isolates, one used clinical specimens, and three used both. We used a summary receiver operating characteristic (SROC) curve and Q* index to perform meta-analysis and summarize diagnostic accuracy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Twelve of 14 studies that applied LiPA to isolates had sensitivity greater than 95%, and 12 of 14 had specificity of 100%. The four studies that applied LiPA directly to clinical specimens had 100% specificity, and sensitivity that ranged between 80% and 100%. The SROC curve had an&lt;BR&gt;area of 0.99 and Q* of 0.97.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: LiPA is a highly sensitive and specific test for the detection of rifampicin resistance in culture isolates. The test appears to have relatively lower sensitivity when used directly on clinical specimens. More evidence is needed before LiPA can be used to detect MDR-TB among populations at risk in clinical practice.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285409</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947365435]]&gt;</url>
    <title>A complex picture  HIV and other Sexually Transmitted Infections in the United Kingdom: 2006</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,LYMPHOGRANULOMA VENEREUM (LGV),SYPHILIS,HERPES,CHLAMYDIA,GONORRHOEA,HIV/AIDS,GENITAL WARTS (HPV),COMPLICATED PREGNANCY,WOMEN'S HEALTH,PROVISION OF CARE,PEDICULOSIS PUBIS,PUBLIC HEALTH,LGV,PELVIC INFLAMMATORY DISEASE,TRICHOMONAS,SYPHILIS,INFECTIONS,BACTERIAL VAGINOSIS,CHLAMYDIA,CANDIDA,CHANCROID,DONOVANOSIS,GENITAL HERPES,HIV,GONORRHOEA,GENITAL WARTS (HPV),ANTENATAL PROBLEMS,SEXUAL HEALTH,INFECTIONS,OCT 08,NEISSERIA GONORRHOEA,VIRUSES,HUMAN PAPILLOMAVIRUS (HPV),HUMAN IMMUNODEFICIENCY VIRUS (HIV),HERPES SIMPLEX VIRUS (HSV),BACTERIA,CHLAMYDIA,MICROORGANISM,NEISSERIA,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,MALE UROGENITAL DISORDERS,HIV,ADDED 2008]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>‘A Complex Picture’ profiles the increasing complexity inherent to the evaluation and management of the continuing HIV and STI epidemics. The report also highlights, through the presentation and description of epidemiological data, how despite increasing complexity, HIV and STI surveillance systems in the UK have evolved to remain one of the world’s most comprehensive and informative systems.</description>
    <body>&lt;![CDATA[ This is the fourth combined annual report, marking the 25th anniversary of the first reported case of acquired immunodeficiency syndrome (AIDS) in the United Kingdom (UK) by reflecting upon the significant changes that have occurred over this period in the HIV and STI epidemics. Epidemiological shifts and developments in the sexual health field have led to changes in the structure of sexual health services and different approaches in clinical management. With surveillance playing a key role in informing clinical practice, service delivery and the targeting and monitoring of prevention interventions, it is essential that surveillance systems are not only timely and accurate but also flexible. ‘A Complex Picture’ profiles the increasing complexity inherent to the evaluation and management of the continuing HIV and STI epidemics. The report also highlights, through the presentation and description of epidemiological data, how despite increasing complexity, HIV and STI surveillance systems in the UK have evolved to remain one of the world’s most comprehensive and informative systems.]]&gt;</body>
  </document>
  <document>
    <id>285411</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm]]&gt;</url>
    <title>A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States - Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents</title>
    <publicationDate>2005-12-23T00:00:00</publicationDate>
    <publisher>Morbidity and Mortality Weekly Report</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,BLOOD AND BODY FLUIDS,TRANSMISSION MODE,HEPATITIS,INFECTIOUS DISEASES,PREVENTION AND CONTROL,PREVENTION,INFECTIONS,VACCINES / IMMUNISATION,VERTICAL TRANSMISSION,HEPATITIS B,MICROORGANISM,HEPATITIS B VIRUS,HEPATITIS VIRUS,VIRUSES,MALE UROGENITAL DISORDERS,HEPATITIS B,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report is the first of a two-part statement from the Advisory Committee on Immunization Practices (ACIP) that updates the strategy to eliminate hepatitis B virus (HBV) transmission in the United States. The report provides updated recommendations to improve prevention of perinatal and early childhood HBV transmission, including implementation of universal infant vaccination beginning at birth, and to increase vaccine coverage among previously unvaccinated children and adolescents. Strategies to enhance implementation of the recommendations include 1) establishing standing orders for administration of hepatitis B vaccination beginning at birth; 2) instituting delivery hospital policies and procedures and case management programs to improve identification of and administration of immunoprophylaxis to infants born to mothers who are hepatitis B surface antigen (HBsAg) positive and to mothers with unknown HBsAg status at the time of delivery; and 3) implementing vaccination record reviews for all children aged 11--12 years and children and adolescents aged &amp;lt;19 years who were born in countries with intermediate and high levels of HBV endemicity, adopting hepatitis B vaccine requirements for school entry, and integrating hepatitis B vaccination services into settings that serve adolescents. The second part of the ACIP statement, which will include updated recommendations and strategies to increase hepatitis B vaccination of adults, will be published separately.]]&gt;</body>
  </document>
  <document>
    <id>285413</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5516a1.htm]]&gt;</url>
    <title>A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States - Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>Morbidity and Mortality Weekly Report</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HEPATITIS,TRANSMISSION MODE,BLOOD AND BODY FLUIDS,VACCINES / IMMUNISATION,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,HEPATITIS B,VIRUSES,HEPATITIS VIRUS,HEPATITIS B VIRUS,MICROORGANISM,INFECTIOUS DISEASES,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,HEPATITIS B,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report, the second of a two-part statement from the Advisory Committee on Immunization Practices (ACIP), provides updated recommendations to increase hepatitis B vaccination of adults at risk for HBV infection. The first part of the ACIP statement, which provided recommendations for immunization of infants, children, and adolescents, was published previously (CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of infants, children, and adolescents. MMWR 2005;54[No. RR-16]:1--33). &lt;/P&gt;
&lt;P&gt;In settings in which a high proportion of adults have risks for HBV infection (e.g., sexually transmitted disease/human immunodeficiency virus testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting services to IDUs, health-care settings targeting services to MSM, and correctional facilities), ACIP recommends universal hepatitis B vaccination for all unvaccinated adults. In other primary care and specialty medical settings in which adults at risk for HBV infection receive care, health-care providers should inform all patients about the health benefits of vaccination, including risks for HBV infection and persons for whom vaccination is recommended, and vaccinate adults who report risks for HBV infection and any adults requesting protection from HBV infection. &lt;/P&gt;
&lt;P&gt;To promote vaccination in all settings, health-care providers should implement standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine clinical services, not require acknowledgment of an HBV infection risk factor for adults to receive vaccine, and use available reimbursement mechanisms to remove financial barriers to hepatitis B vaccination. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345544</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ije.oxfordjournals.org/cgi/content/abstract/dyp308v1]]&gt;</url>
    <title>A consistent log-linear relationship between tuberculosis incidence and body mass index</title>
    <publicationDate>2009-10-09T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Low weight for height is an established risk factor for tuberculosis (TB), and recent studies suggest that overweight is a protective factor. No previous systematic review has been done to explore the consistency and establish the gradient of this apparent ‘dose–response’ relationship.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: A systematic literature review was carried out to identify cohort studies that collected data on weight and height at baseline and that used a diagnosis of active TB as the study outcome. Weight-for-height measures used in the original studies were transformed into body mass index (BMI). Exponential trend lines were fitted to each data set.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Six studies were included. In all of them, there was a log-linear inverse relationship between TB incidence and BMI, within the BMI range 18.5–30 kg/m2. The average slope gave a reduction in TB incidence of 13.8% [95% confidence interval 13.4–14.2] per unit increase in BMI. The dose–response relationship was less certain at BMI &amp;lt;18.5 and &amp;gt;30 kg/m2.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: There is a strong and consistent log-linear relationship between TB incidence and BMI across a variety of settings with different levels of TB burden. More research is required to test the relationship at very low and very high BMI levels, to establish the biological mechanism linking BMI with risk of TB and to establish the potential impact on the global TB epidemic of changing nutritional status of populations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285414</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.gvt-journal.com/content/pdf/1479-0556-6-3.pdf]]&gt;</url>
    <title>A DNA vaccine against tuberculosis based on the 65 kDa heat-shock protein differentially activates human macrophages and dendritic cells.</title>
    <publicationDate>2008-01-21T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,INFECTIONS,MYCOBACTERIUM,INFECTIOUS DISEASES,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ BACKGROUND: A number of reports have demonstrated that rodents immunized with DNA vaccines can produce antibodies and cellular immune responses presenting a long-lasting protective immunity. These findings have attracted considerable interest in the field of DNA vaccination. We have previously described the prophylactic and therapeutic effects of a DNA vaccine encoding the Mycobacterium leprae 65 kDa heat shock protein (DNA-HSP65) in a murine model of tuberculosis. As DNA vaccines are often less effective in humans, we aimed to find out how the DNA-HSP65 stimulates human immune responses. 

Methods: To address this question, we analysed the activation of both human macrophages and dendritic cells (DCs) cultured with DNA-HSP65. Then, these cells stimulated with the DNA vaccine were evaluated regarding the expression of surface markers, cytokine production and microbicidal activity. 

Results: It was observed that DCs and macrophages presented different ability to uptake DNA vaccine. Under DNA stimulation, macrophages, characterized as CD11b+/CD86+/HLA-DR+, produced high levels of TNF-alpha, IL-6 (pro-inflammatory cytokines), and IL-10 (anti-inflammatory cytokine). Besides, they also presented a microbicidal activity higher than that observed in DCs after infection with M. tuberculosis. On the other hand, DCs, characterized as CD11c+/CD86+/CD123-/BDCA-4+/IFN-alpha-, produced high levels of IL-12 and low levels of TNF-alpha, IL-6 and IL-10. Finally, the DNA-HSP65 vaccine was able to induce proliferation of peripheral blood lymphocytes. 

Conclusions: Our data suggest that the immune response is differently activated by the DNA-HSP65 vaccine in humans. These findings provide important clues to the design of new strategies for using DNA vaccines in human immunotherapy. ]]&gt;</body>
  </document>
  <document>
    <id>345522</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2009/9789241598194_eng.pdf]]&gt;</url>
    <title>A guide to monitoring and evaluation for collaborative TB/HIV activities</title>
    <publicationDate>2009-03-02T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,TUBERCULOSIS,HIV/AIDS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide to monitoring and evaluation has been developed to assist the management of TB and HIV control programmes to implement collaborative TB/HIV activities. It is intended to facilitate the collection of standardized data and help in the interpretation and dissemination of these data for programme improvement. It also aims to ensure consistency across all agencies and stakeholders involved in HIV, TB and collaborative TB/HIV activities, avoiding duplication of effort in data collection by providing a core set of internationally accepted and standardized indicators for monitoring and evaluating programme performance. These indicators have been developed in collaboration with the 2008 PEPFAR revision process of TB/HIV indicators and are also incorporated into the latest monitoring and evaluation tool kit (2009 version) produced by the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). The data collected using these standardized indicators will provide further evidence of the benefits of collaborative TB/HIV activities. It is expected that these&lt;BR&gt;indicators will also ensure harmonization of data collection for various partners and donors. Data collection and reporting should be integrated into a single existing national M&amp;amp;E system wherever possible, in accordance with the “Three Ones” principles. This guide does not&amp;nbsp;detail the information required by programmes to monitor progress towards expanding the Stop TB Strategy or services for HIV prevention, care and treatment, since this is well documented elsewhere. However, much of the information gathered for these two purposes will be of assistance in the overall M&amp;amp;E of collaborative TB/HIV activities. Universal access to TB/HIV collaborative activities necessitates both programmes scaling up their activities to detect and treat both diseases in the same manner. The new case-finding indicator in this guide is designed to monitor progress towards this element of universal access.&lt;/P&gt;
&lt;P&gt;The first version of this guide, published by WHO in 2004, took account of collaborative TB/HIV activities as an integral part of national and international responses to the joint TB/HIV epidemics. The indicators developed then, together with subsequent field experience, have informed updates of existing guides to monitoring and evaluation (M&amp;amp;E) for both TB and HIV control programmes. This version of the guide has been updated to reflect further field experience in monitoring TB/HIV activities and to harmonize the indicators with the revisions of the WHO-recommended TB and HIV recording and reporting formats.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285416</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://pediatrics.aappublications.org/cgi/content/abstract/109/5/e70?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;searchid=1065088899310_745&amp;stored_search=&amp;FIRSTINDEX=0&amp;volume=109&amp;firstpage=e70&amp;journalcode=pediatrics]]&gt;</url>
    <title>A meta-analysis of randomized, controlled trials comparing short- and long-course antibiotic therapy for urinary tract infections in children</title>
    <publicationDate>2002-05-05T00:00:00</publicationDate>
    <publisher>Pediatrics</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ URINARY TRACT,BODY PART AFFECTED,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper aims to determine whether long-course antibiotic therapy is more effective than short-course therapy for the treatment of urinary tract infections (UTIs) in children, and to explore potential sources of heterogeneity in the results of existing studies. A review of this paper is available from the Centre for Reviews and Dissemination (DARE abstract 20021117 - http://nhscrd.york.ac.uk/online/dare/20021117.htm)]]&gt;</body>
  </document>
  <document>
    <id>345958</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/k0146l2t14183666/fulltext.pdf]]&gt;</url>
    <title>A new vaccine for tuberculosis: the challenges of development and deployment</title>
    <publicationDate>2009-05-05T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>QUALITATIVE STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,PREVENTION,CHILDHOOD VACCINES,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,VACCINES / IMMUNISATION,BCG,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB) is one of the world’s leading causes of death due to infection and efforts to control TB would be substantially aided by the availability of an improved TB vaccine. There are currently nine new TB vaccines in clinical development, and the first efficacy trials are due to commence in 2009. There are many complex ethical issues which arise at all stages of TB vaccine development, from the need to conduct trials in developing countries to informed consent and the process of ethical review. While it is important that these issues are discussed, it may also be timely to consider the challenges which may arise if a vaccine in clinical development proves to be highly effective. We examine a number of scenarios where decisions on the deployment of a new TB vaccine may impact on the rights and liberty of the individual.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>285422</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://clinicaltrials.plosjournals.org/archive/1555-5887/1/6/pdf/10.1371_journal.pctr.0010028-S.pdf]]&gt;</url>
    <title>A Randomized Controlled Trial of Folate Supplementation When Treating Malaria in Pregnancy with Sulfadoxine-Pyrimethamine</title>
    <publicationDate>2006-10-20T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,MALARIA,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIPARASITICS,INFECTIONS,TREATMENT,TRAVEL ASSOCIATED INFECTIONS,PARASITES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Sulfadoxine-pyrimethamine (SP) is an antimalarial drug that acts on the folate metabolism of the malaria parasite. This study investigated whether folate (FA) supplementation in a high or a low dose affected the efficacy of SP for the treatment of uncomplicated malaria in 488 pregnant women at three hospitals in Western Kenya in a randomized, placebo-controlled, double-blind trial. 

Results showed that concomitant use of 5 mg FA supplementation compromised the efficacy of SP for the treatment of uncomplicated malaria in pregnant women. Countries that use SP for treatment or prevention of malaria in pregnancy need to evaluate their antenatal policy on timing or dose of FA supplementation.]]&gt;</body>
  </document>
  <document>
    <id>388595</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1281953645706]]&gt;</url>
    <title>A report on the management of diarrhoea in care homes</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE,INFECTIONS,POPULATION GROUPS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ANTIMICROBIAL RESISTANCE,ADULTS,OLDER PEOPLE,CLOSTRIDIUM,MICROORGANISM,BACTERIA,CLOSTRIDIUM DIFFICILE,ADDED 2010,WHAT'S NEW,SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Clostridium difficile is a healthcare-associated infection of the intestine and is the main cause of antibiotic-associated diarrhoea and colitis. It is a major public health problem and mainly affects elderly patients and those with underlying illnesses. Although rates of Clostridium difficile infection (CDI) in England have decreased recently, the number of cases remains high. Efforts to reduce C.difficile&amp;nbsp; infection rates have been initiated in care homes, led by national guidance. This reflects the concentration of vulnerable people in such settings, where use of antibiotics and gastric acid suppressants is common.&lt;/P&gt;
&lt;P&gt;This study aimed to find out how well diarrhoea is managed and treated in nursing and residential homes (care homes), to identify areas where knowledge and practice could be improved.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345499</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/bsc/tmih/2009/00000014/00000008/art00009]]&gt;</url>
    <title>A systematic review and meta-analysis of molecular epidemiological studies of tuberculosis: development of a new tool to aid interpretation</title>
    <publicationDate>2009-08-14T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objectives&lt;/STRONG&gt;: The proportion of tuberculosis cases in a population that are clustered (i.e. share identical strains of Mycobacterium tuberculosis) reflects ongoing M. tuberculosis transmission. It varies markedly, but it is unclear how much of this variation reflects measurable differences in study design, setting and the patient population. We aimed to assess the relative impact of these factors and develop a tool to improve interpretation of the proportion clustered from an individual study. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: We systematically reviewed all population-based TB clustering studies that used IS6110 RFLP as their main DNA fingerprinting technique. Meta-regression was used to see how much of the variation in the proportion clustered between studies could be explained by variables describing study design, setting and population. We compared expected clustering, based on study design and setting, with that observed. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Forty-six studies were included. Just four factors related to study design and setting-study duration, sampling fraction, handling of low band strains and tuberculosis incidence-explained 28% of the variation in the proportion clustered. Additionally including average patient age and proportion foreign born explained 60% of the variation in clustering for industrialized countries. Comparison of expected and observed proportions showed that for some studies the expected proportion clustered differed strongly from that observed. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: We were able to account for much of the variation in the proportion clustered. The comparison of expected and observed clustering allows for a more valid comparison of studies and provides a tool for identifying outliers that warrant further investigation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394431</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20630991]]&gt;</url>
    <title>A systematic review and meta-analysis of quantitative interviewing tools to investigate self-reported HIV and STI associated behaviours in low- and middle-income countries</title>
    <publicationDate>2010-07-14T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>QUALITATIVE STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: Studies identifying risks and evaluating interventions for human immunodeficiency virus (HIV) and other sexually transmitted infections often rely on self-reported measures of sensitive behaviours. Such self-reports can be subject to social desirability bias. Concerns over the accuracy of these measures have prompted efforts to improve the level of privacy and anonymity of the interview setting. This study aims to determine whether such novel tools minimize misreporting of sensitive information.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Systematic review and meta-analysis of studies in low- and middle-income countries comparing traditional face-to-face interview (FTFI) with innovative tools for reporting HIV risk behaviour. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Cochran's chi-squared test of heterogeneity was performed to explore differences between estimates. Pooled estimates were determined by gender, region, education, setting and question time frame using a random effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: We found and included 15 data sets in the meta-analysis. Most studies compared audio computer-assisted self interview (ACASI) with FTFI. There was significant heterogeneity across studies for three outcomes of interest: 'ever had sex' (I(2) = 93.4%, P &amp;lt; 0.001), non-condom use (I(2) = 89.3%, P &amp;lt; 0.001), and number of partners (I(2) = 75.3%, P &amp;lt; 0.001). For the fourth outcome, 'forced sex', there was homogenous increased reporting by non-FTFI methods (OR 1.47; 95% CI 1.11-1.94). Overall, non-FTFI methods were not consistently associated with a significant increase in the reporting of all outcomes. However, there was increased reporting associated with non-FTFI with region (Asia), setting (urban), education (&amp;gt;60% had secondary education) and a shorter question time frame.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Contrary to expectation, differences between FTFI and non-interviewer-administered interview methods for the reported sensitive behaviour investigated were not uniform. However, we observed trends and variations in the level of reporting according to the outcome, study and population characteristics. FTFI may not always be inferior to innovative interview tools depending on the sensitivity of the question as well as the population assessed.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307685</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-2458-8-15.pdf]]&gt;</url>
    <title>A systematic review of delay in the diagnosis and treatment of tuberculosis.</title>
    <publicationDate>2008-01-14T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT,DIAGNOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Early diagnosis and immediate initiation of treatment are essential for an effective tuberculosis (TB) control program. Delay in diagnosis is significant to both disease prognosis at the individual level and transmission within the community. Most transmissions occur between the onset of cough and initiation of treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: A systematic review of 58 studies addressing delay in diagnosis and treatment of TB was performed. We found different definitions of, for example, debut of symptoms, first appropriate health care provider, time to diagnosis, and start of treatment. Rather than excluding studies that failed to meet strict scientific criteria (like in a meta-analysis), we tried to extract the "solid findings" from all of them to arrive on a more global understanding of diagnostic delay in TB.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: The main factors associated with diagnostic delay included human immunodeficiency virus; coexistence of chronic cough and/or other lung diseases; negative sputum smear; extrapulmonary TB; rural residence; low access (geographical or sociopsychological barriers);&lt;BR&gt;initial visitation of a government low-level healthcare facility, private practitioner, or traditional healer; old age; poverty; female sex; alcoholism and substance abuse; history of immigration; low educational level; low awareness of TB; incomprehensive beliefs; self-treatment; and stigma.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: The core problem in delay of diagnosis and treatment seemed to be a vicious cycle of repeated visits at the same healthcare level, resulting in nonspecific antibiotic treatment and failure to access specialized TB services. Once generation of a specific diagnosis was in reach, TB treatment was initiated within a reasonable period of time.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330540</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6T7M-4TP1FDG-7-3&amp;_cdi=5062&amp;_user=855288&amp;_orig=search&amp;_coverDate=01%2F31%2F2009&amp;_sk=998959998&amp;view=c&amp;wchp=dGLbVtb-zSkWA&amp;md5=6e1bab5942b0afa3ac13fe5c93edbe9e&amp;ie=/sdarticle.pdf]]&gt;</url>
    <title>A systematic review of randomized controlled trials of prenatal and postnatal vitamin A supplementation of HIV-infected women</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,ADULTS,CHILDREN,PREGNANT WOMEN,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We searched the Cochrane Library, MEDLINE, EMBASE, AIDSearch, and Gateway to assess the effect of prenatal and/or postnatal vitamin A supplementation on the risk of mother-to-child transmission (MTCT) of HIV and other pregnancy outcomes. We included 5 trials totaling 7528 women (4 trials of prenatal and 1 trial of postnatal supplementation). Overall, there was no evidence of an effect of prenatal and/or postnatal vitamin A supplementation on the risk of MTCT of HIV (Relative Risk [RR] 1.06, 95% Confidence Interval [CI] 0.89-1.26). However, prenatal vitamin A supplementation significantly improved birth weight (weighted mean difference 89.78; 95% CI, 84.73-94.83), but there was no evidence of an effect on stillbirths (RR 0.99; 95% CI, 0.68-1.43), preterm births (RR 0.88; 95% CI, 0.65-1.19), death before 24 months among live births (RR 1.08; 95% CI, 0.91-1.29), and maternal death (RR 0.83; 95% CI, 0.59-1.17). The available evidence does not support vitamin A supplementation of HIV-infected pregnant and lactating women, despite improvement in birth weight.]]&gt;</body>
  </document>
  <document>
    <id>345451</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://informahealthcare.com/doi/abs/10.1517/17530050802665694?prevSearch=allfield%253A%2528A%2B]]&gt;</url>
    <title>A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate</title>
    <publicationDate>2009-03-02T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ANTIMICROBIAL RESISTANCE,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: The emergence of multidrug-resistant tuberculosis (MDR-TB) has prompted the development of rapid drug susceptibility assays with a focus on rifampin in recent years. Systematic reviews with evaluation of predictive values for different assays are scarce. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;: MEDLINE was searched on 6 September 2008 for English articles that contain concurrent original data for generating summary measures of sensitivity, specificity and likelihood ratios of rapid rifampin susceptibility assays. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results/conclusions&lt;/STRONG&gt;: Significant heterogeneity was found in likelihood ratios across studies of all assays except nitrate reductase assay and colorimetric assays. Although rapid assays are fairly reliable for ruling out MDR-TB, careful consideration of clinical risk factors is required before using these assays to rule in MDR-TB under different epidemiological settings.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393930</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.human-resources-health.com/content/pdf/1478-4491-8-8.pdf]]&gt;</url>
    <title>A systematic review of task-shifting for HIV treatment and care in Africa</title>
    <publicationDate>2010-03-31T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Shortages of human resources for health (HRH) have severely hampered the rollout of antiretroviral therapy (ART) in sub-Saharan Africa. Current rollout models are hospital- and physician-intensive. Task shifting, or delegating tasks performed by physicians to staff with lower-level qualifications, is considered a means of expanding rollout in resource-poor or HRH-limited settings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We conducted a systematic literature review. Medline, the Cochrane library, the Social Science Citation Index, and the South African National Health Research Database were searched with the following terms: task shift*, balance of care, non-physician clinicians, substitute health care worker, community care givers, primary healthcare teams, cadres, and nurs* HIV. We mined bibliographies and corresponded with authors for further results. Grey literature was searched online, and conference proceedings searched for abstracts.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: We found 2960 articles, of which 84 were included in the core review. 51 reported outcomes, including research from 10 countries in sub-Saharan Africa. The most common intervention studied was the delegation of tasks (especially initiating and monitoring HAART) from doctors to nurses and other non-physician clinicians. Five studies showed increased access to HAART through expanded clinical capacity; two concluded task shifting is cost effective; 9 showed staff equal or better quality of care; studies on non-physician clinician agreement with physician decisions was mixed, with the majority showing good agreement.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Task shifting is an effective strategy for addressing shortages of HRH in HIV treatment and care. Task shifting offers high-quality, cost-effective care to more patients than a physician-centered model. The main challenges to implementation include adequate and sustainable training, support and pay for staff in new roles, the integration of new members into healthcare teams, and the compliance of regulatory bodies. Task shifting should be considered for careful implementation where HRH shortages threaten rollout programmes.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394238</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6T63-50RV8G5-1-5&amp;_cdi=5019&amp;_user=8810565&amp;_pii=S0376871610002401&amp;_origin=search&amp;_coverDate=08%2F11%2F2010&amp;_sk=999999999&amp;view=c&amp;wchp=dGLbVlW-zSkzk&amp;md5=6aee5c9eecf77938e8f8dd700a32d445&amp;ie=/sdarticle.pd]]&gt;</url>
    <title>A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization</title>
    <publicationDate>2010-08-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Alcohol use disorders (AUDs) are highly prevalent and associated with non-adherence to antiretroviral therapy, decreased health care utilization and poor HIV treatment outcomes among HIV-infected individuals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: To systematically review studies assessing the impact of AUDs on: (1) medication adherence, (2) health care utilization and (3) biological treatment outcomes among people living with HIV/AIDS (PLWHA).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DATA SOURCES&lt;/STRONG&gt;: Six electronic databases and Google Scholar were queried for articles published in English, French and Spanish from 1988 to 2010. Selected references from primary articles were also examined.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;REVIEW METHODS&lt;/STRONG&gt;: Selection criteria included: (1) AUD and adherence (N=20); (2) AUD and health services utilization (N=11); or (3) AUD with CD4 count or HIV-1 RNA treatment outcomes (N=10). Reviews, animal studies, non-peer reviewed documents and ongoing studies with unpublished data were excluded. Studies that did not differentiate HIV+ from HIV- status and those that did not distinguish between drug and alcohol use were also excluded. Data were extracted, appraised and summarized.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DATA SYNTHESIS AND CONCLUSIONS&lt;/STRONG&gt;: Our findings consistently support an association between AUDs and decreased adherence to antiretroviral therapy and poor HIV treatment outcomes among HIV-infected individuals. Their effect on health care utilization, however, was variable.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394181</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20133272]]&gt;</url>
    <title>A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Thomas Land Publishers Incorporated</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;PURPOSE&lt;/STRONG&gt;: Several randomized, controlled trials (RCTs) have tested strategies to prevent sexual acquisition of HIV infection, but their quality has been variable. We aimed to identify, describe, and evaluate the quality of RCTs studying biomedical interventions to prevent HIV acquisition by sexual transmission.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;/STRONG&gt;: We conducted a systematic review to identify all RCTs evaluating the efficacy of biomedical HIV prevention interventions. We assessed seven generic and content-specific quality components important in HIV prevention trials, factors influencing study power, co-interventions provided, and trial ethics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: We identified 26 eligible RCTs. The median number of quality components judged to be in adequate or unclear was 3 (range 1-4) in 1992-1998, 3 (range 1-4) in 1999-2003, and 0 (range0-2) in 2004-2008 (p &amp;lt; .001). Common problems that may have biased results included low retention (median 84%), poor adherence to interventions requiring on going use (median &amp;lt; or =78%), and lower HIV incidence than expected a priori (in 8 of 11 trials where evaluable).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Reporting of trials of biomedical HIV prevention interventions has improved over time. However, quality improvement is needed in several key areas that influence study power, including participant retention, adherence to interventions, and estimation of expected HIV incidence.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392300</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2809%2970300-7/abstract]]&gt;</url>
    <title>Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,DIAGNOSIS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,OCT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We systematically reviewed the accuracy of serological tests for recent infections with HIV that have become widely used for measuring population patterns incidence of HIV. Across 13 different assays, sensitivity to detect recent infections ranged from 42-100% (median 89%). Specificity for detecting established infections was between 49.5% and 100% (median 86.8%) and was higher for infections of durations longer than 1 year (median 98%, range 31.5-100.0). For four different assays, comparisons were made between assay-derived population incidence estimates and a reference incidence estimate. The median percentage difference between the assay-derived incidence and reference incidence was 26.0%. Serological assays have reasonable sensitivity for the detection of recent infection with HIV, but are vulnerable to misclassifying established infections as recent-potentially leading to biases in incidence estimates. This conclusion is highly qualified by the apparent absence of a standardised approach to assay evaluation. There is an urgent need for an internationally agreed framework for evaluating and comparing these tests.]]&gt;</body>
  </document>
  <document>
    <id>285433</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/333/7575/949?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=purdy&amp;andorexactfulltext=and&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Acne</title>
    <publicationDate>2006-11-04T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Acne is an easily treated cause of disfigurement and psychological morbidity. It affects more than 80% of people at some point in their life, up to 14% of whom consult their general practitioner (GP) and 0.3% a dermatologist.
About 3.5 million consultations with GPs occur in the United Kingdom annually for acne. Morbidity can be high and associated with disfigurement, pain, loss of confidence, and impairment of normal social and workplace function, with documented effects on quality of life including depression, dysmorphobia, and even suicide.]]&gt;</body>
  </document>
  <document>
    <id>285434</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop25.pdf]]&gt;</url>
    <title>Actinomyces selective agar (MSOP 25)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>345430</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://erj.ersjournals.com/cgi/content/abstract/09031936.00054709v1]]&gt;</url>
    <title>Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis</title>
    <publicationDate>2009-10-19T00:00:00</publicationDate>
    <publisher>The European Respiratory Society</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CLIENT GROUPS,SERVICE DELIVERY,INFECTIOUS DISEASES,DISEASES AND CONDITIONS,ETHNICITY AND HEALTH,NOT ROUTINELY OFFERED,NOT ROUTINELY OFFERED,INFECTIOUS DISEASES,TUBERCULOSIS,ADULT,CHILD,SCREENING,INFECTIONS,REFUGEES AND ASYLUM SEEKERS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,POPULATION GROUPS,ADULTS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10,IMMIGRANTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Although there is no evidence that imported tuberculosis increases the incidence of the disease in the host countries, the rise in migration worldwide raises concerns regarding the adequacy of surveillance and control of immigrant-associated tuberculosis in low incidence countries. Assessing the performance of screening of immigrants for tuberculosis is key to rationalize the control policies to detect and manage immigrant-associated tuberculosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We performed a systematic review and meta-analysis to determine the yield of active screening for tuberculosis among new immigrants at the point of entry.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The yield for pulmonary tuberculosis was 3.5 cases per thousand screened (95% CI 2.9–4.1, I2=94%), for refugees, asylum seekers and regular immigrants the estimates were 11.9 (95% CI 6.7–17.2, I2=92%), 2.8 (95% CI 2.0–3.7, I2=96%) and 2.7 (95% CI 2.0–3.4, I2=81%), respectively. The yield estimates for immigrants from Europe, Africa and Asia were 2.4 (95% CI 1.3–3.4, I2=51.5%), 6.5 (95% CI 3.2–10.0, I2=62%) and 11.2 (95% CI 6.2–16.1, I2=95%), respectively.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;These results provide useful data to inform the development of coherent policies and rational screening services to detect immigrant-associated tuberculosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346446</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Acupuncture-transmitted-infections.aspx]]&gt;</url>
    <title>Acupuncture-transmitted infections</title>
    <publicationDate>2010-03-19T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HEPATITIS,INFECTIONS,PREVENTION,INFECTION CONTROL,HEPATITIS B,SKIN AND NAIL INFECTIONS,MRSA INFECTION,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,HEPATITIS VIRUS,HEPATITIS B VIRUS,VIRUSES,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS,MICROORGANISM,BACTERIA,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Infections spread by acupuncture needles are under-diagnosed worldwide,” BBC News reported. It said that doctors in Hong Kong have called for tighter infection controls and regulation of acupuncture practices.&lt;/P&gt;
&lt;P&gt;The news story is based on an editorial published in the British Medical Journal by a group of doctors from the University of Hong Kong. The authors describe cases and outbreaks of infections associated with acupuncture since the 1970s, as well as the types and sources of these infections. They make several recommendations on how such infections could be avoided.&lt;/P&gt;
&lt;P&gt;The data given in this editorial are from global sources, and UK rates of infection are not given. People who want to have acupuncture in the UK should ensure that they use a registered practitioner. When it is carried out properly by a qualified practitioner, acupuncture is safe. Acupuncturists should only use disposable needles and the skin around the needle insertion site should be sterilised with a wipe. Serious side effects or complications arising from treatment are extremely rare. For more information, go to Health A-Z: acupuncture.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;When conducted properly by a qualified practitioner, acupuncture is safe. There are a number of acupuncture organisations in the UK that practitioners can join if they hold certain qualifications and these organisations can help&amp;nbsp;people find a qualified acupuncture practitioner in their area. For more information, go to &lt;A href="http://www.nhs.uk/Conditions/Acupuncture/Pages/Risks.aspx" target="_blank"&gt;Safety and regulation of acupuncture&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Woo PCY,&amp;nbsp; Lin AWC, Lau SKP, Yuen K-W. &lt;A href="http://www.bmj.com/cgi/content/extract/340/mar18_1/c1268" target="_blank"&gt;Acupuncture transmitted infections.&lt;/A&gt;&amp;nbsp;&lt;EM&gt;BMJ&lt;/EM&gt; 2010; 340:c1268&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285436</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.london.nhs.uk/lempig/AcuteBronchiolitis.doc]]&gt;</url>
    <title>Acute bronchiolitis</title>
    <publicationDate>2002-04-01T00:00:00</publicationDate>
    <publisher>LEMPIG</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The guideline addresses the diagnosis and treatment of Acute Bronchiolitis in its mild, moderate and severe forms.]]&gt;</body>
  </document>
  <document>
    <id>285438</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/infect/commoneye/resources/merec_bulletin_vol17_no3_acute_bronchitis.pdf]]&gt;</url>
    <title>Acute Bronchitis: MeReC Bulletin</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>NHS</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,RESPIRATORY INFECTIONS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Bulletin looks at the management of common infections, such as acute bronchitis, in primary care. It considers which patients are likely to benefit from antibiotic treatment, either because their symptoms are probably due to bacterial infection rather than viral infection, or because they are at risk of complications from the infection. The evidence to support antibiotic treatment, symptomatic treatment and delayed prescriptions is discussed.]]&gt;</body>
  </document>
  <document>
    <id>285440</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/infect/commoneye/resources/merec_bulletin_vol17_no3_acute_otitis_media.pdf]]&gt;</url>
    <title>Acute Otitis Media: MeReC Bulletin</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>NHS</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,CONTACT,TRANSMISSION MODE,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,INFECTIONS,TREATMENT,EAR INFECTIONS,OTITIS MEDIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Bulletin looks at the management of common infections, such as acute otitis media, in primary care. It considers which patients are likely to benefit from antibiotic treatment, either because their symptoms are probably due to bacterial infection rather than viral infection, or because they are at risk of complications from the infection. The evidence to support antibiotic treatment, symptomatic treatment and delayed prescriptions is discussed.]]&gt;</body>
  </document>
  <document>
    <id>285441</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/infect/commoneye/resources/merec_bulletin_vol17_no3_acute_sinusitis.pdf]]&gt;</url>
    <title>Acute sinusitits: MeReC Bulletin</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>NHS</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,TREATMENT,RESPIRATORY INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This bulletin looks at the management of common infections, such as acute sinusitis, in primary care. It considers which patients are likely to benefit from antibiotic treatment, either because their symptoms are probably due to bacterial infection rather than viral infection, or because they are at risk of complications from the infection. The evidence to support antibiotic treatment, symptomatic treatment and delayed prescriptions is discussed.]]&gt;</body>
  </document>
  <document>
    <id>285442</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/infect/commoneye/resources/merec_bulletin_vol17_no3_acute_uti.pdf]]&gt;</url>
    <title>Acute Uncomplicated Urinary Tract Infection in Women: MeReC Bulletin</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>NHS</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,URINARY TRACT,BODY PART AFFECTED,BLOOD AND BODY FLUIDS,TRANSMISSION MODE,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,INFECTIONS,URINARY TRACT INFECTION,TREATMENT,E. COLI,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This bulletin looks at the management of common infections, such as urinary tract infections in women, in primary care. It considers which patients are likely to benefit from antibiotic treatment, either because their symptoms are probably due to bacterial infection rather than viral infection, or because they are at risk of complications from the infection. The evidence to support antibiotic treatment, symptomatic treatment and delayed prescriptions is discussed.]]&gt;</body>
  </document>
  <document>
    <id>345429</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://informahealthcare.com/doi/abs/10.3109/00365540903428158]]&gt;</url>
    <title>Adenosine deaminase and tuberculous meningitis-A systematic review with meta-analysis</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,BRAIN AND SPINAL CORD INFECTIONS,MENINGITIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculous meningitis (TBM) is a severe infection of the central nervous system, particularly in developing countries. Prompt diagnosis and treatment are necessary to decrease the high rates of disability and death associated with TBM. The diagnosis is often time and labour intensive; thus, a simple, accurate and rapid diagnostic test is needed. The adenosine deaminase (ADA) activity test is a rapid test that has been used for the diagnosis of the pleural, peritoneal and pericardial forms of tuberculosis. However, the usefulness of ADA in TBM is uncertain. The aim of this study was to evaluate ADA as a diagnostic test for TBM in a systematic review. A systematic search was performed of the medical literature (MEDLINE, LILACS, Web of Science and EMBASE). The ADA values from TBM cases and controls (diagnosed with other types of meningitis) were necessary to calculate the sensitivity and specificity. Out of a total of 522 studies, 13 were included in the meta-analysis (380 patients with TBM). The sensitivity, specificity and diagnostic odds ratios (DOR) were calculated based on arbitrary ADA cut-off values from 1 to 10 U/l. ADA values from 1 to 4 U/l (sensitivity &amp;gt;93% and specificity &amp;lt;80%) helped to exclude TBM; values between 4 and 8 U/l were insufficient to confirm or exclude the diagnosis of TBM (p = 0.07), and values &amp;gt;8 U/l (sensitivity &amp;lt;59% and specificity &amp;gt;96%) improved the diagnosis of TBM (p &amp;lt; 0.001). None of the cut-off values could be used to discriminate between TBM and bacterial meningitis. In conclusion, ADA cannot distinguish between bacterial meningitis and TBM, but using ranges of ADA values could be important to improve TBM diagnosis, particularly after bacterial meningitis has been ruled out. The different methods used to measure ADA and the heterogeneity of data do not allow standardization of this test as a routine.]]&gt;</body>
  </document>
  <document>
    <id>393380</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/h678m56641730350/]]&gt;</url>
    <title>Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,POPULATION GROUPS,ADULTS,INJECTING DRUG USERS (IDUS),MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We conducted a meta-analysis of studies assessing adherence to highly active antiretroviral therapy (HAART) and a qualitative systematic review of factors associated with better HAART outcomes among HIV+ drug users (DU). Thirty-eight studies were considered, which analyzed 14,960 patients (11,394 HIV+ DU, 76.2%). Overall adherence (pooled percent of DU classified as adherent in each study) was 0.60 (95% CI: 0.52-0.68), similar to levels identified by studies conducted with HIV+ patients who are not drug users. Time frame used to measure adherence was an independent predictor of inter-study heterogeneity. The systematic review identified better HAART outcomes among former DU, those with less severe psychiatric conditions, those receiving opioid substitution therapy and/or psychosocial support. Patients initiating HAART with lower viral load and higher CD4 counts, and those without co-infections also had better treatment outcomes. Our findings suggest that HIV+ DU tend to be inappropriately assumed to be less adherent and unlikely to achieve desirable treatment outcomes, when compared to their non-DU cohort.]]&gt;</body>
  </document>
  <document>
    <id>307665</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000011/art00005]]&gt;</url>
    <title>Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada [Review article]</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,TREATMENT,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;BACKGROUND: There is renewed attention to the critical role of successfully treating latent tuberculosis infection (LTBI) in reducing the overall impact of tuberculosis (TB). However, levels of treatment adherence are consistently low in industrialized countries such as the United States and Canada.&lt;/P&gt;
&lt;P&gt;OBJECTIVE: A systematic review of studies in the US and Canada was undertaken to analyze measurement of adherence to treatment of LTBI (TLTBI), TLTBI completion rates, predictors of TLTBI adherence and TLTBI adherence interventions.&lt;/P&gt;
&lt;P&gt;METHODS: PUBMED, MEDLINE and PsycINFO electronic databases were searched for quantitative studies published between 1997 and 2007. Full texts of articles were reviewed for data abstraction and studies were critically examined for their methodology and rigor. The present review presents outcomes from 78 studies.&lt;/P&gt;
&lt;P&gt;RESULTS: Adherence and completion rates of TLTBI are suboptimal across high-risk groups, regardless of regimen. Associations between adherence and patient factors, clinic facilities or treatment characteristics were found to be inconsistent across studies. Several adherence interventions have been developed to improve TLTBI adherence in the US and Canada; however, no single intervention has shown consistent effectiveness.&lt;/P&gt;
&lt;P&gt;CONCLUSION: LTBI must be effectively treated if the goal of TB elimination is to be realized. Consistently employing tools for measuring and improving adherence is fundamental. Identifying barriers to adherence and treatment completion will facilitate the development of effective, appropriate interventions. A `one-size-fits-all' approach to treatment for TLTBI adherence is not likely to succeed across all settings. Innovative approaches can inspire future interventions and suggest solutions for the current problems facing LTBI programs and their patients.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330312</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/d80715086767npv3/]]&gt;</url>
    <title>Adolescents and HIV: Prevention and Clinical Care</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Current Medicine Group PLC</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ POPULATIONS,GROUPS,INDIVIDUAL BEHAVIOUR,SEXUAL HEALTH,OUTCOMES,DETERMINANTS,PUBLIC HEALTH,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MONTHLY ADDITIONS,PREVENTION,AGE GROUPS,YOUNG PEOPLE,CHILDREN,COMMUNICABLE DISEASES,HIV INFECTION,POPULATION GROUPS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2009,ADOLESCENTS,2009 DECEMBER,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The incidence of HIV infection has increased to alarming proportions among minority youth, in particular among young men who have sex with men and among teenage girls. The unique socioeconomic, behavioral, and emotional vulnerability of adolescents for sexually transmitted diseases, including HIV, requires early identification of HIV infection for linkage to care. Differences in the clinical and psychosocial presentations of youth with perinatally versus behavioral acquired HIV infection are important and influence the acceptance of illness, self-efficacy, and antiretroviral treatment adherence. The ideal multidisciplinary team approach of culturally sensitive services for youth integrates clinical care, psychosocial and peer support interventions, transition planning, primary and secondary prevention, as well as comprehensive reproductive adolescent health services.]]&gt;</body>
  </document>
  <document>
    <id>308973</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nature.com/nrmicro/journal/v4/n6/abs/nrmicro1419.html]]&gt;</url>
    <title>Advances in tuberculosis vaccine strategies.</title>
    <publicationDate>2006-06-05T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,VACCINES / IMMUNISATION,INFECTIONS,PREVENTION,MARCH 09,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MYCOBACTERIUM TUBERCULOSIS,BCG,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB), an ancient human scourge, is a growing health problem in the developing world. Approximately two million deaths each year are caused by TB, which is the leading cause of death in HIV-infected individuals. Clearly, an improved TB vaccine is desperately needed. Heterologous prime–boost regimens probably represent the best hope for an improved vaccine regimen to prevent TB. This first generation of new vaccines might also complement drug treatment regimens and be effective against reactivation of TB from the latent state, which would significantly enhance their usefulness.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>308574</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/cgi/content/abstract/149/10/689]]&gt;</url>
    <title>Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.</title>
    <publicationDate>2008-11-18T00:00:00</publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TREATMENT,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ BACKGROUND: Treatment of latent tuberculosis infection with isoniazid for 9&lt;BR&gt;months is complicated by poor patient adherence and the need for close follow-up &lt;BR&gt;of side effects, especially hepatotoxicity. Shorter and safer regimens are&lt;BR&gt;needed. OBJECTIVE: To compare the frequency of adverse events and treatment&lt;BR&gt;completion in 2 treatment regimens for latent tuberculosis infection. DESIGN:&lt;BR&gt;Multicenter, randomized, open-label trial. SETTING: Tuberculosis clinics located &lt;BR&gt;in university hospitals in Canada, Brazil, and Saudi Arabia. PATIENTS: 847&lt;BR&gt;patients without a contraindication for rifampin and requiring treatment for&lt;BR&gt;latent tuberculosis infection. INTERVENTION: Four months of daily rifampin&lt;BR&gt;therapy or 9 months of daily isoniazid therapy. MEASUREMENTS: Grade 3 to 4&lt;BR&gt;drug-related adverse events resulting in drug discontinuation (primary outcome), &lt;BR&gt;and on-time treatment completion, grade 1 to 2 drug-related adverse events, and&lt;BR&gt;changes in liver enzymes and hematologic variables (secondary outcomes). RESULTS:&lt;BR&gt;Seventeen of 422 participants who started isoniazid therapy developed grade 3 to &lt;BR&gt;4 adverse events compared with 7 of 418 who started rifampin therapy (risk&lt;BR&gt;difference [rifampin minus isoniazid], -2.3% [95% CI, -5% to -0.1%]; P = 0.040). &lt;BR&gt;Grade 3 or 4 hepatitis occurred in 16 of 422 isoniazid recipients compared with 3&lt;BR&gt;of 418 rifampin recipients (risk difference, -3.1% [CI, -5% to -1%]; P = 0.003). &lt;BR&gt;Grade 1 or 2 adverse events attributed to study drugs occurred with similar&lt;BR&gt;frequency. Asymptomatic reduction in platelet and leukocyte counts were more&lt;BR&gt;frequent in rifampin recipients. More patients completed rifampin treatment (78%)&lt;BR&gt;than isoniazid treatment (60%) (difference, 18% [CI, 12% to 24%]; P &amp;lt; 0.001]).&lt;BR&gt;LIMITATION: The study did not measure efficacy, and the open-label design may&lt;BR&gt;increase the chance of bias in ascertainment of adverse events. CONCLUSION:&lt;BR&gt;Treatment of latent tuberculosis with 4 months of rifampin leads to fewer serious&lt;BR&gt;adverse events and better adherence than 9 months of isoniazid. These findings&lt;BR&gt;justify a large-scale trial to compare the efficacy of rifampin with that of&lt;BR&gt;isoniazid.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>285446</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f11.pdf]]&gt;</url>
    <title>Aerobic Plate Count at 30 degrees C: Spiral Plate Method (F11)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285447</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f10.pdf]]&gt;</url>
    <title>Aerobic Plate Count at 30 degrees C: Surface Plate Method (F10)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285448</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp2.pdf]]&gt;</url>
    <title>Aesculin hydrolysis test (BSOP TP2)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CARDIOVASCULAR,BODY PART AFFECTED,FOOD/WATER,URINARY TRACT,INFECTIONS,MICROORGANISM,LISTERIA MONOCYTOGENES,BACTERIA,STREPTOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>321483</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Ageandantivirals.aspx]]&gt;</url>
    <title>Age and antivirals</title>
    <publicationDate>2009-07-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,ADULTS,OLDER PEOPLE,POPULATION GROUPS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,JULY 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The journal BMC Infectious Diseases has published research evaluating the age-prioritisation of antivirals during an influenza pandemic. The Daily Mail referred to the study in an article: “Will mass use of Tamiflu leave Britain all but defenceless as swine flu becomes resistant?”.&lt;/P&gt;
&lt;P&gt;The newspaper voices the concerns of a representative from the British Medical Association, Dr Peter Holden, who has questioned the policy of giving the antiviral to people with mild symptoms. He said the policy places extra strain on the NHS, increases the possibility of the virus developing immunity to the drug and exposes people who would otherwise have a mild illness to potential side effects of the drug.&lt;/P&gt;
&lt;P&gt;The debate over the widespread use of antivirals is complex. The Department of Health’s approach to treat symptomatic people is part of a well-considered treatment strategy to reduce the spread of infection in this country. Antiviral resistance is possible, but the government is monitoring this situation closely.&lt;/P&gt;
&lt;P&gt;However, the study referred to in the news article has little relevance to the issue of antiviral resistance in the UK. The study aims to give some guidance on how to prioritise antiviral stockpiles if these are limited. Making some assumptions about the flu virus, the study concludes that treating all cases and providing prophylaxis to younger individuals is the only intervention resulting in "a significant reduction of the clinical attack rate and requiring a relatively small stockpile of antivirals". The Daily Mail has misinterpreted the findings of this study by suggesting that not giving Tamiflu to pensioners in UK would cut the chance of resistance.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285449</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp3.pdf]]&gt;</url>
    <title>Agglutination test (BSOP TP3)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,SALMONELLA,BACTERIA,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>331155</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://data.unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf]]&gt;</url>
    <title>AIDS epidemic update 2009</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>UNAIDS and WHO</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DETERMINANTS,OUTCOMES,PUBLIC HEALTH,SEXUAL HEALTH,INDIVIDUAL BEHAVIOUR,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,MONTHLY ADDITIONS,HIV INFECTION,COMMUNICABLE DISEASES,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2009,NOV 09,2009 DECEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report is divided into separate chapters that summarize epidemiological trends in individual regions. While regional differences remain, several themes are discernible:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;AIDS continues to be a major global health priority.&lt;/LI&gt;
&lt;LI&gt;There is geographic variation between and within countries and regions. &lt;/LI&gt;
&lt;LI&gt;The epidemic is evolving. &lt;/LI&gt;
&lt;LI&gt;There is evidence of successes in HIV prevention.&lt;/LI&gt;
&lt;LI&gt;Improved access to treatment is having an impact.&lt;/LI&gt;
&lt;LI&gt;There is increased evidence of risk among key populations. &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345660</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/tb/publications/2009/airborne/airborne_web02.pdf]]&gt;</url>
    <title>AIRBORNE: A journey into the challenges and solutions to stopping MDR-TB and XDR-TB</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN&gt;"Airborne" is a powerful exploration into the challenges and solutions to addressing M/XDR-TB in the world today. The book, written by John Donnelly, features interviews, stories and images from across the globe. &lt;/SPAN&gt;&lt;BR&gt;&lt;A href="http://video.who.int/streaming/tb/tb_donnelly.wmv" target="_blank"&gt;Video preview of the book by author Donnelly&lt;/A&gt; &lt;BR clear=all&gt;
&lt;P&gt;&lt;SPAN class=dots&gt;::&lt;/SPAN&gt; &lt;A href="http://www.who.int/entity/tb/publications/2009/airborne/interviews/foreword_dr_m_chan/en/index.html" target="_blank"&gt;Foreword by Dr Margaret Chan, WHO Director-General&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN class=dots&gt;::&lt;/SPAN&gt; &lt;A href="http://www.who.int/entity/tb/publications/2009/airborne/background/introduction/en/index.html" target="_blank"&gt;Introduction by author John Donnelly&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN class=dots&gt;::&lt;/SPAN&gt; &lt;A href="http://www.who.int/entity/tb/publications/2009/airborne/photos/gallery/en/index.html" target="_blank"&gt;Photo gallery: the frontline&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN class=dots&gt;::&lt;/SPAN&gt; &lt;A href="http://www.who.int/entity/tb/publications/2009/airborne/airborne_web02.pdf" target="_blank"&gt;Download the complete book [pdf 3.13Mb]&lt;/A&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307706</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.informapharmascience.com/doi/abs/10.1517/17425240802600662]]&gt;</url>
    <title>Alginate-based sustained release drug delivery systems for tuberculosis</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Informa Pharmaceutical Science</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Drug delivery systems have wide biomedical applications owing to their distinct therapeutic advantages, such as controlled release of drugs over prolonged periods, protection against premature drug degradation, reduction in drug toxicity and drug–drug interactions. All these factors are important considerations in the treatment of chronic infectious diseases such as tuberculosis. In tuberculosis, patient non-compliance is a vexing problem which is responsible not only for treatment failure, but also for the emergence of multi-drug resistant cases. Alginate, a natural polymer, has attracted researchers owing to its ease of availability, compatibility with hydrophobic as well as hydrophilic molecules, biodegradability under physiological conditions, lack of toxicity and the ability to confer sustained release potential. It is not therefore surprising that the controlled release phenomenon of this polymer has been documented for a vast array of drugs. In particular, the ability of alginate to co-encapsulate multiple antitubercular drugs and offer a controlled release profile is likely to have a major impact in enhancing patient compliance for better management of tuberculosis.]]&gt;</body>
  </document>
  <document>
    <id>285453</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD000238]]&gt;</url>
    <title>Ambulatory oxygen for chronic obstructive pulmonary disease</title>
    <publicationDate>2002-01-21T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Little is known about the effectiveness of ambulatory domicilary oxygen therapy. At present ambulatory oxygen in the UK is provided with small oxygen cylinders but in other countries such as the USA and Italy, liquid oxygen systems with higher oxygen carrying capacity are widely used. Both these systems are used without adequate evidence of their effectiveness.

Objectives
To determine the effectiveness of long-term ambulatory domicilary oxygen therapy in patients with chronic obstructive pulmonary disease.

Search strategy
The Cochrane Airways Group specialised trials register was searched. In addition, bibliographies of each trial retrieved were also searched for additional papers that may contain further studies. Authors of identified trials were contacted for other published and unpublished studies. Searches were current as of August 2004.

Selection criteria
Only randomised controlled trials in patients with chronic obstructive pulmonary disease were considered for inclusion. Trials must have randomised patients into long-term ambulatory oxygen therapy or placebo while at home. Ambulatory oxygen can be provided either through portable oxygen cylinders or with liquid oxygen canisters and the placebo group using compressed or liquid air.

Data collection and analysis
Two reviewers assessed all potential trials independently. Data abstraction was completed by one reviewer and re-checked by the second reviewer.

Main results
Only two studies met the inclusion criteria. These provided data on 70 patients. Statistically significant effects of oxygen were found in only one of the studies, a crossover trial involving 9 patients with severe hypoxia at rest. This study reported a reduction in minute ventilation at maximal exercise (WMD -11.00 L/min; 95%CI -17.53 , -4.47L/min) and an increase in PaO2 at rest (WMD 17.00 mmHg; 95%CI 9.13,24.87 L/min) with oxygen therapy when compared to placebo. The other study recruited patients who did not have resting hypoxaemia. An update search conducted in August 2004 did not identify any new studies for inclusion in the review.

Authors' conclusions
Evidence available to date does not allow any firm conclusions to be drawn concerning the effectiveness of ambulatory domicilary oxygen therapy in patients with COPD. Further studies are required in order to understand the role of ambulatory oxygen in the management of patients with COPD on long-term oxygen therapy. These studies should separate patients who desaturate from those who do not desaturate.
--------------------------------------------------------------------------------
Synopsis
More research needed on the effects of portable oxygen for people with COPD (chronic obstructive pulmonary disease).

Supplementary (portable or ambulatory) oxygen therapy (in addition to fixed or domiciliary oxygen therapy) is a necessity for active patients who leave their homes and for daily activities. Although ambulatory oxygen therapy is prescribed for such patients little is known about the effectiveness of long-term ambulatory oxygen therapy in such situations. A review was conducted to determine the effectiveness of long-term ambulatory oxygen therapy. Only two trials were found with one of the trials reporting significant improvements in ventilation and arterial oxygen saturation. From the evidence to date, it is not possible to determine whether patients on long-term oxygen therapy should be provided with ambulatory oxygen during exercise and for activities of daily living. Further studies are required in order to understand the role of ambulatory oxygen in patients with chronic obstructive pulmonary disease.]]&gt;</body>
  </document>
  <document>
    <id>285454</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop46.pdf]]&gt;</url>
    <title>Aminoglycoside and glycopeptide assays in clinical microbiology laboratories (QSOP46)</title>
    <publicationDate>2007-01-08T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Assays of antibiotics in blood or cerebrospinal fluid are performed for four main reasons:

• To ensure adequate therapeutic concentrations are reached for optimal outcome
• To avoid toxic concentrations
• To study the pharmocokinetics of the antibiotic
• To establish the correlates of achievable drug concentrations and microbial susceptibility
with clinical outcome

In clinical laboratories, monitoring of aminoglycosides and glycopeptides is performed for the
first two reasons, whereas the latter two are normally only required for clinical trials.
Note: Commercially available drugs are often a mixture of biologically active substances (eg
gentamicin) all of which must be detectable by the assay system used.]]&gt;</body>
  </document>
  <document>
    <id>394470</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907488]]&gt;</url>
    <title>An algorithm for tuberculosis screening and diagnosis in people with HIV</title>
    <publicationDate>2010-02-25T00:00:00</publicationDate>
    <publisher>Massachusetts Medical Society</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,DIAGNOSIS,MICROORGANISM,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Tuberculosis screening is recommended for people with human immunodeficiency virus (HIV) infection to facilitate early diagnosis and safe initiation of antiretroviral therapy and isoniazid preventive therapy. No internationally accepted, evidence-based guideline addresses the optimal means of conducting such screening, although screening for chronic cough is common.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We consecutively enrolled people with HIV infection from eight outpatient clinics in Cambodia, Thailand, and Vietnam. For each patient, three samples of sputum and one each of urine, stool, blood, and lymph-node aspirate (for patients with lymphadenopathy) were obtained for mycobacterial culture. We compared the characteristics of patients who received a diagnosis of tuberculosis (on the basis of having one or more specimens that were culture-positive) with those of patients who did not have tuberculosis to derive an algorithm for screening and diagnosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Tuberculosis was diagnosed in 267 (15%) of 1748 patients (median CD4+ T-lymphocyte count, 242 per cubic millimeter; interquartile range, 82 to 396). The presence of a cough for 2 or 3 weeks or more during the preceding 4 weeks had a sensitivity of 22 to 33% for detecting tuberculosis. The presence of cough of any duration, fever of any duration, or night sweats lasting 3 or more weeks in the preceding 4 weeks was 93% sensitive and 36% specific for tuberculosis. In the 1199 patients with any of these symptoms, a combination of two negative sputum smears, a normal chest radiograph, and a CD4+ cell count of 350 or more per cubic millimeter helped to rule out a diagnosis of tuberculosis, whereas a positive diagnosis could be made only for the 113 patients (9%) with one or more positive sputum smears; mycobacterial culture was required for most other patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: In persons with HIV infection, screening for tuberculosis should include asking questions about a combination of symptoms rather than only about chronic cough. It is likely that antiretroviral therapy and isoniazid preventive therapy can be started safely in people whose screening for all three symptoms is negative, whereas diagnosis in most others will require mycobacterial culture.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315560</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19214]]&gt;</url>
    <title>An outbreak caused by hantavirus in the Black Sea region of Turkey, January – May 2009</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>Eurosurveillance</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,TRAVEL ASSOCIATED INFECTIONS,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We present a preliminary report of 12 laboratory-confirmed cases of haemorrhagic fever with renal syndrome (HFRS) in Turkey, diagnosed between January and May 2009 according to the clinical symptoms and serological confirmation. Studies are still ongoing to better understand the dynamics of the reservoir population as well as the epidemiological characteristics and risk factors among humans. &lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>285460</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ajph.org/cgi/content/abstract/83/12/1679?ijkey=04bd4cc8adbf5bceaabd513e6feac05bde97ab7d&amp;keytype2=tf_ipsecsha]]&gt;</url>
    <title>An outbreak of hepatitis A among health care workers: risk factors for transmission</title>
    <publicationDate>1993-01-01T00:00:00</publicationDate>
    <publisher>American Journal of Public Health </publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,HEPATITIS,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,VIRUSES,HEPATITIS VIRUS,HEPATITIS A VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ OBJECTIVES. The purpose of this study was to investigate a nosocomial outbreak of hepatitis A that occurred in the burn treatment center of a referral hospital. METHODS. Retrospective cohort and case-control studies were performed to determine acquisition rates and risk factors for transmission. Adjusted infection rates were calculated by week of exposure. A case-control study was conducted to determine potential mechanisms for nosocomial acquisition. Recently infected health care workers were defined as case patients; exposed, serosusceptible health care workers without infection served as controls. RESULTS. The outbreak of hepatitis A affected 11 health care workers and 1 other burn patient (1 secondary patient case). All 11 health care workers became ill after the admission of a man and his 8-month-old son who developed hepatitis A while in the hospital. The cumulative incidence risk ratio was elevated for health care workers caring for either the infant or the father during the same week of exposure. The case-control study implicated the behavior of eating on the hospital ward as the single most important risk factor for infection. CONCLUSION. Inadequate hand-washing and subsequent oral contamination appear responsible for the outbreak. Hospitals may witness other institutional outbreaks if health care workers regularly eat on the wards. ]]&gt;</body>
  </document>
  <document>
    <id>342747</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_111676.pdf]]&gt;</url>
    <title>Annual HPV vaccine uptake in England: 2008/2009</title>
    <publicationDate>2010-01-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DETERMINANTS,OUTCOMES,PUBLIC HEALTH,GROUPS,POPULATIONS,GENDER,SEXUAL HEALTH,MANAGEMENT &amp; INTERVENTIONS,INDIVIDUAL BEHAVIOUR,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,GENITAL WARTS (HPV),SERVICE SECTORS,INTERNATIONAL,PRIMARY CARE SERVICES,HEALTH MANAGEMENT,WOMEN'S HEALTH,GYNAECOLOGICAL TUMOURS,CERVICAL CANCER,PREVENTION,VACCINATION,MONTHLY ADDITIONS,INFECTIONS,FEMALE,SEXUALLY TRANSMITTED INFECTIONS,GENITOURINARY DISEASES,AGE GROUPS,YOUNG PEOPLE,CERVICAL CANCER,CANCER,INFECTION CONTROL,MALIGNANT,POPULATION BASED &amp; PREVENTATIVE SERVICES,HEALTH PROTECTION,SERVICES,CHILDHOOD VACCINES,CERVICAL CANCER VACCINE (HPV 16,HUMAN PAPILLOMAVIRUS (HPV),VIRUSES,MICROORGANISM,VACCINES / IMMUNISATION,MAY 2010,JAN 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A summary of HPV vaccination uptake across England at PCT, SHA and national level for the first year of the programme. This includes additional data from Devolved Authorities and comparisons with available international equivalent programmes.]]&gt;</body>
  </document>
  <document>
    <id>285462</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD000371]]&gt;</url>
    <title>Anthelmintic drugs for treating worms in children: effects on growth and cognitive performance</title>
    <publicationDate>2000-04-24T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
In communities where helminth (worm) infections are common, they may contribute to poor nutritional status, anaemia, and impaired growth and learning in children. The World Health Organization, the World Bank and others recommend that children are routinely given deworming drugs in developing countries. This requires resources to deliver.

Objectives
To summarise the effects of anthelmintic drug treatment in children in relation to their growth and cognitive performance.

Search strategy
We searched the Cochrane Infectious Diseases Group Specialized Register (August 2004), CENTRAL) The Cochrane Library Issue 3, 2004), MEDLINE (1966 to August 2004), EMBASE (1980 to August 2004), and LILACS (August 2004). We contacted experts in the field.

Selection criteria
Randomised and quasi-randomised trials of drug treatment compared with placebo or no drug treatment for intestinal helminths in children.

Data collection and analysis
Trial quality was assessed and data were extracted independently by two reviewers. Study authors were contacted for additional information.

Main results
Thirty trials involving more than 1500 children were included. There was potential for bias from inadequate concealment of allocation. Studies varied in relation to target groups, drugs administered and treatment regimens. Compared to placebo or no drug treatment, drug treatment for helminths was associated with some positive effects on change in weight, height and skinfold thickness. However there was significant heterogeneity between the results of the trials.

There were some positive effects on mean weight change in the trials reporting this outcome; after a single dose (any anthelminth) the pooled estimate was 0.17 kg, (95% CI 0.10 to 0.25; fixed effects model assumed); and 0.38 kg (95% CI 0.00 to 0.77; random effects model assumed). Results from trials giving multiple doses showed mean weight change under one year of follow up of 0.10 kg (95% CI 0.04 to 0.17; fixed effects assumed); or 0.15 (95% CI 0.00 to 0.30; random effects assumed). At more than one year of follow up, mean weight change was 0.12 kg (95% CI -0.02 to 0.26; fixed effects assumed) and 0.43 (95% CI -0.61 to 1.47; random effects model assumed).

Results from studies of cognitive performance were mixed and inconclusive.

Authors' conclusions
There is some limited evidence that routine treatment of children in areas where helminths are common has small effects on weight gain, but this is not consistent between trials. There is insufficient evidence to know whether this intervention improves cognitive performance. Our interpretation of these results is that the current public health programme investments in this intervention, based on the expectation that there will be an improvement in growth and learning, are not based on consistent or reliable evidence.]]&gt;</body>
  </document>
  <document>
    <id>285468</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://aac.asm.org/cgi/reprint/46/9/3026]]&gt;</url>
    <title>Antibiotic Pharmacodynamics in Surgical Prophylaxis: an Association between Intraoperative Antibiotic Concentrations and Efficacy</title>
    <publicationDate>2002-09-01T00:00:00</publicationDate>
    <publisher>Antimicrobial Agents and Chemotherapy</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ANTIMICROBIALS,ANTIBIOTICS,PREVENTION,PREVENTION AND CONTROL,INFECTIONS,TREATMENT,SURGICAL PROPHYLAXIS,OCT 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The authors have undertaken analysis of gentamicin levels in patients given prophylactic gentamicin and metronidazole for colorectal surgery. The relationship between gentamicin levels at the time of closure and the risk if post-operative infection was examined. The authors concluded that the gentamicin concentration at the time of surgical closure was one of the strongest independent risk factors for post-operative infection.]]&gt;</body>
  </document>
  <document>
    <id>285474</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD004539.pub2]]&gt;</url>
    <title>Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults</title>
    <publicationDate>2005-04-20T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,TREATMENT,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Secondary peritonitis is associated with a high mortality rate and if not treated successfully leads to development of abscesses, severe sepsis and multi-organ failure. Source control and adjunctive antibiotics are the mainstay of treatment. However, no conclusive evidence suggest that one antibiotic regimen is better than any other but at the same time have a lower toxicity.

Objectives
To ascertain the efficacy and adverse effects of different antibiotic regimens in treating intra-abdominal infections in adults. Outcomes were divided into primary (clinical success and effectiveness in reducing mortality) and secondary (microbiological success, preventing wound infection, intra-abdominal abscess, clinical sepsis, remote infection, superinfection, adverse reactions, duration of treatment required, effectiveness in reducing hospitalised stay, and time to defervescence).

Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library, Issue 4, 2004), MEDLINE (from 1966 to November 2004), EMBASE (from 1980 to November 2004) and Cochrane Colorectal Cancer Group specialised register SR-COLOCA.
Bibliographies of identified studies were screened for further relevant trials. 

Selection criteria
Randomised and quasi-randomised controlled trials comparing different antibiotic regimens in the treatment of secondary peritonitis in adults were selected. Trials reporting gynaecological or traumatic peritonitis were excluded from this review. Ambiguity regarding suitability of trials were discussed among the review team.

Data collection and analysis
Six reviewers independently assessed trial quality and extracted data. Data collection was standardised using data collection form to ensure uniformity among reviewers. Statistical analyses were performed using the random effects model and the results expressed as odds ratio for dichotomous outcomes, or weight mean difference for continuous data with 95% confidence intervals.

Main results
Fourty studies with 5094 patients met the inclusion criteria. Sixteen different comparative antibiotic regimens were reported. All antibiotics showed equivocal comparability in terms of clinical success. Mortality did not differ between the regimens. Despite the potential high toxicity profile of regimens using aminoglycosides, this was not demonstrated in this review. The reason for this could be the inherent bias within clinical trials in the form of patient selection and stringency in monitoring drug levels.

Authors' conclusions
No specific recommendations can be made for the first line treatment of secondary peritonitis in adults with antibiotics, as all regimens showed equivocal efficacy. Other factors such as local guidelines and preferences, ease of administration, costs and availability must therefore be taken into consideration in deciding the antibiotic regimen of choice. Future trials should attempt to stratify patients and perform intention-to-treat analysis to allow better external validity.
--------------------------------------------------------------------------------
Synopsis
Antibiotics are effective in preventing post-operative complications following infection of the peritoneum (peritonitis), but there is no evidence to support that one regimen is superior to another, and at the same time has less side effects.
Patients with peritonitis originated from the gut will often require surgery. Antibiotics are useful in the treatment of the ongoing infection and for prevention of post-operative complications.
This review does not result in specific recommendations for any antibiotic regimen for the first line treatment of secondary peritonitis in adults, as all regimens showed equivocal efficacy. Other factors such as local guidelines and preferences, ease of administration, costs and availability must therefore be taken into consideration in deciding the antibiotic regimen of choice. More large scale trials are needed, and future trials should attempt to stratify patients and perform intention-to-treat analysis to allow better external validity. ]]&gt;</body>
  </document>
  <document>
    <id>285477</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD002941]]&gt;</url>
    <title>Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis</title>
    <publicationDate>2003-10-20T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,BODY PART AFFECTED,DIGESTIVE TRACT,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,TREATMENT,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Acute pancreatitis is a common acute abdominal emergency which lacks specific therapy. In severe attacks, areas of the pancreas may become necrotic. The mortality risk rises to &gt;40% if sterile necrosis becomes superinfected, usually with gut derived aerobic organisms. Experimental and clinical studies indicate a window of opportunity of 1-2 weeks, when superinfection, and thus high-risk surgical debridement, may be prevented by administering systemic antibiotics to 'sterilise' tissues adjacent to necrotic areas. There are theoretical risks of encouraging antibacterial resistance and opportunistic fungal infections.

Objectives
To determine the effectiveness and safety of prophylactic antibiotic therapy in patients with severe acute pancreatitis who have developed pancreatic necrosis.

Search strategy
MEDLINE, EMBASE, and the Cochrane Library were searched. We also examined other sources including Conference Abstracts (published and unpublished data).

Selection criteria
Randomised controlled trials (RCT) were sought using the search strategy detailed below. No linguistic limitations were applied. RCTs were selected in which antibacterial therapy was evaluated in patients with severe acute pancreatitis associated with pancreatic necrosis proven by intravenous contrast-enhanced computed tomography (CT). 
No linguistic limitations were applied. Searching was undertaken initially in November 2001 and updated in March 2003.

Data collection and analysis
Two reviewers extracted data from trial publications independently, concerning rates for the primary end-points: with respect to: all cause mortality and rates of infection of pancreatic necrosis (proven by microbiological examination of fine needle aspirate or operative specimens). In addition, secondary end-points included peri-pancreatic sepsis, remote sepsis (respiratory, urinary, central venous line sources), operative rates, length of hospital stay, adverse events including the incidence of drug resistant microorganisms and opportunistic fungal infection.

Main results
It was possible to evaluate mortality in all four included studies, and it demonstrated a survival advantage for antibiotic therapy (Odds ratio 0.32, p=0.02). Pancreatic sepsis (infected necrosis) was also measurable in all four studies and showed an advantage for therapy (Odds ratio 0.51, p=0.04). Extra-pancreatic infection could be evaluated in three studies, but showed no significant advantage for therapy (Odds ratio 0.47, p=0.05).Operative treatment data was available in three studies, but surgery rates were not significantly reduced (Odds ratio 0.55, p=0.08). Fungal infections showed no strongly increased preponderance with therapy (Odds ratio 0.83, p=0.7), but there were no data on infection with resistant organisms. Length of hospital stay could only be evaluated in two studies and was not significantly different. Sub-group analyses planned for the influence on outcome measures of the antibiotic regimen, the time of commencement of therapy in relation to symptom onset and/or hospitalisation, duration of therapy, and aetiology could not be performed as no data were available.

Authors' conclusions
Despite variations in drug agent, case mix, duration of treatment and methodological quality (especially the lack of double blinded studies), there was strong evidence that intravenous antibiotic prophylactic therapy for 10 to 14 days decreased the risk of superinfection of necrotic tissue and mortality in patients with severe acute pancreatitis with proven pancreatic necrosis at CT. Further studies are required to confirm all of the benefits suggested (in particular the need for operative debridement), to provide more adequate data on adverse effects, to address the choice of antibacterial agents and effects of varying duration of therapy, and whether outcome is related to aetiology.
--------------------------------------------------------------------------------
Synopsis
Acute pancreatitis is a life-threatening condition which is primarily inflammatory . However in severe attacks pancreatic necrosis may occur. Death can result if necrotic tissue becomes superinfected requiring surgical debridement. Despite a strong rationale for antibiotic prophylaxis to prevent superinfection, adverse effects have been reported and the results of individual randomised controlled trials are inconclusive.]]&gt;</body>
  </document>
  <document>
    <id>285480</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://heart.bmjjournals.com/cgi/content/full/79/2/207?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;andorexactfulltext=and&amp;searchid=1088439916535_3514&amp;stored_search=&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;volume=79&amp;firstpage=207&amp;resourcetype=1&amp;journalcode=heartjnl]]&gt;</url>
    <title>Antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis</title>
    <publicationDate>1998-02-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ SPECIFIC DRUGS,CARDIOVASCULAR,BODY PART AFFECTED,OTHER PRESCRIBING,EMERGENCY CARE,CLINICAL LIBRARY,CARDIOVASCULAR,PRESCRIBING,ENDOCARDITIS,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,INFECTIONS,TREATMENT,STAPHYLOCOCCUS,STAPHYLOCOCCUS AUREUS,STREPTOCOCCUS,MICROORGANISM,BACTERIA,ENTEROCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Endocarditis Working Party of the British Society for Antimicrobial Chemotherapy first issued recommendations for the treatment of streptococcal and staphylococcal endocarditis in 1985. Since then numerous reports have been published of the results of treatment with the recommended regimens and with other antibiotics, some of which were not available in 1985, and the American Heart Association has recently reviewed its guidelines for antibiotic treatment. Revised diagnostic criteria and new therapeutic procedures have also become available and many more patients have had prosthetic valves implanted. We have reviewed our recommendations in light of these developments and our wish to have simplified up to date guidelines that are most appropriate for use in the UK. They are intended to cover more than 90% of the cases of infective endocarditis seen in the UK, which are caused by streptococci, enterococci and staphylococci. ]]&gt;</body>
  </document>
  <document>
    <id>285481</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD004783.pub2]]&gt;</url>
    <title>Antibiotics for acute laryngitis in adults</title>
    <publicationDate>2004-01-24T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Acute laryngitis is a common illness worldwide. Diagnosis is often made by case history alone and treatment is often directed towards controlling symptoms.

Objectives
The aim of this review was to assess the effectiveness of different antibiotic therapies in adults suffering acute laryngitis. A secondary objective was to report the rates of adverse events associated with these treatments.

Search strategy
We systematically screened the following electronic databases: the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2004); MEDLINE (January 1966 to June Week 3 2004); and EMBASE (1974 to June 2004), LILACS (from 1982 to the 40th edition) and BIOSIS (1980 to June 2002). Other strategies included hand searching relevant journals, searching ongoing trial databases and general databases such as Alta Vista. 

Selection criteria
Randomized controlled trials comparing any antibiotic therapy with placebo in acute laryngitis. The main outcome measurement was objective voice scores.

Data collection and analysis
Data were independently extracted by two people and then descriptively synthesised.

Main results
Only two trials met study inclusion criteria after extensive literature searches. One hundred patients were randomly selected to receive either penicillin V (800 mg twice a day for five days), or an identical placebo, in a study of penicillin V in acute laryngitis in adults. A tape recording of each patient reading a standardised text was obtained during the first visit, subsequently during re-examination after one and two weeks, and at follow up after two to six months. No significant differences were found between the groups. The trial also measured symptoms reported by patients and found no significant differences.

The second trial investigated erythromycin for treating acute laryngitis in 106 adults. The mean objective voice scores measured at the first visit, at re-examination after one and two weeks, and at follow up after two to six months did not significantly differ between control and intervention groups. At one week there were significant beneficial differences in the severity of reported vocal symptoms as judged by the patients (p = 0.042). Comparing the erythromycin and placebo groups on subjective voice scores the a priori relative risk (RR) was 0.7 (95% confidence interval (CI) 0.51 to 0.96, p = 0.034) and the number needed to treat (NNT) was 4.5.

Authors' conclusions
Antibiotics appear to have no benefit in treating acute laryngitis. Erythromycin could reduce voice disturbance at one week and cough at two weeks when measured subjectively. We consider that these outcomes are not relevant in clinical practice. The implications for practice are that prescribing antibiotics should not be done in the first instance as they will not objectively improve symptoms.
--------------------------------------------------------------------------------
Synopsis
Available data suggests that antibiotics (penicillin V and erythromycin) are of limited use for most adults with acute laryngitis

Acute laryngitis is an inflammation of the larynx. The most common symptoms are hoarseness, fever, sore throat, postnasal discharge and difficulty in swallowing. This review found that penicillin V and erythromycin appear to have no benefit in treating acute laryngitis. Erythromycin could reduce voice disturbance at one week and cough at two weeks when measured subjectively. We consider these outcomes are not relevant in clinical practice as the modest benefits from antibiotics may not outweigh their cost, adverse effects, or negative consequences on antibiotic resistance patterns.]]&gt;</body>
  </document>
  <document>
    <id>285500</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD002218]]&gt;</url>
    <title>Antibiotics versus control for toxoplasma retinochoroiditis</title>
    <publicationDate>2002-01-21T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,INFECTIONS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Acute toxoplasma retinochoroiditis causes transient symptoms of ocular discomfort and may lead to permanent visual loss. Antibiotic treatment primarily aims to reduce the risk of permanent visual loss, recurrent retinochoroiditis, and the severity and duration of acute symptoms. There is uncertainty about the effectiveness of antibiotic treatment.

Objectives
The objective of this review was to compare the effects of antibiotics versus placebo or no treatment for toxoplasma retinochoroiditis.

Search strategy
We searched the Cochrane Controlled Trials Register - CENTRAL/CCTR, which contains the Cochrane Eyes and Vision Group Specialised Register (Cochrane Library Issue 2, 2001), MEDLINE (1966 to August 2001), EMBASE (1980 to September 2001), Dissertation Abstracts (1861 to June 2001), LILACS (1982 to 1998), Pascal (1984 to March 2000), proceedings of the Association for Research in Vision and Ophthalmology (1980 to 2001), international symposia on uveitis, and reference lists of review articles. Pharmaceutical companies were contacted for unpublished trials.

Selection criteria
We included randomised controlled trials that compared any systemic antibiotic treatment against placebo or no treatment. Trials that included immunocompromised patients were excluded.

Data collection and analysis
The primary outcomes for this review were visual acuity at least three months after treatment and risk of recurrent retinochoroiditis. Secondary outcomes were improvement in symptoms and signs of intraocular inflammation, size of lesion and adverse events. Effect measures were pooled using a random effects model.

Main results
Three trials, which randomised a total of 173 participants, met the inclusion criteria. All trials were methodologically poor. None reported the effect of treatment on visual acuity. Two studies reported results for recurrent retinochoroiditis: one (124 participants) found a significant reduction in participants with chronic recurrent disease who were treated for 14 months: relative risk 0.28 (95% confidence interval 0.10 to 0.78); the other (20 participants) found no evidence of an effect in participants with acute toxoplasma retinochoroiditis (relative risk 1.00, 95% confidence interval 0.07 to 13.87). Two studies reported an improvement in intraocular inflammation in treated compared with untreated participants and one study reported no difference. Two studies found an increased risk of adverse events in treated participants.

Authors' conclusions
There is a lack of evidence to support routine antibiotic treatment for acute toxoplasma retinochoroiditis. There is weak evidence to suggest that long-term treatment of patients with chronic recurrent toxoplasma retinochoroiditis may reduce recurrence. Placebo controlled trials of patients with acute and chronic toxoplasma retinochoroiditis affecting any part of the retina are required to determine the effectiveness of antibiotic treatment.
-------------------------------------------------------------------------------
Synopsis
Not yet known whether antibiotics can prevent vision loss due to parasitic infection of the eye (toxoplasma retinochoroiditis).

If the parasite Toxoplasma gondii gets into the retina (light sensitive layer inside the eye) and the choroid (layer of the eyeball near the retina) it can cause toxoplasma retinochoroiditis. This causes inflammation that can scar the retina and impair vision. The infection can keep returning, increasing the chances of damage. Antibiotics can be used to try and reduce the inflammation and scarring, or used long-term to try and stop the infection from re-emerging. The review found that there is no strong evidence that antibiotics (short or long-term) prevent vision loss. More trials are needed, including trials of newer antibiotics.]]&gt;</body>
  </document>
  <document>
    <id>285465</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop11.pdf]]&gt;</url>
    <title>Anti-HIV screening (VSOP 11)</title>
    <publicationDate>2009-08-21T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,BLOOD AND BODY FLUIDS,TRANSMISSION MODE,HIV/AIDS,INFECTIONS,VERTICAL TRANSMISSION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,HIV,MALE UROGENITAL DISORDERS,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Standard Operating Protocol comtains an algorithm for screening for HIV.]]&gt;</body>
  </document>
  <document>
    <id>296266</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1220427012056]]&gt;</url>
    <title>Antimicrobial Resistance - inevitable but not unmanageable</title>
    <publicationDate>2008-09-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,OCT 08,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ANTIMICROBIAL RESISTANCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Report on antimicrobial resistance]]&gt;</body>
  </document>
  <document>
    <id>296264</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216798080469]]&gt;</url>
    <title>Antimicrobial Resistance and Prescribing in England, Wales and Northern Ireland, 2008</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,OCT 08,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ANTIMICROBIAL RESISTANCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This is the fifth report from the Health Protection Agency (HPA) aimed at providing an overview of antimicrobial resistance in a range of pathogens of public health importance. While this report focuses on data collected by the HPA during 2007, trend data over a longer period of time are also presented to highlight that antimicrobial resistance is not a static problem but one that changes over time. As in previous reports, the emphasis is on surveillance activities undertaken by the HPA, but data on resistance in bacteria from animals, kindly provided by colleagues in the Veterinary Laboratories Agency (VLA), are also included, reflecting inter-agency collaboration on a problem that impacts on both human&amp;nbsp; and animal health.]]&gt;</body>
  </document>
  <document>
    <id>296265</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1204100435389]]&gt;</url>
    <title>Antimicrobial resistance in England, Wales, and Northern Ireland</title>
    <publicationDate>2008-02-27T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ANTIMICROBIAL RESISTANCE,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,OCT 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report provides a detailed overview of antimicrobial resistance in a range of pathogens (bacteria, viruses, fungi, and protozoa) of public health importance]. The majority of the data presented relate to England, Wales, and Northern Ireland, although some data from other European countries are included reflecting the participation of the HPA in the European Antimicrobial Resistance Surveillance Scheme (EARSS).]]&gt;</body>
  </document>
  <document>
    <id>285510</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.blackwell-synergy.com/doi/abs/10.1111/j.1469-0691.2007.01813.x]]&gt;</url>
    <title>Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1)--report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Blackwell Synergy</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFECTIONS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This review describes the methods available for drug susceptibility testing of Mycobacterium tuberculosis. The methods have been developed over several decades and are restricted to specialised centres in most European countries, as they are technically demanding, require appropriate isolation facilities and can be difficult to interpret. The absolute concentration, resistance ratio and proportion methods can all give accurate results, provided that they are carefully quality-controlled and standardised. Automated rapid culture and molecular methods have been evaluated at large reference centres and in multicentre collaborations, and perform well for testing susceptibility to most first- and second-line anti-tuberculosis drugs. Accuracy is more important than rapid testing, and this is most reliably achieved if drug susceptibility tests are done in a small number of well-equipped, experienced laboratories that participate and perform well in an international drug susceptibility testing quality assessment scheme. The WHO Supranational Laboratory Quality Control Network offers a global scheme that assesses the ability of participating laboratories to identify isoniazid, rifampicin, ethambutol and streptomycin resistance. Second-line drug resistance testing is currently being standardised, and such testing should only be performed at the national reference laboratories in western and central European countries because of the relatively small number of cases and the concomitant difficulty of maintaining testing proficiency in multiple centres performing small numbers of tests. There is a need to expand international external quality assessment to include second-line drug susceptibility testing. ]]&gt;</body>
  </document>
  <document>
    <id>285512</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T84-3RJRCBS-2&amp;_user=910131&amp;_coverDate=08%2F31%2F1997&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=8a486886e820c4ec9a0b1b59a07ecc64]]&gt;</url>
    <title>Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis</title>
    <publicationDate>1997-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective. The aims of this study were to assess which antibiotic is most effective in the treatment of acute maxillary sinusitis in otherwise healthy adults and adolescents, and which has the fewest side effects. 

Design. To assess the short-term effects of antimicrobial treatments, a meta-analysis was performed using Mantel-Haenszel procedures on 16 comparative, randomized studies with a total number of 3358 patients. No placebo-controlled studies were available. Antimicrobial treatments were categorized according to type, spectrum, ß-lactamase inhibition, and bactericidal effect. Outcomes were clinical cure, clinical success, and adverse events. 

Results. When studies were analyzed separately, we found significant differences between cefpodoxim and cefaclor in relation to clinical cure, and between loracarbef and doxycycline in relation to clinical success. When data was pooled, sulphonamides were significantly more effective than penicillins in relation to clinical cure, and macrolids were more effective than penicillins in relation to clinical success, whereas cephalosporins caused significantly less adverse events than penicillins. When studies were stratified (standard classic meta-analysis), antibiotics with ß-lactamase inhibition offered significantly more clinical cures than antibiotics without ß-lacta-mase inhibition. However, this significant effect was only due to one study from Southern Europe, published before 1991. 

Conclusion. Differences in outcome between antimicrobial treatments of acute sinusitis in otherwise healthy adults and adolescents appear to be small. Therefore, the cheapest antimicrobial treatment can be se-lected. ]]&gt;</body>
  </document>
  <document>
    <id>345962</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.expert-reviews.com/doi/abs/10.1586/erv.09.111]]&gt;</url>
    <title>Antituberculous vaccine development: a perspective for the endemic world</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Future Science Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MYCOBACTERIUM,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,VACCINES / IMMUNISATION,BCG,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Several new antituberculous vaccine candidates that are effective against primary infection in preclinical animal models have now entered the early phases of clinical trials. Many of these clinical trials involve subunit vaccines, recombinant bacillus Calmette–Guérin (BCG), or improvement of BCG immunity by boosting with subunit vaccines or recombinant viral vectors expressing immunodominant TB antigens. The burning question at this stage is: will the current vaccines be effective in the endemic world where the diverse and complex challenges of TB exist? These challenges include protection of those individuals who are already vaccinated with BCG, those already exposed to environmental mycobacteria and those infected with latent TB or HIV. This review focuses on the available BCG vaccine, new TB vaccines in the pipeline and what type of vaccines are actually needed in high-burden endemic countries.]]&gt;</body>
  </document>
  <document>
    <id>333389</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/Antivirals-and-swine-flu.aspx]]&gt;</url>
    <title>Antivirals and swine flu</title>
    <publicationDate>2009-12-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,ANTIVIRALS,ANTIMICROBIALS,RESPIRATORY INFECTIONS,TREATMENT,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,ADDED 2009,DEC 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Several newspapers have reported today on a review of the effectiveness of antivirals for treating and preventing flu. The Daily Express said that "Tamiflu does not work on healthy patients who get swine flu".&lt;/P&gt;
&lt;P&gt;While there is little evidence that antivirals prevent the transmission of flu, or cut the risk of complications, it is wrong to state that “Tamiflu does not work”. This well-conducted review found that antivirals have a significant effect in reducing the duration of flu symptoms by about one day.&lt;/P&gt;
&lt;P&gt;The review does have some weaknesses, one of which was the limited number of quality studies that were suitable for inclusion. An issue identified here is that there is a lack of evidence, rather than there is no evidence. As the researchers state, more published trials in this area are needed.&lt;/P&gt;
&lt;P&gt;Overall, for healthy people with seasonal flu, antivirals will probably only give minimal relief of symptoms and the researchers’ view that these drugs should be considered optional for this group seems appropriate.&lt;/P&gt;
&lt;P&gt;It is important to make clear that this is not a review of the effectiveness of antivirals for swine flu as it looked at trials on seasonal flu. Also, the subjects were healthy adults so the results do not apply to children or people with underlying health conditions. People in at-risk groups, such as those with compromised immune systems and pregnant women, are advised to start taking antivirals as soon as possible if they contract flu.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The researchers conclude that oseltamivir and zanamivir have modest effectiveness against the symptoms of influenza in otherwise healthy adults. However, overall they are not effective for preventing flu symptoms when taken as prophylaxis (a preventative treatment) by people who have been exposed to flu.&lt;/P&gt;
&lt;P&gt;They say that the drugs may be regarded as optional for reducing the symptoms of seasonal influenza, but that there is limited evidence that they reduce the risk of complications.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Jefferson T, Jones M, Doshi P, Del Mar C. &lt;A href="http://www.bmj.com/cgi/content/full/339/dec07_2/b5106" target="_blank"&gt;Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.&lt;/A&gt; BMJ 2009; 339: b5106&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285519</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140673606679701/abstract]]&gt;</url>
    <title>Antivirals for influenza in healthy adults: systematic review</title>
    <publicationDate>2006-01-28T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,TRANSMISSION MODE,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFECTIONS,ANTIVIRALS,ANTIMICROBIALS,PREVENTION AND CONTROL,PANDEMIC INFLUENZA,SEASONAL INFLUENZA,TREATMENT,INFLUENZA VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Use of antivirals is recommended for the control of seasonal and pandemic influenza. Our aim was to review the evidence of efficacy, effectiveness, and safety of registered antivirals against naturally occurring influenza in healthy adults.]]&gt;</body>
  </document>
  <document>
    <id>320573</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Antiviralsinpregnancy.aspx]]&gt;</url>
    <title>Antivirals in pregnancy</title>
    <publicationDate>2009-07-13T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,PANDEMIC INFLUENZA,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,SWINE INFLUENZA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;As with all influenza viruses, the Pandemic (H1N1) 2009 virus is of particular risk to pregnant women, and especially those in their third trimester. This review looked at research into the safety of the antiviral drugs oseltamivir (Tamiflu) and zanamivir (Relenza) in pregnant and breastfeeding women.&lt;/P&gt;
&lt;P&gt;A choice of drug is based on several factors, and prescribers should read this summary alongside advice from the &lt;A href="http://www.hpa.org.uk/" target="_blank"&gt;Health Protection Agency&lt;/A&gt;.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>308627</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?title=Application+of+the+Genotype+MTBDR&amp;title_type=title&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>Application of the Genotype MTBDR assay directly on sputum specimens.</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Genotype® MTBDR assay was tested for its capability to detect rifampicin (RMP) and isoniazid (INH) resistance (r) and susceptibility (s) directly from 42 smear-positive sputum specimens (15 RMPr/INHr, 2 RMPs/INHr and 25 RMPs/INHs Mycobacterium tuberculosis complex strains). The concordance between the MTBDR assay and conventional drug susceptibility testing was 100%.]]&gt;</body>
  </document>
  <document>
    <id>285524</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop12.pdf]]&gt;</url>
    <title>Avoiding cross-contamination risks in the food laboratory (QSOP 12)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>345032</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/iuatld/ijtld/2009/00000013/00000011/art00005?token=0053152cc0f1d437a63736a6f2c47415d3e666a44502e6e6f644a467b4d616d3f4e4b34e6da9ec62532]]&gt;</url>
    <title>Bacille Calmette-Guérin vaccine-related disease in HIV-infected children: a systematic review.</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,TUBERCULOSIS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,PREVENTION,INFECTIONS,CHILDREN,POPULATION GROUPS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,CHILDHOOD VACCINES,MICROORGANISM,BACTERIA,VACCINES / IMMUNISATION,BCG,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To describe the characteristics and risk of bacille Calmette-Guérin (BCG) vaccine related disease in human immunodeficiency virus (HIV) infected infants.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Systematic literature review of articles published from 1950 to April 2009 in the English language. We identified all microbiologically confirmed cases of disseminated BCG disease in vertically HIV-infected children reported in the literature.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Sixteen observational studies and 11 case reports/series were included. Observational studies suffered from high rates of loss to follow-up and death. Loco-regional BCG disease was reported in both HIV-infected and non-infected children. Disseminated BCG disease was reported only in children with immunodeficiency and only in studies employing sophisticated laboratory techniques. Sixty-nine cases of disseminated BCG were identified in the literature: 47 cases were reported in six observational studies, the majority (41/47) from the Western Cape of South Africa. A Brazilian cohort study reported no cases of disseminated BCG amongst 66 HIV-infected children observed over a 7-year period. A recent South African surveillance study reported 32 cases of disseminated BCG over a 3-year period, estimating the risk of disseminated BCG to be 992 per 100?000 vaccinations in HIV-infected children. Few cases of severe disseminated TB were reported in the cohort studies among HIV-infected children vaccinated with BCG.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Data on the risk of BCG vaccination in HIV-infected children are limited. Targeted surveillance for BCG complications employing sophisticated diagnostic techniques is required to inform vaccination policy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285525</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop18.pdf]]&gt;</url>
    <title>Bacillus cereus selective agar (MSOP18)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACILLUS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A selective medium which is capable of detecting small numbers of Bacillus cereus cells and spores in the presence of large numbers of other contaminating organisms. The low concentration of peptone and the addition of sodium pyruvate improves egg yolk precipitation and enhances sporulation. Bromothymol blue is a pH indicator which detects mannitol&lt;BR&gt;utilisation. The primary diagnostic feature of B. cereus on this medium is the precipitation of hydrolysed lecithin and the failure to utilise mannitol. The medium is made selective by the addition of polymixin B which inhibits Gram-negative bacteria.&lt;/P&gt;
&lt;P&gt;Polymixin pyruvate egg yolk mannitol bromothymol blue agar (PEMBA) is recommended for clinical specimens. Mannitol egg yolk polymixin agar (MEYP) is recommended for food samples.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285540</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop21.pdf]]&gt;</url>
    <title>Baird Parker agar (MSOP 21)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,DIGESTIVE TRACT,CARDIOVASCULAR,BLOOD AND BODY FLUIDS,INFECTIONS,BACTERIA,MICROORGANISM,STAPHYLOCOCCUS,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>308956</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/1471-2458/8/385/abstract/]]&gt;</url>
    <title>Barriers for introducing HIV testing among tuberculosis patients in Jogjakarta, Indonesia: a qualitative study.</title>
    <publicationDate>2008-11-12T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>QUALITATIVE STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIOUS DISEASES,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,DIAGNOSIS,BACTERIA,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MYCOBACTERIUM TUBERCULOSIS,VIRUSES,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: HIV and HIV-TB co-infection are slowly increasing in Indonesia. WHO recommends HIV testing among TB patients as a key response to the dual HIV-TB epidemic. Concerns over potential negative impacts to TB control and lack of operational clarity have hindered progress. We investigated the barriers and opportunities for introducing HIV testing perceived by TB patients and providers in Jogjakarta, Indonesia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: We offered Voluntary Counselling and Testing (VCT) to TB patients in parallel to a HIV prevalence survey. We conducted in-depth interviews with 33 TB patients, 3 specialist physicians and 3 disease control managers. We also conducted 4 Focus Group Discussions (FGDs) with nurses. All interviews and FGDs were recorded and data analysis was supported by the QSR N6® software.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Patients' and providers' knowledge regarding HIV was poor. The main barriers perceived by patients were: burden for accessing VCT and fear of knowing the test results. Stigma caused concerns among providers, but did not play much role in patients' attitude towards VCT. The main barriers perceived by providers were communication, patients feeling offended, stigmatization and additional burden.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Introduction of HIV testing among TB patients in Indonesia should be accompanied by patient and provider education as well as providing conditions for effective communication.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392301</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://eurpub.oxfordjournals.org/content/20/4/422.abstract]]&gt;</url>
    <title>Barriers to HIV testing in Europe: a systematic review</title>
    <publicationDate>2009-12-10T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,DIAGNOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,OCT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: In the European Union (EU) and neighbouring countries, HIV/AIDS, of all infectious diseases, has one of the highest morbidity and mortality rates. An estimated 30% of people living with HIV are unaware of their infection, and may therefore not benefit from timely treatment or may transmit HIV to others, unknowingly. Evidence shows that opportunities are being missed to diagnose HIV infections in EU Member States, particularly in regular health care settings. There is a need to better understand the barriers to HIV testing and counselling with the aim to contribute to the decrease of the number of undiagnosed people.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A systematic review of literature on HIV testing barriers in Europe was conducted, applying a free text strategy with a set of search terms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: A total of 24 studies published in international peer-reviewed journals and meeting the review's eligibility criteria were identified. Fourteen studies report on barriers at the level of the patient; six on barriers at health care provider level and seven on institutional barriers referring to the policy level. The barriers described are centralized around low-risk perception; fear and worries; accessibility of health services, reluctance to address HIV and to offer the test; and scarcity of financial and well trained human resources.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Some barriers to HIV testing and counselling have been illustrated in the literature. Nevertheless, there is lack of structured information on barriers considering (i) legal, administrative and financial factors, (ii) attitudes and practices of health care providers and (iii) perception of patients. Such data is critical to improve effectiveness of HIV testing and counselling.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285541</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.healthpromotionagency.org.uk/Resources/parentschild/immunisation/pdfs/BCG.pdf]]&gt;</url>
    <title>BCG and tuberculosis. Be wise - immunise</title>
    <publicationDate>2003-08-01T00:00:00</publicationDate>
    <publisher>Health Promotion Agency for Northern Ireland</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,CONTACT,RESPIRATORY TRACT,BODY PART AFFECTED,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document is aimed at 10-14 year olds and gives guidance on tuberculosis: what it is, how to recognise the symptoms, immunisation programme.]]&gt;</body>
  </document>
  <document>
    <id>392804</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/1414746638qk5n23/]]&gt;</url>
    <title>Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We conducted a systematic review of behavioral change interventions to prevent the sexual transmission of HIV among women and girls living in low- and middle-income countries. PubMed/MEDLINE, Web of Science, the Cochrane Library, and other databases and bibliographies were systematically searched for trials using randomized or quasi-experimental designs to evaluate behavioral interventions with HIV infection as an outcome. We identified 11 analyses for inclusion reporting on eight unique interventions. Interventions varied widely in intensity, duration, and delivery as well as by target population. Only two analyses showed a significant protective effect on HIV incidence among women and only three of ten analyses that measured behavioral outcomes reduced any measure of HIV-related risk behavior. Ongoing research is needed to determine whether behavior change interventions can be incorporated as independent efficacious components in HIV prevention packages for women or simply as complements to biomedical prevention strategies.]]&gt;</body>
  </document>
  <document>
    <id>392798</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908966/pdf/BLT.09.068213.pdf]]&gt;</url>
    <title>Behavioural interventions for HIV positive prevention in developing countries: a systematic review and meta-analysis</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To assess the evidence for a differential effect of positive prevention interventions among individuals infected and not infected with human immunodeficiency virus (HIV) in developing countries, and to assess the effectiveness of interventions targeted specifically at people living with HIV.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We conducted a systematic review and meta-analysis of papers on positive prevention behavioural interventions in developing countries published between January 1990 and December 2006. Standardized methods of searching and data abstraction were used. Pooled effect sizes were calculated using random effects models.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FINDINGS&lt;/STRONG&gt;: Nineteen studies met the inclusion criteria. In meta-analysis, behavioural interventions had a stronger impact on condom use among HIV-positive (HIV+) individuals (odds ratio, OR: 3.61; 95% confidence interval, CI: 2.61-4.99) than among HIV-negative individuals (OR: 1.32; 95% CI: 0.77-2.26). Interventions specifically targeting HIV+ individuals also showed a positive effect on condom use (OR: 7.84; 95% CI: 2.82-21.79), which was particularly strong among HIV-serodiscordant couples (OR: 67.38; 95% CI: 36.17-125.52). Interventions included in this review were limited both in scope (most were HIV counselling and testing interventions) and in target populations (most were conducted among heterosexual adults or HIV-serodiscordant couples).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Current evidence suggests that interventions targeting people living with HIV in developing countries increase condom use, especially among HIV-serodiscordant couples. Comprehensive positive prevention interventions targeting diverse populations and covering a range of intervention modalities are needed to keep HIV+ individuals physically and mentally healthy, prevent transmission of HIV infection and increase the agency and involvement of people living with HIV.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285543</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.crestni.org.uk/publications/blood_transfusion.pdf]]&gt;</url>
    <title>Better use of blood in Northern Ireland - guidelines for blood transfusion practice</title>
    <publicationDate>2001-01-01T00:00:00</publicationDate>
    <publisher>CREST</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,CARDIOVASCULAR,BLOOD AND BODY FLUIDS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document contains four guidelines on the following aspects of blood transfusion practice: red cell transfusion; the management of acute massive blood loss; the use of blood components in obstetrics; neonatal transfusion. The guidelines are of relevance to all Northern Ireland GP's who use blood. Audit tools are provided for each guideline.]]&gt;</body>
  </document>
  <document>
    <id>285545</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop48.pdf]]&gt;</url>
    <title>Bile aesculin agar (MSOP 48)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,BODY PART AFFECTED,URINARY TRACT,TRANSMISSION MODE,INFECTIONS,BACTERIA,ENTEROCOCCUS,MICROORGANISM,STREPTOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285546</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp5.pdf]]&gt;</url>
    <title>Bile solubility test (BSOP TP5)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,STREPTOCOCCUS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>307683</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journalofinfection.com/article/S0163-4453(08)00211-9/abstract]]&gt;</url>
    <title>Biomarkers for TB treatment response: Challenges and future strategies</title>
    <publicationDate>2008-08-04T00:00:00</publicationDate>
    <publisher>The British Infection Society</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TREATMENT,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Currently the ultimate success of anti-TB therapy is measured by the relapse rate within the first 2 years after treatment. The long duration of clinical trials that rely on this outcome constitute a disincentive for the pharmaceutical industry to develop new TB drugs. Biomarkers for relapse measurable during early treatment may shorten clinical trials. Additionally pre-treatment markers could allow stratification of patients into groups with different treatment requirements for improved clinical management. Currently there is a lack of sufficiently validated biomarkers with good individual predictive value and an urgent need for candidate markers and their evaluation in prospective studies. This review provides an overview of novel biomarkers for TB treatment response and outcome focusing on immunological markers in serum. Additionally, the challenges and roadblocks biomarker research is currently faced with are highlighted.]]&gt;</body>
  </document>
  <document>
    <id>285547</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6W8X-4NT250B-1&amp;_user=910131&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=53a3a9bffd66fe097cab9a2b9063a060]]&gt;</url>
    <title>Biomarkers of treatment response in clinical trials of novel antituberculosis agents.</title>
    <publicationDate>2007-07-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,BODY PART AFFECTED,RESPIRATORY TRACT,AIRBORNE,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Global initiatives have been launched to develop improved tuberculosis chemotherapy. New drugs and potential treatment-shortening regimens require careful assessment in clinical trials, but existing markers of treatment outcome—clinical cure and relapse—require prolonged follow-up of patients. There is, therefore, a need to find alternative biomarkers or surrogate endpoints predictive of response. Effective treatment requires drugs with sterilising activity to produce clinical cure without relapse, and thus a useful biomarker for a drug under trial must predict the likelihood of relapse. We explore the strengths and weaknesses of existing biomarkers, which assess either host response or mycobacterial load. Change in mycobacterial burden is likely to be the best indicator of treatment outcome, but the optimum study techniques remain undefined. Finally, we propose methods to assess candidate markers, and how these candidate markers could be implemented in future clinical trials.]]&gt;</body>
  </document>
  <document>
    <id>285548</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop1.pdf]]&gt;</url>
    <title>Blood and chocolate agar (MSOP 1)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285549</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop10.pdf]]&gt;</url>
    <title>Blood borne virus testing in dialysis patients (VSOP 10)</title>
    <publicationDate>2008-02-20T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HEPATITIS VIRUS,HEPATITIS B VIRUS,HEPATITIS C VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods, which include standard operating procedures (SOPs), algorithms and guidance notes, promote high quality practices and help to assure the comparability of diagnostic information obtained in different laboratories. This in turn facilitates standardisation of surveillance underpinned by research, development and audit and promotes public health and patient confidence in their healthcare services. The methods are well referenced and represent a good minimum standard for clinical and public health microbiology. However, in using National Standard Methods, laboratories should take account of local requirements and may need to undertake additional investigations. The methods also provide a reference point for method development.]]&gt;</body>
  </document>
  <document>
    <id>388526</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/can-virus-cause-obesity-by-body-fat-attack.aspx]]&gt;</url>
    <title>Body fat virus link still unproven</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,POPULATION GROUPS,ADENOVIRUS,CHILDREN,MICROORGANISM,VIRUSES,ADDED 2010,WHAT'S NEW,SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A virus “could make children obese by attacking fat cells”, according to the Daily Mail. It said that the virus causes fat cells to multiply, “triggering a massive gain in weight”.&lt;/P&gt;
&lt;P&gt;This news story is based on a small study that compared a group of obese children with children of a healthy weight. It looked for evidence of a previous infection by a virus called AD36. The study found that 22% of the obese children and 7% of the non-obese children had antibodies (substances produced by the body to fight disease) against the virus. However, this study did not follow the children over time, so it cannot determine whether the children were exposed to the virus before gaining weight or if they were infected once they were already obese. As such, it cannot determine whether AD36 causes or increases the likelihood of putting on excessive weight in childhood.&lt;/P&gt;
&lt;P&gt;Additionally, the study did not take into account lifestyle factors such as exercise or diet, so it is unclear whether these contributed to the children’s weight gain. For now, eating an appropriate diet and taking regular exercise are the most important ways to maintain a healthy weight.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The researchers suggest that this small cross sectional study demonstrates an association between exposure to AD36 and childhood obesity. Various limitations to this study mean that it should be interpreted cautiously:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Firstly, no causal link can be established as measurements were taken at one point in time and it is not possible to determine whether the children put on weight before or after being exposed to the virus. &lt;/LI&gt;
&lt;LI&gt;The study found that only 22% of the obese children were positive for AD36 antibodies and 7% of the non-obese children had this antibody. This indicates that other factors are likely to contribute to obesity and that the association is not particularly strong. &lt;/LI&gt;
&lt;LI&gt;The study did not take into account lifestyle factors such as diet and exercise, which may have differed between the obese and non-obese children. &lt;/LI&gt;
&lt;LI&gt;The study included children over a large age range (8-18 years) and found that older children were more likely to have been exposed to the virus (or at least have the AD36-specific antibodies). It is not clear from the research how the likelihood of being obese changes with age in children. The data was not adjusted for age, despite the fact that the participants’ ages ranged from pre-pubescence to near adulthood. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;As the researchers acknowledge, further research is needed to determine whether the susceptibility to viruses differs between obese children and non-obese children and also to understand how long the AD36 antibodies persist after infection in both groups. To assess whether AD36 has any influence on the likelihood of becoming obese, a larger population of non-obese children would have to be followed over time to assess whether exposure to the virus affected their subsequent likelihood of putting on weight. &lt;/P&gt;
&lt;P&gt;If future&amp;nbsp;&lt;A href="http://www.nhs.uk/news/Pages/Newsglossary.aspx#Longitudinalstudy" target="_blank"&gt;longitudinal studies&lt;/A&gt; are designed to investigate this association, they should adjust for the factors already known to influence obesity.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Gabbert C, Donohue M, Arnold J and Schwimmer JB. &lt;A href="http://pediatrics.aappublications.org/cgi/content/abstract/peds.2009-3362v1" target="_blank"&gt;Adenovirus 36 and Obesity in Children and Adolescents&lt;/A&gt;. &lt;EM&gt;Pediatrics&lt;/EM&gt;, Sep 20 2010 (published online)&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>308532</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000010/art00011]]&gt;</url>
    <title>Bodyweight gain to predict treatment outcome in patients with pulmonary tuberculosis in Peru.</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,ANTIBIOTICS,ANTIMICROBIALS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,TREATMENT,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;SETTING&lt;/STRONG&gt;: Tuberculosis control programmes of two health care centres in the central rainforest of Peru. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To evaluate if bodyweight gain (BWG) predicts treatment outcome in patients with pulmonary tuberculosis (PTB). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: Retrospective cohort study of adults with PTB diagnosed between 1995 and 2004. BWG was assessed after month 1 of treatment, after the initial phase and at the end of treatment. Patients were stratified into two BWG categories, &amp;lt; or = 5% and &amp;gt;5%. Failures and relapses were grouped together as unsuccessful treatment outcome. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: A total of 650 patients were included: 7.2% (n = 47) had an&lt;BR&gt;unsuccessful outcome. Unsuccessful outcome was associated with BWG &amp;lt; or = 5% at the end of treatment (RR 2.05, 95%CI 1.10-3.80), but not at the completion of month 1 (RR 0.99, 95%CI 0.52-1.88) or at completion of the initial phase (RR 1.46, 95%CI 0.82-2.57). Median BWG at completion of the initial phase was higher in cured patients (P = 0.007). BWG &amp;lt; or = 5% at end of treatment (RR 2.35, 95%CI 1.17-4.72), initial sputum smear 2+ (RR 2.48, 95%CI 1.14-5.31) and positive smear microscopy at month 2 (RR 4.0, 95%CI 1.30-12.31) were independent predictors of unsuccessful treatment outcome. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: BWG &amp;lt; or = 5% at the end of treatment, high bacterial load and lack of sputum conversion correlate with unsuccessful treatment outcome in this setting. New discriminative cut-offs for BWG are proposed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330367</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/122482000/abstract]]&gt;</url>
    <title>Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,ANTIVIRALS,ANTIMICROBIALS,INFECTIONS,POPULATION GROUPS,CHILDREN,OTHER TREATMENT METHODS,TREATMENT,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective: Paediatric HIV treatment must address various special considerations. Administration of pharmacokinetically enhanced protease inhibitors (PIs) can improve paediatric therapeutic outcomes. The objective of this study was to review the use of boosted PI regimens in children.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Methods: Systematic literature searches of published manuscripts and conference databases using generic drug names and specific keywords were performed to ensure thorough and balanced reporting of available data.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Results: Boosted PI regimens offer multiple options across a range of ages and are efficacious in naïve and experienced children; safety and tolerability are similar to those observed in adults. Novel boosted PI simplification approaches may foster adherence and diminish resistance.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Conclusions: Boosted PIs are key components of first- and second-line treatments in children. Identifying factors associated with the response to highly active antiretroviral therapy in children may ultimately permit individualized therapies.]]&gt;</body>
  </document>
  <document>
    <id>321487</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/NeurologicalSwineFluEffectOnChildren.aspx]]&gt;</url>
    <title>Brain problems from swine flu</title>
    <publicationDate>2009-07-24T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,JULY 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Centers for Disease Control in the US has published the first report on brain complications from swine flu in children, based on case studies from Texas. Although these complications have been previously described in association with infections from seasonal flu, they have not yet been described in relation to the influenza A (H1N1) virus, swine flu.&lt;/P&gt;
&lt;P&gt;This case series of four Dallas patients aged 7-17 years gives details of the symptoms and testing of the individuals who had neurological complications such as brain inflammation and seizures. All four patients were treated with antiviral therapies and recovered fully without any long-term brain damage.&lt;/P&gt;
&lt;P&gt;The information shared through such reports is valuable for clinicians across the globe, helping build a profile of the behaviour of this new disease.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379595</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Breast-milk-and-immunity.aspx]]&gt;</url>
    <title>Breast milk 'raises' immunity</title>
    <publicationDate>2010-06-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,VACCINE PREVENTABLE DISEASES,POPULATION GROUPS,ADULTS,PREGNANT WOMEN,CHILDREN,JUNE 10,ADDED 2010,WHAT'S NEW]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Breast milk is better for babies than formula because it “kick starts their immune system”, The Daily Telegraph reported.&lt;/P&gt;
&lt;P&gt;This news story is from a small laboratory study testing a new non-invasive method for extracting genetic information from the gut cells found in infant stool samples. The researchers also wanted to compare the intestinal genetic profiles of babies that were breastfed to those of formula-fed babies.&lt;/P&gt;
&lt;P&gt;This study did find a difference in gene activity in the cells from the guts of breastfed compared with bottle-fed babies. However, it is uncertain whether this is due to any difference between the immune systems of breastfed and bottle-fed babies. Also, the babies were not randomly assigned to receive either breast or formula milk, so it is possible that other factors could have caused these differences. Further larger studies are needed.&lt;/P&gt;
&lt;P&gt;Breast milk is known to help protect babies against various disorders and boost their immune defences. While this study may be of scientific interest and merit, these results do not offer any new information about the relative benefits of breastfeeding.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study found that genetic material from the infant intestine can be isolated from stool samples. The researchers say that analysis of this genetic material suggests that the genetic pathways of breastfed infants differ from those found in infants fed formula milk.&lt;/P&gt;
&lt;P&gt;The results of this small study&amp;nbsp;could be of great interest to other scientists in the field. Its main purpose appears to have been to test the practicality and usefulness of a new method for examining cells from babies’ guts. However, it does not, by itself, tell us anything new about the practical health benefits of breastfeeding compared to formula feeding.&lt;/P&gt;
&lt;P&gt;In terms of investigating the effects of breastfeeding compared to bottle-feeding, the infants were not randomly assigned to either type of feeding, so the study may be affected by confounding. This means that differences between the babies other than the type of feeding may be contributing to any differences in gene activity seen. The researchers did try to ensure that the babies in the groups were similar in some areas, but other factors could still be having an effect. For example, the researchers did not test exactly which cells the genetic material was coming from, and this could have differed between infants.&lt;/P&gt;
&lt;P&gt;It has been established that breast milk helps protect babies against various disorders and boosts their immune defences at a time when their immune system is still developing.&lt;/P&gt;
&lt;P&gt;The technique is likely to need further development, and the results of this study will need replication in larger, more comprehensive studies.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Chapkin RS, Zhao C, Ivanov I, et al. &lt;A href="http://ajpgi.physiology.org/cgi/content/abstract/298/5/G582" target="_blank"&gt;Noninvasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells.&lt;/A&gt;&amp;nbsp;&lt;EM&gt;Am J Physiol Gastrointest Liver Physiol&lt;/EM&gt; 2010: 298: G582-G589&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388795</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/breastfeeding-helps-babies-fight-infection.aspx]]&gt;</url>
    <title>Breastfeeding 'fights infection'</title>
    <publicationDate>2010-09-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,INFECTIONS,POPULATION GROUPS,URINARY TRACT INFECTION,MOUTH AND GUM INFECTIONS,EYE INFECTIONS,CONJUNCTIVITIS,RESPIRATORY INFECTIONS,CHILDREN,PREGNANT WOMEN,ADULTS,OTITIS MEDIA,EAR INFECTIONS,SEPT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Exclusive breastfeeding for six months wards off baby infections,” reported the BBC. “Regardless of other factors, such as good healthcare and vaccination programmes, breastfeeding still gives babies a boost,” explained the website.&lt;/P&gt;
&lt;P&gt;The story is based on a study which found that babies who were breastfed exclusively for six months had fewer infections during the first year of life. They were also less likely to be admitted to hospital with an infection than babies who were partially breastfed or not breastfed at all.&lt;/P&gt;
&lt;P&gt;The findings of this large study support previous research, which showed that breastfed babies are less prone to a variety of infections. The study also suggests that partial breastfeeding (giving the baby a mix of breast and formula milk, other fluids or solids) does not provide the same protection. &lt;/P&gt;
&lt;P&gt;However, certain aspects of this study could make its result less reliable. First, instead of relying on medical records, researchers asked mothers to remember in detail how many infections their babies had had and how severe the infections were. Second, only 91 of the 926 babies whose mothers took part were exclusively breastfed. This is a small number of babies on which to base the results.&lt;/P&gt;
&lt;P&gt;Also, when the researchers considered other factors which might influence the results, such as parental health and education, breastfeeding was only associated with a reduction in respiratory infections, such as coughs and colds. It did not significantly reduce other types of infection.&lt;/P&gt;
&lt;P&gt;The Department of Health advises mothers to exclusively breastfeed babies for the first six months of life.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large and reasonably well-conducted study supports previous findings on the protective nature of breast milk. It also suggests that only breastfeeding exclusively confers protection against infection and that partial breastfeeding seems to have no protective effect. However, as the researchers note, their study has limitations, in particular its reliance on mothers recalling precise information about the severity and frequency of their children’s infections. Also, it should be noted that although there was a trend for reduced risk of all of the common infections examined, exclusive breastfeeding during the first six months significantly reduced the risk of chest infection only. Although the researchers adjusted their results for confounding factors, it is possible that other unmeasured confounders could have influenced the results. The relatively small number of babies who were exclusively breastfed (91 out of 926) is a further limitation.&lt;/P&gt;
&lt;P&gt;Current Department of Health advice to mothers is to exclusively breastfeed babies for the first six months of life. Alongside the various other benefits of breastfeeding, this study lends support to its protective effect against common infections during the first six months of life.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ladomenou F, Moschandreas J, Kafatos A &lt;EM&gt;et al. &lt;/EM&gt;&lt;A href="http://adc.bmj.com/content/early/2010/08/24/adc.2009.169912.abstract" target="_blank"&gt;Protective effect of exclusive breastfeeding against infections during infancy: a prospective study&lt;/A&gt;. &lt;EM&gt;Archives of Disease in Childhood&lt;/EM&gt;, 27 September 2010 (published online first) &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>381019</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1274090951247]]&gt;</url>
    <title>Briefing note for GPs: returning travellers from the FIFA World Cup in South Africa</title>
    <publicationDate>2010-06-11T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,SEXUALLY TRANSMITTED INFECTIONS,TUBERCULOSIS,MALARIA,MEASLES,INFLUENZA,INFECTIONS,RABIES,ZOONOSES,TRAVEL ASSOCIATED INFECTIONS,RESPIRATORY INFECTIONS,VACCINE PREVENTABLE DISEASES,JULY 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The 2010 FIFA World Cup takes place in South Africa in June and July with more than 20,000 people from the UK expected to attend1. An additional 35,000 UK visitors are expected to visit South Africa in June for reasons unrelated to the World Cup. Most of these travellers would not be expected to experience adverse health events during their trips. There are however a number of infections that clinicians should be aware of in assessing travellers returning from South Africa who are unwell or concerned about their health, and for which this briefing provides outline information and/or links to further advice, including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Gastrointestinal diseases 
&lt;LI&gt;Malaria 
&lt;LI&gt;Rabies 
&lt;LI&gt;Measles 
&lt;LI&gt;Rift Valley Fever 
&lt;LI&gt;African tick bite fever 
&lt;LI&gt;Sexually transmitted infections and blood borne viruses 
&lt;LI&gt;Influenza 
&lt;LI&gt;Tuberculosis (including drug resistant forms) 
&lt;LI&gt;Meningococcal infection&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;New information about any outbreaks or infectious disease threats associated with the World Cup will be posted on the &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;Page&amp;amp;HPAwebAutoListName/Page/1274089970728" target="_blank"&gt;HPA website &lt;/A&gt;and on the &lt;A href="http://www.nathnac.org/" target="_blank"&gt;National Travel Health Network and Centre (NaTHNaC) website&lt;/A&gt;, where a searchable database of global outbreaks is also maintained.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285550</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop32.pdf]]&gt;</url>
    <title>Brilliant green agar (MSOP 32)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285558</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/man_ibd.pdf]]&gt;</url>
    <title>British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome</title>
    <publicationDate>2000-01-01T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The specific recommendations in these guidelines refer to IBS but because of extensive overlap, much of the general recommendation also applies to other functional disorders including non-ulcer dyspepsia and non-cardiac chest pain. However, to avoid lack of focus in this report, specific recommendations for these latter conditions will be addressed in separate guidelines.]]&gt;</body>
  </document>
  <document>
    <id>285560</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sign.ac.uk/pdf/sign91.pdf]]&gt;</url>
    <title>Bronchiolitis in Children - A National Clinical Guideline</title>
    <publicationDate>2006-11-24T00:00:00</publicationDate>
    <publisher>NHS Quality Improvement Scotland</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,RESPIRATORY TRACT,AIRBORNE,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIVIRALS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ SIGN have put together this guideline to reduce the variation in management of bronchiolitis in children, and aim to reduce the use of unecessary therapies and investigations, particularly in acute cases. 

This guideline provides evidence based recommendations on the prevention, diagnosis, investigation, treatment and management of bronchiolitis. Specific attention has been given to the appropriate use of diagnostic, referral and prognostic tools, particularly for those in primary care.  ]]&gt;</body>
  </document>
  <document>
    <id>285566</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop9.pdf]]&gt;</url>
    <title>Burkholderia cepacia selective agar (MSOP 9)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285568</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/eid/content/13/2/pdfs/259.pdf]]&gt;</url>
    <title>Campylobacter Antimicrobial Drug Resistance among Humans, Broiler Chickens, and Pigs, France</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Emerging Infectious Diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,FAECAL/ORAL,INFECTIONS,CAMPYLOBACTER,INFECTIOUS DISEASES,CAMPYLOBACTER,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The authors describe isolates from human Campylobacter infection in the French population and the isolates’ antimicrobial drug resistance patterns since 1986 and compare the trends with those of isolates from broiler chickens and pigs from 1999 through 2004. Among 5,685 human Campylobacter isolates, 76.2% were C. jejuni, 17.2% C. coli, and 5.0% C. fetus. Resistance to nalidixic acid increased from 8.2% in 1990 to 26.3% in 2004 (p&amp;lt;10-3), and resistance to ampicillin was high over time. Nalidixic acid resistance was greater for C. coli (21.3%) than for C. jejuni (14.9%, p&amp;lt;10-3). C. jejuni resistance to ciprofloxacin in broilers decreased from 31.7% in 2002 to 9.0% in 2004 (p = 0.02). The patterns of resistance to quinolones and fluoroquinolones were similar between 1999 and 2004 in human and broiler isolates for C. jejuni. These results suggest a potential benefit of a regulation policy limiting use of antimicrobial drugs in food animals.]]&gt;</body>
  </document>
  <document>
    <id>285569</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/S0163-4453(03)00042-2]]&gt;</url>
    <title>Campylobacter coli - an important foodborne pathogen</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Journal of Infection</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,MICROORGANISM,BACTERIA,CAMPYLOBACTER,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objectives: Campylobacters are the most common bacterial cause of infectious intestinal disease (IID) in temperate countries. C. jejuni is the predominant cause of campylobacter IID, but the impact of other, less prevalent species has largely been ignored. Here, we present estimates of the burden of indigenously acquired foodborne disease (IFD) due to Campylobacter coli, the second most common cause of human campylobacteriosis. Methods: Data from surveillance sources and specific epidemiologic studies were used to calculate the number of illnesses, presentations to general practice (GP), hospital admissions, hospital occupancy and deaths due to indigenous foodborne C. coli IID in England and Wales for the year 2000. Results: We estimate that in the year 2000, C. coli accounted for over 25,000 cases of IFD. This organism was responsible for more than 12,000 presentations to GP, 1000 hospital admissions, nearly 4000 bed days of hospital occupancy and 11 deaths. The cost to patients and the National Health Service was estimated at nearly £4 million. Conclusions: Although C. coli comprises a minority of human campylobacter disease, its health burden is considerable and greater than previously thought. Targeted research on this organism is required for its successful control. ]]&gt;</body>
  </document>
  <document>
    <id>285571</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop20.pdf]]&gt;</url>
    <title>Campylobacter selective agar (MSOP 20)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,FAECAL/ORAL,INFECTIONS,CAMPYLOBACTER,INFECTIOUS DISEASES,CAMPYLOBACTER,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Two choices of Campylobacter selective agar are recommended for clinical specimens - modified CCDA and Skirrow’s medium.&lt;/P&gt;
&lt;P&gt;Modified CCDA with casein hydrolysate is recommended for the isolation of Campylobacter species from food and water samples.&lt;/P&gt;
&lt;P&gt;Skirrow’s medium will support the growth of enteric Campylobacter species and suppress faecal flora. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345449</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20081663]]&gt;</url>
    <title>Can ELISpot replace the tuberculin skin test for latent tuberculosis?</title>
    <publicationDate>2009-11-12T00:00:00</publicationDate>
    <publisher>British Journal of Nursing</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,DIAGNOSIS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Screening and treatment of latent tuberculosis infection (LTBI) prior to anti-tumour necrosis factor alpha (anti-TNF-alpha) therapy has been shown to decrease the incidence of active tuberculosis (TB) by more than 80%, and is recommended by the British Thoracic Society. In the absence of a gold standard test for LTBI, conventional screening currently involves taking a clinical history of risk factors, a chest X-ray and a tuberculin skin test (TST) which can be difficult to interpret in immunosuppressed patients. Alternative cellular immune-based screening tests have been developed to detect Mycobacterium tuberculosis. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM&lt;/STRONG&gt;: To examine, evaluate and summarize the quality of evidence on the use of interferon gamma release assay (the ELISpot test) in the diagnosis of latent tuberculosis prior to initiation of anti-TNF-alpha and examine the agreement with the tuberculin skin test. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Ovid Medline, Embase and the Cochrane library were searched using search terms that included tuberculosis, each of the current anti-TNF-alpha biological agents, TST and interferon-gamma release assay. Terms were searched using MeSH (medical subject headings) terms and/or free text where relevant. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Discordance between tuberculin skin test and ELISpot is greater in individuals who have had the bacillus Calmette-Guérin (BCG) vaccination and are taking corticosteroids. ELISpot technique using CFP-10 and ESAT-6 antigens is more sensitive than TST in detecting M. tuberculosis infection in patients taking corticosteroids. ELISpot avoids cross-reaction with BCG, making it a more specific test in this group of patients. Agreement between the tests was found to be fair (72.8% kappa value=0.38). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Tuberculosis resulting from reactivation of latent tuberculosis following treatment with anti-TNF is a continuing problem. Screening reduces the risk but does not eliminate it. Further studies are needed into the cost-effectiveness and sensitivity of ELISpot and the tuberculin skin test in routine clinical practice.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393445</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/exercise-and-colds.aspx]]&gt;</url>
    <title>Can exercise ward off colds?</title>
    <publicationDate>2010-11-02T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,COMMON COLD,RHINOVIRUS,VIRUSES,MICROORGANISM,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The best way to stave off a cold this winter is to exercise regularly,” reported The Daily Telegraph. It said a study has found that people who did regular exercise and felt fit cut their risk of a cold by almost half.&lt;/P&gt;
&lt;P&gt;This research found that people who said they exercised on five or more days a week reported fewer days with cold symptoms and less severe symptoms than people who did little exercise and said they were unfit. The association between fewer cold symptoms was also seen in people who just perceived themselves to be fit.&lt;/P&gt;
&lt;P&gt;There is no doubt that regular exercise has health benefits and it may strengthen the immune system. However, this study was relatively short, lasting only 12 weeks, and relied on the participants reporting their exercise and cold symptoms themselves, which introduces the possibility of error. As such, the findings do not provide particularly robust evidence that exercise reduces the risk of colds. Ideally, longer studies are needed to confirm this association.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study found a relationship between people’s reported exercise levels and fitness, and the frequency and severity of the cold symptoms they experienced over 12 weeks. Some factors need to be considered when judging its findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The researchers took into account certain confounders that might have affected the relationship observed. However, as they point out, they did not adjust for all possible confounders, including how much people were exposed to cold germs at home (especially from children) or at work. This could have had a significant effect on the frequency with which people caught a cold.&lt;/LI&gt;
&lt;LI&gt;Secondly, the study relied on people reporting their own exercise and fitness levels and the frequency of their cold symptoms. This introduces the possibility of error, even though validated methods were used to measure cold symptoms. For example, people who perceived themselves as very fit might have been less inclined to report a cold as severe.&lt;/LI&gt;
&lt;LI&gt;The study only asked people about leisure-time exercise and did not take into account any aerobic exercise they might have done at other times, such as at work.&lt;/LI&gt;
&lt;LI&gt;Finally, the study was only 12 weeks long and looked at two subgroups during two different seasons, which makes its findings less robust. Had it been longer, or revisited the same groups for two or three years, the results may have been different.&lt;/LI&gt;
&lt;LI&gt;Despite these limitations, regular physical activity has established health benefits, in particular for the heart. Longer studies that take objective measures of the participants’ aerobic abilities would give a better idea of the benefits of exercise for warding off viruses. Until then, there is even more reason to exercise regularly if it could reduce the risk of coughs and colds.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Nieman DC, Henson DA,&amp;nbsp; Austin MD, Sha W.&amp;nbsp;&lt;A href="http://bjsm.bmj.com/content/early/2010/09/30/bjsm.2010.077875.abstract" target="_blank"&gt;Upper respiratory tract infection is reduced in physically fit and active adults.&lt;/A&gt; &lt;EM&gt;British Journal of Sports Medicine&lt;/EM&gt; November 1 2010 (published online first) &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>393958</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.2009.02759.x/abstract]]&gt;</url>
    <title>Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,HEPATITIS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,INJECTING DRUG USERS (IDUS),ADULTS,HEPATITIS C,POPULATION GROUPS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HEPATITIS C VIRUS,HEPATITIS VIRUS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Human immunodeficiency virus (HIV) outbreaks occur among injecting drug users (IDUs), but where HIV is low insight is required into the future risk of increased transmission. The relationship between hepatitis C virus (HCV) and HIV prevalence among IDUs is explored to determine whether HCV prevalence could indicate HIV risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Systematic review of IDU HIV/HCV prevalence data and regression analysis using weighted prevalence estimates and time-series data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: HIV/HCV prevalence estimates were obtained for 343 regions. In regions other than South America/sub-Saharan Africa (SAm/SSA), mean IDU HIV prevalence is likely to be negligible if HCV prevalence is &amp;lt;30% (95% confidence interval 22-38%) but increases progressively with HCV prevalence thereafter [linearly (beta = 0.39 and R(2) = 0.67) or in proportion to cubed HCV prevalence (beta = 0.40 and R(2) = 0.67)]. In SAm/SSA, limited data suggest that mean HIV prevalence is proportional to HCV prevalence (beta = 0.84, R(2) = 0.99), but will be much greater than in non-SAm/SSA settings with no threshold HCV prevalence that corresponds to low HIV risk. At low HCV prevalences (&amp;lt;50%), time-series data suggest that any change in HIV prevalence over time is likely to be much smaller (&amp;lt;25%) than the change in HCV prevalence over the same time-period, but that this difference diminishes at higher HCV prevalences.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: HCV prevalence could be an indicator of HIV risk among IDUs. In most settings, reducing HCV prevalence below a threshold (30%) would reduce substantially any HIV risk, and could provide a target for HIV prevention.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285572</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/csr/sars/casedefinition/en/]]&gt;</url>
    <title>Case Definition for Surveillance of Severe Acute Respiratory Syndrome (SARS)</title>
    <publicationDate>2003-05-01T00:00:00</publicationDate>
    <publisher>World Health Organization (WHO)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INSECT BITE,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,SARS CORONA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective 
To describe the epidemiology of SARS and to monitor the magnitude and the spread of this disease, in order to provide advice on prevention and control.]]&gt;</body>
  </document>
  <document>
    <id>285573</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp8.pdf]]&gt;</url>
    <title>Catalase test (BSOP TP8)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285574</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/travel/]]&gt;</url>
    <title>CDC Traveller's Health</title>
    <publicationDate>2006-07-11T00:00:00</publicationDate>
    <publisher>Centres for Disease Control and Prevention (CDC)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,RESPIRATORY TRACT,CENTRAL NERVOUS SYSTEM,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,CONTACT,AIRBORNE,BLOOD AND BODY FLUIDS,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,BACTERIA,MICROORGANISM,TRAVEL VACCINES,VIRUSES,PARASITES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This webpage provides links to destination specific health information, vaccinations, references and resources including the Yellow Book (2005-6), FAQ section, information for specific groups for example those travelling with children or those with special needs, news and outbreak notices. ]]&gt;</body>
  </document>
  <document>
    <id>285576</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop23.pdf]]&gt;</url>
    <title>Cefixime tellurite sorbitol MacConkey (SMAC) agar (MSOP 23)</title>
    <publicationDate>2005-05-31T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FAECAL/ORAL,FOOD/WATER,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,ESCHERICHIA COLI INFECTION,INFECTIONS,MICROORGANISM,BACTERIA,E. COLI,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A selective medium for the isolation of Escherichia coli O157. The formulation is based on a modified MacConkey agar and contains 1% D-sorbitol instead of lactose. E. coli O157 is not capable of fermenting sorbitol within 24h. The medium is recommended for screening only as other organisms will be found to be non-sorbitol fermenting. The medium is made selective by the addition of cefixime and potassium tellurite which suppress other non-sorbitol fermenting organisms with no inhibitory effects on E. coli O157.]]&gt;</body>
  </document>
  <document>
    <id>285577</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop15.pdf]]&gt;</url>
    <title>Cefsulodin Irgasan novobiocin (CIN) agar (MSOP 15)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285578</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop11.pdf]]&gt;</url>
    <title>Charcoal blood agar with cephalexin (MSOP 11)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,CONTACT,AIRBORNE,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>392581</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/child-swine-flu-deaths-analysed.aspx]]&gt;</url>
    <title>Child swine flu deaths analysed</title>
    <publicationDate>2010-10-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,CHILDREN,POPULATION GROUPS,RESPIRATORY INFECTIONS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,ADDED 2010,WHAT'S NEW,SWINE INFLUENZA,OCT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The flu pandemic in England killed 70 children in 2009,” The Guardian has reported. The newspaper says that “most of those who died had pre-existing health problems but one in five were healthy before they caught the virus”.&lt;/P&gt;
&lt;P&gt;The news story was based on a report that examined all of England’s swine flu deaths in children under 18 during the 2009 pandemic. The research found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However, the reasons behind this ethnic bias were not determined.&lt;/P&gt;
&lt;P&gt;This report has illustrated that there may be children who are more at risk of dying from certain flu strains, a phenomenon that will require further research. Also, this research was carried out in England where the overall proportion of children who died during the pandemic was low, at a rate of six per million people. The researchers have now called for an analysis of global data on childhood mortality to help us further understand and prevent childhood deaths from seasonal and pandemic flu.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a useful report that has analysed child deaths related to pandemic influenza A H1N1 in England, which identified that there may be certain children who were more at risk from this strain of flu than others. However, the researchers acknowledge that overall there was a small number of child deaths in the UK related to the pandemic, therefore an international study that pooled data from a larger, world-wide number of children who had died would be greatly informative. Such as study might improve understanding of what factors increase the risk of death in children following exposure to similar flu strains.&lt;/P&gt;
&lt;P&gt;The authors point to a few limitations of the research, noting that correctly recording deaths can be difficult, especially when classifying deaths as having occurred pre- or post hospital admission. They took steps to record this as accurately as possible and to take into account those children who may not have sought medical help.&lt;/P&gt;
&lt;P&gt;This report has raised questions that require further follow-up, such as why particular ethnic groups had an increased mortality rate, and what is the most appropriate antiviral treatment plan for children. It also highlighted that some pre-existing conditions carried a higher risk of death from this flu strain. This will need to be addressed when planning a response to future pandemics.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sachedina N, Donaldson LJ. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961195-6/fulltext" target="_blank"&gt;Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study&lt;/A&gt;. The Lancet, September 27 2010 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285582</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.healthpromotionagency.org.uk/Resources/parentschild/immunisation/pdfs/childhood%20guidance%202006.pdf]]&gt;</url>
    <title>Childhood Immunisation: Guidance notes for professionals</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher></publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENINGOCOCCAL MENINGITIS,MUMPS,MEASLES,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,HAEMOPHILUS,VACCINE PREVENTABLE DISEASES,VIRUSES,NEISSERIA MENINGITIDIS,MICROORGANISM,BACTERIA,HAEMOPHILUS INFLUENZAE,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance notes on immunisation for healthcare professionals]]&gt;</body>
  </document>
  <document>
    <id>285584</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop37.pdf]]&gt;</url>
    <title>Chlamydia trachomatis infection - Testing by Nucleic Acid Amplification Test (NAATs) (VSOP 37)</title>
    <publicationDate>2008-09-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHLAMYDIA,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,WOMEN'S HEALTH,SEXUAL HEALTH,CHLAMYDIA,INFECTIONS,CHLAMYDIA,BACTERIA,MICROORGANISM,CHLAMYDIA,BACTERIAL,MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance contains an algorithm to follow when testing for Chlamydia trachomatis infection using nucleic acid amplificiation tests (NAATs).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379599</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/clean-teeth-cuts-heart-disease.aspx]]&gt;</url>
    <title>Clean teeth 'reduce heart risk'</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MOUTH AND GUM INFECTIONS,MAY 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Brushing your teeth twice a day could save you from a heart attack”, the Daily Mail reported.&lt;/P&gt;
&lt;P&gt;This news story is based on a study of how often people brushed their teeth and their risk of cardiovascular disease. People who never or rarely brushed their teeth were 70% more likely to develop cardiovascular disease than those who brushed twice a day. People with poor oral hygiene also had higher blood levels of a specific chemical marker of inflammation thought to increase risk.&lt;/P&gt;
&lt;P&gt;This study did not establish a cause-and-effect relationship between oral health and cardiovascular disease. It is possible that people who brushed their teeth more may simply have lived healthier lives.&lt;/P&gt;
&lt;P&gt;However, these findings are in line with other research suggesting a link between gum disease, inflammation and cardiovascular disease. While not proof of a causal relationship, this study does add further weight to the suggestion that brushing may reduce the risk of cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is the first large study to look at a possible association between self-reported toothbrushing habits and the risk of cardiovascular disease. Its findings are in line with other studies showing a link between gum disease, inflammation and heart disease, although, as the researchers point out, it cannot prove cause and effect. Its analysis used data gathered from a large, rigorously designed population survey that was linked to patient databases and followed people for a reasonably long period of time. It has also used recognised statistical methods.&lt;/P&gt;
&lt;P&gt;However it should be noted that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;although the study took account of other factors that might influence the development cardiovascular disease (such as smoking), it is possible that the results may have still been influenced by factors that were not measured or incompletely measured. &lt;/LI&gt;
&lt;LI&gt;Toothbrushing habits were self-reported, which could increase the chance of obtaining inaccurate data. The study did not look at clinical data on gum disease, although, as the researchers point out, previous research has shown a correlation between self-reported gum disease and clinical evaluations of the condition. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;de Oliveira C, Watt R, Hamer M. &lt;A href="http://www.bmj.com/cgi/content/full/340/may27_1/c2451" target="_blank"&gt;Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 2010;340:c2451&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285586</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://thorax.bmj.com/cgi/reprint/63/1/67]]&gt;</url>
    <title>Clinical application of a rapid lung-orientated immunoassay in individuals with possible tuberculosis.</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,TRANSMISSION MODE,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,MYCOBACTERIUM,TREATMENT,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ BACKGROUND:
Immunological ex vivo assays to diagnose tuberculosis (TB) have great potential but have largely been blood-based and poorly evaluated in active TB. Lung sampling enables combined microbiological and immunological testing and uses higher frequency antigen-specific responses than in blood. 

METHODS: A prospective evaluation was undertaken of a flow cytometric assay measuring the percentage of interferon-gamma synthetic CD4+ lymphocytes following stimulation with purified protein derivative of Mycobacterium tuberculosis (PPD) in bronchoalveolar lavage fluid from 250 sputum smear-negative individuals with possible TB. A positive assay was defined as &gt;1.5%. 

RESULTS: Of those who underwent lavage and were diagnosed with active TB, 95% (106/111) had a positive immunoassay (95% CI 89% to 98%). In 139 individuals deemed not to have active TB, 105 (76%) were immunoassay negative (95% CI 68% to 82%). Of the remaining 24% (34 cases) with a positive immunoassay, a substantial proportion had evidence of untreated TB; in two of these active TB was subsequently diagnosed. Assay performance was unaffected by HIV status, disease site or BCG vaccination. In culture-positive pulmonary cases, response to PPD was more sensitive than nucleic acid amplification testing (94% vs 73%). The use of early secretory antigen target-6 (ESAT-6) responses in 71 subjects was no better than PPD, and 19% of those with culture-confirmed TB and a positive PPD immunoassay had no detectable response to ESAT-6. 

CONCLUSIONS: These findings suggest that lung-orientated immunological investigation is a potentially powerful tool in diagnosing individuals with sputum smear-negative active TB, regardless of HIV serostatus. ]]&gt;</body>
  </document>
  <document>
    <id>285600</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowDetailView&amp;TermToSearch=1609165&amp;ordinalpos=7&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Clinical features of influenza</title>
    <publicationDate>1992-03-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,BODY PART AFFECTED,AIRBORNE,TRANSMISSION MODE,INFLUENZA,INFECTIONS,INFECTIOUS DISEASES,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza, an acute, usually self-limited, febrile illness of global importance, appears virtually every year and infects the respiratory tract either sporadically, as a local outbreak, or as a widespread epidemic. The most severe outbreak known, the 1918 to 1919 influenza A pandemic, was responsible for an estimated 20 million deaths globally. In the United States, the influenza pandemics of 1957 and 1968 were associated with an attack rate of up to 50% and an estimated 100,000 deaths. Interpandemic influenza is responsible for considerable morbidity and mortality, which exceed that associated with the introduction of the pandemic strain. Influenza B infections resemble those due to influenza A, but are associated with fewer deaths. Features of influenza include headache, myalgia, malaise, anorexia, sore throat, nonproductive cough, sneezing, and nasal discharge; these symptoms are not pathognomic for influenza, and asymptomatic infection can occur. The pulmonary complications of influenza include pneumonia (viral and bacterial), croup, asthma, and bronchitis. Myocarditis and pericarditis are occasional cardiac complications. In addition to Reye's syndrome, a range of neurologic complications have been noted, including confusion, convulsions, psychosis, neuritis, Guillain-Barré syndrome, coma, transverse myelitis, and encephalomyelitis. Influenza has also been associated with the toxic shock syndrome, myositis, myoglobinuria, and renal failure. In view of its enormous human and economic toll, influenza remains a major target for improved vaccines and vaccine delivery, and antiviral treatment and prophylaxis. ]]&gt;</body>
  </document>
  <document>
    <id>285603</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/clinguidehepc.pdf]]&gt;</url>
    <title>Clinical guidelines on the management of Hepatitis C</title>
    <publicationDate>2001-07-01T00:00:00</publicationDate>
    <publisher>Royal College of Physicians and the British Society of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BLOOD AND BODY FLUIDS,BODY PART AFFECTED,CARDIOVASCULAR,INFECTIONS,MICROORGANISM,HEPATITIS C VIRUS,HEPATITIS VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These evidence based guidelines indicate that patients infected with Hepatitis C virus (HCV) should be referred to a clinician with a particular interest in the infection. Patients must have access to adequate counselling from a health carer with knowledge and experience of chronic HCV infection. All patients must have access to appropriate diagnostic and therapeutic options available in the management of HCV infection]]&gt;</body>
  </document>
  <document>
    <id>285605</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/ncidod/eid/vol8no2/pdf/01-0521.pdf]]&gt;</url>
    <title>Clinical Issues in the Prophylaxis, Diagnosis, and Treatment of Anthrax</title>
    <publicationDate>2002-02-01T00:00:00</publicationDate>
    <publisher>Emerging Infectious Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,ANTHRAX,ANTHRAX VACCINE,ZOONOSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ On November 18, 2001, a meeting was held at the Centers for Disease Control and Prevention (CDC),&amp;nbsp;to discuss the prophylaxis, diagnosis, and treatment of anthrax. Participants included clinicians and health department personnel from areas where anthrax cases were identified, infectious disease experts, representatives of professional societies, and experts from federal agencies. A patient recovering from inhalational anthrax also described her illness. This publication provides a&amp;nbsp;summary of the presentations and discussion.]]&gt;</body>
  </document>
  <document>
    <id>315571</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19217]]&gt;</url>
    <title>Clinical laboratory practices for the detection of rotavirus in England and Wales: can surveillance based on routine laboratory testing data be used to evaluate the impact of vaccination?</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>Eurosurveillance</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,PREVENTION,INFECTIONS,VACCINES / IMMUNISATION,CHILDHOOD VACCINES,VIRUSES,MICROORGANISM,MAY 09,ROTAVIRUS,ROTAVIRUS VACCINE,ROTAVIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Two rotavirus vaccines have recently been licensed in Europe. Rotavirus surveillance data in many European countries are based on reports of laboratory-confirmed rotavirus infections. If surveillance data based on routine laboratory testing data are to be used to evaluate the impact of vaccination programmes, it is important to determine how the data are influenced by differences in testing practices, and how these practices are likely to affect the ability of the surveillance data to represent trends in rotavirus disease in the community. We conducted a survey of laboratory testing polices for rotavirus gastroenteritis in England and Wales in 2008. 60% (94/156) of laboratories responded to the survey. 91% of reporting laboratories offered routine testing for rotavirus all year round and 89% of laboratories offered routine rotavirus testing of all stool specimens from children under the age of five years. In 96% of laboratories, rotavirus detection was presently done either by rapid immunochromatographic tests or by enzyme-linked immunosorbent assay. Currently, rotavirus testing policies among laboratories in England and Wales are relatively homogenous. Therefore, surveillance based on laboratory testing data is likely to be representative of rotavirus disease trends in the community in the most frequently affected age groups (children under the age of five years) and could be used to help determine the impact of a rotavirus vaccine.]]&gt;</body>
  </document>
  <document>
    <id>285609</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/content/extract/350/9/904]]&gt;</url>
    <title>Clinical Practice Cellulitis</title>
    <publicationDate>2004-02-26T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.]]&gt;</body>
  </document>
  <document>
    <id>330527</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/4165147r34t48r50/]]&gt;</url>
    <title>Clinical practice treatment of HIV infection in children</title>
    <publicationDate>2009-01-17T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,ANTIMICROBIALS,PREVENTION,ANTIVIRALS,PREGNANT WOMEN,CHILDREN,ADULTS,TREATMENT,POPULATION GROUPS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,PROPHYLAXIS,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Perinatal transmission remains the main cause of HIV infection in the pediatric population. Treatment of HIV-infected children has become less of a problem in resource-rich countries with a remarkable decrease of perinatal infections, resulting in an effective prevention of mother-to-child transmission and antiretroviral treatment of HIV infection in pediatrics because of differences in drug pharmacokinetics, the lack of available licensed drugs, the use of different immunologic markers and age-related adherence issues. This review, for the general pediatrician, summarizes the most recent pediatric data and guidelines for treatment of HIV. Recommendations for when to initiate therapy are more aggressive in children than in adults, particularly in infants because disease progression in children is more rapid. The indications to start therapy differ by age and are based on international immunologic and clinical classification system for HIV infection. At present, combination regimens of at least three drugs are recommended. Moreover, therapies must also consider the potential complications in these children currently treated for a long time.]]&gt;</body>
  </document>
  <document>
    <id>285611</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/333/7563/334]]&gt;</url>
    <title>Clinical Review - Infective endocarditis</title>
    <publicationDate>2006-08-12T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,CARDIOVASCULAR,BODY PART AFFECTED,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT,BACTERIA,MICROORGANISM,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The investigation and management of infective endocarditis in the developed world have changed radically over the past 30 years. Non-invasive imaging, molecular science, diagnostic protocols, and curative surgery have all become commonplace, yet the incidence remains unchanged and annual mortality approaches 40%.

The lack of impact of modern medicine reflects important changes in the causes of the disease. In Western populations in particular, chronic rheumatic heart disease is now an uncommon antecedent, whereas degenerative valve disease in elderly people, intravenous drug misuse, preceding valve replacement, or vascular instrumentation have become increasingly frequent, coinciding with an increase in staphylococcal infections and those due to fastidious organisms. 

Furthermore, previously undetected pathogens are now being identified with the disease, and multidrug resistant bacteria challenge conventional treatment regimens. Meanwhile, rheumatic valve disease remains endemic in the developing world, where modern investigations and management are the privilege of the well off few who live in large urban areas.

This review outlines the modern understanding, investigation, and management of this perplexing and enigmatic condition.]]&gt;</body>
  </document>
  <document>
    <id>345036</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.landesbioscience.com/journals/13/article/9310/]]&gt;</url>
    <title>Clinical studies of TB vaccines</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Landes Bioscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,CHILDHOOD VACCINES,MICROORGANISM,BACTERIA,BCG,VACCINES / IMMUNISATION,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis will not be brought under control without a more effective TB vaccine being made available. The only currently licensed TB vaccine, BCG, was discovered nearly 100 years ago, confers only variable and incomplete protection again pulmonary TB and is contraindicated in infants infected with HIV. New priming and boosting vaccines have been developed, have shown promise in preclinical and early clinical studies and are now approaching Phase IIB proof of concept and Phase III efficacy trials. Likely target populations include infants, adolescents and HIV infected adults. Phase III trials will need to be multi centre, enrol very large cohorts of subjects and follow them up for at least two years for clinical endpoints. There are insufficient efficacy trial sites globally. Such sites require a combination of high TB rates in target populations, clinical and laboratory support and infrastructure, and surveillance systems capable of detecting all important and relevant events in trial participants. Over the last decade significant progress has been made in assessing potential sites and assisting them to develop the necessary capacity to participate in future efficacy trials of new TB vaccines.]]&gt;</body>
  </document>
  <document>
    <id>285614</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop52.pdf]]&gt;</url>
    <title>Clostridium difficile cefoxitin-cycloserine agar (MSOP 52)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,INFECTIONS,CLOSTRIDIUM,CLOSTRIDIUM DIFFICILE,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285615</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop33.pdf]]&gt;</url>
    <title>Clostridium perfringens selective agar (TSC) (MSOP 33)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>384333</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/genes-may-control-meningitis-b-risk.aspx]]&gt;</url>
    <title>Clue to meningitis risk</title>
    <publicationDate>2010-08-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MENINGITIS,MENINGOCOCCAL VACCINE (MENC),CHILDHOOD VACCINES,BRAIN AND SPINAL CORD INFECTIONS,BACTERIA,MICROORGANISM,VACCINES / IMMUNISATION,NEISSERIA MENINGITIDIS,AUG 10,WHAT'S NEW,ADDED 2010,NEISSERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"Researchers have found 'the strongest evidence so far' that genetic factors can increase the risk of a person developing meningitis," reported The Guardian. The newspaper said the discovery could help in the search for a vaccine.&lt;/P&gt;
&lt;P&gt;This was a large, well-conducted study that compared the DNA of children who had contracted meningococcal meningitis with the DNA of healthy children. It identified several genetic variants in a region of DNA containing genes associated with a part of the immune system, including a variant in the gene that produces a protein called complement factor H (CFH). Variations in this region are linked to susceptibility to disease, and the findings may help with the development of a vaccine against type B meningococcal meningitis.&lt;/P&gt;
&lt;P&gt;An effective vaccine against type C meningococcal meningitis is already given to children in the UK and has greatly reduced deaths from this disease in this country. Research into the development of a vaccine effective against type B meningococcal meningitis is likely to continue.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a well-conducted and well-reported genome-wide association study using recognised methods in this field of research. This study did not detect any of the genetic associations with meningococcal disease that other studies have noted, possibly because it used different methods or because these earlier studies were in smaller groups of people and so had less power to detect associations.&lt;/P&gt;
&lt;P&gt;If this study does result in a vaccine for type B meningitis, it is likely to require further research and may be several years in the making. Positively, the researchers say that the link between the CFH variants and risk of disease seems to be “strain independent”. In other words, it exists regardless of which strain of Neisseria meningitidis (i.e. whether type B or type C) has infected the children. This is because the strain that these children had is likely to have differed across the three cohorts, as some were collected before the type C vaccine was introduced and some after. The researchers say there is potential for a meningococcal B vaccine resulting from the identification of factor H.&lt;/P&gt;
&lt;P&gt;These findings will be of interest to geneticists and ultimately to clinicians, particularly if it aids the development of a vaccine for type B meningococcal meningitis. The vaccine for type C became available in the UK in the late 1990s and greatly reduced deaths from this disease. Any insight that can further the development of a vaccination for type B will be very welcome. It is important to note that these findings cannot be generally applied to meningitis caused by other bacteria or viruses.&lt;/P&gt;
&lt;P&gt;Meningitis requires early recognition and urgent treatment. Symptoms include severe headache, neck stiffness, difficulty in looking at bright lights (photophobia), fever, nausea and vomiting and altered consciousness, confusion and fitting as infection progresses. In babies and young children, these characteristic signs and symptoms may not be present, and parents should be alert to either irritability or lethargy and excessive crying, fever, vomiting or poor feeding, bulging fontanelle, either a stiff or floppy body or fitting. If there is progression to septicaemia (infection of the blood), a rash which does not blanch with pressure may appear. If meningitis is suspected, seek medical attention immediately.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Davila S,&amp;nbsp;Wright VJ, Chuen Khor C &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/ng/journal/vaop/ncurrent/abs/ng.640.html" target="_blank"&gt;Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease&lt;/A&gt;. &lt;EM&gt;Nature Genetics 2010&lt;/EM&gt;; Published online, August 8 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285616</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp10.pdf]]&gt;</url>
    <title>Coagulase test (BSOP TP10)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CARDIOVASCULAR,BODY PART AFFECTED,BLOOD AND BODY FLUIDS,INFECTIONS,BACTERIA,MICROORGANISM,STAPHYLOCOCCUS,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>308929</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ijdvl.com/temp/ijdvl743194-389237_104843.pdf]]&gt;</url>
    <title>Co-infection with human immunodeficiency virus and tuberculosis.</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Indian Association of Dermatologists, Venereologists &amp; Leprologists</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The World Health Organisation (WHO) declared the global tuberculosis (TB) epidemic to be a public health emergency in 1993. Despite signs that the epidemic may be slowing down, the actual number of TB cases continues to rise.[sup] [1] HIV and TB are closely associated; HIV promotes the progression from latent TB infection to active disease and TB is the leading infectious killer of people living with HIV. The fight against HIV/AIDS and TB remains among the higher priorities for WHO.]]&gt;</body>
  </document>
  <document>
    <id>285617</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w4.pdf]]&gt;</url>
    <title>Colony count by the pour plate method (W4)</title>
    <publicationDate>2004-08-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285618</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/infect/commoneye/resources/merec_bulletin_vol17_no3_common_cold.pdf]]&gt;</url>
    <title>Common Cold: MeReC Bulletin</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>NHS</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,AIRBORNE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIOUS DISEASES,INFECTIONS,COMMON COLD,RHINOVIRUS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This bulletin looks at the management of common infections, such as the common cold, in primary care. It considers which patients are likely to benefit from antibiotic treatment, either because their symptoms are probably due to bacterial infection rather than viral infection, or because they are at risk of complications from the infection. The evidence to support antibiotic treatment, symptomatic treatment and delayed prescriptions is discussed.]]&gt;</body>
  </document>
  <document>
    <id>285620</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/eid/content/13/2/pdfs/236.pdf]]&gt;</url>
    <title>Community-associated Methicillin resistant Staphylococcus aureus Isolates Causing Healthcare associated Infections</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Centers for Disease Control and Prevention</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,TREATMENT,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The authors noted a marked increase in healthcare-associated (HA) methicillin-resistant Staphylococcus aureus (MRSA) infections caused by isolates phenotypically consistent with
community-associated (CA)-MRSA strains. To study this trend, they retrospectively examined all HA-MRSA isolates from patients in their institution during 1999–2004. 

Antimicrobial drug-susceptibility phenotype and genotype were consistent in 21 (91%) of 23 isolates. In conclusion, MRSA isolates phenotypically similar to CA strains have become the predominant isolates associated with HA-MRSA in this hospital.]]&gt;</body>
  </document>
  <document>
    <id>308630</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/reprint/44/2/350?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=Marjamaki+&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis.</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>American Society for Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,DIAGNOSIS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Two commercially available DNA line probe assays, Genotype MTBDR and INNO-LiPA Rif. TB, were evaluated for their abilities to detect resistance to isoniazid (INH) and rifampin (RIF) in 52 Mycobacterium tuberculosis isolates. The test results were compared to those obtained by phenotypic drug susceptibility testing and sequencing. Compared to the results of phenotypic drug susceptibility testing, the Genotype MTBDR test results were concordant for INH for 47 of the 52 (90.4%) isolates, and both the Genotype MTBDR and the INNO-LiPA Rif. TB test results were concordant for RIF for 51 of the 52 (98.1%) isolates. The Genotype MTBDR test results correlated with the sequencing results for 48 of the 52 (92.3%) isolates and the INNO-LiPA&lt;BR&gt;Rif. TB results for 50 of the 52 (96.2%) isolates. Both assays are useful for the rapid screening of M. tuberculosis isolates obtained from patients suspected of having multidrug-resistant tuberculosis, but the GenoType MTBDR assay has the advantage of being able to detect resistance to both INH and RIF simultaneously.]]&gt;</body>
  </document>
  <document>
    <id>285623</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/mmwr/PDF/rr/rr5309.pdf]]&gt;</url>
    <title>Compendium of Animal Rabies Prevention and Control, 2004: National Association of State Public Health Veterinarians, Inc. (NASPHV)</title>
    <publicationDate>2004-06-25T00:00:00</publicationDate>
    <publisher>Morbidity and Mortality Weekly Report (MMWR)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,CONTACT,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ "Rabies is a fatal viral zoonosis and a serious public health problem (1). The purpose of this compendium is to provide information to veterinarians, public health officials, and others concerned with rabies prevention and control. These recommendations serve as the basis for animal rabies-control programs throughout the United States and facilitate standardization of procedures among jurisdictions, thereby contributing to an effective national rabies-control program. This document is reviewed annually and revised as necessary. Parenteral vaccination procedure recommendations are contained in Part I; Part II details the principles of rabies control; all animal rabies vaccines licensed by the United States Department of Agriculture (USDA) and marketed in the United States are listed in Part III. 
The material in this report originated in the National Center for Infectious Diseases, James M. Hughes, M.D., Director, and the Division of Viral and Rickettsial Diseases, James W. LeDuc, Ph.D., Director. "
]]&gt;</body>
  </document>
  <document>
    <id>285625</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop18.pdf]]&gt;</url>
    <title>Complement fixation tests (VSOP 18)</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>308571</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?author=Munseri&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;SETTING&lt;/STRONG&gt;: Isoniazid preventive therapy (IPT) has not been widely implemented due to questions about acceptance, adherence and side effects. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To examine factors related to completion of IPT among human immunodeficiency virus (HIV) infected subjects in Tanzania. DESIGN: HIV-infected subjects in the DarDar TB vaccine trial with CD4 cell counts &amp;gt;or=200 cells/mm(3) and a positive tuberculin skin test (TST) were counseled, offered IPT for 6 months and seen monthly.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Among 1932 subjects, TST results were positive in 631 (33%): 568 (90%) were offered IPT, 565 (99%) accepted and three (&amp;lt;1%) refused. Of the 565 subjects who accepted IPT, 493 (87%) completed treatment and 72 (13%) did not. Non-completion was physician-initiated in 24 (33%, due to active TB or side effects), patient-initiated in 42 (58%, due to self-cessation or loss to follow-up) and due to death in 6 (8%, unrelated to IPT). Interviews were conducted among 109 completers and 20 non-completers (12 physician- and 8 patient-initiated). Completers were motivated by fear of TB (44%), understanding&amp;nbsp; the importance of IPT (32%) and counseling (22%). Patient-initiated non-completers were dissuaded by stigma (58%), side effects (14%) and travel distance (1%). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: HIV-infected subjects provided with counseling,&lt;BR&gt;monthly follow-up and travel reimbursement have high rates of IPT completion with minimal side effects.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394183</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.jiasociety.org/content/pdf/1758-2652-13-34.pdf]]&gt;</url>
    <title>Concurrent sexual partnerships do not explain the HIV epidemics in Africa: a systematic review of the evidence</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The notion that concurrent sexual partnerships are especially common in sub-Saharan Africa and explain the region's high HIV prevalence is accepted by many as conventional wisdom. In this paper, we evaluate the quantitative and qualitative evidence offered by the principal proponents of the concurrency hypothesis and analyze the mathematical model they use to establish the plausibility of the hypothesis.We find that research seeking to establish a statistical correlation between concurrency and HIV prevalence either finds no correlation or has important limitations. Furthermore, in order to simulate rapid spread of HIV, mathematical models require unrealistic assumptions about frequency of sexual contact, gender symmetry, levels of concurrency, and per-act transmission rates. Moreover, quantitative evidence cited by proponents of the concurrency hypothesis is unconvincing since they exclude Demographic and Health Surveys and other data showing that concurrency in Africa is low, make broad statements about non-African concurrency based on very few surveys, report data incorrectly, report data from studies that have no information about concurrency as though they supported the hypothesis, report incomparable data and cite unpublished or unavailable studies. Qualitative evidence offered by proponents of the hypothesis is irrelevant since, among other reasons, there is no comparison of Africa with other regions.Promoters of the concurrency hypothesis have failed to establish that concurrency is unusually prevalent in Africa or that the kinds of concurrent partnerships found in Africa produce more rapid spread of HIV than other forms of sexual behaviour. Policy makers should turn attention to drivers of African HIV epidemics that are policy sensitive and for which there is substantial epidemiological evidence.]]&gt;</body>
  </document>
  <document>
    <id>308975</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.jci.org/articles/view/34614/pdf]]&gt;</url>
    <title>Confronting the scientific obstacles to global control of tuberculosis.</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>The American Society for Clinical Investigation</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MARCH 09,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB) is a major threat to global health, recently exacerbated by the emergence of highly drug-resistant forms of the disease-causing pathogen and synergy with HIV/AIDS. In 2006, the Stop TB Partnership published “The global plan to stop TB: 2006–2015,” which set out a vision of halving the prevalence of and mortality caused by the disease by 2015, followed by eliminating the disease as a public health problem by 2050. This vision depends on the development of improved diagnostics, simpler treatment, and more effective vaccination. Recently, active translational research pipelines directed toward each of these goals have been established, but improved understanding of the fundamental biology of this complex disease will prove to be the key to radical advances in TB control.]]&gt;</body>
  </document>
  <document>
    <id>285627</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947407702]]&gt;</url>
    <title>Control of diphtheria: Guidance for Consultants in Communicable Disease Control</title>
    <publicationDate>1999-12-04T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,DIPHTHERIA,DIPHTHERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines for the control and management of diphtheria are intended for consultants in communicable disease control and regional epidemiologists in England and Wales. They are intended to complement existing guidelines from WHO. The guidelines cover the immediate steps to be taken following identification of a case, what is required to confirm the diagnosis, steps to be taken to minimise the likelihood of further linked cases, and what should be done to disseminate information after a case. Appendix 2 is an Information Sheet for contacts of a case. &lt;/P&gt;
&lt;P&gt;Publication history information: Guideline published more than 5 years ago, but publisher has confirmed the guideline's continued validity (March 2005).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285628</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6WJP-4C1FC92-5-1&amp;_cdi=6884&amp;_user=910131&amp;_orig=search&amp;_coverDate=04/30/2004&amp;_qd=1&amp;_sk=999439995&amp;view=c&amp;wchp=dGLbVlz-zSkWb&amp;md5=52ca742557126acf5ada1b980ac0f89d&amp;ie=/sdarticle.pdf]]&gt;</url>
    <title>Control of endemic MRSA - what is the evidence? A personal view</title>
    <publicationDate>2004-01-23T00:00:00</publicationDate>
    <publisher>Journal of Hospital Infection</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BLOOD AND BODY FLUIDS,CONTACT,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,INFECTIONS,TREATMENT,MICROORGANISM,BACTERIA,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper highlights that there is only limited literature regarding the control of endemic MRSA. It indicates that introduction of measures to control MRSA outbreaks in hospitals may not be generalisable to other settings and that minimum effective measure required to contain MRSA are not known. This paper provides a review of the literature including observational studies and RCTs and indicates that further well-designed studies are required. ]]&gt;</body>
  </document>
  <document>
    <id>285630</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdr/archives/CDRreview/1995/cdrr1395.pdf]]&gt;</url>
    <title>Control of meningococcal disease : guidance for consultants in communicable disease control</title>
    <publicationDate>1995-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,CENTRAL NERVOUS SYSTEM,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,NEISSERIA MENINGITIDIS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These guidelines are intended to form a basis for developing professional audit in liaison with microbiologists and clinicians. cover the following topics: what emergency actions are reasonable to reduce the risk of morbidity and mortality; what is required to confirm the diagnosis; what steps should be taken to minimise the likelihood of further linked cases; what should be done to disseminate information after a case; how to manage clusters of cases.
Publication history information: Guideline published more than 5 years ago, but publisher has confirmed the guideline's continued validity (March 2005).]]&gt;</body>
  </document>
  <document>
    <id>285631</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/327/7425/1177]]&gt;</url>
    <title>Controlling methicillin resistant Staphylococcus aureus</title>
    <publicationDate>2003-11-22T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,CARDIOVASCULAR,CONTACT,INFECTIONS,MICROORGANISM,BACTERIA,STAPHYLOCOCCUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS AUREUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Methicillin resistant Staphylococcus aureus (MRSA) is a major cause of hospital acquired infection worldwide, posing a growing threat to public health. It belongs to a species of ubiquitous and versatile organisms that are continually adapting to new antimicrobial and environmental challenges, often through gene transfers even from distantly related organisms such as vertebrates. Why is MRSA important? Some strains are eminently transmissible, resulting in large numbers of infections in hospitals. Bacteraemia data for England and Wales show that MRSA as a proportion of total Staphylococcus aureus bacteraemias rose from under 2% in 1990 to 42% in 2000 one of the highest reported rates in Europe. ]]&gt;</body>
  </document>
  <document>
    <id>285632</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/content/short/297/20/2251]]&gt;</url>
    <title>Controversies and Misconceptions in Malaria Chemoprophylaxis for Travelers</title>
    <publicationDate>2007-05-23T00:00:00</publicationDate>
    <publisher>Journal of American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,MALARIA,INFECTIONS,TRAVEL ASSOCIATED INFECTIONS,MOSQUITO,PARASITES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Context:  Controversies in malaria prevention arise from the absence of data, conflicting data between different studies, conflicting recommendations, deviation of local practice from scientific data, and varying risk thresholds. Misconceptions about the seriousness of malaria, the tolerability of chemoprophylaxis drugs, and the efficacy and safety of repellents contribute to the controversies. 

Objectives:  To compare several national guidelines on malaria chemoprophylaxis to identify variations in recommendations. We reviewed studies on tolerability of mefloquine with particular focus on its neuropsychiatric adverse effects and influence on performance. We also describe why most recommended chemoprophylactic regimens fail to prevent relapses of Plasmodium vivax malaria and review available options. 

Evidence Acquisition:  We searched scientific publications in MEDLINE via PubMED for relevant articles with a cutoff date of December 2006 using the search terms malaria, chemoprophylaxis, travel, mefloquine, neuropsychiatric adverse events, tolerability, vivax malaria, and primaquine. Additional references were obtained from bibliographies of the selected articles. There were no language restrictions. 

Evidence Synthesis:  Gaps and conflicts exist among current guidelines. Health authorities vary in the chemoprophylaxis drugs they recommend, the indications for continuous prophylaxis vs no prophylaxis, and the use of standby emergency treatment. Despite widespread reports on the adverse effects of mefloquine, controlled studies found that serious neuropsychiatric adverse events occur at rates comparable with or lower than other chemoprophylaxis drugs. Moreover, mefloquine does not appear to impair performance while driving, flying, or diving. Vivax malaria causes significant illness in travelers, but current first-line chemoprophylaxis agents do not prevent relapses of vivax malaria. Although not licensed in most countries as primary prophylaxis, primaquine effectively prevents relapses of vivax malaria. 

Conclusions:  Prevention of malaria in travelers requires detailed knowledge of malaria epidemiology and host-vector-parasite interactions. Decisions are complicated by a lack of standardized recommendations, controversies, and misconceptions. Improved international consensus is indicated to minimize conflicting guidelines, clarify controversies, and promote adherence to preventive measures.]]&gt;</body>
  </document>
  <document>
    <id>285634</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T1B-48CW83Y-7&amp;_user=910131&amp;_coverDate=04%2F19%2F2003&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=e5b5da4c39325f0c86833d0a77045bc7]]&gt;</url>
    <title>Coronavirus as a possible cause of severe acute respiratory syndrome</title>
    <publicationDate>2003-04-19T00:00:00</publicationDate>
    <publisher>The Lancet</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MICROORGANISM,SARS CORONA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ An outbreak of severe acute respiratory syndrome (SARS) was reported in Hong Kong. This paper investigates the viral cause and clinical presentation among 50 patients.]]&gt;</body>
  </document>
  <document>
    <id>285637</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.38181.482222.55]]&gt;</url>
    <title>Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis</title>
    <publicationDate>2004-08-28T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CARDIOVASCULAR,BLOOD AND BODY FLUIDS,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective To assess the effects of corticosteroids on mortality in patients with severe sepsis and septic shock. 

Data sources Randomised and quasi-randomised trials of corticosteroids versus placebo (or supportive treatment alone) retrieved from the Cochrane infectious diseases group's trials register, the Cochrane central register of controlled trials, Medline, Embase, and LILACS. 

Review method Two pairs of reviewers agreed on eligibility of trials. One reviewer entered data on to the computer and four reviewers checked them. We obtained some missing data from authors of trials and assessed methodological quality of trials. 

Results 16/23 trials (n = 2063) were selected. Corticosteroids did not change 28 day mortality (15 trials, n = 2022; relative risk 0.92, 95% confidence interval 0.75 to 1.14) or hospital mortality (13 trials, n = 1418; 0.89, 0.71 to 1.11). There was significant heterogeneity. Subgroup analysis on long courses ( 5 days) with low dose ( 300 mg hydrocortisone or equivalent) corticosteroids showed no more heterogeneity. The relative risk for mortality was 0.80 at 28 days (five trials, n = 465; 0.67 to 0.95) and 0.83 at hospital discharge (five trials, n = 465, 0.71 to 0.97). Use of corticosteroids reduced mortality in intensive care units (four trials, n = 425, 0.83, 0.70 to 0.97), increased shock reversal at 7 days (four trials, n = 425; 1.60, 1.27 to 2.03) and 28 days (four trials, n = 425, 1.26, 1.04 to 1.52) without inducing side effects. 

Conclusions For all trials, regardless of duration of treatment and dose, use of corticosteroids did not significantly affect mortality. With long courses of low doses of corticosteroids, however, mortality at 28 days and hospital morality was reduced. ]]&gt;</body>
  </document>
  <document>
    <id>285639</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/322970]]&gt;</url>
    <title>Counterpoint: Invasive Aspergillosis and the Environment - Rethinking Our Approach to Prevention</title>
    <publicationDate>2001-11-01T00:00:00</publicationDate>
    <publisher>University of Chicago Press</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,MICROORGANISM,FUNGI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Preventive measures are important in the control of invasive aspergillosis (IA) because diagnosis is difficult and the outcome of treatment is poor. If effective strategies are to be devised, it will be essential to have a clearer understanding of the sources and routes of transmission of Aspergillus species. Nosocomial outbreaks of IA highlight the fact that Aspergillus spores are common in the hospital environment. However, in general, such outbreaks are uncommon. Most cases of IA are sporadic in nature, and many of them are now being acquired outside of the hospital setting. Housing patients in high-energy particulate airfiltered hospital rooms helps prevent IA, but it is feasible and cost-effective only for the highest-risk groups and for limited periods. Control measures, which are designed to protect patients from exposure to spores outside the hospital, are even more difficult. Nevertheless, now that high-risk patients are spending more time outside of the hospital, the cost benefits of antifungal prophylaxis and other preventive measures require careful evaluation.]]&gt;</body>
  </document>
  <document>
    <id>392792</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/q61l6r176qq0vp20/fulltext.pdf]]&gt;</url>
    <title>Couples-focused behavioral interventions for prevention of HIV: systematic review of the state of evidence</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RELATIONSHIPS,POPULATIONS,MANAGEMENT &amp; INTERVENTIONS,SEXUAL HEALTH,INDIVIDUAL BEHAVIOUR,OUTCOMES,DETERMINANTS,PUBLIC HEALTH,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,MONTHLY ADDITIONS,PREVENTION,PERSONAL RELATIONSHIPS,HEALTHCARE &amp; HEALTH SERVICES,COMMUNICABLE DISEASES,HIV INFECTION,SERVICES,THERAPY,POPULATION BASED &amp; PREVENTATIVE SERVICES,INFECTION CONTROL,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,NOVEMBER 2010,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ HIV is frequently transmitted in the context of partners in a committed relationship, thus couples-focused HIV prevention interventions are a potentially promising modality for reducing infection. We conducted a systematic review of studies testing whether couples-focused behavioral prevention interventions reduce HIV transmission and risk behavior. We included studies using randomized controlled trial designs, quasi-randomized controlled trials, and nonrandomized controlled studies. We searched five electronic databases and screened 7,628 records. Six studies enrolling 1,084 index couples met inclusion criteria and were included in this review. Results across studies consistently indicated that couples-focused programs reduced unprotected sexual intercourse and increased condom use compared with control groups. However, studies were heterogeneous in population, type of intervention, comparison groups, and outcomes measures, and so meta-analysis to calculate pooled effects was inappropriate. Although couples-focused approaches to HIV prevention appear initially promising, additional research is necessary to build a stronger theoretical and methodological basis for couples-focused HIV prevention, and future interventions must pay closer attention to same-sex couples, adolescents, and young people in relationships.]]&gt;</body>
  </document>
  <document>
    <id>330341</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?title=Current+and+future+antiretroviral+treatment+option&amp;]]&gt;</url>
    <title>Current and Future Antiretroviral Treatment Options in Paediatric HIV Infection</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>Adis International</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,ANTIVIRALS,ANTIMICROBIALS,INFECTIONS,TREATMENT,POPULATION GROUPS,CHILDREN,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Because of a lack of prevention policies or problems in implementing prevention of mother-to-child transmission (P-MTCT), most of the 1500 daily new HIV infections in children aged&amp;lt;15 years are caused by MTCT. Fifteen percent of all HIV-infected individuals are children, but the vast majority lack access to highly active antiretroviral therapy (HAART), which can drastically reduce morbidity and mortality. There are 22 antiretroviral drugs currently approved by the US FDA for use in the treatment of HIV-infected adults and adolescents, but only 12 of these drugs are approved for use in children. Antiretroviral drugs belong to four major classes: nucleoside and nucleotide analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and fusion inhibitors. According to international guidelines developed by organizations including WHO, the Paediatric European Network for Treatment of AIDS (PENTA) and the US National Institutes of Health (US-NIH), the treatment of choice for HIV-infected children and adults is a combination of two NRTIs (backbone treatment) plus a third potent agent from a different class, either an NNRTI or a ritonavir-boosted protease inhibitor. There are specific challenges in treating HIV-infected children, including uncertainty about the best time to start treatment, the need for more paediatric formulations, the lack of pharmacokinetic studies for new drugs, and incomplete dosing guidelines. Furthermore, the most appropriate regimen for an individual child depends on a variety of factors, including the age of the child; the availability of appropriate drug formulations; the potency, complexity and toxicity of the drug regimen; the home situation; the child and caregiver's ability to adhere to the regimen; and the child's antiretroviral treatment history. In addition, antiretroviral drugs are not licensed for all age groups and the drugs are often not affordable. This review describes NNRTI and protease inhibitors as key components of first- and second-line antiretroviral therapy (ART), focusing on the rationale for choosing an NNRTI- versus protease inhibitor-based regimen based on the results of available phase II and III studies. Some of the new agents available for children as second-line and salvage therapy both on- and off-label are also discussed. The drug regimens described in this review are relevant to clinicians in developed and developing countries. The availability of new, potent compounds with different resistance and toxicity profiles may represent an alternative option to interclass switching and could redefine ART strategy, including the option of first-line NRTI-sparing regimens.]]&gt;</body>
  </document>
  <document>
    <id>330559</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.lww.com/co-hivandaids/Abstract/2009/07000/Current_issues_in_prevention_of_mother_to_child.16.aspx]]&gt;</url>
    <title>Current issues in prevention of mother-to-child transmission of HIV-1</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,PREGNANT WOMEN,POPULATION GROUPS,CHILDREN,ADULTS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Purpose of review&lt;/STRONG&gt;: To review new evidence in prevention of mother-to-child-transmission of HIV-1, which establishes, in principle, the feasibility of greatly improved effectiveness in developing countries. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recent findings&lt;/STRONG&gt;: This review presents evidence that demonstrates that a large gap in prevention of mother-to-child-transmission [MTCT] is being increasingly bridged. Recent studies have addressed issues on postnatal transmission of HIV-1 through breastfeeding. Breastfeeding transmission affects the majority of HIV-infected pregnant women and children in the world and who live in Africa and are often poor. Prevention of unwanted pregnancies in all women living in high HIV prevalence regions will probably reduce the risk of HIV-positive pregnancies. These studies demonstrate the success of the following three types of interventions: primary prevention of HIV-1 in women;prophylaxis with antiretroviral drugs in breastfeeding infants;prophylaxis with antiretroviral drugs for lactating mothers.It is also clear that key barriers to implementing these findings in developing countries are weak and ineffectual health systems. Therefore, identifying needs for improving health service delivery are critical; an example of the synergy between prevention and treatment through integrated services is given. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: Recent data on primary prevention of HIV-1 in women of child-bearing age, and use of antiretrovirals in breastfeeding infants and lactating mothers, report successful interventions for the prevention of breastfeeding transmission of HIV-1. Health infrastructure improvement in developing countries is central to the application of research findings to implementation of MTCT programmes.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308970</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6TD4-4N2M5DT-3-1&amp;_cdi=5188&amp;_user=855288&amp;_orig=browse&amp;_coverDate=05%2F10%2F2007&amp;_sk=999749980&amp;view=c&amp;wchp=dGLbVlW-zSkzS&amp;md5=e5c7843d7330f9fb7617c190fb37806b&amp;ie=/sdarticle.pdf]]&gt;</url>
    <title>Current status of TB vaccines.</title>
    <publicationDate>2007-01-29T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,VACCINES / IMMUNISATION,INFECTIONS,PREVENTION,MYCOBACTERIUM,TUBERCULOSIS,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM TUBERCULOSIS,BCG,MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ During last 10 years, there has been extensive work for the development of potential tuberculosis vaccine candidates using the mice and guinea pig models. Though till date several promising candidates have been identified and at least eight vaccines have entered clinical evaluation. These recent advances in the clinical testing of new TB vaccines are very exciting and promising. However, there is a need to continue the search for additional vaccine candidates or vaccination strategies.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>285644</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop2.pdf]]&gt;</url>
    <title>Cystine lactose electrolyte deficient (CLED) agar (MSOP 2)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285645</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop28.pdf]]&gt;</url>
    <title>Cytomegalovirus serology (VSOP 28)</title>
    <publicationDate>2007-10-12T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,MICROORGANISM,CYTOMEGALOVIRUS (CMV),VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285949</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1197637044441]]&gt;</url>
    <title>Deliberate and Accidental Releases</title>
    <publicationDate>2003-04-30T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ZOONOSES,ANTHRAX,SMALLPOX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The term "deliberate release" refers to any intentional spread of a biological or chemical agent, such as might occur in a biowarfare or bioterrorist incident. A release may be overt, i.e., is clearly identifiable. There may have been a prior warning, or the release may be apparent, either due to the use of an explosive device, or because a suspicious substance is obviously visible. Alternatively a release may be covert, with a concealed release of a biological or chemical agent. In these circumstances, the release will not become apparent until the first cases of disease arise.]]&gt;</body>
  </document>
  <document>
    <id>285647</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/jinf.2001.0802]]&gt;</url>
    <title>Dengue and Other Emerging Flaviviruses</title>
    <publicationDate>2001-02-01T00:00:00</publicationDate>
    <publisher>Journal of Infection</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,BRAIN AND SPINAL CORD INFECTIONS,DENGUE FEVER,WEST NILE FEVER,TRAVEL ASSOCIATED INFECTIONS,ZOONOSES,TICKS,ENCEPHALITIS,TRAVELLERS,ADULTS,TICK-BORNE ENCEPHALITIS,JAPANESE ENCEPHALITIS,POPULATION GROUPS,MICROORGANISM,TRAVEL VACCINES,MOSQUITO,PARASITES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Flaviviruses are among the most important emerging viruses known to man. Most are arboviruses (arthropod-borne) being transmitted by mosquitoes or ticks. They derived from a common ancestor 10–20000 years ago and are evolving rapidly to fill new ecological niches. Many are spreading to new geographical areas and causing increased numbers of infections. Traditionally, three clinical syndromes are recognized: fever-arthralgia-rash, viral haemorrhagic fever, and neurological disease, though for some flaviviruses the disease pattern is changing. Dengue, the most important flavivirus, is transmitted between humans by Aedes mosquitoes. Recent work is elucidating the pathogenesis of its most severe form, dengue haemorrhagic fever. Yellow fever, which has epidemiological similarities to dengue, was under control in the mid-20th century, but is once again increasing. Japanese encephalitis virus is numerically the most important cause of epidemic encephalitis; its geographical area is expanding despite the availability of vaccines. Other mosquito-borne neurotropic flaviviruses with clinical and epidemiological similarities are found across the globe. These include St Louis encephalitis virus, Murray Valley encephalitis virus, and West Nile virus, which recently reached the Americas for the first time. In cooler northern climates ticks are more important vectors. Tick-borne encephalitis virus occurs across large parts of Eastern Europe and the Commonwealth of Independent states. The tick-borne haemorrhagic flaviviruses, Omsk haemorrhagic fever and Kyasanur Forrest disease are localized in small areas.]]&gt;</body>
  </document>
  <document>
    <id>285650</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp12.pdf]]&gt;</url>
    <title>Deoxyribonuclease test (BSOP TP12)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285652</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/MeningitisC/fs/en]]&gt;</url>
    <title>Department of Health webpage on Meningitis C</title>
    <publicationDate>2001-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENINGOCOCCAL MENINGITIS,CONTACT,TRANSMISSION MODE,INFECTIONS,VACCINE PREVENTABLE DISEASES,INFECTIOUS DISEASES,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The UK was the first country to introduce the meningitis C conjugate (MenC) vaccine. Since 1999, the MenC vaccine has been part of the routine childhood immunisation programme and uptake levels have been close to 90%. The programme, targeted at under-20 year olds, has been a huge success, with a 90% reduction in cases in that age group. However, young adults between 20 and 24 years of age and all first year college and university students are still at risk and should be vaccinated. ]]&gt;</body>
  </document>
  <document>
    <id>285653</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/F18.pdf]]&gt;</url>
    <title>Detection and Enumeration of Enterobacteriaceae (F18)</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285654</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w13.pdf]]&gt;</url>
    <title>Detection and enumeration of Legionella species by centrifugation (W13)</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285655</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w12.pdf]]&gt;</url>
    <title>Detection and enumeration of Legionella species by filtration and centrifugation (W12)</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285656</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w14.pdf]]&gt;</url>
    <title>Detection and enumeration of Legionella species by positive pressure membrane filtration (W14)</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285657</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w15.pdf]]&gt;</url>
    <title>Detection and enumeration of Legionella species in biofilms and sediments (W15)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285658</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f19.pdf]]&gt;</url>
    <title>Detection and Enumeration Of Listeria Monocytogenes And Other Listeria Species (F19)</title>
    <publicationDate>2007-12-13T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIOUS DISEASES,INFECTIONS,LISTERIOSIS,BACTERIA,LISTERIA MONOCYTOGENES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The method described is applicable to the detection and enumeration of Listeria monocytogenes and other Listeria species in all food types including milk and dairy products and in environmental swabs. &lt;/P&gt;
&lt;P&gt;Background: European legislation containing microbiological food safety criteria for L. monocytogenes came into force in England on 11.1.06. These criteria either specify absence in 25g of sample or a level below 100 colony forming units (cfu) per gram at any point in the shelf life of the ready-to-eat food. L.monocytogenes results exceeding the food safety criteria are judged to be legally unsatisfactory. There is also a requirement for producers of ready-to-eat foods that may pose a L. monocytogenes risk to public health to swab the food processing areas and equipment for the presence of L. monocytogenes as part of their sampling scheme. &lt;/P&gt;
&lt;P&gt;Current PHLS/HPA guidelines for most ready-to-eat foods contain guideline criteria for total Listeria species. The presence of species of Listeria other than L. monocytogenes is used to indicate the likelihood that L. monocytogenes may also be present in other parts of the batch of food or environment. Samples containing more than 100 cfu of other Listeria species are considered unsatisfactory and their presence above this level requires investigation. &lt;/P&gt;
&lt;P&gt;In order to assess the level of contamination in these foods direct enumeration of the organism is carried out on solid selective media. In some ready-to-eat foods such as soft ripened cheeses, pâtés and vacuum or modified atmosphere packed cooked meats with a long assigned shelf life, the very presence of Listeria is significant due to the organism’s ability to multiply to significant levels during refrigerated storage. For these foods, an enrichment procedure is also required to determine presence or absence in a defined quantity of food. &lt;/P&gt;
&lt;P&gt;The method described is based on BS EN ISO 11290 parts 1 and 2. These are internationally recognised horizontal methods for the detection and enumeration of L. monocytogenes. A chromogenic isolation medium is used that results in the formation of blue-green colonies by Listeria species due to the ß-glucosidase activity of these bacteria. Further distinction between the species is obtained by the inclusion of phosphatidylinositol or lecithin7-9 which is hydrolysed by the phospholipase enzyme produced by L. monocytogenes and L. ivanovii but not other Listeria species to produce an opaque halo around the colony. &lt;/P&gt;
&lt;P&gt;This method differs from the current ISO 11290-1 and 11290-2 in a number of minor ways. However both these ISO methods are currently under review. The significant differences between the procedures described in F19 and the proposed revised ISO methods are that only one isolation agar is specified in F19 for the detection method and the volume to be applied to the agar for enumeration in F19 is 0.5 mL per plate instead of 0.1 mL (or 1 mL across three 140 mm plates).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285660</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f21.pdf]]&gt;</url>
    <title>Detection of Campylobacter species (F21)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FAECAL/ORAL,FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,CAMPYLOBACTER,INFECTIOUS DISEASES,BACTERIA,CAMPYLOBACTER,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scope:&lt;BR&gt;The method described is applicable to the detection of thermotolerant Campylobacter species in all food types and environmental samples including swabs.&lt;/P&gt;
&lt;P&gt;Background:&lt;BR&gt;Campylobacter species (C. jejuni, C. coli and C. lari,) are the most frequently identified agents of acute infective diarrhoea in most developed countries. Consequently, the detection of Campylobacter species in a 25 g sample of a ready-to-eat food is considered to be significant2. Poultry and raw milk are common sources of infection. Food treatments, such as heating, freezing or chilling can cause sub-lethal injury to Campylobacter species, resulting in increased sensitivity to some antibiotics and lowered resistance to elevated incubation temperatures. The enrichment culture method described uses Bolton broth which allows resuscitation and recovery of injured organisms. The method is based on ISO 10272-13 and is also recommended by the Food and Drugs Administration4. It will detect strains of Campylobacter that are capable of growth at 41.5°C; these include C. jejuni, C. coli and C. lari but usually not C. fetus, the organism associated with abortion in cattle and sheep.&lt;/P&gt;
&lt;P&gt;This method follows ISO 10272-1 for isolation of Campylobacter but does not use a second isolation medium. The confirmation tests used are similar to those specified in ISO 10272-1 but include an optional latex agglutination test. The test for growth at 25°C has not been included.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285659</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w8.pdf]]&gt;</url>
    <title>Detection of Campylobacter species in water (W8)</title>
    <publicationDate>2007-10-24T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,FAECAL/ORAL,INFECTIONS,CAMPYLOBACTER,MICROORGANISM,CAMPYLOBACTER,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The method described is applicable to the detection of thermotolerant Campylobacter species in all types of water. &lt;/P&gt;
&lt;P&gt;Background: Water is potentially an important reservoir of campylobacters and is an established vehicle for the transmission of these organisms to man and domestic animals. Waterborne outbreaks of Campylobacter enteritis have been reported from various countries. Potable water supplies can become contaminated with campylobacters, but natural waters including rivers and coastal waters may be used for recreational purposes and may present potential risks. As campylobacters are a major cause of gastroenteritis it may occasionally be necessary to examine samples of water as part of epidemiological investigations or as part of local authority surveillance programmes. This method is based on that described in the Microbiology of Drinking Water 2002 and ISO/DIS 17995 – Water Quality – Detection and enumeration of thermotolerant Campylobacter species. Enrichment procedures using Bolton broth and Preston broth are included because studies within the HPA London Food Water and Environmental Laboratory have shown that Bolton broth permits the detection of Campylobacter species from clean waters but the more selective Preston broth is better for detection from dirty waters. &lt;/P&gt;
&lt;P&gt;Information note 1: The selective supplements used in these media have been modified by some commercial suppliers by replacing cycloheximide with amphotericin and renaming them as ‘Modified’. However the enrichment broths in principle are unchanged and the initial nomenclature of “Bolton broth” and “Preston broth“ has been retained in this SOP. The terminology “Modified Preston broth” is also used for Preston broth with the addition of cefoperazone which is also known as Exeter broth. The formulation of Exeter broth with cefoperazone has not been used in this method. &lt;/P&gt;
&lt;P&gt;Information note 2: This method can be used to obtain a semi-quantitative result by using multiple volumes. ISO 8199:2005 recommends the use of five or more parallel tubes (100mL volumes).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285662</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w16.pdf]]&gt;</url>
    <title>Detection of E. coli O157 (W16)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CONTACT,FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,INSECT BITE,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285661</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f17.pdf]]&gt;</url>
    <title>Detection of Escherichia coli o157 by Immunomagnetic Bead Separation (F17)</title>
    <publicationDate>2005-05-12T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,ESCHERICHIA COLI INFECTION,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,FAECAL/ORAL,CONTACT,INFECTIONS,MICROORGANISM,E. COLI,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;SCOPE OF DOCUMENT&lt;BR&gt;The method described is applicable to the detection of Escherichia coli O157 in all food types and&lt;BR&gt;environmental samples.&lt;/P&gt;
&lt;P&gt;BACKGROUND&lt;BR&gt;Escherichia coli O157 that produces vero-cytotoxin is an important foodborne pathogen causing&lt;BR&gt;symptoms ranging from mild diarrhoea to haemorrhagic colitis and haemolytic uraemic syndrome.&lt;/P&gt;
&lt;P&gt;Many outbreaks and sporadic cases have been associated with consumption of undercooked beef or&lt;BR&gt;dairy products such as untreated milk. However, infections due to E. coli O157 are increasing and a wide&lt;BR&gt;range of foods have been associated with outbreaks. These include cooked meat products, vegetables,&lt;BR&gt;salad vegetables, coleslaw, and acid based foods such as mayonnaise, apple cider, yoghurt and&lt;BR&gt;fermented sausages. Microbiological guidelines for ready-to-eat foods2 recommend the absence of&lt;BR&gt;E. coli O157 in 25 g. Specific tests for E. coli O157 are usually carried out on selected foods eg foods&lt;BR&gt;implicated in outbreaks and those submitted in surveys.&lt;/P&gt;
&lt;P&gt;Unlike most other strains of E. coli, the majority of O157 strains do not ferment sorbitol within 24 hours&lt;BR&gt;and are ß glucuronidase negative. However variant strains of E. coli O157 have been reported that are&lt;BR&gt;sorbitol and ß glucuronidase positive. Detection of E. coli O157 in foods has proved difficult but the&lt;BR&gt;methods described in this document have successfully isolated the organism from naturally contaminated&lt;BR&gt;and artificially inoculated foods. Vero-cytotoxin producing strains of E. coli O157 (VTEC) cause&lt;BR&gt;potentially serious illness in humans; they have a low infective dose and laboratory acquired infections&lt;BR&gt;have been reported. Therefore isolation and identification of these organisms must be carried out by&lt;BR&gt;trained laboratory personnel in properly equipped laboratories, under the control of a qualified&lt;BR&gt;microbiologist (see section 3 – Safety Considerations).&lt;/P&gt;
&lt;P&gt;The method has been derived from the work of two groups3-5 and involves analysis for the presence of&lt;BR&gt;E. coli O157 in 25 g of sample. It is very similar to BS EN ISO 16654:20016 but differs in that&lt;BR&gt;immunomagnetic separation is automated (for safety reasons as well as efficiency) and only one isolation&lt;BR&gt;agar is specified.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285663</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f13.pdf]]&gt;</url>
    <title>Detection of Salmonella species (F13)</title>
    <publicationDate>2008-07-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,FAECAL/ORAL,INFECTIONS,SALMONELLA,MICROORGANISM,BACTERIA,SALMONELLA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The method described is applicable to the detection of Salmonella species in all food types, including milk and dairy products, molluscan shellfish and other fish products, and to its detection in environmental samples such as swabs and dishcloths.]]&gt;</body>
  </document>
  <document>
    <id>285664</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w7.pdf]]&gt;</url>
    <title>Detection of Salmonella Species (W7)</title>
    <publicationDate>2006-07-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FAECAL/ORAL,BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIOUS DISEASES,INFECTIONS,SALMONELLA,SALMONELLA,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The method described is applicable to the isolation and detection of Salmonella species from all types of water. Salmonella species are concentrated by membrane filtration (non-turbid waters) or a filter&lt;BR&gt;pad with filter aid (turbid waters).&lt;/P&gt;
&lt;P&gt;BACKGROUND&lt;BR&gt;Surface waters and reservoirs are particularly liable to pollution from animals and birds, and Salmonella species may be detected when only small numbers of indicator organisms are present eg Escherichia coli. For technical reasons, detection tests for Salmonella species are not routinely&lt;BR&gt;carried out on all samples. However, potable waters may be examined as part of epidemiological investigations into the source of enteric infections, and river or recreational waters may be examined as part of local authority surveillance programmes. Coastal or inland waters as directed by the Bathing Waters (Classification) Regulations 19912 may also be examined at specified intervals for Salmonella species.&lt;/P&gt;
&lt;P&gt;This method is based on the method described in the Draft ISO 192503. This uses Rappaport Vassiliadis soya peptone (RVS) broth, which is highly effective for recovery of Salmonella from water with a high level of background contamination. For toxicological reasons it also replaces the use of a selenite medium by Muller Kauffmann tetrathionate novobiocin broth (MKTTn) for the isolation of serotypes of Salmonella that are inhibited by the constituents of RVS broth. Although extensive trials&lt;BR&gt;have been performed to demonstrate the efficacy of these media for the recovery of Salmonella Typhi4,5 and Salmonella Paratyphi4,5, it is recognised that the combination of these two selective media&lt;BR&gt;may not allow recovery of all these strains. This method therefore retains the use of selenite cystine (SC) broth6 for samples in which Salmonella Typhi and Salmonella Paratyphi are specifically sought.&lt;/P&gt;
&lt;P&gt;Two isolation media are specified; these are Xylose Lysine Deoxycholate (XLD) agar and Brilliant Green agar (BGA). If Salmonella Typhi or Salmonella Paratyphi are specifically sought these isolation media should be supplemented with another selective plating medium that does not contain a high concentration of brilliant green, as this may inhibit the recovery of these strains.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330430</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.lww.com/aidsonline/Abstract/2009/05150/Detection_of_tuberculosis_in_HIV_infected_children.11.aspx]]&gt;</url>
    <title>Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay</title>
    <publicationDate>2009-05-29T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,TUBERCULOSIS,INFECTIONS,DIAGNOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,BACTERIA,ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: To evaluate an enzyme-linked immunospot assay (ELISPOT) for the diagnosis of tuberculosis (TB) in HIV-infected children with suspected TB and to compare the performance of ELISPOT with the tuberculin skin test (TST). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: Interferon-gamma responses to Mycobacterium tuberculosis-specific antigens were measured by ELISPOT in HIV-infected children with suspected TB. HIV-infected and HIV-uninfected children without TB were taken for comparison. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Results were available for 188 children, of whom 139 (74%) were HIV-infected. Of these, 22 were classified as having definite TB: 24 probable TB, 14 possible TB and 128 not having TB. The median (range) age of patients was 20 (10-54.1) months. Median interferon-gamma responses to early-secreted antigenic target-6 and culture filtrate protein-10 were higher in children with definite or probable TB compared with children without TB (P &amp;lt; 0.002). In HIV-infected children with an interpretable ELISPOT result, the ELISPOT was positive in 14/21 (66%) with definite TB. A significantly higher proportion of HIV-infected children with definite or probable TB had a positive ELISPOT compared with a positive TST [25/39 (64%) vs. 10/34 (29%), P = 0.005]. In contrast to TST, results from ELISPOT were not affected by young age or severe immunosuppression. In HIV-infected children without active TB disease, 27% had a positive ELISPOT, suggesting latent TB infection. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: ELISPOT is more sensitive than TST for the detection of active TB in HIV-infected children. However, the sensitivity of current ELISPOT assays is not sufficiently high to be used as a rule out test for TB.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285665</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/milk_dairy/pdf/d7.pdf]]&gt;</url>
    <title>Determination of alkaline Phosphatase Activity in Pasteurised Milk and Cream - Fluorimetric Method (D7)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,INFECTIONS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285666</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/milk_dairy/pdf/d6.pdf]]&gt;</url>
    <title>Determination of peroxidase activity (Storch test) in milk (D6)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285667</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/content/abstract/351/17/1741]]&gt;</url>
    <title>Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults</title>
    <publicationDate>2004-10-21T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENINGOCOCCAL MENINGITIS,TRANSMISSION MODE,BODY PART AFFECTED,CONTACT,AIRBORNE,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,INFECTIOUS DISEASES,MICROORGANISM,BACTERIA,NEISSERIA MENINGITIDIS,MYCOBACTERIUM TUBERCULOSIS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ 545 patients over 14years old from two centres in Vietnam randomly allocated to dexamethasone or placebo in conjunction with standard quadruple antituberculous chemotherapy for TB meningitis.
No significant difference between groups in primary outcome (death or severe disability at 9 months) 
Significantly reduced mortality in dexamethasone group (most marked in those with mild disease at entry)
Only significant secondary outcome was reduced time to fever clearance in steroid group
Mortality significantly higher amongst HIV-infected adults but no significant benefit from dexamethasone treatment
Significantly fewer adverse drug reactions to antituberculous therapy in dexamethasone group]]&gt;</body>
  </document>
  <document>
    <id>285668</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sign.ac.uk/pdf/sign66.pdf]]&gt;</url>
    <title>Diagnosis and management of childhood otitis media in primary care</title>
    <publicationDate>2003-02-01T00:00:00</publicationDate>
    <publisher>Scottish Intercollegiate Guidelines Network (SIGN)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This guideline provides recommendations based on current evidence for best practice in the management of acute otitis media and otitis media with effusion. It provides evidence about detection, management, referral and follow-up of children with these conditions. It excludes discussion of surgical management such as the insertion of grommets nor does it address the needs of children with genetic or facial abnormalities. The guideline is likely to be of interest to GPs, practice nurses, audiologists, paediatricians, otolaryngologists, audiological physicians, health visitors, social workers, public health physicians, users of services and all other professions caring for children.]]&gt;</body>
  </document>
  <document>
    <id>285669</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/content/full/326/7388/539]]&gt;</url>
    <title>Diagnosis and management of scalp ringworm</title>
    <publicationDate>2003-03-08T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,INFECTIOUS DISEASES,ANTIFUNGALS,PREVENTION AND CONTROL,ANTIMICROBIALS,INFECTIONS,TREATMENT,ATHLETE'S FOOT/TINEA,SKIN AND NAIL INFECTIONS,MICROORGANISM,FUNGI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Scalp ringworm is reaching epidemic proportions in parts of Britain's cities. Prompt diagnosis is needed to stop it spreading from child to child, but the varied presentation makes it easy to miss. This paper discusses the current epidemic, illustrates the clinical presentations of the disease, and describes the methods for diagnosis and management.]]&gt;</body>
  </document>
  <document>
    <id>285670</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpch.ac.uk/publications/clinical_docs/UTI_in_children.pdf]]&gt;</url>
    <title>Diagnosis and management of urinary tract infections in children under two years - assessment of practice against published guidelines</title>
    <publicationDate>2001-03-13T00:00:00</publicationDate>
    <publisher>Royal College of Paediatrics and Child Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,URINARY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance on the management and diagnosis of urinary tract infections in children under 2 years of age, assessment of practice against published guidelines. The report provides information under the following headings: summary, introduction, aims, methods, results, discussion, conclusions, recommendations and references.  Figures, tables and appendices are also included, as well as a list of abbreviations.]]&gt;</body>
  </document>
  <document>
    <id>303666</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947417467]]&gt;</url>
    <title>Diagnosis of Chlamydia: Quick Reference Guide for General Practices for Consultation and Local Adaptation</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,CHLAMYDIA,WOMEN'S HEALTH,CHLAMYDIA,SEXUAL HEALTH,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT,JAN 09,BACTERIA,CHLAMYDIA,MICROORGANISM,ADDED 2009,CHLAMYDIA,BACTERIAL,MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This quick reference guide for general practices includes information about testing, diagnosis and treatment of chlamydia. &lt;/P&gt;
&lt;P&gt;For this document in word format, click &lt;A href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947422721" target="_blank"&gt;here&lt;/A&gt;. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304161</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947419406]]&gt;</url>
    <title>Diagnosis of Helicobacter pylori (HP) in dyspepsia: Quick Reference Guide for Primary Care</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ BREATH TESTS,STOOL TESTS,HELICOBACTER PYLORI,DIAGNOSTIC PROCEDURES,STOMACH,GASTROENTEROLOGY &amp; LIVER DISEASES,RECENT ADDITIONS,DYSPEPSIA,INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,INFECTIONS,JAN 09,TREATMENT,MICROORGANISM,BACTERIA,HELICOBACTER PYLORI,INFECTIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To improve the diagnosis of infectious disease in primary care 
&lt;LI&gt;To improve use of the microbiology laboratory in primary care 
&lt;LI&gt;To target the use of antibiotics and anti-fungals in primary care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Production:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The templates have been produced in consultation with GPs and specialists in the field. 
&lt;LI&gt;They are in agreement with other guidance, including Prodigy, SIGN and NICE. 
&lt;LI&gt;The guidance is fully referenced and graded. 
&lt;LI&gt;The guidance is not all-encompassing, as it is meant to be quick reference. If more detail is required we suggest referral to the websites and references quoted. 
&lt;LI&gt;The guidance is updated annually. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Local adaptation:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The guidance will need to be taken forward in collaboration between laboratories, PCTs and secondary care providers. 
&lt;LI&gt;Recommendations can be changed to suit local service delivery and sampling protocols. 
&lt;LI&gt;Change in laboratory use may increase or decrease laboratory workload and have financial implications for laboratories and Primary Care Trusts (PCTs). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Your feedback:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;We welcome, in fact encourage, opinions on the advice given and future topics we should cover. 
&lt;LI&gt;Comments should be submitted to Dr Cliodna McNulty, Head, HPA Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN. Email: &lt;A href="mailto:jill.whiting@hpa.org.uk" target="_blank"&gt;jill.whiting@hpa.org.uk&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For a copy of this guidance in word format, click &lt;A href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947347671" target="_blank"&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285672</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://archinte.ama-assn.org/cgi/reprint/161/17/2116?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=1&amp;andorexacttitle=and&amp;andorexacttitleabs=and&amp;andorexactfulltext=and&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;volume=161&amp;firstpage=2116&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza.</title>
    <publicationDate>2001-01-24T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,BODY PART AFFECTED,AIRBORNE,TRANSMISSION MODE,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,SEASONAL INFLUENZA,PANDEMIC INFLUENZA,INFLUENZA VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Successful treatment of influenza depends on an accurate diagnosis of the illness and prompt intervention. However, there is a lack of data comparing clinical diagnosis vs laboratory diagnostic techniques.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394472</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20926704]]&gt;</url>
    <title>Diagnosis of pulmonary tuberculosis by microscopic observation drug susceptibility assay in HIV positive patients</title>
    <publicationDate>2010-10-06T00:00:00</publicationDate>
    <publisher>American Society for Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Microscopic observation drug susceptibility assay (MODS) is a novel and promising test for the early diagnosis of tuberculosis (TB). We evaluated the MODS assay for the early diagnosis of TB in HIV positive patients presenting to Pham Ngoc Thach Hospital for Tuberculosis and Lung Diseases in southern Vietnam. 738 consecutive sputum samples collected from 307 HIV-positive individuals suspected of TB were tested by smear, MODS and MGIT. The diagnostic sensitivity and specificity of MODS compared to microbiological gold standard (either smear or MGIT) was 87% and 93%, respectively. The sensitivity of smear, MODS and MGIT were 57%, 71% and 75%, respectively against clinical gold standard (MODS vs smear: P&amp;lt;0.001, MODS vs MGIT: P=0.03). Clinical gold standard was defined as patients who had clinical examination and treatment consistent with tuberculosis, with or without microbiological confirmation. For diagnosis of smear negative patients, the sensitivity of MODS and MGIT were 38% and 45%, respectively (P=0.08). The median time to detection of MODS and MGIT were 8 days and 11 days, respectively, and 11 and 17 days, respectively, for smear negative samples. Original bacterial/fungal contamination rate of MODS was 1.1% while it was 2.6% for MGIT. The cross-contamination rate of MODS was 4.7%. In conclusion, MODS is a sensitive, specific and rapid test which is appropriate for detection of HIV-associated TB; the cost and ease of use make it particularly useful in resource limited settings.]]&gt;</body>
  </document>
  <document>
    <id>304730</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947404720]]&gt;</url>
    <title>Diagnosis of UTI - Quick reference guide for primary care</title>
    <publicationDate>2006-12-22T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,URINARY TRACT INFECTION,JAN 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To improve the diagnosis of infectious disease in primary care 
&lt;LI&gt;To improve use of the microbiology laboratory in primary care 
&lt;LI&gt;To target the use of antibiotics and anti-fungals in primary care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Production:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The templates have been produced in consultation with GPs and specialists in the field. 
&lt;LI&gt;They are in agreement with other guidance, including Prodigy, SIGN and NICE. 
&lt;LI&gt;The guidance is fully referenced and graded. 
&lt;LI&gt;The guidance is not all-encompassing, as it is meant to be quick reference. If more detail is required we suggest referral to the websites and references quoted. 
&lt;LI&gt;The guidance is updated annually. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Local adaptation:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The guidance will need to be taken forward in collaboration between laboratories, PCTs and secondary care providers. 
&lt;LI&gt;Recommendations can be changed to suit local service delivery and sampling protocols. 
&lt;LI&gt;Change in laboratory use may increase or decrease laboratory workload and have financial implications for laboratories and Primary Care Trusts (PCTs). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Your feedback:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;We welcome, in fact encourage, opinions on the advice given and future topics we should cover. 
&lt;LI&gt;Comments should be submitted to Dr Cliodna McNulty, Head, HPA Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN. Email: &lt;A href="mailto:jill.whiting@hpa.org.uk" target="_blank"&gt;jill.whiting@hpa.org.uk&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285674</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/110/17/2747]]&gt;</url>
    <title>Diagnosis, treatment and management of Kawasaki Disease</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR,BODY PART AFFECTED,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Aims: These recommendations for the initial evaluation, treatment in the acute phase, and long-term management of patients with Kawasaki disease are intended to assist physicians in understanding the range of acceptable approaches for caring for patients with Kawasaki disease. The ultimate decisions for case management must be made by physicians in light of the particular conditions presented by individual patients.
Intended audience: Medical and healthcare professionals.
Publication history information: A multidisciplinary committee of experts was convened to revise the American Heart Association recommendations for diagnosis, treatment, and long-term management of Kawasaki disease.  Their findings were published in December 2004.
Access:  Available to the general public.]]&gt;</body>
  </document>
  <document>
    <id>345442</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/reprint/47/3/569]]&gt;</url>
    <title>Diagnostic accuracy of in-house PCR for pulmonary tuberculosis in smear-positive patients: meta-analysis and metaregression</title>
    <publicationDate>2009-01-14T00:00:00</publicationDate>
    <publisher>American Society for Microbiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,DIAGNOSIS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In-house PCR (hPCR) could speed differential diagnosis between tuberculosis (TB) and nontuberculous mycobacterial disease in patients with positive smears and pulmonary infiltrates, but its reported accuracy fluctuates across studies. We conducted a systematic review and meta-analysis of hPCR sensitivity and specificity for smear-positive TB diagnosis, using culture as the reference standard. After searching English language studies in MEDLINE and EMBASE, we estimated cumulative accuracy by means of summary receiver operating characteristic analysis. The possible influence of hPCR procedures and study methodological features on accuracy was explored by univariate metaregression, followed by multivariate adjustment of items selected as significant. Thirty-five articles (1991 to 2006) met the inclusion criteria. The pooled estimates of the diagnostic odds ratio, sensitivity, and specificity (random-effect model) were, respectively, 60 (confidence interval [CI], 29 to 123), 0.96 (CI, 0.95 to 0.97), and 0.81 (CI, 0.78 to 0.84), but significant variations (mainly in specificity) limit their clinical applicability. The quality of the reference test, the detection method, and real-time PCR use explained some of the observed heterogeneity. Probably due to the limited study power of our meta-analysis and to the wide differences in both laboratory techniques and methodological quality, only real-time PCR also displayed a positive impact on accuracy in the multivariate model. Currently, hPCR can be confidently used to exclude TB in smear-positive patients, but its low specificity could lead to erroneous initiation of therapy, isolation, and contact investigation. As the inclusion of samples from treated patients could have artificially reduced specificity, future studies should report mycobacterial-culture results for each TB and non-TB sample analyzed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Read the structured abstract by the Centre for Reviews and Dissemination &lt;A href="nelh:331831:0" name=internalLink&gt;here&lt;/A&gt;.&lt;A href="nelh:331831:0" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308661</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/reprint/44/12/4384?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=portaels&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay.</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>American Society for Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The INNO-LiPA.Rif TB test (LiPA) has only been applied to a limited number of clinical specimens. To assess the utility of this test for detecting Mycobacterium tuberculosis complex DNA and rifampin (RMP) resistance, 420 sputum samples comprising specimens from untreated (n=160) and previously treated (n=260) patients from 11 countries in Asia, Africa, Europe, and Latin America were tested. DNA was extracted from sputum samples by using a modification of the Boom's method, while the rpoB core region was amplified by nested PCR. The results were analyzed in conjunction with those obtained by Ziehl-Neelsen (ZN) microscopy and by culture on solid media. The LiPA test was positive for M. tuberculosis complex DNA in 389 (92.9%) specimens, including 92.0% (286 of 311) ZN-positive and 94.5% (103 of 109) ZN-negative specimens. Of these, 30.6% were RMP resistant. In contrast, 74.3% of the specimens were positive for M. tuberculosis by culture, and 30.8% of them were RMP resistant. LiPA detected M. tuberculosis complex DNA in 92.4% (110 of 119) of the culture-positive and 100.0% (41 of 41) of the culture-negative specimens from untreated patients. There was a 99.6% concordance between the RMP resistance as determined by culture and by the LiPA test. With an optimal DNA extraction method, LiPA allows rapid detection of M. tuberculosis complex DNA and RMP resistance directly from sputum specimens. LiPA can still provide useful information when culture fails for various reasons. The rapid availability of this information is necessary to adjust patient treatment and avoid the risk of amplification of drug resistance.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>285677</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f20.pdf]]&gt;</url>
    <title>Direct Enumeration of Escherichia coli (F20)</title>
    <publicationDate>2005-05-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,FAECAL/ORAL,TRANSMISSION MODE,GASTROENTERITIS,ESCHERICHIA COLI INFECTION,GASTROINTESTINAL INFECTIONS,INFECTIONS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scope:&lt;BR&gt;The method described is applicable to the enumeration of E.coli in food products except molluscan shellfish and also frozen and dried food products which may contain stressed organisms. It is not applicable to dairy products.&lt;/P&gt;
&lt;P&gt;Background:&lt;BR&gt;The presence of Escherichia coli in food is regarded as an indication of contamination with organisms of faecal origin. Counts of E.coli of 100 colony forming units per gram (cfu/g) or greater are considered to be unsatisfactory for ready-to-eat foods. Guidelines for cookchill foods specify counts&lt;BR&gt;of l0 cfu/g or greater as unsatisfactory. Commercial guidelines for ready-to-eat food generally set the target value at 10 cfu/g for E.coli.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345576</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-2334-9-67.pdf]]&gt;</url>
    <title>Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis</title>
    <publicationDate>2009-05-20T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ANTIMICROBIAL RESISTANCE,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: One of the challenges facing the tuberculosis (TB) control programmes in resource-limited settings is lack of rapid techniques for detection of drug resistant TB, particularly multi drug resistant tuberculosis (MDR TB). Results obtained with the conventional indirect susceptibility testing methods come too late to influence a timely decision on patient management. More rapid tests directly applied on sputum samples are needed. This study compared the sensitivity, specificity and time to results of four direct drug susceptibility testing tests with the conventional indirect testing for detection of resistance to rifampicin and isoniazid in M. tuberculosis. The four direct tests included two in-house phenotypic assays - Nitrate Reductase Assay (NRA) and Microscopic Observation Drug Susceptibility (MODS), and two commercially available tests - Genotype MTBDR and Genotype MTBDRplus (Hain Life Sciences, Nehren, Germany).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A literature review and meta-analysis of study reports was performed. The Meta-Disc software was used to analyse the reports and tests for sensitivity, specificity, and area under the summary receiver operating characteristic (sROC) curves. Heterogeneity in accuracy estimates was tested with the Spearman correlation coefficient and Chi-square. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Eighteen direct DST reports were analysed: NRA - 4, MODS- 6, Genotype MTBDR - 3 and Genotype MTBDRplus - 5. The pooled sensitivity and specificity for detection of resistance to rifampicin were 99% and 100% with NRA, 96% and 96% with MODS, 99% and 98% with Genotype MTBDR, and 99% and 99% with the new Genotype MTBDRplus, respectively. For isoniazid it was 94% and 100% for NRA, 92% and 96% for MODS, 71% and 100% for Genotype MTBDR, and 96% and 100% with the Genotype MTBDRplus, respectively. The area under the summary receiver operating characteristic (sROC) curves was in ranges of 0.98 to 1.00 for all the four tests. Molecular tests were completed in 1 - 2 days and also the phenotypic assays were much more rapid than conventional testing. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Direct testing of rifampicin and isoniazid resistance in M. tuberculosis was found to be highly sensitive and specific, and allows prompt detection of MDR TB.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393677</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//infections/ViewResource.aspx?resID=393677]]&gt;</url>
    <title>Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,TREATMENT,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Directly observed therapy has been recommended to improve adherence for patients with HIV infection who are on highly active antiretroviral therapy, but the benefit and cost-effectiveness of this approach has not been established conclusively. We did a systematic review and meta-analysis of randomised trials of directly observed versus self-administered antiretroviral treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We did duplicate searches of databases (from inception to July 27, 2009), searchable websites of major HIV conferences (up to July, 2009), and lay publications and websites (March-July, 2009) to identify randomised trials assessing directly observed therapy to promote adherence to antiretroviral therapy in adults. Our primary outcome was virological suppression at study completion. We calculated relative risks (95% CIs), and pooled estimates using a random-effects method.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FINDINGS&lt;/STRONG&gt;: 12 studies met our inclusion criteria; four of these were done in groups that were judged to be at high risk of poor adherence (drug users and homeless people). Ten studies reported on the primary outcome (n=1862 participants); we calculated a pooled relative risk of 1.04 (95% CI 0.91-1.20, p=0.55), and noted moderate heterogeneity between the studies (I(2)= 53.8%, 95% CI 0-75.7, p=0.0247) for directly observed versus self-administered treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;INTERPRETATION&lt;/STRONG&gt;: Directly observed antiretroviral therapy seems to offer no benefit over self-administered treatment, which calls into question the use of such an approach to support adherence in the general patient population.&lt;/P&gt;
&lt;P&gt;Read the &lt;A href="nelh:334166:0" name=internalLink&gt;structured abstract &lt;/A&gt;by the Centres for Review and Dissemination&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394450</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19912634]]&gt;</url>
    <title>Disability and HIV/AIDS - a systematic review of literature on Africa</title>
    <publicationDate>2009-11-13T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This systematic review focuses on empirical work on disability and HIV/AIDS in Africa in the past decade and considers all the literature currently accessible. The review presents data from different surveys and summarizes the findings. In this way, it convincingly reveals that people with disabilities are very vulnerable to contracting HIV, and lack access to information, testing and treatment. The review further reveals gaps in the research and areas of concern. While vulnerability and accessibility have been investigated, there are few prevalence studies or evaluations available. A certain amount of work has focused on the deaf population, but little has been done for other disability groups. A growing area of concern is sexual abuse and exploitation of people with disabilities. Only a few studies or interventions focus on this crucial area.]]&gt;</body>
  </document>
  <document>
    <id>388796</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/disease-shaped-human-genetics.aspx]]&gt;</url>
    <title>Disease and history link</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ADDED 2010,WHAT'S NEW,SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“People from traditionally urban areas could be genetically better suited to fighting infection,” BBC News reported.&lt;/P&gt;
&lt;P&gt;The news is based on a study that looked at how resistance to infectious disease may be linked to urban living in our ancestors. The study's authors described the process as “evolution in action” and the findings could help explain differences in disease resistance seen around the world.&lt;/P&gt;
&lt;P&gt;The study analysed DNA from 17 global populations and compared the frequency of a particular gene variant known to protect against infectious diseases, including TB. It found that the protective gene was more common in populations that had been living in large settlements for longer, supporting the theory that urbanisation led to disease resistance. However, this resistance appears to have developed due to natural selection in the face of disease and not because of any particular benefit of city living. While fascinating, the study should be seen as an investigation of our distant past but does not show that people living in urban areas today are better at fighting off infection.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Despite some shortcomings, this research is an interesting attempt to understand how ancient interactions between settlement, infectious disease and environmental pressure have contributed to our genetics today. The study found a link between the length of urbanisation of a population and the frequency of a particular protective genetic variant in modern times. The researchers acknowledge that their measure of the urbanisation history of a population may be “an inaccurate measure of the extent of exposure to urbanisation” under certain circumstances.&lt;/P&gt;
&lt;P&gt;The findings add to the evidence that infectious diseases were linked with urbanisation and, in turn, resistance to those diseases. The theory is that in urban areas with high levels of infectious disease, people who had genetic variants giving them resistance to infection would be more likely to survive and reproduce. They would, therefore, pass on these variants, which would gradually become more common in the population over the generations.&lt;/P&gt;
&lt;P&gt;While the findings contribute to our understanding of how disease may have altered our genetics over successive generations, it cannot tell us whether a rural or urban lifestyle is healthier for the modern individual.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Barnes I, Duda A, Pybus O, Thomas MG.&amp;nbsp;&lt;A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1558-5646.2010.01132.x/abstract" target="_blank"&gt;Ancient urbanisation predicts generic resistance to tuberculosis&lt;/A&gt;. &lt;EM&gt;Evolution&lt;/EM&gt;, September 14 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>392303</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/d8831g61l7153k27/]]&gt;</url>
    <title>Disparity in hospital utilization of rapid HIV-1 testing for women in labor with undocumented HIV status</title>
    <publicationDate>2010-03-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,DIAGNOSIS,ADULTS,PREGNANT WOMEN,POPULATION GROUPS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,OCT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: The implementation of rapid HIV-1 testing for women in labor with undocumented HIV status is an essential tool for the prevention of perinatal HIV transmission. Unfortunately, practices of rapid HIV testing for women with unknown HIV status in labor have not been studied. We evaluated the utilization of rapid HIV testing prior to and after implementation of CDC recommendations as well as factors that may affect the utilization rate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN STUDY&lt;/STRONG&gt;: participants were randomly selected from all deliveries (n = 2,359) six months prior to (n = 422) and after (n = 403) hospital implementation of the rapid HIV testing protocol. We reviewed prenatal and labor/delivery records to identify HIV testing history during pregnancy and HIV status at admission; we studied Rapid HIV testing utilization in respect to the implementation of the CDC recommendation; and we analyzed maternal sociodemographic and perinatal factors in association with rapid HIV testing utilization.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Unknown HIV status at admission was recorded for 22.0% of women who gave birth prior to, and 18.1% after, implementation of the hospital policy due to either no offering or no acceptance of HIV testing during the pregnancy. Among those eligible for rapid HIV testing, 7.6% were tested prior to, and 9.6% were tested after, implementation of the new policy. As compared with tested women, women not tested were more likely to be white, married, and to have received prenatal primary care from a private physician.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: We found that low utilization of rapid HIV-1 testing for women in labor with undocumented HIV status is mostly associated with the sociodemographic inequality of the population of women served. Continuous education of health care providers and a systematic review of rapid HIV testing utilization in the hospital setting are needed in order to achieve successful implementation of the current CDC recommendations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345960</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19722896]]&gt;</url>
    <title>DNA vaccines against mycobacterial diseases</title>
    <publicationDate>2009-09-08T00:00:00</publicationDate>
    <publisher>Future Drugs Ltd.</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,PREVENTION,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,BCG,VACCINES / IMMUNISATION,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Bacteria belonging to the genus Mycobacterium can cause several infectious diseases affecting humans and animals. Here, we reviewed the latest advances in the development of DNA vaccines against TB, Buruli ulcer and Johne's disease. Current understanding of the immunity to the respective causative pathogens indicates that the use of DNA vaccines encoding mycobacterial antigens could lead to efficient vaccination strategies. Moreover, characterization of protective mycobacterial antigens has been greatly facilitated by the analysis of immune responses induced after DNA vaccination. In addition, work aiming at optimizing DNA vaccines against mycobacterial diseases and research related to the controversial development of postexposure and therapeutic DNA vaccines are also discussed.]]&gt;</body>
  </document>
  <document>
    <id>327561</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Does-a-virus-cause-ME.aspx]]&gt;</url>
    <title>Does a virus cause ME?</title>
    <publicationDate>2009-10-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ENCEPHALITIS,BRAIN AND SPINAL CORD INFECTIONS,VIRUSES,MICROORGANISM,ADDED 2009,OCT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The front page of today’s &lt;EM&gt;Independent&lt;/EM&gt; asks whether scientists have found the cause of ME (myalgic encephalitis), also known as chronic fatigue syndrome (CFS). The newspaper reported that researchers have found a “strong link” with a retrovirus called XMRV.&lt;/P&gt;
&lt;P&gt;This study compared blood samples from 101 CFS patients with samples from 218 people without it. It found evidence of the XMRV virus in about two-thirds of the people with CFS and less than 4% of people without the disease.&lt;/P&gt;
&lt;P&gt;These findings alone do not prove that the virus causes CFS, because they do not show whether the infection occurred before or after CFS developed. The research paper is cautious in its conclusions, saying that XMRV “may” be a contributing factor to CFS, but the opposite may also be true: CFS may make people more susceptible to infection with this virus.&lt;/P&gt;
&lt;P&gt;Despite these limitations, these findings will be of interest to the research community, doctors and patients. Larger&amp;nbsp;studies&amp;nbsp;and research that establishes whether the XMRV infection occurs before or after the onset of CFS&amp;nbsp;will be needed before any conclusions can be drawn.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has identified an association between the presence of XMRV viral DNA and chronic fatigue syndrome (CFS).&lt;/P&gt;
&lt;P&gt;However, it is not yet possible to say for certain whether the virus causes CFS, a fact that is acknowledged by the authors of the research. This is because the presence of the virus was assessed in people who already had CFS, and so it is not clear if the infection happened before they developed the disease.&lt;/P&gt;
&lt;P&gt;An alternative possibility is that people who already have CFS have altered immune systems that make them more susceptible to these viruses.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lombardi VC, Ruscetti FW, Das Gupta J, et al.&amp;nbsp;&lt;A href="http://www.sciencemag.org/cgi/content/abstract/sci;1179052v1" target="_blank"&gt;Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome.&lt;/A&gt; &lt;EM&gt;Science&lt;/EM&gt;; Published online October 8 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencemag.org/cgi/content/summary/326/5950/215-a" target="_blank"&gt;Chronic Fatigue and Prostate Cancer: A Retroviral Connection?&lt;/A&gt;&amp;nbsp;&lt;EM&gt;Science,&lt;/EM&gt; October 9 2009: 326; p215&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>392346</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.2009.02826.x/abstract]]&gt;</url>
    <title>Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,DETERMINANTS,OUTCOMES,INDIVIDUAL BEHAVIOUR,SUBSTANCE MISUSE,MANAGEMENT &amp; INTERVENTIONS,SETTINGS,POPULATIONS,GROUPS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTION CONTROL,POPULATION BASED &amp; PREVENTATIVE SERVICES,SERVICES,HIV INFECTION,COMMUNICABLE DISEASES,PRISONS,BUILDINGS,DISADVANTAGED GROUPS,PEOPLE WITH HIV OR AIDS,MONTHLY ADDITIONS,INFECTIONS,POPULATION GROUPS,ADULTS,INJECTING DRUG USERS (IDUS),MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOVEMBER 2010,OCT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objectives&lt;/STRONG&gt;:&amp;nbsp; To review systematically the evidence on opioid substitution treatment (OST) in prisons in reducing injecting-related human immunodeficiency virus (HIV) risk behaviours.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;:&amp;nbsp; Systematic review in accordance with guidelines of the Cochrane Collaboration. Electronic databases were searched to identify studies of prison-based opioid substitution treatment programmes that included assessment of effects of prison OST on injecting drug use, sharing of needles and syringes and HIV incidence. Published data were used to calculate risk ratios for outcomes of interest. Risk ratios were not pooled due to the low number of studies and differences in study designs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;:&amp;nbsp; Five studies were included in the review. Poor follow-up rates were reported in two studies, and representativeness of the sample was uncertain in the remaining three studies. Compared to inmates in control conditions, for treated inmates the risk of injecting drug use was reduced by 55–75% and risk of needle and syringe sharing was reduced by 47–73%. No study reported a direct effect of prison OST on HIV incidence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;:&amp;nbsp; There may be a role for OST in preventing HIV transmission in prisons, but methodologically rigorous research addressing this question specifically is required. OST should be implemented in prisons as part of comprehensive HIV prevention programmes that also provide condoms and sterile injecting and tattooing equipment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Read the review by the Centre for Reviews and Dissemination &lt;A href="nelh:379359:1" name=internalLink&gt;here&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285679</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/334/7590/413?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=dog+bite&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Dog Bites</title>
    <publicationDate>2007-02-24T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Wound management is as important as use of antimicrobials in preventing infection. Primary closure should be avoided in limb injuries where possible because of increased risk of infection. For patients considered to be at higher risk of infection, the prophylaxis of choice is co-amoxiclav. Erythromycin or flucloxacillin should never be used alone prophylactically as Pasteurella infection is usually resistant. Infected wounds presenting within 12 hours of injury are usually due to Pasteurella multocida. Patients at particularly high risk of infection are immunosuppressed patients, particularly those with asplenia or cirrhosis or those who have had a mastectomy]]&gt;</body>
  </document>
  <document>
    <id>285680</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/content/full/328/7438/499]]&gt;</url>
    <title>Drink plenty of fluids: a systematic review of evidence for this recommendation in acute respiratory infections</title>
    <publicationDate>2004-02-28T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PNEUMONIA,INFLUENZA,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIONS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Doctors often recommend drinking extra fluids to patients with respiratory infections. Theoretical benefits for this advice are replacing insensible fluid losses from fever and respiratory tract evaporation, correcting dehydration from reduced intake, and reducing the viscosity of mucus.To many this advice is self evident and justified on the basis that even if the benefit is uncertain, or at best small, at least it is harmless. 

However, there are theoretical reasons for increased fluid intake to cause harm. Antidiuretic hormone conserves fluid by stimulating water reabsorption from the renal collecting ducts. Increased antidiuretic hormone secretion has been reported in adults and children with lower respiratory tract infections of bronchitis, bronchiolitis, and pneumonia of viral and bacterial aetiology. It is uncertain if this also occurs in upper respiratory tract infections. 
]]&gt;</body>
  </document>
  <document>
    <id>384326</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/drug-resistant-superbug-in-UK.aspx]]&gt;</url>
    <title>Drug-resistant bacteria reach UK</title>
    <publicationDate>2010-08-11T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ENTEROCOCCUS AND GRE/VRE,ANTIMICROBIAL RESISTANCE,MICROORGANISM,BACTERIA,KLEBSIELLA PNEUMONIAE,E. COLI,ADDED 2010,WHAT'S NEW,AUG 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A “new superbug” could make antibiotics redundant, according to The Daily Telegraph.&amp;nbsp; It reported 37 cases of patients having surgery in India or Pakistan and returning to the UK with infections that do not respond to antibiotics.&lt;/P&gt;
&lt;P&gt;The research behind these headlines has identified a range of bacteria (such as salmonella and E. coli) that have developed resistance to many powerful antibiotics, including the carbapenem antibiotics usually reserved for severe infections. This new resistance is due to the bacteria carrying a gene that produces an enzyme called NDM-1. Bacteria can acquire resistance by receiving the gene from other bacteria.&lt;/P&gt;
&lt;P&gt;While this may sound worrying, the public should not be alarmed by this news. So far there has only been a small number of cases and it is not clear how serious the infections were. However, it does highlight the important message that antibiotics should only be used when absolutely necessary, because the more they are used the more likely it is that bacteria will develop a resistance against them. Regular hand-washing will also help to prevent infections in the first place.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Antibiotics are one of medicine’s most powerful tools for fighting infection and disease: as such, antibiotic resistance is a potentially serious problem and a long-standing concern within public health. The growing problem of antibiotic resistance has arisen due to the widespread use of antibiotics and the natural diversity of microbes, which have the ability to adapt and transform into new strains with new properties. As part of this adaptation process, new strains can develop resistance against antibiotics that they would previously have been susceptible to (cured by).&lt;/P&gt;
&lt;P&gt;The findings of this research are highly important because the presence of NDM-1 made these Enterobacteria resistant to most antibiotics they would normally be susceptible to (including ß-lactam, fluoroquinolone and aminoglycoside drugs). Most notably, the presence of NDM-1 conveyed resistance against the types of antibiotics that would normally be reserved for fighting severe infections caused by bacteria normally resistant to these more common types of antibiotic.&lt;/P&gt;
&lt;P&gt;The NDM-1-positive samples from the UK and India also came from a diverse range of bacterial strains, which means the presence of NDM-1 was not confined to a few common strains of E. coli and Klebsiella pneumonia (the most common types of Enterobacteria carrying NDM-1). Worryingly, this suggests that this was not just a single international outbreak with the same strain of a particular bacterium. This finding supports the fact that the NDM-1 gene, being located on the bacterial plasmid, can be easily transferred to other bacteria. As one of the researchers says, the NDM-1 gene may have “an alarming potential to spread and diversify among bacterial populations.”&lt;/P&gt;
&lt;P&gt;The authors say that the emergence of NDM-1 positive bacteria could be a serious global public health concern as there are few antibiotics that are effective against NDM-1. It is also worrying that the isolates in India came from people presenting with common community-acquired infections, suggesting the bacteria with this enzyme may be widespread in the environment, in India at least.&lt;/P&gt;
&lt;P&gt;As the researchers conclude, there is the potential of NDM-1 to be a worldwide public health problem, and coordinated international surveillance is necessary.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Kumarasamy K, Toleman MA, Walsh TR &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2810%2970143-2/abstract" target="_blank"&gt;Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study&lt;/A&gt;. The Lancet Infectious Diseases [Published Online] August 11 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>379596</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/urinary-tract-infections-resistant-to-antibiotics.aspx]]&gt;</url>
    <title>Drug-resistant urinary infections</title>
    <publicationDate>2010-05-18T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,URINARY TRACT INFECTION,MICROORGANISM,BACTERIA,E. COLI,ADDED 2010,MAY 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Urinary tract infections may become resistant to antibiotics through the “overuse of antibiotics in the farming industry”, BBC News has said.&lt;/P&gt;
&lt;P&gt;The news is based on research on the bacterium E. coli, a common cause of urinary tract infections. The researchers looked at E. coli grown from the urine and stool samples of humans and from the stool samples from various animals.&lt;/P&gt;
&lt;P&gt;They tested the urine and stool’s resistance to an antibiotic called gentamicin. Animal and human samples that proved resistant were found to have specific genetic sequences in common, suggesting that the strains had transferred genes for resistance between each other.&lt;/P&gt;
&lt;P&gt;The study did not look at how antibiotic resistance in the bacteria could be transferred between animals and humans, therefore it does not indicate whether it is possible to transmit resistance through eating meat. Regardless, it is well known that when dealing with infections patients should correctly use prescribed antibiotics and take their whole course of treatment to help prevent bacteria from developing antibiotic resistance.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a small study, which found that resistance to the antibiotic gentamicin was granted by the same gene sampled from both animals and humans.&amp;nbsp;However, it did not look at the possible routes by which this resistance may be transmitted between animals and humans. For example, it could not say whether consuming animals with antibiotic-resistant E. coli in their guts is a possible route of transmission. It did however highlight the way that antibiotic resistance can be transferred between bacteria.&lt;/P&gt;
&lt;P&gt;This study was carried out in Hong Kong where meat consumed by the population is produced by Chinese farms. It is not clear whether the antibiotic use in Chinese farms would differ from antibiotic use in British farms. It is well known that antibiotic resistance is a great public health concern, and antibiotics should be carefully prescribed by doctors and vets. It is also important that if patients are prescribed antibiotics, they should take the whole course of treatment in order to avoid pathogenic bacteria in their bodies developing antibiotic resistance.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ho PL, Wong RC, Lo SW &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://jmm.sgmjournals.org/cgi/content/abstract/59/6/702" target="_blank"&gt;Genetic identity of aminoglycoside-resistance genes in Escherichia coli isolates from human and animal sources&lt;/A&gt;. &lt;EM&gt;Journal of Medical Microbiology&lt;/EM&gt; 59 (2010), 702-707&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330445</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/595885?cookieSet=1]]&gt;</url>
    <title>Early immunological predictors of neurodevelopmental outcomes in HIV-infected children</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Infectious Diseases Society of America</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,PREGNANT WOMEN,CHILDREN,ADULTS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;:&lt;BR&gt;A previous analysis of children infected with human immunodeficiency virus (HIV) in the Women and Infants Transmission Study showed a strong correlation between low activated CD8(+) T lymphocytes in the first 2 months of life and good immunological prognosis. We sought to extend these observations to neurodevelopmental prognosis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;:&lt;BR&gt;Ninety-eight HIV-infected children born before 1994 with flow cytometric data from the first 2 months of life and adequate neurodevelopmental testing through age 30 months were studied. Children were divided into those with low (&lt;OR=5% ( high or cells) CD8(+)CD38(+) &lt;or="25%" cells CD8(+)HLA-DR(+)&gt;5% CD8(+)HLA-DR(+) cells or &amp;gt;25% CD8(+)CD38(+) cells) immune activation at 1 and/or 2 months of age. Analysis was performed using survival analysis, Cox's proportional hazard regression, and longitudinal regression models. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;:&lt;BR&gt;Absence of immune activation, measured as &lt;OR=5% CD8(+)CD38(+) &lt;or="25%" cells CD8(+)HLA-DR(+) P &lt; seen. not was and outcomes neurodevelopmental between association Significant (P=".005)." present also index development mental the with An syndrome immunodeficiency acquired to progression load, viral count, cell CD4 for adjustment after persisted This life. of year third through infant scales Bayley developmental psychomotor on performance better associated strongly cells,&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;:&lt;BR&gt;In this prospective cohort study of HIV-infected children, there was a significant favorable association of low immune activation in peripheral T cells at age 1 or 2 months, measured by a low percentage of CD8(+)HLA-DR(+) cells, with subsequent psychomotor and mental development. This association was independent of other indices of severity and progression of HIV infection.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308939</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?author=Hatwiinda&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia.</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,DIAGNOSIS,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Zambia faces overlapping tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics; however, care for co-infected patients often occurs through separate, vertical programs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: To establish a program to integrate TB and HIV services in Lusaka primary care centers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: In collaboration with the Zambian Ministry of Health, TB-HIV integration activities began in December 2005 and were expanded to seven health centers by March 2007. Principal activities included developing staff capacity to manage co-infected patients, implementing HIV testing within TB departments and establishing referral systems between departments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Using a provider-initiated approach, 2053 TB patients were offered HIV testing. Seventy-seven per cent agreed to be tested; 69% of those tested were HIV-infected. Of these, 59% were enrolled in HIV care. The proportion of antiretroviral treatment (ART) program enrollees who were TB-HIV co-infected increased by 38% after program implementation. The median CD4 count among co-infected patients was 161 cells/µl, with 88% eligible for ART.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Integration of HIV testing and referral services into urban primary care centers identified many co-infected patients and significantly increased the proportion of TB patients among people accessing HIV care. Ongoing challenges include maximizing the number of patients accepting HIV testing and overcoming barriers to enrollment into HIV care.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394473</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910370]]&gt;</url>
    <title>Early versus standard antiretroviral therapy for HIV-infected adults in Haiti</title>
    <publicationDate>2010-07-15T00:00:00</publicationDate>
    <publisher>Massachusetts Medical Society</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,TREATMENT,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: For adults with human immunodeficiency virus (HIV) infection who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter and who live in areas with limited resources, the optimal time to initiate antiretroviral therapy remains uncertain.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We conducted a randomized, open-label trial of early initiation of antiretroviral therapy, as compared with the standard timing for initiation of therapy, among HIV-infected adults in Haiti who had a confirmed CD4+ T-cell count that was greater than 200 and less than 350 per cubic millimeter at baseline and no history of an acquired immunodeficiency syndrome (AIDS) illness. The primary study end point was survival. The early-treatment group began taking zidovudine, lamivudine, and efavirenz therapy within 2 weeks after enrollment. The standard-treatment group started the same regimen of antiretroviral therapy when their CD4+ T-cell count fell to 200 per cubic millimeter or less or when clinical AIDS developed. Participants in both groups underwent monthly follow-up assessments and received isoniazid and trimethoprim-sulfamethoxazole prophylaxis with nutritional support.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Between 2005 and 2008, a total of 816 participants--408 per group--were enrolled and were followed for a median of 21 months. The CD4+ T-cell count at enrollment was approximately 280 per cubic millimeter in both groups. There were 23 deaths in the standard-treatment group, as compared with 6 in the early-treatment group (hazard ratio with standard treatment, 4.0; 95% confidence interval [CI], 1.6 to 9.8; P=0.001). There were 36 incident cases of tuberculosis in the standard-treatment group, as compared with 18 in the early-treatment group (hazard ratio, 2.0; 95% CI, 1.2 to 3.6; P=0.01).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Early initiation of antiretroviral therapy decreased the rates of death and incident tuberculosis. Access to antiretroviral therapy should be expanded to include all HIV-infected adults who have CD4+ T-cell counts of less than 350 per cubic millimeter, including those who live in areas with limited resources. (ClinicalTrials.gov number, NCT00120510.)&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392306</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.cambridge.org/action/displayAbstract?aid=7819816]]&gt;</url>
    <title>Economic evaluation, human immunodeficiency virus infection and screening: a review and critical appraisal of economic studies</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>Cambridge University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,DIAGNOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,OCT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: The aim of this study was to review, systematically and critically, evidence used to derive estimates of cost-effectiveness of human immunodeficiency virus (HIV) screening.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A systematic review was conducted. Searched were three main electronic bibliographic databases from 1993 to 2008 using key words including HIV, mass screening, HAART, economic evaluation, cost-effectiveness analysis, modeling. We included studies of sexually transmitted HIV infection in both sexes, including studies comparing diagnostic testing protocols and partner notification. Outcomes included were cases of HIV infection detected, deterioration to the AIDS state, secondary transmission of HIV, the quality-adjusted life-years/survival, costs, and cost-effectiveness of HIV screening.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Eighty-four papers were identified; ten of which were formal economic evaluations, one cost study, three effectiveness studies, and three systematic reviews of HIV prevention programs. The predominant assertion was that HIV screening is cost-effective; methodological problems, such as the preponderance of static models which are inappropriate for infectious diseases, varying perspectives from which the studies were analyzed, and arbitrary threshold incremental cost-effectiveness ratio levels, limited the validity of these findings, and their usefulness in informing health policy decisions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: The majority of published economic evaluations are based on inappropriate static models. This flaw renders the results of these studies as inconclusive and the purported cost-effectiveness of HIV screening debatable. The results of this review could form a basis for consideration of further research and analysis by health economists into the cost-effectiveness of HIV screening.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392391</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0009628]]&gt;</url>
    <title>Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review</title>
    <publicationDate>2010-03-10T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,OCT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN class=sub_abstract_label&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: &lt;/SPAN&gt;&lt;SPAN&gt;There is conclusive evidence from observational data and three randomized controlled trials that circumcised men have a significantly lower risk of becoming infected with the human immunodeficiency virus (HIV). The aim of this study was to systematically review economic evaluations on adult male circumcision (AMC) for prevention of heterosexual acquisition of HIV in men.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=sub_abstract_label&gt;&lt;STRONG&gt;METHODS AND FINDINGS&lt;/STRONG&gt;: &lt;/SPAN&gt;&lt;SPAN&gt;Studies were identified from the following bibliographic databases: MEDLINE (Ovid), EMBASE (Ovid), Cochrane Library (Wiley's internet version), NHS EED and DARE Office of Health Economics HEED. The searches were conducted in November 2009. The Drummond 10-point checklist was used for methodological critique of the economic evaluations. Cost data were inflated and converted to 2008 US dollars (US$). Of 264 identified papers, only five met the inclusion criteria and were included in the review. The studies were published between 2006 and 2009. Most of the studies were carried out from the perspective of government healthcare payer. The time horizon ranged from 10 to 20 years. All studies reported that AMC is cost-effective. The reported cost per HIV infection averted ranged from US$174 to US$2808. The key driver of the cost-effectiveness models was circumcision efficacy.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=sub_abstract_label&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: &lt;/SPAN&gt;&lt;SPAN&gt;All published economic evaluations offered the same conclusion that AMC is cost-effective and potentially cost-saving for prevention of heterosexual acquisition of HIV in men. On these grounds, AMC may be seen as a promising new form of strategy for prevention of HIV and should be implemented in conjunction with other evidence-based prevention methods.&lt;/SPAN&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330462</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://pediatrics.aappublications.org/cgi/content/abstract/123/1/e121]]&gt;</url>
    <title>Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>American Academy of Pediatrics</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,CHILDREN,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADOLESCENTS,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;:&lt;BR&gt;Vitamin D insufficiency occurs commonly in HIV-infected youth in the United States. In light of the importance of vitamin D for skeletal and nonskeletal health, including innate immunity, developing methods for improving vitamin D status in HIV-infected children and adolescents is an important area of clinical research. The objective of this study was to evaluate the effect of administration of oral cholecalciferol, 100,000 IU every 2 months, and 1 g/day calcium on serum 25-hydroxyvitamin D concentrations, serum and urine calcium, and HIV disease progression during a 12-month period. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;:&lt;BR&gt;HIV-infected children and adolescents who were aged 6 to 16 years were randomly assigned to receive vitamin D (100,000 IU bimonthly) and calcium (1 g/day; n = 29) or double placebo (n = 27). Serum 25-hydroxyvitamin D concentrations as measured by radioimmunoassay, albumin-corrected calcium concentrations, and spot urinary calcium-creatinine ratios were determined monthly. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;:&lt;BR&gt;No abnormalities in serum calcium concentration were observed. One participant who received placebo developed hypercalciuria. No group differences were seen in the change in CD4 count or CD4% or viral load during 12 months. The overall mean monthly serum 25-hydroxyvitamin D concentrations were higher in the group that received vitamin D and calcium than in the placebo group, as was the monthly serum 25-hydroxyvitamin D area under the curve. After completing 12 months of study, 2 (6.7%) participants in the group that received vitamin D and calcium had a trough serum 25-hydroxyvitamin D concentration &amp;lt;20 ng/mL compared with 14 (50%) in the placebo group. Twelve (44.4%) in the group that received vitamin D and calcium had a trough serum 25-hydroxyvitamin D concentration of &amp;gt; or =30 ng/mL compared with 3 (11.1%) in the placebo group. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;:&lt;BR&gt;Administration of oral cholecalciferol to HIV-infected children and adolescents at a dosage of 100,000 IU every 2 months, together with 1 g/day calcium, is safe and results in significant increases in serum 25-hydroxyvitamin D concentrations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393391</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.lww.com/jaids/pages/articleviewer.aspx?year=2010&amp;issue=06010&amp;article=00009&amp;type=abstract]]&gt;</url>
    <title>Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,TREATMENT,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;INTRODUCTION&lt;/STRONG&gt;: Directly observed therapy of highly active antiretroviral therapy (DOT-HAART) is a feasible adherence intervention. Prospective DOT-HAART studies have shown mixed results, and optimal target groups have yet to be defined. We performed a meta-analysis and systematic review to assess the effect of DOT-HAART on adherence and virologic and immunologic response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We performed a comprehensive search through August 2009 to identify peer-reviewed controlled studies that involved outpatient DOT-HAART among adults and reported at least 1 outcome assessed in this meta-analysis. Random-effects meta-analyses were performed; differences in effect on virologic suppression were examined using stratified meta-analyses and meta-regression on several study characteristics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Seventeen studies met inclusion criteria. Compared with control groups, DOT-HAART recipients were more likely to achieve an undetectable viral load (random effects risk ratio 1.24, 95% confidence interval (CI): 1.08 to 1.41), a greater increase in CD4 cell count (random effects weighted mean difference 43 cells/microL, 95% CI: 12 to 74 cells/microL), and HAART adherence of &amp;gt; or =95% (random effects risk ratio 1.17, 95% CI: 1.03 to 1.32). Results varied with respect to virologic response. DOT-HAART did not have a significant effect on virologic suppression when restricted to randomized controlled studies. Post-treatment effect was not observed in a limited number of studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: DOT-HAART had a significant effect on virologic, immunologic, and adherence outcomes, although its efficacy was not supported when restricting analysis to randomized controlled trials. DOT-HAART shows greatest treatment effect when targeting individuals with greater risk of nonadherence and when delivering the intervention that maximizes participant convenience and provides enhanced adherence support. Further investigation is needed to assess the postintervention effect and cost-effectiveness of DOT-HAART.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345459</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736385/pdf/pmed.1000146.pdf]]&gt;</url>
    <title>Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis</title>
    <publicationDate>2009-09-06T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,TREATMENT,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Treatment regimens for active tuberculosis (TB) that are intermittent, or use rifampin during only the initial phase, offer practical advantages, but their efficacy has been questioned. We conducted a systematic review of treatment regimens for active TB, to assess the effect of duration and intermittency of rifampin use on TB treatment outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods and Findings&lt;/STRONG&gt;: PubMed, Embase, and the Cochrane CENTRAL database for clinical trials were searched for randomized controlled trials, published in English, French, or Spanish, between 1965 and June 2008. Selected studies utilized standardized treatment with rifampin-containing regimens. Studies reported bacteriologically confirmed failure&lt;BR&gt;and/or relapse in previously untreated patients with bacteriologically confirmed pulmonary TB. Pooled cumulative incidences of treatment outcomes and association with risk factors were computed with stratified random effects metaanalyses. Meta-regression was performed using a negative binomial regression model. A total of 57 trials with 312 arms and 21,472 participants were included in the analysis. Regimens utilizing rifampin only for the first 1–2 mo had significantly higher rates of failure, relapse, and acquired drug resistance, as compared to regimens that used rifampin for 6 mo. This was particularly evident when there was initial drug resistance to isoniazid, streptomycin, or both. On the other hand, there was little evidence of difference in failure or relapse with daily or intermittent schedules of treatment administration, although there was insufficient published evidence of the efficacy of twice-weekly rifampin administration throughout therapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: TB treatment outcomes were significantly worse with shorter duration of rifampin, or with initial drug resistance to isoniazid and/or streptomycin. Treatment outcomes were similar with all intermittent schedules evaluated, but there is insufficient evidence to support administration of treatment twice weekly throughout therapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330427</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/reprint/360/18/1815.pdf]]&gt;</url>
    <title>Effect of early versus deferred antiretroviral therapy for HIV on survival</title>
    <publicationDate>2009-05-30T00:00:00</publicationDate>
    <publisher>Massachusetts Medical Society</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,ANTIMICROBIALS,ANTIVIRALS,TREATMENT,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Background:&lt;BR&gt;The optimal time for the initiation of antiretroviral therapy for symptomatic patients with human immunodeficiency virus (HIV) infection is uncertain.&lt;/P&gt;
&lt;P&gt;Methods:&lt;BR&gt;We conducted two parallel analyses involving a total of 17,517 symptomatic patients with HIV infection in the United States and Canada who received medical care during the period from 1996 through 2005. None of the patients had undergone previous antiretroviral therapy. In each group, we stratified the patients according to the CD4+ count (351 to 500 cells per cubic millimeter or &amp;gt;500 cells per cubic millimeter) at the&lt;BR&gt;initiation of antiretroviral therapy. In each group, we compared the relative risk of death for patients who initiated therapy when the CD4+ count was above each of the two thresholds of interest (early-therapy group) with that of patients who deferred therapy until the CD4+ count fell below these thresholds (deferred-therapy group).&lt;/P&gt;
&lt;P&gt;Results:&lt;BR&gt;In the first analysis, which involved 8362 patients, 2084 (25%) initiated therapy at a CD4+ count of 351 to 500 cells per cubic millimeter, and 6278 (75%) deferred therapy. After adjustment for calendar year, cohort of patients, and demographic and clinical characteristics, among patients in the deferred-therapy group there was an increase in the risk of death of 69%, as compared with that in the early-therapy group (relative risk in the deferred-therapy group, 1.69; 95% confidence interval [CI], 1.26 to 2.26;&lt;BR&gt;P&amp;lt;0.001). In the second analysis involving 9155 patients, 2220 (24%) initiated therapy at a CD4+ count of more than 500 cells per cubic millimeter and 6935 (76%) deferred therapy. Among patients in the deferred-therapy group, there was an increase in the risk of death of 94% (relative risk, 1.94; 95% CI, 1.37 to 2.79; P&amp;lt;0.001).&lt;/P&gt;
&lt;P&gt;Conclusions:&lt;BR&gt;The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285690</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/334/7585/136?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=karpakis&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.</title>
    <publicationDate>2007-01-20T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,TUBERCULOSIS,TRANSMISSION MODE,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT,MYCOBACTERIUM,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This study aimed to investigate the impact of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV, using a two centre prospective double blind placebo controlled
trial. The participants were children aged at least 8 weeks with HIV, to whom Isoniazid or a placebo was given with co-trimoxazole either daily or three times a week. Two tertiary healthcare centres in South Africa were used. The main outcome measures used were mortality, incidence of tuberculosis, and adverse events.

Data on 263 children (median age 24.7 months) were available when the data safety monitoring board recommended discontinuing the placebo arm; 132 (50%) were taking isoniazid. The median follow-up was 5.7 (interquartile range 2.0-9.7) months. Mortality was lower in the isoniazid group than in the placebo group (11 (8%) v 21 (16%), hazard ratio 0.46, 95% confidence interval 0.22 to 0.95, P = 0.015) by intention to treat analysis. The benefit applied across Centers for Disease Control clinical categories and in all ages. The reduction in mortality was similar in children on three times a week or daily isoniazid. The incidence of tuberculosis was lower in the isoniazid group (5 cases, 3.8%) than in the placebo group (13 cases, 9.9%) (hazard ratio 0.28, 0.10 to 0.78, P = 0.005). All cases of tuberculosis confirmed by culture were in children in the placebo group.

In conclusion, prophylaxis with isoniazid has an early survival benefit and reduces incidence of tuberculosis in children with HIV. Prophylaxis may offer an effective public health intervention to reduce mortality in such children in settings with a high prevalence of tuberculosis.]]&gt;</body>
  </document>
  <document>
    <id>394241</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6W8X-50C121X-D-7&amp;_cdi=6666&amp;_user=8810565&amp;_pii=S1473309910700931&amp;_origin=search&amp;_coverDate=07%2F31%2F2010&amp;_sk=999899992&amp;view=c&amp;wchp=dGLbVlz-zSkWA&amp;md5=b411c1de0f447c3209e54716550892de&amp;ie=/sdarticle.pd]]&gt;</url>
    <title>Effect of treating co-infections on HIV-1 viral load: a systematic review</title>
    <publicationDate>2010-07-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Co-infections contribute to HIV-related pathogenesis and often increase viral load in HIV-infected people. We did a systematic review to assess the effect of treating key co-infections on plasma HIV-1-RNA concentrations in low-income countries. We identified 18 eligible studies for review: two on tuberculosis, two on malaria, six on helminths, and eight on sexually transmitted infections, excluding untreatable or non-pathogenic infections. Standardised mean plasma viral load decreased after the treatment of co-infecting pathogens in all 18 studies. The standardised mean HIV viral-load difference ranged from -0.04 log(10) copies per mL (95% CI -0.24 to 0.16) after syphilis treatment to -3.47 log(10) copies per mL (95% CI -3.78 to -3.16) after tuberculosis treatment. Of 14 studies with variance data available, 12 reported significant HIV viral-load differences before and after treatment. Although many of the viral-load reductions were 1.0 log(10) copies per mL or less, even small changes in plasma HIV-RNA concentrations have been shown to slow HIV progression and could translate into population-level benefits in lowering HIV transmission risk.]]&gt;</body>
  </document>
  <document>
    <id>285691</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/cgi-bin/resolve?JID34830]]&gt;</url>
    <title>Effect of Treatment of Latent Tuberculosis Infection on the T Cell Response to Mycobacterium tuberculosis Antigens </title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Journal of Infectious Diseases</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Most cases of latent tuberculosis infection (LTBI) do not cause symptoms during the lifetime of the infected person. Longitudinal analysis of the immune response of healthy Mycobacterium tuberculosisinfected people might, therefore, give insight into the basis of protective immunity. In a longitudinal study, we documented the effect that treatment had on the T cell response to M. tuberculosis antigens in 33 healthy people with LTBI. Preventive treatment of LTBI resulted in a 1.8-fold average increase in the numbers of interferon (IFN)producing T cells within 26±4 days (P=.006), followed by a decrease by the end of the treatment period (82±6 days; P=.004). There was no significant overall change in the T cell response to any antigen in a control group (n=8) of patients who elected radiological follow-up. Using live M. tuberculosis strain H37Rv as a stimulant in an enzyme-linked immunospot assay in sensitized individuals, we showed that isoniazid, but not rifampin, led to an increase in the number of IFN-producing cells. These results suggest that the integrity of the bacterial cell wall is important for M. tuberculosis in avoiding immune recognition by T cells and favor a dynamic model of LTBI.]]&gt;</body>
  </document>
  <document>
    <id>285693</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/333/7581/1241]]&gt;</url>
    <title>Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,BODY PART AFFECTED,AIRBORNE,TRANSMISSION MODE,INFLUENZA,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ OBJECTIVE: To determine whether vaccination of care home staff against influenza indirectly protects residents. 
DESIGN: Pair matched cluster randomised controlled trial. 
SETTING: Large private chain of UK care homes during the winters of 2003-4 and 2004-5. 
PARTICIPANTS: Nursing home staff (n=1703) and residents (n=2604) in 44 care homes (22 intervention homes and 22 matched control homes). 
INTERVENTIONS: Vaccination offered to staff in intervention homes but not in control homes. MAIN OUTCOME MEASURES: The primary outcome was all cause mortality of residents. Secondary outcomes were influenza-like illness and health service use in residents. 
RESULTS: In 2003-4 vaccine coverage in full time staff was 48.2% (407/884) in intervention homes and 5.9% (51/859) in control homes. In 2004-5 uptake rates were 43.2% (365/844) and 3.5% (28/800). National influenza rates were substantially below average in 2004-5. In the 2003-4 period of influenza activity significant decreases were found in mortality of residents in intervention homes compared with control homes (rate difference -5.0 per 100 residents, 95% confidence interval -7.0 to -2.0) and in influenza-like illness (P=0.004), consultations with general practitioners for influenza-like illness (P=0.008), and admissions to hospital with influenza-like illness (P=0.009). No significant differences were found in 2004-5 or during periods of no influenza activity in 2003-4. 
CONCLUSIONS: Vaccinating care home staff against influenza can prevent deaths, health service use, and influenza-like illness in residents during periods of moderate influenza activity.]]&gt;</body>
  </document>
  <document>
    <id>285694</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/content/abstract/332/7553/1299]]&gt;</url>
    <title>Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review</title>
    <publicationDate>2006-06-03T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,INFECTIONS,TREATMENT,NEISSERIA MENINGITIDIS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective: To review the evidence for effectiveness of treatment with antibiotics before admission in reducing case fatality from meningococcal disease. 

Design: Systematic review. 

Data sources: Cochrane register of trials and systematic reviews, database of abstracts of reviews of effectiveness, health technology assessment, and national research register in England and Wales, Medline, Embase, and CAB Health. 

Included studies: Studies describing vital outcome of at least 10 cases of meningococcal disease classified by whether or not antibiotics were given before admission to hospital. 

Results: 14 observational studies met the review criteria. Oral antibiotic treatment given before admission was associated with reduced mortality among cases (combined risk ratio 0.17, 95% confidence interval 0.07 to 0.44). In seven studies in which all included patients were seen in primary care, the association between parenteral antibiotics before admission and outcome was inconsistent (2 for heterogeneity 11.02, P = 0.09). After adjustment for the proportion given parenteral antibiotics before admission, there was no residual heterogeneity. A higher proportion of patients given parenteral antibiotics before admission was associated with reduced mortality after such treatment and vice versa (P = 0.04). 

Conclusion: Confounding by severity is the most likely explanation both for the beneficial effect of oral antibiotics and the harmful effect observed in some studies of parenteral antibiotics. We cannot conclude whether or not antibiotics given before admission have an effect on case fatality. The data are consistent with benefit when a substantial proportion of cases are treated.]]&gt;</body>
  </document>
  <document>
    <id>285695</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.328.7452.1339]]&gt;</url>
    <title>Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review</title>
    <publicationDate>2004-06-05T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,VACCINES / IMMUNISATION,PREVENTION,PREVENTION AND CONTROL,TREATMENT,BACTERIA,MICROORGANISM,NEISSERIA MENINGITIDIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective To summarise the evidence for the role of antibiotics in preventing further cases of meningococcal disease through chemoprophylaxis given to the index patient, household contacts, and children in day care settings after a single case. 
Design Systematic review. 
Methods Studies were identified by searching Embase (1983-2003), Medline (1965-2003), and CAB Health (1973-2003) and by contacting the World Health Organization and the European meningococcal disease surveillance network and examining references of identified papers. The review included all studies with at least 10 cases in which outcomes were compared between treated and untreated groups. 
Main outcome measure Subsequent cases of meningococcal disease 1-30 days after onset of disease in the index patient. 
Results Four observational studies and one small trial met the inclusion criteria. Meta-analysis of studies on chemoprophylaxis given to household contacts showed a significant reduction in risk (risk ratio 0.11, 95% confidence interval 0.02 to 0.58). The number needed to treat to prevent a case was estimated as 218 (121 to 1135). Primary outcome data were not available in studies of chemoprophylaxis given to the index patient: when prophylaxis had not been given, rate of carriage after discharge from hospital was estimated as 3% (0 to 6), probably an underestimate of the true rate. No studies of chemoprophylaxis in day care settings were identified that met the inclusion criteria. 
Conclusion There have been no high quality experimental trials looking at control policies for meningococcal disease. The best available evidence is from retrospective studies. The risk of meningococcal disease in household contacts of a patient can be reduced by an estimated 89% if they take antibiotics known to eradicate meningococcal carriage. Chemoprophylaxis should be recommended for the index patient and all household contacts. ]]&gt;</body>
  </document>
  <document>
    <id>330335</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(08)70180-4/abstract#]]&gt;</url>
    <title>Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,ANTIMICROBIALS,ANTIVIRALS,CHILDREN,POPULATION GROUPS,TREATMENT,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Assessment of antiretroviral treatment programmes for HIV-infected children in sub-Saharan Africa is important to enable the development of effective care and improve treatment outcomes. We review the effectiveness of paediatric antiretroviral treatment programmes in sub-Saharan Africa and discuss the implications of these findings for the care and treatment of HIV-infected children in this region. Available reports indicate that programmes in sub-Saharan Africa achieve treatment outcomes similar to those in North America and Europe. However, progress in several areas is required to improve the care of HIV-infected children in sub-Saharan Africa. The findings emphasise the need for low-cost diagnostic tests that allow for earlier identification of HIV infection in infants living in sub-Saharan Africa, improved access to antiretroviral treatment programmes, including expansion of care into rural areas, and the integration of antiretroviral treatment programmes with other health-care services, such as nutritional support.]]&gt;</body>
  </document>
  <document>
    <id>285696</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/333/7580/1193]]&gt;</url>
    <title>Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial </title>
    <publicationDate>2006-11-07T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,PNEUMONIA,AIRBORNE,CONTACT,BODY PART AFFECTED,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,INFECTIONS,TREATMENT,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This study aimed to compare the effectiveness of an early switch to oral antibiotics with the standard 7 day course of intravenous antibiotics in severe community acquired pneumonia in a multicentre randomised controlled trial which took place in 5 teaching hospitals and 2 university medical centres in the Netherlands. 

302 patients in non-intensive care wards with severe community acquired pneumonia participated, 265 patients fulfilled the study requirements. The study was carried out using 3 days of treatment with intravenous antibiotics followed, when clinically stable, by oral antibiotics or by 7 days of intravenous antibiotics. The main outcome measures were clinical cure and length of hospital stay. 

The authors concluded that the early switch from intravenous to oral antibiotics in patients with severe community acquired pneumonia was safe and decreased length of hospital stay by 2 days. ]]&gt;</body>
  </document>
  <document>
    <id>393369</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20375876]]&gt;</url>
    <title>Effectiveness of HIV prevention for youth in sub-Saharan Africa: systematic review and meta-analysis of randomized and nonrandomized trials</title>
    <publicationDate>2010-05-15T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: Systematically assess the effectiveness of HIV-prevention interventions in changing sexual behaviour of young people (10-25 years) in sub-Saharan Africa.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Three online databases were searched using prespecified terms. Additional articles were identified on websites of international organizations and by searching bibliographies. Randomized and nonrandomized trials of interventions aiming to reduce risk behaviour were included as well as single-arm studies reporting effects of differential exposure to an intervention. Data were extracted independently in duplicate using predefined data fields.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Thirty-one studies on 28 interventions met the inclusion criteria, including 11 randomized trials. Difficulties with implementing planned activities were reportedly common and differential exposure to intervention was high. Two hundred and seventeen outcome measures were extracted: 88 early (within 1 year of intervention) and 129 late outcomes (more than 1 year after the end of the intervention). Sex education and condom promotion among youth did not increase sexual behaviour as well as risky sexual behaviour. No positive effects on sexual behaviour were detected either and condom use at last sex only increased among males [relative risk = 1.46; 95% confidence interval = 1.31-1.64]. One study reported a reduction of herpes simplex virus-2, but not HIV incidence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: There remains a stark mismatch between the HIV burden in youth and the number of attempts to design and test prevention interventions - only two trials report biological outcomes. More effective interventions targeting youth are needed. Attention should go to studying implementation difficulties, sex differences in responses to interventions, determinants of exposure to interventions and perhaps inclusion of other factors apart from HIV/AIDS which influence sexual behaviour.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285697</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/326/7401/1235]]&gt;</url>
    <title>Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.</title>
    <publicationDate>2003-06-07T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,BODY PART AFFECTED,AIRBORNE,TRANSMISSION MODE,INFLUENZA,INFECTIONS,ANTIMICROBIALS,ANTIVIRALS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,TREATMENT,INFECTIOUS DISEASES,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective: To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and prevention of influenza A and B. 

Design: Systematic review and meta-analyses of randomised controlled trials. 

Data sources: Published studies were retrieved from electronic bibliographic databases; supplementary data were obtained from the manufacturers. 

Selection of studies: Randomised controlled, double blind trials that were published in English, had data available before 31 December 2001, evaluated treatment or prevention of naturally occurring influenza with zanamivir or oseltamivir (if given using the formulation and dosage licensed for clinical use), and reported at least one end point of relevance. 

Review methods: The main outcome measures were the median time to the alleviation of symptoms (for treatment trials) and number of flu episodes avoided (for prevention trials). Three population groups were defined: children aged 12 years and under; otherwise healthy individuals aged 12 to 65 years; and "high risk" individuals (those with certain chronic medical conditions or aged 65 years and older). 

Results: Seventeen treatment trials and seven prevention trials identified met the inclusion criteria. All trials included compared one of the drugs against placebo or standard care. Treatment of children, otherwise healthy individuals, and high risk populations with zanamivir reduced the median duration of symptoms in days respectively by 1.0 (95% confidence interval 0.5 to 1.5), 0.8 (0.3 to 1.3), and 0.9 (-0.1 to 1.9) for the intention to treat population. The corresponding results, in days, for oseltamivir were 0.9 (0.3 to 1.5), 0.9 (0.3 to 1.4), and 0.4 (-0.7 to 1.4). The effect of giving zanamivir and oseltamivir prophylactically resulted in a relative reduction of 70-90% in the odds of developing flu, depending on the strategy adopted and the population studied. 

Conclusions: Evidence from randomised controlled trials consistently supports the view that both oseltamivir and zanamivir are clinically effective for treating and preventing flu. However, evidence is limited for the treatment of certain populations and for all prevention strategies. ]]&gt;</body>
  </document>
  <document>
    <id>393679</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/648079]]&gt;</url>
    <title>Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis</title>
    <publicationDate>2009-12-15T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TREATMENT,CHILDREN,POPULATION GROUPS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Responses to antiretroviral therapy (ART) among human immunodeficiency virus (HIV)-infected children in resource-limited settings have recently been reported, but outcomes vary. We sought to derive pooled estimates of the 12-month rate of virologic suppression (HIV RNA, &amp;lt;400 copies/mL) and gain in CD4 cell percentage (DeltaCD4%) for children initiating ART in resource-limited settings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We conducted a systematic review and meta-analysis of published reports of HIV RNA and CD4 outcomes for treatment-naive children aged 0-17 years old by means of the Medline, EMBASE (Excerpta Medica Database), and LILACS (Latin American and Caribbean Health Sciences Literature) electronic databases and the Cochrane Clinical Trials Register. Pooled estimates of the reported proportion with HIV RNA &amp;lt;400 copies/mL and DeltaCD4% after 12 months of ART were derived using patient-level estimates and fixed- and random-effects models. To approximate intention-to-treat analyses, in sensitivity analyses children with missing 12-month data were assumed to have HIV RNA&amp;gt;400 copies/mL or DeltaCD4% of zero.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: In patient-level estimates after 12 months of ART, the pooled proportion with virologic suppression was 70% (95% confidence interval [CI], 67%-73%); the pooled DeltaCD4% was 13.7% (95% CI, 11.8%-15.7%). Results from the fixed- and random-effects models were similar. In approximated intention-to-treat analyses, the pooled estimates decreased to 53% with virologic suppression (95% CI, 50%-55%) and to a DeltaCD4% of 8.5% (95% CI, 5.5%-11.4%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Pooled estimates of reported virologic and immunologic benefits after 12 months of ART among HIV-infected children in resource-limited settings are comparable with those observed among children in developed settings. Consistency in reporting on reasons for missing data will aid in the evaluation of ART outcomes in resource-limited settings.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330304</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.atypon-link.com/GPI/doi/abs/10.1521/aeap.2009.21.3.181]]&gt;</url>
    <title>Effectiveness of Peer Education Interventions for HIV Prevention in Developing Countries: A Systematic Review and Meta-Analysis</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>The Guilford Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Peer education for HIV prevention has been widely implemented in developing countries, yet the effectiveness of this intervention has not been systematically evaluated. We conducted a systematic review and meta-analysis of peer education interventions in developing countries published between January 1990 and November 2006. Standardized methods of searching and data abstraction were utilized. Merged effect sizes were calculated using random effects models. Thirty studies were identified. In meta-analysis, peer education interventions were significantly associated with increased HIV knowledge (odds ratio [OR]: 2.28; 95%, confidence interval [CI]:1.88, 2.75), reduced equipment sharing among injection drug users (OR: 0.37; 95% CI: 0.20, 0.67), and increased condom use (OR: 1.92; 95% CI: 1.59, 2.33). Peer education programs had a nonsignificant effect on sexually transmitted infections (OR: 1.22; 95% CI:0.88, 1.71). Meta-analysis indicates that peer education programs in developing countries are moderately effective at improving behavioral outcomes but show no significant impact on biological outcomes. Further research is needed to determine factors that maximize the likelihood of program success.]]&gt;</body>
  </document>
  <document>
    <id>330306</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.atypon-link.com/GPI/doi/pdf/10.1521/aeap.2008.20.6.465]]&gt;</url>
    <title>Effects and effectiveness of life skills education for HIV prevention in young people</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>The Guilford Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,PREVENTION,INFECTIONS,POPULATION GROUPS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 09,ADOLESCENTS,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ For 20 years, “life skills” education has been advocated as a key component of HIV and AIDS education for young people. But what do terms such as life skills imply, and what evidence is there that a life skills-based approach really works? This article reviews the literature on the effects and effectiveness of life skills-based education for HIV prevention. Evaluated interventions were identified by using three search strategies. The review identified a surprising number of rigorously designed and evaluated interventions from Africa, Latin America, Asia, and the Pacific. Most interventions used life skills training as a component of the overall education strategy. Programs worked best to positively influence knowledge, attitudes, intentions, skills, and abilities. Programs rarely produced consistent effects on sexual behavior. Also, life skills, training had little effect on biological outcomes. The narrow focus on achieving behavioral outcomes may be at the loss of documenting other positive impacts.]]&gt;</body>
  </document>
  <document>
    <id>297863</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18544018]]&gt;</url>
    <title>Efficacy of Antiretroviral Drugs in Reducing Mother-to-Child Transmission of HIV in Africa: A Meta-Analysis of Published Clinical Trials</title>
    <publicationDate>2008-06-02T00:00:00</publicationDate>
    <publisher>Mary Ann Liebert Inc</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,ANTIVIRALS,ANTIMICROBIALS,PREVENTION AND CONTROL,INFECTIONS,POPULATION GROUPS,NOV 08,TREATMENT,ADULTS,CHILDREN,PREGNANT WOMEN,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2008]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Antiretroviral drugs (ARVs) have been shown to be efficacious in decreasing mother-to-child transmission (MTCT) of HIV. A summary estimate of the efficacy of ARVs in reducing MTCT is important for modeling and policy decisions. However, no one has hitherto attempted to generate this summary estimate for Africa, the continent with the greatest HIV/AIDS burden. This study estimates the efficacy of ARVs in reducing MTCT in Africa through a meta-analysis of published studies conducted in Africa. Using an a priori protocol, Medline, EMBASE, and the Cochrane Library were searched for primary studies that measured MTCT of HIV, had ARVs as the exposure to the mother, and were conducted in Africa. Extracted data included characteristics of the study, population, quality, exposure, and results. The data were analyzed using a random effects model with each trial arm as a data point. Ten randomized clinical trials conducted in West, East, and Southern Africa published from 1999 to 2007 satisfied the inclusion criteria. They ranged in sample size from 139 to 1797, and used different ARV regimens as the exposure to the mother antepartum, intrapartum, or postpartum, and to the baby. The combined effect estimate of using ARVs is 10.6% (95% CI: 8.6–13.1) transmission at 4–6 weeks and 21.0% (95% CI: 15.5–27.7) transmission for placebo. This represents approximately 50% efficacy. The result is stable and not driven by any single study. All regimens were well tolerated. We conclude that ARV use to reduce MTCT of HIV in Africa is efficacious and well tolerated.&lt;/P&gt;
&lt;P&gt;AIDS Res Hum Retroviruses. 2008 Jun;24(6):827-37&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285698</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jac.oxfordjournals.org/cgi/reprint/50/2/231?maxtoshow=&amp;hits=10&amp;RESULTFORMAT=&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=50&amp;firstpage=231&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomised, double-blind, placebo-controlled trial</title>
    <publicationDate>2002-04-26T00:00:00</publicationDate>
    <publisher>Journal of Antimicrobial Chemotherapy</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HIV/AIDS,CARDIOVASCULAR,BODY PART AFFECTED,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),FUNGI,CANDIDA ALBICANS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,MALE UROGENITAL DISORDERS,HIV]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A prospective, double-blind, randomised study assessing the clinical efficacy and tolerence of intermittent (weekly) fluconazole as secondary prophylaxis in HIV infected patients with previous proven oropharyngeal candidiasis. The emergence of resistant strains of Candida sp. to fluconazole was also assessed. There was a statistically significant reduction in both the number of relapses and time to relapse for the fluconazole group compared to placebo. Fluconazole was extremely well tolerated, and the development of significant resistance was not detected during the study period (although a few resistant strains were identified in both active and placebo treatment groups).]]&gt;</body>
  </document>
  <document>
    <id>320716</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/Elderlytakelisteriagamble.aspx]]&gt;</url>
    <title>Elderly take listeria 'gamble'</title>
    <publicationDate>2009-06-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,INFECTIONS,POPULATION GROUPS,LISTERIOSIS,ADULTS,OLDER PEOPLE,MICROORGANISM,LISTERIA MONOCYTOGENES,BACTERIA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Listeria poisonings are on the rise because the elderly are taking chances with use-by dates, newspapers reported. The Times said that the 'waste not, want not' ethos of the post-war period could be responsible for the increase in the number of cases of food poisoning. The Daily Mail said that rising food prices and fixed incomes mean that pensioners are keeping food for longer than they should.&lt;/P&gt;
&lt;P&gt;The news reports are based on information from The Food Standards Agency (FSA), which says that people aged 60 and over are more likely than younger people to take risks with use-by dates. The FSA said that eating food past its use-by date increases the risk of food poisoning from listeria. There has been a recent surge in the number of cases of listeria, many of which have been in the over-60s, a high-risk group for the potentially deadly bug.&lt;/P&gt;
&lt;P&gt;Dr Andrew Wadge, chief scientist at the FSA, said, "There are some really simple steps people can take to prevent getting ill in the first place. Be aware that use-by dates indicate how long food will remain safe, and then make sure you stick to them. Always follow the storage instructions on the label. And keep your fridge cold enough: between 0°C and 5°C is ideal."&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286047</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop16.pdf]]&gt;</url>
    <title>Electron microscopy using solid phase immune electron microscopy (VSOP 16)</title>
    <publicationDate>2007-09-13T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,FAECAL/ORAL,TRANSMISSION MODE,INFECTIOUS DISEASES,NOROVIRUS,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,NOROVIRUS INFECTION,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,VIRUSES,NOROVIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This procedure has been used with success to detect noroviruses (Norwalk-like viruses) from faeces, vomit samples from outbreaks of non-bacterial gastroenteritis and parvovirus B19 from biopsy material from cases of hydrops foetalis. In the case of noroviruses, multiple serotypes exist and it should be borne in mind that a capture antibody from a single serum may only be active against some of these serotypes. The technique may be easily adapted to use either IgG or IgM as the capturing antibody.]]&gt;</body>
  </document>
  <document>
    <id>285700</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop14.pdf]]&gt;</url>
    <title>Electron microscopy: Differential Centrifugation (Double-Spin Method) VSOP 14 (Under Review)</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This procedure describes the concentration of virus using differential centrifugation before grid
preparation. This method has been found to be suitable for the examination of faecal specimens, urine specimens, tissue biopsy homogenates and the examination of cell cultures for the presence of viruses.

A homogenised specimen is centrifuged at low speed to remove large debris and bacteria. The clarified suspension is then subjected to one or more cycles of ultracentrifugation to recover any virus particles present. The procedure can be used to concentrate viruses from any type of specimen that can be homogenised in suspension. It is useful in any situation where there is sufficient extract to allow concentration to be performed (minimum volume 1 mL).

It is currently recommended that ultracentrifugation, ammonium sulphate precipitation (VSOP 15 –
Electron microscopy: Ammonium sulphate precipitation), or immune capture (VSOP 16 – Electron
microscopy using solid phase immune electron microscopy) is used for all faecal specimens from
outbreaks of gastroenteritis.]]&gt;</body>
  </document>
  <document>
    <id>285701</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop13.pdf]]&gt;</url>
    <title>Electron Microscopy: Floatation (direct) method (VSOP 13)</title>
    <publicationDate>2007-02-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This procedure provides a rapid method for the direct examination of clinical specimens that are
expected to contain very large numbers of virus particles.

This method does not use virus concentration prior to the preparation of grids. It is therefore useful only in situations where the virus is expected to be present in high titre, for example, faecal samples from children under 5 years of age with acute diarrhoea or vesicle fluids or crusts collected from vesicular lesions. It is a rapid technique and may successfully demonstrate viruses present in the sample. It is generally accepted that 106 - 109 virus particles per gram of starting material are required to give a reliable result using this technique2. This procedure is not recommended for the examination of samples from outbreaks of gastroenteritis where a viral aetiology is suspected. Immune capture (VSOP 16 – Electron Microscopy using solid phase immune electron microscopy), Differential centrifugation (VSOP 14 – Electron microscopy: Differential centrifugation (double-spin method) or Ammonium sulphate precipitation (VSOP 15 – Electron microscopy: Ammonium sulphate precipitation) are recommended for the examination of samples from outbreaks of gastroenteritis where a viral aetiology is suspected.

This procedure must not be used on samples suspected of containing smallpox or any other
category 4 organism.
]]&gt;</body>
  </document>
  <document>
    <id>395108</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/truvada-anti-hiv-pill-prevention-test.aspx]]&gt;</url>
    <title>Encouraging results for anti-HIV pill</title>
    <publicationDate>2010-11-26T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have tested the “first anti-HIV pill to provide effective protection against the disease”, The Independent has reported.&lt;/P&gt;
&lt;P&gt;The news comes from an international study looking at whether a pill combining two antiviral drugs could reduce new HIV infections among 2,500 HIV-negative men and transgender women who have sex with men. This population is considered to have higher risk of exposure to the virus. Compared with a dummy placebo drug the daily pill reportedly cut the risk of contracting HIV by 44%. All participants had also received condoms and counselling on how to reduce the risk of contracting HIV.&lt;/P&gt;
&lt;P&gt;While the group receiving antiviral drugs did have a lower rate of new infections it should be noted that the drug did not provide full protection – 36 people were newly infected, compared with 64 in the placebo group. While the rate of side effects was low in both groups over the three-year study, further research is also needed to establish dosage, safety and tolerance over longer periods.&lt;/P&gt;
&lt;P&gt;While this preliminary research is encouraging, the eventual development of drugs to prevent HIV infection would not diminish the importance of awareness and condom use, which are two key tools for preventing the spread of HIV and other sexually transmitted infections.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a well-conducted study that assessed the use of an oral prophylactic treatment for HIV in a higher risk population. Although the treatment did reduce the number of new infections in this group compared with placebo, it did not prevent transmission entirely. The researchers also highlighted that the participants’ behaviour changed in some ways after enrolment in the study, including increased condom use and a reduction in higher risk behaviour. These changes may reflect the influence of the additional services, such as counselling, testing and dispensing of condoms, that were provided alongside the study drugs.&lt;/P&gt;
&lt;P&gt;The researchers caution of the possible risk of prescribing the drug out of a trial setting. They suggest that the positive moves towards prevention displayed by the participants may not necessarily be adopted by users due to increased expectation of the benefits of the drug. Alongside these concerns, further research will be needed to establish the long-term safety and tolerance of the treatment and to define the minimum protective drug concentration.&lt;/P&gt;
&lt;P&gt;As it stands, this research provides encouraging but preliminary evidence that prophylactic antiretroviral treatments could provide an additional benefit alongside safer sex practices and education among a specific high-risk population. As such, it may potentially slow down the spread of HIV within similar populations, but needs further testing among other social groups.&lt;/P&gt;
&lt;P&gt;While the development of effective drug-based HIV prophylaxis would be an important step in the right direction, it should be emphasised that this would not diminish the importance of barrier methods of contraception, such as condoms, which remain the best method of preventing transmission of HIV and other sexually transmitted infections.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Grant RM, Lama JR, Anderson PL et al. &lt;A href="http://www.nejm.org/doi/full/10.1056/NEJMoa1011205" target="_blank"&gt;Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men&lt;/A&gt;. New England Journal of Medicine, November 23 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285712</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jac.oxfordjournals.org/cgi/reprint/50/4/577]]&gt;</url>
    <title>Enterococcal intravascular catheter-related bloodstream infection: management and outcome of 61 consecutive cases</title>
    <publicationDate>2002-11-11T00:00:00</publicationDate>
    <publisher>Journal of Antimicrobial Chemotherapy</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR,BODY PART AFFECTED,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT,MICROORGANISM,ENTEROCOCCUS,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The management of 61 consecutive episodes of enterococcal intravascular catheter related bloodstream infection (CRBSI) in a large general hospital was reviewed. The majority of infections occurred in renal patients (62%) and there was a bimodal age distribution (infants and the elderly). 50 (82%) of infections were caused by Enterococcus faecalis (the remainder due to Enterococcus faecium). Outcome was assessed with respect to whether infection was managed with line removal (as occurred in 48 cases), and the antimicrobial therapy given; no antibiotics or a cell-wall active agent (beta-lactam or glycopeptide) with or without gentamicin. All other therapy was deemed inappropriate. Overall, infection was cured in 45 patients (74%), recurred in 9 (15%) and failed in 7 (11%, all of whom died). Line removal was significantly associated with cure of infection (p=0.003), and in those where the line was not removed, use of a cell-wall active agent plus gentamicin achieved cure significantly more often than using a cell-wall active agent alone (p&lt;0.05). All episodes where inappropriate or no antimicrobial therapy was employed, and the line was not removed, resulted in failure. The authors conclude that line removal is effective (and may be sufficient in the absence of appropriate antimicrobial therapy) in treating enterococcal CRBSI. However if the line is not removed, combination antibiotic therapy with gentamicin is more likely to result in a cure of infection than therapy with either vancomycin or ampicillin alone.]]&gt;</body>
  </document>
  <document>
    <id>285713</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f23.pdf]]&gt;</url>
    <title>Enumberation of Enterobacteriaceae by the Colony Count Technique (F23)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,BACTERIA,KLEBSIELLA PNEUMONIAE,MICROORGANISM,SALMONELLA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285714</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w9.pdf]]&gt;</url>
    <title>Enumeration of Aeromonas species by membrane filtration (W9)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285715</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f15.pdf]]&gt;</url>
    <title>Enumeration of Bacillus cereus and other Bacillus species (F15)</title>
    <publicationDate>2005-05-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACILLUS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The method described is applicable to the enumeration of B.cereus and other Bacillus species in all food types. The media used will recover most species including all those implicated in food poisoning.]]&gt;</body>
  </document>
  <document>
    <id>285717</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f14.pdf]]&gt;</url>
    <title>Enumeration of Clostridium perfringens (F14)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,CONTACT,FOOD/WATER,DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285716</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w5.pdf]]&gt;</url>
    <title>Enumeration of clostridium perfringens by membrane filtration (W5)</title>
    <publicationDate>2004-08-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,CONTACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285718</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w2.pdf]]&gt;</url>
    <title>Enumeration of coliform bacteria and Escherichia Coli by membrane filtration (W2)</title>
    <publicationDate>2007-10-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,FAECAL/ORAL,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,ESCHERICHIA COLI INFECTION,INFECTIONS,MICROORGANISM,BACTERIA,E. COLI,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;SCOPE OF DOCUMENT&lt;BR&gt;The method described is applicable to the enumeration of coliform bacteria and Escherichia coli in water samples intended for human consumption and in pool waters by the membrane filtration technique. It may be used for environmental and recreational water samples but not for designated bathing waters sampled under the bathing water regulations. These samples are analysed using methods detailed by the Environment Agency.&lt;/P&gt;
&lt;P&gt;INTRODUCTION&lt;BR&gt;Background&lt;BR&gt;Coliform bacteria are widely regarded as the most reliable microbiological indicator of water quality. They are found in the human and animal intestine and may serve as indicators of potential faecal pollution but may also be environmental in origin. ‘Faecal coliform bacteria’ and E. coli are only found in human and animal intestines and tests for their presence in water are necessary to confirm that pollution is of human and/or animal origin. The term ‘faecal coliform’ is not precise and is consequently not used in this National Standard Method (NSM). In the context of water microbiology in the United Kingdom faecal coliform bacteria are regarded as being E. coli.&lt;BR&gt;Coliform bacteria and E. coli are sensitive to the disinfection processes used in water treatment and do not usually multiply in water particularly in temperate zones. These organisms should not be present in a 250 mL sample of mineral waters or drinking waters in bottles and containers or 100 mL for other waters of potable quality.&lt;/P&gt;
&lt;P&gt;This method is based on the method described in the Microbiology of Drinking Water 2002 document.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285719</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/milk_dairy/pdf/d4.pdf]]&gt;</url>
    <title>Enumeration of coliforms - colony count at 30°C (D4)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,FOOD/WATER,DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285720</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w18.pdf]]&gt;</url>
    <title>Enumeration of coliforms and Escherichia Coli by Idexx (Colilert 18) Quanti-TrayTM (W18)</title>
    <publicationDate>2005-05-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,FAECAL/ORAL,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,ESCHERICHIA COLI INFECTION,GASTROENTERITIS,INFECTIONS,MICROORGANISM,BACTERIA,E. COLI,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scope&lt;BR&gt;The method described is applicable to the enumeration of coliform bacteria and Escherichia coli in samples of potable quality water, pool waters and environmental waters. It may be used for environmental fresh water samples but not for bottled mineral waters or for designated bathing waters sampled under the bathing water regulations. It is particularly appropriate for samples likely to contain small numbers of coliform bacteria and E. coli, such as many private water supplies, since it reduces&lt;BR&gt;the work required for confirmation giving a confirmed result within 22 hours.&lt;/P&gt;
&lt;P&gt;Background&lt;BR&gt;The total coliform bacterial count is widely regarded as the most reliable indicator of potable water quality. Coliform bacteria are found in the human and animal intestine but may also be environmental in origin. Consequently, they serve as indicators of potential faecal pollution. E. coli is only found in human and animal intestines and tests for its presence in water are necessary to confirm that pollution is of human or animal origin.&lt;BR&gt;Coliform bacteria and E. coli are sensitive to the disinfection processes used in water treatment and do not multiply in water. They can also be used as indicators of pool waters. They should not be present in 100 mL of waters of potable quality or pool waters.&lt;/P&gt;
&lt;P&gt;Quanti-TrayTM is a multi-well most probable number (MPN) method incorporating a defined substrate medium which contains o-nitrophenyl-ß-D-galactopyranoside (ONPG) and 4-methyl-umbelliferyl-ß-Dglucuronide&lt;BR&gt;(MUG). After incubation at 37°C for 18-22 hours coliform bacteria produce a yellow colour due to the production of ß-galactosidase and E. coli also produces fluorescence as a result of the action of ß-glucuronidase. The MPN is calculated from the number of positive wells.&lt;/P&gt;
&lt;P&gt;This method has been subjected to extensive validation trials in the UK for use with mains drinking water and private water supplies and is incorporated in the Microbiology of Drinking Water 2002 document.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285721</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/milk_dairy/pdf/d5.pdf]]&gt;</url>
    <title>Enumeration of coliforms and presumptive Escherichia coli by the most probable number (MPN) technique (D5)</title>
    <publicationDate>2005-05-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,ESCHERICHIA COLI INFECTION,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,FAECAL/ORAL,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,INFECTIONS,INFECTIOUS DISEASES,E. COLI,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scope&lt;BR&gt;The method described combines detection of coliforms and presumptive E. coli in a liquid medium containing 4-methylumbelliferyl-ß-D glucuronide (MUG) and calculation of the number of coliforms and/or presumptive E. coli by the most probable number (MPN) technique after incubation at 30°C. It is particularly suitable for use when levels are likely to be low (less than 100/g or 10/ml).&lt;/P&gt;
&lt;P&gt;Background&lt;BR&gt;The Dairy Products (Hygiene) Regulations 1995 and the accompanying guidance notes contain microbiological standards for the presence of Escherichia coli and guidelines for coliforms in milk and dairy products sampled at a production holding or heat treatment establishment. The standard and guideline values vary according to the type of product being examined. Although the regulations specify methods to be used they also state that any other internationally recognised method may be used. Provisional International Standard 170: 1994 is specified in the regulations for enumeration of E. coli. It also allows enumeration of presumptive coliforms. &lt;/P&gt;
&lt;P&gt;The method described here extends this international standard method to allow confirmation of coliforms as described in ISO 4831/ BS 5763&lt;BR&gt;part 34, and the revised version of ISO 5541 part 25.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285722</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w3.pdf]]&gt;</url>
    <title>Enumeration of enterococci by membrane filtration (W3)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285723</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f16.pdf]]&gt;</url>
    <title>Enumeration of Escherichia coli in Raw Molluscs by the Multiple Tube Technique (F16)</title>
    <publicationDate>2005-05-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,FAECAL/ORAL,GASTROINTESTINAL INFECTIONS,ESCHERICHIA COLI INFECTION,GASTROENTERITIS,INFECTIONS,BACTERIA,E. COLI,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scope&lt;BR&gt;The method described is applicable to the enumeration of Escherichia coli in bivalves collected for the classification of harvesting areas and for uncooked ready - to - eat bivalve molluscs and gastropods.&lt;/P&gt;
&lt;P&gt;Background&lt;BR&gt;Molluscs are estuarine shellfish and are liable to gross faecal contamination from sewage pollution from the waters in which they are harvested. Bivalve molluscs, which include oysters, clams, mussels and&lt;BR&gt;cockles, feed and respire by filter feeding mechanisms. This may result in accumulation of sewage derived pathogens in the body tissue.&lt;BR&gt;The EC Directive 91/4921 stipulates conditions for the production and placing on the market of live bivalve molluscs. It provides for an end product standard, and the classification of shellfish harvesting areas into&lt;BR&gt;categories according to the degree of contamination with faecal indicator bacteria present in samples of shellfish flesh. Escherichia coli is presently used in the United Kingdom as an indicator of faecal contamination.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The microbiological criteria are specified for the classification of shellfish harvesting areas and for live bivalve molluscs intended for immediate consumption. This method is a modification of the method produced by a Ministry of Agriculture, Fisheries and Food, Department of Health, and Public Health Laboratory Service Working Group that is described in Practical Food Microbiology. The modified method uses a chromogenic substrate for the identification of E. coli. The method gives general&lt;BR&gt;guidelines for sample preparation and enumeration of E. coli in bivalve molluscs by the most probable number technique. It is the UK standard method for testing shellfish.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285724</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w6.pdf]]&gt;</url>
    <title>Enumeration of Pseudomonas aeruginosa by membrane filtration (W6)</title>
    <publicationDate>2007-12-21T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The method gives general guidelines for the enumeration or detection of Pseudomonas aeruginosa in all types of water samples by the membrane filtration technique. It is generally applicable to water with a low background flora eg water intended for human consumption and pool waters.]]&gt;</body>
  </document>
  <document>
    <id>285727</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/F22.pdf]]&gt;</url>
    <title>Enumeration of ß-glucuronidase positive Escherichia coli - Most Probable Number method (F22)</title>
    <publicationDate>2005-12-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,ESCHERICHIA COLI INFECTION,FAECAL/ORAL,BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,TRANSMISSION MODE,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,E. COLI,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scope&lt;BR&gt;The method described is applicable to the detection and enumeration of Escherichia coli in all food types, including milk and dairy products.&lt;/P&gt;
&lt;P&gt;Background&lt;BR&gt;Regulation (EC) 852/2004 on the hygiene of foodstuffs and regulation (EC) 853/ 2004 will be enacted in English law on 1.1.06 as the Food Hygiene Regulations 2005. Associated legislation specifies microbiological criteria and methods for testing for a number of food commodities. Included in the&lt;BR&gt;hygiene criteria are specifications for Escherichia coli, to be applied at the end of the manufacturing process of shelled and shucked products of cooked crustaceans and molluscan shellfish, pre-cut fruit and vegetables, unpasteurised fruit and vegetable juices and minced meat, meat products and mechanically separated meat. For cheeses made from milk that has undergone heat treatment, a hygiene criterion is applied at the beginning of the ripening period for cheeses unable to support the growth of E.coli and at the end of the ripening period if able to support the growth of E.coli, ie: at the time of manufacturing when the E.coli count is expected to be highest. The legislation also specifies the methods to be used, which&lt;BR&gt;for shelled and shucked products of cooked crustaceans and molluscan shellfish is the horizontal method ISO TS 16649-36, a Most Probable Number method. There is also a food safety criterion for Escherichia&lt;BR&gt;coli applied to live bivalve molluscs, echinoderms, tunicates and gastropods, for which ISO TS 16649-3 is specified, and this is addressed by Standard Method F16 – Enumeration of Escherichia coli in Raw Molluscs by the Multiple Tube Technique.&lt;/P&gt;
&lt;P&gt;The method described below is based on ISO TS 16649-3. It allows detection of Escherichia coli and enumeration by the most probable number (MPN) technique after incubation at 37°C. It is particularly&lt;BR&gt;suitable for use when levels are likely to be low (less than 100/g or 10/mL), and for recovery from products (dried, frozen etc) when the target organism is likely to be stressed. Although other parts of ISO&lt;BR&gt;16649 are specified in the legislation for examining the remainder of the food commodities listed above, part 3 is also suitable due to the nature of the samples and the use of the following method is recommended for routine purposes.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285726</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f12.pdf]]&gt;</url>
    <title>Enumeration of Staphylococcus aureus (F12)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,CONTACT,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285725</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w10.pdf]]&gt;</url>
    <title>Enumeration of Staphylococcus aureus by membrane filtration (W10)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFECTIONS,BACTERIA,MICROORGANISM,STAPHYLOCOCCUS,STAPHYLOCOCCUS AUREUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285728</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w22.pdf]]&gt;</url>
    <title>Enumeration of viable micro-organisms: Aerobic colony count by membrane filtration method (W 22)</title>
    <publicationDate>2007-12-21T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) gives general guidelines for the enumeration of viable
mesophilic micro-organisms which do not have specialised nutritional requirements after aerobic
incubation at 35°C for 72 hours (endoscope washer disinfector (WD) rinse waters) or 21°C for 7 days (ultrapure dialysis fluid).

If particular micro-organisms are of concern, other recovery conditions (growth medium, incubator temperature etc) should be used as appropriate. The method should be carried out as an installation, operational, or periodic test for endoscope WDs or ultrapure dialysis fluids when requested by the user.]]&gt;</body>
  </document>
  <document>
    <id>345502</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://erj.ersjournals.com/cgi/content/abstract/33/4/871]]&gt;</url>
    <title>Epidemiology and clinical management of XDR-TB: a systematic review by TBNET</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>The European Respiratory Society</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,TREATMENT,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Extensively drug-resistant tuberculosis (XDR-TB) is present in all regions and poses serious challenges for public health and clinical management. Laboratory diagnosis is difficult and little evidence exists to guide clinicians in treating people with XDR-TB effectively. To summarise the available data on diagnosis and treatment, the current authors performed a systematic review on 13 recent studies of the epidemiology and clinical management of XDR-TB.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Studies that met inclusion criteria were reviewed, in order to assess methodology, treatment regimens and treatment outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Meta-analysis of currently available data is not possible because of inconsistent definitions and methodologies. Data show that XDR-TB can be successfully treated in up to 65% of patients, particularly those who are not co-infected with HIV. However, treatment duration is longer and outcomes are in general poorer than for non-XDR TB patients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;To strengthen the evidence for extensively drug-resistant tuberculosis diagnosis, treatment and prevention, future studies should: 1) be prospective in design; 2) adopt standardised, internationally accepted definitions; 3) use quality-assured laboratory testing for all first- and second-line drugs; and 4) collect data on an agreed-upon set of standard variables, allowing for comparisons across studies. Early diagnosis and aggressive management of extensively drug-resistant tuberculosis provide the best chance of positive outcome, but prevention is still paramount.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Read the structured abstract by the Centre for Reviews and Dissemination &lt;A href="nelh:342947:1" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285732</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jac.oxfordjournals.org/cgi/reprint/44/suppl_2/3]]&gt;</url>
    <title>Epidemiology and pathogenesis of influenza</title>
    <publicationDate>1999-11-01T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFLUENZA,BODY PART AFFECTED,AIRBORNE,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza A, B and C all have a segmented genome, although only certain influenza A subtypes and influenza B cause severe disease in humans. The two major proteins of influenza are the surface glycoproteins-haemagglutinin (HA) and neuraminidase (NA). HA is the major antigen for neutralizing antibodies and is involved in the binding of virus particles to receptors on host cells. Pandemics are a result of novel virus subtypes of influenza A, created by reassortment of the segmented genome (antigenic shift), whereas annual epidemics are a result of evolution of the surface antigens of influenza A and B virus (antigenic drift). The rapid evolution of influenza viruses highlights the importance of surveillance in identifying novel circulating strains. Infectivity of influenza depends on the cleavage of HA by specific host proteases, whereas NA is involved in the release of progeny virions from the cell surface and prevents clumping of newly formed virus. In birds, the natural hosts of influenza, the virus causes gastrointestinal infection and is transmitted via the faeco-oral route. Virulent avian influenza strains, which cause systemic disease, have an HA that is cleaved by proteases present in all cells of the body, rather than by proteases restricted to the intestinal tract. In mammals, replication of influenza subtypes appears restricted to respiratory epithelial cells. Most symptoms and complications, therefore, involve the respiratory tract. However, systemic complications are sometimes observed and other viral genes besides the HA, including the NA, may be involved in determination of virulence of influenza strains in mammals.]]&gt;</body>
  </document>
  <document>
    <id>285734</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ajmc.com/files/articlefiles/AMSub5_2000MontoS255_64.pdf]]&gt;</url>
    <title>Epidemiology and Virology of Influenza Illness</title>
    <publicationDate>2000-03-01T00:00:00</publicationDate>
    <publisher>Ascend Media</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,AIRBORNE,BODY PART AFFECTED,INFLUENZA,TRANSMISSION MODE,INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Although researchers have demonstrated that influenza illness has affected societies for
many centuries, in more recent decades, the World Health Organization and the Centers for
Disease Control and Prevention have developed sophisticated means of tracking the virus’ activity around the globe. The importance of tracking influenza activity lies not only in detecting what is circulating in other countries, but also in enabling global manufacturers of vaccine to prepare the appropriate A and B compositions for the impending epidemic. Tracking influenza also allows quantification of its great toll in terms of morbidity and mortality. Influenza has broad societal and financial impact, with as much as $12 to $14 billion in indirect economic impact in the United States annually and a significant increase in physician visits for febrile respiratory illness. For example, during many influenza outbreaks visits to family care physicians and internal medicine specialists can increase by 150% to 450%. 

Influenza presents an ongoing public health issue because of the virus’ ability to continually reinvent itself. Antigenic drift, caused by subtle changes in influenza’s surface proteins, partially accounts for annual epidemic outbreaks of the illness. Antigenic shift that occurs because of major changes in the viral hemagglutinin and sometimes in the neuraminidase, the other surface
protein, results in the more widespread and lethal pandemic forms of influenza. Moreover, type A influenza is not an exclusively human infection. By understanding how both of these types of changes occur in waterfowl, the virus’ primary nonhuman hosts, scientists can develop both drugs and epidemiological strategies to avert or minimize the most severe effects of influenza]]&gt;</body>
  </document>
  <document>
    <id>394185</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20610949]]&gt;</url>
    <title>Epidemiology of HIV infection in the Middle East and North Africa</title>
    <publicationDate>2010-07-24T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: The Middle East and North Africa (MENA) region continues to be perceived as a region with very limited HIV epidemiological data, raising many controversies about the status of the epidemic in this part of the world. The objective of this review and synthesis was to address the dearth of strategic interpretable data on HIV in MENA by delineating a data-driven overview of HIV epidemiology in this region.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A comprehensive systematic review of HIV, sexually transmitted infections (STIs) and risk behavior studies in MENA, irrespective of design, was undertaken. Sources of data included Medline for peer-reviewed publications, Google Scholar for other scientific literature published in nonindexed local and regional journals, international organizations reports and databases, country-level reports and database including governmental and nongovernmental organizations publications, as well as various other institutional documents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Over 5000 sources of data related to HIV and STIs were identified and reviewed. The quality of data and nature of study designs varied substantially. There was no evidence for a sustainable HIV epidemic in the general population in any of the MENA countries, except possibly for southern Sudan. The general pattern in different countries in MENA points towards emerging epidemics in high-risk populations including injecting drug users, men who have sex with men (MSM) and to a lesser extent female sex workers, with heterogeneity between countries on the relative role of each of these high-risk groups. Exogenous HIV exposures among nationals linked to travel abroad appeared to be the dominant HIV transmission pattern in a few MENA countries with no evidence for much epidemic or endemic transmission. The role of bridging populations in bridging the HIV infection to the general population was found to be very limited.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Although they do not provide complete protection against HIV spread, near universal male circumcision and possibly the prevailing sexually conservative cultural norms seemed to have played so far a protective role in slowing and limiting HIV transmission in MENA relative to other regions. If the existing social and epidemiological context remains largely the same, HIV epidemic transmission is likely to remain confined to high-risk populations and their sexual partners, in addition to exogenous exposures. HIV prevention efforts in this region, which continue to be stymied by stigma associated with HIV/AIDS and related risk behaviors, need to be aggressively expanded with a focus on controlling HIV spread along the contours of risk and vulnerability. There is still a window of opportunity to control further HIV transmission among high-risk groups in MENA that, if missed, may entail a health and socioeconomic burden that the region, in large part, is unprepared for.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285736</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/507558]]&gt;</url>
    <title>Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Infectious Diseases Society of America</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFLUENZA,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,VACCINES / IMMUNISATION,TREATMENT,VACCINE PREVENTABLE DISEASES,INFLUENZA,INFLUENZA VACCINE,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The US Centers for Disease Control and Prevention (CDC) uses a 7-component national surveillance system for influenza that includes virologic, influenza-like illness, hospitalization, and mortality data. In addition, some states and health organizations collect additional influenza surveillance data that complement the CDC’s surveillance system. Current surveillance data from these programs, together with national hospitalization and mortality data, have been used in statistical models to estimate the annual burden of disease associated with influenza in the United States for many years. National influenza surveillance data also have been used in suitable models to estimate the possible impact of future pandemics. As part of the public health response to the 2003–2004 influenza season, which was noteworthy for its severe effect among children, new US surveillance activities were undertaken. Further improvements in national influenza surveillance systems will be needed to collect and analyze data in a timely manner during the next pandemic.]]&gt;</body>
  </document>
  <document>
    <id>325307</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/Epidemiologyofswineflufatalities.aspx]]&gt;</url>
    <title>Epidemiology of swine flu deaths</title>
    <publicationDate>2009-08-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,PANDEMIC INFLUENZA,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SEPT 09,ADDED 2009,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Research describing the characteristics of 574 swine-flu related deaths up to July 16 2009 has been published online. The general themes from this research have already been communicated by policy makers across the world. However, this study gives some new data to back up the claims and helps build a more accurate picture of the underlying conditions that contributed to risk of death in the first 10 weeks of the pandemic.&lt;/P&gt;
&lt;P&gt;This French study of swine-flu related deaths looked at worldwide data and found that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The elderly may be protected from infection (except in Australia and Canada).&lt;/LI&gt;
&lt;LI&gt;There was underlying disease in at least half of the fatal cases. Taking data recording issues into account this could be as high as 90%.&lt;/LI&gt;
&lt;LI&gt;Pregnancy and having an underlying metabolic condition are particular risk factors.&lt;/LI&gt;
&lt;LI&gt;The researchers looked at the role of obesity and diabetes as risk factors for death from swine flu, despite the fact that these are not usually considered as factors for previous pandemics or for seasonal influenza. Their results showed that 13 cases with either or both of these risk factors died (from 241 recorded deaths). More research will be needed to confirm whether this rate is more than could be expected. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;In previous pandemics, most deaths have been in the very young, the elderly or those with underlying disease, and most cases involve short illness not requiring hospitalisation. The exception is the 1918-1919 pandemic, which had a high mortality rate in healthy young adults and an estimated CFR of 2-3%.&lt;/P&gt;
&lt;P&gt;The authors note that even with a low CFR, seasonal influenza epidemics can cause a large number of complications as the absolute number of cases can be high. Previous estimates for the current pandemic have been for three to five million cases of severe illness and 250,000 to 500,000 deaths worldwide.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Vaillant L, La Ruche G, Tarantola A, Barboza P, for the epidemic intelligence team at InVS.&amp;nbsp;&lt;A href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19309" target="_blank"&gt;Epidemiology of fatal cases associated with pandemic h1n1 influenza 2009.&lt;/A&gt; Eurosurveillance 2009; 14: Issue 33 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285738</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop6.2.pdf]]&gt;</url>
    <title>Epstein-Barr virus serology (VSOP 6.2)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285740</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TD4-4JGJG22-3&amp;_user=910131&amp;_coverDate=05%2F15%2F2006&amp;_alid=622360365&amp;_rdoc=1&amp;_fmt=summary&amp;_orig=search&amp;_cdi=5188&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=1&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=7f2c719481e2af3db34e12ae4bcc89ca]]&gt;</url>
    <title>Estimating the risk population in relation to influenza vaccination policy</title>
    <publicationDate>2006-03-15T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,AIRBORNE,BODY PART AFFECTED,INFLUENZA,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ There are many small differences in national influenza vaccination polices, some are age elated and others morbidity related. This study examines a large English general practice database for 2003 to estimate the size of the England and Wales population at risk because of co-morbidity and to make recommendations on the choice of morbidity codes for use when estimating demand for vaccine and in auditing medical records to assess vaccination uptake. Morbidity codes relevant to the assessment of risk were defined and the database was analysed to estimate the annual period prevalence of the various diseases and groups of diseases. A set of morbidity codes is recommended which taken together include 3.2% of age group 0–14 years, 7.5% of 15–44 years and 16.6% of 45–64 years. ]]&gt;</body>
  </document>
  <document>
    <id>285741</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ewgli.org/data/european_guidelines.htm]]&gt;</url>
    <title>European Guidelines for Control and Prevention of Travel Associated Legionnaires' Disease</title>
    <publicationDate>2002-07-01T00:00:00</publicationDate>
    <publisher>The European Working Group for Legionella Infections</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The guidelines outline a standard approach to control and prevention of travel associated Legionnaires' Disease across all European countries. Parts 1-2 explain how the reporting and response procedures for clusters of cases should now operate within Europe. Parts 3-4 of the guidelines are very technical and are written for engineers and people involved with maintenance of water systems in hotels and other buildings.]]&gt;</body>
  </document>
  <document>
    <id>394195</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nmanet.org/images/uploads/Publications/OC1221.pdf]]&gt;</url>
    <title>Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>The National Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The purpose of this systematic review was to identify studies that evaluated HIV/AIDS disparities by examining differences in the receipt of antiretroviral therapy and differences in mortality between blacks and whites in the United States. The authors conducted 2 Web-based literature searches of the MEDLINE database for published peer reviewed scientific articles that analyzed black race as a predictor of antiretroviral therapy and mortality. Five reports met the criteria for the antiretroviral literature search, whereas seven reports met the criteria for the mortality literature search. After evaluating individual study results, it appears the evidence to identify racial differences in the receipt of antiretroviral therapy as well as the evidence to document disparities in mortality is either limited or mixed. Further research is needed to support or refute the hypothesis that there are inequalities for blacks with HIV/AIDS.]]&gt;</body>
  </document>
  <document>
    <id>330460</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://pediatrics.aappublications.org/cgi/reprint/123/1/175]]&gt;</url>
    <title>Evaluation and management of the infant exposed to HIV-1 in the United States</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>American Academy of Pediatrics</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,ADULTS,CHILDREN,PREGNANT WOMEN,DIAGNOSIS,POPULATION GROUPS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The pediatrician plays a key role in the prevention of mother-to-child transmission of HIV-1 infection. For infants born to women with HIV-1 infection identified during pregnancy, the pediatrician ensures that antiretroviral prophylaxis is provided to the infant to decrease the risk of acquiring HIV-1 infection and promotes avoidance of postnatal HIV-1 transmission by advising HIV-1-infected women not to breastfeed. The pediatrician should perform HIV-1 antibody testing for infants born to women whose HIV-1 infection status was not determined during pregnancy or labor. For HIV-1-exposed infants, the pediatrician monitors the infant for early determination of HIV-1 infection status and for possible short- and long-term toxicity from antiretroviral exposures. Provision of chemoprophylaxis for Pneumocystis jiroveci pneumonia and support of families living with HIV-1 by providing counseling to parents or caregivers are also important components of care.]]&gt;</body>
  </document>
  <document>
    <id>285743</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.jr2.ox.ac.uk/bandolier/band88/b88-2.html]]&gt;</url>
    <title>Even more on MMR</title>
    <publicationDate>2001-06-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,MUMPS,MEASLES,INFECTIONS,VACCINES / IMMUNISATION,PREVENTION,PREVENTION AND CONTROL,VACCINE PREVENTABLE DISEASES,MICROORGANISM,RUBELLA VIRUS,VIRUSES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This webpage provides links to :
Measles vaccines and inflammatory bowel disease 
Results 
Autism, MMR and GP visits 
Results 
Comment ]]&gt;</body>
  </document>
  <document>
    <id>330493</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://tropej.oxfordjournals.org/cgi/reprint/54/6/361?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=1&amp;author1=molyneux&amp;andorexacttitle=and&amp;andorexacttitleabs=and&amp;andorexactfulltext=and&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Evidence behind the WHO guidelines: Hospital care for children: The usefulness of azole prophylaxis against cryptococcal meningitis in HIV-positive children</title>
    <publicationDate>2008-09-08T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,PREVENTION,BRAIN AND SPINAL CORD INFECTIONS,CHILDREN,POPULATION GROUPS,MENINGITIS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADDED 2009,PROPHYLAXIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The World Health Organization has produced guidelines for the management of common illnesses in hospitals with limited resources. This series reviews the scientific evidence behind WHO’s recommendations. The WHO guidelines and more reviews are available at &lt;A href="http://www.ichrc.org/" target="_blank"&gt;http://www.ichrc.org&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;This review addresses the question: The usefulness of azole prophylaxis against cryptococcal meningitis in HIV-positive children. The WHO Pocketbook of Hospital Care for Children recommends that if a HIV positive child has cryptococcal meningitis then treat with amphotericin for 14 days then fluconazole for a further 8 weeks. Fluconazole prophylaxis is then started after treatment. (Pocketbook p. 218)&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330479</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://tropej.oxfordjournals.org/cgi/reprint/55/2/78?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=1&amp;author1=Azzopardi+&amp;andorexacttitle=and&amp;andorexacttitleabs=and&amp;andorexactfulltext=and&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Evidence behind the WHO guidelines: Hospital care for children: What is the evidence that BCG vaccination should not be used in HIV-infected children?</title>
    <publicationDate>2009-03-10T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,PREVENTION,CHILDREN,POPULATION GROUPS,CHILDHOOD VACCINES,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,VACCINES / IMMUNISATION,BCG,ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The World Health Organization has produced guidelines for the management of common illnesses in hospitals with limited resources. This series reviews the scientific evidence behind WHO’s recommendations. The WHO guidelines, and more reviews are available at: &lt;A href="http://www.ichrc.org/" target="_blank"&gt;http://www.ichrc.org&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;This review addresses the question: What is the evidence that BCG vaccination should not be used in HIV-infected children? The WHO Pocketbook of Hospital Care for Children recommends children who have or who are suspected to have human immunodeficiency virus (HIV) infection but are not yet symptomatic should be given all appropriate vaccines including Bacillus Calmette–Gue´rin (BCG). (Pocketbook chapter 8.3.1, p. 214). This guideline has been updated in 2007 as discussed below to withhold BCG in HIV-infected children regardless of symptomatology.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285748</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/326/7401/1256]]&gt;</url>
    <title>Extracts from "Best Treatments": Treating head lice</title>
    <publicationDate>2003-06-07T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,INFECTIONS,MICROORGANISM,HEADLICE,LICE,PARASITES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This clinical review highlights the best treatments for head lice.]]&gt;</body>
  </document>
  <document>
    <id>319867</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1227688128096]]&gt;</url>
    <title>Eye of the Needle: 2008</title>
    <publicationDate>2008-11-28T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HEPATITIS,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,HEALTHCARE WORKERS,ADULTS,NOV 08,DIAGNOSIS,POPULATION GROUPS,POST-EXPOSURE PROPHYLAXIS,HEPATITIS C,HEPATITIS B,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HEPATITIS VIRUS,HEPATITIS C VIRUS,HEPATITIS B VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Data collected through the Health Protection Agency (HPA) Centre for Infections scheme indicate that: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Since our previous report, a further 914 incidents were reported to the scheme between 2006-2007.&lt;/LI&gt;
&lt;LI&gt;Percutaneous injuries involving hollowbore needles remain the most commonly reported occupational exposures in the healthcare setting (between2000-2007,68% of all percutaneous exposures).&lt;/LI&gt;
&lt;LI&gt;HCV exposures to infected source patients remain the greatest proportion of percutaneous exposures reported (48%, 1113/229 between 2000-2007).&lt;/LI&gt;
&lt;LI&gt;Numerically, between 2000-2007 most occupational exposures involved nursing professionals. However by profession, medical professionals (doctors and dentists) reported a higher number of occupational exposures than nursing professionals in 2007 (200 compared to 191).&amp;nbsp; About a third of the incidents involving doctors were reported to be in Senior House Officers.&lt;/LI&gt;
&lt;LI&gt;Of concern is that over a third of incidents occurring between 2000-2007 in the ward or in Accident &amp;amp; Emergency (A&amp;amp;E) (43% and 37% respectively), and around 20% in intensive care and in operating theatres (22% and 20% respectively) were preventable with proper adherence to universal precautions and safe disposal of clinical waste.&lt;/LI&gt;
&lt;LI&gt;HCWs exposed to HCV-positive source patients are still not routinely receiving follow-up testing in line with national guidance; only 22% (40/184) in 2007 had the correct type of tests at the correct time points.&lt;/LI&gt;
&lt;LI&gt;In 2006-2007, there were a further three patient to HCW HCV transmissions following percutaneous exposure, bringing the total number of HCV seroconversions in HCWs reported between 1997 and 2007 to 14 cases in England. In addition, we have been notified of one case in Scotland. To date, no cases have been reported from Wales or Northern Ireland.&lt;/LI&gt;
&lt;LI&gt;Most (78%) HCWs exposed to an HIV positive source patient began HIV PEP after sustaining a significant exposure in 2007. Of these, a third (37%) commenced treatment within an hour of the exposure, and 89% within 24 hours.&lt;/LI&gt;
&lt;LI&gt;Since 1999, there have been no new reported cases of HIV seroconversions following percutaneous exposures of HCWs to HIV positive source patients. This brings the total number of UK HIV documented seroconversions reported by 2007 to five.&lt;/LI&gt;
&lt;LI&gt;Although it was highlighted that there were difficulties surrounding the reporting of exposures, such as lack of knowledge and logistic aspects, initial analyses of the community OH audit indicate that (where information was given) the majority of reporting centres do provide services to community staff.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>308610</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?title=Factors+associated+with+a+clinician%27s+decision+to&amp;title_type=tka&amp;year_from=1998&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=2]]&gt;</url>
    <title>Factors associated with a clinician's decision to stop anti-tuberculosis treatment before completion.</title>
    <publicationDate>2008-04-04T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: To investigate the diagnosis of pulmonary tuberculosis (PTB) and factors associated with a clinician's decision to stop anti-tuberculosis treatment before completion. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: The medical charts of all citizens of Taipei City, Taiwan, reported to have received treatment for PTB in 2003 were investigated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Of 1126 PTB patients, 512 (45.5%) started treatment immediately based solely on chest X-ray (CXR) findings; treatment for 214 (19.0%) was based on a positive sputum smear for acid-fast bacilli, for 261 (23.2%) it was based on other findings and for 139 (12.3%) it was based on a positive mycobacterial culture. Of the 1126 PTB patients, 156 (13.9%) had their diagnosis of TB changed by a clinician. Multivariate analysis shows that patients whose diagnosis was based on CXR or other findings, female patients, patients who interrupted treatment for 2 months, patients who continued care at other health facilities (transfer) and patients with lung cancer were significantly more likely to have their diagnosis changed than other groups. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: A substantial proportion of patients were prescribed anti-tuberculosis treatment based on CXR findings alone, and a considerable proportion were advised to stop treatment before completing a full course, findings that require the immediate attention of Taiwan's National Tuberculosis Programme.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308521</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B75GP-4TPWW0R-4&amp;_user=855288&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000046143&amp;_version=1&amp;_urlVersion=0&amp;_userid=855288&amp;md5=02bde1a78b8bce15f9fdc5eaf99dfe62]]&gt;</url>
    <title>Factors associated with tuberculosis treatment default among HIV-infected tuberculosis patients in Thailand.</title>
    <publicationDate>2008-10-19T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Ensuring completion of tuberculosis (TB) treatment remains a major public health problem. In HIV-infected patients, TB is the most common severe opportunistic infection. Few studies have evaluated risk factors for TB treatment default in HIV-infected patients. We conducted a prospective, observational study of HIV-infected TB patients in Thailand. Patients underwent standardised evaluations at the beginning of TB treatment, at the end of the intensive phase and at the end of TB treatment. TB treatment outcomes were assessed according to WHO guidelines. The analysis was limited to patients who defaulted or who had treatment success. Of the 554 patients analysed, 61 (11%) defaulted. In multivariate analysis, factors associated with TB treatment default included incarceration history [adjusted odds ratio (AOR) 2.0, 95% CI 1.1-3.7), smoking (AOR 2.3, 95% CI 1.3-4.1) and having a symptom complaint score &amp;gt;15 (AOR 3.4, 95%&amp;nbsp;CI 1.4-8.0); one marker of wealth, namely owning a refrigerator, was protective (AOR 0.4, 95% CI 0.2-0.8). Default during TB treatment was a significant problem &lt;BR&gt;in HIV-infected patients. Reducing default may require enhancing services for&lt;BR&gt;patients with a history of incarceration or smoking and designing patient-centred systems to address poverty and patient wellness.]]&gt;</body>
  </document>
  <document>
    <id>345540</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/fulltext/122455294/PDFSTART?CRETRY=1&amp;]]&gt;</url>
    <title>Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review</title>
    <publicationDate>2009-12-15T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ There has been conflicting evidence concerning the possible association between tuberculosis (TB) and subsequent risk of lung cancer. To investigate whether currently published epidemiological studies can clarify this association, we performed a systematic review of 37 case-control and 4 cohort studies (published between January 1966 and January 2009) and a meta-analysis of risk estimates, with particular attention to the role of smoking, passive smoking and the timing of diagnosis of TB on this relationship. Data for the review show a significantly increased lung cancer risk associated with preexisting TB. Importantly, the association was not due to confounding by the effects of tobacco use (RR=1.8, 95% confidence interval (CI)=1.4-2.2, among never smoking individuals), lifetime environmental tobacco smoke exposure (RR=2.9, 95%CI=1.6-5.3, after controlling) or the timing of diagnosis of TB (the increased lung cancer risk remained 2-fold elevated for more than 20 years after TB diagnosis). Interestingly, the association was significant with adenocarcinoma (RR=1.6, 95%CI=1.2-2.1), but no significant associations with squamous and small cell type of lung cancer were observed. Although no causal mechanism has been demonstrated for such an association, present study supports a direct relation between TB and lung cancer, especially adenocarcinomas.]]&gt;</body>
  </document>
  <document>
    <id>285757</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop3.pdf]]&gt;</url>
    <title>Fastidious anaerobe agar (MSOP 3)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285758</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop26.pdf]]&gt;</url>
    <title>Fastidious anaerobe broth (MSOP 26)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>394427</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890973/pdf/1758-2652-13-S2-S4.pdf]]&gt;</url>
    <title>Fathers and HIV: considerations for families</title>
    <publicationDate>2010-06-23T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Fathers are intricately bound up in all aspects of family life. This review examines fathers in the presence of HIV: from desire for a child, through conception issues, to a summary of the knowledge base on fathers within families affected by HIV.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A mixed-methods approach is used, given the scarcity of literature. A review is provided on paternal and male factors in relation to the desire for a child, HIV testing in pregnancy, fatherhood and conception, fatherhood and drug use, paternal support and disengagement, fatherhood and men who have sex with men (MSM), and paternal effects on child development in the presence of HIV. Literature-based reviews and systematic review techniques are used to access available data Primary data are reported on the issue of parenting for men who have sex with men.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Men with HIV desire fatherhood. This is established in studies from numerous countries, although fatherhood desires may be lower for HIV-positive men than HIV-negative men. Couples do not always agree, and in some studies, male desires for a child are greater than those of their female partners. Despite reduced fertility, support and services, many proceed to parenting, whether in seroconcordant or serodiscordant relationships. There is growing knowledge about fertility options to reduce transmission risk to uninfected partners and to offspring.Within the HIV field, there is limited research on fathering and fatherhood desires in a number of difficult-to-reach groups. There are, however, specific considerations for men who have sex with men and those affected by drug use. Conception in the presence of HIV needs to be managed and informed to reduce the risk of infection to partners and children. Further, paternal support plays a role in maternal management.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Strategies to improve HIV testing of fathers are needed. Paternal death has a negative impact on child development and paternal survival is protective. It is important to understand fathers and fathering and to approach childbirth from a family perspective.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325293</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/Firstresultsfromvaccinetrial.aspx]]&gt;</url>
    <title>First results from vaccine trial</title>
    <publicationDate>2009-09-11T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,PREVENTION,INFECTIONS,INFLUENZA VACCINE,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,VACCINES / IMMUNISATION,MICROORGANISM,SWINE INFLUENZA,ADDED 2009,SEPT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A study published in the New England Journal of Medicine has described early tests of a swine flu vaccine in Australia. The results suggest that a single dose of the vaccine may be enough to produce an immune response, and that the vaccine appears to be safe in the short term with mostly mild to moderate side effects.&lt;/P&gt;
&lt;P&gt;These findings are encouraging. This early research indicates that a single dose of this vaccine should prepare the body to fight off the virus but it does not show how effective the vaccine is in preventing swine flu or its longer-term safety.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study reports on the early testing of the swine flu vaccine produced in Australia. The results suggest that a single dose of this vaccine may be enough to produce an immune response and that the vaccine seems reasonably safe in the short term. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yang Y, Sugimoto JD, Halloran ME &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.sciencemag.org/cgi/content/abstract/sci;1177373v1" target="_blank"&gt;The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus.&lt;/A&gt; &lt;EM&gt;Science&lt;/EM&gt;, September 10 2009-09-11&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388523</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/getting-flu-jab-cuts-heart-attack-risk.aspx]]&gt;</url>
    <title>Flu jab 'may cut heart attacks'</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,INFLUENZA VACCINE,RESPIRATORY INFECTIONS,SEASONAL INFLUENZA,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,VACCINES / IMMUNISATION,SEPT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The winter flu jab may prevent heart attacks,” reported The Daily Telegraph. The newspaper said that having a seasonal flu jab may reduce the risk of a heart attack by one-fifth.&lt;/P&gt;
&lt;P&gt;The story is based on research that analysed data on 79,000 UK patients. The study compared rates of heart attacks in people given the flu vaccine with those in people who were not vaccinated. Researchers say that the flu vaccination was associated with a 19% lower rate of heart attacks, which may be due to the jab preventing chest infections that lead to heart attacks.&lt;/P&gt;
&lt;P&gt;While this study was well conducted, it cannot prove that vaccination cuts heart risk. It is possible that other health and lifestyle factors may have affected the results. For example, those people who were vaccinated may have been more likely to see their doctor and, therefore, adopt behaviour to prevent heart problems. However, the researchers adjusted their findings for a number of important factors, which increases the likelihood that the results are valid.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large, well-conducted study suggests that the annual flu vaccine may protect against heart attacks, even in people without known risk factors for heart disease. The researchers minimised the possibility of bias by including all cases of heart attack within a given time period, carefully matching them to controls and only including patients who had at least five years’ up-to-date information on the database. They also adjusted their findings for important confounders. Additionally, the size of this study means that its results are more likely to be reliable.&lt;/P&gt;
&lt;P&gt;However, this type of study cannot prove that a particular intervention (in this case, flu vaccination) causes an effect (prevention of heart attack). This is because it is possible that confounding factors (both measured and unmeasured) may have had an influence on the results. As the authors note, they did not account for some confounders such as stressful life events, and data was missing on some confounders such as smoking status, blood pressure, BMI and cholesterol levels (although they carried out additional calculations to take into account the missing data).&lt;/P&gt;
&lt;P&gt;While we cannot tell whether there is a reduced risk of heart attacks from receiving a flu vaccination, we do know that immunisation is a powerful tool for protecting vulnerable groups from some of the harms of flu and pneumonia. Just like heart attacks, flu and pneumonia kill thousands of people every year. The winter flu season is approaching and anyone who knows or thinks they would benefit from a vaccination should read our guide to &lt;A href="http://www.nhs.uk/Conditions/Flu-jab/Pages/Whyitshouldbedone.aspx" target="_blank"&gt;getting a flu jab&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Siriwardena AN, Gwini SM, Coupland CAC. &lt;A href="http://www.cmaj.ca/cgi/content/abstract/cmaj.091891v1" target="_blank"&gt;Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study&lt;/A&gt;. &lt;EM&gt;Canadian Medical Association Journal&lt;/EM&gt;, September 20 2010 (published online ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286384</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;HPAwebStandard/HPAweb_C/1203496898041?p=1158945066450]]&gt;</url>
    <title>Focus on Prevention - HIV and other Sexually Transmitted Infections in the United Kingdom in 2003 - An update: November 2004</title>
    <publicationDate>2004-11-05T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CONTACT,GENITAL WARTS (HPV),TRANSMISSION MODE,LYMPHOGRANULOMA VENEREUM (LGV),HERPES,CHLAMYDIA,SYPHILIS,GONORRHOEA,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIOUS DISEASES,WOMEN'S HEALTH,GONORRHOEA,HIV,DONOVANOSIS,GENITAL WARTS (HPV),GENITAL HERPES,BACTERIAL VAGINOSIS,CHLAMYDIA,CANDIDA,CHANCROID,PROVISION OF CARE,TRICHOMONAS,SYPHILIS,PELVIC INFLAMMATORY DISEASE,LGV,PUBLIC HEALTH,PEDICULOSIS PUBIS,SEXUAL HEALTH,INFECTIONS,TREPONEMA PALLIDUM,PUBIC LICE,VIRUSES,NEISSERIA GONORRHOEA,HERPES SIMPLEX VIRUS (HSV),HUMAN PAPILLOMAVIRUS (HPV),HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,BACTERIA,CHLAMYDIA,HIV,MALE UROGENITAL DISORDERS,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report highlights ways in which the Agency and its collaborators contribute to HIV and STI prevention - whether through the implementation of specific health interventions or in the monitoring and evaluation of screening and prevention programmes. The report also focuses on specific population subgroups for whom targeted prevention interventions remain an urgent priority. However, a report of this nature can only summarise a small portion of all prevention activities being provided in the field. It is therefore our intention to draw attention to our progress in delivering those effective interventions being implemented at the national level, and to highlight areas for improvement.]]&gt;</body>
  </document>
  <document>
    <id>285763</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/publications/2006/tb_report/focus_on_tb.pdf]]&gt;</url>
    <title>Focus on Tuberculosis Annual surveillance report 2006 - England, Wales and Northern Ireland</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Focus on Tuberculosis is the first annual surveillance report that brings together surveillance information on the occurrence of tuberculosis in England, Wales, and Northern Ireland from multiple sources. It provides a comprehensive overview of current trends in the numbers of tuberculosis cases, drug susceptibility, treatment outcome, and outbreak surveillance. 
The report is based on national surveillance of tuberculosis from 2000 to 2005 but has a particular emphasis on 2005 which is the most recent year for which complete data are available. The report provides a detailed picture of the disease in England, Wales, and Northern Ireland and examines recent trends. It provides a baseline for the assessment of the effectiveness of the measures being implemented to strengthen control of tuberculosis in this country. 
The report is an important source of information for the public and professionals and gives an insight into the extent of the current problem with tuberculosis and the challenges that are yet to be met in controlling it.]]&gt;</body>
  </document>
  <document>
    <id>285764</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://cvi.asm.org/cgi/reprint/14/9/1239]]&gt;</url>
    <title>Follow-up study of tuberculosis-exposed supermarket customers with negative tuberculin skin test results in association with positive gamma interferon release assay results.</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>American Society of Microbiology</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,TUBERCULOSIS,TRANSMISSION MODE,INFECTIONS,MYCOBACTERIUM,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We report a follow-up study of 29 subjects with negative tuberculin skin test (TST) results in association with positive gamma interferon release assay (IGRA) results, mainly due to responses to CFP-10 in the T-SPOT.TB assay, during a contact investigation. One year later, 12/29 subjects (41%) had converted to positive TST results in association with negative IGRA results. ]]&gt;</body>
  </document>
  <document>
    <id>285766</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop39.pdf]]&gt;</url>
    <title>Food and water law sources for food, water and environmental laboratories (QSOP 39)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>326810</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/chicken-food-poisoning-bug.aspx]]&gt;</url>
    <title>Food poisoning bug in chicken</title>
    <publicationDate>2009-10-07T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,CAMPYLOBACTER,CAMPYLOBACTER,BACTERIA,MICROORGANISM,OCT 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A government food survey released yesterday has found that most raw chicken sold in the UK contains campylobacter, a bacterium that can cause food poisoning. The survey, by the Food Standards Agency (FSA), checked for the presence of campylobacter in over 3,000 samples of fresh chicken, and found that 65% were contaminated with traces of the bacteria.&lt;/P&gt;
&lt;P&gt;Campylobacter is estimated to cause 300,000 cases of food poisoning annually. While a number of newspaper reports today described it as a “deadly bug”, only around 70 of these cases are fatal each year .&lt;/P&gt;
&lt;P&gt;However, the risk of food poisoning can be avoided by cooking meat thoroughly. This kills any campylobacter it contains. Good food hygiene while preparing raw poultry will prevent the bacterium from spreading to other food.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.express.co.uk/posts/view/132514/Killer-bug-in-most-chickens" target="_blank"&gt;Killer bug in most chickens&lt;/A&gt;. &lt;EM&gt;Daily Express&lt;/EM&gt;, October 7 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.telegraph.co.uk/foodanddrink/foodanddrinknews/6265152/Deadly-food-bug-in-65pc-of-chicken-FSA-study-says.html" target="_blank"&gt;Deadly food bug in 65pc of chicken, FSA study says&lt;/A&gt;. &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;, October 7 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.independent.co.uk/life-style/food-and-drink/news/bug-found-in-twothirds-of-supermarket-chicken-1798717.html" target="_blank"&gt;Bug found in two-thirds of supermarket chicken&lt;/A&gt;. &lt;EM&gt;The Independent&lt;/EM&gt;, October 7 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://news.bbc.co.uk/1/hi/health/8292632.stm" target="_blank"&gt;Two-thirds of chicken 'has bug'&lt;/A&gt;. BBC News, October 7 2009&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>315025</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1231419800356]]&gt;</url>
    <title>Foreign travel-associated illness – a focus on those visiting friends and relatives: 2008 report</title>
    <publicationDate>2008-12-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CLIENT GROUPS,INFECTIOUS DISEASES,SERVICE DELIVERY,CULTURAL COMPETENCE,DISEASES AND CONDITIONS,ETHNICITY AND HEALTH,INFECTIOUS DISEASES,INFECTIONS,TRAVEL ASSOCIATED INFECTIONS,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ People travel abroad for all sorts of reasons, and the reason why they travel affects where they go, and therefore their risk of acquiring infectious disease. In recent years, the number of visits abroad made by United Kingdom (UK) residents to visit friends and relatives (VFR) has increased and VFR travel often involves travel to regions that have a higher risk of certain, preventable, infectious diseases such as malaria, typhoid, paratyphoid, and hepatitis A. For these diseases, a disproportionate burden falls on those who have undertaken VFR travel. To reduce the number of cases of travel associated illness reported in the UK, particular attention needs to be given to protecting the health of these travellers.]]&gt;</body>
  </document>
  <document>
    <id>285768</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop50.pdf]]&gt;</url>
    <title>Fraser broth (MSOP 50)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS,LISTERIA MONOCYTOGENES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>296784</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089716?IdcService=GET_FILE&amp;dID=175758&amp;Rendition=Web]]&gt;</url>
    <title>From deep clean to keep clean: learning from the deep clean programme</title>
    <publicationDate>2008-10-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,OCT 08,INFECTION CONTROL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This compendium is designed to identify areas of good practice arising from the national deep clean initiative and become a basis for sharing learning across organisations]]&gt;</body>
  </document>
  <document>
    <id>285773</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/publications/2006/fungal_disease/fungal_diseases_report_06.pdf]]&gt;</url>
    <title>Fungal Diseases in the UK</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CONTACT,URINARY TRACT,TRANSMISSION MODE,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIFUNGALS,TREATMENT,MICROORGANISM,FUNGI,CANDIDA ALBICANS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The current provision of support for diagnosis and treatment: assessment and proposed network solution]]&gt;</body>
  </document>
  <document>
    <id>285776</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop3.pdf]]&gt;</url>
    <title>Gastroenteritis: outbreaks - minimum testing algorithm (VSOP 3) Under Review</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,VIRUSES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285777</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop2.pdf]]&gt;</url>
    <title>Gastroenteritis: sporadic cases - minimum testing algorithm (VSOP 2)</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,CONTACT,TRANSMISSION MODE,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285778</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop5.pdf]]&gt;</url>
    <title>GC selective agar (New York City) (MSOP 5)</title>
    <publicationDate>2005-05-31T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GONORRHOEA,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,BRAIN AND SPINAL CORD INFECTIONS,MENINGITIS,NEISSERIA MENINGITIDIS,NEISSERIA GONORRHOEA,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ GC selective agar (New York City) is&amp;nbsp;a selective nutritious medium for the isolation of Neisseria gonorrhoeae and Neisseria meningitidis. The medium is enriched by the addition of lysed blood. Yeast autolysate is added as a growth supplement. Starch absorbs toxic metabolites. Phosphates act as buffers to maintain a neutral pH.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>285834</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w1.pdf]]&gt;</url>
    <title>General technique for the detection and enumeration of bacteria by negative pressure membrane filtration (W1)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This method is applicable to waters from a wide range of sources including potable waters, pool waters and surface waters. It is not applicable to the isolation of Legionella species by positive pressure filtration for which an alternative method is available.]]&gt;</body>
  </document>
  <document>
    <id>308634</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://erj.ersjournals.com/cgi/content/abstract/32/5/1165?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=zwerling&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT]]&gt;</url>
    <title>GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis.</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>The European Respiratory Society</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,DIAGNOSIS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The global extensively drug-resistant tuberculosis (TB) response plan calls for implementation of rapid tests to screen patients at risk of drug-resistant TB. Currently, two line probe assays exist, the INNO-LiPA(R)Rif.TB assay (Innogenetics, Ghent, Belgium) and the GenoType MTBDR assay (Hain LifeScience GmbH, Nehren, Germany). While LiPA studies have been reviewed, the accuracy of GenoType assays has not been systematically reviewed. The present authors carried out a systematic review and used meta-analysis methods appropriate for diagnostic accuracy. After the literature searches, 14 comparisons for rifampicin and 15 comparisons for isoniazid were identified in 10 articles that used GenoType MTBDR assays. Accuracy results were summarised in forest plots and pooled using bivariate random-effects regression. The pooled sensitivity (98.1%, 95% confidence interval (CI) 95.9-99.1) and specificity (98.7%, 95% CI 97.3-99.4) estimates for rifampicin resistance were very high and consistent across all subgroups, assay versions and specimen types. The accuracy for isoniazid was variable, with lower sensitivity (84.3%, 95% CI 76.6-89.8) and more inconsistent than specificity (99.5%, 95% CI 97.5-99.9). GenoType MDTBR assays demonstrate excellent accuracy for rifampicin resistance, even when used on clinical specimens. While specificity is excellent for isoniazid, sensitivity estimates were modest and variable. Together with data from demonstration projects, the meta-analysis provides evidence for policy making and clinical practice.]]&gt;</body>
  </document>
  <document>
    <id>308632</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/reprint/46/1/393?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=Cirillo+&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis.</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>American Society for Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In a previous publication (1), we evaluated the Genotype MTBDR (GT-MTBDR; Hain Lifescience, Nehren, Germany) assay as a rapid diagnostic tool for multidrug resistance (MDR) detection in Mycobacterium tuberculosis isolates and clinical specimens. The main limitation of the test was the low sensitivity for isoniazid resistance detection (70%), due to the targeting of only one (katG) of the genes involved (2). Furthermore, the test performance on clinical specimens was suboptimal because of the lack of a clear hybridization signal (unpublished data).]]&gt;</body>
  </document>
  <document>
    <id>399613</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/gps-urge-at-risk-people-to-take-flu-vaccine.aspx]]&gt;</url>
    <title>'Get flu jab now,' GPs urge those at risk</title>
    <publicationDate>2010-12-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,INFECTIOUS DISEASES,INFLUENZA,RESPIRATORY INFECTIONS,INFLUENZA VACCINE,SWINE INFLUENZA,SWINE FLU VACCINE,ADDED 2010,WHAT'S NEW,DEC 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The flu vaccine has featured heavily in recent news, with reports that people are avoiding having the vaccine as they are concerned about its&amp;nbsp;&lt;A href="http://www.nhs.uk/conditions/pandemic-flu/Pages/Introduction.aspx" target="_blank"&gt;swine flu&lt;/A&gt; component. The British Medical Association (BMA) has written to the government, warning about the “myths” that are circulating about the safety of this year’s seasonal flu vaccine. It said that the regular seasonal outbreak could be much more serious as a result of the low uptake. Dr Laurence Buckman, Chairman of BMA’s GPs Committee, said:&lt;/P&gt;
&lt;P&gt;“Family doctors are already seeing high rates of influenza and they have been telling us that they are also seeing a lower uptake than usual for seasonal flu immunisation. Myths persist about the safety of the vaccine, especially after swine flu. The vaccine has been thoroughly tested and we strongly urge patients to make an appointment with their GP and get vaccinated.”&lt;/P&gt;
&lt;P&gt;People in at-risk groups are urged to get vaccinated as soon as possible. Pregnant women are being offered the&amp;nbsp;&lt;A href="http://www.nhs.uk/conditions/Flu-jab/Pages/Introduction.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;seasonal jab&lt;/A&gt; for the first time as they have been judged to be at greater risk from the H1N1 virus. Professor David Salisbury, Director of Immunisation at the Department of Health said:&lt;/P&gt;
&lt;P&gt;"The effects of flu are not to be underestimated. It is not the same as getting a cold and can seriously affect your health.&lt;/P&gt;
&lt;P&gt;"If you are in a risk group, then I would urge you to visit your GP surgery and get the vaccination as soon as possible. It is not too late to get vaccinated for your protection and that of your family."&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Certain people are at greater risk of developing serious complications of flu, such as bronchitis and pneumonia. These may require hospital treatment. A large number of elderly people die from flu every winter.&lt;/P&gt;
&lt;P&gt;The seasonal flu vaccine is offered free of charge to these at-risk groups to protect them from catching flu and developing these complications.&lt;/P&gt;
&lt;P&gt;Also, this winter (2010-11) the seasonal flu vaccine will be offered to all pregnant women who have not previously been vaccinated against H1N1 (swine) flu.&lt;/P&gt;
&lt;P&gt;It is recommended that you have a flu jab if you:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;are 65 or over &lt;/LI&gt;
&lt;LI&gt;have a serious medical condition (see box) &lt;/LI&gt;
&lt;LI&gt;live in a residential or nursing home &lt;/LI&gt;
&lt;LI&gt;are the main carer for an elderly or disabled person whose welfare may be at risk if you fall ill &lt;/LI&gt;
&lt;LI&gt;are a healthcare or social care professional directly involved in patient care &lt;/LI&gt;
&lt;LI&gt;work with poultry &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;If you are the parent of a child (over six months) with a long-term condition, speak to your GP about the flu jab. Your child's condition may get worse if they catch flu.&lt;/P&gt;
&lt;P&gt;If you are the carer of an elderly or disabled person, make sure they have had their flu jab.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285842</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6W8X-4NHNHPD-S&amp;_user=910131&amp;_coverDate=05%2F31%2F2007&amp;_rdoc=22&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%236666%232007%23999929994%23650080%23FLA%23display%23Volume)&amp;_cdi=6666&amp;_sort=d&amp;_docanchor=&amp;_ct=25&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=695c662fb2ba50fe09f0de66751c68e5]]&gt;</url>
    <title>Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Science Direct</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ New tools for controlling tuberculosis are urgently needed. Despite our emerging understanding of the biogeography of Mycobacterium tuberculosis, the implications for development of new diagnostics, drugs, and vaccines is unknown. M tuberculosis has a clonal genetic population structure that is geographically constrained. Evidence suggests strain-specific differences in virulence and immunogenicity in light of this global phylogeography. We propose a strain selection framework, based on robust phylogenetic markers, which will allow for systematic and comprehensive evaluation of new tools for tuberculosis control.]]&gt;</body>
  </document>
  <document>
    <id>345526</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/tb/publications/global_report/2009/en/index.html]]&gt;</url>
    <title>Global tuberculosis control - epidemiology, strategy, financing</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report is the 13th annual report on global control of tuberculosis (TB) published by the World Health Organization (WHO) in a series that started in 1997. Its main purpose is to provide a comprehensive and up-to-date assessment of the TB epidemic and progress in controlling the disease at global, regional and country levels, in the context of global targets set for 2015. Results are based primarily on data reported to WHO via its standard TB data collection form in 2008 and on the data that were collected every year from 1996 to 2007. The 196 countries and territories that reported data in 2008 account for 99.6% of the world’s estimated number of TB cases and 99.7% of the world’s population.]]&gt;</body>
  </document>
  <document>
    <id>285844</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop35.pdf]]&gt;</url>
    <title>Glucose agar (MSOP 35)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285845</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop38.pdf]]&gt;</url>
    <title>Good laboratory practice when performing molecular amplification assays (QSOP 38)</title>
    <publicationDate>2006-08-02T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance note describes key elements of how to organise facilities for polymerase chain reaction (PCR) testing including workflow, reagents, consumables and staff within a molecular diagnostic laboratory. Whilst the guidelines are largely relevant to the majority of PCR applications, they are most relevant where ‘in-house’ assays are in use and may be less&lt;BR&gt;relevant when using commercial kits, and to other amplification procedures.&lt;/P&gt;
&lt;P&gt;These guidelines apply to many modifications of the basic PCR protocol eg nested PCR, although no specific provision is made within the guidelines.&lt;/P&gt;
&lt;P&gt;The ability of PCR to produce large numbers of copies of a target sequence from minute quantities - sometimes single copies - of DNA has provided the exquisite sensitivity that makes PCR a powerful diagnostic tool. However, this ability also necessitates that extreme care be taken to avoid the generation of false-positive results.&lt;/P&gt;
&lt;P&gt;False-positive results can result from sample-to-sample contamination and, perhaps more commonly, from the carry-over of DNA from a previous amplification of the same target. Other sources of contamination may include cloned DNA and virus cell cultures. &lt;/P&gt;
&lt;P&gt;Careful consideration should be given to facility design and operation within clinical laboratories in which nucleic acid amplification-based assays are performed. This document describes procedures that will help to minimise the carry-over of amplified DNA. Increasingly, Health Protection Agency molecular assays are being developed in closed tube formats (eg&lt;BR&gt;LightCycler™, Taqman™) as preferred platforms for establishing diagnostic assays.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388520</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/human-malaria-parasites-from-gorillas.aspx]]&gt;</url>
    <title>'Gorillas may be origin of malaria'</title>
    <publicationDate>2010-09-23T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,MALARIA,INFECTIONS,PLASMODIUM,TRAVEL ASSOCIATED INFECTIONS,MICROORGANISM,PARASITES,MOSQUITO,ADDED 2010,WHAT'S NEW,SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Malaria first passed to humans from gorillas thousands of years ago,” the Daily Mail&amp;nbsp; reported. The newspaper said that the new discovery that gorillas can also host the human malaria parasite raises hopes of a vaccine for the disease.&lt;/P&gt;
&lt;P&gt;The story comes from research that analysed the genetics of malarial parasites in the faeces of chimpanzees and gorillas living wild in central Africa. It found that a parasite present in the western gorilla species was nearly identical in its genetic make-up to Plasmodium falciparum, the most common and most harmful malaria parasite that infects humans. This suggests that the two parasites had a common ancestor.&lt;/P&gt;
&lt;P&gt;This novel study may provide clues about the nature of malarial parasites and better ways to control malaria. However, it is debatable whether it will lead to the development of a vaccine in the near future, as newspapers have suggested. The best way to avoid malaria infection is to use simple but effective prevention measures such as antimalarial tablets and mosquito nets when visiting areas where malaria is prevalent.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study suggests that the closest relative of the Plasmodium falciparum parasite, which causes human malaria, is a malarial parasite in western gorillas, and that a common ancestor may have been passed from gorillas to humans in the past. &lt;/P&gt;
&lt;P&gt;Further research is needed into whether cross-species transmission between gorillas and humans is currently occurring. The findings of such studies may have implications for future research on the best way to eradicate the disease.&lt;/P&gt;
&lt;P&gt;While this avenue of research may eventually have some application in the treatment of malaria, prevention remains a vitally important strategy in the fight against this disease. Relatively simple steps, such as taking anti-malarial tablets and using mosquito nets and insecticide, can help prevent infection. Anyone visiting regions where there is a risk of malaria should read up on &lt;A href="http://www.nhs.uk/Conditions/Malaria/Pages/Prevention.aspx" target="_blank"&gt;malaria prevention&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Liu W, Li Y, Learn GH &lt;I&gt;et al&lt;/I&gt;. &lt;A href="http://www.nature.com/nature/journal/v467/n7314/full/nature09442.html" target="_blank"&gt;Origin of the human malaria parasite Plasmodium falciparum in gorillas&lt;/A&gt;. &lt;I&gt;Nature&lt;/I&gt; 467, 420-425 (23 September 2010)&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319871</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245914960426]]&gt;</url>
    <title>GRASP 2008 Report: Trends in Antimicrobial Resistant Gonorrhoea</title>
    <publicationDate>2009-06-30T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GONORRHOEA,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,ANTIMICROBIAL RESISTANCE,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,TREATMENT,MICROORGANISM,BACTERIA,NEISSERIA GONORRHOEA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Resistance to third-generation cephalosporins, the current recommended first-line treatment for gonorrhoea, is emerging in England and Wales, and the first examples of reduced susceptibility to ceftriaxone were observed in 2008.&lt;/LI&gt;
&lt;LI&gt;An apparent outbreak of high-level resistance to penicillin and tetracycline associated with sexual contact abroad emerged in 2007 and is ongoing in 2008.&lt;/LI&gt;
&lt;LI&gt;Ciprofloxacin resistance is now endemic in England and Wales, accounting for 28% of all isolates tested in 2008.&lt;/LI&gt;
&lt;LI&gt;Treatment of gonorrhoea is likely to become increasingly problematic as new types of resistance emerge.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345890</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/Grounded-mozzies-may-halt-dengue.aspx]]&gt;</url>
    <title>'Grounded' mozzies may halt dengue</title>
    <publicationDate>2010-02-23T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,DENGUE FEVER,TRAVEL ASSOCIATED INFECTIONS,ADULTS,TRAVELLERS,MICROORGANISM,PARASITES,MOSQUITO,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;BBC News reports that “scientists are breeding a genetically altered strain of mosquito in an effort to curb the spread of dengue fever”. The dengue virus is carried by Aedes aegypti mosquitoes in tropical and sub-tropical regions, and spread by the female mosquitoes when they bite. Dengue affects up to 100 million people a year and there is no vaccine or treatment for the infection.&lt;/P&gt;
&lt;P&gt;The researchers in this study carried out genetic modifications on Aedes aegypti mosquitoes that resulted in preventing the wing muscles in the females from developing. The affected females cannot fly, making them susceptible to predators and unable to find a mate or feed.&lt;/P&gt;
&lt;P&gt;The researchers’ aim is to reduce wild mosquito populations by releasing genetically modified male mosquitoes back into the wild, whose female offspring will be affected, thereby in time reducing the populations that carry dengue.&lt;/P&gt;
&lt;P&gt;This research shows promise as a method of controlling Aedes aegypti populations, but further studies will be needed to determine how well the genetically engineered male mosquitoes compete with normal male mosquitoes in the wild for mates, and how well they suppress wild mosquito populations.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has shown that it is possible to genetically engineer the Aedes aegypti mosquito to produce females that cannot fly, and therefore cannot feed or mate, but leave males unaffected. The logic is that if these male genetically engineered mosquitoes are introduced into the wild and breed with normal females, the female offspring will not be able to reproduce, and this should reduce the wild mosquito population.&lt;/P&gt;
&lt;P&gt;The researchers acknowledge that further tests will be needed to determine how well the genetically engineered male mosquitoes compete with normal male mosquitoes in mating, and how well they suppress wild mosquito populations. In addition, further studies are needed to look at whether these techniques could be applied to other mosquito species. The fact that malaria is spread by more than one type of mosquito means that it may be harder than dengue to tackle using this approach.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Guoliang Fu G, Lees RS, Nimmo D, et al.&amp;nbsp;&lt;A href="http://www.pnas.org/content/early/2010/02/16/1000251107.abstract?sid=" target="_blank"&gt;Female-specific flightless phenotype for mosquito control.&lt;/A&gt; PNAS 2010; Published online before print February 22&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285848</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/36234366.1/iuatld/ijtld/2006/00000010/00000010/art00004/A8CAD079F1B34F6D1174311239FE429BC8931BE346.pdf?link=http://www.ingentaconnect.com/error/delivery&amp;format=pdf]]&gt;</url>
    <title>Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 1: Introduction and Diagnosis of Tuberculosis in Children.</title>
    <publicationDate>2006-10-10T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,TUBERCULOSIS,TRANSMISSION MODE,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,MYCOBACTERIUM,TREATMENT,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ About one million children develop tuberculosis (TB) annually worldwide, accounting for about 11% of all TB cases. Children with TB differ from adults in their immunological and  pathophysiological response in ways that may have important implications for the prevention, diagnosis and treatment of TB in children. There is an urgent need to improve the diagnosis and management of children with TB, and the prevention of TB in children, by ensuring their inclusion under the implementation of the Stop TB strategy by National TB Programmes. Critical areas for further research include a better understanding of the epidemiology of childhood TB, vaccine development, the development of better diagnostic techniques, new drug development, and the optimal formulations and dosing of first- and second-line TB drugs in children.

Specifically regarding the diagnosis of TB in children, this relies on a careful and thorough assessment of all the evidence derived from a careful history, clinical examination and relevant investigations, e.g., tuberculin skin test, chest radiograph and sputum smear microscopy. Although bacteriological confirmation of TB is not always possible, it should be sought whenever possible, e.g., by sputum microscopy in children with suspected pulmonary TB who are old enough to produce a sputum sample. A trial of treatment with TB medications is not generally
recommended as a method to diagnose TB in children. New, improved diagnostic tests are urgently needed.]]&gt;</body>
  </document>
  <document>
    <id>285850</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/SARS/primarycare.htm]]&gt;</url>
    <title>Guidance for primary care practitioners on investigation, management and reporting of SARS cases and contacts (including community infection control)</title>
    <publicationDate>2003-10-20T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,AIRBORNE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,VIRUSES,SARS CORONA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This online factsheet provides guidance for primary care practitioners on investigation, management and reporting of SARS cases and contacts. It includes the following sections;
Background
Case definition 
Assessing and managing
Community infection control
Management of contacts
Surveillance]]&gt;</body>
  </document>
  <document>
    <id>307712</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/49203208.1/iuatld/ijtld/2008/00000012/00000003/art00004/176A6C1EEA5D9E73123618625687B4FD7D30751661.pdf?link=http://www.ingentaconnect.com/error/delivery&amp;format=pdf]]&gt;</url>
    <title>Guidance for the implementation of best practice for the care of patients with tuberculosis</title>
    <publicationDate>2008-03-03T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The first two chapters of Best practice for the care of patients with tuberculosis: a guide for low-income countries include an introduction and guidance regarding implementation of best practice. The background to how the guide was developed is significant, as it was developed in collaboration with nurses and other health workers working in the most challenging settings. It therefore provides realistic and practical guidance for best practice where patient loads are large and resources are stretched. Guidance regarding standard setting and clinical audit is an important part of enabling people to recognise the strengths that already exist in their practice and approach those areas that require change in a systematic and practical way. The guide itself consists of a series of standards covering different aspects of patient care, from the moment they seek health care with symptoms to their diagnosis to early stages of treatment, directly observed treatment, the continuation phase and transfer of treatment. There are also standards relating specifically to HIV testing and the care of patients co-infected with tuberculosis and HIV. The standards themselves will appear in full in the subsequent chapters of this series.]]&gt;</body>
  </document>
  <document>
    <id>293332</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1206520183347]]&gt;</url>
    <title>Guidance for the Management of Norovirus Infection in Cruise Ships 2007</title>
    <publicationDate>2007-07-02T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,GASTROENTEROLOGY &amp; LIVER DISEASES,GASTRITIS,STOMACH,INFECTIONS,SMALL INTESTINE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,NOROVIRUS,INFECTIOUS DISEASES,FOOD/WATER,CONTACT,FAECAL/ORAL,TRANSMISSION MODE,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,NOROVIRUS INFECTION,MICROORGANISM,VIRUSES,NOROVIRUS,FEBRUARY 2010,ENTERITIS,NOROVIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines from the Health Protection Agency, Maritime and Coastguard Agency, and Association of Port Health Authorities, are for health professionals, port health, and other agency staff and the crew of affected vessels for the identification and management of norovirus outbreaks aboard cruise vessels. They also form the basis of a standard approach to minimise the impact of the disease being brought aboard a vessel by passengers and crew, particularly during periods of heightened activity of the virus in the UK and other countries where a significant number of passengers are due to join the vessel. This is not a prescriptive document as it is recognised that each individual incident has to be managed according to the circumstances prevailing and the decisions of the outbreak control group will reflect such variations in circumstances.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314724</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcm.org.uk/EasySiteWeb/GatewayLink.aspx?alId=60439]]&gt;</url>
    <title>Guidance notes for midwives on swine flu</title>
    <publicationDate>2009-05-12T00:00:00</publicationDate>
    <publisher>Royal College of Midwives</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GOOD PRACTICE,RESPIRATORY INFECTIONS,INFLUENZA,AVIAN INFLUENZA,INFECTIOUS DISEASES,HEALTH SERVICE STAFF,QUALITY AND MONITORING,SERVICE SECTORS,RISK MANAGEMENT,PUBLIC HEALTH,HEALTH MANAGEMENT,ANTENATAL PROBLEMS,INFECTIONS,WOMEN'S HEALTH,COMPLICATED PREGNANCY,INFECTIONS,STANDARDS OF PRACTICE,PREVENTION,ANTIVIRALS,ANTIMICROBIALS,VACCINES / IMMUNISATION,PANDEMIC INFLUENZA,SEASONAL INFLUENZA,POPULATION GROUPS,POST-EXPOSURE PROPHYLAXIS,INFLUENZA VACCINE,HEALTHCARE WORKERS,INFECTION CONTROL,ADULTS,TREATMENT,DIAGNOSIS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,MAY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The RCM has issued guidance notes for midwives about the swine influenza H1N1 outbreak. The guidance describes the differences between seasonal, swine and avian influenza, symptoms, avoiding infection, and information to tell women and their families.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285851</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/hepatitis_c/pdf/HepCguidelines.pdf]]&gt;</url>
    <title>Guidance on the investigation and management of occupational exposure to Hepatitis C</title>
    <publicationDate>1999-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (CDPH)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CARDIOVASCULAR,BLOOD AND BODY FLUIDS,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,HEPATITIS C VIRUS,HEPATITIS VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document updates previous PHLS guidance on the risks and management of occupational exposure to Hepatitis C. In line with recent guidance from the UK Health Departments, the PHLS now recommends that all source patients, subject to appropriate consent, should be tested for Hepatitis C infection. A baseline serum should be obtained from the exposed health care worker and stored for at least two years.
Publication history information: Guideline published more than 5 years ago, but publisher has confirmed the guideline's continued validity (March 2005).

CDPH vol 2, no 4, December 1999, pp258]]&gt;</body>
  </document>
  <document>
    <id>285853</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/pegylated_2003.doc]]&gt;</url>
    <title>Guidance on the treatment of Hepatitis C incorporating the use of pegylated interferons</title>
    <publicationDate>2003-03-01T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BLOOD AND BODY FLUIDS,CARDIOVASCULAR,BODY PART AFFECTED,INFECTIONS,VIRUSES,HEPATITIS VIRUS,HEPATITIS C VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Clinical guidelines issued by the BSG in July 2001 (1) on the management of Hepatitis C recommended the use of Interferon alpha and Ribavirin in patients with moderate or severe chronic hepatitis C as determined by liver biopsy. This is consistent with NICE HTA Guidance No 14 published in October 2000. The recent licensing of two formulations of pegylated interferon with proven superior efficacy in treating chronic hepatitis C has necessitated review of these guidelines. 
The current guidance does not address the issue of who should be treated, but issues  recommendations on how to use pegylated interferons in patients eligible for treatment according to previously published guidelines. However it should be recognised that these guidelines apply to adults only and not to paediatric patients.  ]]&gt;</body>
  </document>
  <document>
    <id>285854</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/page.aspx?o=101627]]&gt;</url>
    <title>Guidance on treatment of chronic hepatitis C infection</title>
    <publicationDate>2000-10-01T00:00:00</publicationDate>
    <publisher>National Institute of Clinical Excellence</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR,BODY PART AFFECTED,BLOOD AND BODY FLUIDS,TRANSMISSION MODE,INFECTIOUS DISEASES,HEPATITIS,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIVIRALS,TREATMENT,HEPATITIS C,MICROORGANISM,HEPATITIS C VIRUS,HEPATITIS VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This is a review and extension of Technology Appraisal Guidance No. 14 issued in October 2000. NICE has issued guidance to the NHS in England and Wales on the use of pegylated interferons, ribavarin and alfa interferon for the treatment of hepatitis C. Listed below are the key documents for this appraisal; click on the title to link to the relevant document.]]&gt;</body>
  </document>
  <document>
    <id>381004</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ecdc.europa.eu/en/healthtopics/tick_borne_diseases/public_health_measures/Documents/1006_Guidance%20Doc.pdf]]&gt;</url>
    <title>Guidance: ECDC Communication Toolkit on Tick-borne diseases</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,TICKS,ZOONOSES,LYME DISEASE,MICROORGANISM,PARASITES,TICK-BORNE ENCEPHALITIS,TICK-BORNE DISEASES,JULY 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The overall objective of the ECDC Communication Toolkit on Tick-borne Diseases 2010 is to assist EU and EEA/EFTA countries in raising awareness about the health risks related to ticks amongst the selected target audiences and to encourage the adoption of preventive measures to help reduce the risk of developing tick-borne diseases.&lt;/P&gt;
&lt;P&gt;The strategy chosen to meet this objective is to provide practical advice and template materials that communicators in Member States’ health authorities can use in line with the specific aims and needs of their health communication activities. All template materials have been drafted in a format designed to ease duplication and dissemination and take into account adaptability and respect for cost considerations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285856</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nottingham.ac.uk/paediatric-guideline/diarrhoeaguideline.pdf]]&gt;</url>
    <title>Guideline for the management of children presenting to hospital with diarrhoea, with or without vomiting</title>
    <publicationDate>2002-11-01T00:00:00</publicationDate>
    <publisher>Wellchild</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ ESCHERICHIA COLI INFECTION,GASTROENTERITIS,CHOLERA,CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE,GASTROINTESTINAL INFECTIONS,TRANSMISSION MODE,FAECAL/ORAL,DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,INFECTIONS,CAMPYLOBACTER,SALMONELLA,SHIGELLA,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,CLOSTRIDIUM,VIRUSES,SHIGELLA,SALMONELLA,ENTEROVIRUS,MICROORGANISM,BACTERIA,CLOSTRIDIUM DIFFICILE,CAMPYLOBACTER,E. COLI,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline aims to provide clinicians with recommendations for the management of children presenting with diarrhoea, with or without vomiting; to promote consistency of patient care; to guide and assist the decision making process of junior doctors seeing the patient in the first instance;&amp;nbsp; to promote the use of oral rehydration as appropriate treatment for the majority of children presenting with gastroenteritis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285858</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/meningo/guidelines.htm]]&gt;</url>
    <title>Guidelines and Advice on Meningitis</title>
    <publicationDate>2005-02-04T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,CONTACT,TRANSMISSION MODE,MENINGOCOCCAL MENINGITIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM,NEISSERIA MENINGITIDIS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This webpage provides links to Guidelines for Public Health Management of Meningococcal Disease in the UK (CDPH 2002; 5(3):177-264), Practical Guidelines for responding to an outbreak of meningococcal disease among university students based on experience in Southampton (CDPH 1999; 2 (3): 168-73) and Surveillance of impact of meningococcal serogroup C conjugate vaccination programme in England and Wales.]]&gt;</body>
  </document>
  <document>
    <id>285944</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947373093]]&gt;</url>
    <title>Guidelines for Action in the Event of a Deliberate Release - Smallpox</title>
    <publicationDate>2008-05-12T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,SMALLPOX,SMALLPOX VACCINE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The HPA guideline covers: background and clinical information; clinical procedures; laboratory procedures; Public Health procedures; and a list of national specialists. A deliberate release of smallpox is considered a serious threat because: it is infectious by the airborne route; the illness is severe and has a high case-fatality rate; and survivors are often left with disfiguring scars, which may affect the face.]]&gt;</body>
  </document>
  <document>
    <id>285859</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHVol3/no1/vtec.pdf]]&gt;</url>
    <title>Guidelines for control of infection with Vero cytotoxin producing Escherichia coli (VTEC)</title>
    <publicationDate>2000-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (HPA)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,CONTACT,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,INFECTIONS,MICROORGANISM,BACTERIA,E. COLI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document reviews the clinical and epidemiological features of VTEC O157 infection, describes the principles of microbiological investigation and laboratory safety, and presents recommendations for the prevention of spread of VTEC O157. The recommendations consider direct spread of infection from animals, foodborne spread, the institutions in which spread is more likely to occur (nursing homes, schools and children's day nurseries), and groups at particular risk of acquiring and transmitting infection (such as food handlers and those unable to maintain high standards of hygiene for themselves and their carers). 
CDPH 2000; 3: 14-23
Publication history information: Guideline published more than 5 years ago, but publisher has confirmed the guideline's continued validity (March 2005).]]&gt;</body>
  </document>
  <document>
    <id>285860</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpch.ac.uk/publications/clinical_docs/GGPsorethroat.pdf]]&gt;</url>
    <title>Guidelines for good practice - management of acute and recurring sore throat and indications for tonsillectomy</title>
    <publicationDate>2000-12-01T00:00:00</publicationDate>
    <publisher>Royal College of Paediatrics and Child Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These recommendations have been derived from an original guideline document produced by SIGN. This RCPCH guideline presents evidence-based recommendations for the management of acute and recurring sore throat and indications for tonsillectomy for children. It is aimed at those working in primary care, but is relevant to all health professionals who care for children with sore throat. The statements only address tonsillectomy for recurring sore throat and do not address tonsillectomy for suspected malignancy or as a treatment for sleep apnoea, peritonsillar abscess or other conditions. The aim of this guideline is to provide reasonable criteria for referral for tonsillectomy.]]&gt;</body>
  </document>
  <document>
    <id>285861</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHvol5/No2/Guidelines1.pdf]]&gt;</url>
    <title>Guidelines for investigating single cases of legionnaires' disease.</title>
    <publicationDate>2002-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (CDPH)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These guidelines for the investigation of a single case of legionnaires' disease have been updated from those produced in 1994 to take account of developments in microbiological and environmental diagnostic capabilities and the recognition that infection may be acquired from the patient's domestic water system. The new guidelines recommendc that when a case of legionnaires' disease has been diagnosed, it should be investigated to determine whether it is part of an outbreak or cluster, work related, suspected to be a hospital acquire infection or is travel associated. If information concerning the patient's movements during the incubation period shows it to be none of these, then appropriate environmental investigations should be considered which might include the patient's domestic water system as a potential source of infection. The guidelines are designed to provide advice and information to all public health personnel involved in the control and prevention of legionnaires' disease.

CDPH 2002; 5(2): 157-62]]&gt;</body>
  </document>
  <document>
    <id>285863</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947320057]]&gt;</url>
    <title>Guidelines for managing outbreaks of sexually transmitted infections at a local, district or regional level.</title>
    <publicationDate>2002-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CHLAMYDIA,HERPES,GONORRHOEA,LYMPHOGRANULOMA VENEREUM (LGV),SYPHILIS,GENITAL WARTS (HPV),SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIOUS DISEASES,WOMEN'S HEALTH,SEXUAL HEALTH,CHLAMYDIA,CHANCROID,CANDIDA,BACTERIAL VAGINOSIS,GONORRHOEA,GENITAL WARTS (HPV),HIV,GENITAL HERPES,DONOVANOSIS,PROVISION OF CARE,TRICHOMONAS,SYPHILIS,PELVIC INFLAMMATORY DISEASE,LGV,PUBLIC HEALTH,PEDICULOSIS PUBIS,INFECTIONS,PREVENTION AND CONTROL,PUBIC LICE,TREPONEMA PALLIDUM,OTHER TREATMENT METHODS,TREATMENT,BACTERIA,MICROORGANISM,NEISSERIA GONORRHOEA,VIRUSES,HEPATITIS VIRUS,HEPATITIS C VIRUS,HERPES SIMPLEX VIRUS (HSV),HEPATITIS B VIRUS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN PAPILLOMAVIRUS (HPV)]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Sexually Transmitted infections (STIs) are a major public health concern. Their increasing incidence and associated complications place a significant burden on existing GUM services. Recently reported STI outbreaks signify a failure in public health control measures, for which proactive planning and coordination of disease control interventions are required. This guidance on the management of STI outbreaks was written to help improve the control and prevention of STI outbreaks at local and regional levels and is written primarily for Public Health Specialists, CCDCs (Consultants in Communicable Disease Control), Directors of Public Health, GUM Physicians and Regional Epidemiologists. The guidance outlines the principles of outbreak investigation and proposes a framework for districts to approach the management of local STI outbreaks. The guidance also highlights the roles of the key players, with suggestions for establishing formal working relationships. The guidance has been produced by the PHLS in consultation with the Association of Genitourinary Medicine (AGUM), the Public Health Medicine Environmental Group (PHMEG), and the Medical Society for the Study of Venereal Diseases (MSSVD).]]&gt;</body>
  </document>
  <document>
    <id>285864</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHvol1/no4/guidelines.pdf]]&gt;</url>
    <title>Guidelines for optimal surveillance of Clostridium difficile infection in hospitals</title>
    <publicationDate>1998-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (CDPH)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,CONTACT,TRANSMISSION MODE,INFECTIONS,CLOSTRIDIUM,MICROORGANISM,CLOSTRIDIUM DIFFICILE,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The availability of surveillance data on C.difficile infection in hospitals in England and Wales is being jeopardised by the trend not to culture the organism for diagnostic purposes. NHS trust laboratories  that no longer have the ability to isolate C. difficile can not investigate putative outbreaks or monitor antimicrobial susceptibilities. These laboratories may now need to rely on their local public health laboratory for such investigations. Recent recommendations from the DH/PHLS have highlighted the need for culture in outbreak investigations for surveillance purposes and for monitoring animicrobial susceptibilities. It is important, therefore, that NHS diagnostic laboratories and public health laboratories, in particular, retain the ability to isolate C.difficile. A cost-effective approach is described that will facilitate surveillance by typing of strains and also enable their antimicrobial susceptibilities to be monitored. ]]&gt;</body>
  </document>
  <document>
    <id>285868</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/07/08/32/04070832.pdf]]&gt;</url>
    <title>Guidelines for Smallpox Response and Management in the Post-Eradication Era</title>
    <publicationDate>2003-12-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,SMALLPOX VACCINE,SMALLPOX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Smallpox plan outlines the pre-and post-event activities that need to be, or would be, undertaken, in response to a smallpox emergency.]]&gt;</body>
  </document>
  <document>
    <id>285870</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/cd_body.pdf]]&gt;</url>
    <title>Guidelines for the investigation of chronic diarrhoea (tests for malabsorption), 2nd edition</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>GUT</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These guidelines are directed at consultant gastroenterologists, specialist registrars in training, and GP's, and refer specifically to adult not paediatric gastroenterology. Their purpose is to provide guidance on the best available methods of investigating symptoms of chronic diarrhoea. They attempt to rationalise the approach to investigation in the context of this common clinical scenario.
Published in GUT 2003;52 (Suppl V):v1-v15]]&gt;</body>
  </document>
  <document>
    <id>285873</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/ibd.pdf]]&gt;</url>
    <title>Guidelines for the management of inflammatory bowel disease in adults</title>
    <publicationDate>2004-09-01T00:00:00</publicationDate>
    <publisher>GUT</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIOUS DISEASES,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Ulcerative colitis (UC) and Crohn's disease (CD) (collectively termed inflammatory bowel disease (IBD)), are complex disorders reflected by wide variation in clinical practice.&amp;nbsp; These guidelines, commissioned by the BSG for clinicians and allied health professionals caring for patients with IBD in the UK, provide an evidence based document describing good clinical practice for investigation and treatment.&amp;nbsp; The guidelines are intended to bring consistency, but should not necessarily be regarded as the standard of care for all patients. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285875</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHvol3/No3/guides_micro.pdf]]&gt;</url>
    <title>Guidelines for the microbiological quality of some ready-to-eat foods sampled at point of sale</title>
    <publicationDate>1996-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (CDPH)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These guidelines for the microbiological quality of ready-to-eat foods represent a revision and expansion of guidelines first published by the PHLS in September 1992 and revised in March 1996. This document reviews the changes and the reasons they were made and sets out the new guidelines. It also clarifies the role of food examiners in interpreting the microbiological results of formal samples.

Publication history information: First published September 1992, revised March 1996, September 2000. Although published more than 5 years ago, but publisher has confirmed the guideline's continued validity.
CDPH vol 3, no 3, September 2000, pp163]]&gt;</body>
  </document>
  <document>
    <id>313741</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/h1n1flu/]]&gt;</url>
    <title>H1N1 Flu (Swine Flu)</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Centers for Disease Control and Prevention</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,PUBLIC HEALTH,INFECTIOUS DISEASES,INFLUENZA,RESPIRATORY INFECTIONS,MONTHLY ADDITIONS,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,INFLUENZA,RESPIRATORY DISORDERS,INFECTIONS,VACCINES / IMMUNISATION,INFLUENZA VACCINE,POST-EXPOSURE PROPHYLAXIS,DIAGNOSIS,TREATMENT,INFECTION CONTROL,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,MAY 09,SWINE INFLUENZA,2009 JUNE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In response to an intensifying outbreak in the United States and internationally caused by a new influenza virus of swine origin, the World Health Organization raised the worldwide pandemic alert level to Phase 5External Web Site Policy. on April 29, 2009. A Phase 5 alert is a “strong signal that a pandemic is imminent and that the time to finalize the organization, communication, and implementation of the planned mitigation measures is short.”&lt;/P&gt;
&lt;P&gt;The United States Government has declared a public health emergency in the United States. CDC’s response goals are to reduce transmission and illness severity, and provide information to help health care providers, public health officials and the public address the challenges posed by this emergency. CDC is issuing and updating interim guidance daily in response to the rapidly evolving situation. CDC’s Division of the Strategic National Stockpile (SNS) continues to send antiviral drugs, personal protective equipment, and respiratory protection devices to all 50 states and U.S. territories to help them respond to the outbreak. The swine influenza A (H1N1) virus is susceptible to the prescription antiviral drugs oseltamivir and zanamivir. In addition, the Federal Government and manufacturers have begun the process of developing a vaccine against this new virus.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321490</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/1918PandemicAndSwineFlu.aspx]]&gt;</url>
    <title>H1N1 traced to 1918 pandemic</title>
    <publicationDate>2009-07-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,ADDED 2009,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The virus responsible for the Spanish flu in 1918 created a ‘viral legacy’ that continues to this day, according to a &lt;A href="http://content.nejm.org/cgi/content/full/NEJMp0904819" target="_blank"&gt;study published &lt;/A&gt;recently in the New England Journal of Medicine.&lt;/P&gt;
&lt;P&gt;According to the authors of the report, the Spanish flu's H1N1 virus, which caused tens of millions of deaths in 1918, was also transmitted from humans to pigs during the pandemic. Tracing the lineage of the virus in this research shows that it continues to evolve in both humans and pigs 90 years later.&lt;/P&gt;
&lt;P&gt;All human-adapted influenza A viruses "are descendants, direct or indirect, of that founding virus" says Jeffrey Taubenberger, a co-author of the report and a senior investigator at the Laboratory of Infectious Diseases of the National Institute of Allergy and Infectious Diseases in the US.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Key points from this research&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;All flu viruses contain eight genes in total, including two that contain instructions for producing the proteins hemagglutinin (H) and neuraminidase (N), which allow the virus to attach to a host cell and spread from cell-to-cell.&lt;/LI&gt;
&lt;LI&gt;There are 16 sub-types of the H protein and nine sub-types of the N protein a flu virus can possess. This offers 144 possible HN combinations, but to date, only three (H1N1, H2N2 and H3N2) have been observed to be fully adapted for infecting humans.&lt;/LI&gt;
&lt;LI&gt;There are other combinations, such as H5N1, a strain of bird flu virus, but these have only occasionally infected a small number of humans.&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285900</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop45.pdf]]&gt;</url>
    <title>Haemadsorption of viruses (VSOP 45)</title>
    <publicationDate>2006-08-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,RESPIRATORY INFECTIONS,INFECTIONS,VIRUSES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Many viruses (eg influenza, parainfluenza, measles and mumps virus and some picornaviruses) contain surface glycoproteins known as haemagglutinins (HA). These are capable of binding red blood cells. As these viruses replicate in cell culture, HA molecules appear on the cell surface. If red blood cells of the appropriate species are added to the cell culture tube in which the virus is replicating, they will adhere to the cell sheet - a phenomenon known as haemadsorption. The presence of haemadsorbing viruses can therefore be detected several days before a cytopathic effect becomes apparent. Identification can then be confirmed using methods such as haemagglutination inhibition, haemadsorption inhibition, or, most commonly nowadays, immunofluorescence.]]&gt;</body>
  </document>
  <document>
    <id>285901</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://aac.asm.org/cgi/reprint/46/8/2723]]&gt;</url>
    <title>Haematological Effects of Linezolid: Summary of clinical experience</title>
    <publicationDate>2002-05-02T00:00:00</publicationDate>
    <publisher>Antimicrobial Agents and Chemotherapy</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Review of haematologic adverse effects related to the use of linezolid. Evaluation of clinical trials made and evidence found for increased risk of thrombocytopenia and anaemia with treatment &gt;/= 2 weeks. Abnormalities mild and reversible but appropriate monitoring recommended.]]&gt;</body>
  </document>
  <document>
    <id>285902</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop28.pdf]]&gt;</url>
    <title>Haemophilus ducreyi selective agar (MSOP 28)</title>
    <publicationDate>2005-05-31T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,HAEMOPHILUS,HAEMOPHILUS DUCREYI,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A selective medium for the isolation of Haemophilus ducreyi. Vancomycin is used to inhibit Gram-positive organisms. IsoVitaleX is added as a growth factor supplement. The medium which isolates the highest proportion of strains is C-HgCh. The highest isolation rates are obtained using a combination of C-HgCh plus MH-HBC.]]&gt;</body>
  </document>
  <document>
    <id>285905</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop5.pdf]]&gt;</url>
    <title>Handling and transport of samples (for the purposes of UKAS accreditation) (QSOP 5)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285906</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop17.pdf]]&gt;</url>
    <title>Handling of formal food samples in the laboratory (QSOP 17)</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285908</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://archpedi.ama-assn.org/cgi/reprint/161/12/1162]]&gt;</url>
    <title>Health Care Utilization for Pneumonia in Young Children After Routine Pneumococcal Conjugate Vaccine Use in the United States</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Journal of American Medical Association</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENINGOCOCCAL MENINGITIS,TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,STREPTOCOCCUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective:
To estimate the effect of 7-valent pneumococcal conjugate vaccine (PCV7) on rates of pneumonia-related health care utilization and costs in children younger than 2 years. 

Design:
Retrospective population study. 

Setting:  Approximately 40 large employers each year, from 1997 to 2004. 

Participants:  Enrollees in the MarketScan databases collected by Thomson Medstat. 

Main Exposure:  Pneumococcal conjugate vaccine immunization program. 

Main Outcome Measures:  Rates of International Classification of Diseases, Ninth Revision–coded hospitalizations and ambulatory visits due to all-cause and pneumococcal pneumonia and their medical expenditures. 

Results:  Comparing the rates in 2004 with those in the baseline period of 1997 to 1999 among children younger than 2 years, hospitalizations due to all-cause pneumonia declined from 11.5 to 5.5 per 1000 children (52.4% decline; P &lt; .001) and ambulatory visits due to all-cause pneumonia declined from 99.3 to 58.5 per 1000 children (41.1% decline; P &lt; .001). Rates of hospitalizations due to pneumococcal pneumonia declined from 0.6 to 0.3 per 1000 children (57.6% decline; P &lt; .001) and rates of ambulatory visits declined from 1.7 to 0.9 per 1000 children (46.9% decline; P &lt; .001). Projecting from these data to the US population, the total estimated direct medical expenditures for all-cause pneumonia–related hospitalizations and ambulatory visits in young children were reduced from an annual average of $688.2 million during the period of 1997 to 1999 to $376.7 million in 2004 (45.3% decline and approximately $310 million decrease). 

Conclusions:  In children younger than 2 years, the age group targeted for vaccination, pneumonia-related health care utilization in a privately insured population declined substantially following PCV7 introduction. These results suggest that PCV7 may play an important role in reducing the burden of pneumonia, resulting in major savings in medical care cost.]]&gt;</body>
  </document>
  <document>
    <id>285909</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4005547]]&gt;</url>
    <title>Health Information for Overseas travel - The Yellow Book</title>
    <publicationDate>2001-10-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INSECT BITE,AIRBORNE,FAECAL/ORAL,CONTACT,BLOOD AND BODY FLUIDS,FOOD/WATER,TRANSMISSION MODE,MALARIA,HIV/AIDS,MENINGOCOCCAL MENINGITIS,HEPATITIS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,GASTROENTERITIS,CHOLERA,GASTROINTESTINAL INFECTIONS,PREVENTION,PREVENTION AND CONTROL,INFECTIONS,VACCINE PREVENTABLE DISEASES,DIPHTHERIA,TETANUS,TUBERCULOSIS,RESPIRATORY INFECTIONS,HEPATITIS A,HEPATITIS B,MENINGITIS,POST-EXPOSURE PROPHYLAXIS,HEPATITIS A VACCINE,TYPHOID VACCINE,YELLOW FEVER VACCINE,HEPATITIS B VACCINE,TICK-BORNE ENCEPHALITIS,TETANUS VACCINE,RABIES VACCINE,MENINGOCOCCAL MENINGITIS (TYPE A),JAPANESE ENCEPHALITIS,CHOLERA VACCINE,TYPHOID,DENGUE FEVER,BRAIN AND SPINAL CORD INFECTIONS,ENCEPHALITIS,TRAVEL ASSOCIATED INFECTIONS,SALMONELLA,SHIGELLA,NEISSERIA MENINGITIDIS,VIRUSES,PARASITES,SARS CORONA VIRUS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HEPATITIS B VIRUS,HEPATITIS A VIRUS,HEPATITIS VIRUS,MICROORGANISM,BACTERIA,MALARIA PROPHYLAXIS,TRAVEL VACCINES,VACCINES / IMMUNISATION,NEISSERIA,PROPHYLAXIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Health Information for Overseas Travel was first issued in 1995 as a companion volume to the well established UK Health Departments' memorandum Immunisation against Infectious Disease (the 'Green Book'). It was well received, especially by doctors and practice nurses giving travel health advice in primary care, and is now commonly referred to as the UK 'Yellow Book'. Since that first edition, there has been a major increase in the amount of travel&amp;shy;related information available both to health professionals and travellers, in books, the media and via the Internet. The origins and significance of the information are not always clear, however, and the advice may not be consistent with that usually given in the UK. The aim of this book is therefore still relevant: to provide a concise and authoritative one&amp;shy;stop source of information about the common health risks to travellers and how to reduce them. It is not a statement of Government policy. It is advisory rather than prescriptive, emphasising the need to assess the risks for the individual traveller, while recognising the limitations of the data on which such assessments sometimes have to be made. Risk behaviours are also discussed, and emphasis put on measures travellers themselves can take to protect their health abroad. Further sources of advice are provided for more specialised problems outside the scope of this book.]]&gt;</body>
  </document>
  <document>
    <id>285911</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/SARS/pdfs/SARSContingencyDec03.pdf]]&gt;</url>
    <title>Health Protection Agency Contingency Plan for Severe Acute Respiratory Syndrome (SARS)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INSECT BITE,TRANSMISSION MODE,CONTACT,AIRBORNE,INFECTIONS,MICROORGANISM,SARS CORONA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The emergence of SARS has necessitated the development of a contingency plan for a co-ordinated response from the HPA to any possible outbreak. This document describes the arrangements that the HPA has put in place to prepare for and respond to outbreaks of SARS.]]&gt;</body>
  </document>
  <document>
    <id>296263</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947403055]]&gt;</url>
    <title>Health Protection in the 21st Century - Understanding the Burden of Disease</title>
    <publicationDate>2008-02-15T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,OCT 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Health Protection Agency has produced this report in order to determine the cost of both new problems and those that continue today.&lt;/P&gt;
&lt;P&gt;It is intended that this report should identify the current and future health protection priorities and provide a useful framework to help underpin the strategies of other organisations involved with health outcomes and to raise awareness. This is for discussion and information and is not definitive but is the first step in what will be an continuing process in collaboration with the many stakeholders and partners of the HPA.&lt;/P&gt;
&lt;P&gt;N.B. Infectious Diseases are convered in section 4, which can be found on pages 28 to 42.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324809</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1281954479045]]&gt;</url>
    <title>Healthcare-Associated Infections and Antimicrobial Resistance: 2009/10</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,NOROVIRUS,GASTROINTESTINAL INFECTIONS,CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE,PREVENTION,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,MRSA INFECTION,NOROVIRUS INFECTION,ENTEROCOCCUS AND GRE/VRE,ANTIMICROBIAL RESISTANCE,INFECTION CONTROL,CLOSTRIDIUM,VIRUSES,NOROVIRUS,MICROORGANISM,CLOSTRIDIUM DIFFICILE,BACTERIA,WHAT'S NEW,ADDED 2010,SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;A total of 1,898 cases of MRSA bacteraemia were reported in 2009/10, representing a 35% reduction in cases from the previous year when 2,935 cases were reported. 
&lt;LI&gt;In the same period, 25,604 cases of CDI were reported, representing a 29% reduction from the previous year when 36,095 cases were reported. 
&lt;LI&gt;Monthly reports of mandatory surveillance data, along with quarterly and annual tables were introduced. 
&lt;LI&gt;The e-Bug project, to support teaching in schools, was launched in September 2009. 
&lt;LI&gt;The web-based data capture system to record cases of MRSA and CDI is being redesigned to help NHS trusts submit data and use it more effectively.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Healthcare-associated infections continue to be a high priority for the agency. Surveillance data and epidemiological reports are produced for MRSA bacteraemia, CDI, norovirus, glycopeptide-resistant enterococci (GREs), surgical site infections (SSIs) and other organisms causing bloodstream infections.&lt;/P&gt;
&lt;P&gt;Read the report from 2008/2009 &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1252326222452" target="_blank"&gt;here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285914</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop24.pdf]]&gt;</url>
    <title>Helicobacter pylori selective agar (MSOP 24)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,HELICOBACTER PYLORI,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285916</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop27.pdf]]&gt;</url>
    <title>Hepatitis A virus acute infection serology (VSOP 27)</title>
    <publicationDate>2007-10-12T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,TRANSMISSION MODE,BLOOD AND BODY FLUIDS,INFECTIONS,INFECTIOUS DISEASES,HEPATITIS VIRUS,HEPATITIS A VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285923</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcm.org.uk/files/info/documents/190602121840%2D73%2D1%2Edoc]]&gt;</url>
    <title>Hepatitis B : a serious hazard</title>
    <publicationDate>1999-03-01T00:00:00</publicationDate>
    <publisher>The Royal College of Midwives</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,TRANSMISSION MODE,CARDIOVASCULAR,BODY PART AFFECTED,BLOOD AND BODY FLUIDS,INFECTIONS,HEPATITIS B VIRUS,HEPATITIS VIRUS,VIRUSES,MICROORGANISM,HEPATITIS B,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Hepatitis B is a serious condition associated with acute morbidity. Typically infection occurs by transfer of body fluids, and occupationally-acquired infection is a real risk to healthcare workers involved in exposure prone procedures. For midwives, occupational risk is most strongly associated with needlestick injuries and splashes of contaminated body fluids at delivery. These risks have been kept relatively low by the adoption of universal precautions and by high vaccination coverage among healthcare workers. In 1998 the Department of Health recommended that all pregnant women should be offered antenatal screening for hepatitis B, and that babies born to infected mothers should receive a complete course of immunisation at birth.]]&gt;</body>
  </document>
  <document>
    <id>391962</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C%20_EU_neighbourhood.pdf]]&gt;</url>
    <title>Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies</title>
    <publicationDate>2010-09-30T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,OUTCOMES,SETTINGS,MANAGEMENT &amp; INTERVENTIONS,HEPATITIS,INFECTIOUS DISEASES,INFECTIONS,MONTHLY ADDITIONS,INFECTION CONTROL,SCREENING,POPULATION BASED &amp; PREVENTATIVE SERVICES,SERVICES,LIVER DISORDERS,HEPATITIS,GEOGRAPHY,EUROPEAN UNION,HEPATITIS C,HEPATITIS B,ADDED 2010,WHAT'S NEW,OCT 10,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Infection with hepatitis B and C virus (HBV and HCV, respectively) affects the liver and results in a broad spectrum of disease outcomes. An infection with HBV can spontaneously resolve and lead to protective immunity, result in a chronic infection and, in rare cases, cause acute liver failure with a high risk of dying. In contrast to HBV, an infection with HCV becomes chronic in most cases. People with chronic hepatitis B and/or C virus infection remain infectious to others and are at risk of serious liver disease such as liver cirrhosis or hepatocellular cancer (HCC) later in life. HBV infection is widely present: approximately one third of the world’s population has been exposed to the virus, and an estimated 350 million people are chronically infected. More than 500 000 people die each year of hepatitis-B-related diseases. The World Health Organization estimates that two to three percent of the world’s population are infected with HCV, resulting in a total number of 120 to 170 million people.There is a distinct geographical variation in both HBV and HCV prevalence and incidence in the European Union and neighbouring countries.]]&gt;</body>
  </document>
  <document>
    <id>391963</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ecdc.europa.eu/en/press/news/Documents/1010_HepatitisAandB_info_sheet.pdf]]&gt;</url>
    <title>Hepatitis B and C: Current situation in EU/EEA</title>
    <publicationDate>2010-09-30T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HEPATITIS,INFECTIONS,HEPATITIS B,HEPATITIS C,MICROORGANISM,HEPATITIS VIRUS,HEPATITIS B VIRUS,HEPATITIS C VIRUS,VIRUSES,OCT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;ECDC coordinated two studies on hepatitis B and C in the EU and released two technical reports:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;‘Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies’ (literature review)&lt;/LI&gt;
&lt;LI&gt;‘Hepatitis B and C surveillance and prevention in Europe’ (Overview of national surveillance systems and prevention programmes for hepatitis B and C)&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285919</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop9.pdf]]&gt;</url>
    <title>Hepatitis B in pregnancy (VSOP 9)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,CARDIOVASCULAR,BODY PART AFFECTED,TRANSMISSION MODE,HEPATITIS,INFECTIONS,MICROORGANISM,VIRUSES,HEPATITIS VIRUS,HEPATITIS B VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285920</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop7.pdf]]&gt;</url>
    <title>Hepatitis B surface antigen reactive (VSOP 7)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HEPATITIS,TRANSMISSION MODE,CARDIOVASCULAR,BODY PART AFFECTED,BLOOD AND BODY FLUIDS,INFECTIONS,INFECTIOUS DISEASES,HEPATITIS B VIRUS,HEPATITIS VIRUS,VIRUSES,MICROORGANISM,HEPATITIS B,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285921</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop4.pdf]]&gt;</url>
    <title>Hepatitis B virus serology (VSOP 4)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,BLOOD AND BODY FLUIDS,BODY PART AFFECTED,CARDIOVASCULAR,TRANSMISSION MODE,HEPATITIS,INFECTIONS,MICROORGANISM,VIRUSES,HEPATITIS VIRUS,HEPATITIS B VIRUS,INFECTIOUS DISEASES,MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>394225</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B7CPT-513F07J-1-B&amp;_cdi=17975&amp;_user=8810565&amp;_pii=S1201971210024562&amp;_origin=search&amp;_coverDate=09%2F25%2F2010&amp;_sk=999999999&amp;view=c&amp;wchp=dGLzVzb-zSkzV&amp;md5=dfcf827e0c97d5e7817cd35e8ad62850&amp;ie=/sdarticle.p]]&gt;</url>
    <title>Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis</title>
    <publicationDate>2010-09-24T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,HEPATITIS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HEPATITIS B,HEPATITIS C,HEPATITIS VIRUS,HEPATITIS C VIRUS,HEPATITIS B VIRUS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: Hepatitis B virus (HBV), hepatitis C virus (HCV), and the human immunodeficiency virus (HIV) are endemic in Africa. However, hepatitis co-infection rates among HIV-infected individuals remain controversial. The aim of this review was to determine the prevalence of HBV and HCV in HIV-infected patients in sub-Saharan Africa and to analyze whether HIV is associated with a higher HBV/HCV prevalence in that region.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN AND METHODS&lt;/STRONG&gt;: We performed a systematic review and meta-analysis. Studies reporting HBV and HCV prevalence data amongst HIV-infected patients in sub-Saharan Africa were included. Weighted means and medians across studies were calculated. Studies including an HIV-negative control group were used for meta-analysis. Risk ratios (RRs) were calculated using a random effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Sixty studies were included. Among HIV-infected individuals, mean HBsAg and anti-HCV prevalence rates were 15% and 7%, respectively. RRs for a positive HBsAg and a positive anti-HCV were 1.40 (95% confidence interval (CI) 1.16-1.69) and 1.60 (95% CI 1.05-2.45) for HIV-infected, as compared to HIV-uninfected, patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Many HIV-positive individuals in sub-Saharan Africa are HBV or HCV co-infected. HIV is associated with a higher prevalence of both HBV and HCV in this region. However, this association is less evident than that observed in Western countries and varies between studies.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285925</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/09/79/56/04097956.pdf]]&gt;</url>
    <title>Hepatitis C Essential information for professionals and guidance on testing</title>
    <publicationDate>2004-07-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,CARDIOVASCULAR,BODY PART AFFECTED,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,VIRUSES,HEPATITIS VIRUS,HEPATITIS C VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This best practice, policy document produced by the Department of Health provides essential information to healthcare professionals on the prevention and control of Hepatitis C it also provides guidance on testing. It is fully referenced but also reflects professional expert opinion. 
The purpose of this document is to inform health professionals about hepatitis C and assist them in offering hepatitis C testing to patients who may have been at risk of infection.
The document provides information and advice on:-
Epidemiology, prevalence and how the virus is transmitted 
The natural history of hepatitis C infection 
Groups who should be offered testing 
Pre and post test discussion 
Hepatitis C tests 
Referral for specialist management and treatment for hepatitis C 
Further sources of information and references
The guidance is published to support implementation of the Hepatitis C Action plan for England]]&gt;</body>
  </document>
  <document>
    <id>315022</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1228894676145]]&gt;</url>
    <title>Hepatitis C in the UK: 2008 report</title>
    <publicationDate>2008-12-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HEPATITIS,INFECTIONS,HEPATITIS C,HEPATITIS C VIRUS,HEPATITIS VIRUS,VIRUSES,MICROORGANISM,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report details the action being taken at a local and national level to tackle hepatitis C across the United Kingdom (UK). Since the Agency's first annual hepatitis report for England, published in 2005, government action plans have been published in all countries of the UK. Each of the plans reflects the different priorities and concerns of that country, taking into consideration the differing systems for service delivery and the level of local accountability versus national coordination within each country. The countries are at different stages of implementation but all share common goals. We outline here the common major achievements and aspirations that are shared across the UK.]]&gt;</body>
  </document>
  <document>
    <id>333438</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259152221464]]&gt;</url>
    <title>Hepatitis C in the UK: 2009 report</title>
    <publicationDate>2009-12-11T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SETTINGS,MANAGEMENT &amp; INTERVENTIONS,OUTCOMES,PUBLIC HEALTH,INFECTIOUS DISEASES,HEPATITIS,INFECTIONS,MONTHLY ADDITIONS,COMMUNICABLE DISEASES,COMMUNICABLE DISEASES,GEOGRAPHY,MANAGEMENT &amp; POLICY,NATIONAL,HEPATITIS,LIVER DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,INFORMATION,SERVICES,SCREENING,HEPATITIS C,VIRUSES,HEPATITIS VIRUS,HEPATITIS C VIRUS,MICROORGANISM,ADDED 2009,DEC 09,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;All primary care organisations in England and Wales should ensure that integrated pathways of care are available for patients with hepatitis C (ideally coordinated through a clinical network). 
&lt;LI&gt;Strategic health authorities in England should take the lead in supporting local commissioners to ensure complete implementation of the hepatitis C Action Plan across all PCTs in their regions. 
&lt;LI&gt;Commissioners and providers of services for injecting drug users in Wales and Northern Ireland need to review their programmes to ensure that a broad range of prevention services (in addition to needle and syringe exchange) is available. 
&lt;LI&gt;Primary care organisations in England should develop mechanisms for obtaining reliable data on the number of patients referred, seen and treated for hepatitis C. 
&lt;LI&gt;Lead agencies in Northern Ireland, Scotland and Wales need to urgently initiate expanded public information campaigns to raise awareness of hepatitis C. 
&lt;LI&gt;Lead agencies in Wales and Northern Ireland should investigate the need for targeted public information campaigns to raise awareness of hepatitis C in individuals from the Indian sub-continent. 
&lt;LI&gt;Commissioners and providers need to ensure that a high rate of testing in those attending specialist services for drug users is maintained. Lead agencies in all UK countries should ensure widespread access to testing for hepatitis C using alternative specimens (for example, oral fluid and dried blood spot). 
&lt;LI&gt;Providers of prison health services should develop testing strategies and care pathways that allow equitable access to treatment services for offenders. 
&lt;LI&gt;Lead agencies in all countries should assess the impact of awareness campaigns, by monitoring testing outside of high risk group settings. 
&lt;LI&gt;National and local agencies should make efforts to understand and improve the completeness of routine surveillance systems for hepatitis C. 
&lt;LI&gt;All commissioners of HCV services should evaluate the coverage of HCV testing services in their area and ensure that laboratories have appropriate pathways for referring samples for confirmatory testing. 
&lt;LI&gt;National surveillance centres should develop systems for assessing and monitoring the incidence of hepatitis C in key risk groups. This includes injecting drug users, and if appropriate, HIV positive MSMs.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285927</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop5.pdf]]&gt;</url>
    <title>Hepatitis C virus serology (VSOP 5)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,CARDIOVASCULAR,BODY PART AFFECTED,TRANSMISSION MODE,HEPATITIS,INFECTIONS,MICROORGANISM,VIRUSES,HEPATITIS VIRUS,HEPATITIS C VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285928</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop6.pdf]]&gt;</url>
    <title>Hepatitis, jaundice and abnormal LFTs (VSOP 6)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,TRANSMISSION MODE,BLOOD AND BODY FLUIDS,INFECTIONS,INFECTIOUS DISEASES,HEPATITIS C VIRUS,HEPATITIS B VIRUS,HEPATITIS VIRUS,CYTOMEGALOVIRUS (CMV),VARICELLA ZOSTER VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>330529</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/ben/chr/2009/00000007/00000003/art00015]]&gt;</url>
    <title>HIV and HCV progression in parenterally coinfected children</title>
    <publicationDate>2009-05-04T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,HEPATITIS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,HEPATITIS C,ADULTS,CHILDREN,PREGNANT WOMEN,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HEPATITIS VIRUS,HEPATITIS C VIRUS,VIRUSES,MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Shared transmission routes of HCV and HIV mean parenteral HIV/HCV coinfection still occurs, often in resource- limited settings. The extent to which coinfection and treatment impact on morbidity and mortality in HIV/HCV coinfected children remains unknown thus optimal management and treatment is difficult to achieve. Using data from a unique, large, prospective cohort of parenterally HIV/HCV coinfected children in Libya we determine the immunological, virological and clinical profiles of HIV/HCV coinfected children documenting the natural and treated history of parenterally acquired coinfection for the first time in such a large group. 160 parenterally HIV/HCV coinfected children were analysed. Thirty-three (21%) received antiretroviral treatment (ART) for HIV disease during follow-up. In children receiving ART, HIV RNA viral load decreased in two-thirds 6-12 months after initiation. 85% (17/20) experienced a positive immunological response to ART with a median increase in CD4 cell count z-score of 131%%. Half had progressed to moderate or severe immunosuppression and/or moderate or severe clinical symptoms three years after infection. In those who progressed during follow-up, 85% had done so within three years of infection. Children progressing to moderate or severe immunosuppression and/or clinical symptoms were significantly more likely to be receiving ART. This novel investigation of the natural and treated history of parenterally HIV/HCV coinfected children in a large prospectively followed group demonstrates minimal clinical symptoms and immunosuppression to date, despite low prevalence of treatment, and a response to ART similar to vertically HIV-only infected children.]]&gt;</body>
  </document>
  <document>
    <id>330519</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.lww.com/co-hivandaids/Abstract/2009/07000/HIV_in_adolescents_in_sub_Saharan_Africa.11.aspx]]&gt;</url>
    <title>HIV in adolescents in sub-Saharan Africa</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADOLESCENTS,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Purpose of review&lt;/STRONG&gt;: In this review, we summarize existing evidence on the effectiveness of different intervention approaches to HIV prevention in adolescents - focusing on studies that are either from or are relevant to sub-Saharan Africa. In addition, we include a brief review of other salient issues relevant to HIV prevention research in adolescents. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recent findings&lt;/STRONG&gt;: Although numerous adolescent behavioural HIV prevention interventions have been evaluated, few have assessed their impact on HIV endpoints or been undertaken in Africa. In the three trials from Africa, which had HIV endpoints, none of the interventions had an impact on HIV, although all affected some knowledge and attitudes and reported behaviours. In one of these trials, there was a borderline effect on herpes simplex virus-2 incidence. Adolescents have typically been excluded from trials of biological interventions, although they are likely to benefit from these interventions if found to be effective. Despite the regulatory difficulties, they must be considered for inclusion in these trials as an important target population. Although structural determinants of infection appear to be key drivers of the epidemic in young people in sub-Saharan Africa, few have been rigorously evaluated; those that have have been shown to be promising evidence for their future role in prevention. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: Young people in sub-Saharan Africa, particularly young women, continue to bear the brunt of the HIV epidemic. Adolescents must be an important focus for HIV prevention programming and research. It is increasingly clear that multilevel approaches to prevention will be required to reduce rates of HIV in this age group.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>331512</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1287145367237]]&gt;</url>
    <title>HIV in the United Kingdom: 2010 Report</title>
    <publicationDate>2010-11-26T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GENITOURINARY MEDICINE,PROFESSIONS &amp; SPECIALTIES,HIV &amp; AIDS,DIAGNOSIS &amp; INVESTIGATION,INFECTIONS,SKIN DISORDERS,WOMEN'S HEALTH,SEXUAL HEALTH,ANTENATAL PROBLEMS,INFECTIONS,CO-EXISTING DISEASE,HIV,COMPLICATED PREGNANCY,DISORDERS,EPIDEMIOLOGY,STATISTICS,SCREENING,COMMUNICABLE DISEASES,GROUPS,SETTINGS,POPULATIONS,OUTCOMES,PUBLIC HEALTH,HIV INFECTION,GEOGRAPHY,NATIONAL,PEOPLE WITH HIV OR AIDS,MONTHLY ADDITIONS,INFECTIONS,INFECTIOUS DISEASES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,HIV &amp; AIDS,EPIDEMIOLOGY &amp; QUALITY OF LIFE,SEXUALLY TRANSMITTED,VIRAL INFECTIONS,2009 DECEMBER,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Key findings for 2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The number of people living with HIV in the UK reached an estimated 86,500. A quarter of these people were unaware of their infection. 
&lt;LI&gt;New diagnoses among men who have sex with men (MSM) remained high (2,760); four out of five probably acquired their infection in the UK.&amp;nbsp; 
&lt;LI&gt;Of the people newly diagnosed in 2009, 1,130 probably acquired their infection heterosexually within the UK, accounting for a third of heterosexuals diagnosed. 
&lt;LI&gt;One in six MSM, and one in sixteen heterosexuals newly diagnosed with HIV had acquired their infection within the previous 4-5 months before diagnosis. 
&lt;LI&gt;A total of 6,630 people were newly diagnosed as HIV-infected. This represents a fourth year-on-year decline, largely due to fewer diagnoses among people infected heterosexually abroad, mostly in Sub-Saharan Africa. 
&lt;LI&gt;Some 65,000 individuals accessed HIV care, of whom one in five were aged 50 years or over. Since 2000 there has been a three-fold increase in the number of individuals accessing care and a fourfold increase among older (greater than 50 years) individuals. 
&lt;LI&gt;Half of adults were diagnosed with HIV at a late stage of infection in 2009 (CD4 counts less than 350 per mm3 within three months of diagnosis), the stage at which treatment is recommended to begin. &lt;BR&gt;Thirty-seven English primary care trusts (PCTs) had a prevalence of diagnosed HIV greater than 2 per 1,000 population, the threshold at which expanded HIV testing should be implemented. 
&lt;LI&gt;Uptake of HIV testing was 95% in antenatal clinics and 77% among STI clinic attendees in England. 
&lt;LI&gt;The quality of HIV care received is high. Based on London data, 80% of newly diagnosed patients were seen in an HIV clinic within one month of diagnosis; 90% had an undetectable viral load (less than 50 copies/ml) one year after starting therapy; and 93% of those in care for more than a year had a CD4 count above 200 cells per mm3.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;Read the HIV in the UK reports from &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259151891830" target="_blank"&gt;2009 &lt;/A&gt;and &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1227515298354" target="_blank"&gt;2008&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393931</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20699682]]&gt;</url>
    <title>HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: HIV incidence estimates are essential for understanding the evolution of the HIV epidemic and the impact of interventions. Tests for recent HIV infection allow incidence estimation based on a single cross-sectional survey. The BED IgG-Capture Enzyme Immunoassay (BED assay) is a commercially available and widely used test for recent HIV infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: In a systematic literature search for BED assay studies, we identified 1181 unique studies, 1138 of which were excluded based on titles or abstracts. We conducted reviews of the 43 remaining publications and a further 23 studies identified on conference Web sites or by colleagues. Thirty-nine articles were included in the final review. We investigated the sensitivity of incidence values to various estimation methods and parameter choices.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: BED assay surveys have been conducted on 5 continents in general populations and high-risk groups, using 1 or more of 10 distinct incidence formulae. Most studies used estimators that do not account for assay imperfection. Those studies that correct for assay imperfection commonly do not use locally valid assay parameters. Incidence estimates were very sensitive to methodological and parameter choices. Most confidence intervals provided good assessment of uncertainty due to counting error, but only a few incorporated parameter uncertainty.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: BED assay surveys can produce valid HIV incidence estimates, but many studies have not sufficiently accounted for assay imperfection. Future studies should (1) report all information necessary for incidence point and uncertainty estimation, (2) use an unbiased estimator with locally valid assay calibration parameters, and (3) compute confidence intervals that take into account parameter uncertainty.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394191</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898825/pdf/1471-2458-10-317.pdf]]&gt;</url>
    <title>HIV prevalence among female sex workers, drug users and men who have sex with men in Brazil: a systematic review and meta-analysis</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,ADULTS,INJECTING DRUG USERS (IDUS),POPULATION GROUPS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: The Brazilian response towards AIDS epidemic is well known, but the absence of a systematic review of vulnerable populations horizontal line men who have sex with men (MSM), female sex workers (FSW), and drug users (DU) remains a main gap in the available literature. Our goal was to conduct a systematic review and meta-analysis of studies assessing HIV prevalence among MSM, FSW and DU, calculating a combined pooled prevalence and summarizing factors associated the pooled prevalence for each group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Nine electronic databases (MEDLINE via PubMed, EMBASE, Cochrane CENTRAL, AIDSLINE, AMED, CINAHL, TOXNET, SciELO, and ISI-Web of Science) were searched for peer-reviewed papers published in English, French, Spanish or Portuguese, from 1999 to 2009. To be included in the review, studies had to measure HIV prevalence and/or incidence as the primary outcome among at least one specific population under analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: The studies targeting the three populations analyzed mostly young participants aged 30 years or less. Among FSW, eight studies were selected (3,625 participants), consistently identifying higher condom use with sexual clients than with occasional and stable partners. The combined HIV prevalence for FSW was 6.2 (95% CI: 4.4-8.3). Ten studies targeting MSM were identified (6,475 participants). Unprotected anal intercourse was commonly reported on those studies, but with great variability according to the nature of the relationship - stable vs. occasional sex partners--and sexual practice--receptive vs. insertive anal sex. Pooled HIV prevalence for MSM was 13.6 (95% CI: 8.2-20.2). Twenty nine studies targeting DU were identified (13,063 participants). Those studies consistently identified injection drug use and syringe/needle sharing as key predictors of HIV-infection, as well as engagement in sex work and male-to-male sex. The combined HIV prevalence across studies targeting DU was 23.1 (95% CI: 16.7-30.2).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: FSW, MSM and DU from Brazil have a much risk of acquiring HIV infection compared to the general population, among which HIV prevalence has been relatively low (~0.6%). Those vulnerable populations should be targeted by focused prevention strategies that provide accurate information, counseling and testing, as well as concrete means to foster behavior change (e.g. access to condoms, drug abuse treatment, and clean syringes in the case of active injecting drug users), tailored to gender and culture-specific needs. Programs that provide these services need to be implemented on public health services throughout the country, in order to decrease the vulnerability of those populations to HIV infection.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394465</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19996347]]&gt;</url>
    <title>HIV prevalence and testing practices among tuberculosis cases in London: a missed opportunity for HIV diagnosis?</title>
    <publicationDate>2010-01-04T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,DIAGNOSIS,MICROORGANISM,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Universal testing for HIV in patients with tuberculosis (TB) has been advocated for over a decade. The aim of this study was to describe the prevalence and testing practices of HIV in TB centres in London.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A cohort study was undertaken of all patients with TB in Greater London in 2003-4 (n = 1941). Logistic regression was used to assess factors affecting being offered and accepting testing and having a positive HIV result.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: The overall known prevalence of HIV was 9.9% (193/1941). In those with a test result (including those diagnosed previously) it was 25.6%. Overall, 50.8% of patients aged &amp;gt; or =20 years without previous testing were offered HIV testing and, of these, 73% accepted. In multivariable analysis, factors associated with being HIV positive were age 20-49 years, black ethnicity and being born overseas. Those with smear-negative disease and with a poor understanding of English were significantly less likely to be offered HIV testing. Factors associated with refusal of an offered test were female gender or age &amp;gt;49 years. HIV status was not associated with smear status, drug resistance or death, but was associated with CNS disease (OR 1.8, 95% CI 1.0 to 3.0, p = 0.003).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Nearly half the patients with TB in London in 2003-4 were not offered HIV testing. In those offered testing, uptake was high. Patients in higher risk groups were more likely to be offered testing but, even within the highest risk groups, testing was not universally offered. This represents a missed opportunity for diagnosing HIV in patients with TB in London.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393372</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-2458-9-S1-S5.pdf]]&gt;</url>
    <title>HIV prevention cost-effectiveness: a systematic review</title>
    <publicationDate>2009-11-18T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,PREVENTION,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: After more than 25 years, public health programs have not been able to sufficiently reduce the number of new HIV infections. Over 7,000 people become infected with HIV every day. Lack of convincing evidence of cost-effectiveness (CE) may be one of the reasons why implementation of effective programs is not occurring at sufficient scale. This paper identifies, summarizes and critiques the CE literature related to HIV-prevention interventions in low- and middle-income countries during 2005-2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Systematic identification of publications was conducted through several methods: electronic databases, internet search of international organizations and major funding/implementing agencies, and journal browsing. Inclusion criteria included: HIV prevention intervention, year for publication (2005-2008), setting (low- and middle-income countries), and CE estimation (empirical or modeling) using outcomes in terms of cost per HIV infection averted and/or cost per disability-adjusted life year (DALY) or quality-adjusted life year (QALY).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: We found 21 distinct studies analyzing the CE of HIV-prevention interventions published in the past four years (2005-2008). Seventeen CE studies analyzed biomedical interventions; only a few dealt with behavioral and environmental/structural interventions. Sixteen studies focused on sub-Saharan Africa, and only a handful on Asia, Latin America and Eastern Europe. Many HIV-prevention interventions are very cost effective in absolute terms (using costs per DALY averted), and also in country-specific relative terms (in cost per DALY measured as percentage of GDP per capita).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: There are several types of interventions for which CE studies are still not available or insufficient, including surveillance, abstinence, school-based education, universal precautions, prevention for positives and most structural interventions. The sparse CE evidence available is not easily comparable; thus, not very useful for decision making. More than 25 years into the AIDS epidemic and billions of dollars of spending later, there is still much work to be done both on costs and effectiveness to adequately inform HIV prevention planning.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314731</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.unicef.org.uk/publications/pdf/HIVpreventionreport.pdf]]&gt;</url>
    <title>HIV prevention with young people: The key to tackling the epidemic</title>
    <publicationDate>2009-05-06T00:00:00</publicationDate>
    <publisher>UNICEF</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,OUTCOMES,GROUPS,POPULATIONS,AGE GROUPS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,COMMUNICABLE DISEASES,YOUNG PEOPLE,CHILDREN,HIV INFECTION,MONTHLY ADDITIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,MAY 09,MALE UROGENITAL DISORDERS,HIV,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS,2009 DECEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report seeks to describe the current situation of the epidemic, the key challenges faced by adolescents and young people, and the actions that UNICEF is taking to respond in each region.]]&gt;</body>
  </document>
  <document>
    <id>308946</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?author=Jittimanee&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>HIV testing and care of the patient co-infected with tuberculosis and HIV.</title>
    <publicationDate>2008-08-04T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,DIAGNOSIS,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Human immunodeficiency virus (HIV) infection poses one of the greatest challenges to tuberculosis (TB) control, with TB killing more people with HIV infection than any other condition. The standards in this chapter cover provider-initiated HIV counselling and testing and the care of HIV-infected patients with TB. All TB patients who have not previously been diagnosed with HIV infection should be encouraged to have an HIV test. Failing to do so is to deny people access to the care and treatment they might need, especially in the context of the wider availability of treatments that prevent infections associated with HIV. A clearly defined plan of care for those found to be co-infected with TB and HIV should be in place, with procedures to ensure that the patient has access to this care before offering routine testing for HIV in persons with TB. It is acknowledged that people caring for TB patients should ensure that those who are HIV-positive are transferred for the appropriate ongoing care once their TB treatment has been completed. In some cases, referral for specialised HIV-related treatment and care may be necessary during treatment for TB. The aim of these standards is to enable patients to remain as healthy as possible, whatever their HIV status. &lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>330296</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.medicinejournal.co.uk/article/S1357-3039(09)00097-8/abstract]]&gt;</url>
    <title>HIV testing and monitoring</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,DIAGNOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Approximately one-third of HIV-infected persons in Europe and North America are unaware of their infection. There has been a call for doctors to improve the uptake of HIV testing, and for testing to be ‘normalized’ and incorporated into routine practice. Current screening tests allow the combined detection of HIV antibodies and p24 antigen, and can detect the infection within 6–8 weeks. Simple and rapid point-of-care tests are also available. Due to the presence of maternal antibodies, HIV diagnosis in children is based on the detection of viral nucleic acid in blood. Measuring the viral RNA in plasma (‘viral load’) plays a pivotal role in HIV management, and can be useful in diagnosing acute infection prior to the appearance of antibody and p24 antigen. Among untreated patients, the viral load predicts the rate of disease progression. In treated patients, it measures the success of antiretroviral therapy as a surrogate marker for immunological and clinical success. Drug resistance testing is also a key management tool, both in diagnosing transmitted drug resistance and in patients who experience treatment failure to guide drug selection.]]&gt;</body>
  </document>
  <document>
    <id>392762</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929353/pdf/dyq057.pdf]]&gt;</url>
    <title>HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention</title>
    <publicationDate>2010-04-20T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: The human immunodeficiency virus (HIV) infectiousness of anal intercourse (AI) has not been systematically reviewed, despite its role driving HIV epidemics among men who have sex with men (MSM) and its potential contribution to heterosexual spread. We assessed the per-act and per-partner HIV transmission risk from AI exposure for heterosexuals and MSM and its implications for HIV prevention.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Systematic review and meta-analysis of the literature on HIV-1 infectiousness through AI was conducted. PubMed was searched to September 2008. A binomial model explored the individual risk of HIV infection with and without highly active antiretroviral therapy (HAART).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: A total of 62,643 titles were searched; four publications reporting per-act and 12 reporting per-partner transmission estimates were included. Overall, random effects model summary estimates were 1.4% [95% confidence interval (CI) 0.2-2.5)] and 40.4% (95% CI 6.0-74.9) for per-act and per-partner unprotected receptive AI (URAI), respectively. There was no significant difference between per-act risks of URAI for heterosexuals and MSM. Per-partner unprotected insertive AI (UIAI) and combined URAI-UIAI risk were 21.7% (95% CI 0.2-43.3) and 39.9% (95% CI 22.5-57.4), respectively, with no available per-act estimates. Per-partner combined URAI-UIAI summary estimates, which adjusted for additional exposures other than AI with a 'main' partner [7.9% (95% CI 1.2-14.5)], were lower than crude (unadjusted) estimates [48.1% (95% CI 35.3-60.8)]. Our modelling demonstrated that it would require unreasonably low numbers of AI HIV exposures per partnership to reconcile the summary per-act and per-partner estimates, suggesting considerable variability in AI infectiousness between and within partnerships over time. AI may substantially increase HIV transmission risk even if the infected partner is receiving HAART; however, predictions are highly sensitive to infectiousness assumptions based on viral load.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Unprotected AI is a high-risk practice for HIV transmission, probably with substantial variation in infectiousness. The significant heterogeneity between infectiousness estimates means that pooled AI HIV transmission probabilities should be used with caution. Recent reported rises in AI among heterosexuals suggest a greater understanding of the role AI plays in heterosexual sex lives may be increasingly important for HIV prevention.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298236</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2008/9789241596596_eng.pdf]]&gt;</url>
    <title>HIV transmission through breastfeeding</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,PREGNANT WOMEN,ADULTS,NOV 08,POPULATION GROUPS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2008]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This publication is an update of the review of current knowledge on HIV transmission through breastfeeding, with a focus on information made available between 2001 and 2007. It reviews scientific evidence on the risk of HIV transmission through breastfeeding, the impact of different feeding options on child health outcomes, and conceivable strategies to reduce HIV transmission through breastfeeding with an emphasis on the developing world.&lt;/P&gt;
&lt;P&gt;The publication provides the evidence base and rationale for two additional documents in the revised HIV and infant feeding series; HIV and Infant Feeding. Guidelines for decision-makers (ISBN 92 4 159122 6) and HIV and Infant Feeding. A guide for health-care managers and supervisors (ISBN 92 4 159123 4).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325783</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/HIV-vaccine-cuts-infection.aspx]]&gt;</url>
    <title>HIV vaccine cuts infection</title>
    <publicationDate>2009-09-24T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,SEPT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An experimental HIV vaccine cuts infections by a third, newspapers reported. &lt;EM&gt;The Guardian&lt;/EM&gt; called it a “breakthrough”, and the first evidence of a possible vaccine against AIDS.&amp;nbsp;It&amp;nbsp;said a trial in more than 16,000 men in Thailand found vaccinated men&amp;nbsp;had a 31% lower risk of infection.&lt;/P&gt;
&lt;P&gt;The news reports are based on an announcement by the US Military HIV Research Program and the Thai Ministry of Public Health. The full reports of the science behind this announcement have not been published yet, so it is not possible to report on specific details.&lt;/P&gt;
&lt;P&gt;This result has been greeted with varying degrees of optimism by scientists and organisations involved in HIV vaccine research. Many advise caution in that the effect was modest and that it is “early days”. It is also not yet known whether the findings apply to strains of HIV that are common outside of Thailand.&lt;/P&gt;
&lt;P&gt;The researchers say they have already “learned a great deal from this study, particularly in terms of conducting large-scale HIV prevention trials, and will continue to learn more as additional research is conducted”.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The findings from this vaccine trial have been welcomed by researchers and organisations involved in vaccine research and undoubtedly by HIV patients too. Critics and supporters of the trial are reported to have been just as surprised by the findings. &lt;/P&gt;
&lt;P&gt;Importantly, a detailed data analysis of the study’s results is currently underway and a formal report is being written. The peer review and scrutiny process that accompanies such a process will be important to highlight any potential problems with the trial. &lt;/P&gt;
&lt;P&gt;The differences in infection rate between the groups are modest and a further in-depth data analysis by researchers&amp;nbsp;is underway. &lt;/P&gt;
&lt;P&gt;Most experts in the field appear to be cautiously optimistic about these findings, and say that it is “early days yet”, but the results appear to show there is potential for an effective vaccine for HIV. Commentators say the research is promising and especially welcome for AIDS researchers after 25 years of searching for a vaccine.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="https://www01.hjf.org/apps/internet/hivnewscenter.nsf/phase3" target="_blank"&gt;US Military HIV Research Program: RV144 Phase III HIV Vaccine Trial.&lt;/A&gt;&amp;nbsp;Press release and fact sheet&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>321550</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/hiv/topics/research/prs/index.htm]]&gt;</url>
    <title>HIV/AIDS Prevention Research Synthesis Project</title>
    <publicationDate>2009-05-07T00:00:00</publicationDate>
    <publisher>Centres for Disease Control and Prevention (CDC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,SYPHILIS,LYMPHOGRANULOMA VENEREUM (LGV),CHLAMYDIA,GONORRHOEA,HERPES,HIV/AIDS,GENITAL WARTS (HPV),INFECTIONS,TREPONEMA PALLIDUM,BACTERIA,CHLAMYDIA,MICROORGANISM,VIRUSES,NEISSERIA GONORRHOEA,HUMAN PAPILLOMAVIRUS (HPV),HUMAN IMMUNODEFICIENCY VIRUS (HIV),HERPES SIMPLEX VIRUS (HSV),ADDED 2009,NEISSERIA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The HIV/AIDS Prevention Research Synthesis (PRS) Project, through its ongoing efficacy review process, identifies evidence-based HIV behavioral interventions to help HIV prevention planners and providers in the U.S. select interventions most appropriate for their communities. These are listed in the&amp;nbsp; &lt;A href="http://www.cdc.gov/hiv/topics/research/prs/evidence-based-interventions.htm" target="_blank"&gt;2008 Compendium of Evidence-based HIV Prevention Interventions&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The PRS review of community-level HIV behavioral interventions is now complete. New efficacy criteria were developed for evaluating &lt;A href="http://www.cdc.gov/hiv/topics/research/prs/community-level-interventions.htm" target="_blank"&gt;community-level interventions &lt;/A&gt;through multiple consultations with HIV researchers and methodologists. As a result, 5 new evidence-based community-level interventions were added, on May 7, 2009, to the &lt;A href="http://www.cdc.gov/hiv/topics/research/prs/evidence-based-interventions.htm" target="_blank"&gt;2008 Compendium&lt;/A&gt;. Also, 1 new evidence-based individual-level intervention was added.&lt;/P&gt;
&lt;P&gt;All of the interventions cataloged on this site are evidence-based behavioral interventions for persons at high risk of acquiring or transmitting HIV. These interventions represent the strongest HIV behavioral interventions in the literature to date that have been rigorously evaluated and have demonstrated efficacy in reducing HIV or STD incidence or HIV-related risk behaviors (e.g., unprotected sex, needle sharing) or promoting safer behaviors (e.g., being abstinent, using condoms).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394456</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/hiv/pub/9789241599450/en/index.html]]&gt;</url>
    <title>HIV/AIDS programme highlights 2008-2009</title>
    <publicationDate>2010-05-03T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report highlights WHO’s contributions towards Universal Access in 2008 and 2009. It describes how WHO works and identifies specific achievements in each of the five strategic areas. While the Organization's contributions to the HIV response draw upon the initiatives and expertise of WHO’s six regional and 140 country offices, as well as roughly 30 different departments within WHO Headquarters, this report focuses particular attention on achievements of the HIV/AIDS Department in the 2008–2009 biennium.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://whqlibdoc.who.int/publications/2010/9789241599450_eng.pdf" target="_blank"&gt;Report in English [pdf 3.03Mb]&lt;/A&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>331570</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ecdc.europa.eu/en/publications/Publications/0912_SUR_HIV_AIDS_surveillance_in_Europe.pdf]]&gt;</url>
    <title>HIV/AIDS surveillance in Europe 2008</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,DETERMINANTS,PUBLIC HEALTH,SEXUAL HEALTH,SUBSTANCE MISUSE,INDIVIDUAL BEHAVIOUR,SETTINGS,POPULATIONS,ANALYSIS &amp; RESEARCH,GROUPS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,MONTHLY ADDITIONS,INFECTIONS,PEOPLE WITH HIV OR AIDS,GEOGRAPHY,MEASUREMENT,METHODS,EUROPEAN UNION,HIV INFECTION,COMMUNICABLE DISEASES,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,JANUARY 2010,DEC 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;HIV infection remains of major public health importance in Europe, with evidence of increasing transmission of HIV in several European countries according to the new HIV/AIDS surveillance data for Europe released on 1 December.&lt;/P&gt;
&lt;P&gt;To mark the launch of the ECDC report and World Aids Day, ECDC, together with the Swedish Presidency, is organising a scientific seminar at the European Parliament in Brussels focusing on men having sex with men (MSM).&lt;/P&gt;
&lt;P&gt;ECDC Director Zsuzsanna Jakab who is due to speak at the scientific seminar in the European Parliament in Brussels says:&lt;/P&gt;
&lt;P&gt;“Our report indicates that we have seen a resurgence of high risk sexual behaviour in Europe among men who have sex with men. This is leading to rising rates of HIV infection among these men in EU countries, as well as outbreaks of other sexually transmitted infections.&lt;/P&gt;
&lt;P&gt;Efforts to promote safer sex in this group have proved difficult and we must continue to support public health experts to devise new and innovative interventions; but they cannot succeed in isolation.&lt;BR&gt;In all EU countries there are cultural and political sensitivities around the subject of men having sex with men and we all need to break free of these taboos, and talk more openly about the issue of HIV among men who have sex with men.”&lt;/P&gt;
&lt;P&gt;The main findings of the surveillance report are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;In the EU/EEA, 25 656 HIV cases were diagnosed in 2008 and reported by 27 of 30 countries (no data from Austria, Denmark or Liechtenstein), a rate of 61 per million population. The three countries with the highest rates of HIV cases in 2008 are Estonia, Latvia and United Kingdom. Furthermore, rates of around 100 HIV cases per million population were reported by Portugal, Belgium, Luxembourg and Italy. 
&lt;LI&gt;Thirteen per cent of HIV infections diagnosed in 2008 (with information on age) were reported in 15- to 24-year old individuals and 30% (with information on gender) were female. 
&lt;LI&gt;In the EU/EEA, the predominant mode of transmission for HIV infection is sex between men, followed by heterosexual contact. Around 42% of the cases reported to be heterosexually acquired were diagnosed in individuals originating from countries with generalised HIV/AIDS epidemics. &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>394203</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873981/pdf/pone.0010736.pdf]]&gt;</url>
    <title>HIV/TB co-infection in mainland China: a meta-analysis</title>
    <publicationDate>2010-05-20T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,TUBERCULOSIS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: TB and HIV co-epidemic is a major public health problem in many parts of the world, particularly in developing counties. We aimed to summarize the prevalence of TB and HIV co-infection in mainland China, using meta-analysis based on systematic review of published articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We systematically reviewed published studies, from the MEDLINE and Chinese BioMedical Literature Databases, on the prevalence of HIV infection among TB patients and on the prevalence of TB among HIV/AIDS population until 15 April 2010, and quantitatively summarized the estimates using meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: In total, 29 studies were included in this review, with consistently homogeneous results. TB patients, for whom the summary prevalence of HIV infection was 0.9% (0.6%-1.4%) in mainland China, were found to be a potential target population for HIV screening. The prevalence of TB among HIV/AIDS population was 7.2% (4.2%-12.3%), but this was much higher when the analyses were restricted to AIDS patients (22.8%). Significantly higher prevalence was observed for males and hospital-based studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Our analyses indicated that the prevalence of HIV/TB co-infection in China deserves special attention, screening of TB among HIV/AIDS populations should be attached more importance, which would be much more helpful for treatment of both diseases.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308905</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thieme-connect.com/DOI/DOI10.1055/s-0028-1085703]]&gt;</url>
    <title>HIV-associated Tuberculosis: Diagnostic and treatment challenges.</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Thieme Medical Publishers</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,DIAGNOSIS,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB) and the human immunodeficiency virus (HIV) are, individually, two of the world's greatest ongoing public health threats. In combination, the two diseases can be even more devastating. HIV significantly increases an individual's chances of reactivation of latent TB infection and progression to active TB disease. HIV's associated immunosuppression makes it more difficult to diagnose active TB due to a higher likelihood of atypical and extrapulmonary presentation and poorer performance of standard diagnostic tools. TB is the major cause of death in individuals infected with HIV, and the combination of both illnesses creates unique treatment challenges for providers due to interactions between antituberculous and antiretroviral medications, overlapping drug toxicities, and the immune reconstitution inflammatory syndrome. Magnifying these challenges even further is the fact that much of the burden of TB/HIV coinfection exists in some of the world's most resource-limited settings. Concerted efforts are needed to identify rapid and accurate diagnostic tools for active TB disease and latent TB infection (LTBI) that are practical and inexpensive and that perform well in individuals with HIV infection. Also needed are effective and feasible strategies to optimize management of both conditions in the coinfected patient.]]&gt;</body>
  </document>
  <document>
    <id>285935</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jinf.2004.04.001]]&gt;</url>
    <title>Hospital management of adults with severe acute respiratory syndrome (SARS) if SARS re-emerges - updated 10 February 2004</title>
    <publicationDate>2004-04-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,ANTIVIRALS,ANTIMICROBIALS,TREATMENT,SARS,MICROORGANISM,VIRUSES,SARS CORONA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ SARS is a potentially severe and highly infectious disease to which healthcare workers involved in the management of cases are particularly vulnerable. These guidelines briefly summarise optimal and safe practice for clinicians involved in the emergency care of patients with probable or confirmed SARS.]]&gt;</body>
  </document>
  <document>
    <id>330543</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://pdfs.journals.lww.com/pedresearch/2009/05001/Host_Genetic_Determinants_of_Human.9.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1258628263795;payload|mY8D3u1TCCsNvP5E421JYPPlNl9ZUXrQDsjmMHeXqBgfxP56d5BAis+WhfSrPR1S6lcHrAT5WTvTkrI7Jc1zUq2UlEn8]]&gt;</url>
    <title>Host genetic determinants of human immunodeficiency virus infection and disease progression in children</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,PREGNANT WOMEN,POPULATION GROUPS,CHILDREN,ADULTS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Increasing data support host genetic factors as important determinants of human immunodeficiency virus type 1 (HIV-1) susceptibility, mother-to-child transmission (MTCT) and disease progression. Of these genetic mediators, those impacting innate and adaptive immune responses appear to play a critical role in viral infectivity and pathogenesis. During primary infection, CCR5 using virus is predominantly transmitted and polymorphisms that affect the expression of CCR5 alter the risk for MTCT and rate of disease. Chemokines that naturally bind to co-receptors alter infectivity and viral pathogenesis. Additional genes that affect innate immunity including those encoding for MBL2 and those modulating the adaptive immune response including CX3CR1 and HLA types can significantly modify susceptibility and response to HIV-1 infection. As young children develop, the dependence on certain arms of the immune system varies and can alter the effect of genetic variants. Additionally, host genetic factors may alter the response to antiretrovirals. Finally, because HIV-infected children progress more rapidly than adults and have fewer background co-factors such as drug use and co-infections, the effects of host factors on HIV-1 disease may be more clearly identified. In this review, we summarize available data on the impact of host genetics on MTCT and disease progression of HIV-infected children.]]&gt;</body>
  </document>
  <document>
    <id>285936</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000001/art00010]]&gt;</url>
    <title>How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis?</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,INFECTIONS,MYCOBACTERIUM,TREATMENT,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ SETTING: The diagnosis of tuberculosis (TB) may be rejected in the absence of symptoms such as fever, sweats or weight loss.

OBJECTIVES: To determine how frequently these features and blood test evidence of inflammation were absent in individuals with TB.

METHODS: Prospective cohort study of 175 unselected subjects diagnosed with TB at a UK TB service between 2003 and 2006.

RESULTS: Eight (5%) subjects identified by screening and 24 (14%) without culture confirmation were excluded. Of the remaining 143, fever, sweats or weight loss were absent in respectively 37%, 39% and 38%. All three symptoms were absent in 25%. In 88 subjects with pulmonary disease, all three symptoms were absent in 20% (10% of smear-positive cases). Overall, C-reactive protein was normal in 15%, erythrocyte sedimentation rate in 21% and lactate dehydrogenase in 55%. In a multivariable model, factors associated with absent symptoms included drug-resistant TB (adjusted odds ratio [aOR] 3.58, P = 0.004) and female sex (aOR 3.15, P = 0.004).

CONCLUSIONS: In our population, TB, including pulmonary disease, frequently presented without fever, sweats or weight loss and with normal blood inflammatory markers. This information is of as much relevance to policy makers seeking to improve active case detection as to clinicians and the general public. ]]&gt;</body>
  </document>
  <document>
    <id>285937</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jac.oupjournals.org/cgi/content/abstract/50/2/241]]&gt;</url>
    <title>How strong is the evidence that antibiotic use is a risk factor for antibiotic-resistant, community-acquired urinary tract infection?</title>
    <publicationDate>2002-05-16T00:00:00</publicationDate>
    <publisher>Journal of Antimicrobial Chemotherapy</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,RENAL TRACT INFECTIONS,BODY PART AFFECTED,URINARY TRACT,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT,BACTERIA,MICROORGANISM,MALE UROGENITAL DISORDERS,MALE BLADDER DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Literature review of evidence that previous exposure to antibiotics increases the risks of acquiring antibiotic-resistant UTI in the community. 14 studies were identified that met the inclusion criteria. These are divided into ecological (5) and individual studies (10) (one study both). The ecological studies suggest higher prescribing rates increase the resistance rates to some antibiotics, but not others. Some of the studies on individuals had similar findings, but the lack of controls for compounding factors and risk factors for UTI, plus failure to differentiate between reinfection and recurrence, make firm conclusions difficult to make.]]&gt;</body>
  </document>
  <document>
    <id>285938</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHvol7/No1/7_1summary9.htm]]&gt;</url>
    <title>How to do it? Practical guidance on organising mass antibiotic prophylaxis for a large school after a cluster of meningococcal disease</title>
    <publicationDate>2004-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (CDPH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,CONTACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA,NEISSERIA MENINGITIDIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper aims to identify and address problems in planning mass prophylaxis against meningitis. It provides a practical checklist with commentary on potential issues based on local experience. ]]&gt;</body>
  </document>
  <document>
    <id>285939</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop7.pdf]]&gt;</url>
    <title>Hoyle's tellurite agar (MSOP 7)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285940</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947315628]]&gt;</url>
    <title>HPA Guidelines for Action in the Event of a Deliberate Release - Botulism</title>
    <publicationDate>2007-04-16T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,INFECTIONS,CLOSTRIDIUM BOTULINUM,CLOSTRIDIUM,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The HPA guideline covers: background and clinical information; clinical procedures; laboratory procedures; Public Health procedures; and a list of national specialists. A deliberate release may involve airborne dissemination of toxin, producing botulism through inhalation or contamination of water or food supplies with toxin or bacteria.]]&gt;</body>
  </document>
  <document>
    <id>285941</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947355003]]&gt;</url>
    <title>HPA Guidelines for Action in the Event of a Deliberate Release - Brucellosis</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ZOONOSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Health Protection Agency guideline on brucellosis covers: background and clinical information, clinical procedures, laboratory procedures, public health procedures and a list of national specialists. They aim to guide clinical and public health action in the event of a deliberate release of brucella. &lt;/P&gt;
&lt;P&gt;Intended audience: Healthcare, laboratory and public health professionals. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285942</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947396073]]&gt;</url>
    <title>HPA Guidelines for Action in the Event of a Deliberate Release - Plague</title>
    <publicationDate>2007-04-13T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ZOONOSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The HPA guideline covers: background and clinical information; clinical procedures; laboratory procedures; Public Health procedures; and a list of national specialists. The creation of an infectious plague aerosol is not easy, but there may be a threat from the deliberate release of large quantities of Y. pestis, in aerosol. This threat is considered severe because: the organism can cause severe rapidly fatal infection; secondary cases may arise from contact with cases of pneumonic plague; and the disease has previously had a reputation that caused disruption in the population.]]&gt;</body>
  </document>
  <document>
    <id>285943</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947387885]]&gt;</url>
    <title>HPA Guidelines for Action in the Event of a Deliberate Release - Q fever</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ZOONOSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The guidelines provide information for action in the event of a deliberate release of coxiella burnetii (Q fever).&amp;nbsp; Areas covered are background and clinical information, clinical procedures, laboratory procedures, public health procedures.&amp;nbsp; A list of national experts is also provided. &lt;/P&gt;
&lt;P&gt;Intended audience: Healthcare, laboratory and public health professionals. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285943</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947387885]]&gt;</url>
    <title>HPA Guidelines for Action in the Event of a Deliberate Release - Q fever</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ZOONOSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The guidelines provide information for action in the event of a deliberate release of coxiella burnetii (Q fever).&amp;nbsp; Areas covered are background and clinical information, clinical procedures, laboratory procedures, public health procedures.&amp;nbsp; A list of national experts is also provided. &lt;/P&gt;
&lt;P&gt;Intended audience: Healthcare, laboratory and public health professionals. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285945</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947387885]]&gt;</url>
    <title>HPA Guidelines for Action in the Event of a Deliberate Release - Q Fever</title>
    <publicationDate>2007-11-06T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,DENGUE FEVER,MARBURG HAEMORRHAGIC FEVER,EBOLA HAEMORRHAGIC FEVER,LASSA FEVER,TRAVEL ASSOCIATED INFECTIONS,TRAVELLERS,ADULTS,POPULATION GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines are intended for healthcare, laboratory and public health professionals to guide clinical, laboratory and public health action in the event of a deliberate release of Coxiella burnetii, the causative organism of Q Fever.&lt;/P&gt;
&lt;P&gt;Areas addressed are background and clinical information, clinical procedures, laboratory procedures and a list of national specialists.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285945</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947387885]]&gt;</url>
    <title>HPA Guidelines for Action in the Event of a Deliberate Release - Q Fever</title>
    <publicationDate>2007-11-06T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,DENGUE FEVER,MARBURG HAEMORRHAGIC FEVER,EBOLA HAEMORRHAGIC FEVER,LASSA FEVER,TRAVEL ASSOCIATED INFECTIONS,TRAVELLERS,ADULTS,POPULATION GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines are intended for healthcare, laboratory and public health professionals to guide clinical, laboratory and public health action in the event of a deliberate release of Coxiella burnetii, the causative organism of Q Fever.&lt;/P&gt;
&lt;P&gt;Areas addressed are background and clinical information, clinical procedures, laboratory procedures and a list of national specialists.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316042</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1243467944074]]&gt;</url>
    <title>HPA Surveillance Systems: Swine Influenza (H1N1swl)</title>
    <publicationDate>2009-05-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,SWINE INFLUENZA,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The current swine influenza (H1N1swl) situation is monitored in England through a range of surveillance systems and specific epidemiological studies e.g. of clusters occurring in schools. This briefing provides an overview of the surveillance systems that have been used since the outset of the epidemic in the UK, in April 2009.]]&gt;</body>
  </document>
  <document>
    <id>285948</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/malaria/guidelines.htm]]&gt;</url>
    <title>HPA webpage of Malaria Guidelines </title>
    <publicationDate>2003-09-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR,BODY PART AFFECTED,BLOOD AND BODY FLUIDS,TRANSMISSION MODE,INSECT BITE,MALARIA,INFECTIONS,TRAVEL ASSOCIATED INFECTIONS,MICROORGANISM,PARASITES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Statement on homeopathic remedies for malaria 

Change in malaria chemoprophylaxis recommendations for southern Africa 
Due to increasing drug resistance the current recommendation of proguanil and chloroquine is no longer felt to be appropriate. 

Travellers to malarial areas within Namibia , Botswana and Zimbabwe are now recommended to take mefloquine, doxycycline or atovaquone/proguanil (Malarone®) as malaria chemoprophylaxis.  The choice of drug should be determined in consultation with the traveller and take into account potential medical contraindications to individual agents.

Malaria chemoprophylaxis for areas affected by the Earthquake and Tsunamis of 26 December 2004 Continuing surveillance since the 26th December 2004 has shown no significant evidence of altered or increased risk of malaria in Tsunami-affected areas.

Advisors of travellers visiting these areas, who are seeking information on protection from malaria, should be guided by the advice given below in the 'Guidelines for malaria prevention in travellers from the United Kingdom for 2003', with the attached updates for succeeding years.

Guidelines for malaria prevention in travellers for the United Kingdom for 2003. Published in Communicable Disease and Public Health ( 421 KB)  
Update to the above Guidelines for malaria prevention in travellers for the United Kingdom for 2003. Published 1 December 2004 ( 125 KB) 

 
Malaria prophylaxis for long-term travellers. Published in Communicable Disease and Public Health ( 244 KB)  

Medicines and Healthcare products Regulatory Agency Yellow Card Adverse Drug Reactions Reporting Scheme: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&amp;nodeId=755
Advice on other travel related issues can be found on the NaTHNaC website at www.nathnac.org]]&gt;</body>
  </document>
  <document>
    <id>316041</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1243467927021]]&gt;</url>
    <title>HPA Weekly National Influenza Report</title>
    <publicationDate>2009-05-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,RESPIRATORY INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In light of the recent outbreak of the novel influenza A (H1N1swi) virus, the weekly influenza&lt;BR&gt;reports will recommence. Daily updates will also be providedIn light of the recent outbreak of the novel influenza A (H1N1swi) virus, the weekly influenza&lt;BR&gt;reports will recommence. Daily updates will also be provided]]&gt;</body>
  </document>
  <document>
    <id>326614</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/Cervical-cancer-vaccine-QA.aspx]]&gt;</url>
    <title>HPV vaccine in the clear</title>
    <publicationDate>2009-10-02T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,GENITAL WARTS (HPV),PREVENTION,INFECTIONS,VACCINES / IMMUNISATION,CERVICAL CANCER VACCINE (HPV 16,CHILDHOOD VACCINES,MICROORGANISM,HUMAN PAPILLOMAVIRUS (HPV),VIRUSES,OCT 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A pathologist has confirmed that the human papilloma virus (HPV) vaccine did not cause the death of Natalie Morton, a schoolgirl from Coventry.&lt;/P&gt;
&lt;P&gt;Early media speculation suggested the anti-cancer jab could be responsible, but a post-mortem has found that she died from a large malignant tumour of the heart and lungs.&lt;/P&gt;
&lt;P&gt;Dr Caron Grainger, joint director of public health for NHS Coventry and Coventry City Council, said, “The pathologist has confirmed today at the opening of the inquest into the death of Natalie Morton that she died from a large malignant tumour of unknown origin in the heart and lungs. There is no indication that the HPV vaccine, which she had received shortly before her death, was a contributing factor to the death, which could have arisen at any point.”&lt;/P&gt;
&lt;P&gt;“We hope that this news will reassure parents that the vaccine is safe and that they should continue to encourage their daughters to be protected against cervical cancer. The HPV vaccination programme will continue as planned in the city from Monday.”&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313572</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1240812234677?p=1240812234677]]&gt;</url>
    <title>Human Swine Influenza: information for health professionals (updated 20th July 2009)</title>
    <publicationDate>2009-07-20T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,VACCINES / IMMUNISATION,INFECTIONS,PREVENTION,ANTIVIRALS,ANTIMICROBIALS,RESPIRATORY INFECTIONS,POPULATION GROUPS,INFLUENZA VACCINE,DIAGNOSIS,TREATMENT,INFECTION CONTROL,HEALTHCARE WORKERS,ADULTS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Slowing the spread in the early stages of the influenza A/H1N1v (swine flu) pandemic has given the HPA and the health service time to learn more about the new virus, build up antiviral and antibiotic stockpiles, and start to develop a pandemic specific vaccine.&lt;/P&gt;
&lt;P&gt;The focus is now on treating those affected by the virus.&lt;/P&gt;
&lt;P&gt;This section contains advice and information for healthcare professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381204</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/universal-flu-vaccine.aspx]]&gt;</url>
    <title>Hunt for universal flu vaccine</title>
    <publicationDate>2010-07-16T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,RESPIRATORY INFECTIONS,INFLUENZA VACCINE,MICROORGANISM,VACCINES / IMMUNISATION,INFLUENZA VIRUS,VIRUSES,JULY 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A single flu jab that kills off any strain of the virus for decades will soon be a reality,” reported the Daily Express.&lt;/P&gt;
&lt;P&gt;The news story is based on early research in animals, testing ‘plasmid vaccines’ aimed at immunising the body against multiple strains of the H1N1 flu virus. The researchers found that when given in combination with a seasonal booster vaccine, the plasmid vaccines protected against numerous H1N1 strains. When combined with the adenovirus 5 booster, they also gave protection against other viral strains as well.&lt;/P&gt;
&lt;P&gt;These findings are promising, and it looks as though this method may produce wider protection than existing vaccination methods. However, this research is in the early stages and has not yet progressed beyond the laboratory. It seems likely that this approach will be tested in humans at some stage, but when this may happen is unknown. The newspaper reports are premature in saying the vaccine confers protection against ‘every strain’.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is complex and valuable scientific research. It found that H1N1 and H3N2 plasmid vaccines in combination with the seasonal booster, gave protection against numerous H1N1 and H3N2 strains. When the H1N1 plasmid was combined with the adenovirus 5 booster, protection was given against other viral strains as well (H5N1 and H2N2 strains).&lt;/P&gt;
&lt;P&gt;The research is in the early stages and has so far been carried out only in animal models. The newsreports of a vaccine that protects against ‘every strain’ are premature. The current experiments have not tested whether the vaccine can produce effective antibodies against every strain of influenza virus that has ever circulated.&lt;/P&gt;
&lt;P&gt;As influenza vaccines are constantly changing, the effects on these newer strains also cannot be predicted. However, it does look as though this method could produce wider protection than existing vaccination methods. As such, the findings are promising, and it seems likely that this approach will be tested in humans in future.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Wei C-J, Boyington JC, McTamney PM, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.sciencemag.org/cgi/content/abstract/sci;science.1192517v1" target="_blank"&gt;Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination.&lt;/A&gt; Science 2010, Published online July 15. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388527</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/hygiene-washing-your-hands.aspx]]&gt;</url>
    <title>Hygiene claims just won't wash</title>
    <publicationDate>2010-09-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PREVENTION,INFECTION CONTROL,SEPT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Using a hand dryer after washing your hands “is so unhygienic that it might be better to not wash at all”, according to The Daily Telegraph.&amp;nbsp; The newspaper said that the moisture left after only partially drying your hands with an electric dryer makes the spread of bacteria more likely.&lt;/P&gt;
&lt;P&gt;The news comes from a laboratory study which compared different hand-drying techniques in 14 volunteers who washed their hands in standard ways. It suggested that ultra-rapid hand dryers and conventional warm-air hand dryers removed similar amounts of bacteria from the hands as long as the dryers were used for an adequate length of time. It also suggested that rubbing your hands together while drying them may release more bacteria from the surface of the skin after washing. These results do not mean that using hand dryers is “unhygienic”, or that not washing your hands is better.&lt;/P&gt;
&lt;P&gt;Effective hand washing is very important for reducing the transfer of bacterial and viral infections, so studies identifying the best hand hygiene methods are useful. Larger studies, and studies under normal hand-washing conditions, would be helpful to confirm the findings of this study. While the Telegraph seems to imply that avoiding hand washing may be a better idea, this is unlikely to be the case, and the best option is likely to be simply washing and drying your hands thoroughly.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Overall, this study suggests that newer ultra-rapid air dryers and conventional warm-air hand dryers perform similarly if used for the recommended lengths of time. It also suggests that rubbing hands together while using a conventional warm-air dryer may reduce the effects of hand washing. There are a few points to note:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;New hand dryers were used in this study, and volunteers used standard methods of hand contamination, hand washing and drying. This is an appropriate way to compare the potential effects of different hand dryers. However, these conditions may not be representative of what happens when people wash and dry their hands in real-life settings. &lt;/LI&gt;
&lt;LI&gt;The ultra-rapid hand dryer was only better than the conventional warm-air hand dryers if the latter were used for shorter periods than intended by the manufacturers (10 seconds as opposed to 30-35 seconds). This suggests that, for maximum effect, the hands should be left under the drying airstream of warm-air dryers for the full length of drying time. &lt;/LI&gt;
&lt;LI&gt;It was unclear whether researchers were&amp;nbsp;&lt;A href="http://www.nhs.uk/news/Pages/Newsglossary.aspx#Blinding" target="_blank"&gt;blinded&lt;/A&gt; to which hand-drying method the subjects used. Ideally, the researchers would not have known which drying method was used to provide each sample being tested for bacteria. &lt;/LI&gt;
&lt;LI&gt;Many bacteria are harmless. However, the type of bacteria found on the hands, and therefore whether they might be harmful, was not assessed in the study. &lt;/LI&gt;
&lt;LI&gt;The second part of the study, which assessed the effects of hand rubbing, only used the conventional driers for 15 seconds. Had they been used for the recommended 30-35 seconds, the results might have been different. &lt;/LI&gt;
&lt;LI&gt;The study was relatively small. For each drying method, there was variation between individuals in the amount of bacteria transferred after hand drying. Testing in larger groups of people would be helpful to confirm results. &lt;/LI&gt;
&lt;LI&gt;New hand dryers were used in this study, so any bacteria found on the hands after drying would have come from the hands themselves or contact with meat in the first part of the study, not the dryer. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This study does not suggest that you are better off not washing your hands than using a hand dryer. It did not compare the amount of bacteria on the hands without any washing and after washing and drying. Effective hand washing is very important to reduce the risk of passing on infectious agents, so studies looking at the best way to reduce bacterial transfer are useful.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Snelling AM, Saville T, Stevens D and Beggs CB. &lt;A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2672.2010.04838.x/full" target="_blank"&gt;Comparative evaluation of the hygienic efficacy of an ultra-rapid hand dryer vs conventional warm air hand dryers&lt;/A&gt;. &lt;EM&gt;Journal of Applied Microbiology&lt;/EM&gt;, September 7 2010 (early view publication) &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285953</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop13.pdf]]&gt;</url>
    <title>Hyne's desoxycholate citrate agar (DCA) (MSOP 13)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,TRANSMISSION MODE,INSECT BITE,INFECTIONS,SALMONELLA,SHIGELLA,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285954</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm]]&gt;</url>
    <title>Identification and Diagnosis of Leishmaniasis</title>
    <publicationDate>2001-10-29T00:00:00</publicationDate>
    <publisher>Centers for Disease Control and Prevention (CDC)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INSECT BITE,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,PARASITES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This online factsheet for the public provides information about Leishmaniasis including causal agent, life cycle, geographic distribution, clinical features, laboratory diagnosis and treatment. 
Please note that this page was produced in the US and that clinical practice in the UK may differ.]]&gt;</body>
  </document>
  <document>
    <id>285955</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid14.pdf]]&gt;</url>
    <title>Identification of anaerobic cocci DRAFT (BSOP ID14)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the characterisation of anaerobic cocci bacteria. An anaerobic coccus gives good growth on blood agar under strict anaerobic conditions and fails to grow on chocolate blood agar after up to seven days in air and 10% CO2. Identification of this group of organisms to species level is difficult without the use of techniques such as gas-liquid chromatography (GLC). Because of the large number of species, it is difficult to provide genus definitions and a single biochemical table to differentiate all species. In the routine laboratory, susceptibility to metronidazole is frequently used as an indicator of an anaerobe being present in a clinical specimen. It is important to consider anaerobes regardless of metronidazole susceptibility in certain clinical specimens or situations where anaerobes are suspected. Financial pressures on laboratories in the UK mean that few GLCs are now available for identifying anaerobes.

Anaerobic sporing organisms are described in BSOPID 8 - Identification of Clostridium species .
Anaerobic gram negative rods are described in BSOP ID 25 – Identification of anaerobic gram
negative rods Actinomyces spp and other anaerobic non-sporing gram positive rods are to be found in BSOP ID 10.]]&gt;</body>
  </document>
  <document>
    <id>285956</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid9.pdf]]&gt;</url>
    <title>Identification of Bacillus species (BSOP ID 9)</title>
    <publicationDate>2007-09-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACILLUS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the identification of Bacillus species. The organisms described in this document are those which may be isolated from clinical material, although not all have been shown to cause human disease.]]&gt;</body>
  </document>
  <document>
    <id>285957</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid5.pdf]]&gt;</url>
    <title>Identification of Bordetella pertussis and Bordetella parapertussis from selective agar (BSOP ID5)</title>
    <publicationDate>2007-09-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the identification of Bordetella pertussis and
Bordetella parapertussis, isolated from pernasal swabs on charcoal blood agar with cefalexin, to
species level.]]&gt;</body>
  </document>
  <document>
    <id>285958</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid23.pdf]]&gt;</url>
    <title>Identification of Campylobacter species (BSOP ID 23)</title>
    <publicationDate>2007-11-21T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,FAECAL/ORAL,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,CAMPYLOBACTER,CAMPYLOBACTER,BACTERIA,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method (NSM) describes the preliminary identification of Campylobacter to species level. &lt;/P&gt;
&lt;P&gt;Taxonomy: The family Campylobacteraceae (proposed in 1991) includes two closely related genera, Campylobacter and Arcobacter. The genus Campylobacter contains 14 species. &lt;/P&gt;
&lt;P&gt;Characteristics: Members of the family Campylobacteraceae are curved, S-shaped or spiral Gram-negative rods; coccal forms may be seen under sub-optimal conditions. On selective agar the colonies are grey/white or creamy grey and moist in appearance. They are motile, microaerophilic (optimum 5 - 10% oxygen) and oxidase positive. Campylobacter species do not ferment or oxidise carbohydrates. A well-recognised problem associated with identification of Campylobacter species is the lack of effective discriminating tests. The species most commonly associated with diarrhoeal disease in humans are thermophilic ie they will grow at 42 - 43°C and 37°C, but not at 25°C. &lt;/P&gt;
&lt;P&gt;Principles of identification: Preliminary identification of Campylobacter species from primary culture is by colonial appearance, Gram stain, growth in oxygen and oxidase test. Species differentiation is difficult because of the lack of discriminating tests available in most routine microbiology laboratories.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285959</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid8.pdf]]&gt;</url>
    <title>Identification of Clostridum species (BSOP ID8)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,TRANSMISSION MODE,FOOD/WATER,CONTACT,DIGESTIVE TRACT,CENTRAL NERVOUS SYSTEM,BODY PART AFFECTED,INFECTIONS,CLOSTRIDIUM,INFECTIOUS DISEASES,MICROORGANISM,BACTERIA,CLOSTRIDIUM DIFFICILE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 
The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 
Background information on National Standard Methods
Your attention is drawn to the Terms of Use of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285960</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid2.pdf]]&gt;</url>
    <title>Identification of Corynebacterium diptheriae, Corynebacterium ulcerans and Corynebacterium pseudotuberculosis (BSOP ID2)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This NSM describes the identification of Corynebacterium diphtheriae, Corynebacterium ulcerans and Corynebacterium pseudotuberculosis isolated from throat, skin and other sites, to species level. These organisms may be isolated from suspected cases of classical diphtheria, cutaneous diphtheria and although uncommon from other clinical infections such as pharyngitis or chronic skin infections. The importance of toxin production by pathogenic Corynebacterium species is highlighted. The document also describes the identification of non-toxigenic species, Corynebacterium jeikeium, Corynebacterium striatum and clinically significant species.]]&gt;</body>
  </document>
  <document>
    <id>285961</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid16.pdf]]&gt;</url>
    <title>Identification of Enterobacteriaceae (BSOP ID16)</title>
    <publicationDate>2007-11-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,FAECAL/ORAL,TRANSMISSION MODE,GASTROENTERITIS,ESCHERICHIA COLI INFECTION,GASTROINTESTINAL INFECTIONS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,SALMONELLA,SHIGELLA,ENTEROCOCCUS,E. COLI,KLEBSIELLA PNEUMONIAE,BACTERIA,MICROORGANISM,SHIGELLA,SALMONELLA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standards Method (NSM) describes the identification of members of the family Enterobacteriaceae. There are a large number of species included in the family. In routine clinical microbiology laboratories it is usual to attempt identification by use of biochemical tests. The level of identification depends on the site of infection, the immune status of the host and the need for epidemiological surveillance. &lt;/P&gt;
&lt;P&gt;Because of the large number of species involved, this NSM will concentrate on the most common genera and species isolated from clinical specimens. The identification of Enterobacteriaceae can be simplified by taking advantage of the fact that three species comprise 80 to 95% of all isolates in the clinical setting. These are Esherichia coli, Klebsiella pneumoniae and Proteus mirabilis. The other species can be easily identified using biochemical tests. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285962</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid22.pdf]]&gt;</url>
    <title>Identification of Escherichia coli O157 (BSOP ID22)</title>
    <publicationDate>2007-11-21T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INSECT BITE,TRANSMISSION MODE,FOOD/WATER,CONTACT,DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,BACTERIA,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This NSM describes the identification of presumptive Vero cytotoxin-producing Escherichia coli O157 (VTEC O157) isolated from faeces. These strains are associated with a wide spectrum of disease including haemolytic uraemic syndrome (HUS).

INTRODUCTION:
Taxonomy:
Vero cytotoxin-producing E. coli O157 (VTEC O157) is a member of the genus Escherichia and the family Enterobacteriaceae.

Characteristics:
VTEC O157 is a Gram-negative rod. On sorbitol MacConkey agar (SMAC) or SMAC containing
cefixime and tellurite (CTSMAC), the colonies are colourless and 2-3mm in diameter. VTEC O157
differs from other members of the genus Escherichia in that it does not usually ferment sorbitol (a
characteristic that is exploited by the selective media3) and is â-glucuronidase-negative. Most VTEC O157 are motile and possess the flagellar antigen H7, but at least 20% in England and Wales are phenotypically non-motile. They are facultatively anaerobic. Strains are oxidase-negative and usually produce gas from glucose. Some strains show atypical biochemistry eg they are anaerogenic, nonlactose fermenting, indole-negative or urea-positive. Some VTEC O157 strains have been found to ferment sorbitol and to be â-glucuronidase-positive.

VTEC O157 is highly infective, and the infective dose is less than 50 organisms. Laboratory acquired infections have been documented.

Principles of Identification:
Presumptive VTEC O157 isolates from primary culture are identified by colonial appearance on
CTSMAC, serology (agglutination with O157-specific antisera) and biochemical tests. Some
commercial biochemical tests may give a doubtful or a low percentage profile for E. coli O157 as the fermentation of sorbitol is heavily weighted for other E. coli strains8, and care must be taken with the interpretation of the profile. All isolates of presumptive E. coli O157 should be referred to the Reference Laboratory for confirmation of identification, serotyping, phagetyping and Vero cytotoxin testing. All identification tests should ideally be performed from non-selective agar to take into account the variations that may occur with biochemical tests such as sorbitol fermentation.

Where the clinical evidence is suggestive of VTEC infection (particularly in children under 15 years and adults over 65 years) and no presumptive sorbitol non-fermenting E. coli O157 colonies are observed on SMAC or CTSMAC/SMAC agar, we recommend that clinical laboratories should:
• Test sorbitol fermenting colonies for agglutination with E. coli O157 antiserum
• Confirm the identification of agglutination-positive O157 colonies as E. coli
• Send presumptive isolate(s) to the Reference Laboratory (LEP, CfI, HPA Colindale) for
confirmation, phage typing and detection of VT genes
Faecal samples from appropriate cases from whom VTEC O157 have not been isolated should be submitted to LEP for detection of VTEC strains belonging to serogroups other than O157.]]&gt;</body>
  </document>
  <document>
    <id>285963</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid17.pdf]]&gt;</url>
    <title>Identification of glucose non-fermenting rods (BSOP ID 17) </title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CONTACT,AIRBORNE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,PNEUMONIA,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) includes the identification of Pseudomonas species,
Burkholderia species and other glucose non-fermenting Gram-negative bacilli that have been
associated with human infection. It describes the identification of Pseudomonas aeruginosa and
Burkholderia cepacia complex (Bcc) from selective media, and members of this diverse group of
organisms from a variety of primary isolation media.

The bacteria described in this NSM are aerobic and non-sporing. They may oxidise glucose and are catalase-positive. Some species are able to grow anaerobically in the presence of nitrate, and many produce water-soluble pigments. 

Colonies on primary isolation media are presumptively identified by colonial morphology, Gram stain, oxidase activity and pigment production. The oxidase reaction is an important discriminatory test. Oxidase positive, glucose non-fermenting, Gram-negative bacilli such as Pseudomonas aeruginosa may be termed as “pseudomonads”. Further identification is determined by further phenotypic tests and/or referral to a suitable Reference Laboratory. All identification tests are ideally performed from non-selective agar.

Non-fermenting Gram-negative bacilli are associated with a wide range of infections, predominantly of nosocomial origin. Such infections usually occur in patients with identifiable defects of local and/or systemic immunity. These bacteria can be isolated from a wide variety of environmental sources and can cause infection via contaminated medical devices or “pseudo-infection” due to their survival/growth in blood sampling tubes or laboratory media.]]&gt;</body>
  </document>
  <document>
    <id>285964</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid12.pdf]]&gt;</url>
    <title>Identification of Haemophilus species and the Hacek group of organisms (BSOP ID 12)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BLOOD AND BODY FLUIDS,BODY PART AFFECTED,CARDIOVASCULAR,INFECTIONS,HAEMOPHILUS,BACTERIA,HAEMOPHILUS INFLUENZAE,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285965</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid26.pdf]]&gt;</url>
    <title>Identification of Helicobacter species (BSOP ID26)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,MICROORGANISM,HELICOBACTER PYLORI,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the identification of Helicobacter species with
particular reference to isolation from gastric biopsies for more information regarding gastric biopsies see BSOP 55 - Investigation of gastric biopsies for Helicobacter pylori . The organisms may also be isolated from other specimens such as blood, although this is rare.]]&gt;</body>
  </document>
  <document>
    <id>285966</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid18.pdf]]&gt;</url>
    <title>identification of Legionella species (BSOP ID18)</title>
    <publicationDate>2007-11-12T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the presumptive identification of Legionella species isolated from clinical specimens to genus level. For information on which specimens to use for the investigation of Legionella species refer to BSOP 47 - Investigation of specimens for Legionella species.

Full identification of Legionella species is not cost-effective in most routine clinical microbiology
laboratories and isolates should be sent to the Reference Laboratory.

INTRODUCTION:
Taxonomy:
The family Legionellaceae includes 52 species and in excess of 60 serogroups. Legionella
pneumophila is responsible for 95 per cent of infections with Legionella species. There are 16
serogroups of L. pneumophila, but serogroup 1 accounts for the majority of strains from human
infections.

Characteristics:
The family Legionellaceae consists of faintly staining, Gram-negative, pleomorphic rods. They generally appear as coccobacilli in tissue or secretions, but may become filamentous in culture. The organisms are aerobic and will not grow on blood agar or buffered charcoal yeast extract agar without cysteine. The presence of soluble iron in the media also helps to support their growth.

Members of the genus are relatively inert biochemically, catalase-positive (some may be only weakly catalase-positive), oxidase-variable and possess polar flagella.

Some species other than L. pneumophila fluoresce blue-white under long-wave UV light (360nm ± 20nm) whilst others fluoresce dull yellow or brick red.

Principles of identification:
Colonies isolated on Legionella selective agar are identified by colonial morphology, Gram’s stain and by the requirement of L-cysteine for growth. All isolates from clinical specimens should be sent to the Reference Laboratory for confirmation and further identification.]]&gt;</body>
  </document>
  <document>
    <id>285967</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid3.pdf]]&gt;</url>
    <title>Identification of Listeria species, non-toxigenic corynebacterium species and other non-sporing gram-positive rods (BSOP ID3)</title>
    <publicationDate>2007-10-24T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,LISTERIOSIS,MICROORGANISM,BACTERIA,LISTERIA MONOCYTOGENES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method (NSM) describes the identification of Listeria species and other non-sporing Gram-positive rods (except Corynebacterium species) isolated from clinical specimens to genus or species level.&lt;/P&gt;
&lt;P&gt;For the identification of Corynebacterium species refer to BSOPID 2 - Identification of Corynebacterium diphtheriae, Corynebacterium ulcerans and Corynebacterium pseudotuberculosis .&lt;/P&gt;
&lt;P&gt;A systematic approach is used to differentiate clinically encountered, morphologically similar, aerobic and facultatively anaerobic, non-sporing Gram-positive rods. The true branching organisms such as Actinomyces, Nocardia and Streptomyces species and those which produce spores are not described in this NSM. Rapidly growing Mycobacterium species may also be isolated on the media described in this document and acid-fast bacilli should be referred to the Reference Laboratory.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285968</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid11.pdf]]&gt;</url>
    <title>Identification of Moraxella species and morphologically similar organisms (BSOP ID11)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 
The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 
Background information on National Standard Methods
Your attention is drawn to the Terms of Use of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>285969</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid6.pdf]]&gt;</url>
    <title>Identification of Neisseria species (BSOP ID 6)</title>
    <publicationDate>2008-05-30T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GONORRHOEA,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,MENINGOCOCCAL MENINGITIS,INFECTIONS,MENINGITIS,VACCINE PREVENTABLE DISEASES,BRAIN AND SPINAL CORD INFECTIONS,MICROORGANISM,BACTERIA,NEISSERIA MENINGITIDIS,NEISSERIA GONORRHOEA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method (NSM) describes the identification of pathogenic Neisseria species isolated from clinical specimens and their differentiation from non-pathogenic Neisseria species and the related genera of Moraxella and Kingella. The identification of these two genera is covered in &lt;A href="http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid11.pdf" target="_blank"&gt;BSOP ID 11 - Identification of Moraxella Species and Morphologically Similar Organisms&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285970</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid13.pdf]]&gt;</url>
    <title>Identification of Pasteurella species and morphologically similar bacteria (BSOP ID 13)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the procedure for the phenotypic identification of Pasteurella species and distinguishes these from morphologically similar species.]]&gt;</body>
  </document>
  <document>
    <id>285971</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid24.pdf]]&gt;</url>
    <title>Identification of Salmonella species (BSOP ID24)</title>
    <publicationDate>2007-11-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,DIGESTIVE TRACT,FOOD/WATER,BODY PART AFFECTED,FAECAL/ORAL,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,ESCHERICHIA COLI INFECTION,INFECTIONS,SALMONELLA,SHIGELLA,MICROORGANISM,BACTERIA,KLEBSIELLA PNEUMONIAE,E. COLI,SALMONELLA,SHIGELLA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method (NSM) describes the identification of Salmonella species. The majority of Salmonellae are isolated from faeces but the organism may be isolated from other specimens such as blood, bone marrow and urine. &lt;/P&gt;
&lt;P&gt;Taxonomy: Serotypes of Salmonella and Arizona belong to the family Enterobacteriaceae and are now considered to belong to two species Salmonella Bongori (formerly subspecies V) and Salmonella Enterica (comprising six subspecies: I = enterica, II = salamae, IIIa = arizonae, IIIb = diarizonae, IV = houtenae, and VI = indica). Most (&amp;gt;99.5%) salmonella isolates from humans are serotypes of Salmonella Enterica. The nomenclature adopted in this NSM follows the advice from the Judicial Commission of the International Committee on Systematics of Prokaryotes. It is likely however, that laboratories will continue to report serotypes as species for some time to come. &lt;/P&gt;
&lt;P&gt;Characteristics: Salmonella species are Gram-negative rods. On blood agar, colonies are 2 - 3 mm in diameter. Colonies are generally lactose non-fermenters. Salmonella species are motile (with a few exceptions), facultatively anaerobic, produce acid from glucose usually with the production of gas, and are oxidasenegative. Most produce hydrogen sulphide except Salmonella Paratyphi A and Salmonella Typhi, which is a weak producer. T&lt;/P&gt;
&lt;P&gt;hey are identified with a combination of serological and biochemical tests. Salmonella species are classified and identified into serotypes according to the Kauffmann-White scheme, which currently contains in excess of 2000 serotypes. Primary subdivision is into “O” serogroups (those which share a common somatic antigen), and these are then subdivided on the basis of “H” (flagella) antigens. Strains of Salmonella Typhi may produce Vi antigen, which is an acidic polysaccharide layer outside the cell wall. When fully developed it renders the bacteria agglutinable with Vi antiserum and inagglutinable by “O” antiserum. Antigens similar to Vi may also be found in some strains of Salmonella Paratyphi C and Salmonella Dublin. Laboratory acquired infections of salmonella including Salmonella Typhi have been reported. Principles of identification: Isolates are identified by a combination of colonial appearance, serology (agglutination with specific antisera) and biochemical testing. If confirmation of identification is required, isolates should be sent to the Reference Laboratory.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285972</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid20.pdf]]&gt;</url>
    <title>Identification of Shigella species (BSOP ID20)</title>
    <publicationDate>2007-11-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIOUS DISEASES,FAECAL/ORAL,BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,TRANSMISSION MODE,INFECTIONS,SHIGELLA,SHIGELLA,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method (NSM) describes the identification of Shigella species with particular reference to isolation from faeces. &lt;/P&gt;
&lt;P&gt;Taxonomy: The genus Shigella belongs to the family Enterobacteriaceae and consists of four species; Shigella dysenteriae, Shigella flexneri, Shigella boydii, and Shigella sonnei. Each of the species, with the exception of S. sonnei, is subdivided by serotype. &lt;/P&gt;
&lt;P&gt;Characteristics: Shigella species are small Gram-negative rods. They produce pink colonies on XLD medium and colourless colonies on DCA. Shigella species are facultative anaerobes, are non-motile, oxidasenegative, urease-negative, do not decarboxylate lysine and all except S. dysenteriae type 1 are catalase-positive. The species may be differentiated by biochemical tests and serology of their lipopolysaccharides. The majority of Shigella species, except S. flexneri 6, and S. boydii 13 and 14, ferment sugars without gas production. S. boydii, S. flexneri and S. sonnei, with a few exceptions, ferment mannitol; S. dysenteriae does not. S. sonnei, and S. dysenteriae type 1 are the only species that are ONPG-positive. S. boydii 13 are Ornithine positive, and some may be ONPG positive. Shigella species are highly infective. The infective dose is particularly low with S. dysenteriae, which may require as few as 10-100 organisms to cause infection. &lt;/P&gt;
&lt;P&gt;Principles of identification: Isolates from primary culture are identified by colonial appearance, biochemical tests and serology (agglutination with specific antisera). Plesiomonas shigelloides cross reacts with S. sonnei antisera. If confirmation of identification is required, isolates should be sent to the Reference Laboratory. All identification tests should ideally be performed from non-selective agar.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285973</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid7.pdf]]&gt;</url>
    <title>Identification of Staphylococcus species, micrococcus species and rothia species (BSOP ID 7)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA,STAPHYLOCOCCUS,STREPTOCOCCUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS AUREUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the procedure for the identification and differentiation of Staphylococcus aureus, Staphylococcus species, Micrococcus species and Rothia species. For the identification of catalase-negative Gram-positive cocci see BSOPID 4 - Identification of Streptococcus Species, Enterococcus Species and Morphologically Similar Organisms

INTRODUCTION:
The staphylococci most frequently associated with human infection are S. aureus, S. epidermidis and S. saprophyticus. Other Staphylococcus species may also be associated with human infection.

Taxonomy:
More than thirty species of staphylococci have been recognised, most of which are found only in lower mammals. Staphylococcus aureus is coagulase positive; Staphylococcus intermedius, Staphylococcus hyicus and Staphylococcus schleiferi may also be coagulase positive. The coagulase-negative staphylococci (CNS) can be divided into six major groups, but the species found on humans are located within only two of those groups.

Characteristics:
Staphylococcus species are Gram-positive, non-motile, non-sporing cocci occurring singly, in pairs and in irregular clusters: size may be variable. Colonies are opaque and may be white or cream and are occasionally yellow or orange. The optimum growth temperature is 30°C - 37°C. They are facultative anaerobes and have a fermentative metabolism. Staphylococcus species are usually catalase-positive and oxidase-negative. Nitrate is often reduced to nitrite. Some species are susceptible to lysis by lysostaphin but not by lysozyme and are usually able to grow in 10% sodium chloride. Some species produce extracellular toxins6. Staphylococci may be identified by the production of deoxyribonuclease (DNase) and/or a heat-stable DNase (thermostable nuclease).
]]&gt;</body>
  </document>
  <document>
    <id>285974</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid4.pdf]]&gt;</url>
    <title>Identification of Streptoccocus species, Enterococcus species and morphologically similar organisms (BSOP ID 4)</title>
    <publicationDate>2007-09-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ENTEROCOCCUS AND GRE/VRE,STREPTOCOCCUS,ENTEROCOCCUS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the identification of Streptococcus and Enterococcus species isolated from clinical material to genus or species level by phenotypic methods. Organisms morphologically similar to streptococci, which may be found in clinical specimens, are also included. In view of the constantly evolving taxonomy of this group of organisms, phenotypic methods alone may not adequately identify organisms to species level. This NSM adopts a simplified approach based on grouping organisms with similar phenotypic attributes. Further identification may be necessary where clinically or epidemiologically indicated.]]&gt;</body>
  </document>
  <document>
    <id>285975</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid19.pdf]]&gt;</url>
    <title>Identification of Vibrio species (BSOP ID 19)</title>
    <publicationDate>2007-11-12T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,CHOLERA,TRANSMISSION MODE,DIGESTIVE TRACT,BODY PART AFFECTED,FOOD/WATER,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,CHOLERA VACCINE,MICROORGANISM,TRAVEL VACCINES,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method (NSM) describes the identification of Vibrio species. &lt;/P&gt;
&lt;P&gt;Taxonomy: The genus Vibrio is a member of the family Vibrionaceae and consists of at least 34 recognised species. Vibrio cholerae can be serogrouped into 155 groups on the basis of somatic antigens. Epidemic strains usually belong to serogroup O1, which can be further subdivided into Inaba, Ogawa and Hikojima subtypes. Epidemic strains of V. cholerae O1 can be further differentiated into El Tor and Classical biotypes. Strains not belonging to serogroup O1 are generally referred to as V. cholerae non-O1. In 1993 an outbreak of epidemic cholera began in Bengal caused by a new serogroup of non-O1 V. cholerae. Although initial isolates of this serogroup (O139) were resistant to vibriostatic agent O129, recently isolated strains are sensitive. &lt;/P&gt;
&lt;P&gt;Characteristics: Vibrio species are curved, Gram-negative rods. They produce colonies 2 - 3 mm in diameter on blood agar and colonies on thiosulphate citrate bile salt sucrose (TCBS) are either yellow or green. Vibrio species are facultative anaerobes, motile by a single polar flagellum, and are oxidase-positive (except Vibrio metschnikovii). They are usually sensitive to the vibriostatic agent O129 (2,4-diamino-6, 7-diisopropylpteridine phosphate – 150 ìg disc). Growth is stimulated by sodium ions (halophilic) - the concentration required is reflected in the salinity of their natural environment. V. cholerae (the causative agent of cholera) is not halophilic. V. cholerae O1 depends on the detection of the O1 antigen on the surface of the bacterium, and therefore does not identify V. cholerae O139 strains. V. cholerae O1 classical biotype is VP-negative and is sensitive to polymyxin (50 IU disc). V. cholerae O1 El Tor biotype is VP-positive and is resistant to polymyxin. Twelve species of the genus Vibrio have been incriminated in gastrointestinal and extra-intestinal diseases in man - the most important of these is cholera. &lt;/P&gt;
&lt;P&gt;Principles of identification: Isolates from primary culture are identified by colonial appearance, Gram’s stain, serology (agglutination with specific antisera) and biochemical testing. If confirmation of identification is required, isolates should be sent to the Reference Laboratory. All identification tests should ideally be performed from non-selective agar. The oxidase test may give false negative results if performed from TCBS agar. It should be noted that V. hollisae will not grow on TCBS.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285976</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid21.pdf]]&gt;</url>
    <title>Identification of Yersinia species from faeces (BSOP ID 21)</title>
    <publicationDate>2007-11-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,CONTACT,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the identification of Yersinia enterocolitica and
Yersinia pseudotuberculosis isolated from faeces. The organisms may also be isolated from other specimens such as blood, lymph nodes and abscesses.

INTRODUCTION:
Taxonomy:
The genus Yersinia belongs to the family Enterobacteriaceae and contains 11 species.

Characteristics:
Yersinia species are Gram-negative rods. Y. enterocolitica colonies give a “bulls-eye” appearance on CIN (cefsulodin, Irgasan, novobiocin) medium. Y. pseudotuberculosis colonies on CIN medium are smaller with a deep-red centre with a sharp border surrounded by a translucent zone. Yersinia species are facultative anaerobes, oxidase-negative and ferment glucose with little or no gas production. They are non-motile at 37°C, but, with the exception of Y. pestis, are motile at 22 - 29°C. Phenotypic characteristics are often temperature dependent and more are expressed by cultures at 22 – 29°C rather than 35 - 37°C.

Principles of identification:
Isolates from primary faecal culture are identified by colonial appearance on selective media and
biochemical tests. If confirmation of identification is required, isolates should be sent to the Reference Laboratory. All identification tests should ideally be performed from non-selective agar.]]&gt;</body>
  </document>
  <document>
    <id>285980</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ajrccm.atsjournals.org/cgi/content/abstract/200709-1311PPv1?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author2=wilkinson&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Immune Reconstitution and "Unmasking" of Tuberculosis during Antiretroviral Therapy.</title>
    <publicationDate>2008-01-17T00:00:00</publicationDate>
    <publisher>American Thoracic Society</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,CONTACT,AIRBORNE,BLOOD AND BODY FLUIDS,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,ANTIVIRALS,PREVENTION AND CONTROL,MYCOBACTERIUM,TREATMENT,MICROORGANISM,BACTERIA,VIRUSES,MYCOBACTERIUM TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB) is the most common opportunistic disease in HIV-infected patients during the initial months of antiretroviral therapy (ART) and presents a great challenge to ART programs in resource-limited settings. The mechanisms underlying development of TB in this period are complex. Some cases may represent progression of undiagnosed sub-clinical disease present prior to starting ART, emphasizing the importance of careful screening strategies for TB. It has been suggested that progression in such cases is due to immune reconstitution disease -a phenomenon in which dysregulated restoration of pathogen-specific immune responses triggers the presentation of sub-clinical disease. However, while some cases have exaggerated or overtly inflammatory manifestations consistent with existing case definitions for IRD, many others do not. Moreover, since ART-induced immune recovery is a time-dependent process, active TB may develop as a consequence of persisting immunodeficiency. All these mechanisms are likely to be important, representing a spectrum of complex interactions between mycobacterial burden and changing host immune response. We propose that the potential range of effects of ART includes (i) shortening of the time for sub-clinical TB to become symptomatic (a phenomenon often referred to as 'unmasking'); (ii) increased rapidity of initial onset of TB symptoms, and (iii) heightened intensity of clinical manifestations. We suggest that the term 'ART-associated TB' be used to refer collectively to all cases of TB presenting during ART and that 'immune reconstitution disease' be used to refer to the sub-set of ART-associated TB cases in which the effect on disease severity results in exaggerated and overtly inflammatory disease. ]]&gt;</body>
  </document>
  <document>
    <id>393394</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6W8X-4YNJ3CS-M-2&amp;_cdi=6666&amp;_user=8810565&amp;_pii=S1473309910700268&amp;_origin=search&amp;_coverDate=04%2F30%2F2010&amp;_sk=999899995&amp;view=c&amp;wchp=dGLzVlz-zSkzV&amp;md5=fa70da158535e160168e300c8cf80d06&amp;ie=/sdarticle.pd]]&gt;</url>
    <title>Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis</title>
    <publicationDate>2010-04-05T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In patients with HIV-1 infection who are starting combination antiretroviral therapy (ART), the incidence of immune reconstitution inflammatory syndrome (IRIS) is not well defined. We did a meta-analysis to establish the incidence and lethality of the syndrome in patients with a range of previously diagnosed opportunistic infections, and examined the relation between occurrence and the degree of immunodeficiency. Systematic review identified 54 cohort studies of 13 103 patients starting ART, of whom 1699 developed IRIS. We calculated pooled cumulative incidences with 95% credibility intervals (CrI) by Bayesian methods and did a random-effects metaregression to analyse the relation between CD4 cell count and incidence of IRIS. In patients with previously diagnosed AIDS-defining illnesses, IRIS developed in 37.7% (95% CrI 26.6-49.4) of those with cytomegalovirus retinitis, 19.5% (6.7-44.8) of those with cryptococcal meningitis, 15.7% (9.7-24.5) of those with tuberculosis, 16.7% (2.3-50.7) of those with progressive multifocal leukoencephalopathy, and 6.4% (1.2-24.7) of those with Kaposi's sarcoma, and 12.2% (6.8-19.6) of those with herpes zoster. 16.1% (11.1-22.9) of unselected patients starting ART developed any type of IRIS. 4.5% (2.1-8.6) of patients with any type of IRIS died, 3.2% (0.7-9.2) of those with tuberculosis-associated IRIS died, and 20.8% (5.0-52.7) of those with cryptococcal meningitis died. Metaregression analyses showed that the risk of IRIS is associated with CD4 cell count at the start of ART, with a high risk in patients with fewer than 50 cells per microL. Occurrence of IRIS might therefore be reduced by initiation of ART before immunodeficiency becomes advanced.]]&gt;</body>
  </document>
  <document>
    <id>285982</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpch.ac.uk/publications/recent_publications/Immunocomp.pdf]]&gt;</url>
    <title>Immunisation of the immunocompromised child</title>
    <publicationDate>2002-02-01T00:00:00</publicationDate>
    <publisher>RCPCH</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,AIRBORNE,CONTACT,TRANSMISSION MODE,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Immunisation works because the intact immune system generates memory and specificity.  Immune dysfunction due to disease or the treatment of disease affects different elements of the immune system to varying degrees, which determines the effectiveness and safety of specific vaccines.  Some immunocompromised children and adolescents at particluar risk of certain infections will benefit from extra immunisations.]]&gt;</body>
  </document>
  <document>
    <id>285986</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/immunoglobulin/pdfs/ig_diphtheria.pdf]]&gt;</url>
    <title>Immunoglobulin Handbook - chapter on Diphtheria</title>
    <publicationDate>2001-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This chapter of the immunoglobulin handbook provides information on indications, dosage and notes for diphtheria.]]&gt;</body>
  </document>
  <document>
    <id>285987</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/immunoglobulin/pdfs/ig_hep_a.pdf]]&gt;</url>
    <title>Immunoglobulin Handbook - chapter on Hepatitis A</title>
    <publicationDate>2001-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,FOOD/WATER,TRANSMISSION MODE,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,VIRUSES,HEPATITIS VIRUS,HEPATITIS A VIRUS,MICROORGANISM,TRAVEL VACCINES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This chapter of the immunoglobulin handbook highlights indications for administering immunoglobulin for hepatitis A.]]&gt;</body>
  </document>
  <document>
    <id>285988</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/immunoglobulin/pdfs/ig_polio.pdf]]&gt;</url>
    <title>Immunoglobulin Handbook - chapter on Polio</title>
    <publicationDate>2001-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This chapter of the immunoglobulin handbook provides information on indications, dosage and notes for Polio.]]&gt;</body>
  </document>
  <document>
    <id>285989</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/immunoglobulin/pdfs/ig_rabies.pdf]]&gt;</url>
    <title>Immunoglobulin Handbook - chapter on Rabies</title>
    <publicationDate>2001-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,VIRUSES,MICROORGANISM,TRAVEL VACCINES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This chapter of the immunoglobulin handbook provides information on indications, dosage and notes for Rabies.]]&gt;</body>
  </document>
  <document>
    <id>285990</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/immunoglobulin/pdfs/ig_rubella.pdf]]&gt;</url>
    <title>Immunoglobulin handbook - chapter on Rubella</title>
    <publicationDate>2004-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,MICROORGANISM,VIRUSES,RUBELLA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This chapter of the immunoglobulin handbook provides information on indications, dosage and notes for Rubella.]]&gt;</body>
  </document>
  <document>
    <id>308984</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thieme-connect.com/ejournals/abstract/pneumologie/doi/10.1055/s-2008-1038096]]&gt;</url>
    <title>Immunology of tuberculosis and current status of vaccine development.</title>
    <publicationDate>2008-03-03T00:00:00</publicationDate>
    <publisher>Thieme Medical Publishers</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,MARCH 09,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MYCOBACTERIUM TUBERCULOSIS,BCG,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Even 125 year after the discovery of Mycobacterium tuberculosis as the aetiological agent of tuberculosis by Robert Koch, tuberculosis is still a global health emergency according to WHO. The high infection rate with M. tuberculosis that persists in the human host until a weakened host immune system allows a reactivation and complicated and expensive antituberculous chemotherapy urgently demand the development of new vaccines. Increasing numbers of multidrug-resistant tuberculosis, especially in the successor states of the former Soviet Union and China, further complicate an efficient tuberculosis control. For decades, there was no new release of an antituberculous drug to efficiently fight tuberculosis. Hence, also drug development has to keep up with the development of resistance by the pathogen. The following review describes the immune response to M. tuberculosis infection and the deduction of strategies for novel vaccines. Thanks to international financial support, several new vaccine candidates are already in the pipeline and close to clinical testing phases.]]&gt;</body>
  </document>
  <document>
    <id>330441</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://pediatrics.aappublications.org/cgi/content/abstract/123/3/935]]&gt;</url>
    <title>Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection</title>
    <publicationDate>2009-03-03T00:00:00</publicationDate>
    <publisher>American Academy of Pediatrics</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,CHILDREN,POPULATION GROUPS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADOLESCENTS,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Background:&lt;BR&gt;Little is known concerning the impact of HIV status disclosure on quality of life, leaving clinicians and families to rely on research of children with other terminal illnesses.&lt;/P&gt;
&lt;P&gt;Objectives:&lt;BR&gt;The purpose of this work was to examine the impact of HIV disclosure on pediatric quality of life and to describe the distribution of age at disclosure in a perinatally infected pediatric population.&lt;/P&gt;
&lt;P&gt;Methods:&lt;BR&gt;A longitudinal analysis was conducted of perinatally HIV-infected youth =5 years of age enrolled in a prospective cohort study, Pediatric AIDS Clinical Trials Group 219C, with =1 study visit before and after HIV disclosure. Age-specific quality-of-life instruments were completed by primary caregivers at routine study visits. The distribution of age at disclosure was summarized. Six quality-of-life domains were assessed, including general health perception, symptom distress, psychological status, health care utilization, physical functioning, and social/role functioning. For each domain, mixed-effects models were fit to estimate the effect of disclosure on quality of life.&lt;/P&gt;
&lt;P&gt;Results:&lt;BR&gt;A total of 395 children with 2423 study visits were analyzed (1317 predisclosure visits and 1106 postdisclosure visits). The median age at disclosure was estimated to be 11 years. Older age at disclosure was associated with earlier year of birth. Mean domain scores were not significantly different at the last undisclosed visit compared with the first disclosed visit, with the exception of general health perception. When all of the visits were considered, 5 of 6 mean domain scores were lower after disclosure, although the differences were not significant. In mixed-effects models, disclosure did not significantly impact quality of life for any domain.&lt;/P&gt;
&lt;P&gt;Conclusions:&lt;BR&gt;Age at disclosure decreased significantly over time. There were no statistically significant differences between predisclosure and postdisclosure quality of life; therefore, disclosure should be encouraged at an appropriate time.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308653</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/reprint/45/9/3111?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=kamanzi&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Implementation validation performed in Rwanda to determine whether the INNO-LiPA Rif.TB line probe assay can be used for detection of multidrug-resistant Mycobacterium tuberculosis in low-resource countries.</title>
    <publicationDate>2007-09-03T00:00:00</publicationDate>
    <publisher>American Society for Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Implementation validation performed in Rwanda to determine whether the INNO-LiPA Rif.TB line probe assay can be used for detection of multidrug-resistant Mycobacterium tuberculosis in low-resource countries. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394458</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=562]]&gt;</url>
    <title>Implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2010 Progress Report</title>
    <publicationDate>2010-09-29T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In 2004, high level representatives of European and central Asian countries issued the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and central Asia. This report provides findings from a review of progress made towards its implementation. It is based on data from 49 countries and reflects the contributions of a wide range of individuals and organisations.&lt;/P&gt;
&lt;P&gt;A summary of this report has also been published by ECDC and can be found &lt;A href="http://www.ecdc.europa.eu/en/publications/Publications/100720_implementing_dublic_declaration_hiv_aids_2010_progress_report.pdf" target="_blank"&gt;here&lt;/A&gt;. The full report can be found &lt;A title="" href="http://staging.ecdcdmz.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=562" target="_blank"&gt;here&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285994</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/329/7467/663]]&gt;</url>
    <title>Implications of the incidence of influenza-like illness in nursing homes for influenza chemoprophylaxis: descriptive study. </title>
    <publicationDate>2004-09-18T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,INFLUENZA,INFECTIONS,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,ANTIVIRALS,ANTIMICROBIALS,TREATMENT,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza causes substantial morbidity and mortality among nursing home residents. In September 2003, the National Institute for Clinical Excellence (NICE) issued guidelines for the use of neuraminidase inhibitors for flu prophylaxis. These state that oseltamivir should be given to all residents in nursing and residential homes each time a single case of influenza-like illness (ILI) is
recognised in a resident or staff member and when flu is known to be circulating in the community. Oseltamivir is effective for flu prophylaxis in young healthy people, but there is little evidence of its effectiveness in elderly nursing home residents. Estimates of its cost effectiveness vary widely. Last winter, from 3 November 2003 to 25 January 2004, we conducted surveillance for ILI in a chain of nursing homes across England. The data allow an analysis of the implications of implementing the NICE guidelines.]]&gt;</body>
  </document>
  <document>
    <id>285996</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001379&amp;representation=PDF]]&gt;</url>
    <title>Incidence of Tuberculosis and the Predictive Value of ELISPOT and Mantoux Tests in Gambian Case Contacts</title>
    <publicationDate>2008-01-02T00:00:00</publicationDate>
    <publisher>PLoS (Public Library of Science)</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,CONTACT,INFECTIONS,MYCOBACTERIUM,INFECTIOUS DISEASES,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Studies of Tuberculosis (TB) case contacts are increasingly being utilised for understanding the relationship between M. tuberculosis and the human host and for assessing new interventions and diagnostic tests. We aimed to identify the incidence rate of new TB cases among TB contacts and to relate this to their initial Mantoux and ELISPOT test results.

Methods and Findings
After initial Mantoux and ELISPOT tests and exclusion of co-prevalent TB cases, we followed 2348 household contacts of sputum smear positive TB cases. We visited them at 3 months, 6 months, 12 months, 18 months and 24 months, and investigated those with symptoms consistent with TB. Those who were diagnosed separately at a government clinic had a chest x-ray. Twenty six contacts were diagnosed with definite TB over 4312 person years of follow-up (Incidence rate 603/100,000 person years; 95% Confidence Interval, 370–830). Nine index and secondary case pairs had cultured isolates available for genotyping. Of these, 6 pairs were concordant and 3 were discordant. 2.5% of non-progressors were HIV positive compared to 12% of progressors (HR 6.2; 95% CI 1.7–22.5; p = 0.010). 25 secondary cases had initial Mantoux results, 14 (56%) were positive ; 21 had initial ELISPOT results, 11 (52%) were positive; 15 (71%) of 21 tested were positive by one or the other test. Of the 6 contacts who had concordant isolates with their respective index case, 4 (67%) were Mantoux positive at recruitment, 3 (50%) were ELISPOT positive; 5 (83%) were positive by one or other of the two tests. ELISPOT positive contacts, and those with discordant results, had a similar rate of progression to those who were Mantoux positive. Those negative on either or both tests had the lowest rate of progression.

Conclusions
The incidence rate of TB disease in Gambian TB case contacts, after screening for co-prevalent cases, was 603/100,000 person years. Since initial ELISPOT test and Mantoux tests were each positive in only just over half of cases, but 71% were positive by one or other test, positivity by either might be the best indication for preventive treatment. These data do not support the replacement of the Mantoux test by an ELISPOT test in The Gambia or similar settings.]]&gt;</body>
  </document>
  <document>
    <id>285998</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp19.pdf]]&gt;</url>
    <title>Indole test (BSOP TP 19)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CONTACT,FOOD/WATER,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,BACTERIA,KLEBSIELLA PNEUMONIAE,MICROORGANISM,SALMONELLA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>303808</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1203582652789]]&gt;</url>
    <title>Infectious Diarrhoea - The Role of Microbiological Examination of Faeces</title>
    <publicationDate>2007-12-13T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,JAN 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To improve the diagnosis of infectious disease in primary care 
&lt;LI&gt;To improve use of the microbiology laboratory in primary care 
&lt;LI&gt;To target the use of antibiotics and anti-fungals in primary care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Production:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The templates have been produced in consultation with GPs and specialists in the field. 
&lt;LI&gt;They are in agreement with other guidance, including Prodigy, SIGN and NICE. 
&lt;LI&gt;The guidance is fully referenced and graded. 
&lt;LI&gt;The guidance is not all-encompassing, as it is meant to be quick reference. If more detail is required we suggest referral to the websites and references quoted. 
&lt;LI&gt;The guidance is updated annually. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Local adaptation:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The guidance will need to be taken forward in collaboration between laboratories, PCTs and secondary care providers. 
&lt;LI&gt;Recommendations can be changed to suit local service delivery and sampling protocols. 
&lt;LI&gt;Change in laboratory use may increase or decrease laboratory workload and have financial implications for laboratories and Primary Care Trusts (PCTs). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Your feedback:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;We welcome, in fact encourage, opinions on the advice given and future topics we should cover. 
&lt;LI&gt;Comments should be submitted to Dr Cliodna McNulty, Head, HPA Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN. Email: &lt;A href="mailto:jill.whiting@hpa.org.uk" target="_blank"&gt;jill.whiting@hpa.org.uk&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For a copy of this in word, click &lt;A href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1203582652750" target="_blank"&gt;here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308979</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/bpl/fmr/2008/00000032/00000005/art00004]]&gt;</url>
    <title>Influence of BCG vaccine strain on the immune response and protection against tuberculosis.</title>
    <publicationDate>2008-08-04T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,MARCH 09,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MYCOBACTERIUM TUBERCULOSIS,BCG,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Bacille Calmette-Guérin (BCG) vaccine has been used for more than 80 years to protect against tuberculosis. Worldwide, over 90% of children are immunized with BCG, making it the most commonly administered vaccine, with more than 120 million doses used each year. Although new tuberculosis vaccines are under investigation, BCG will remain the cornerstone of the strategy to fight the worsening tuberculosis pandemic for the foreseeable future. The recent delineation of genetic differences between BCG vaccine strains has renewed interest in the influence of the vaccine strain on the protective efficacy against tuberculosis. This review critically examines the data from animal and human studies comparing BCG vaccine strains. Although there is good evidence to support the notion that the induced immune response and protection afforded against tuberculosis differs between BCG vaccine strains, currently, there are insufficient data to favour or recommend one particular strain. Identifying BCG strains with superior protection would have a dramatic effect on tuberculosis control at a population level: a small increment in protection provided by BCG immunization will prevent large numbers of cases of severe tuberculosis and deaths, particularly in children.]]&gt;</body>
  </document>
  <document>
    <id>286002</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140673603148544/abstract]]&gt;</url>
    <title>Influenza</title>
    <publicationDate>2003-11-22T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TRANSMISSION MODE,INFLUENZA,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIONS,PREVENTION AND CONTROL,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,VACCINES / IMMUNISATION,TREATMENT,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Although most influenza infections are self-limited, few other diseases exert such a huge toll of suffering and economic loss. Despite the importance of influenza, there had been, until recently, little advance in its control since amantadine was licensed almost 40 years ago. During the past decade, evidence has accrued on the protection afforded by inactivated vaccines and the safety and efficacy in children of live influenza-virus vaccines. There have been many new developments in vaccine technology. Moreover, work on viral neuraminidase has led to the licensing of potent selective antiviral drugs, and economic decision modelling provides further justification for annual vaccination and a framework for the use of neuraminidase inhibitors. Progress has also been made on developing near-patient testing for influenza that may assist individual diagnosis or the recognition of widespread virus circulation, and so optimise clinical management. Despite these advances, the occurrence of avian H5N1, H9N2, and H7N7 influenza in human beings and the rapid global spread of severe acute respiratory syndrome are reminders of our vulnerability to an emerging pandemic. The contrast between recent cases of H5N1 infection, associated with high mortality, and the typically mild, self-limiting nature of human infections with avian H7N7 and H9N2 influenza shows the gaps in our understanding of molecular correlates of pathogenicity and underlines the need for continuing international research into pandemic influenza. Improvements in animal and human surveillance, new approaches to vaccination, and increasing use of vaccines and antiviral drugs to combat annual influenza outbreaks are essential to reduce the global toll of pandemic and interpandemic influenza.]]&gt;</body>
  </document>
  <document>
    <id>286002</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140673603148544/abstract]]&gt;</url>
    <title>Influenza</title>
    <publicationDate>2003-11-22T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TRANSMISSION MODE,INFLUENZA,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIONS,PREVENTION AND CONTROL,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,VACCINES / IMMUNISATION,TREATMENT,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Although most influenza infections are self-limited, few other diseases exert such a huge toll of suffering and economic loss. Despite the importance of influenza, there had been, until recently, little advance in its control since amantadine was licensed almost 40 years ago. During the past decade, evidence has accrued on the protection afforded by inactivated vaccines and the safety and efficacy in children of live influenza-virus vaccines. There have been many new developments in vaccine technology. Moreover, work on viral neuraminidase has led to the licensing of potent selective antiviral drugs, and economic decision modelling provides further justification for annual vaccination and a framework for the use of neuraminidase inhibitors. Progress has also been made on developing near-patient testing for influenza that may assist individual diagnosis or the recognition of widespread virus circulation, and so optimise clinical management. Despite these advances, the occurrence of avian H5N1, H9N2, and H7N7 influenza in human beings and the rapid global spread of severe acute respiratory syndrome are reminders of our vulnerability to an emerging pandemic. The contrast between recent cases of H5N1 infection, associated with high mortality, and the typically mild, self-limiting nature of human infections with avian H7N7 and H9N2 influenza shows the gaps in our understanding of molecular correlates of pathogenicity and underlines the need for continuing international research into pandemic influenza. Improvements in animal and human surveillance, new approaches to vaccination, and increasing use of vaccines and antiviral drugs to combat annual influenza outbreaks are essential to reduce the global toll of pandemic and interpandemic influenza.]]&gt;</body>
  </document>
  <document>
    <id>313226</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1202115586990?p=1202115586990]]&gt;</url>
    <title>Influenza</title>
    <publicationDate>2009-04-27T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,RESPIRATORY INFECTIONS,INFECTIONS,PANDEMIC INFLUENZA,MICROORGANISM,INFLUENZA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Health Protection Agency's Influenza information</description>
    <body>&lt;![CDATA[ The Health Protection Agency's influenza informations, including pandemic influenza]]&gt;</body>
  </document>
  <document>
    <id>313226</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1202115586990?p=1202115586990]]&gt;</url>
    <title>Influenza</title>
    <publicationDate>2009-04-27T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,RESPIRATORY INFECTIONS,INFECTIONS,PANDEMIC INFLUENZA,MICROORGANISM,INFLUENZA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Health Protection Agency's Influenza information</description>
    <body>&lt;![CDATA[ The Health Protection Agency's influenza informations, including pandemic influenza]]&gt;</body>
  </document>
  <document>
    <id>286004</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/influenza/seasonal/antivirals.htm]]&gt;</url>
    <title>Influenza - Antiviral Drugs</title>
    <publicationDate>2006-03-22T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFLUENZA,AIRBORNE,BODY PART AFFECTED,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIVIRALS,VACCINES / IMMUNISATION,PREVENTION,TREATMENT,INFECTIOUS DISEASES,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This webpage provides guidelines on the use of antiviral drugs for influenza]]&gt;</body>
  </document>
  <document>
    <id>313745</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/csr/disease/swineflu/en/index.html]]&gt;</url>
    <title>Influenza A(H1N1)</title>
    <publicationDate>2009-04-30T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,PUBLIC HEALTH,RESPIRATORY INFECTIONS,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY DISORDERS,INFLUENZA,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,MONTHLY ADDITIONS,VACCINES / IMMUNISATION,INFLUENZA VACCINE,POST-EXPOSURE PROPHYLAXIS,DIAGNOSIS,TREATMENT,INFECTION CONTROL,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,SWINE INFLUENZA,MAY 09,2009 JUNE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;WHO is coordinating the global response to human cases of influenza A(H1N1) and monitoring the corresponding threat of an influenza pandemic. Information on this page tracks the evolving situation and provides access to both technical guidelines and information useful for the general public.&lt;/P&gt;
&lt;P&gt;Up-to-date numbers of cases are included in the most recent disease outbreak. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315569</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19216]]&gt;</url>
    <title>Influenza A(H5N1): an overview of the current situation</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>Eurosurveillance</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,AVIAN INFLUENZA,INFLUENZA,RESPIRATORY INFECTIONS,INFECTIONS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza viruses continue to threaten the world with a new pandemic. While currently attention is focused on the newly emerged A(H1N1) virus, the avian influenza A(H5N1) virus is still a cause of concern.&amp;nbsp; Extended research is focused on the genetic evolution of the viruses, as well as their susceptibility to available antiviral drugs.&amp;nbsp; One of the major priorities of the World Health Organization is to develop candidate vaccines, four of which are already licensed for use in the European Union. Since the last influenza pandemic in 1968, our knowledge of the influenza virus and its biology has greatly increased, revealing new avenues in the research for antiviral strategies and the development of effective vaccines.]]&gt;</body>
  </document>
  <document>
    <id>286006</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://adc.bmj.com/cgi/reprint/90/5/532?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=Booy+&amp;andorexactfulltext=and&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps? </title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,INFECTIONS,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,INFECTIOUS DISEASES,MICROORGANISM,INFLUENZA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza is a disease of global public health significance. Traditionally the emphasis has been on adult disease because of the impact of influenza related mortality in the elderly and other high risk groups. However, it is becoming increasingly better recognised that young children suffer considerable morbidity from influenza. There are also potential consequences for siblings, parents, other carers, and extended family members in terms of secondary infections and carer leave. Influenza infection in childhood could be effectively prevented through vaccination. However, the United States is the only industrialised country currently recommending universal influenza vaccination for young children (between the ages of 6 and 23 months), as opposed to vaccinating only those with high risk conditions.]]&gt;</body>
  </document>
  <document>
    <id>286008</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://oem.bmj.com/cgi/reprint/64/4/223]]&gt;</url>
    <title>Influenza immunisation: attitudes and beliefs of UK healthcare workers.</title>
    <publicationDate>2006-12-20T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIONS,ANTIMICROBIALS,ANTIVIRALS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,TREATMENT,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ 11,670 healthcare workers in six UK hospitals were surveyed using a postal questionnaire. 19% had taken up influenza immunisation during winter 2002/3. Vaccination was well tolerated, with a low prevalence of side effects (13%) and associated time off work (2%). The majority of subjects who accepted vaccination (66%) were most strongly influenced by the personal benefits of protection against influenza. Prevention of sickness absence and protection of patients were the prime motivation for only 10% and 7% of subjects, respectively. Among 3967 who declined vaccination, the most common primary demotivators were concern about safety (31%) and efficacy (29%). 22% were most strongly deterred by lack of time to attend for vaccination. Free text answers indicated that 37% declined because of a perceived low ratio of personal benefits to adverse effects. Subjects said they would be persuaded to take up vaccination in future by easier access (36%), more information about personal benefit and risk (34%) and more information about effects on staff absence (24%). ]]&gt;</body>
  </document>
  <document>
    <id>388579</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1274091833950]]&gt;</url>
    <title>Influenza Pandemic Preparedness Update</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,PANDEMIC INFLUENZA,RESPIRATORY INFECTIONS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In response to the ongoing need to update and inform colleagues of the latest news and developments in relation to seasonal, avian and pandemic influenza, Influenza Preparedness Updates have been launched and will be issued on a 4-6 weekly basis.]]&gt;</body>
  </document>
  <document>
    <id>286009</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://adc.bmj.com/cgi/reprint/91/1/5]]&gt;</url>
    <title>Influenza related hospital admissions in children: evidence about the burden keeps growing but the route to policy change remains uncertain</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,RESPIRATORY TRACT,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,INFLUENZA,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,INFECTIOUS DISEASES,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza has long been recognised as a disease which affects children; however, it is only fairly recently that the literature on this subject has switched focus from community settings towards the burden of hospitalisations. This issue carries an article by Frank Beard and
colleagues which draws attention to the issue in Sydney, Australia and addresses the issue in a quantitative as well as a qualitative way. It follows on from, and replicates the methodologies employed by similar pivotal studies in the USA and Hong Kong.]]&gt;</body>
  </document>
  <document>
    <id>286012</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jpubhealth.oxfordjournals.org/cgi/reprint/27/4/371]]&gt;</url>
    <title>Influenza vaccine uptake and distribution in England and Wales using data from the General Practice Research Database, 1989/90-2003/04. </title>
    <publicationDate>2005-10-05T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,RESPIRATORY TRACT,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,INFLUENZA,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,INFECTIOUS DISEASES,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background:
Routinely collected data from patients registered with general practices participating in the General Practice Research Database (GPRD) were used to analyse influenza vaccine uptake and distribution in England and Wales between 1989/90 and 1996/97. Major changes to influenza
immunization policy were introduced in 1998 and 2000 when immunization of the elderly became age related rather than risk related. This new study examines trends in vaccine uptake for high- and low-risk patients and the impact of the policy changes on uptake in the elderly.

Methods:
Between 0.5 and 2.7 million patients registered with practices participating in the GPRD from 1989 to 2004 were included. Data were examined by age group, medical risk group and evidence of vaccination per study year.

Results:
Vaccine uptake among high-risk persons aged 65 or more increased from 36.7 per cent in 1989/90 to 72.1 per cent in 2003/04. For the same period, uptake rates for highrisk persons under 65 years increased from 10.8 to 24.3 per cent. For those at high risk, uptake by females was higher in all age groups up to 65 years. Of those that were vaccinated, a higher proportion of the 65 and over were vaccinated in October each year compared with the high risk under 65 (p &lt; 0.001).

Conclusions:
Coverage among high-risk patients in younger age groups continues to fall well below satisfactory levels, especially among the youngest groups. Government policy should now focus on ways to improve uptake in these patients.]]&gt;</body>
  </document>
  <document>
    <id>286013</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TD4-4HDP8S2-3&amp;_user=910131&amp;_coverDate=03%2F10%2F2006&amp;_rdoc=9&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%235188%232006%23999759988%23616854%23FLA%23display%23Volume)&amp;_cdi=5188&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=30&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=268cf3e29099e17e07170d16f986bf23]]&gt;</url>
    <title>Influenza vaccine uptake in adults aged 50–64 years: Policy and practice in England 2003/2004</title>
    <publicationDate>2006-03-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,PREVENTION AND CONTROL,PREVENTION,ANTIVIRALS,ANTIMICROBIALS,INFECTIONS,VACCINES / IMMUNISATION,TREATMENT,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A small national study was carried out in England in 2003/2004 to ascertain the views of primary care trusts (PCTs) and general practitioners (GPs) on whether influenza immunisation should be extended to all people aged 50–64 years from the current recommendation of 65 years or more. Results showed that as many primary care trusts would be in favour, as would not be in favour. A similarly divided view was expressed by general practitioners. Vaccine uptake rates for high-risk (HR) and low-risk (LR) adults aged 50–64 years in the study population were higher in those practices where the GP was in favour of a more inclusive policy of offering flu vaccine to all persons aged 50 years or more, compared with those that did not favour this policy (60% versus 54% HR (p = 0.02) and 16% versus 11% LR (p = 0.02)). Higher rates of vaccine uptake for low-risk patients aged 50–64 years were also reported from practices where GPs perceived a greater health benefit of immunisation for this age group. Although policy for recommending vaccine to all patients aged 50 years or more is established elsewhere, opinion on whether such a policy should be adopted in England is currently divided amongst those providing local health services. ]]&gt;</body>
  </document>
  <document>
    <id>286014</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TD4-471NJNM-1&amp;_user=910131&amp;_coverDate=03%2F07%2F2003&amp;_rdoc=17&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%235188%232003%23999789988%23381860%23FLA%23display%23Volume)&amp;_cdi=5188&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=38&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=fa81136c75245664c7f39431cb7fd8b4]]&gt;</url>
    <title>Influenza vaccine uptake in the elderly: results from a rapid assessment of the effectiveness of new government policy in England for the winters 2000/2001 and 2001/2002 </title>
    <publicationDate>2003-03-07T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,RESPIRATORY TRACT,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,INFLUENZA,VACCINES / IMMUNISATION,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,INFECTIOUS DISEASES,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Immunisation against influenza is an important means of reducing morbidity and mortality mongst high-risk groups, and especially the elderly. Although immunisation has been recommended for these groups for many years, no timely or comprehensive monitoring at the national level was carried out in England before the beginning of this century. Annual numbers of doses dministered were available, but not to whom they were given. This paper describes the results of a national rapid reporting scheme for England that was introduced by the Department of Health (DH) and PHLS Communicable Disease Surveillance Centre (CDSC). The scheme collected monthly data on influenza immunisation uptake among people aged 65 or more during the winters of 2000/2001 and 2001/2002. Results showed that DH annual targets of 60 and 65%, respectively were both met, although considerable variation occurred at the local levels. The feasibility of this method of monitoring immunisation uptake in the elderly is discussed. ]]&gt;</body>
  </document>
  <document>
    <id>286015</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TD4-4PBG0HW-3&amp;_user=910131&amp;_coverDate=09%2F28%2F2007&amp;_rdoc=9&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%235188%232007%23999749960%23668588%23FLA%23display%23Volume)&amp;_cdi=5188&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=26&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=8a5a8a5285d29847dd316d05368f76db]]&gt;</url>
    <title>Influenza vaccine: The challenge of antigenic drift </title>
    <publicationDate>2007-09-28T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,INFECTIONS,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza continues to have a major worldwide impact, resulting in considerable human suffering and economic burden. The regular recurrence of influenza epidemics is thought to be caused by antigenic drift, and a number of studies have shown that sufficient changes can accumulate in the virus to allow influenza to reinfect the same host. To address this, influenza vaccine content is reviewed annually to ensure protection is maintained, despite the emergence of drift variants; however, it is not always possible to capture every significant drift, partly due to the timing of the recommendations. Vaccine mismatch can impact on vaccine effectiveness, and has significant epidemiological and economical consequences, as was seen most apparently in the 1997–1998 influenza season. To meet the challenge of antigenic drift, vaccines that confer broad protection against heterovariant strains are needed against seasonal, epidemic and pandemic influenza. In addition to the use of vaccine adjuvants, emerging research areas include development of a universal vaccine and the use of vaccines that exploit mechanisms of cross-protective immunity. ]]&gt;</body>
  </document>
  <document>
    <id>286016</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thieme-connect.com/ejournals/abstract/srccm/doi/10.1055/s-2007-976487]]&gt;</url>
    <title>Influenza: Evolving Strategies in Treatment and Prevention </title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Thieme Publishing Group </publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,RESPIRATORY TRACT,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,INFLUENZA,INFECTIONS,VACCINES / IMMUNISATION,PREVENTION,ANTIMICROBIALS,ANTIVIRALS,PREVENTION AND CONTROL,TREATMENT,INFECTIOUS DISEASES,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza A and B are important causes of respiratory illness in all age groups. Influenza causes seasonal outbreaks globally, and (rarely) pandemics. In the United States, seasonal influenza epidemics account for &gt; 200,000 hospitalizations and &gt; 30,000 deaths annually. More than 90% of deaths are in the elderly. The toll is considerably higher during pandemics. Clinical features of influenza infection overlap with other respiratory pathogens (particularly viruses). The diagnosis is often delayed due to low suspicion and the limited use of specific diagnostic tests. Rapid diagnostic tests are widely available and allow detection of influenza antigen in respiratory secretions within 1 hour; however, sensitivity ranges from 40 to 80%. Currently, four drugs are available to treat or prevent influenza. These include the adamantanes (i.e., amantadine and rimantadine) and the neuraminidase inhibitors (i.e., oseltamivir and zanamivir). Adamantanes are active against influenza A but not influenza B. However, recent emergence of adamantane resistance has rendered these agents ineffective. Hence, adamantanes are not currently recommended in the United States. The neuraminidase inhibitors (NAIs) are effective in treating influenza A or B, and for prophylaxis in selected adults and children. Resistance to NAIs is rare, but influenza strains resistant to oseltamivir have been detected. Vaccines are the cornerstone of influenza control. Currently, trivalent inactivated vaccine (TIV) and live attenuated influenza vaccine (LAIV) are available. These agents reduce mortality and morbidity in high-risk patients (i.e., the elderly or patients with comorbidities), and expanding the use of vaccines to healthy children and adults reduces the incidence of influenza, pneumonia, and hospitalizations due to respiratory illnesses in the community. ]]&gt;</body>
  </document>
  <document>
    <id>286003</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TD4-4KBWXJK-2&amp;_user=910131&amp;_coverDate=10%2F30%2F2006&amp;_rdoc=4&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%235188%232006%23999759957%23636089%23FLA%23display%23Volume)&amp;_cdi=5188&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=14&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=621a24cdcc4fcb2136e24fed559625de]]&gt;</url>
    <title>Influenza-related mortality in the Italian elderly: No decline associated with increasing vaccination coverage </title>
    <publicationDate>2006-10-30T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,BODY PART AFFECTED,AIRBORNE,INFLUENZA,TRANSMISSION MODE,PREVENTION,VACCINES / IMMUNISATION,ANTIVIRALS,ANTIMICROBIALS,PREVENTION AND CONTROL,INFECTIONS,TREATMENT,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We investigated trends in influenza-related mortality among the elderly population in Italy associated with increased vaccination coverage. Using Italian vital statistics data, we studied monthly death rates for pneumonia and influenza and all-cause for persons =65 years of age by 5-year age groups for 1970–2001. Using a classic seasonal regression modelling approach, we estimated the age-specific seasonal excess mortality rates among Italian elderly as a measure of influenza-related deaths. We studied trends in excess mortality after adjusting for population aging and analyzing separately seasons dominated by the severe A/H3N2 subtype and those dominated by other circulating influenza subtypes. After the late 1980s, no decline in age-adjusted excess mortality was associated with increasing influenza vaccination distribution primarily targeted for the elderly. These findings suggest that either the vaccine failed to protect the elderly against mortality (possibly due to immune senescence), and/or the vaccination efforts did not adequately target the frailest elderly. As in the US, our study challenges current strategies to best protect the elderly against mortality, warranting the need for better controlled trials with alternative vaccination strategies. ]]&gt;</body>
  </document>
  <document>
    <id>307688</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/cgi/reprint/149/2/123.pdf]]&gt;</url>
    <title>Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis</title>
    <publicationDate>2008-07-18T00:00:00</publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Despite the increasing prevalence of drug-resistant tuberculosis, most low- and middle-income countries use standardized regimens, without assessment of drug susceptibility.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Purpose&lt;/STRONG&gt;: To perform a systematic review and meta-analysis of the effect of initial drug resistance and treatment regimen on tuberculosis treatment outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Sources&lt;/STRONG&gt;: PubMed, the Cochrane Central Database of Clinical Trials, and EMBASE were searched for studies published in English from 1965 to June 2007. Additional studies were identified from cited references.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study Selection&lt;/STRONG&gt;: Randomized, controlled trials and cohort studies of standardized treatment of previously untreated patients with culture-confirmed pulmonary tuberculosis. Drug-susceptibility testing was done on pretreatment isolates from all patients and from patients with treatment failure or relapse.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Extraction&lt;/STRONG&gt;: Two authors reviewed the studies for methods, initial drug resistance, treatment regimens, and outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Synthesis&lt;/STRONG&gt;: Pooled cumulative incidences were computed with random-effects meta-analyses. Association between risk factors andoutcomes were determined by using stratified analyses. The cumulative incidence of acquired drug resistance with initially pan-sensitive strains was 0.8% (95% CI, 0.5% to 1.0%) compared with 6% (CI, 4% to 8%) with initially single drug–resistant strains and 14% (CI, 9% to 20%) with initially polydrug-resistant strains. Failure and relapse were most strongly associated with initial drug resistance. Failure was also associated with shorter duration of rifampin therapy and nonuse of streptomycin, whereas the rate of relapse was higher with shorter duration of rifampin therapy and nonuse of pyrazinamide.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Limitations&lt;/STRONG&gt;: Few studies included HIV-infected persons, and treatment outcomes were pooled despite considerable heterogeneity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Treatment outcomes were substantially worse in the presence of initial drug resistance, which has important implications in resource-limited settings in which drug resistance is prevalent.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286021</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/deliberate_release/Unknown/unusual_illness.pdf]]&gt;</url>
    <title>Initial investigation and management of outbreaks and incidences of unusual illnesses - with particular reference to events that may be due to clinical, biological or radiological causes, including deliberate release</title>
    <publicationDate>2004-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,FOOD/WATER,AIRBORNE,BODY PART AFFECTED,DIGESTIVE TRACT,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,VIRUSES,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This guidance produced by the HPA and NRPB for NHS staff provides information on initial investigation and management of outbreaks and incidences of unusual illnesses - with particularl reference to events that may be due to clinical, biological or radiological causes, including deliberate release.]]&gt;</body>
  </document>
  <document>
    <id>286023</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop52.pdf]]&gt;</url>
    <title>Inoculation of culture media (QSOP 52)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This NSM describes the basic methods of inoculating culture media with specimens, and sub-culturing of organisms from one medium to another.]]&gt;</body>
  </document>
  <document>
    <id>286024</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop45.pdf]]&gt;</url>
    <title>Installation, operation, maintenance and performance testing of the "Dynal BeadRetriever" Requirements of Food Examiners, Experts Witnesses and Witnessess of Fact Acting For/On Behalf of the Health (QSOP 45)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>308960</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?author=Vandebriel&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>Integrating TB and HIV care in rural Rwanda.</title>
    <publicationDate>2008-03-03T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIOUS DISEASES,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,DIAGNOSIS,BACTERIA,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MYCOBACTERIUM TUBERCULOSIS,VIRUSES,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Setting&lt;/STRONG&gt;: Rwanda has generalised human immunodeficiency virus (HIV) and tuberculosis (TB) epidemics. The Rwandan Ministry of Health approved a policy on TB-HIV collaborative activities in 2005. The present study is a report on the results of the integrated TB and HIV activities at a rural health care site between July 2005 and June 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: Activities included provider-initiated HIV testing and counselling (PITC) of TB patients and the implementation of a standardised TB screening questionnaire for in-patients on medical wards and HIV-infected out-patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Of a total 259 TB patients registered, 87% with unknown HIV status or who were HIV-negative accepted PITC. Overall, 48% (125/259) of TB patients were HIV-infected. The proportion of TB patients ever tested for HIV increased from 82% (138/169) in 2004-2005 to 93% (240/259) in 2005-2006 (P &amp;lt; 0.001). Of the 770 in-patients screened for TB, 162 (21%) tested positive, of whom 53 (33%) were diagnosed with TB; 39 (76%) of these were HIV co-infected. Three hundred out-patients with HIV were screened for TB; 80 (27%) tested positive, of whom 11 (14%) were diagnosed with TB.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Discussion&lt;/STRONG&gt;: Activities integrating TB and HIV were feasible in a rural health care setting. PITC was successful in TB patients and unrecognised TB was common, particularly among HIV-infected in-patients.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394200</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/656282]]&gt;</url>
    <title>Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,TUBERCULOSIS,HIV/AIDS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,DIAGNOSIS,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: The World Health Organization (WHO) recommends cough as the trigger for tuberculosis screening in human immunodeficiency virus (HIV)-infected patients, with acid-fast bacillus (AFB) smear as the initial diagnostic test. Our objective was to assess the yield and cost of a more intensive tuberculosis screening in HIV-infected patients starting antiretroviral therapy (ART) in Durban, South Africa.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We prospectively enrolled adults, regardless of tuberculosis signs/symptoms, who were undergoing ART training from May 2007 to May 2008. After the symptom screen, patients expectorated sputum for AFB smear, tuberculosis polymerase chain reaction (PCR), and mycobacterial culture. Sensitivity and specificity of different symptoms and tests, alone and in combination, were compared with the reference standard of 6-week tuberculosis culture results. Program costs included personnel, materials, and cultures.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Of 1035 subjects, 487 (59%) were female; median CD4 cell count was 100 cells/microL. A total of 210 subjects (20%) were receiving tuberculosis treatment and were excluded. Of the remaining 825 subjects, 158 (19%) had positive sputum cultures, of whom 14 (9%) had a positive AFB smear and 82 (52%) reported cough. The combination of cough, other symptoms, AFB smear, and chest radiograph had 93% sensitivity (95% confidence interval, 88%-97%) and 15% specificity (95% confidence interval, 13%-18%). The incremental cost of intensive screening including culture was $360 per additional tuberculosis case identified.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Nearly 20% of patients starting ART in Durban, South Africa, had undiagnosed, culture-positive pulmonary tuberculosis. Despite WHO recommendations, neither cough nor AFB smear were adequately sensitive for screening. Tuberculosis sputum cultures should be performed before ART initiation, regardless of symptoms, in areas with a high prevalence of HIV and tuberculosis.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345957</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/fulltext/122341752/PDFSTART]]&gt;</url>
    <title>Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development</title>
    <publicationDate>2009-04-21T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,PREVENTION,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,CHILDHOOD VACCINES,BCG,VACCINES / IMMUNISATION,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with M. tuberculosis. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti-mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.]]&gt;</body>
  </document>
  <document>
    <id>308667</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ijidonline.com/article/PIIS1201971208001045/abstract]]&gt;</url>
    <title>Interferon-gamma release assays (IGRAs) in high-endemic settings: could they play a role in optimizing global TB diagnostics?. Evaluating the possibilities of using IGRAs to diagnose active TB in a rural African setting</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The number of patients suffering from tuberculosis (TB) globally is increasing. Due to the HIV epidemic, most patients suffering from TB reside in sub-Saharan Africa. In order to improve TB diagnostics, new tests – interferon-gamma release assays (IGRAs) – have been developed over the last decade. In this paper we evaluate the possible use of these tests in diagnosing or excluding active TB in high HIV-burden, resource-limited settings. The inability to differentiate between active and latent TB, limited data on IGRA performance in HIV-infected patients, observed false-negative results, high costs, and logistic problems limit the potential benefit of IGRAs. We also present two theoretical study designs in order to further assess IGRAs. Setting up a study on this subject is complicated by the frequent unavailability of mycobacterial cultures, the difficulty in acquiring prospective data, and the impossibility of denying treatment to a patient suspected of having active TB. We feel that current evidence does not support the implementing of IGRAs in clinical practice in settings with high endemic latent TB infection (LTBI) and high HIV prevalence. As these settings are the ones that suffer the most from the TB epidemic, we believe that the role of IGRAs in global TB control is questionable.]]&gt;</body>
  </document>
  <document>
    <id>286028</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://download.thelancet.com/pdfs/journals/1473-3099/PIIS1473309906706284.pdf]]&gt;</url>
    <title>International standards for tuberculosis care.</title>
    <publicationDate>2006-11-06T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,TREATMENT,MYCOBACTERIUM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Part of the reason for failing to bring about a more rapid reduction in tuberculosis incidence worldwide is the lack of effective involvement of all practitioners—public and private—in the provision of high quality tuberculosis care. While health-care providers who are part of national tuberculosis programmes have been trained and are expected to have adopted proper diagnosis, treatment, and public-health practices, the same is not likely to be true for nonprogramme
providers. Studies of the performance of the private sector conducted in several diff erent parts of the world suggest that poor quality care is common. The basic principles of care for people with, or suspected of having, tuberculosis are the same worldwide: a diagnosis should be established promptly; standardised treatment regimens should be used with appropriate treatment support and supervision; response to treatment should be monitored; and essential public-health responsibilities must be carried out. Prompt and accurate diagnosis, and effective treatment are essential for good patient care and tuberculosis control. All providers who undertake evaluation and treatment of patients with tuberculosis must recognise that not only are they delivering care to an individual, but they are also assuming an important public-health function. The International Standards for Tuberculosis Care (ISTC) describe a widely endorsed level of care that all practitioners should seek to achieve in managing individuals who have, or are suspected of having, tuberculosis. The document is intended to engage all care providers in delivering high quality care for patients of all ages, including those with smear-positive, smear-negative, and extra-pulmonary tuberculosis, tuberculosis caused by drug-resistant Mycobacterium tuberculosis complex, and tuberculosis combined with HIV infection.]]&gt;</body>
  </document>
  <document>
    <id>286029</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop32.pdf]]&gt;</url>
    <title>Interpretation of NAMAS Information Sheet (NIS 42) for laboratories (QSOP 32)</title>
    <publicationDate>2002-09-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>393363</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.publish.csiro.au/view/journals/dsp_journal_fulltext.cfm?nid=164&amp;f=SH09079]]&gt;</url>
    <title>Interventions for young people in Australia to reduce HIV and sexually transmissible infections: a systematic review</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>CSIRO Publishing</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,DETERMINANTS,OUTCOMES,INDIVIDUAL BEHAVIOUR,SEXUAL HEALTH,MANAGEMENT &amp; INTERVENTIONS,POPULATIONS,SETTINGS,GROUPS,HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MONTHLY ADDITIONS,INFECTION CONTROL,POPULATION BASED &amp; PREVENTATIVE SERVICES,SERVICES,HIV INFECTION,SEXUALLY TRANSMITTED INFECTIONS,GENITOURINARY DISEASES,COMMUNICABLE DISEASES,AGE GROUPS,YOUNG PEOPLE,INTERNATIONAL ISSUES,AREAS,AREA BASED INITIATIVES,GEOGRAPHY,PLACES,PEOPLE WITH HIV OR AIDS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOVEMBER 2010,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Like young people in other developed countries, sexually active young Australians can have an increased risk of acquiring sexually transmissible infections (STIs). This paper reviews intervention programs that aim to reduce the incidence and transmission of HIV and STIs among young people in Australia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Articles were identified from seven databases. Intervention studies conducted in Australia that included young people aged 12-25 years were reviewed. A two-dimensional matrix consisting of 'setting' and 'intervention type' was developed to categorize each study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Forty-two studies met the inclusion criteria, and the majority were uncontrolled intervention studies. Of these, 23/42 studies measured participation in chlamydia +/- other STI testing and found that the highest participation rates took place in non-clinical and non-general practice health care settings. Four studies facilitated access to testing indirectly, through the internet or other media. Ten studies involved the provision of education and measured its impact on factors such as knowledge, attitudes and/or behaviour. Three studies involved novel immunisation strategies for either hepatitis B or human papillomavirus vaccines. Two studies evaluated the impact of enhanced STI surveillance programs on prevalence rates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Proactive STI testing in non-clinical and some health settings appears feasible and achieves higher testing rates than in general practice; however, more evaluation of testing strategies in general practice settings is required. New technologies such as the internet and SMS are useful adjuncts for influencing behaviours such as condom use and STI testing. Media campaigns that promote STI testing can have a positive impact on testing rates.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394235</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817741/pdf/pone.0009119.pdf]]&gt;</url>
    <title>Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis</title>
    <publicationDate>2010-02-09T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Intravaginal practices are commonly used by women to manage their vaginal health and sexual life. These practices could, however, affect intravaginal mucosal integrity. The objectives of this study were to examine evidence for associations between: intravaginal practices and acquisition of HIV infection; intravaginal practices and vaginal infections; and vaginal infections and HIV acquisition.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODOLOGY/PRINCIPAL FINDINGS&lt;/STRONG&gt;: We conducted a systematic review of prospective longitudinal studies, searching 15 electronic databases of journals and abstracts from two international conferences to 31(st) January 2008. Relevant articles were selected and data extracted in duplicate. Results were examined visually in forest plots and combined using random effects meta-analysis where appropriate. Of 2120 unique references we included 22 publications from 15 different studies in sub-Saharan Africa and the USA. Seven publications from five studies examined a range of intravaginal practices and HIV infection. No specific vaginal practices showed a protective effect against HIV or vaginal infections. Insertion of products for sex was associated with HIV in unadjusted analyses; only one study gave an adjusted estimate, which showed no association (hazard ratio 1.09, 95% confidence interval, CI 0.71, 1.67). HIV incidence was higher in women reporting intravaginal cleansing but confidence intervals were wide and heterogeneity high (adjusted hazard ratio 1.88, 95%CI 0.53, 6.69, I(2) 83.2%). HIV incidence was higher in women with bacterial vaginosis (adjusted effect 1.57, 95%CI 1.26, 1.94, I(2) 19.0%) and Trichomonas vaginalis (adjusted effect 1.64, 95%CI 1.28, 2.09, I(2) 0.0%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS/SIGNIFICANCE&lt;/STRONG&gt;: A pathway linking intravaginal cleaning practices with vaginal infections that increase susceptibility to HIV infection is plausible but conclusive evidence is lacking. Intravaginal practices do not appear to protect women from vaginal infections or HIV and some might be harmful.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306188</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1229594195568]]&gt;</url>
    <title>Introduction to infection control in care homes</title>
    <publicationDate>2009-12-18T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,INFECTIONS,INFECTION CONTROL,FEB 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a series of seven short films. These are designed to provide staff with an introduction to infection control.&lt;/P&gt;
&lt;P&gt;These seven short films include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Preventing Infection&lt;/LI&gt;
&lt;LI&gt;Hand Hygiene&lt;/LI&gt;
&lt;LI&gt;Person Protective Equipment&lt;/LI&gt;
&lt;LI&gt;Prevention of exposure to Blood and Body fluids&lt;/LI&gt;
&lt;LI&gt;Clinical Equipment&lt;/LI&gt;
&lt;LI&gt;General Equipment&lt;/LI&gt;
&lt;LI&gt;Management of Laundry&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Infection control nurses have provided expert advice throughout filming and production of the training resource. Every effort has been made to ensure that the advice provided is based on the best available evidence&lt;BR&gt;while providing advice that can be easily adopted and put into practice. The DVD can be can be used to supplement existing infection control training programs for care homes. It will also provide practical assistance to help comply with the Department of Health Code of Practice as and when it is issued.&lt;/P&gt;
&lt;P&gt;This valuable resource can be can be used to supplement existing training programs. It will also provide practical assistance to help comply with the Department of Health Code of Practice as and when it is issued.&lt;/P&gt;
&lt;P&gt;Care homes, Health Protection Units, and other relevant stakeholders will receive the DVD towards the end of February 2009, free of charge.&lt;/P&gt;
&lt;P&gt;The Health Protection Agency would like to thank everybody who contributed to these films within the Agency, Department of Health, the Infection Prevention Society, Commission for Social Care Inspection. Particular thanks are given to residents and staff at Anchor Nursing Homes and Willowdale Lodge, Southend on Sea.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286037</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopid/pdf/bsopid1.pdf]]&gt;</url>
    <title>Introduction to the preliminary identification of medically important bacteria (BSOP ID 1)</title>
    <publicationDate>2007-10-15T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The aim of this document is to provide a guide to the preliminary identification of the common bacteria which may be encountered in clinical specimens. It is intended to lead the user to a more detailed identification SOP and is designed to be used for cultures of bacteria isolated on agar plates and not for identification of bacteria in direct smears.

INTRODUCTION:
Identification of bacteria by diagnostic laboratories is based on phenotypic characteristics, usually by direct comparison of unknown bacteria with those of type cultures2. Greater confidence in identification is in direct proportion to the number of similar characteristics. In medical microbiology, experience of the types of specimens, the infection and the bacteria associated with those sites of infection is useful as an aid in preliminary identification. When identifying bacteria it should be remembered that many of their characteristics might be variable. In addition, species within a genus may differ in some characteristics eg Capnocytophaga canimorsus is oxidase positive, whereas Capnocytophaga ochracea is oxidase negative. For this reason some genera may appear in more than one table or chart. Clinical information should also be taken into consideration during the identification process.

Characteristics:
When classifying microorganisms, all known characteristics are taken into consideration, but certain characteristics are selected and used for the purpose of identification. Primary identification usually involves a few simple tests2 such as morphology (usually shown by Gram stain), growth in the presence or absence of air, growth on various types of culture media, catalase and oxidase tests. Using these few simple tests it is usually possible to place organisms, provisionally, in one of the main groups of medical importance.

Principles of Identification:
There are three basic methods of identification. The first relies heavily on the experience of the investigator: a judgement is made on the probable identity of the organism based on clinical data, cultural and atmospheric characteristics. A limited range of tests are then used to confirm or disprove the hypothesis. This relies heavily on a stable pattern of phenotypic characteristics.
If identification is not made using the first principle, a different approach may be used subjecting the organism to a battery of tests, such as those found in commercial identification systems. The data is collated and compared to standard texts or used to create a numerical profile to obtain identification.

The final method follows a step-by-step approach to identification. Fundamental characteristics of the organism are determined by primary identification tests such as a Gram stain, oxidase or catalase. Results of these tests indicate secondary or even tertiary tests to confirm the identity of the subject. This is a systematic approach and does not rely on the expertise of the investigator. The disadvantage of this system involves the primary tests, incorrect results at this stage can lead the investigator down an incorrect path, which wastes both time and resources and may also lead to an erroneous result. It is also a time consuming process; further tests cannot be set up until results of the previous investigations are known.
Conditions under which tests are conducted should be defined as reactions may vary.]]&gt;</body>
  </document>
  <document>
    <id>286038</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop14.pdf]]&gt;</url>
    <title>Investigation of abscesses and post-operative wound and deep-seated wound infections (BSOP 14)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286039</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop15.pdf]]&gt;</url>
    <title>Investigation of bile (BSOP 15)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286041</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop37.pdf]]&gt;</url>
    <title>Investigation of blood cultures (for organisms other than Mycobacterium species) (BSOP 37)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,ENTEROCOCCUS,ACINETOBACTER BAUMANII,BACTERIA,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS AUREUS,STREPTOCOCCUS,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286040</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop7.pdf]]&gt;</url>
    <title>Investigation of blood cultures for Mycobacterium species (BSOP 7)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BLOOD AND BODY FLUIDS,BODY PART AFFECTED,CARDIOVASCULAR,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286042</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop38.pdf]]&gt;</url>
    <title>Investigation of Bone Marrow (BSOP 38)</title>
    <publicationDate>2007-11-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,BRAIN AND SPINAL CORD INFECTIONS,SALMONELLA,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Methods (NSM) describes the processing and microbiological investigation of bone marrow sent for clinical diagnostic purposes only. INTRODUCTION: Microbiological examination of bone marrow is an invasive technique infrequently performed for the investigation of pyrexia of unknown origin (PUO) and occasionally for other indications. It is sometimes undertaken when other less invasive investigations and diagnostic imaging have failed to determine a cause, or, more frequently, when infection is part of the differential diagnosis in the investigation of haematological abnormalities The demonstration of microorganisms in bone marrow, by microscopy, culture or nucleic acid amplification techniques, has been shown to be useful for diagnosis of infection with a limited number of bacteria, fungi, parasites and viruses, although some workers suggest that bone marrow cultures should not be advocated for immunocompetent patients. Bone marrow is aspirated from the posterior iliac crest or the sternum. A core biopsy may also be collected and this is examined histologically for evidence of granulomata and microorganisms. The aspirate is the preferred specimen for microbiological studies.]]&gt;</body>
  </document>
  <document>
    <id>286043</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop57.pdf]]&gt;</url>
    <title>Investigation of Bronchoalvelolar Lavage, Sputum, and Associated Specimens (BSOP 57)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286045</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop27.pdf]]&gt;</url>
    <title>Investigation of cerebrospinal fluid (BSOP 27)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CENTRAL NERVOUS SYSTEM,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286044</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop22.pdf]]&gt;</url>
    <title>Investigation of cerebrospinal fluid shunts (BSOP 22)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286046</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop15.pdf]]&gt;</url>
    <title>Investigation of clinical specimens by electron microscopy using concentration by ammonium sulphate precipitation (VSOP 15)</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286048</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop25.pdf]]&gt;</url>
    <title>Investigation of continuous ambulatory peritoneal dialysis fluid (BSOP 25)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286049</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop35.pdf]]&gt;</url>
    <title>Investigation of Cytomegalovirus infection by Roche Lightcycler PCR (VSOP35)</title>
    <publicationDate>2007-01-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,CYTOMEGALOVIRUS (CMV),VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This SOP is for use with the Roche LightCycler™ and describes a single round quantitative
polymerase chain reaction (QPCR) with sequence-specific detection through hybridisation for
cytomegalovirus (CMV) in clinical specimens2-4.
The PCR provides a rapid and sensitive method for the diagnosis of CMV infection. The QPCR can also be used for patient monitoring to determine the rate of increase in viral load that may identify patients at the greatest risk of CMV disease and to establish when therapeutic intervention is appropriate.]]&gt;</body>
  </document>
  <document>
    <id>286050</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop39.pdf]]&gt;</url>
    <title>Investigation of dermatological specimens for superficial mycoses (BSOP 39)</title>
    <publicationDate>2007-03-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Standard Method describes the procedures used to isolate dermatophytes, non-dermatophyte moulds and other fungi from skin, nail and hair specimens.

For descriptions and illustrations of structures observed on microscopy and/or culture refer to
reference textbooks2-5 or the ‘doctor fungus’ website at http://www.doctorfungus.org/.]]&gt;</body>
  </document>
  <document>
    <id>286051</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop1.pdf]]&gt;</url>
    <title>Investigation of ear swabs and associated specimens (BSOP 1)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document describes the bacteriological investigation of ear swabs and associated specimens.

Infections of the ear can be divided into otitis externa and otitis media.]]&gt;</body>
  </document>
  <document>
    <id>286053</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop2.pdf]]&gt;</url>
    <title>Investigation of eye swabs and canalicular pus (BSOP 2)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286054</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop30.pdf]]&gt;</url>
    <title>Investigation of faeces specimens for bacterial pathogens (BSOP 30)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,ESCHERICHIA COLI INFECTION,TRANSMISSION MODE,FAECAL/ORAL,FOOD/WATER,INFECTIONS,SHIGELLA,SALMONELLA,CAMPYLOBACTER,MICROORGANISM,BACTERIA,CAMPYLOBACTER,E. COLI,SALMONELLA,SHIGELLA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method briefly outlines the bacteria responsible for enteric infection and methods for their isolation. &lt;/P&gt;
&lt;P&gt;It recommends routine screening of faeces for Campylobacter, Salmonella, Shigella and Escherichia coli o157 on all diarrhoeal (semi-formed or liquid) faeces. However, consideration should be given to the “three day rule” for collection of faeces samples from hospitalised patients (see section below “Collection of faeces samples” page 6). In addition faeces may be screened for individual organisms as indicated by clinical details. A short section on viruses implicated in enteric disease is included in this introduction. Algorithms for the isolation and identification of these viruses are available (VSOP 2 - Gastroenteritis: sporadic cases and VSOP 3 - Gastroenteritis: Outbreaks ). The microscopy section includes standard methods for the preparation of faecal parasite concentrations and cryptosporidium smears. Investigation of faecal parasites is fully described in BSOP 31 - Investigation of specimens other than blood for parasites . For details of Clostridium difficile refer to BSOP 10 - Processing of faeces for Clostridium difficile&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286055</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop26.pdf]]&gt;</url>
    <title>Investigation of fluids from normally sterile sites (BSOP 26)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286056</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop23.pdf]]&gt;</url>
    <title>Investigation of gastric aspirates and infection screen swabs from neonates (BSOP 23)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ PREGNANCY OUTCOME,NEONATAL AND INFANT CARE,NEONATAL AND INFANT CARE,POSTNATAL DISORDERS,POSTNATAL CARE,WOMEN'S HEALTH,NORMAL PREGNANCY,COMPLICATED PREGNANCY,INFECTIONS,FETAL OUTCOME,HAEMOPHILUS,MICROORGANISM,BACTERIA,HAEMOPHILUS INFLUENZAE,LISTERIA MONOCYTOGENES,STAPHYLOCOCCUS,STAPHYLOCOCCUS AUREUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This SOP describes the processing and bacteriological investigation of gastric aspirates and infection screen swabs from neonates.]]&gt;</body>
  </document>
  <document>
    <id>286057</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop55.pdf]]&gt;</url>
    <title>Investigation of gastric biopsies for Helicobacter pylori (BSOP 55)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,HELICOBACTER PYLORI,BACTERIA,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286058</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop28.pdf]]&gt;</url>
    <title>Investigation of genital tract and associated specimens (BSOP 28)</title>
    <publicationDate>2005-05-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,GONORRHOEA,INFECTIONS,MICROORGANISM,BACTERIA,NEISSERIA GONORRHOEA,FUNGI,CANDIDA ALBICANS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This SOP describes the examination of genital specimens for the presence of &lt;EM&gt;Neisseria gonnorhoeae&lt;/EM&gt;, yeasts, beta hamolytic streptococci and other specific target organisms (including &lt;EM&gt;Trichomonas vaginalis&lt;/EM&gt;), and the microscopic diagnosis of bacterial vaginosis (BV).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286059</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop23.pdf]]&gt;</url>
    <title>Investigation of human herpes viruses (excluding herpes genitalis) (VSOP 23)</title>
    <publicationDate>2002-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,CYTOMEGALOVIRUS (CMV),VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286060</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop52.pdf]]&gt;</url>
    <title>Investigation of intraocular fluids and corneal scrapings (BSOP 52)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286061</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop20.pdf]]&gt;</url>
    <title>Investigation of intravascular cannulae and associated specimens (BSOP 20)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286062</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop4.pdf]]&gt;</url>
    <title>Investigation of mouth swabs (BSOP 4)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,BACTERIA,CANDIDA ALBICANS,FUNGI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This NSM describes the processing and bacteriological investigation of mouth swabs.]]&gt;</body>
  </document>
  <document>
    <id>286063</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop5.pdf]]&gt;</url>
    <title>Investigation of nose swabs (BSOP 5)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,HAEMOPHILUS,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS,BACTERIA,HAEMOPHILUS INFLUENZAE,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document describes the processing and bacteriological investigation of nose swabs.]]&gt;</body>
  </document>
  <document>
    <id>286064</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop34.pdf]]&gt;</url>
    <title>Investigation of pregnant patient with rash illness (VSOP 34)</title>
    <publicationDate>2005-05-16T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CHICKENPOX,INFECTIOUS DISEASES,COMPLICATED PREGNANCY,WOMEN'S HEALTH,ANTENATAL PROBLEMS,INFECTIONS,INFECTIONS,PARVOVIRUS B19,ADULTS,PREGNANT WOMEN,VACCINE PREVENTABLE DISEASES,RUBELLA,SKIN AND NAIL INFECTIONS,POPULATION GROUPS,MICROORGANISM,VIRUSES,VARICELLA ZOSTER VIRUS,RUBELLA VIRUS,HERPES SIMPLEX VIRUS (HSV)]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This is a clinical algorithm designed to help identify the types and causes of rashes seen in pregnant women.]]&gt;</body>
  </document>
  <document>
    <id>286065</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop56.pdf]]&gt;</url>
    <title>Investigation of Red Rash (QSOP 56)</title>
    <publicationDate>2007-01-31T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,SYPHILIS,HERPES,MEASLES,INFECTIONS,SKIN AND NAIL INFECTIONS,VACCINE PREVENTABLE DISEASES,RUBELLA,PARVOVIRUS B19,TREPONEMA PALLIDUM,EPSTEIN-BARR VIRUS (EBV),HUMAN IMMUNODEFICIENCY VIRUS (HIV),RUBELLA VIRUS,MEASLES VIRUS,VIRUSES,STAPHYLOCOCCUS,STREPTOCOCCUS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Guidance Note describes the identification of infection with those viruses that are capable of causing red rash as a major symptom of disease. Rashes may occur either as a direct result of infection of the skin, or as a secondary phenomenon due to the host immune response or an interaction between host immune response and virus in the skin. For the most part the rashes that arise from viruses that replicate in the skin are typically vesicular (poxviruses, herpes simplex, varicella-zoster), or nodular (papillomavirus) lesions. Rashes may be morbilliform (erythematous macules and papules) or scarlatiniform (confluent blanching erythema). Viral rashes and drug reactions are usually morbilliform, while scarlatiniform rashes tend to be seen in bacterial infections which produce exotoxins.]]&gt;</body>
  </document>
  <document>
    <id>286067</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop19.pdf]]&gt;</url>
    <title>Investigation of sinus aspirate (BSOP 19)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286068</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop11.pdf]]&gt;</url>
    <title>Investigation of skin and superficial wound swabs (BSOP 11)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286069</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop6.pdf]]&gt;</url>
    <title>Investigation of specimens for Bordetella species (BSOP 6)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,CONTACT,RESPIRATORY TRACT,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286070</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop36.pdf]]&gt;</url>
    <title>Investigation of specimens for ectoparasites (BSOP 36)</title>
    <publicationDate>2006-06-26T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,INFECTIONS,MICROORGANISM,PARASITES,PUBIC LICE,LICE,HEADLICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ It is important to ascertain whether an ectoparasitic infection is the cause of a patient’s symptoms or a potential vector of disease. Ectoparasites are recognised by their size, colour, and morphological appearance. Reference to an appropriate ectoparasite identification key may aid identification. 

This SOP deals with the most important human ectoparasites; the fleas, lice, bedbugs, ticks and mites. The myiasis flies are also included in this SOP although only a few species are obligate parasites of mammals.

The arthropod ectoparasites are structurally unrelated and form a biological rather than a taxonomic group. Most parasitic arthropods are ectoparasites (live on the outside of their host) but certain species are more intimately associated with their human and animal hosts.
The morphology of fleas, lice, bedbugs, ticks and mites shows several features adapted for an ectoparasitic life. These include the absence of wings, presence of spines and bristles, terminal claws on legs for clinging to fur/feathers of hosts, and a tough chitinous body. These features reduce the risk of dislodgement of the parasite by the host (as there may be intense host grooming or scratching in response to any infestation).
]]&gt;</body>
  </document>
  <document>
    <id>286071</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop47.pdf]]&gt;</url>
    <title>Investigation of specimens for Legionella species (BSOP 47)</title>
    <publicationDate>2005-05-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Isolation of the organism is the definitive method of diagnosis of Legionnaires’ disease. Culture is reported as being slightly more sensitive than immunofluorescent techniques and is highly specific (&gt;99%). The fastidious nature of Legionella species makes special media and selective techniques essential for optimum isolation. Culture should be performed whenever possible because of the importance of epidemiological investigations in establishing the source in an outbreak. Heavily contaminated specimens may be processed to remove contaminants by a variety of methods. Heat treatment and specimen dilution are the simplest to perform and the recommended methods for clinical specimens. Two temperature/time combinations may be used for decontamination. They are 50°C for 30 minutes or 60°C for 1-3 minutes. As the volume of the specimen and the container dimensions affect the time required to heat to 60°C, heating to 50°C is simpler to control. This SOP therefore recommends heat decontamination is performed at 50°C for 30 minutes. Other methods of decontamination include acid treatment (which is mainly used for environmental samples). 

Plate cultures should be examined using a low power binocular microscope and oblique incident
lighting to demonstrate the typical ground glass, iridescent colonial appearance. Sputum with squamous cell contamination may be positive for L. pneumophila so specimens should be processed regardless of purulence.

Detection of urinary antigen
Urinary antigen detection is a very convenient method of diagnosing Legionnaires’ disease. Antigen becomes detectable soon after onset of symptoms and the test may remain positive for several weeks, even after other tests have become negative. Antigen detection is a highly specific method (&gt;99%) of diagnosing legionellosis, its sensitivity being similar to that of culture (80-85%). Equivocal EIA results should be examined by a second person and repeated.

Direct or indirect Immunofluorescence microscopy
Immunofluorescence microscopy may be used for the demonstration of organisms in clinical material. Direct fluorescent antibody (DFA) microscopy is a rapid method for the detection of Legionella. Smears of almost any type of lower respiratory tract specimen are appropriate for this type of test. Anti-L. pneumophila antibody (preferably a monoclonal antibody reactive against all serogroups) labelled with fluorescent dye is applied to the smear, the antibody binding to any L. pneumophila present. These tagged organisms may then be visualised by fluorescence microscopy. The indirect fluorescent antibody test (IFAT) is a two-stage test, first incubating the smear with a hyperimmune antiserum and washing, then applying a fluoresceinisothiocyanate-conjugated (FITC) immunoglobulin.
Factors to consider with immunofluorescent techniques are:
• sensitivity can be affected by the area of the well used for the smear
• appropriate controls are essential
• a negative result may not exclude infection
• detection of a minimum of five fluorescing rods are required to report a positive result27
• cross reactions with other bacteria have been reported
Compared with culture, the immunofluorescent techniques are relatively insensitive methods (25-
70%). However, provided an experienced microbiologist performs the test meticulously,
specificities have been reported to be as high as 95%.

Antibody detection
Antibody, traditionally the most widely used technique for diagnosis, has now largely been displaced by urinary antigen testing. However it is still a useful test in outbreak investigations or to establish a disgnosis retrospectively. Paired sera showing a four-fold rise in titre, or the detection of L. pneumophila antigen in urine are diagnostic of Legionnaires’ disease. A single high titre in combination with a suggestive clinical history affords a presumptive diagnosis of Legionnaires’ disease. Techniques include a latex agglutination screening test, an IFA test and enzyme immunoassays (EIA). Cross-reactions with antibodies to Campylobacter species, Pseudomonas species and other bacteria can occur.]]&gt;</body>
  </document>
  <document>
    <id>286072</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop40.pdf]]&gt;</url>
    <title>Investigation of Specimens for Mycobacterium species (BSOP 40)</title>
    <publicationDate>2003-06-02T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CONTACT,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,MYCOBACTERIUM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The following series of procedures have been developed for the detection and isolation of
mycobacteria from a variety of clinical samples. Three different methods are recommended for the decontamination of samples but there is no evidence that one method is optimum and laboratories should select the method that they prefer. Use of automated systems plus solid media is recommended for greater recovery of mycobacteria. The combined application of both phenotypic and molecular technologies gives the most efficient approach to the laboratory diagnosis of tuberculous and non-tuberculous disease.

Management, prevention and control of TB are not covered by this National Standard Method but are described in ‘NICE tuberculosis clinical guideline’ developed by the National Collaborating Centre for Chronic Conditions.]]&gt;</body>
  </document>
  <document>
    <id>286073</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop29.pdf]]&gt;</url>
    <title>Investigation of specimens for screening for MRSA (BSOP 29)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286074</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop31.pdf]]&gt;</url>
    <title>Investigation of specimens other than blood for parasites (BSOP 31)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PARASITES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286075</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop9.pdf]]&gt;</url>
    <title>Investigation of throat swabs (BSOP 9)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,CONTACT,AIRBORNE,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,BACTERIA,STREPTOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286076</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop17.pdf]]&gt;</url>
    <title>Investigation of tissues and biopsies (BSOP 17)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286077</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop59.pdf]]&gt;</url>
    <title>Investigation of Toxoplasma Infection in pregnancy (QSOP 59)</title>
    <publicationDate>2006-11-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,CARDIOVASCULAR,MUSCULOSKELETAL,INFECTIONS,ANTENATAL PROBLEMS,WOMEN'S HEALTH,COMPLICATED PREGNANCY,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This guidance note summarises current knowledge regarding risk of transmission and
clinical outcome and will provide a summary of strategies for the investigation and
management of suspected or confirmed toxoplasma infection. The principal aim is to address
cases where toxoplasma infection acquired by the mother during or immediately prior to
pregnancy is suspected or confirmed. Therefore, the issue of prenatal screening for
toxoplasma infection will not be considered.]]&gt;</body>
  </document>
  <document>
    <id>286078</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop41.pdf]]&gt;</url>
    <title>Investigation of urine (BSOP 41)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ URINARY TRACT,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286079</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop55.pdf]]&gt;</url>
    <title>Investigation of Vesicular Rashes (QSOP 55)</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286082</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/publications/2005/esbl_report_05/default.htm]]&gt;</url>
    <title>Investigations into multi-drug resistant ESBL-producing Escherichia coli strains causing infection in England</title>
    <publicationDate>2005-09-12T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIGESTIVE TRACT,BODY PART AFFECTED,URINARY TRACT,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,TREATMENT,MICROORGANISM,BACTERIA,E. COLI,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Since 2003, new highly resistant strains of the bacterium Escherichia coli have become widespread in England and parts of Northern Ireland . These strains of E. coli are able to destroy a large number of common antibiotics, making the infections they cause very difficult to treat. The bacteria produce enzymes called extended-spectrum ß-lactamases (ESBLs) that destroy, and confer resistance to, antibiotics. ESBL-producing microbes are not new, having first been recognised in the 1980s. But the new strains produce a particular type of ESBL, the CTX-M type, which is able to break down a wider range of antibiotics. These strains were unrecorded in the UK prior to 2000. They have spread rapidly since 2003, causing infections such as urinary tract infections (UTIs) in hospital patients as well as those treated in the community. The emergence of CTX-M types is a concern for several reasons, outlined below. This report describes investigations carried out by the Health Protection Agency and recommends further action. ]]&gt;</body>
  </document>
  <document>
    <id>345491</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680616/pdf/pone.0005561.pdf]]&gt;</url>
    <title>Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Tuberculosis (TB) is an important cause of human suffering and death. Human immunodeficiency virus (HIV), multi-drug resistant TB (MDR-TB), and extensive drug resistant tuberculosis (XDR-TB) have emerged as threats to TB control. The association between MDR-TB and HIV infection has not yet been fully investigated. We conducted a systematic review and meta-analysis to summarize the evidence on the association between HIV infection and MDR-TB. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods and Results&lt;/STRONG&gt;: Original studies providing Mycobacterium tuberculosis resistance data stratified by HIV status were identified using MEDLINE and ISI Web of Science. Crude MDR-TB prevalence ratios were calculated and analyzed by type of TB (primary or acquired), region and study period. Heterogeneity across studies was assessed, and pooled prevalence ratios were generated if appropriate. No clear association was found between MDR-TB and HIV infection across time and geographic locations. MDR-TB prevalence ratios in the 32 eligible studies, comparing MDR-TB prevalence by HIV status, ranged from 0.21 to 41.45. Assessment by geographical region or study period did not reveal noticeable patterns. The summary prevalence ratios for acquired and primary MDR-TB were 1.17 (95% CI 0.86, 1.6) and 2.72 (95% CI 2.03, 3.66), respectively. Studies eligible for review were few considering the size of the epidemics. Most studies were not adjusted for confounders and the heterogeneity across studies precluded the calculation of a meaningful overall summary measure. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: We could not demonstrate an overall association between MDR-TB and HIV or acquired MDR-TB and HIV, but our results suggest that HIV infection is associated with primary MDR-TB. Future well-designed studies and surveillance in all regions of the world are needed to better clarify the relationship between HIV infection and MDR-TB.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308988</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.expert-reviews.com/doi/abs/10.1586/14760584.7.9.1341]]&gt;</url>
    <title>Is intranasal vaccination a feasible solution for tuberculosis?</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>Expert Reviews Ltd</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,MARCH 09,MYCOBACTERIUM,TUBERCULOSIS,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM TUBERCULOSIS,BCG,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Bacille Calmette–Guerin (BCG) vaccine has been the only licensed tuberculosis (TB) vaccine administered to humans and, until today, more than 3 billion people have received BCG. However, despite the use of BCG, TB remains a global epidemic with a third of the world population being infected. Regardless of the protection induced by BCG in childhood TB, BCG vaccination fails to protect against pulmonary TB in adults, which represents more than 85% of the total TB burden. Therefore, the development of safe and efficacious TB vaccines that can confer potent protection in the lung mucosa has remained a major challenge to TB vaccinologists. Intranasal vaccination by different antigen formulations has shown promising results in the augmentation of immunity and the combat of the pathogens at the site of infection. This article will focus on the potential of intranasal vaccination and mucosal adjuvants for the development of new-generation TB vaccines.]]&gt;</body>
  </document>
  <document>
    <id>286083</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/water/pdf/w17.pdf]]&gt;</url>
    <title>Isolation and identification of Acanthamoeba species (W17)</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFECTIONS,MICROORGANISM,PARASITES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286084</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop24.pdf]]&gt;</url>
    <title>Isolation of enteroviruses and parechoviruses (VSOP 24 UNDER REVIEW)</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,ENTEROVIRUS,VIRUSES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286085</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop17.pdf]]&gt;</url>
    <title>Isolation of herpes simplex virus associated with herpes genitalis (VSOP 17)</title>
    <publicationDate>2007-07-27T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HERPES,WOMEN'S HEALTH,SEXUAL HEALTH,GENITAL HERPES,INFECTIONS,DIAGNOSIS,MICROORGANISM,VIRUSES,HERPES SIMPLEX VIRUS (HSV),MALE UROGENITAL DISORDERS,MALE SEXUALLY TRANSMITTED INFECTIONS,HERPES,VIRAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method describes the isolation and identification of herpes simplex virus (HSV) from genital specimens.]]&gt;</body>
  </document>
  <document>
    <id>286086</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop21.pdf]]&gt;</url>
    <title>Isolation of viruses associated with infections of the eye: Keratoconjunstivitis (VSOP 21)</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This National Standard Method (NSM) describes the detection and isolation of viruses in material from the conjunctiva and cornea of the eye. Detection of viruses within the eye (eg CMV and VZV retinitis) is not described in this NSM.

 For more detailed information on cell culture refer to VSOP 39 – Procedure for the
propagation of cell cultures for virus isolation. Parasites and bacteria, including Chlamydia trachomatis, are dealt with in other NSMs.]]&gt;</body>
  </document>
  <document>
    <id>286088</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/518939]]&gt;</url>
    <title>John F. Enders Lecture 2006: Antivirals for Influenza</title>
    <publicationDate>2007-07-15T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,VACCINES / IMMUNISATION,TREATMENT,INFLUENZA VACCINE,SEASONAL INFLUENZA,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The long history of influenza drug development has both contributed practical advances in antiviral chemotherapy and improved the understanding of influenza pathogenesis and epidemiology. The role played by these antivirals continues to grow with the dual threats of seasonal and pandemic influenza. The neuraminidase inhibitors are proven effective for the chemoprophylaxis and treatment of influenza A and B, although early therapy is essential for disease mitigation. Studies of topically applied zanamivir have demonstrated the importance of viral replication in the lower respiratory tract, even in uncomplicated influenza. Antiviral resistance, especially to the M2 ion channel inhibitors, sometimes limits clinical utility. Oseltamivir-resistant variants may emerge during treatment but have not yet circulated widely and are usually less fit than wild-type virus; most retain susceptibility to zanamivir. The transmission fitness cost of these resistant variants is drug-, neuraminidase subtype–, and mutation-specific. Continued vigilance in drug resistance surveillance is imperative, as is research into the development of new agents that will provide the potential for alternative and combination antiviral therapy.]]&gt;</body>
  </document>
  <document>
    <id>286089</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop51.pdf]]&gt;</url>
    <title>Laboratory detection and reporting of bacteria with extended spectrum ß-Lactamases (QSOP 51)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,INFECTIONS,TREATMENT,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286090</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.mja.com.au/public/issues/185_10_201106/dwy10867_fm.pdf]]&gt;</url>
    <title>Laboratory diagnosis of human seasonal and pandemic influenza virus infection</title>
    <publicationDate>2006-09-20T00:00:00</publicationDate>
    <publisher>Australasian Medical Publishing Company</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,BODY PART AFFECTED,AIRBORNE,INFECTIONS,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ • Laboratory diagnosis is important to distinguish influenza from other respiratory virus infections. It will be especially important in detecting the first cases of pandemic influenza.
• Good quality respiratory tract sampling is needed to maximise diagnostic yield in influenza infection. 
• In the appropriate clinical setting, pandemic strain-specific nucleic acid testing is the initial test of choice for suspected pandemic influenza. It is more sensitive than virus isolation, and more sensitive and specific than serology, immunofluorescence and other antigen detection methods.
• Virus isolation is needed to monitor new influenza strains and for vaccine development. Analysis of influenza isolates is undertaken by the World Health Organization Global Influenza Surveillance Network.
• Monitoring for antiviral resistance will be needed with widespread use of neuraminidase inhibitors for treatment and prophylaxis during a pandemic.]]&gt;</body>
  </document>
  <document>
    <id>286092</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop30.pdf]]&gt;</url>
    <title>Laboratory diagnosis of Legionella infections in the HPA.  (QSOP 30)</title>
    <publicationDate>2002-09-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286093</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHvol2/no4/guides_coryne.pdf]]&gt;</url>
    <title>Laboratory guidelines for the diagnosis of infections caused by Corynebacterium diphtheriae and C. ulcerans.</title>
    <publicationDate>1999-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (CDPH)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,CONTACT,INFECTIONS,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These guidelines represent an application of the WHO European Region's maunal for the laboratory diagnosis of diphtheria for laboratories in the UK, but they could be applied to laboratories overseas. the manual was rewritten in response to the re-emergence of diphtheria in eastern Europe and the emergence of other infections caused by Corynebacterium diphtheriae and C. ulcerans in the UK and overseas. The guidelines summarise recommendations and procedures for the microbiological diagnosis of infections caused by toxigenic and non-toxigenic isolates of corynebacteria, with particular reference to C.diphtheriae and C. ulcerans. 
CDPH 1999: 2: 250-7]]&gt;</body>
  </document>
  <document>
    <id>286095</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop36.pdf]]&gt;</url>
    <title>Lactose gelatin medium (MSOP 36)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286096</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/content/abstract/45/10/3393]]&gt;</url>
    <title>Large sequence polymorphisms classify Mycobacterium tuberculosis strains with ancestral spoligotyping patterns.</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>American Society of Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,INFECTIOUS DISEASES,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Genomic deletion analysis revealed that strains of Mycobacterium tuberculosis exhibiting spoligotyping patterns with almost all spacers present belong either to a strain lineage that includes the W-Beijing strain family or to the ancestral strain lineage of M. tuberculosis. ]]&gt;</body>
  </document>
  <document>
    <id>286097</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop29.pdf]]&gt;</url>
    <title>Legionella selective agar (MSOP 29)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>379594</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Legionnaires-risk-from-wiper-water.aspx]]&gt;</url>
    <title>Legionnaires' risk from wiper water</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,LEGIONNAIRE'S DISEASE,LEGIONELLA PNEUMOPHILA,RESPIRATORY INFECTIONS,BACTERIA,MICROORGANISM,WHAT'S NEW,ADDED 2010,JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Windscreen wiper water may be the cause of 20% of cases of Legionnaires' disease in England and Wales,” the BBC warned. It reported that the Health Protection Agency (HPA) has said that simply adding screenwash to wiper fluid kills the bacteria and could save lives.&lt;/P&gt;
&lt;P&gt;The news story is based on the results from a preliminary study by the HPA. Researchers carried out a case-control study, surveying the driving habits and known risk factors of the 75 surviving Legionnaires’ patients whose infection was community acquired between July 2008 and March 2009 in England and Wales. They also surveyed a matched control group to see which exposures were more common in those with disease. They calculated that about 22% of infections in people under 70 could be attributed to being in a car without screenwash.&lt;/P&gt;
&lt;P&gt;The HPA says more research is needed to see whether using screenwash could help prevent the disease and that they are looking into this. This may be preliminary research, but in the meantime it may be advisable for drivers to use screenwash to avoid this unproven, yet plausible risk.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The HPA says that more research is needed to see whether the use of screenwash in wiper fluid could play a role in preventing disease and that they are looking into this. Until there are more conclusive results, it may be advisable to add screenwash to your car’s wiper fluid according to manufacturers’ instructions.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Wallensten A, Oliver I, Ricketts K &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.springerlink.com/content/t92532v54003150g" target="_blank"&gt;Windscreen wiper fluid without added screenwash in motor vehicles: a newly identified risk factor for Legionnaires' disease.&lt;/A&gt; &lt;EM&gt;European Journal of Epidemiology&lt;/EM&gt; 2010, June 8&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>308983</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.expert-reviews.com/doi/abs/10.1586/14760584.7.8.1165]]&gt;</url>
    <title>Lessons for tuberculosis vaccines from respiratory virus infection.</title>
    <publicationDate>2008-10-06T00:00:00</publicationDate>
    <publisher>Expert Reviews Ltd</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MARCH 09,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ There is a worldwide epidemic of increasingly drug-resistant TB. Bacillus Calmette–Guérin vaccination provides partial protection against disseminated disease in infants but poor protection against later pulmonary TB. Cell-mediated protection against respiratory virus infections requires the presence of T cells in lung tissues, and the most effective prime–boost immunizations for Mycobacterium tuberculosis also induce lung-resident lymphocytes. These observations need to be taken into account when designing future vaccines against M. tuberculosis.]]&gt;</body>
  </document>
  <document>
    <id>393386</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890972/pdf/1758-2652-13-S2-S3.pdf]]&gt;</url>
    <title>Lessons learned from family-centred models of treatment for children living with HIV: current approaches and future directions</title>
    <publicationDate>2010-06-23T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,CHILDREN,POPULATION GROUPS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Despite strong global interest in family-centred HIV care models, no reviews exist that detail the current approaches to family-centred care and their impact on the health of children with HIV. A systematic review of family-centred HIV care programmes was conducted in order to describe both programme components and paediatric cohort characteristics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We searched online databases, including PubMed and the International AIDS Society abstract database, using systematic criteria. Data were extracted regarding programme setting, staffing, services available and enrolment methods, as well as cohort demographics and paediatric outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: The search yielded 25 publications and abstracts describing 22 separate cohorts. These contained between 43 and 657 children, and varied widely in terms of staffing, services provided, enrolment methods and cohort demographics. Data on clinical outcomes was limited, but generally positive. Excellent adherence, retention in care, and low mortality and/or loss to follow up were documented.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: The family-centred model of care addresses many needs of infected patients and other household members. Major reported obstacles involved recruiting one or more types of family members into care, early diagnosis and treatment of infected children, preventing mortality during children's first six months of highly active antiretroviral therapy, and staffing and infrastructural limitations. Recommendations include: developing interventions to enrol hard-to-reach populations; identifying high-risk patients at treatment initiation and providing specialized care; and designing and implementing evidence-based care packages. Increased research on family-centred care, and better documentation of interventions and outcomes is also critical.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394243</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6T86-4X7GMM9-1-3&amp;_cdi=5078&amp;_user=8810565&amp;_pii=S0300571209002139&amp;_origin=search&amp;_coverDate=01%2F31%2F2010&amp;_sk=999619998&amp;view=c&amp;wchp=dGLzVzz-zSkzk&amp;md5=065272cde703c8d4511813ab3d333ec2&amp;ie=/sdarticle.pd]]&gt;</url>
    <title>Levels of salivary IgA antibodies to Candida spp. in HIV-infected adult patients: a systematic review</title>
    <publicationDate>2010-01-04T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),FUNGI,CANDIDA ALBICANS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To perform a systematic review of published data with the aim of evaluating the levels of IgA antibodies to Candida albicans in HIV-infected adult patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: The search strategy was based on PubMed, Web of Science, Google Scholar, Cochrane and EMBASE databases. Also, the reference lists of included studies were searched. All abstracts found by electronic searches were independently scrutinized by two reviewers. To be eligible for review, the controlled studies had to present the following characteristics: samples of both HIV-infected adults and noninfected adults; appropriate HIV-diagnostic tests for both patient groups (case and control); IgA-diagnostic test applied to a similar population sample.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Of 144 studies found, only six met the initial eligibility criteria, but three were excluded after a thorough analysis. To assess the methodological quality of the three remaining studies, they were categorized according the risk of bias. The three selected studies revealed that the levels of C. albicans-specific IgA antibody were higher in HIV-infected individuals compared with the control group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Adequate IgA antibody responses to C. albicans appear to be maintained, since the levels of these antibodies were higher in all studies selected. Although the findings of this systematic review are encouraging, the scientific evidence should be interpreted carefully because there are only a few reports in the literature, mostly because of the lack of important methodological details or the varying methodologies employed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394231</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20081392]]&gt;</url>
    <title>Linking family planning with HIV/AIDS interventions: a systematic review of the evidence</title>
    <publicationDate>2009-11-30T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To conduct a systematic review of the literature and examine the effectiveness, optimal circumstances, and best practices for strengthening linkages between family planning and HIV interventions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: Systematic review of peer-reviewed articles and unpublished program reports ('promising practices') evaluating interventions linking family planning and HIV services.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Articles were included if they reported post-intervention evaluation results from an intervention linking family planning and HIV services between 1990 and 2007. Systematic methods were used for searching, screening, and data extraction. Quality assessment was conducted using a 9-point rigor scale.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Sixteen studies were included in the analysis (10 peer-reviewed studies and six promising practices). Interventions were categorized into six types: family planning services provided to HIV voluntary counseling and testing (VCT) clients, family planning and VCT services provided to maternal and child health clients, family planning services provided to people living with HIV, community health workers provided family planning and HIV services, VCT provided to family planning clinic clients, and VCT and family planning services provided to women receiving postabortion care. Average study design rigor was low (3.25 out of 9). Most studies reported generally positive or mixed results for key outcomes; no negative results were reported.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Interventions linking family planning and HIV services were generally considered feasible and effective, though overall evaluation rigor was low.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394229</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918569/pdf/1758-2652-13-26.pdf]]&gt;</url>
    <title>Linking sexual and reproductive health and HIV interventions: a systematic review</title>
    <publicationDate>2010-07-19T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: The international community agrees that the Millennium Development Goals will not be achieved without ensuring universal access to both sexual and reproductive health (SRH) services and HIV/AIDS prevention, treatment, care and support. Recently, there has been increasing awareness and discussion of the possible benefits of linkages between SRH and HIV programmes at the policy, systems and service delivery levels. However, the evidence for the efficacy of these linkages has not been systematically assessed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We conducted a systematic review of the evidence for interventions linking SRH and HIV. Structured methods were employed for searching, screening and data extraction. Studies from 1990 to 2007 reporting pre-post or multi-arm evaluation data from SRH-HIV linkage interventions were included. Study design rigour was scored on a nine-point scale. Unpublished programme reports were gathered as "promising practices".&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Of more than 50,000 citations identified, 185 studies were included in the review and 35 were analyzed. These studies had heterogeneous interventions, populations, objectives, study designs, rigour and measured outcomes. SRH-HIV linkage interventions were generally considered beneficial and feasible. The majority of studies showed improvements in all outcomes measured. While there were some mixed results, there were very few negative findings. Generally, positive effects were shown for key outcomes, including HIV incidence, sexually transmitted infection incidence, condom use, contraceptive use, uptake of HIV testing and quality of services. Promising practices (n = 23) tended to evaluate more recent and more comprehensive programmes. Factors promoting effective linkages included stakeholder involvement, capacity building, positive staff attitudes, non-stigmatizing services, and engagement of key populations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Existing evidence provides support for linkages, although significant gaps in the literature remain. Policy makers, programme managers and researchers should continue to advocate for, support, implement and rigorously evaluate SRH and HIV linkages at the policy, systems and service levels.&lt;/P&gt;
&lt;P&gt;Read the &lt;A href="nelh:374691:1" name=internalLink&gt;structured abstract &lt;/A&gt;by the Centre for Reviews and Dissemination. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286099</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop22.pdf]]&gt;</url>
    <title>Listeria selective agar (MSOP 22)</title>
    <publicationDate>2005-05-31T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,LISTERIOSIS,MICROORGANISM,BACTERIA,LISTERIA MONOCYTOGENES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A selective medium for the isolation of Listeria. Columbia agar base is the nutrient base to which selective inhibitors are added. Lithium chloride is used to inhibit enterococci and acriflavine inhibits some Gram-negative and Gram-positive organisms. Further selective agents added are colistin, fosfomycin, cefotetan and cyclohexamide. Aesculin is included as a differential indicator. Listeria monocytogenes hydrolyses aesculin to form aesculutin which reacts with the iron salt to give a black precipitate around the colonies.&lt;/P&gt;
&lt;P&gt;Oxford Listeria selective agar is recommended for either clinical specimens or food samples. PALCAM is recommended for food samples.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308985</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.informapharmascience.com/doi/abs/10.1517/14712598.8.2.201]]&gt;</url>
    <title>Live tuberculosis vaccines based on phoP mutants: A step towards clinical trials</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>Informa Pharmaceutical Science</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MARCH 09,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Bacillus Calmette–Guérin (BCG) is the only preventive treatment for tuberculosis in humans, but this live vaccine confers variable protection against pulmonary tuberculosis in adults. Advances in the understanding of Mycobacterium tuberculosis immunopathogenesis have renewed hopes of developing new prophylactic vaccines conferring better protection than BCG. The authors describe here state-of-the-art attenuated live vaccines based on inactivation of the phoP gene, a transcriptional regulator of key virulence networks in M. tuberculosis. Recent preclinical testing of live vaccines based on phoP inactivation has demonstrated proof of concept, with a high degree of attenuation and protection against disease observed in various animal models. These results demonstrate that phoP mutants are promising new live vaccines for tuberculosis prevention. The steps that now need to be followed, to take these live vaccines towards clinical trials, are also reviewed, together with the potential of these vaccines to replace BCG.]]&gt;</body>
  </document>
  <document>
    <id>307703</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/abstract/336/7642/484]]&gt;</url>
    <title>Long term efficacy of DOTS regimens for tuberculosis: systematic review.</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: To identify published studies assessing tuberculosis recurrence after successful treatment with standard short course regimens for six months to determine the strength and sufficiency of evidence to support current guidelines.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design&lt;/STRONG&gt;: Systematic review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources&lt;/STRONG&gt;: Medline, Embase, Cochrane clinical trials register, specialist tuberculosis journals, and reference lists. Only English language publications were eligible. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods&lt;/STRONG&gt;: Studies were included irrespective of methodology or quality. Abstracted information included inclusion and exclusion criteria for participants, duration of follow-up, and definitions of treatment success and disease recurrence. The primary outcome was the proportion of successfully treated patients recorded with recurrent tuberculosis during the follow-up period.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: 17 study arms from 16 studies met the inclusion criteria; 10 were controlled clinical trials and six were either studies done under programmatic conditions or observational studies from functioning tuberculosis programmes. Although several clinical trials supported the use of daily treatment regimens, studies reporting tuberculosis recurrence after intermittent regimens were&lt;BR&gt;limited. Few studies carried out under routine programmatic conditions reported disease recurrence. Overall there was wide variation in recurrence after successful treatment, ranging from 0% to 14%. Considerable heterogeneity across studies precluded the systematic assessment of factors contributing to tuberculosis recurrence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: Despite DOTS (directly observed treatment, short course) being implemented for more than 10 years and millions of patients treated for tuberculosis, few studies have assessed the ability of standard DOTS regimens to result in lasting cure for patients treated under routine programmatic conditions.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286100</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001104/pdf_fs.html]]&gt;</url>
    <title>Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation(Cochrane Review)</title>
    <publicationDate>2006-07-19T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Chronic obstructive pulmonary disease (COPD) is characterised by partially reversible airflow limitation. Many patients have little reversibility to short acting bronchodilators, but long acting bronchodilators are frequently advocated.

Objectives
To determine the effectiveness of long acting beta-2 adrenoceptor agonists in COPD patients with low reversibility to short-acting bronchodilators.

Search strategy
The Cochrane Airways Group register was searched. Bibliographies of identified randomised controlled trials (RCTs) were also searched. Authors of identified RCTs were contacted for other published and unpublished studies and unpublished studies were obtained from pharmaceutical companies.

Selection criteria
All RCTs over four weeks in duration comparing treatment with long-acting beta-2 adrenoceptor agonists (salmeterol or formoterol) with placebo in patients with stable poorly-reversible COPD.

Data collection and analysis
Data extraction and study quality assessment was performed independently by two reviewers. Where further or missing data were required, authors of studies were contacted.

Main results
Eight RCTs met the inclusion criteria review. Six were parallel group studies of 12-16 weeks in duration and two were cross-over studies with four week treatment arms. All eight assessed the efficacy of salmeterol in COPD compared to placebo. Few of the results could be combined in meta-analyses because of differences in methods of reporting data. Isolated trials reported an improvement in one or other outcome in favour of salmeterol, but the only possible meta-analysis of FEV1 showed no overall benefit (Standardised mean difference 0.14 (95% Confidence Interval -0.16, 0.44, n=4). There was no consistent effect on Health Related Quality of Life or symptoms scores. 
Overall, breathlessness was not reduced, but in one study more subjects in the salmeterol group had low Borg dyspnoea scores compared to placebo (Peto Odds Ratio = 0.60, 95% CI: 0.40; 0.88). There was no effect on COPD exacerbations over the short period of the studies.

Authors' conclusions
In the few studies that could be included in this review, treatment of patients with COPD with long acting beta-2 agonists produces only small increases in FEV1. The improvement in airways function does not seem to be associated with a consistent effect on other outcomes such as health related quality of life or reductions in breathlessness.
--------------------------------------------------------------------------------
Synopsis
The aim of this review was to determine the effectiveness of long acting bronchodilating drugs such as salmeterol or formoterol in the treatment of chronic obstructive pulmonary disease [COPD (emphysema/chronic bronchitis)]. We found eight studies that reported the effects of long acting beta-2 agonists in people with COPD. All were with salmeterol (Serevent). There were inconsistent benefits of salmeterol. Where there were benefits, they were very small and would not support a general recommendation for the use of these drugs in COPD.]]&gt;</body>
  </document>
  <document>
    <id>298231</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ucl.ac.uk/paediatric-epidemiology/pdfs/MTCT_AIDS2008.pdf]]&gt;</url>
    <title>Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006.</title>
    <publicationDate>2008-05-11T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,NOV 08,ADULTS,PREGNANT WOMEN,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2008]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim&lt;/STRONG&gt;: In the United Kingdom (UK) and Ireland, avoidance of breastfeeding and alternative combinations of antiretroviral therapy regimen and mode of delivery are recommended according to maternal clinical status. The aim of this analysis was to explore the impact of different strategies to prevent mother-to-child transmission at a population level.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design&lt;/STRONG&gt;: Comprehensive national surveillance study.&lt;/P&gt;
&lt;P&gt;Methods: Pregnancies in diagnosed HIV-infected women in the UK and Ireland are notified to the National Study of HIV in Pregnancy and Childhood; infant infection status is subsequently reported. Factors associated with transmission in this observational study were explored for singleton births between 2000 and 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: The overall mother-to-child transmission rate was 1.2% (61/5151, 95% confidence interval: 0.9-1.5%), and 0.8% (40/4864) for women who received at least 14 days of antiretroviral therapy. Transmission rates following combinations recommended in British guidelines were 0.7% (17/2286) for highly active antiretroviral therapy with planned Caesarean section, 0.7% (4/559) for highly active antiretroviral therapy with planned vaginal delivery, and 0% (0/464) for zidovudine monotherapy with planned Caesarean section (P = 0.150). Longer duration of highly active antiretroviral therapy was associated with reduced transmission after adjusting for viral load, mode of delivery and sex (adjusted odds ratio = 0.90 per week of highly active antiretroviral therapy, P = 0.007). Among 2117 infants born to women on highly active antiretroviral therapy with viral load less than 50 copies/ml, only three (0.1%) were infected, two with evidence of in-utero transmission.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Sustained low HIV transmission rates following different combinations of interventions in this large unselected population are encouraging. Current options for treatment and delivery offered to pregnant women according to British guidelines appear to be effective.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286102</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop37.pdf]]&gt;</url>
    <title>MacConkey agar (MSOP 37)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM,SALMONELLA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286103</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.328.7450.1251]]&gt;</url>
    <title>Main presentations of sexually transmitted infections in men</title>
    <publicationDate>2004-05-22T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,SYPHILIS,CHLAMYDIA,GONORRHOEA,INFECTIONS,VIRUSES,CANDIDA ALBICANS,FUNGI,LICE,PUBIC LICE,PARASITES,HUMAN PAPILLOMAVIRUS (HPV),HERPES SIMPLEX VIRUS (HSV),MICROORGANISM,CHLAMYDIA,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Some sexually transmitted infections, such as gonorrhoea and chlamydial infection, have different presentations in the two sexes because of differences in genital anatomy. This chapter focuses on infections of the male urethra, epididymis, testis, and prostate. Anal and oral symptoms are also covered because these are encountered more often among men, especially men who have sex with men.]]&gt;</body>
  </document>
  <document>
    <id>286182</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/publications/reports/NCSPa-rprt-06_07.pdf]]&gt;</url>
    <title>Maintaining Momentum: National Chlamydia Screening Programme Annual Report 2005/6</title>
    <publicationDate>2007-11-30T00:00:00</publicationDate>
    <publisher>National Chlamydia Screening Programme</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHLAMYDIA,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,WOMEN'S HEALTH,SEXUAL HEALTH,CHLAMYDIA,INFECTIONS,CHLAMYDIA,BACTERIA,MICROORGANISM,MALE SEXUALLY TRANSMITTED INFECTIONS,MALE UROGENITAL DISORDERS,BACTERIAL,CHLAMYDIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Annual report of the National Chlamydia Screening Programme in England 2006/07]]&gt;</body>
  </document>
  <document>
    <id>392359</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19850225]]&gt;</url>
    <title>Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,OCT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Male circumcision provides long-term indirect protection to women by reducing the risk of heterosexual men becoming infected with HIV. In this Review, we summarise the evidence for a direct effect of male circumcision on the risk of women becoming infected with HIV. We identified 19 epidemiological analyses, from 11 study populations, of the association of male circumcision and HIV risk in women. A random-effects meta-analysis of data from the one randomised controlled trial and six longitudinal analyses showed little evidence that male circumcision directly reduces risk of HIV in women (summary relative risk 0.80, 95% CI 0.53-1.36). Definitive data would come from a further randomised controlled trial of circumcision among men infected with HIV in serodiscordant heterosexual relationships, but this would involve enrolling about 10 000 couples and is likely to be logistically unfeasible. As circumcision services for HIV prevention are scaled-up in high HIV prevalence settings, rapid integration with existing prevention strategies would maximise benefits for both men and women. Rigorous monitoring is essential to ensure that any adverse effects on women are detected and minimised.]]&gt;</body>
  </document>
  <document>
    <id>347278</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Man-flu-myth-or-real.aspx]]&gt;</url>
    <title>Man flu: real or myth?</title>
    <publicationDate>2010-03-25T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Man flu is real, reported the Daily Mirror. Many newspapers reported the news that scientists have found men suffer from flu more because they “invest in their spirit of adventure at the expense of their immune system” (The Daily Telegraph).&lt;/P&gt;
&lt;P&gt;The news is based on a mathematical model developed by Cambridge researchers, which they themselves found surprising. They say that if males are more exposed to infection than females, perhaps through riskier behaviours, it is possible that they evolve less effective immune systems. They say that this result is at “odds with intuitive expectations”.&lt;/P&gt;
&lt;P&gt;Many newspapers have reported this story, some putting forward additional theories of how testosterone might interfere with immunity. In general, surprising findings from models should be treated cautiously, and any plausible theory of an immune difference between the sexes will need testing in real-life studies. For now, man flu (different responses between the sexes to flu) remains unproven.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;As with all modelling studies, the results depend on the underlying assumptions, and in this case on the way that the researchers have made mathematical links between recovery rates, death rates and the ability to reproduce, in the theoretical population.&lt;/P&gt;
&lt;P&gt;There are other theories that the male immune system may be influenced by testosterone, which the researchers did not consider. They also did not measure immunity in men or women. In addition, the researchers do not suggest in their research paper that their model has any implications for human health.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;One of the six models begins with the assumption that men have a higher susceptibility to infection. The results of this model have been reported as supporting the case for man flu. However, the finding is purely hypothetical at this stage and results from demonstrating that, under certain assumptions, these men will lose more of their ability to fight off infection. 
&lt;LI&gt;The assumption that immunity is inherited in a ‘Mendelian’ way or by a single gene, is just that, an assumption. Much more research would be needed to test if this is actually the case. 
&lt;LI&gt;The fact that sexual selection (how the choice of a partner may influence the inheritance and prevalence of certain traits) was not included in this model is a limitation to the study. The researchers acknowledge this and hope to include this in future models.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Overall, this modelling study suggests several possible patterns for how immunity might be inherited differently among the sexes - however, these are only theories. Headlines that ‘man flu’ is real and not a myth are unjustified. Any plausible theory of an immune difference between the sexes would need testing in real-life studies, ones that also include assessment of the difference within each sex grouping, too.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Restif O and Amos W.&amp;nbsp;&lt;A href="http://rspb.royalsocietypublishing.org/content/early/2010/03/23/rspb.2010.0188.short?rss=1" target="_blank"&gt;The evolution of sex-specific immune defences&lt;/A&gt;. &lt;EM&gt;Proceedings of the Royal Society, Biological Sciences&lt;/EM&gt;2010; Published online before print, March 24 2010 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286105</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947382005]]&gt;</url>
    <title>Management and control of Viral Haemorrhagic Fevers</title>
    <publicationDate>1996-12-01T00:00:00</publicationDate>
    <publisher>The Stationery Office</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INSECT BITE,TRANSMISSION MODE,BLOOD AND BODY FLUIDS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIVIRALS,TRAVEL ASSOCIATED INFECTIONS,EBOLA HAEMORRHAGIC FEVER,LASSA FEVER,MARBURG HAEMORRHAGIC FEVER,DENGUE FEVER,ADULTS,OTHER TREATMENT METHODS,TRAVELLERS,TREATMENT,POPULATION GROUPS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This guidance is prepared in consultation with HSE, by the ACDP which was appointed by the Health and Safety Commission as part of its formal advisory structure and by Health Ministers. The guidance represents what is considered to be good practice by members of the Committee.]]&gt;</body>
  </document>
  <document>
    <id>304732</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408846]]&gt;</url>
    <title>Management of Abnormal Vaginal Discharge in Women - Quick reference guide for primary care</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,CHLAMYDIA,GONORRHOEA,WOMEN'S HEALTH,GONORRHOEA,CANDIDA,BACTERIAL VAGINOSIS,TRICHOMONAS,SEXUAL HEALTH,INFECTIONS,JAN 09,CHLAMYDIA,BACTERIA,MICROORGANISM,CANDIDA ALBICANS,FUNGI,NEISSERIA GONORRHOEA,NEISSERIA,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To improve the diagnosis of infectious disease in primary care 
&lt;LI&gt;To improve use of the microbiology laboratory in primary care 
&lt;LI&gt;To target the use of antibiotics and anti-fungals in primary care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Production:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The templates have been produced in consultation with GPs and specialists in the field. 
&lt;LI&gt;They are in agreement with other guidance, including Prodigy, SIGN and NICE. 
&lt;LI&gt;The guidance is fully referenced and graded. 
&lt;LI&gt;The guidance is not all-encompassing, as it is meant to be quick reference. If more detail is required we suggest referral to the websites and references quoted. 
&lt;LI&gt;The guidance is updated annually. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Local adaptation:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The guidance will need to be taken forward in collaboration between laboratories, PCTs and secondary care providers. 
&lt;LI&gt;Recommendations can be changed to suit local service delivery and sampling protocols. 
&lt;LI&gt;Change in laboratory use may increase or decrease laboratory workload and have financial implications for laboratories and Primary Care Trusts (PCTs). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Your feedback:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;We welcome, in fact encourage, opinions on the advice given and future topics we should cover. 
&lt;LI&gt;Comments should be submitted to Dr Cliodna McNulty, Head, HPA Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN. Email: &lt;A href="mailto:jill.whiting@hpa.org.uk" target="_blank"&gt;jill.whiting@hpa.org.uk&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286109</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop31.pdf]]&gt;</url>
    <title>Management of confirmed parvovirus B19 infection in pregnancy (VSOP 31)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,INFECTIONS,ANTENATAL PROBLEMS,WOMEN'S HEALTH,COMPLICATED PREGNANCY,INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286112</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sign.ac.uk/pdf/sign92.pdf]]&gt;</url>
    <title>Management of Hepatitis C: A National Clinical Guideline (SIGN 92)</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>NHS Quality Improvement Scotland</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BLOOD AND BODY FLUIDS,HEPATITIS,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VIRUSES,HEPATITIS C VIRUS,HEPATITIS VIRUS,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The guideline provides evidence based recommendations covering all stages of the patient care pathway; screening, testing, diagnosis, referral, treatment, care and follow up of infants, children and adults with, or exposed to, HCV infection. The remit encompasses prevention of secondary transmission of the virus but specifically excludes primary prevention of HCV infection. Primary prevention of hepatitis C infection is an important public health concern but is a difficult topic for an evidence based guideline to cover. The principles and evidence for the prevention of all blood borne viruses are generic and reviewing all of this evidence would have been beyond the capacity of any guideline development group, whilst reviewing the HCV evidence alone would have produced a distorted view. 

This guideline will be of interest to all health professionals in primary and secondary care
involved in the management of people with hepatitis C infection.]]&gt;</body>
  </document>
  <document>
    <id>286113</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jac.oupjournals.org/cgi/content/full/45/6/729?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=herpes+virus+infections&amp;andorexactfulltext=and&amp;searchid=1078907396204_99&amp;stored_search=&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=1&amp;journalcode=jac.html]]&gt;</url>
    <title>Management of herpes virus infections following transplantation</title>
    <publicationDate>2000-11-01T00:00:00</publicationDate>
    <publisher>Journal of Antimicrobial Chemotherapy</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,CYTOMEGALOVIRUS (CMV),VARICELLA ZOSTER VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Herpesvirus infections lead to significant morbidity and mortality in transplant recipients. Cytomegalovirus (CMV) is the most important virus in this respect, and prevention of CMV disease has been the subject of a large number of clinical trials. In addition, herpes simplex virus (HSV) and varicella zoster virus (VZV) can lead to severe disease. With regard to Epstein–Barr virus (EBV), post-transplant lymphoproliferative disease (PTLD) is increasingly recognized as a major complication. By contrast, disease association with human herpes virus 6 (HHV-6) and human herpes virus 7 (HHV-7) infections following transplantation requires clarification, as does the natural history of these infections. There is little information available on human herpes virus 8 (HHV-8) infection in the transplant scenario. ]]&gt;</body>
  </document>
  <document>
    <id>308945</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?author=Scano&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings.</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The emergence of extensively drug-resistant tuberculosis (XDR-TB) poses a significant public health threat for human immunodeficiency virus (HIV) programmes and tuberculosis (TB) control efforts. Recent reports demonstrate high mortality rates among HIV-infected multidrugresistant (MDR) and XDR-TB patients compared to those without HIV infection. Transmission of these highly resistant TB strains is occurring both within health facilities and in the community. We review the principles of a sound public health approach to this problem, including early diagnosis, treatment for suspected disease, patient support and adherence and sound infection control measures. In the context of drug-resistant TB, we elaborate on current World Health Organization antiretroviral guidelines addressing management issues related to timing of antiretroviral treatment (ART), drug interactions and drug toxicities among patients receiving both ART and second-line TB regimens. We highlight the important research agenda that exists at the intersection of MDR- and XDR-TB and HIV disease.]]&gt;</body>
  </document>
  <document>
    <id>303663</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340160]]&gt;</url>
    <title>Management Of Infection Guidance For Primary Care For Consultation &amp; Local Adaptation</title>
    <publicationDate>2008-06-05T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,ANTIBIOTICS,ANTIFUNGALS,ANTIVIRALS,ANTIMICROBIALS,INFECTIONS,JAN 09,TREATMENT,RESPIRATORY INFECTIONS,URINARY TRACT INFECTION,ANTIMICROBIAL RESISTANCE,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To provide a simple, best guess approach to the treatment of common infections&amp;nbsp; 
&lt;LI&gt;To promote the safe, effective and economic use of antibiotics&amp;nbsp; 
&lt;LI&gt;To minimise the emergence of bacterial resistance in the community&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For this document in rich text format, click &lt;A href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947333801" target="_blank"&gt;here&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286114</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://thorax.bmj.com/cgi/reprint/55/3/210]]&gt;</url>
    <title>Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999</title>
    <publicationDate>2000-03-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,MYCOBACTERIUM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidelines have been produced for tuberculosis by the British Thoracic Society (BTS), the American Thoracic Society (ATS), the International Union Against Tuberculosis and Lung Disease, and the World Health Organisation. These, however, deal mainly with Mycobacterium tuberculosis complex infections (M tuberculosis, M africanum, and M bovis). With the exception of the ATS guidelines on non-tuberculous mycobacteria, these do not address the opportunist mycobacteria (also called atypical mycobacteria, mycobacteria other than tuberculosis (MOTT), non-tuberculous mycobacteria (NTM), or environmental mycobacteria). ]]&gt;</body>
  </document>
  <document>
    <id>330330</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.lww.com/co-infectiousdiseases/Abstract/2009/06000/Management_of_paediatric_HIV_1_resistance.9.aspx]]&gt;</url>
    <title>Management of paediatric HIV-1 resistance</title>
    <publicationDate>2009-06-22T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,POPULATION GROUPS,CHILDREN,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ANTIMICROBIAL RESISTANCE,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Purpose of review: Children have higher rates of virological failure than adults, often associated with more extensive resistance and limited second-line options. In order to maintain clinical benefits of highly active antiretroviral therapy (HAART) into adulthood, particularly for children starting at a young age, strategies are needed to limit the emergence of resistance and to offer highly effective subsequent lines of therapy. Similarly, well resourced settings face challenges regarding extensive resistance accumulated over the past decade or more, particularly resulting from suboptimal therapies.&lt;/P&gt;
&lt;P&gt;Recent findings: Rates of resistance at failure of nonnucleoside reverse-transcriptase inhibitor based HAART are higher in developing countries than in well resourced settings. In the latter, second-generation protease inhibitors tipranavir and darunavir are promising, with tipranavir now licensed for those above 2 years and darunavir showing good trial results in children above 6 years. However, combination with new classes such as integrase inhibitors (currently in phase I trials) and CCR5 antagonists (no paediatric data yet) will probably be necessary to gain maximal long-term benefits.&lt;/P&gt;
&lt;P&gt;Summary: Common goals in paediatric HIV for both resource-rich and resource-limited settings are to limit vertical transmission, minimize emergence of resistant viruses in both mother and child where prevention of mother-to-child transmission fails, and limit resistance in children starting HAART. Optimal sequencing of regimens in the absence of resistance testing is a priority research area. Paediatric studies using newer classes of agents are of paramount importance, as well as expanding access to existing antiretrovirals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286115</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sign.ac.uk/guidelines/fulltext/34/index.html]]&gt;</url>
    <title>Management of sore throat and indications for tonsillectomy</title>
    <publicationDate>1999-01-01T00:00:00</publicationDate>
    <publisher>Scottish Intercollegiate Guidelines Network (SIGN)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFECTIONS,BACTERIA,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This guideline presents evidence-based recommendations for the management of acute and recurring sore throat and indications for tonsillectomy. The guideline only considers tonsillectomy for recurring sore throat; It does not address tonsillectomy for suspected malignancy or as a treatment for sleep apnoea, peritonsillar abscess or other conditions. The published literature is mainly concerned with a paediatric population and there is little evidence concerning the management of recurring sore throats in adults. The aim of this guideline is to suggest a rational approach to the management of acute sore throat in general practice and to provide reasonable criteria for referral for tonsillectomy. The guideline also provides examples of patient information leaflets (Annexes 2 and 3) which may assist in management and facilitate decision making about operation and suggests areas where further research could be productive.]]&gt;</body>
  </document>
  <document>
    <id>307708</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/section_pdf/337/aug28_1/a1110.pdf]]&gt;</url>
    <title>Managing drug resistant tuberculosis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,TREATMENT,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Antituberculosis drug resistance is increasing both in the United Kingdom and internationally. It has come to greater public attention with the emergence of extensively drug resistant tuberculosis (box 1) in South Africa, where an outbreak proved rapidly fatal among people with advanced HIV infection. In this article we review recent global and UK trends in drug resistant tuberculosis and summarise its diagnosis, treatment, and control. Few data are available from randomised controlled trials to guide treatment of drug resistant tuberculosis, and none for multidrug resistant tuberculosis; this review is based primarily on data from observational epidemiological studies and on national and international guidelines.]]&gt;</body>
  </document>
  <document>
    <id>315501</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1242804139580]]&gt;</url>
    <title>Managing influenza-like illness (ILI) in nursing and residential homes during the current swine influenza outbreak (WHO Phase 5; UK containment phase)</title>
    <publicationDate>2009-05-19T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,PREVENTION,ANTIVIRALS,ANTIMICROBIALS,DIAGNOSIS,TREATMENT,INFECTION CONTROL,OLDER PEOPLE,ADULTS,RESPIRATORY INFECTIONS,POPULATION GROUPS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,MAY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance aims to provide advice on the generic management of cases or outbreaks of flu-like illness in nursing and residential homes and provides specific guidance appropriate to swine influenza. &lt;/P&gt;
&lt;P&gt;General information on swine flu can be found on the Health Protection Agency website at &lt;A href="http://www.hpa.org.uk/" target="_blank"&gt;www.hpa.org.uk&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308911</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.current-reports.com/article_frame.cfm?PubID=HI05-3-1-05&amp;Type=Abstract&amp;KeyWords=Pillay&amp;HitNum=1]]&gt;</url>
    <title>Managing tuberculosis and HIV in sub-Sahara Africa.</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Current Medicine Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,DIAGNOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB) and HIV represent a deadly duo in sub-Sahara Africa, a region most affected by both diseases. The HIV epidemic has aggravated already strained and frequently poorly performing TB control programs. These programs face numerous challenges, and novel, regionally appropriate solutions need to be developed. In the context of TB, some challenges include the rapid diagnosis of active TB in the face of paucibacillary lung disease and atypical presentations with HIV/AIDS, lack of clinical expertise, poor contact tracing, limited laboratory facilities, delayed recognition of drug-resistant TB, increased workload of health care workers, erratic drug supplies, inadequate isolation facilities, and environmental and personal protection in drug-resistant cases. Similar problems exist in the context of HIV but are aggravated by the need for complex antiretroviral drug regimens and lifelong treatment. Treating both conditions invites drug interactions and toxic effects that are common to both HIV and TB treatment and the vexing question of when to introduce antiretroviral treatment in subjects with active TB. Combining HIV and TB care has the potential to bring additional infrastructural and human resources to the respective programs, with synergistic benefits.]]&gt;</body>
  </document>
  <document>
    <id>286118</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop38.pdf]]&gt;</url>
    <title>Mannitol lysine crystal violet brilliant green agar (MSOP 38)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286119</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop10.pdf]]&gt;</url>
    <title>Mannitol salt agar (MSOP 10)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,DIGESTIVE TRACT,CARDIOVASCULAR,BODY PART AFFECTED,FOOD/WATER,INFECTIONS,BACTERIA,MICROORGANISM,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286120</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop51.pdf]]&gt;</url>
    <title>Mannitol selenite broth (MSOP 51)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286121</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4076389&amp;chk=k4KKwh]]&gt;</url>
    <title>Measles Mumps and Rubella Vaccine (MMR) 2002</title>
    <publicationDate>2002-04-30T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,MUMPS,MEASLES,CONTACT,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,VACCINE PREVENTABLE DISEASES,MICROORGANISM,VIRUSES,RUBELLA VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This web document provides information on the safety of MMR vaccine.]]&gt;</body>
  </document>
  <document>
    <id>380539</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/measles-outbreak-in-france.aspx]]&gt;</url>
    <title>Measles outbreak in France</title>
    <publicationDate>2010-07-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,MEASLES,PREVENTION,INFECTIONS,CHILDREN,POPULATION GROUPS,MEASLES,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MICROORGANISM,VACCINES / IMMUNISATION,VIRUSES,MEASLES VIRUS,JULY 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;French authorities have reported an increased number of measles cases in France this year.&lt;/P&gt;
&lt;P&gt;Parents who are planning a holiday in France and have not had their children vaccinated against measles should ensure their children have the measles, mumps and rubella (MMR) vaccine.&lt;/P&gt;
&lt;P&gt;It is never too late to get the MMR vaccine for your child as it provides the best possible protection against measles, mumps and rubella.&lt;/P&gt;
&lt;P&gt;Your GP can provide advice on vaccination or you can visit the vaccination pages on NHS Choices for more information.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;If there isn't time to get the MMR vaccination before you go away, book an appointment with your GP for your child to have it as soon as you get back.&lt;/P&gt;
&lt;P&gt;While you are away, initial symptoms of measles to look out for are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;a rash for at least three days, and 
&lt;LI&gt;fever for at least one day, and 
&lt;LI&gt;at least one of the following: a cough, a head cold or red sore eyes &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;More information about measles&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Choices information about &lt;A href="http://www.nhs.uk/conditions/measles/pages/introduction.aspx" target="_blank"&gt;measles&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS Choices information about &lt;A href="http://www.nhs.uk/conditions/mmr/Pages/Introduction.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;MMR&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Travel advice on &lt;A href="http://www.fco.gov.uk/en/travel-and-living-abroad/when-things-go-wrong/sick-injured" target="_blank"&gt;getting treatment abroad &lt;/A&gt;is on the Foreign and Commonwealth Office's website&lt;/P&gt;
&lt;H2&gt;
&lt;H2&gt;
&lt;H2&gt;
&lt;HR&gt;
&lt;/H2&gt;&lt;/H2&gt;&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345550</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651863/pdf/1477-7525-7-14.pdf]]&gt;</url>
    <title>Measuring health-related quality of life in tuberculosis: a systematic review</title>
    <publicationDate>2009-02-18T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;: Tuberculosis remains a major public health problem worldwide. In recent years, increasing efforts have been dedicated to assessing the health-related quality of life experienced by people infected with tuberculosis. The objectives of this study were to better understand the impact of tuberculosis and its treatment on people's quality of life, and to review quality of life instruments used in current tuberculosis research.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: A systematic literature search from 1981 to 2008 was performed through a number of electronic databases as well as a manual search. Eligible studies assessed multi-dimensional quality of life in people with tuberculosis disease or infection using standardized instruments. Results of the included studies were summarized qualitatively.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Twelve original studies met our criteria for inclusion. A wide range of quality of life instruments were involved, and the Short-Form 36 was most commonly used. A validated tuberculosis-specific quality of life instrument was not located. The findings showed that tuberculosis had a substantial and encompassing impact on patients' quality of life. Overall, the antituberculosis treatment had a positive effect of improving patients' quality of life; their physical health tended to recover more quickly than the mental well-being. However, after the patients successfully completed treatment and were microbiologically 'cured', their quality of life remained significantly worse than the general population.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Tuberculosis has substantially adverse impacts on patients' quality of life, which persist after microbiological 'cure'. A variety of instruments were used to assess quality of life in tuberculosis and there has been no well-established tuberculosis-specific instrument, making it difficult to fully understand the impact of the illness.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286127</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop39.pdf]]&gt;</url>
    <title>Membrane enterococcus agar (MSOP 39)</title>
    <publicationDate>2005-05-31T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ENTEROCOCCUS AND GRE/VRE,MICROORGANISM,ENTEROCOCCUS,VANCOMYCIN RESISTANT ENTEROCOCCUS,BACTERIA,STREPTOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Selective medium for the detection and enumeration of faecal streptococci from water. It is also referred to as Slanetz and Bartley medium.&lt;BR&gt;Enterococci reduce tetrazolium chloride (TTC) to the red dye formazan to produce red, maroon or pink colonies on the medium. However, not all species reduce TTC and so pale or colourless colonies should not be ignored.]]&gt;</body>
  </document>
  <document>
    <id>286131</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T84-40YSCVF-Y&amp;_user=910131&amp;_coverDate=08%2F31%2F2000&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=6db0dc7b7112530b4bc81737ac365792]]&gt;</url>
    <title>Meta-analysis of diagnostic tests for acute sinusitis</title>
    <publicationDate>2000-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ To facilitate management of acute sinusitis, we conducted a meta-analysis of published studies comparing diagnostic tests for this disorder. Thirteen studies were identified through literature search. Based on sinus puncture/aspiration (considered most accurate), 49–83% of symptomatic patients had acute sinusitis. Compared with puncture/aspiration, radiography offered moderate ability to diagnose sinusitis (summary receiver operator curve [SROC] area, 0.83). Using sinus opacity or fluid as the criterion for sinusitis, radiography had sensitivity of 0.73 and specificity of 0.80. Studies evaluating ultrasonography revealed substantial variation in test performance. The clinical evaluation, particularly risk scores formally incorporating history and physical examination findings, had moderate ability to identify patients with positive radiographs (SROC area, 0.74). Many studies were of poor quality, with inadequately described test methods and unblinded test interpretation. In conclusion, acute sinusitis is common among symptomatic patients. Radiography and clinical evaluation (especially risk scores) appear to provide useful information for diagnosis of sinusitis.]]&gt;</body>
  </document>
  <document>
    <id>286132</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/cgi/content/abstract/146/5/340]]&gt;</url>
    <title>Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research</title>
    <publicationDate>2007-03-06T00:00:00</publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ BACKGROUND: Until recently, the tuberculin skin test was the only test for detecting latent tuberculosis (TB) infection, but 2 ex vivo interferon-gamma release assays (IGRAs) are now commercially licensed. 

PURPOSE: To estimate sensitivity, specificity, and reproducibility of IGRAs (commercial or research versions of QuantiFERON [QFT] and Elispot) for diagnosing latent TB infection in healthy and immune-suppressed persons. 

DATA SOURCES: The authors searched MEDLINE and reviewed citations of all original articles and reviews for studies published in English. 

STUDY SELECTION: Studies had evaluated IGRAs using Mycobacterium tuberculosis-specific antigens (RD1 antigens) and overnight (16- to 24-h) incubation times. Reference standards had to be clearly defined without knowledge of test results.

DATA EXTRACTION AND QUALITY ASSESSMENT: Specific criteria for quality assessment were developed for sensitivity, specificity, and reproducibility.

 DATA SYNTHESIS: When newly diagnosed active TB was used as a surrogate for latent TB infection, sensitivity of all tests was suboptimal, although it was higher with Elispot. No test distinguishes active TB from latent TB. Sensitivity of the tuberculin skin test and IGRAs was similar in persons who were categorized into clinical gradients of exposure. Pooled specificity was 97.7% (95% CI, 96% to 99%) and 92.5% (CI, 86% to 99%) for QFT and for Elispot, respectively. Both assays were more specific than the tuberculin skin test in samples vaccinated with bacille Calmette-Guérin. Elispot was more sensitive than the tuberculin skin test in 3 studies of immune-compromised samples. Discordant tuberculin skin test and IGRA reactions were frequent and largely unexplained, although some may be related to varied definitions of positive test results. Reversion of IGRA results from positive to negative was common in 2 studies in which it was assessed. 

LIMITATIONS: Most studies used cross-sectional designs with the inherent limitation of no gold standard for latent TB infection, and most involved small samples with a widely varying likelihood of true-positive and false-positive test results. There is insufficient evidence on IGRA performance in children, immune-compromised persons, and the elderly. 

CONCLUSIONS: New IGRAs show considerable promise and have excellent specificity. Additional studies are needed to better define their performance in high-risk populations and in serial testing. Longitudinal studies are needed to define the predictive value of IGRAs. ]]&gt;</body>
  </document>
  <document>
    <id>286134</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD003265]]&gt;</url>
    <title>Methenamine hippurate for preventing urinary tract infections (Cochrane Review)</title>
    <publicationDate>2001-10-19T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,URINARY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Methenamine salts are often used for the prevention of urinary tract infection (UTI).

Objectives
To assess the effectiveness of methenamine hippurate in preventing UTI.

Search strategy
Published and unpublished randomised controlled trials were identified from the Cochrane Controlled Trials Register, MEDLINE, EMBASE, CINAHL, Current Contents, reference lists of review articles and retrieved trials. The manufacturers' of methenamine salts were contacted for unpublished studies and contact was made with known investigators in the area.

Selection criteria
Randomised and quasi-randomised trials of methenamine hippurate used for the prevention of UTIs in all population groups were eligible for inclusion. A comparison with a control (no treatment) group was a prerequisite to selection.

Data collection and analysis
Two reviewers (BL and TB) performed independent assessment and data extraction using a standardised format. Discrepancies, methodological and interpretative issues were discussed with JS or JC. An exploration of heterogeneity as well as a detailed description of results grouped by population was conducted.

Main results
Eleven studies met the inclusion criteria. All trials were included in a descriptive analysis. Seven trials were included in meta-analyses. Four trials (199 patients) studied symptomatic bacteriuria and six trials (341 patients) studied bacteriuria as an outcome measure. Overall, trial quality was poor. The direction of six of the pooled trials was towards a favourable treatment effect from methenamine hippurate. Interpretation of the pooled estimates was not done in view of underlying heterogeneity. The study by Pettersson 1989 explained some, but not all, of the underlying heterogeneity. This study differed from all others by including patients with known upper renal tract abnormalities. Adverse reactions were mentioned by 10 studies. The rate of adverse events was low. 

Authors' conclusions
There is not enough evidence to conclusively support the use of methenamine hippurate for urinary prophylaxis. An exploration of heterogeneity raises the (hypothesis generating) possibility that methenamine hippurate may have some efficacy in patients without but not in patients with known upper renal tract abnormality (with asymptomatic bacteriuria as the outcome measure). Due to the small sample size and methodological problems within the studies involved, interpretation of these data should be done cautiously. The rate of adverse events reported by the trials was low, which suggests that current usage is unlikely to be causing significant harm. There is a need for a large randomised controlled trial to answer this question.
--------------------------------------------------------------------------------
Synopsis
Not enough evidence on whether methenamine (hexamine) salts can prevent urinary tract infection, but they have few adverse effects and might help

Bladder and kidney infections (urinary tract infections - UTI) can cause vomiting, fever and tiredness, and occasionally kidney damage. Some people are at high risk of repeated UTIs, and they are also more likely to have serious complications (including people with kidney problems, or people who have catheters to release urine). Long-term use of antibiotics can lead to resistance, so methenamine salts (methenamine or hexamine hippurate) are often used. The review found that there is not enough evidence about whether methenamine hippurate can prevent UTIs, although they might work and are worth more research. Adverse effects are minor and uncommon.]]&gt;</body>
  </document>
  <document>
    <id>286135</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002168/pdf_fs.html]]&gt;</url>
    <title>Methylxanthines for exacerbations of chronic obstructive pulmonary disease (Review)</title>
    <publicationDate>2003-04-22T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Most international guidelines currently recommend methylxanthines (e.g., theophylline, aminophylline) for severe exacerbations of chronic obstructive pulmonary disease (COPD), yet clinical trials underlying this recommendation have been small and underpowered.

Objectives
To determine the benefit of methylxanthines compared to placebo for COPD exacerbations.

Search strategy
Randomised controlled trials (RCTs) were identified from the Cochrane Airways Review Group COPD Register, a compilation of systematic searches of CINAHL, EMBASE, MEDLINE and CENTRAL and hand searching of 20 respiratory journals. Primary authors and content experts were contacted to identify eligible studies. Bibliographies from included studies and reviews were searched. Searches are current to March 2005.

Selection criteria
Included studies were limited to RCTs of patients presenting with acute COPD exacerbations, treated with methylxanthines (oral or intravenous) or placebo plus standard care. Two reviewers independently selected articles for inclusion and assessed methodological quality.

Data collection and analysis
Two reviewers independently extracted data. Missing data were obtained from authors or calculated from other data presented in the paper. The data were analysed using the Cochrane Review Manager 4.1. Studies were pooled to yield weighted mean differences (WMD), standardised mean difference (SMD) or odds ratios (OR) and reported using 95% confidence intervals (95%CI).

Main results
From 29 identified references, 4 RCTs met inclusion criteria (169 patients). Mean change in forced expiratory volume in one second (FEV1) at 2 hours was similar in methylxanthine and placebo groups but transiently increased with methylxanthines at 3 days (WMD: 101 ml; 95% CI: 26 to 177). Data on clinical outcomes were sparse. Trends toward improvements in hospitalisation and length-of-stay were offset by a trend toward more relapses at one week. Changes in symptom scores were not significant. Methylxanthines caused more nausea and vomiting than placebo (OR: 4.6; 95% CI: 1.7 to 12.6) and trended toward more frequent tremor, palpitations, and arrhythmias.

Authors' conclusions
Given current evidence, methylxanthines should not be used for COPD exacerbations. Possible beneficial effects in lung function and clinical endpoints were modest and inconsistent, whereas adverse effects were significantly increased. More selective agents, tested in larger randomised trials, are necessary if methylxanthines are to have any role in the treatment of COPD exacerbations.
--------------------------------------------------------------------------------
Synopsis
Methylxanthine drugs such as aminophylline and theophylline are recommended for use in patients who have acute exacerbations (episodes) of chronic obstructive pulmonary disease, particularly for patients unresponsive to standard therapies. This review identified four studies that compared these drugs with placebo. Over the first 2 hours of treatment there was no evidence that patients improved in terms of lung function, although a possible late benefit was detected. The studies do not give a clear indication of whether there was benefit in terms of reduced symptoms or hospital admissions, but side effects were found to be more common with methylxanthines. We conclude that, given current evidence, methylxanthines should not be used for acute exacerbations of chronic obstructive pulmonary disease.]]&gt;</body>
  </document>
  <document>
    <id>286136</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop42.pdf]]&gt;</url>
    <title>Microbiological examination of CSFs, that may contain agents of spongiform encephalopathies (QSOP 42)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,PRIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286137</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/SARS/micro.htm]]&gt;</url>
    <title>Microbiological guidance for taking and handling specimens from suspect SARS patients</title>
    <publicationDate>2003-09-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,AIRBORNE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,SARS CORONA VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This guidance is provided to assist the decision making process of management and sampling of a possible case of SARS in the UK. At the time of writing (January 2005), the world is in an inter-epidemic period for SARS. The most likely sources of infection with SARS coronavirus (SARS CoV) are:

* Laboratory acquired infection in workers handling SARS CoV
* Contact with an animal reservoir of SARS CoV. The reservoir for this virus may involve a wide range of species including civet cats and racoon dogs most commonly found in south east Asia. Such animals may be consumed as wildlife delicacies in parts of south China, Viet Nam and surrounding countries. 
* Contact with an unknown cluster of severe respiratory illness

In the absence of either of these epidemiological risk factors, it is highly unlikely that SARS CoV will be the cause of sporadic community acquired respiratory infection in a returning traveller from SE Asia. Investigation is not recommended in this situation. If, however, there is a cluster of severe respiratory illness associated with a single returning traveller from SE Asia in the absence of other obvious risk factors, investigation may be appropriate.]]&gt;</body>
  </document>
  <document>
    <id>286138</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop44.pdf]]&gt;</url>
    <title>Microbiological investigation of patients with acute lymphadenopathy and fever (QSOP 44)</title>
    <publicationDate>2008-12-11T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ SYPHILIS,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,VACCINE PREVENTABLE DISEASES,RUBELLA,TREPONEMA PALLIDUM,MICROORGANISM,BACTERIA,VIRUSES,RUBELLA VIRUS,CYTOMEGALOVIRUS (CMV),EPSTEIN-BARR VIRUS (EBV),HUMAN IMMUNODEFICIENCY VIRUS (HIV)]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Standard Method (NSM) aims to explain the microbiological investigation of patienstw with acute lymphadenopathy and fever.&lt;/P&gt;
&lt;P&gt;The following infections will be covered:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Epstein Barr Virus (EBV)&lt;/LI&gt;
&lt;LI&gt;Cytomegalovirus (CMV)&lt;/LI&gt;
&lt;LI&gt;Toxoplasma gondii &lt;/LI&gt;
&lt;LI&gt;HIV&lt;/LI&gt;
&lt;LI&gt;Rubella&lt;/LI&gt;
&lt;LI&gt;Syphilis&lt;/LI&gt;
&lt;LI&gt;Lymphogranuloma venereum (LGV)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286139</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/reprint/355/15/1539.pdf]]&gt;</url>
    <title>Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB</title>
    <publicationDate>2006-10-12T00:00:00</publicationDate>
    <publisher>Massachusetts Medical Society</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,CONTACT,AIRBORNE,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,PREVENTION,ANTIBIOTICS,ANTIMICROBIALS,INFECTIONS,TREATMENT,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[  New diagnostic tools are urgently needed to interrupt the transmission of tuberculosis and multidrug-resistant tuberculosis. Rapid, sensitive detection of tuberculosis and multidrug-resistant tuberculosis in sputum has been demonstrated in proof-of-principle studies of the microscopic-observation drug-susceptibility (MODS) assay, in which broth cultures are examined microscopically to detect characteristic growth. ]]&gt;</body>
  </document>
  <document>
    <id>286141</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop40.pdf]]&gt;</url>
    <title>Milk agar with cetrimide (MSOP 40)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286142</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop41.pdf]]&gt;</url>
    <title>Milk plate count agar (MSOP 41)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health PrTotection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286144</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop22.pdf]]&gt;</url>
    <title>Minimum performance testing requirements for food and dairy standard methods (QSOP 22)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286145</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD002086]]&gt;</url>
    <title>Minocycline for acne vulgaris: efficacy and safety</title>
    <publicationDate>2003-01-20T00:00:00</publicationDate>
    <publisher>John Wiley and Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Minocycline is a tetracycline antibiotic that is commonly used in the treatment of moderate to severe acne vulgaris. Although it is more convenient for patients to take than first-generation tetracyclines, as it only needs to be taken once or twice a day and can be taken with food, it is more expensive. Concerns have also been expressed over its safety following the deaths of two patients taking the drug. There is a lack of consensus among dermatologists over the relative risks and benefits of minocycline. As most acne prescribing is undertaken by general practitioners, it is important that guidelines issued to them are based on the best available evidence rather than personal judgements.

Objectives
To collate and evaluate the evidence on the clinical efficacy of minocycline in the treatment of inflammatory acne vulgaris. Specific objectives were to compare the efficacy of minocycline with other drug treatments for acne and to collate information on the incidence of adverse drug reactions.

Search strategy
Randomised controlled trials (RCTs) of minocycline for acne vulgaris were identified by searching the following electronic databases; MEDLINE, EMBASE, Biosis, Biological Abstracts, International Pharmaceutical Abstracts, Cochrane Skin Group's Trial Register, Theses Online, BIDS ISI Science Citation Index, National Research Register, Current Controlled Trials and Bids Index to Scientific and Technical Proceedings. Other strategies used were scanning the references of articles retrieved, hand-searching of major dermatology journals and personal communication with trialists and drug companies.

Selection criteria
To be eligible for the review, studies had to be RCTs comparing the efficacy of minocycline at any dose to active or placebo control, in subjects with inflammatory acne vulgaris. Diagnoses of papulo-pustular, polymorphic and nodular acne were also accepted. Trials were not excluded on the basis of language.

Data collection and analysis
27 randomised controlled trials met the inclusion criteria and were included in this review. The comparators used were placebo (2 studies), oxytetracycline (1), tetracycline (6), doxycycline (7), lymecycline (2), topical clindamycin (3), topical erythromycin/zinc (1), cyproterone acetate/ ethinyloestradiol (1), oral isotretinoin (2), topical fusidic acid (1) and there was one dose response study. Two studies are ongoing and it remains to be clarified whether one further study is a RCT. Major outcome measures used in the trials included lesion counts, acne grades/severity scores, doctors' and patients' global assessments, adverse drug reactions and drop out rates. The quality of each study was assessed independently by two assessors and an effect size calculated where possible. An additional three RCTs and three safety studies were identified by searches conducted in November 2002; these will be reviewed for a major update in early 2003 when it is anticipated that the results of the two ongoing studies will be available.

Main results
The trials were generally small and of poor quality and in many cases the published reports were inadequate for our purpose. Pooling of the studies was not attempted due to the lack of common outcome measures and endpoints and the unavailability of some primary data. Although minocycline was shown to be an effective treatment for acne vulgaris, in only two studies was it found to be superior to other tetracyclines. Both of these were conducted under open conditions and had serious methodological problems. A third study showed it to be more effective than 2% fusidic acid, applied topically, against inflammatory lesions in mild to moderate acne. Differences in the way adverse drug reactions were identified could have accounted for the wide variation between studies in numbers of events reported. This meant that no overall evaluation could be made of incidence rates of adverse events associated with minocycline therapy. No RCT evidence was found to support the benefits of minocycline in acne resistant to other therapies and the dose response has only been evaluated up to eight weeks of therapy.

Authors' conclusions
Minocycline is likely to be an effective treatment for moderate acne vulgaris, but this review found no reliable RCT evidence to justify its continued use first-line, especially given the price differential and the concerns that still remain about its safety. Its efficacy relative to other acne therapies could not be reliably determined due to the poor methodological quality of the trials and lack of consistent choice of outcome measures. Similarly the relative risk of adverse drug reactions could not be ascertained reliably and no recommendations can be made concerning the appropriate dose that should be used. It is hoped that this review will highlight the inadequacy of acne trials in general and encourage improvements in methodological quality and standards of reporting.
-------------------------------------------------------------------------------
Synopsis
Minocycline is an effective antibiotic for acne treatment, although there are concerns about its safety and it is more expensive than other similar antibiotics.

The cause of acne is not fully understood but pores in the skin become blocked and infected due to a build up of excess skin oil, bacteria and other tissue. Antibiotics reduce bacteria and inflammation and minocycline is commonly prescribed to treat acne. It is however more expensive than other similar antibiotics and there are concerns about its safety. The review found that there was no reliable evidence that minocycline was better than any other acne treatment and that more research is needed.]]&gt;</body>
  </document>
  <document>
    <id>286147</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/abstract/71005690/ABSTRACT]]&gt;</url>
    <title>Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly </title>
    <publicationDate>2000-03-31T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,INFLUENZA,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The success of influenza vaccination depends largely on the antigenic match between the influenza vaccine strains and the virus strains actually circulating during the season. In the past, this match has proved to be satisfactory in most seasons. In the 1997/1998 season, however, hemagglutination inhibition (HI) assays with ferret antisera indicated a considerable mismatch between the H3N2 vaccine component and the most prevalent epidemic influenza A(H3N2) virus. The results from antigenic analyses using pre- and postvaccination serum samples from volunteers of various ages, including residents of nursing homes who were more than 60 years of age, were in good agreement with the results obtained with ferret antisera. Homologous serum antibody responses to the H3N2 vaccine component as well as the cross-reactivity of the induced antibodies to the epidemic H3N2 strain, declined with increasing age of the vaccinees. As a consequence of these two effects, 84% of the vaccinees over 75 years of age did not develop HI antibody titers 40 against the major H3N2 virus variant of 1997/1998, suggesting that they were not protected against infection with this virus variant. These findings support the current policy of the World Health Organization (WHO), which is to base worldwide influenza virus surveillance on results predominantly obtained by antigenic analyses of influenza virus isolates with ferret antisera in HI tests. If an antigenic mismatch is observed, the protective efficacy of the vaccine, especially for the elderly, may be insufficient. The observations also support the current policy to include the elderly in serologic efficacy trials.]]&gt;</body>
  </document>
  <document>
    <id>325712</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/MMR-jab-autism-rates.aspx]]&gt;</url>
    <title>MMR jab has not raised autism</title>
    <publicationDate>2009-09-23T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MUMPS,MEASLES,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,MEASLES,VACCINE PREVENTABLE DISEASES,RUBELLA,CHILDHOOD VACCINES,MEASLES VIRUS,MUMPS VIRUS,RUBELLA VIRUS,VIRUSES,MICROORGANISM,SEPT 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The MMR jab is "off the hook", The Guardian reported today, referring to controversial theories that the vaccination may be linked to autism. The newspaper said that new research shows that rates of autistic disorders are similar among adults and children, a finding that further undermines theories that the combined MMR jab is responsible for a supposed rise in cases over recent years.&lt;/P&gt;
&lt;P&gt;The Times reported that the research has spurred the National Autistic Society to get "off the fence" over the supposed link between MMR and autism. The organisation has previously taken a neutral position in the controversial debate but has updated its position statement on autism and the MMR vaccine, adding an acknowledgement that a weight of epidemiological evidence “indicates that there is no statistically significant link between the MMR vaccine and autism”.&lt;/P&gt;
&lt;P&gt;The report behind these stories is based on the findings from the latest Adult Psychiatric Morbidity Survey, carried out in 2007 by the National Centre for Social Research. The survey was completed by 7,400 adults living in English households, with a selection of participants also completing clinical interviews to further investigate mental illness including autistic spectrum disorders (ASD). &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;There are some important issues that should be highlighted:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Only 19 people had a clinically confirmed ASD in phase two of the study. The researchers estimate that if everyone in phase one had been re-interviewed, a total of 72 cases would have been identified. &lt;/LI&gt;
&lt;LI&gt;The number of people confirmed to have ASD is a small sample, so further comparisons between those with and without ASD (for example, in terms of their demographics) should be interpreted cautiously. The researchers say that “great caution is required in interpreting the population distribution of ASD (particularly among women)” because of the small number of ASD cases clinically identified. &lt;/LI&gt;
&lt;LI&gt;Although an association was found between ASD and demographics (a finding that ASD is associated with lower education, greater deprivation, lower IQ and so on) this cannot be interpreted in a causal context. A study design such as this, which is cross-sectional, cannot establish causal links. &lt;/LI&gt;
&lt;LI&gt;The report itself does not mention MMR, but this issue is raised by the NHS’ Information Centre in an accompanying press release. This says, “If MMR were a factor in the development of the condition, prevalence would be expected to be higher among children and young adult age bands because MMR was introduced in 1990/91 and only those currently aged in their early twenties or younger have been routinely offered it.” This seems reasonable. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This report provides further evidence that adds to the many studies showing no link between MMR and autism. These findings will be welcomed by parents, doctors and many others who have been involved in investigating the controversial link first suggested by Dr Andrew Wakefield in 1998.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections/mental-health/mental-health-surveys/autism-spectrum-disorders-in-adults-living-in-households-throughout-england--report-from-the-adult-psychiatric-morbidity-survey-2007" target="_blank"&gt;Autism Spectrum Disorders in adults living in households throughout England - report from the Adult Psychiatric Morbidity Survey 2007&lt;/A&gt;. NHS Information Centre, September 22&amp;nbsp;2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ic.nhs.uk/news-and-events/press-office/press-releases/september-2009/one-in-a-hundred-adults-have-an-autism-spectrum-disorder-says-pioneering-new-study" target="_blank"&gt;Press release&lt;/A&gt;. NHS Information Centre, September 22 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286150</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/abstract/99018529/ABSTRACT]]&gt;</url>
    <title>Molecular diagnosis of influenza.</title>
    <publicationDate>2002-08-22T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The past decade has seen tremendous developments in molecular diagnostic techniques. In particular, the development of PCR technology has enabled rapid and sensitive viral diagnostic tests to influence patient management. Molecular methods used directly on clinical material have an important role to play in the diagnosis and surveillance of influenza viruses. Molecular diagnostic tests that allow timely and accurate detection of influenza are already implemented in many laboratories. The combination of automated purification of nucleic acids with real-time PCR should enable even more rapid identification of viral pathogens such as influenza viruses in clinical material. The recent development of DNA microarrays to identify either multiple gene targets from a single pathogen, or multiple pathogens in a single sample has the capacity to transform influenza diagnosis. While molecular methods will not replace cell culture for the provision of virus isolates for antigenic characterisation, they remain invaluable in assisting our understanding of the epidemiology of influenza viruses.]]&gt;</body>
  </document>
  <document>
    <id>308652</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/tb/features_archive/policy_statement.pdf]]&gt;</url>
    <title>Molecular Line Probe Assays for rapid screening of patients at risk of multi drug-resistant tuberculosis (MDR – TB) : Policy statement</title>
    <publicationDate>2008-06-27T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,DIAGNOSIS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Multidrug-resistant tuberculosis (MDR-TB) poses a formidable challenge to TB control due to its complex diagnostic and treatment challenges. The annual global MDR-TB burden is estimated at around 490 000 cases, or 5% of the global TB burden; however, less than 5% of existing MDR-TB patients are currently being diagnosed as a result of serious laboratory capacity constraints. Alarming increases in MDR-TB, the emergence of extensively drugresistant TB (XDR-TB), potential institutional transmission, and rapid mortality of MDR-TB and XDR-TB patient with HIV co-infection, have highlighted the urgency for rapid screening methods.&lt;/P&gt;
&lt;P&gt;Conventional methods for mycobacteriological culture and drug susceptibility testing (DST) are slow and cumbersome, requiring sequential procedures for isolation of mycobacteria from clinical specimens, identification of Mycobacterium tuberculosis complex, and in vitro testing of strain susceptibility to anti-TB drugs. During this time patients may be inappropriately treated, drug resistant strains may continue to spread, and amplification of resistance may occur. Novel technologies for rapid detection of anti-TB drug resistance have therefore become a priority in TB research and development, and molecular line probe assays focused on rapid detection of rifampicin resistance (alone or in combination with isoniazid) are most advanced.&lt;/P&gt;
&lt;P&gt;Line probe assay technology involves the following steps: First, DNA is extracted from M. tuberculosis isolates or directly from clinical specimens. Next, polymerase chain reaction (PCR) amplification of the resistance-determining region of the gene under question is performed using biotinylated primers. Following amplification, labeled PCR products are hybridized with specific oligonucleotide probes immobilized on a strip. Captured labeled hybrids are detected by colorimetric development, enabling detection of the presence of M. tuberculosis complex, as well as the presence of wild-type and mutation probes for resistance. If a mutation is present in one of the target regions, the amplicon will not hybridize with the relevant probe. Mutations are therefore detected by lack of binding to wild-type probes, as well as by binding to specific probes for the most commonly occurring mutations. The post-hybridization reaction leads to the development of coloured bands on the strip at the site of probe binding and is observed by eye.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286151</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dermatology.cdlib.org/92/reviews/molluscum/diven.html]]&gt;</url>
    <title>Molluscum Contagiosum - Dermatology Online Journal</title>
    <publicationDate>2003-03-01T00:00:00</publicationDate>
    <publisher>Dermatology Online Journal</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Molluscum contagiosum is a disease caused by a poxvirus of the Molluscipox virus genus that produces a benign self-limited papular eruption of multiple umbilicated cutaneous tumors. This common viral disease is confined to the skin and mucous membranes. Transmission requires direct contact with infected hosts or contaminated fomites. It is generally thought to infect humans exclusively, but there are a few isolated reports of Molluscum contagiosum occurring in chickens, sparrows, pigeons, chimpanzees, kangaroos, a dog, and a horse. The infection is found worldwide and has a higher incidence in children, sexually active adults, and those who are immunodeficent.]]&gt;</body>
  </document>
  <document>
    <id>286156</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://thorax.bmj.com/cgi/rapidpdf/thx.2006.073916v1]]&gt;</url>
    <title>Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective</title>
    <publicationDate>2007-07-05T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background: In 1998, the World Health Organisation (WHO) and the International Union Against Tuberculosis and Lung Disease (IUATLD) published recommendations standardising the evaluation of tuberculosis treatment outcome in Europe. These guidelines fail to account for clinically appropriate alterations in the management of patients. 

Objectives: To evaluate tuberculosis treatment outcome in England, Wales and Northern Ireland by re-defining the outcome criteria and investigate factors associated with unsuccessful treatment outcome 12 months after notification. 

Methods: This was a prospective analysis of a cohort of patients diagnosed in England, Wales and Northern Ireland and reported to the Enhanced Tuberculosis Surveillance system in 2001 and 2002. Proportions of success and failure were calculated based on a new set of criteria following discussion with clinicians treating tuberculosis cases. Logistic regression was used to study risk factors for unsuccessful treatment outcome. 

Results: A total of 13,048 cases were notified in the study period. Of the 2,676 that were identified as new sputum smear-positive pulmonary cases, 2,209(82.5%) had treatment outcome data reported. Using the WHO/IUATLD criteria, 76.8% were classified as successful. In contrast, applying the new criteria, the success rate was 87.5%. This rate exceeds the 85% success target set by the WHO. Risk factors for unsuccessful treatment outcome included male sex (OR 1.27; 95%CI 1.08-1.49), being elderly (P-trend &lt;0.001), having pulmonary tuberculosis (OR 1.28; 95%CI 1.08-1.53), and having resistance to any anti-tuberculosis drug (OR 1.90; 95%CI 1.44-2.52). 

Conclusion: The proportion of tuberculosis cases with a successful treatment outcome exceeded the target of 85% success rate based on the modified outcome categories. Although the tuberculosis treatment outcome criteria set by WHO/IUATLD appear to be clear, they mix measures of process and outcome. Further refinement may be necessary in low-incidence high-income countries, especially those with a high mortality among the elderly.]]&gt;</body>
  </document>
  <document>
    <id>286157</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop6.pdf]]&gt;</url>
    <title>Monitoring, maintenance and calibration of autoclaves (for the purposes of UKAS accreditation) (QSOP 6)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286158</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.cambridge.org/action/displayAbstract?fromPage=online&amp;aid=1344820]]&gt;</url>
    <title>Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods</title>
    <publicationDate>2007-02-12T00:00:00</publicationDate>
    <publisher>Cambridge University Press</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,INFLUENZA,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper compared the burden of illness due to a spectrum of respiratory diagnostic categories among persons presenting in a sentinel general practice network in England and Wales during periods of influenza and of respiratory syncytial virus (RSV) activity. During all periods of viral activity, incidence rates of influenza-like illness, bronchitis and common cold were elevated compared to those in baseline periods. The clinical burden of disease associated with RSV is as great if not greater than influenza in patients of all ages presenting to general practitioners.]]&gt;</body>
  </document>
  <document>
    <id>286160</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jech.bmj.com/cgi/reprint/59/7/586?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=pannell&amp;andorexactfulltext=and&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Mortality in children from influenza and respiratory syncytial virus</title>
    <publicationDate>2005-07-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Study objective: To quantify mortality attributable to influenza and respiratory syncytial virus (RSV) infection in children.

Design and methods: Comparison of death rates (all cause and certified respiratory) in England over winters 1989/90 to 1999/00 during and outside influenza and RSV circulation periods. Virus active weeks were defined from clinical and virological surveillance data. Excess deaths associated with weeks of either influenza or RSV activity over virus non-active weeks were estimated in each winter for age groups 1–12 months, 1–4, 5–9, and 10–14 years. The estimate obtained was allotted to influenza and RSV in the proportion derived from independent separate calculations for each virus.

Main results: Average winter respiratory deaths attributed to influenza in children 1 month–14 years were 22 and to RSV 28; and all cause deaths to influenza 78 and to RSV 79. All cause RSV attributed deaths in infants 1–12 months exceeded those for influenza every year except 1989/90; the average RSV and influenza attributed death rates were 8.4 and 6.7 per 100 000 population respectively. Corresponding rates for children 1–4 years were 0.9 and 0.8 and for older children all rates were 0.2 or less, except for an influenza rate of 0.4 in children 10–14 years.

Conclusions: Influenza and RSV account for similar numbers of deaths in children. The impact varies by winter and between age groups and is considerably underestimated if analysis is restricted to respiratory certified deaths. Summing the impact over the 11 winters studied, compared with influenza RSV is associated with more deaths in infants less than 12 months, almost equal numbers in children 1–4 years, and fewer in older children. Improved information systems are needed to investigate paediatric deaths.]]&gt;</body>
  </document>
  <document>
    <id>286161</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop42.pdf]]&gt;</url>
    <title>Motility nitrate medium (MSOP 42)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,FOOD/WATER,DIGESTIVE TRACT,TRANSMISSION MODE,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286162</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp21.pdf]]&gt;</url>
    <title>Motility test (BSOP TP 21)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286163</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop30.pdf]]&gt;</url>
    <title>MRSA selective media (MSOP 30)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CARDIOVASCULAR,BODY PART AFFECTED,BLOOD AND BODY FLUIDS,INFECTIONS,MICROORGANISM,BACTERIA,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286164</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.current-reports.com/article_frame.cfm?PubID=NR07-6-1-02&amp;Type=Abstract=Multidrug%2Dresistant%20tuberculous%2]]&gt;</url>
    <title>Multidrug-resistant tuberculous meningitis.</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Current Medicine Group LLC</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,CONTACT,BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,MENINGOCOCCAL MENINGITIS,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TREATMENT,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Multidrug-resistant tuberculous meningitis is now appearing worldwide, including in the United States, and is difficult to diagnose and treat. We discuss methods to diagnose tuberculous meningitis, review current and experimental assays for determining drug resistance, and consider approaches to management of the patient. We review the epidemiology of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in both pulmonary and meningeal infections, discuss promising molecular methods for determining drug resistance, and review current approaches toward treatment of patients. The incidence of multidrug-resistant tuberculous meningitis is increasing, and diagnosing and treating these patients will be a major challenge. There is a need to improve rapid methods of isolating the organism from cerebrospinal fluid, to advance molecular methods to rapidly test the isolate for antibiotic sensitivity, and to develop new antituberculosis drugs, especially ones that cross the blood-cerebrospinal fluid barrier.]]&gt;</body>
  </document>
  <document>
    <id>308617</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/ncidod/EID/vol12no05/pdfs/04-1339.pdf]]&gt;</url>
    <title>Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom.</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Centers for Disease Control and Prevention</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The United Kingdom Health Protection Agency Mycobacterium Reference Unit offers a national “Fastrack” molecular service for detecting Mycobacterium tuberculosis complex (MTBC) and rifampin resistance by using the INNO-LiPA Rif.TB assay. We analyzed the service in a routine, nontrial context of 1,997 primary clinical specimens, including 658 nonrespiratory specimens. The overall adjusted concordance, sensitivity, specificity, positive predictive&lt;BR&gt;value, and negative predictive value for detecting MTBC were 91.2%, 85.2%, 96.2%, 95.7%, and 86.7%, respectively (unadjusted, 86.7%, 85.2%, 88.2%, 86.9%, and 86.7%), when false-positive samples from patients (n = 83) with a known microbiologic diagnosis of MTBC or patients receiving current or recent antituberculous treatment were excluded. The parameters for detecting rifampin resistance were 99.1%, 95.0%, 99.6%, 92.7%, and 99.7%, respectively. The assay enabled earlier diagnosis of MTBC and rifampin resistance (15.2 days) compared with culturebased techniques (30.7 days).]]&gt;</body>
  </document>
  <document>
    <id>286168</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp22.pdf]]&gt;</url>
    <title>Nagler test (BSOP TP22)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,DIGESTIVE TRACT,BODY PART AFFECTED,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>320024</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/publications/reports/NCSPa-rprt-07_08.pdf]]&gt;</url>
    <title>NCSP: Five years - Annual report of the National Chlamydia Screening Programme in England 2007/08</title>
    <publicationDate>2008-11-28T00:00:00</publicationDate>
    <publisher>National Chlamydia Screening Programme</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,CHLAMYDIA,CHLAMYDIA,SEXUAL HEALTH,WOMEN'S HEALTH,INFECTIONS,BACTERIA,CHLAMYDIA,MICROORGANISM,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Annual report of the National Chlamydia Screening Programme in England 2007/08.&lt;/P&gt;
&lt;P&gt;See previous reports here:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/publications/reports/NCSPa-rprt-06_07.pdf" target="_blank"&gt;November 2007&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/publications/reports/NCSPa-rprt-05_06.pdf" target="_blank"&gt;November 2006&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/publications/reports/NCSPa-rprt-04_05.pdf" target="_blank"&gt;November 2005&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/publications/reports/NCSPa-rprt-03_04.pdf" target="_blank"&gt;November 2004&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286179</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop4.pdf]]&gt;</url>
    <title>Neomycin fastidious anaerobe agar (MSOP 4)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286180</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://fn.bmj.com/cgi/reprint/82/3/F205]]&gt;</url>
    <title>Neonatal group B streptococcal infection in South Bedfordshire, 1993-1998</title>
    <publicationDate>1999-09-15T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,CARDIOVASCULAR,CONTACT,RESPIRATORY TRACT,INFECTIONS,MICROORGANISM,BACTERIA,STREPTOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Key messages
An incidence of early onset GBS infection of 1.15 per 1000 live births has been shown, with increasing incidence over the six year period studied 
The occurrence of late onset, as well as early onset, disease is associated with the presence of risk factors at the time of delivery 
This high prevalence of disease in the population served by the Luton and Dunstable Hospital suggests that a screening or risk factor based approach to prevention would be cost effective ]]&gt;</body>
  </document>
  <document>
    <id>393446</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/common-cold-viruses-fought-in-cells.aspx]]&gt;</url>
    <title>New clue to fighting viruses</title>
    <publicationDate>2010-11-02T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,RHINOVIRUS,COMMON COLD,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A cure for the common cold may be on the way after “a remarkable discovery in a Cambridge laboratory”, The Independent&amp;nbsp; has reported. The newspaper said that new research has identified a previously unkown mechanism that allows the immune system to fight viruses even after they have infected cells.&lt;/P&gt;
&lt;P&gt;In the study, researchers found that antibodies that attached themselves to a virus were able to follow it into cells and help to destroy the virus before it started to reproduce. This is in contrast to the previous understanding that antibodies did not enter cells and were only effective at fighting infection before viruses invade cells.&lt;/P&gt;
&lt;P&gt;This study provides an interesting insight into how viruses and antibodies behave in the body, and uncovers mechanisms that could be targeted by future treatments or therapies. It is not known, however, how quickly or successfully this knowledge will result in remedies or treatments becoming available. This would require development and testing of new drugs, an uncertain process that usually takes a number of years.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study reports an interesting development in understanding of the role that antibodies play in helping the body to fight viral infections. When considering the likelihood of this leading to a ‘cure for the common cold’, it should be noted that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;This was a laboratory study undertaken in cells. A cure for or treatment of any viral disease will require a lot more research into drug development, safety assessment and clinical trials in animal and then human populations. This process would be lengthy and may not necessarily prove successful.&lt;/LI&gt;
&lt;LI&gt;The researchers did not actually use the virus that causes the ‘common cold’ (rhinovirus) in this study, but rather one that can cause other respiratory illnesses (adenovirus) often with similar symptoms.&lt;/LI&gt;
&lt;LI&gt;Viruses can vary in their structure and properties. The findings would need to be replicated with other types of viruses to know whether the antibody response is the same. However, the researchers did observe the effect in a number of different cells types and antibodies.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This is promising research that may lead to a number of useful medical developments. However, it should be emphasised that these may be a long way off.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Mallery, DL, McEwan, WA, Bidgood, SR, et al.&amp;nbsp;&lt;A href="http://www.pnas.org/cgi/doi/10.1073/pnas.1014074107" target="_blank"&gt;Antibodies Q:1 mediate intracellular; 2 immunity through tripartite motif-containing 21 (TRIM21)&lt;/A&gt;. &lt;EM&gt;PNAS 2010&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>328703</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/blood-infection-accident-research.aspx]]&gt;</url>
    <title>New clues on deadly blood infection</title>
    <publicationDate>2009-10-26T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,BACTERAEMIA / SEPTICAEMIA,TREATMENT,OTHER TREATMENT METHODS,ADDED 2009,OCT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have identified an antibody that could “minimise the major internal bleeding seen in traumas like bullet wounds and car crashes”, according to BBC News.&lt;/P&gt;
&lt;P&gt;The research in question found that mice, primates and humans who had serious blood infections (sepsis) also had high levels of a protein called histone in their blood.&lt;/P&gt;
&lt;P&gt;In intact cells, DNA is usually wrapped around this protein, but the newspaper reported that when the cell is damaged the protein is released into the blood, where the scientists believe it can cause internal bleeding by damaging the lining of blood vessel. The researchers found that blocking the actions of histone with an antibody stopped the toxic effects of the protein in mice with sepsis, allowing them to recover from the infection.&lt;/P&gt;
&lt;P&gt;This research identified a potential role for histones in sepsis. Although the results suggested that histones may play a similar role in sepsis in primates, including humans, this is not yet conclusive. The study was limited as it did not state how many baboon and human samples were tested and what proportion of these samples contained histones, so it is unclear if histones increase in the blood stream in all sepsis cases.&lt;/P&gt;
&lt;P&gt;Further research will be needed to confirm the findings in more people with sepsis, and to look at whether histones play a role in other inflammatory diseases. It is important to note that this study does not indicate whether histones play a role in internal bleeding related to non-inflammatory causes, such as accidents.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has identified a potential role for histones in sepsis, a condition that kills several thousand people a year. The majority of the research was carried out on mice, but some experiments on stored blood samples from baboons and humans with sepsis have also identified histones in their blood. Although the results suggest that histones may play a similar role in sepsis in primates, including humans, this is not yet conclusive.&lt;/P&gt;
&lt;P&gt;In particular, the researchers did not report how many baboon and human samples they tested, and what proportion of these samples contained histones, so it is not clear if histones are increased in all cases of sepsis. In addition, no control blood samples from humans without sepsis were tested and this research only looked at sepsis and not other diseases.&lt;/P&gt;
&lt;P&gt;Overall, it seems that further research will be needed to confirm the findings in more humans with sepsis and to look at whether histones play a role in other inflammatory diseases. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Xu J, Zhang X, Pelayo R &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2053.html" target="_blank"&gt;Extracellular histones are major mediators of death in sepsis&lt;/A&gt;. &lt;EM&gt;Nature Medicine&lt;/EM&gt; [published online] October 25 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>328703</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/blood-infection-accident-research.aspx]]&gt;</url>
    <title>New clues on deadly blood infection</title>
    <publicationDate>2009-10-26T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,BACTERAEMIA / SEPTICAEMIA,TREATMENT,OTHER TREATMENT METHODS,ADDED 2009,OCT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have identified an antibody that could “minimise the major internal bleeding seen in traumas like bullet wounds and car crashes”, according to BBC News.&lt;/P&gt;
&lt;P&gt;The research in question found that mice, primates and humans who had serious blood infections (sepsis) also had high levels of a protein called histone in their blood.&lt;/P&gt;
&lt;P&gt;In intact cells, DNA is usually wrapped around this protein, but the newspaper reported that when the cell is damaged the protein is released into the blood, where the scientists believe it can cause internal bleeding by damaging the lining of blood vessel. The researchers found that blocking the actions of histone with an antibody stopped the toxic effects of the protein in mice with sepsis, allowing them to recover from the infection.&lt;/P&gt;
&lt;P&gt;This research identified a potential role for histones in sepsis. Although the results suggested that histones may play a similar role in sepsis in primates, including humans, this is not yet conclusive. The study was limited as it did not state how many baboon and human samples were tested and what proportion of these samples contained histones, so it is unclear if histones increase in the blood stream in all sepsis cases.&lt;/P&gt;
&lt;P&gt;Further research will be needed to confirm the findings in more people with sepsis, and to look at whether histones play a role in other inflammatory diseases. It is important to note that this study does not indicate whether histones play a role in internal bleeding related to non-inflammatory causes, such as accidents.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has identified a potential role for histones in sepsis, a condition that kills several thousand people a year. The majority of the research was carried out on mice, but some experiments on stored blood samples from baboons and humans with sepsis have also identified histones in their blood. Although the results suggest that histones may play a similar role in sepsis in primates, including humans, this is not yet conclusive.&lt;/P&gt;
&lt;P&gt;In particular, the researchers did not report how many baboon and human samples they tested, and what proportion of these samples contained histones, so it is not clear if histones are increased in all cases of sepsis. In addition, no control blood samples from humans without sepsis were tested and this research only looked at sepsis and not other diseases.&lt;/P&gt;
&lt;P&gt;Overall, it seems that further research will be needed to confirm the findings in more humans with sepsis and to look at whether histones play a role in other inflammatory diseases. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Xu J, Zhang X, Pelayo R &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2053.html" target="_blank"&gt;Extracellular histones are major mediators of death in sepsis&lt;/A&gt;. &lt;EM&gt;Nature Medicine&lt;/EM&gt; [published online] October 25 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330280</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/blood-infection-accident-research.aspx]]&gt;</url>
    <title>New clues on deadly blood infection</title>
    <publicationDate>2009-10-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,BACTERAEMIA / SEPTICAEMIA,ADDED 2009,OCT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have identified an antibody that could “minimise the major internal bleeding seen in traumas like bullet wounds and car crashes”, according to BBC News. &lt;/P&gt;
&lt;P&gt;The research in question found that mice, primates and humans who had serious blood infections (sepsis) also had high levels of a protein called histone in their blood.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has identified a potential role for histones in sepsis, a condition that kills several thousand people a year. The majority of the research was carried out on mice, but some experiments on stored blood samples from baboons and humans with sepsis have also identified histones in their blood. Although the results suggest that histones may play a similar role in sepsis in primates, including humans, this is not yet conclusive. &lt;/P&gt;
&lt;P&gt;In particular, the researchers did not report how many baboon and human samples they tested, and what proportion of these samples contained histones, so it is not clear if histones are increased in all cases of sepsis. In addition, no control blood samples from humans without sepsis were tested and this research only looked at sepsis and not other diseases.&lt;/P&gt;
&lt;P&gt;Overall, it seems that further research will be needed to confirm the findings in more humans with sepsis and to look at whether histones play a role in other inflammatory diseases. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Xu J, Zhang X, Pelayo R &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2053.html" target="_blank"&gt;Extracellular histones are major mediators of death in sepsis&lt;/A&gt;. &lt;EM&gt;Nature Medicine&lt;/EM&gt; [published online] October 25 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330280</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/blood-infection-accident-research.aspx]]&gt;</url>
    <title>New clues on deadly blood infection</title>
    <publicationDate>2009-10-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,BACTERAEMIA / SEPTICAEMIA,ADDED 2009,OCT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have identified an antibody that could “minimise the major internal bleeding seen in traumas like bullet wounds and car crashes”, according to BBC News. &lt;/P&gt;
&lt;P&gt;The research in question found that mice, primates and humans who had serious blood infections (sepsis) also had high levels of a protein called histone in their blood.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has identified a potential role for histones in sepsis, a condition that kills several thousand people a year. The majority of the research was carried out on mice, but some experiments on stored blood samples from baboons and humans with sepsis have also identified histones in their blood. Although the results suggest that histones may play a similar role in sepsis in primates, including humans, this is not yet conclusive. &lt;/P&gt;
&lt;P&gt;In particular, the researchers did not report how many baboon and human samples they tested, and what proportion of these samples contained histones, so it is not clear if histones are increased in all cases of sepsis. In addition, no control blood samples from humans without sepsis were tested and this research only looked at sepsis and not other diseases.&lt;/P&gt;
&lt;P&gt;Overall, it seems that further research will be needed to confirm the findings in more humans with sepsis and to look at whether histones play a role in other inflammatory diseases. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Xu J, Zhang X, Pelayo R &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2053.html" target="_blank"&gt;Extracellular histones are major mediators of death in sepsis&lt;/A&gt;. &lt;EM&gt;Nature Medicine&lt;/EM&gt; [published online] October 25 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>321839</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/1HourClamydiaTest.aspx]]&gt;</url>
    <title>New one hour chlamydia test</title>
    <publicationDate>2009-07-31T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CHLAMYDIA,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MICROORGANISM,CHLAMYDIA,BACTERIA,AUGUST 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A urine test can diagnose male chlamydia within an hour, according to the BBC. The sexually transmitted infection, which often has no symptoms, can cause fertility problems and is estimated to be carried by 6.8% of young men in England. This new urine test reportedly enables same-day treatment after a one-hour wait for results.&lt;/P&gt;
&lt;P&gt;The well-conducted study behind this story has demonstrated that the Chlamydia Rapid Test is highly accurate in confirming that a man is not infected. It also has a good, but slightly lower, level of accuracy in correctly identifying that a man did have the infection. The technique also avoids using urethral swabs to extract samples from inside the penis.&lt;/P&gt;
&lt;P&gt;This quick, accurate test is an important step towards both reducing the growing problem of chlamydia in the young and providing rapid treatment for those affected. It is also hoped that men would be more likely to agree to this type of testing, as they currently get tested less often than women. Further testing in a larger set of samples will probably be needed before this test could be brought into current practice.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345959</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B75HM-4XPYVWN-H&amp;_user=8810565&amp;_coverDate=12%2F31%2F2009&amp;_rdoc=1&amp;_fmt=high&amp;_orig=search&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1251438502&amp;_rerunOrigin=scholar.google&amp;_acct=C000046143&amp;_version=1&amp;_url]]&gt;</url>
    <title>New vaccines against tuberculosis</title>
    <publicationDate>2009-12-04T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The only currently licensed tuberculosis (TB) vaccine, bacille Calmette Guérin, confers incomplete protection against tuberculosis, and is not safe in infants infected with the human immunodeficiency virus. A new, safe vaccine regimen, which better protects against lung disease, is urgently needed to control TB in high-burden countries. Multiple candidate vaccines have shown promise in preclinical studies, and are now entering phase 1 to 2B clinical trials. This article discusses progress in the field and issues surrounding safety, reactogenicity, immunogenicity, and efficacy testing of new TB vaccines.]]&gt;</body>
  </document>
  <document>
    <id>308980</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.elsevierhealth.com/periodicals/trstmh/article/PIIS0035920308001120/abstract]]&gt;</url>
    <title>New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil.</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MARCH 09,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The current tuberculosis (TB) vaccine Mycobacterium bovis BCG has been employed for some 70 years in Brazil and lessons from its use should be taken in account for the development or improvement of new TB vaccines. The vast majority of the current population has been vaccinated with BCG, with the possible requirement for a booster immunisation in adulthood for TB protection. BCG Moreau strain also protects against leprosy, meningitis and extrapulmonary forms of TB. Factors related to differences in strain, dosage and BCG administering protocol have been responsible for the variable efficacy of BCG. This vaccine is clearly affected by, as yet unclear, host and/or environmental variables. In this brief review, we describe some aspects of BCG immunisation observed in Brazil that may be of importance for improving or replacing BCG.]]&gt;</body>
  </document>
  <document>
    <id>286269</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/page.aspx?o=11676]]&gt;</url>
    <title>NICE - Guidance on the use of ribavirin and interferon alpha for Hepatitis C</title>
    <publicationDate>2000-10-01T00:00:00</publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BLOOD AND BODY FLUIDS,CARDIOVASCULAR,BODY PART AFFECTED,INFECTIONS,MICROORGANISM,VIRUSES,HEPATITIS C VIRUS,HEPATITIS VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance on the use of ribavirin and interferon alpha - drugs for the treatment of patients with the hepatitis C virus. Section 1 constitutes the institute's guidance and the remainder of the document is structured in the following way: clinical need and practice, the technology, evidence, implications for the NHS, further research, implementation, clinical audit advice and review of guidance. Appendix D contains information for patients.
Patient information can be found at http://www.nice.org.uk/page.aspx?o=17171]]&gt;</body>
  </document>
  <document>
    <id>286273</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/iuatld/ijtld/2007/00000011/00000011/art00004]]&gt;</url>
    <title>Nucleic acid amplification tests for the diagnosis of tuberculous lymphadenitis: a systematic review [Review Article]</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ SETTING: Lymphadenitis is the most common extra-pulmonary manifestation of tuberculosis (TB). Conventional diagnostic methods such as smear microscopy and culture are not very accurate for TB lymphadenitis. Nucleic acid amplification tests (NAAT) may offer additional diagnostic benefit.

OBJECTIVE: To assess, in a systematic review, the performance of NAAT for the diagnosis of tuberculous lymphadenitis.

DESIGN: We performed searches of the literature and identified 36 articles containing 49 comparisons between NAAT and a reference standard for TB lymphadenitis. Sensitivity and specificity estimates from each study were displayed in forest plots and summary receiver operating characteristic (SROC) plots.

RESULTS: Overall study quality was fair, but the quality of reporting was poor in many studies. Estimates of sensitivity and specificity of NAAT were highly heterogeneous across studies, possibly due to variations in populations, study quality and test techniques. Estimates of sensitivity varied between 2% and 100%, and specificity estimates varied between 28% and 100%. Commercial NAAT assays, assays that used more than 20 µl of template and reports containing discrepant analysis provided significantly higher diagnostic accuracy. Blinding, template volume and discrepant analysis may account for some of the observed heterogeneity.

CONCLUSION: Studies on NAAT for TB lymphadenitis produce highly variable and inconsistent results, precluding the determination of clinically meaningful estimates of accuracy. Study reports are not well standardised and often do not contain enough information. Because both false-positive and false-negative results are possible, NAATs will need to be applied in conjunction with conventional methods and interpreted in the context of clinical suspicion. ]]&gt;</body>
  </document>
  <document>
    <id>393383</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/y1720758mj421267/fulltext.pdf]]&gt;</url>
    <title>Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis</title>
    <publicationDate>2010-07-05T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,ANTIVIRALS,ANTIMICROBIALS,TREATMENT,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Treatment guidelines recommend dual nucleoside reverse transcriptase inhibitors (NRTI ) as a part of combination antiretroviral therapy. The objective of this study was to assess the relative efficacy and toxicity of the dual NRTI part of the regimen in antiretroviral-naïve HIV-1-infected adults. A systematic review and meta-analysis of randomized controlled trials assessing highly active antiretroviral therapy (HAART) for treatment-naïve HIV-infected adults with a 48-week follow-up were done. We searched the PubMed, CENTRAL, and EMBASE electronic databases up to April 2009. Proceedings from conferences were reviewed. Data were extracted independently by two reviewers. Primary outcome was viral suppression at 48 weeks. The odds ratio (OR) is reported with its corresponding 95% confidence interval (CI). Twenty-two randomized controlled trials, including 8,184 HIV-treatment-naïve patients, were included. The combination didanosine + lamivudine/emtricitabine (four trials, 1,148 patients) was more effective (OR 0.53, 95% CI 0.41-0.68) for viral load (VL) &amp;gt;50 copies/ml and less toxic (OR 0.52, 95% CI 0.36-0.76) for discontinuation due to adverse events (AE) than its comparators. The combination tenofovir + lamivudine/emtricitabine was more effective and less toxic (OR 0.75, 95% CI 0.58-0.96) only in the 144-week follow-up data (two trials, 1,119 patients). Abacavir + lamivudine had similar efficacy to its comparators (OR 0.81, 95% CI 0.8-1.1), but more AIDS-defining events (OR 3.22, 95% CI 1.24, 8.40). The once-daily combination didanosine + lamivudine/emtricitabine was found to be effective and tolerable. This combination, soon to be generic, should be compared to the current standard of care in a large randomized trial. An effective, safe, and inexpensive alternative to current options is needed.]]&gt;</body>
  </document>
  <document>
    <id>286274</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop43.pdf]]&gt;</url>
    <title>Nutrient agar (MSOP 43)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286275</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop34.pdf]]&gt;</url>
    <title>Nutrient broth (MSOP 34)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286277</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006443/pdf_fs.html]]&gt;</url>
    <title>Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis (Review)</title>
    <publicationDate>2007-07-18T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Omega-3 fatty acids (n-3, fish oil) have been shown to have anti-inflammatory properties. Therefore, n-3 therapy may be beneficial in chronic inflammatory disorders such as ulcerative colitis.

Objectives
To systematically review the efficacy and safety of n-3 for maintaining remission in ulcerative colitis (UC).

Search strategy
The following databases were searched from their inception without language restriction: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Healthstar, PubMed, and ACP journal club. Experts were contacted for unpublished data.

Selection criteria
Randomized placebo-controlled trials (RCT) of fish oil for maintenance of remission in UC were included. Studies must have enrolled patients (of any age group) who were in remission at the time of recruitment, and were followed for at least six months. The intervention must have been fish oil given in pre-defined dosage. Co-interventions were allowed only if they were balanced between the study groups. The primary outcome was relapse rate and the secondary outcome was frequency of adverse events. Other outcomes to assess efficacy were change in disease activity scores and time to first relapse.

Data collection and analysis
Two independent investigators reviewed studies for eligibility, extracted the data and assessed study quality. Meta-analysis weighted by the Mantel-Haenszel method was performed using RevMan 4.2.8 software. Random or fixed effect models were used according to degree of heterogeneity and subgroup analyses were performed to explore heterogeneity. A sensitivity analysis was performed excluding a study of questionable quality .

Main results
The three studies that were included used different formulation and dosing of n-3 but none used enteric coated capsules. The pooled analysis showed a similar relapse rate in the n-3 treated patients and controls (RR 1.02; 95% CI 0.51 to 2.03; P = 0.96). Combining the studies resulted in virtually no statistical heterogeneity (P = 0.93, I2 = 0%). Various subgroup and sensitivity analyses showed similar results. However, the total number of patients enrolled in these studies was small (n = 138). No significant adverse events were recorded in any of the studies and not enough data were available to pool the other secondary outcomes for meta-analysis.

Authors' conclusions
No evidence was found that supports the use of omega 3 fatty acids for maintenance of remission in UC. Further studies using enteric coated capsules may be justified. ]]&gt;</body>
  </document>
  <document>
    <id>286278</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp24.pdf]]&gt;</url>
    <title>ONPG (ß-galactosidase) test (BSOP TP24)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286279</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop36.pdf]]&gt;</url>
    <title>Operation of the Roche MagNA Pure LC automated nucleic acid extraction robot (VSOP 36)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>308920</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/content/abstract/300/4/423]]&gt;</url>
    <title>Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.</title>
    <publicationDate>2008-07-23T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,DIAGNOSIS,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB) and the emerging multidrug-resistant TB epidemic represent major challenges to human immunodeficiency virus (HIV) care and treatment programs in resource-limited settings. Tuberculosis is a major cause of mortality among patients with HIV and poses a risk throughout the course of HIV disease, even after successful initiation of antiretroviral therapy (ART). Progress in the implementation of activities directed at reducing TB burden in the HIV population lags far behind global targets. HIV programs designed for longitudinal care are ideally suited to implement TB control measures and have no option but to address TB vigorously to save patient lives, to safeguard the massive investment in HIV treatment, and to curb the global TB burden. We propose a framework of strategic actions for HIV care programs to optimally integrate TB into their services. The core activities of this framework include intensified TB case finding, treatment of TB, isoniazid preventive treatment, infection control, administration of ART, TB recording and reporting, and joint efforts of HIV and TB programs at the national and local levels.]]&gt;</body>
  </document>
  <document>
    <id>286280</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp25.pdf]]&gt;</url>
    <title>Optochin test  (BSOP TP 25)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,INFECTIONS,STREPTOCOCCUS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286281</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-11.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Conjunctivitis</title>
    <publicationDate>1995-06-22T00:00:00</publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,BACTERIA,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Optometric Clinical Practice Guideline on care of the patient with Conjunctivitis published by the American Optometric Association (AOA) in November 2002 (second edition).  The guideline contains two main sections together with conclusions and references.  The first section is a statement of the problem including a description and classification of conjunctivitis, epidemiology and clinical background.  The second is about the care process including diagnosis (patient history, ocular examination, supplemental testing) and management (basis for treatment, patient education, prognosis and follow up).   There are four appendices, optometric management of the patient with conjunctivits, procedures for obtaining cultures, smears and scrapings, frequency and composition of evaluation and management visits and the ICD-9-CM Classification of Conjunctivitis.

Please note that this guideline was developed in the US and that practice in the UK may differ. ]]&gt;</body>
  </document>
  <document>
    <id>286283</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947389589]]&gt;</url>
    <title>Oral Sex and Sexually Transmitted Infections - A small, but real risk</title>
    <publicationDate>2007-11-17T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BLOOD AND BODY FLUIDS,GENITAL WARTS (HPV),TRANSMISSION MODE,GONORRHOEA,SYPHILIS,CHLAMYDIA,HERPES,LYMPHOGRANULOMA VENEREUM (LGV),HIV/AIDS,HEPATITIS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,CHANCROID,CANDIDA,CHLAMYDIA,BACTERIAL VAGINOSIS,GENITAL HERPES,GENITAL WARTS (HPV),DONOVANOSIS,HIV,GONORRHOEA,PEDICULOSIS PUBIS,PUBLIC HEALTH,LGV,PELVIC INFLAMMATORY DISEASE,SYPHILIS,TRICHOMONAS,PROVISION OF CARE,SEXUAL HEALTH,WOMEN'S HEALTH,INFECTIONS,HEPATITIS C,HEPATITIS B,NEISSERIA GONORRHOEA,VIRUSES,HEPATITIS A VIRUS,HEPATITIS VIRUS,HEPATITIS B VIRUS,HEPATITIS C VIRUS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Oral sex is a broad term that includes fellatio (oral contact with the penis), cunnilingus (oral contact with the vagina), and anilingus (oral contact with the anus). It’s difficult to establish the actual risks associated with these forms of oral sex, and the contribution they may make to the overall number of newly diagnosed cases of HIV or other STIs within the UK. This is generally because it is rare for people to engage in oral sex in isolation from penetrative anal or vaginal intercourse as these are the primary routes by which HIV and other sexually transmitted infections (STIs) are spread.]]&gt;</body>
  </document>
  <document>
    <id>313769</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ecdc.europa.eu/en/Health_topics/novel_influenza_virus/2009_Outbreak/]]&gt;</url>
    <title>Outbreak of influenza A(H1N1) virus</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,ANTIMICROBIALS,ANTIVIRALS,VACCINES / IMMUNISATION,INFECTION CONTROL,DIAGNOSIS,TREATMENT,POST-EXPOSURE PROPHYLAXIS,INFLUENZA VACCINE,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,SWINE INFLUENZA,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The World Health Organization raised the level of pandemic alert from phase 4 to phase 5 on 29 April 2009, following sustained human-to-human transmission of the virus in Mexico and the United States. Countries around the world should now start implementing the actions foreseen in their national pandemic plans. Health experts have anticipated for many years that an influenza pandemic was due. Health officials in the European Union and its Member States have been working intensively on pandemic preparedness since 2005.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>286284</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/ecoli/O157/outbreak_01_07.pdf]]&gt;</url>
    <title>Outbreak Report. National outbreak of Vero cytotoxin-producing Escherichia coli O157 infection associated with lemon and coriander chicken wraps in England and Wales: June-July 2007</title>
    <publicationDate>2008-02-20T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,TRANSMISSION MODE,FOOD/WATER,DIGESTIVE TRACT,BODY PART AFFECTED,INFECTIONS,E. COLI,BACTERIA,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A national outbreak of Vero cytotoxin-producing Escherichia coli (VTEC) O157 infection first identified by Greater Manchester Health Protection Unit (GMHPU) affected 5 English regions and Wales. A joint investigation, led by Local and Regional Services on behalf of the Health Protection Agency (HPA), involved the Centre for Infections (CfI), Food Standards Agency, Environmental Health Departments in Stockport, Preston, and Milton Keynes, and the National Public Health Services, Wales. Case ascertainment included Scotland and Northern Ireland but no cases were reported and Health Protection Scotland and HPA Northern Ireland were not involved further.

Twelve cases were identified linked with lemon and coriander chicken wrap from a single supermarket chain, consumed between 25th and 29th of June. The wraps were supplied by a single food producer in Milton Keynes. Descriptive epidemiology together with results of phenotypic and genotypic tests on human isolates indicated a point source outbreak; the results of the case control study showed a very strong association between consumption of lemon and coriander chicken wrap from the single supermarket chain and being a case (OR 46.40; 95% CI 5.39-8; P= 0.0002).

The product was promptly removed from sale on 6th July by the supermarket on the identification of the first cases. Extensive testing of raw ingredients and products in the food production unit in Milton Keynes did not yield any positive results and nor did testing of faecal samples from staff in the unit.

The Outbreak Control Committee concludes that one contaminated batch of an ingredient in the chicken wrap probably caused the outbreak. Although VTEC O157 infection resulting from contaminated salad and ready to eat foods has previously been reported, this outbreak was unusual in the potentially large numbers at risk of exposure via a newly released food product.
The swift response to this outbreak was facilitated by the early alert of GMHPU by the Stockport microbiologist, the prompt and thorough investigation of the initial cases, quick sharing of information within the HPA, and effective co-ordination with Environmental Health colleagues, NHS laboratories and the Food Standards Agency.]]&gt;</body>
  </document>
  <document>
    <id>286285</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.eurosurveillance.org/em/v12n05/1205-222.asp]]&gt;</url>
    <title>Outbreaks of influenza and influenza-like illness in schools in England and Wales, 2005/06</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,TRANSMISSION MODE,INFLUENZA,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,INFLUENZA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In England and Wales, clinical reports from primary care showed that influenza activity for the season 2005/06 only rose above the base line for four weeks during February 2006. However, outbreaks of influenza-like illness and/or gastrointestinal infection in schools began to be reported to the Health Protection Agency, Centre for Infections in early January 2006. To quantify the type, size and the spread of these outbreaks a reporting form was distributed to local Health Protection Units in England and to Wales for retrospective and prospective weekly completion. 
Between weeks 48/05 and 11/06, a total of 688 school outbreaks were reported, including 658 outbreaks of influenza-like illness with or without other symptoms. The remaining 30 outbreaks listed as gastrointestinal only were excluded from the present analysis. Influenza B was confirmed in 70 outbreaks where testing took place. 61% of the outbreaks were reported from primary schools for children aged 4-11 years. This large scale outbreak in school children with flu-like illness across England and Wales was not picked up by most of the routine surveillance schemes, therefore, we believe that a school absentee monitoring and reporting system may be needed to give an early warning of increased influenza activity, especially for the mild form of the disease caused by influenza B virus. ]]&gt;</body>
  </document>
  <document>
    <id>286289</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp27.pdf]]&gt;</url>
    <title>Oxidation and fermentation of glucose test (BSOP TP27)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>327571</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Oxygen-treatment-and-swine-flu.aspx]]&gt;</url>
    <title>Oxygen therapy in swine flu</title>
    <publicationDate>2009-10-12T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,OTHER TREATMENT METHODS,TREATMENT,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,ADDED 2009,OCT 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A study published today in the Journal of the American Medical Assocation has looked at the outcomes of people with severe respiratory complications from swine flu who required a specific treatment to oxygenate their blood.&lt;/P&gt;
&lt;P&gt;The study was in all people with swine-flu associated acute respiratory distress syndrome (ARDS) in Australian and New Zealand intensive care units during the winter flu season. Patients were given extracorporeal membrane oxygenation (ECMO). This involves pumping a patient's blood through a machine that oxygenates it and removes carbon dioxide before pumping it back into the body.&lt;/P&gt;
&lt;P&gt;By the end of the study, 71% of patients had been successfully discharged from intensive care, 9% were still in intensive care, and about a fifth died (21%). The researchers say that this is a relatively low death rate considering the severity of their condition and the intensity of the ECMO treatment.&lt;/P&gt;
&lt;P&gt;Such studies are useful for planning purposes. The researchers estimate that the EU may need to provide ECMO to approximately 1,300 patients during this winter season.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has given an idea of how frequently ECMO might be required for cases of ARDS associated with swine flu. The study’s strengths include the fact that these patients are likely to represent all patients who received ECMO in Australia and New Zealand during the study period, so it is not likely to have been affected by biases in how patients were selected.&lt;/P&gt;
&lt;P&gt;Such figures are useful for planning. Using these findings, the researchers estimate the European Union might need to provide ECMO to about 1,300 patients during the upcoming winter season.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. &lt;EM&gt;JAMA&lt;/EM&gt; 2009; 302: Published online October 12&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286291</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Influenza/Guidelines/pandemicflupdf07.pdf]]&gt;</url>
    <title>Pandemic flu : clinical management of patients with an influenza-like illness during an influenza pandemic</title>
    <publicationDate>2006-03-29T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,RESPIRATORY INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,ANTIVIRALS,ANTIMICROBIALS,VACCINES / IMMUNISATION,PANDEMIC INFLUENZA,VACCINE PREVENTABLE DISEASES,INFLUENZA,INFLUENZA VACCINE,TREATMENT,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document is intended for use in the UK in the event that the World Health Organisation (WHO) declares that an influenza pandemic has started and the Department of Health in England has declared&amp;nbsp;UK Pandemic Alert Level 2 (cases of pandemic influenza identified within the UK).&amp;nbsp;It contains guidance regarding the treatment on pandemic influenza and covers treatment in both hospitals and the community for adults and children.&amp;nbsp;Once an influenza pandemic is under way users are urged to refer to the most up-to-date version of these guidelines from web-based access points.]]&gt;</body>
  </document>
  <document>
    <id>313771</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/entity/csr/disease/influenza/PIPGuidance09.pdf]]&gt;</url>
    <title>Pandemic influenza preparedness and response</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,RESPIRATORY INFECTIONS,VACCINES / IMMUNISATION,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,INFECTIONS,INFLUENZA VACCINE,POST-EXPOSURE PROPHYLAXIS,PANDEMIC INFLUENZA,TREATMENT,DIAGNOSIS,INFECTION CONTROL,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;WHO previously published pandemic preparedness guidance in 1999 and a revision of that guidance in 2005. Since 2005, there have been advances in many areas of preparedness and response planning. For example, stockpiles of antiviral drugs are now a reality and a WHO guideline has been developed to attempt to stop or delay pandemic influenza at its initial emergence. There is increased understanding of past pandemics, strengthened outbreak communications, greater insight on disease spread and approaches to control, and increasingly sophisticated statistical modeling of various aspects of influenza. Extensive practical experience has been gained from responding to outbreaks of highly pathogenic avian influenza A (H5N1) virus infection in poultry and humans, and from conducting pandemic preparedness and response exercises in many countries. There is greater understanding that pandemic preparedness requires the involvement of not only the health sector, but the whole of society. In 2007, the International Health Regulations (2005) (IHR, 2005) entered into force providing the international community with a framework to address international public health concerns.&lt;/P&gt;
&lt;P&gt;In light of these developments, WHO decided to update its guidance to enable countries to be better prepared for the next pandemic. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313570</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.eurosurveillance.org/images/dynamic/EE/V14N17/art19185.pdf]]&gt;</url>
    <title>Pandemic phase level 4: human cases of the novel influenza A/H1N1 strain confirmed in Scotland and Spain</title>
    <publicationDate>2009-04-30T00:00:00</publicationDate>
    <publisher>Eurosurveillance</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,RESPIRATORY INFECTIONS,INFLUENZA,INFECTIONS,POPULATION GROUPS,TRAVELLERS,ADULTS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,SWINE INFLUENZA,APRIL 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Due to the spread of the ongoing international outbreak of infections with a novel influenza A(H1N1) virus (the so-called ‘swine flu’), the WHO raised the alert level for pandemic influenza to Phase 4 on 27 April 2009. The first cases have been laboratory-confirmed on European territory, two in Spain and two in Scotland.&lt;/P&gt;
&lt;P&gt;The current outbreak is thought to have started in mid-March of this year, with human cases of the novel influenza virus detected in Mexico and the United States (US). As of today, 28 April, 40 confirmed cases have been reported from five different states in the US, six from Canada as well as 33 from Mexico including five deaths. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325312</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/Pandemicwaves.aspx]]&gt;</url>
    <title>Pandemic waves</title>
    <publicationDate>2009-08-14T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,PANDEMIC INFLUENZA,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,AUGUST 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An article in the Journal of the American Medical Association has questioned whether the prevailing belief that the current pandemic flu will return in a more dangerous second wave is justified. The authors also suggest that the second wave of the 1918 pandemic flu was less serious than first thought.&lt;/P&gt;
&lt;P&gt;They say that unproven assumptions about the course of the 1918 Spanish flu pandemic may be leading to misconceptions of what the swine flu virus may do. They say that if summer weather in the northern hemisphere slows the spread of the virus, then when a second increase in cases (the wave) arrives in the autumn/winter, it is by no means certain that any increases in transmissibility or complication rates will occur.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The authors acknowledge the difficulty of predicting the future course of this pandemic. They admit there is always a chance, however small, that the swine flu virus could mutate, with serious consequences for public health. This is the reason behind the prudent approach taken by international public health bodies.&lt;/P&gt;
&lt;P&gt;They conclude by advising readers to remember that, as Kierkegaard said about life, influenza epidemics are lived forwards and understood backwards.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Morens DM. and Taubenberger JK.&amp;nbsp;&lt;A href="http://jama.ama-assn.org/cgi/content/extract/302/6/679" target="_blank"&gt;Understanding Influenza Backward&lt;/A&gt;. JAMA. 2009;302(6):679-680.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>328023</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/paracetamol-vaccine-injection-research.aspx]]&gt;</url>
    <title>Paracetamol affects childhood jabs</title>
    <publicationDate>2009-10-16T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HEPATITIS,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,POLIO VACCINE (IPV),HAEMOPHILUS INFLUENZAE TYPE B VACCINE (HIB),DIPHTHERIA,MENINGITIS,WHOOPING COUGH (PERTUSSIS),POPULATION GROUPS,HEPATITIS B VACCINE,HEPATITIS B,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,POLIO,DIPHTHERIA,HAEMOPHILUS INFLUENZAE TYPE B (HIB),TETANUS,HAEMOPHILUS,BRAIN AND SPINAL CORD INFECTIONS,CLOSTRIDIUM,CHILDREN,VIRUSES,HEPATITIS B VIRUS,HEPATITIS VIRUS,MICROORGANISM,TRAVEL VACCINES,HAEMOPHILUS INFLUENZAE,BACTERIA,OCT 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Giving paracetamol to babies after routine vaccine jabs may lessen the effectiveness of the immunisation, according to BBC News.&lt;/P&gt;
&lt;P&gt;The study behind this coverage is an important and well-conducted trial in which 459 babies receiving their immunisations were either routinely given paracetamol in the 24 hours following their injection or were given none. Although the drug was clearly successful in reducing the risk of a fever developing, it was shown to reduce the immune response to the vaccine, suggesting that it would be less effective. However, although the preventative use of paracetamol had an effect on immune response, using the drug to lower existing fever did not.&lt;/P&gt;
&lt;P&gt;This means that parents should not be concerned about giving paracetamol to their child to treat a raised temperature or associated symptoms of pain and irritability. But if a baby has just had an immunisation, it may be wise only to give them paracetamol if they are unwell, and not to prevent symptoms from occurring.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is an important and well-conducted trial. It has found that routinely giving a baby paracetamol in the 24 hours following their childhood immunisations, although clearly successful in reducing the risk of fever developing, reduces the immune response to the vaccine. This suggests that the vaccination will be less effective.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Prymula R, Siegrist C-A, Chlibek R, &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T1B-4XFXPCC-11&amp;amp;_user=10&amp;amp;_coverDate=10/23/2009&amp;amp;_alid=1050769609&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_cdi=4886&amp;amp;_sort=r&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_ct=904&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=3c315bdb2222975fbc0659787bb704ab" target="_blank"&gt;Effect of prophylactic paracetamol administration&amp;nbsp; at time of&amp;nbsp; vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials&lt;/A&gt;. &lt;EM&gt;The Lancet&lt;/EM&gt; 2009; 374: 1339-1350&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286293</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://erj.ersjournals.com/cgi/content/abstract/30/4/728]]&gt;</url>
    <title>Patient choice promotes adherence in preventive treatment for latent tuberculosis</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>European Respiratory Society</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INDIVIDUAL INVOLVEMENT,PATIENT CHOICE,PPI IN PRACTICE,RESPIRATORY TRACT,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,TUBERCULOSIS,PATIENT AND PUBLIC INVOLVEMENT,INFECTIONS,MYCOBACTERIUM,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The aim of the present study was to compare the effect of patient choice on completion rates and adverse drug reactions for patients treated for latent tuberculosis infection (LTBI) using 3-month rifampicin and isoniazid treatment (3RH) or 6-month isoniazid treatment (6H). Data for all patients treated using 3RH or 6H for LTBI between 1998 and 2004 were analysed. In total, 675 patients attended for chemoprophylaxis. Of these, 314 received 3RH and 277 received 6H. From April 1, 2000, patients were offered a choice of regimen; 53.5% completed the regimen successfully, a further 10.3% potentially completed it successfully and 36.2% failed to complete treatment. Logistic regression analysis suggested that successful completion was more likely in patients who were younger (an association that was lost after removing all patients aged &lt;16 yrs), were offered a choice of regimen and attended all clinic visits before commencing treatment. Treatment was discontinued due to adverse reactions in 16 (5.1%) patients who were prescribed 3RH and 16 (5.8%) who were prescribed 6H. Treatment failure was most likely during the first 4 weeks of treatment for both regimens. At 13 weeks of treatment, more patients taking 6H had stopped compared with those completing the 3RH regimen. Drug costs were greater using 6H compared with 3RH. In conclusion, offering a choice of regimen improves completion. Most patients chose the 3-month rifampicin and isoniazid treatment over the 6-month isoniazid treatment. Adverse drug reaction rates between the two regimens were similar. ]]&gt;</body>
  </document>
  <document>
    <id>393928</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2010.02508.x/abstract]]&gt;</url>
    <title>Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review</title>
    <publicationDate>2010-04-29T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: To estimate the proportion of all-cause adult patient attrition from antiretroviral therapy (ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We identified cohorts within Ovid Medline, ISI Web of Knowledge, Cochrane Database of Systematic Reviews and four conference abstract archives. We summarized retention rates from studies describing observational cohorts from sub-Saharan Africa reporting on adult HIV 1- infected patients initiating first-line three-drug ART. We estimated all-cause attrition rates for 6, 12, 18, 24, or 36 months after ART initiation including patients who died or were lost to follow-up (as defined by the author), but excluding transferred patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: We analysed 33 sources describing 39 cohorts and 226 307 patients. Patients were more likely to be female (median 65%) and had a median age at initiation of 37 (range 34-40). Median starting CD4 count was 109 cells/mm(3). Loss to follow-up was the most common cause of attrition (59%), followed by death (41%). Median attrition at 12, 24 and 36 months was 22.6% (range 7%-45%), 25% (range 11%-32%) and 29.5% (range 13%-36.1%) respectively. After pooling data in a random-effects meta-analysis, retention declined from 86.1% at 6 months to 80.2% at 12 months, 76.8% at 24 months and 72.3% at 36 months. Adjusting for variable follow-up time in a sensitivity analysis, 24 month retention was 70.0% (range: 66.7%-73.3%), while 36 month retention was 64.6% (range: 57.5%-72.1%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Our findings document the difficulties in retaining patients in care for lifelong treatment, and the progress being made in raising overall retention rates.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330486</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://informahealthcare.com/doi/abs/10.1517/14656560903012377?cookieSet=1&amp;journalCode=eop]]&gt;</url>
    <title>Pediatric HIV: New opportunities to treat children</title>
    <publicationDate>2009-08-03T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,CHILDREN,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Treating HIV-infected children remains a challenge due to a lack of treatment options, appropriate drug formulations and, in countries with limited resources, insufficient access to diagnostic tests and treatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: To summarize current data concerning new opportunities to improve the treatment of HIV-infected children. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: This review includes data from the most recently published peer-reviewed publications, guidelines or presentations at international meetings concerning new ways to treat HIV-infected children. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results/Conclusions&lt;/STRONG&gt;: New WHO guidelines recommend starting combination antiretroviral treatment in all infants aged &amp;lt; 1 year. Although this is common practice in some high-income countries, implementation of these recommendations in countries with limited resources is still a challenge. There is still an important gap between the availability of licensed drugs in children compared with adults. There remains a need for further pharmacokinetic studies, and for more pediatric formulations of antiretroviral drugs with improved palatability.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286298</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/content/abstract/320/7228/150]]&gt;</url>
    <title>Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults</title>
    <publicationDate>2000-01-15T00:00:00</publicationDate>
    <publisher>British Medical Journal (BMJ)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,AIRBORNE,CONTACT,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT,MICROORGANISM,BACTERIA,VIRUSES,STREPTOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective: To assess whether treatment with penicillin for three days and the traditional treatment for seven days were equally as effective at accelerating resolution of symptoms in patients with sore throat compared with placebo. 
Design: Randomised double blind placebo controlled trial. 
Setting: 43 family practices in the Netherlands. 
Participants: 561 patients, aged 15-60 years, with sore throat for less than seven days and at least three of the four Centor criteriathat is, history of fever, absence of cough, swollen tender anterior cervical lymph nodes, and tonsillar exudate. 142 patients were excluded for medical reasons and 73 needed penicillin. 
Interventions: Patients were randomly assigned to penicillin V for seven days, penicillin V for three days followed by placebo for four days, or placebo for seven days. 
Main outcome measures: Resolution of symptoms in the first week, eradication of bacteria after two weeks, and recurrences of sore throat after two, four, and six months. 
Results: Symptoms resolved 1.9 and 1.7 days earlier in patients taking penicillin for seven days than in those taking penicillin for three days or placebo respectively. Symptoms resolved 2.5 days earlier in patients with group A streptococci and 1.3 days earlier in patients with high colony counts of non-group A streptococci. 23 (13%) of the placebo group had to be given antibiotics later in the week because of clinical deterioration; three developed a peritonsillar abscess. The eradication rate for group A streptococci was 72% in the seven day penicillin group, 41% in the three day penicillin group, and 7% in the placebo group. Sore throat recurred more often in the three day penicillin group than in the seven day penicillin or placebo groups. 
Conclusion: Penicillin treatment for seven days was superior to treatment for three days or placebo in resolving symptoms of sore throat in patients with group A streptococcal pharyngitis and, possibly, in those with non-group A streptococcal pharyngitis. ]]&gt;</body>
  </document>
  <document>
    <id>330904</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/122664881/abstract]]&gt;</url>
    <title>PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection</title>
    <publicationDate>2009-10-27T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,ANTIMICROBIALS,ANTIVIRALS,POPULATION GROUPS,CHILDREN,TREATMENT,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;PENTA Guidelines aim to provide practical recommendations for treating children with HIV infection in Europe. Changes to guidance since 2004 have been informed by new evidence and by expectations of better outcomes following the ongoing success of antiretroviral therapy (ART). Participation in PENTA trials of simplifying treatment is encouraged. The main changes are in the following sections:&lt;/P&gt;
&lt;P&gt;'When to start ART': Treatment is recommended for all infants, and at higher CD4 cell counts and percentages in older children, in line with changes to adult guidelines. The number of age bands has been reduced to simplify and harmonize with other paediatric guidelines. Greater emphasis is placed on CD4 cell count in children over 5 years, and guidance is provided where CD4% and CD4 criteria differ.&lt;/P&gt;
&lt;P&gt;'What to start with': A three-drug regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) with either a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (PI) remains the first choice combination. Lamivudine and abacavir are the NRTI backbone of choice for most children, based on long-term follow-up in the PENTA 5 trial. Stavudine is no longer recommended. Whether to start with an NNRTI or PI remains unclear, but PENPACT 1 trial results in 2009 may help to inform this. All PIs should be ritonavir boosted.&lt;/P&gt;
&lt;P&gt;Recommendations on use of resistance testing, therapeutic drug monitoring and HLA testing draw from data in adults and from European paediatric cohort studies.&lt;/P&gt;
&lt;P&gt;Recently updated US and WHO paediatric guidelines provide more detailed review of the evidence base. Differences between guidelines are highlighted and explained.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330489</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/nisc/jcamh/2008/00000020/00000002/art00004]]&gt;</url>
    <title>Personality disturbance in adolescents living with HIV/AIDS: A review</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,POPULATION GROUPS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2009,NOV 09,ADOLESCENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper presents a review of theoretical and empirical research on personality disturbance in adolescents living with HIV/AIDS. First we discuss the relationship between mental health in adolescents and HIV/AIDS, and second we provide an overview of personality disturbance in adolescence with particular attention given to: (a) the prevalence and presence of personality disturbance in adolescents living with HIV/AIDS (b) the effect of personality disturbance on compliance on antiretroviral treatment and (c) stress of an HIV diagnosis in adolescents with personality disturbance. In conclusion treatment issues and recommendations are discussed.]]&gt;</body>
  </document>
  <document>
    <id>286301</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.phmeg.org.uk/Documents/Headlice/phmeghl.htm]]&gt;</url>
    <title>PHMEG - Head Lice: a report for Consultants in Communicable Disease Control (CCDCs) The "Stafford Document" </title>
    <publicationDate>1998-05-08T00:00:00</publicationDate>
    <publisher>Public Health Medicine Environmental Group (PHMEG)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PARASITES,HEADLICE,LICE,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The "Stafford Document" includes general information on the diagnosis, prevention, treatment and control of head lice. There is information for primary care, community pharmacists, schools, head teachers and families. 

Published 8th May 1998 and due to be updated shortly.]]&gt;</body>
  </document>
  <document>
    <id>286303</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004551/pdf_fs.html]]&gt;</url>
    <title>Pin site care for preventing infections associated with external bone fixators and pins </title>
    <publicationDate>2004-01-26T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MUSCULOSKELETAL,BODY PART AFFECTED,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Metal pins are used to apply skeletal traction or external fixation devices in the management of orthopaedic fractures. These pins protrude through the skin and are therefore described as 'percutaneous' and much has been written on the management of the associated skin wound. The way in which percutaneous pins are treated may affect the incidence of pin site infection. Recommendations for care are not necessarily evidence based. This review set out to summarise the research evidence on the effect of pin site care on infection rates.

Objectives
To assess the effect on infection rates of different methods of cleansing and dressing orthopaedic percutaneous pin sites.

Search strategy
The following electronic databases were searched: Medline (from 1966), the Cochrane Central Register of Controlled Trials (2003 issue 1) and the Wounds Group Specialised Trials Register (March 2003). In addition reference lists of review articles and relevant trials were also searched and some handsearching undertaken.

Selection criteria
All randomised controlled trials (RCTs) in people comparing the effect on infection rates of different methods of cleansing or dressing orthopaedic percutaneous pin sites were evaluated.

Data collection and analysis
Two reviewers independently assessed the citations retrieved by the search strategies for reports of relevant RCTs.

Main results
Only one trial was eligible for inclusion in the review. Henry (1996) compared cleansing with 0.9% saline, cleansing with 70% alcohol and no cleansing and found significantly fewer infections in pin sites which had not been cleansed.

Authors' conclusions
There is very little evidence as to which pin site care regimen best reduces infection rates. Clearly there is a need for large RCTs to determine the best method of pin site management.
--------------------------------------------------------------------------------
Synopsis
No strong evidence about insertion, care and removal techniques for pins used for attaching traction or other fixation devices into broken arms and legs

Metal pins are sometimes used to apply traction or other external fixation devices into broken arms or legs. These pins pierce through the skin. The way they are inserted, cared for and removed may affect the frequency of infection. Different solutions are used for cleaning around pins, scabs may or may not be removed and massage might be used to drain fluids around the pin. There are different kinds of pins, loosening regimes and removal techniques. However, the review of trials found that there is little strong evidence to show which pin care techniques have the best outcomes.]]&gt;</body>
  </document>
  <document>
    <id>286007</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/Chiefmedicalofficerletters/DH_083812]]&gt;</url>
    <title>PL CMO (2008)3, PL CNO (2008)2, PL CPHO (2008)1: The influenza immunisation programme 2008/09</title>
    <publicationDate>2008-03-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,AIRBORNE,CONTACT,BODY PART AFFECTED,TRANSMISSION MODE,INFLUENZA,INFECTIOUS DISEASES,PREVENTION,PREVENTION AND CONTROL,INFECTIONS,VACCINES / IMMUNISATION,SEASONAL INFLUENZA,PANDEMIC INFLUENZA,INFLUENZA,VACCINE PREVENTABLE DISEASES,INFLUENZA VACCINE,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This letter from the Chief Medical Officer, the Chief Nursing Officer and the Chief Pharmaceutical Officer describes the 2008/2009 influenza immunisation campaign. &lt;/P&gt;
&lt;P&gt;This letter contains details of the annual influenza immunisation campaign, influenza immunisation for health and social care staff, and the poultry worker immunisation programme.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312506</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/Chiefmedicalofficerletters/DH_097550?IdcService=GET_FILE&amp;dID=190244&amp;Rendition=Web]]&gt;</url>
    <title>PL CMO (2009)1, PL CNO (2009)1, PL CPHO (2009)1: the influenza immunisation programme 2009/10</title>
    <publicationDate>2009-04-06T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,RESPIRATORY INFECTIONS,INFECTIOUS DISEASES,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,INFLUENZA VACCINE,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,APRIL 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This letter contains details of the annual influenza immunisation campaign, influenza immunisation for health and social care staff, and the poultry worker immunisation programme.]]&gt;</body>
  </document>
  <document>
    <id>345657</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2009/9789241597715_eng.pdf]]&gt;</url>
    <title>Planning the development of human resources for health for implementation of the Stop TB Strategy</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>World Health Organization and Centers for Disease Control &amp; Prevention</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Planning human resources to achieve the international goals and targets set for global control of tuberculosis (TB) is a complex and challenging management task. Furthermore, countries highly affected by the disease have the additional challenge of tackling a general workforce crisis, and&lt;BR&gt;managers of national TB control programmes are faced daily with the daunting tasks caused by this double crisis.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Managers of health systems are thus confronted by an enormous challenge, or double-bind: how to find the right balance between devoting sufficient staff time to specific diseases and meeting the general health needs of populations in a primary health-care environment. Health priorities compete for attention. Maximizing the quality and quantity of existing human resources to achieve one health goal without jeopardizing another is never an easy decision. Integrating human resources at all levels of the health system provides one way of serving the different&lt;BR&gt;needs for health care. To achieve such integration, close working ties between departments responsible for disease control, health planning, human resources, and health administration need to be established.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The central theme of this handbook points to the need for close&amp;nbsp; collaboration between, and coordination among, national TB control programmes and the departments of health system management or human resources for health of the Ministry of Health and their respective partners. This is necessary to ensure that the health workforce is able to carry out the specific tasks necessary to implement the Stop TB Strategy.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;By offering this practical guidance, we hope to fully equip managers of TB control programmes with the tools necessary for effective collaboration. This in turn will foster the development of integrated human resources equipped to deliver services for TB control within the context of primary health care to reach the TB-related Millennium Development Goals. This handbook offers an opportunity to help countries establish a balanced workforce that will respond to the gamut of primary health-care needs while rigorously pursuing the objective to stop TB.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286304</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop44.pdf]]&gt;</url>
    <title>Plate count agar (MSOP 44)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286305</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/milk_dairy/pdf/d3.pdf]]&gt;</url>
    <title>Plate count test at 21°C (pre-incubated) (D3)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286306</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/milk_dairy/pdf/d2.pdf]]&gt;</url>
    <title>Plate count test at 30°C (D2)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286309</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp29.pdf]]&gt;</url>
    <title>Porphyrin synthesis (ala) test (BSOP TP 29)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,HAEMOPHILUS,BACTERIA,HAEMOPHILUS INFLUENZAE,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286311</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHvol2/no3/guidelines.pdf]]&gt;</url>
    <title>Practical guidelines for responding to an outbreak of meningococcal disease among university students based on experience in Southampton</title>
    <publicationDate>1999-09-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (CDPH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CENTRAL NERVOUS SYSTEM,BODY PART AFFECTED,CONTACT,RESPIRATORY TRACT,INFECTIONS,BACTERIA,MICROORGANISM,NEISSERIA MENINGITIDIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Six students at the University of Southampton developed meningococcal disease in October 1997, five of them with confirmed serogroup C infections, and three died. The outbreak had major organisational and financial implications for the agencies involved. Detailed planning and good working relationships with the management of higher educational institutions can prove invaluable in such situations. This paper summarises the management of the outbreak in Southampton and presents recommendations based on experience. 
Publication history information: Guideline published more than 5 years ago, but publisher has confirmed the guideline's continued validity (March 2005).]]&gt;</body>
  </document>
  <document>
    <id>286315</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencemag.org/cgi/reprint/312/5772/392.pdf]]&gt;</url>
    <title>Predictability and preparedness in influenza control. </title>
    <publicationDate>2006-04-21T00:00:00</publicationDate>
    <publisher>American Association for the Advancement of Science </publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,INFLUENZA,INFECTIONS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The threat of pandemic human influenza looms as we survey the ongoing avian influenza pandemic and wonder if and when it will jump species. What are the risks and how can we plan? The nub of the problem lies in the inherent variability of the virus, which makes prediction difficult. However, it is not impossible; mathematical models can help determine and quantify critical parameters and thresholds in the relationships of those parameters, even if the relationships are nonlinear and obscure to simple reasoning. Mathematical models can derive estimates for the levels of drug stockpiles needed to buy time, how and when to modify vaccines, whom to target with vaccines and drugs, and when to enforce quarantine measures. Regardless, the models used for pandemic planning must be tested, and for this we must continue to gather data, not just for exceptional scenarios but also for seasonal influenza.]]&gt;</body>
  </document>
  <document>
    <id>286317</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000464&amp;representation=PDF]]&gt;</url>
    <title>Predicting pneumonia and influenza mortality from morbidity data.</title>
    <publicationDate>2007-05-23T00:00:00</publicationDate>
    <publisher>PLoS (Public Library of Science)</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,INFECTIONS,INFECTIOUS DISEASES,MICROORGANISM,INFLUENZA VIRUS,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background:
Few European countries conduct reactive surveillance of influenza mortality, whereas most monitor morbidity.

Methodology/Principal Findings:
We developed a simple model based on Poisson seasonal regression to predict excess cases of pneumonia and influenza mortality during influenza epidemics, based on influenza morbidity data and the dominant types/subtypes of circulating viruses. Epidemics were classified in three levels of mortality burden (“high”, “moderate” and “low”). The model was fitted on 14 influenza seasons and was validated on six subsequent influenza seasons. Five out of the six seasons in the validation set were correctly classified. The average absolute difference between observed and predicted mortality was 2.8 per 100,000 (18% of the average excess mortality) and Spearman's rank correlation coefficient was 0.89 (P = 0.05).

Conclusions/Significance:
The method described here can be used to estimate the influenza mortality burden in countries where specific pneumonia and influenza mortality surveillance data are not available.]]&gt;</body>
  </document>
  <document>
    <id>320585</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Predictingswineflumortality.aspx]]&gt;</url>
    <title>Predicting swine flu deaths</title>
    <publicationDate>2009-07-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,SWINE INFLUENZA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Better data is needed to predict the number of swine flu deaths, the BBC has reported. It said that scientists have called for improved data to map the spread of swine flu and to make accurate estimates of the number of people likely to die from the virus.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key points&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The researchers say that current estimates of the projected number of deaths may be innaccurate for several reasons:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Death rates are overestimated because only more severe cases are counted in the total number affected, while mild cases do not appear because they do not present to medical care.&lt;/LI&gt;
&lt;LI&gt;Death rates are underestimated because deaths are attributed to other seemingly unrelated causes besides swine flu, or because of the delay between symptom onset and death (cases who are counted as living at time of assessment may later die).&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388536</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/predictive-test-for-tuberculosis.aspx]]&gt;</url>
    <title>Predictive test for tuberculosis</title>
    <publicationDate>2010-08-19T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,DIAGNOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,WHAT'S NEW,ADDED 2010,AUG 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A predictive blood test for tuberculosis (TB) is "a step closer", according to BBC News. The article said that a “DNA fingerprint in the blood shows promise in identifying which carriers of TB will go on to get symptoms and spread the infection”.&lt;/P&gt;
&lt;P&gt;This study is important and illustrates the power of a relatively new technique called “genomic transcriptional profiling”, but it is too early to know in practice how many of the TB patients identified by the test will go on to develop the disease.&lt;/P&gt;
&lt;P&gt;After some fine-tuning in London, the test was repeated in patients from South Africa, which increases confidence in its accuracy. However, the study did not look at how many patients identified by the test later went on to develop the disease.&lt;/P&gt;
&lt;P&gt;As tests perform differently in different populations, another step in checking its accuracy will involve assessing its performance in developing areas of the world where TB is more common. As the test requires complex expensive machines, this may be easier said than done.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study uses a relatively new and complex genomic test to see if it is possible to identify people with active TB. The researchers also aimed to see whether the test could identify people who have latent TB and who are at risk of developing active TB in the future.&lt;/P&gt;
&lt;P&gt;Diagnostic tests obviously need to be accurate and this is measured in several ways. How good the test is at identifying people with a disease (called sensitivity), and how good it is at identifying people who do not have the disease (called specificity) are two commonly used measures.&lt;/P&gt;
&lt;P&gt;In this study:&lt;/P&gt;
&lt;P&gt;The test had good results for sensitivity and specificity in the highly selected samples tested, suggesting that when disease status is already known the test (the pattern) is good at confirming that a person has active TB and identifying a pattern in those without the disease too. However, it is important to point out that in the test set, there was a sensitivity of only 62%, which means&amp;nbsp;that 38% of samples with latent TB were identified as having active TB by the test (about&amp;nbsp;six out of 16 in absolute terms).&lt;/P&gt;
&lt;P&gt;All the people in the validation set were already known to have TB (active or latent) and so were “selected”. It is important to also measure the test’s accuracy in a population that has not been selected, a later stage of testing that will require following a set of people over time. This is because testing samples taken from people known to have latent TB or active TB before treatment will give better results than when the same test is used as a diagnostic tool in real-life populations with lower rates of active or latent TB.&lt;/P&gt;
&lt;P&gt;Studies of a test’s accuracy in its ability to predict future disease also depend on how many people in the population tested have the condition. The researchers did not test a random sample of people with latent TB to see how well the test does in predicting who goes on to develop active disease. This will be a further step in the research. It is for this reason that the researchers wisely advise further testing of their new exciting technique.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Berry MPR, Graham CM, McNab FW &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.nature.com/nature/journal/v466/n7309/full/nature09247.html" target="_blank"&gt;An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.&lt;/A&gt; &lt;EM&gt;Nature 2010&lt;/EM&gt;; 466: 973-977&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286318</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ajrccm.atsjournals.org/cgi/content/abstract/200711-1613OCv1?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=Loddenkemper&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Predictive Value of a Whole-blood IFN-{gamma} Assay for the Development of Active TB Disease.</title>
    <publicationDate>2008-02-14T00:00:00</publicationDate>
    <publisher>American Thoracic Society</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,AIRBORNE,BODY PART AFFECTED,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ RATIONALE: Numerous studies have been published on the new Mycobacterium tuberculosis (MTB) specific IFN-gamma release assays. However, their prognostic value for progression from latent tuberculosis infection (LTBI) to active tuberculosis (TB) has yet to be established. 

OBJECTIVE: To compare the QuantiFERON-TB-Gold In Tube assay (QFT) with the tuberculin skin test (TST) in recently exposed close contacts of active TB cases with respect to their development of TB disease within 2 years. 

METHODS: Close contacts, 601, of MTB-positive source cases underwent both TST and QFT testing and were subsequently observed for 103 (+/-13.5) weeks. Risk factors for MTB infection were evaluated by multivariate analysis. 

RESULTS: For the TST, 40.4% (243/601) were positive at a 5mm cut-off, while only 66 (11%) were QFT positive. QFT positivity, but not TST, was associated with exposure time (p &lt; 0.0001). Six contacts progressed to TB disease within the two year follow-up and all 6 were from a QFT positive group which had declined preventive treatment (n=41), equating to a progression rate of 14.6% (6/41) among those QFT positive. The progression rate for TST-positives was only 2.3% (5 of 219) and one subject who progressed was TST negative. 

CONCLUSIONS: Results suggest QFT screening determines more accurately than TST the presence of LTBI with at least equivalent sensitivity for predicting progression to TB. The high rate of progression to active TB of those QFT positive (14.6%), far greater than the 2.3% found for those TST positive, has significant health and economic implications for enhanced TB control. ]]&gt;</body>
  </document>
  <document>
    <id>302214</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947408879]]&gt;</url>
    <title>Pregnancy and Tuberculosis: Guidance for Clinicians</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,JAN 09,ADULTS,POPULATION GROUPS,PREGNANT WOMEN,HEALTHCARE WORKERS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This project was initiated to address a perceived lack of readily accessible information for healthcare professionals and members of the public on the advice and care to be offered to pregnant women following exposure to TB.&lt;/P&gt;
&lt;P&gt;These information sheets have been developed for professionals treating / advising pregnant women who have had contact with a person with infectious TB.&lt;/P&gt;
&lt;P&gt;These information sheets are being evaluated, we welcome any feedback. Please click on this &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947349116" target="_blank"&gt;link &lt;/A&gt;to obtain the evaluation form of the leaflets for 'Pregnancy and TB'.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320683</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Healthcare/Children/Maternity/Maternalandinfantnutrition/DH_099965]]&gt;</url>
    <title>Pregnancy, Breastfeeding and Swine Flu A/H1N1</title>
    <publicationDate>2009-05-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,POPULATION GROUPS,ADULTS,PREGNANT WOMEN,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,JUNE 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Women who are breastfeeding should continue while receiving antiviral treatment or prophylaxis as they are not contraindicated in breastfeeding.&lt;/P&gt;
&lt;P&gt;In particular mothers should feed on demand. Where possible additional formula should not be used so that the infant receives as much of the maternal antibodies as possible.&lt;/P&gt;
&lt;P&gt;If a mother is ill, she should continue breastfeeding and increase feeding frequency. If she becomes too ill to feed then expressing milk may still be possible.&lt;/P&gt;
&lt;P&gt;It the baby becomes too ill to breastfeed then expressed milk should be used.&lt;/P&gt;
&lt;P&gt;The risk for swine influenza transmission through breast milk is unknown. However, reports of viraemia with seasonal influenza infection are rare.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286319</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop33.pdf]]&gt;</url>
    <title>Pregnant patient in contact with rash illness (VSOP 33)</title>
    <publicationDate>2005-05-16T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CHICKENPOX,INFECTIOUS DISEASES,ANTENATAL PROBLEMS,INFECTIONS,WOMEN'S HEALTH,COMPLICATED PREGNANCY,INFECTIONS,RUBELLA,VACCINE PREVENTABLE DISEASES,SKIN AND NAIL INFECTIONS,POPULATION GROUPS,PARVOVIRUS B19,PREGNANT WOMEN,ADULTS,MICROORGANISM,VIRUSES,VARICELLA ZOSTER VIRUS,RUBELLA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This clinical algorithm aims to help decide the course of action for pregnant women who have been in contact with a rash illness.]]&gt;</body>
  </document>
  <document>
    <id>286320</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/csr/sars/clinical/en/]]&gt;</url>
    <title>Preliminary Clinical Description of Severe Acute Respiratory Syndrome</title>
    <publicationDate>2003-03-21T00:00:00</publicationDate>
    <publisher>World Health Organization (WHO)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,CONTACT,FOOD/WATER,RESPIRATORY TRACT,INFECTIONS,SARS CORONA VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Severe Acute Respiratory Syndrome (SARS) is a disease of unknown etiology that has been described in patients in Asia, North America, and Europe. The information in this report provides a summary of the clinical characteristics of SARS patients treated in Hong Kong Special Administrative Region (China), Taiwan (China), Thailand, Singapore, the United Kingdom, Slovenia, Canada and the United States since mid-February 2003. This information is preliminary and subject to limitations because of the broad and non-specific case definition.]]&gt;</body>
  </document>
  <document>
    <id>286321</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop12.pdf]]&gt;</url>
    <title>Preparation of coated grids for electron microscopy (VSOP 12 - Under review)</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286322</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/food/pdf/f2.pdf]]&gt;</url>
    <title>Preparation of samples and dilutions (F2)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>313779</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/contents/879476f7-be3e-46d5-b904-e4aa6373aee7.pdf]]&gt;</url>
    <title>Preparations for pandemic influenza: Guidance for hospital medical specialties on management during a pandemic influenza outbreak</title>
    <publicationDate>2009-04-30T00:00:00</publicationDate>
    <publisher>Royal College of Physicians</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,RESPIRATORY INFECTIONS,VACCINES / IMMUNISATION,ANTIVIRALS,ANTIMICROBIALS,PREVENTION,INFECTIONS,INFLUENZA VACCINE,POST-EXPOSURE PROPHYLAXIS,PANDEMIC INFLUENZA,TREATMENT,DIAGNOSIS,INFECTION CONTROL,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Preparations for pandemic influenza has been developed by the Royal College of Physicians to help hospitals and staff coordinate care during an influenza outbreak.&lt;/P&gt;
&lt;P&gt;The guidelines have been developed and edited during recent months with publication originally set for June this year. Due to current global events the College felt an early release of the information&amp;nbsp; was merited, and hence a pre-press version of the guidance can be found below. However, please note that, as yet, the document is still at proof stage (with author corrections still pending) and the document is not in its final navigable format. All data will be present in the final version, which will be released during May to replace this version.&lt;/P&gt;
&lt;P&gt;The document is designed to indicate how specialties could adjust their patterns of work in order to cope during an influenza pandemic when staff and facilities available to care for patients may be reduced. The intended audience for this guidance is those involved in managing and strategic planning of clinical services, and clinical staff working in hospital specialties. Each specialty section has been written by an expert in the field. The document is not designed to provide detailed operational guidance for responding to an influenza pandemic.&lt;/P&gt;
&lt;P&gt;The suggested blue and yellow card system (Appendix) of identifying patients who may or may not need to be seen urgently is a way of organising outpatient referrals in a pandemic, which could be used by consultants in consultation with Trust management.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>303659</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bma.org.uk/images/flupanprep_tcm41-180734.pdf]]&gt;</url>
    <title>Preparing for pandemic influenza - Guidance for GP practices</title>
    <publicationDate>2009-01-07T00:00:00</publicationDate>
    <publisher>British Medical Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PANDEMIC INFLUENZA,VACCINE PREVENTABLE DISEASES,INFLUENZA,JAN 09,INFLUENZA VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document advises practices on what they need to do now and in the future in order to prepare for, and respond to, a pandemic flu outbreak in the UK.&lt;/P&gt;
&lt;P&gt;The guidance is for GPs and their staff in general practice. Practice managers in particular should find it helpful. It will also be of use to primary care organisations (PCOs) and is relevant to patients. The document sets out guidelines for business continuity planning within GP practices and introduces new systems and procedures, such as the National Pandemic Flu Line, which will operate in an influenza pandemic. It also explains why there is a need to take action and how this will help minimise the spread of flu in a pandemic and make the best use of limited health resources.&lt;/P&gt;
&lt;P&gt;This is the first issue of this guidance document. Some aspects of planning for and responding to a flu pandemic have not yet been decided or agreed. This document will be regularly reviewed to include decisions as they are agreed plus any relevant changes, which relate to general practice. It is a living document, and it is therefore very important that you revisit this website regularly.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286323</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHVol3/no4/flu.pdf]]&gt;</url>
    <title>Presentation with influenza-like illness in general practice: implications for use of neuraminidase inhibitors</title>
    <publicationDate>2000-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFLUENZA,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIVIRALS,TREATMENT,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ General practitioners in the Midlands Research Practice Consortium (MidReC), combined list size 140 000, completed questionnaires about 918 patients in whom they had made working diagnoses of influenza-like illness during an outbreak of influenza A H3N2 from 1 December 1999 to 4 February 2000. Adults, more females than males consulted most, reflecting the age and sex
distribution reported to the Royal College of General Practitioners Weekly Returns Service. Illness at presentation was considered severe in 4%, moderately severe in 49%, mild in 45%, and asymptomatic (for example, attended for certificates) in 1% of patients. In seven tenths of patients, the practitioner estimated that the likelihood of influenza was 70% or more and in just over half, 80% or more. Half of patients aged over 75 years were seen at home, but only 7% of those under 55 years. Less than a quarter of patients consulted within two days of having become ill, with the highest consultation frequency on the third and fourth days. Preschool
children presented earliest: 75% were seen within two days, compared with only 17% of adults over 75 years. Four fifths of patients were seen on the same day as they contacted the practice, and 12% on the following day. Given the brief time window for effective antiviral treatment, only a small proportion of patients are likely to be prescribed these drugs unless consulting behaviour, especially in elderly people, changes considerably.]]&gt;</body>
  </document>
  <document>
    <id>286324</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop58.pdf]]&gt;</url>
    <title>Presumptive diagnosis of Enterobacter sakazakii infection (QSOP 58)</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>381022</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ecdc.europa.eu/en/healthtopics/tick_borne_diseases/public_health_measures/Documents/1006_PPT%20HP.pdf]]&gt;</url>
    <title>Prevention and control of tick-borne disease in Europe. Information to healthcare professionals</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ZOONOSES,TICKS,LYME DISEASE,MICROORGANISM,PARASITES,ADDED 2010,TICK-BORNE ENCEPHALITIS,TICK-BORNE DISEASES,JULY 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Tick-borne diseases are infectious diseases transmitted by the bites of infected ticks. As the incidence of tick-borne illnesses is rising, it becomes increasingly important that health professionals are able to distinguish the diverse clinical presentations of these diseases.&lt;/P&gt;
&lt;P&gt;In Europe, tick-borne diseases to be aware of include:&lt;BR&gt;•Lyme borreliosis&lt;BR&gt;•Tick-borne encephalitis (TBE)&lt;BR&gt;•Tick-borne relapsing fever (TBRF)&lt;BR&gt;•Crimean-Congo haemorrhagicfever (CCHF)&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286329</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcog.org.uk/resources/Public/GroupB_strep_no36.pdf]]&gt;</url>
    <title>Prevention of Early Onset Neonatal Group B Streptococcal Disease</title>
    <publicationDate>2003-11-01T00:00:00</publicationDate>
    <publisher>Royal College of Obstetricians and Gynaecologists</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,INFECTIONS,STREPTOCOCCUS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Group B streptococcus is recognised as the most frequent cause of severe early-onset (less than seven days of age) infection in newborn infants. This document provides guidance on prevention of this disease.]]&gt;</body>
  </document>
  <document>
    <id>286330</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm]]&gt;</url>
    <title>Prevention of Hepatitis A Through Active or Passive Immunization</title>
    <publicationDate>2006-05-19T00:00:00</publicationDate>
    <publisher>Centers for Disease Control &amp; Prevention</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,INFECTIONS,MICROORGANISM,VIRUSES,HEPATITIS A VIRUS,HEPATITIS VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Routine vaccination of children is an effective way to reduce hepatitis A incidence in the United States. Since licensure of hepatitis A vaccine during 1995--1996, the hepatitis A childhood immunization strategy has been implemented incrementally, starting with the recommendation of the Advisory Committee on Immunization Practices (ACIP) in 1996 to vaccinate children living in communities with the highest disease rates and continuing in 1999 with ACIP's recommendations for vaccination of children living in states, counties, and communities with consistently elevated hepatitis A rates. These updated recommendations represent the final step in the childhood hepatitis A immunization strategy, routine hepatitis A vaccination of children nationwide. Implementation of these recommendations will reinforce existing vaccination programs, extend the benefits associated with hepatitis A vaccination to the rest of the country, and create the foundation for eventual consideration of elimination of indigenous hepatitis A virus transmission. 

This report updates ACIP's 1999 recommendations concerning the prevention of hepatitis A through immunization (CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1999:48[No. RR-12]:1--37) and includes 1) new data on the epidemiology of hepatitis A in the era of hepatitis A vaccination of children in selected U.S. areas, 2) results of analyses of the economics of nationwide routine vaccination of children, and 3) recommendations for the routine vaccination of children in the United States. Previous recommendations for vaccination of persons in groups at increased risk for hepatitis A or its adverse consequences and recommendations regarding the use of immune globulin for protection against hepatitis A are unchanged from the 1999 recommendations.]]&gt;</body>
  </document>
  <document>
    <id>286332</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.328.7447.1026]]&gt;</url>
    <title>Prevention of respiratory syncytial virus infection in infants</title>
    <publicationDate>2004-05-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This editorial published in the BMJ states that around 20% of admissions for infections of the lower respiratory tract in children are due to RSV. It indicates that palivizumab is effective but too expensive and vaccines are unavailable as yet.]]&gt;</body>
  </document>
  <document>
    <id>393881</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/probiotic-yoghurt-diarrhoea-stomach-upset.aspx]]&gt;</url>
    <title>Probiotics 'ease upset stomachs'</title>
    <publicationDate>2010-11-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,INFECTIONS,TREATMENT,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Probiotics cut stomach upsets by one day,” The Daily Telegraph&amp;nbsp; has reported. The news is based on the findings of a comprehensive review by the Cochrane Collaboration, which looked at 63 studies featuring a total of 8,000 people.&lt;/P&gt;
&lt;P&gt;This large, well-conducted review pooled the results of studies from across the globe to investigate the use of specific probiotic bacterial cultures in the treatment of acute diarrhoea (lasting less than 14 days) believed to be due to an infectious cause. Overall, it found that probiotics reduced the duration of diarrhoea by about 25 hours compared with no treatment.&lt;/P&gt;
&lt;P&gt;However, the studies included highly variable populations, used different definitions of diarrhoea and recovery, and used a range of probiotic types, strains and doses. As such, the review authors highlight the need for further high-quality studies, particularly ones that determine which population groups probiotics may be useful for. As such, they say that no recommendations can be given for using probiotics during infectious diarrhoea in adults or children.&lt;/P&gt;
&lt;P&gt;Rehydration remains the most important consideration in diarrhoea, and medical attention should be sought if diarrhoea is persisting or there are any concerns over the severity of the person’s illness.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;As the researchers of this review appropriately discuss, ‘the marked clinical variability among studies complicates meta-analysis” and therefore “weakens the evidence base to inform clinical practice”. They call for more large, well-designed studies of specific probiotic regimens in specific settings’. In particular, the groups of people that may most benefit from the use of probiotics needs further consideration.&lt;/P&gt;
&lt;P&gt;As such, no recommendations can yet be given for the use of probiotics during infectious diarrhoea in adults or children. Rehydration remains the most important consideration in diarrhoea, and medical attention should be sought if diarrhoea is persisting or there are any concerns over the severity of the person’s illness.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Allen SJ, Martinez EG, Gregorio GV, Dans LF et al. &lt;A href="nelh:237861:1" name=internalLink&gt;Probiotics for treating acute infectious diarrhoea&lt;/A&gt;. The Cochrane Library 2010, Issue 11&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286334</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop37.pdf]]&gt;</url>
    <title>Procedure for dealing with presumptive pathogens isolated from ready-to-eat foods (QSOP 37)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286335</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop58.pdf]]&gt;</url>
    <title>Processing Swabs For Group B Streptococcal Carriage (BSOP 58)</title>
    <publicationDate>2006-06-26T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,MENINGOCOCCAL MENINGITIS,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,TREATMENT,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,STREPTOCOCCUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This SOP describes the processing of specimens from pregnant women for carriage of Group B streptococci (GBS). Recognising that it is not recommended in the UK to screen routinely for GBS (Royal College of Obstetricians and Gynaecologists 2003; National Institute of Clinical Excellence 2003; HPA 2004), this SOP provides a standardised method for culture where clinicians decide to investigate specific patients with conditions considered to confer a high risk of infection. Commercial tests detecting the GBS group antigen extracted from vaginal swabs based upon latex agglutination, ELISA, immunofiltration, immunochromatography, optical immunoassay and other methods are available. However, the evidence accumulated has shown that the sensitivity and specificity of direct antigen tests is inferior to that of culture methods.]]&gt;</body>
  </document>
  <document>
    <id>286362</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.jimmunol.org/cgi/content/abstract/179/10/6919]]&gt;</url>
    <title>Progression of pulmonary tuberculosis and efficiency of bacillus Calmette-Guérin vaccination are genetically controlled via a common sst1-mediated mechanism of innate immunity.</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>The American Association of Immunologists</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,MYCOBACTERIUM,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Using a mouse model for genetic analysis of host resistance to virulent Mycobacterium tuberculosis, we have identified a genetic locus sst1 on mouse chromosome 1, which controls progression of pulmonary tuberculosis. In vitro, this locus had an effect on macrophage-mediated control of two intracellular bacterial pathogens, M. tuberculosis and Listeria monocytogenes. In this report, we investigated a specific function of the sst1 locus in antituberculosis immunity in vivo, especially its role in control of pulmonary tuberculosis. We found that the sst1 locus affected neither activation of Th1 cytokine-producing T lymphocytes, nor their migration to the lungs, but rather controlled an inducible NO synthase-independent mechanism of innate immunity. Although the sst1(S) macrophages responded to stimulation with IFN-gamma in vitro, their responsiveness to activation by T cells was impaired. Boosting T cell-mediated immunity by live attenuated vaccine Mycobacterium bovis bacillus Calmette-Guérin or the adoptive transfer of mycobacteria-activated CD4(+) T lymphocytes had positive systemic effect, but failed to improve control of tuberculosis infection specifically in the lungs of the sst1(S) animals. Thus, in the mouse model of tuberculosis, a common genetic mechanism of innate immunity mediated control of tuberculosis progression in the lungs and the efficiency of antituberculosis vaccine. Our data suggest that in immunocompetent humans the development of pulmonary tuberculosis and the failure of the existing vaccine to protect against it, in some cases, may be explained by a similar defect in a conserved inducible NO synthase-independent mechanism of innate immunity, either inherited or acquired. ]]&gt;</body>
  </document>
  <document>
    <id>286365</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/books/endocarditis/endocarditis.pdf]]&gt;</url>
    <title>Prophylaxis and treatment of infective endocarditis in adults : concise guidelines</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>Royal College of Physicians</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CARDIOVASCULAR,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Aims: Infective endocarditis (IE) is a life-threatening disease which affects individuals with underlying structural cardiac defects. This guidance addresses diagnosis, antiobiotic prophylaxis, medical treatment and the indications for surgery. 
Intended audience: Clinicians involved in the management of patients with IE. 
Publication history information: Published December 2004 
Access: Available to the general public. ]]&gt;</body>
  </document>
  <document>
    <id>286367</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/content/abstract/44/12/4498]]&gt;</url>
    <title>Proposal for Standardization of Optimized Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeat Typing of Mycobacterium tuberculosis</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>American Society of Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Molecular typing based on 12 loci containing variable numbers of tandem repeats of mycobacterial interspersed repetitive units (MIRU-VNTRs) has been adopted in combination with spoligotyping as the basis for large-scale, high-throughput genotyping of Mycobacterium tuberculosis. However, even the combination of these two methods is still less discriminatory than IS6110 fingerprinting. Here, we define an optimized set of MIRU-VNTR loci with a significantly higher discriminatory power. The resolution and the stability/robustness of 29 loci were analyzed, using a total of 824 tubercle bacillus isolates, including representatives of the main lineages identified worldwide so far. Five loci were excluded for lack of robustness and/or stability in serial isolates or isolates from epidemiologically linked patients. The use of the 24 remaining loci increased the number of types by 40%—and by 23% in combination with spoligotyping—among isolates from cosmopolitan origins, compared to those obtained with the original set of 12 loci. Consequently, the clustering rate was decreased by fourfold—by threefold in combination with spoligotyping—under the same conditions. A discriminatory subset of 15 loci with the highest evolutionary rates was then defined that concentrated 96% of the total resolution obtained with the full 24-locus set. Its predictive value for evaluating M. tuberculosis transmission was found to be equal to that of IS6110 restriction fragment length polymorphism typing, as shown in a companion population-based study. This 15-locus system is therefore proposed as the new standard for routine epidemiological discrimination of M. tuberculosis isolates and the 24-locus system as a high-resolution tool for phylogenetic studies. ]]&gt;</body>
  </document>
  <document>
    <id>286368</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/abs/10.1086/521107?prevSearch=%28Prospective+comparison+of+the+tuberculin+skin+test%29+AND+%5Bjournal%3A+cid%5D]]&gt;</url>
    <title>Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis.</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,TRANSMISSION MODE,BODY PART AFFECTED,AIRBORNE,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,INFECTIOUS DISEASES,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ BACKGROUND: Interferon-gamma release assays (IGRAs) are attractive alternatives to the tuberculin skin test (TST) for detecting Mycobacterium tuberculosis infection. However, the inability to definitively confirm the presence of most M. tuberculosis infections hampers assessment of IGRA accuracy. Although IGRAs are primarily indicated for the detection of latent tuberculosis infection, we sought to determine the sensitivity of the TST and 2 whole-blood IGRAs (QuantiFERON-TB assay [QFT] and QuantiFERON-TB Gold assay [QFT-G]) in situations in which infection is confirmed by recovery of M. tuberculosis by culture. 

METHODS: We conducted a prospective, multicenter, cross-sectional comparison study in which 148 persons suspected to have tuberculosis were tested simultaneously with the TST, QFT, and QFT-G. 

RESULTS: M. tuberculosis was cultured from samples from 69 (47%) of 148 persons suspected to have tuberculosis; the TST induration was &gt; or = 5 mm for 51 (73.9%) of the 69 subjects (95% confidence interval [CI], 62.5%-82.8%). The QFT indicated tuberculosis infection for 48 (69.6%) of the 69 subjects (95% CI, 57.9%-79.2%) and was indeterminate for 7 (10.1%). The QFT-G yielded positive results for 46 (66.7%) of the 69 subjects (95% CI, 54.9%-76.7%) and indeterminate results for 9 subjects (13.0%). If subjects with indeterminate QFT-G results were excluded, 46 (76.7%) of 60 subjects (95% CI, 64.6%-85.6%) had positive TST results, and the same number of subjects had positive QFT-G results. HIV infection was associated with false-negative TST results but not with false-negative QFT-G results. 

CONCLUSIONS: The TST, QFT, and QFT-G have similar sensitivity in persons with culture-confirmed infection. As with the TST, negative QFT and QFT-G results should not be used to exclude the diagnosis of tuberculosis in persons with suggestive signs or symptoms. ]]&gt;</body>
  </document>
  <document>
    <id>286370</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop29.pdf]]&gt;</url>
    <title>Protocol for involvement of HPA Laboratories and staff in the investigation of outbreaks food, dairy products and waterborne disease (QSOP 29)</title>
    <publicationDate>2002-09-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>308952</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5711a3.htm]]&gt;</url>
    <title>Provider-initiated HIV testing and counselling of TB patients – Livingstone District, Zambia, September 2004-December 200</title>
    <publicationDate>2008-03-21T00:00:00</publicationDate>
    <publisher>Centers for Disease Control and Prevention</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,DIAGNOSIS,VIRUSES,MYCOBACTERIUM TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis (TB) is the second most common cause of death from infectious disease in the world after human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Immunosuppressed HIV-infected persons are highly susceptible to TB disease, and countries in sub-Saharan Africa have the highest TB incidence rates, primarily because of the HIV epidemic. In Zambia, the TB rate increased during 1984 to 2005 from approximately 100 cases per 100,000 population to 580 cases per 100,000 population. Much of this increase has been attributed to the high rate of coinfection with HIV; currently, an estimated 50% to 70% of TB patients are infected with HIV (N. Kapata, Ministry of Health, Zambia, personal communication, 2008). In 2007, the World Health Organization (WHO) recommended that countries with high coinfection rates develop TB/HIV collaborative activities, including routine provider-initiated HIV testing and counseling (PITC) of TB patients in TB clinical settings, using an "opt-out" approach. This report summarizes results from a PITC pilot study conducted by the Zambian Ministry of Health, with assistance from the CDC Global AIDS Program Zambia, during September 2004 to December 2006 with TB patients at three clinics in the Livingstone District in the Southern Province of Zambia. The results indicated that, among 4,148 persons who had TB diagnosed, 2,072 (50%) were tested for HIV; of these, 1,497 (72%) tested positive. These findings demonstrate the practicality and acceptance of PITC and HIV rapid testing and support the need to expand this program to TB clinical settings in Zambia and other countries with high rates of TB and HIV.]]&gt;</body>
  </document>
  <document>
    <id>308961</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?author=Zachariah&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=4]]&gt;</url>
    <title>Providing HIV care for co-infected TB patients: a perspective from sub-Saharan Africa.</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,TUBERCULOSIS,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,ANTIVIRALS,DIAGNOSIS,TREATMENT,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,VIRUSES,MYCOBACTERIUM TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Human immunodeficiency virus/acquired immune-deficiency syndrome (HIV/AIDS) and tuberculosis (TB) are overlapping epidemics that cause an immense burden of disease in sub-Saharan Africa. This region is home to the majority of the world's co-infected patents, who have higher TB case fatality and recurrence rates than patients with TB alone. A World Health Organization interim policy has been developed to reduce the joint burden of TB-HIV disease, an important component of which is provision of HIV care to co-infected patients. This review focuses on HIV testing of TB patients and, for those who are HIV-positive, the administration of adjunctive cotrimoxazole preventive treatment (CPT) and antiretroviral treatment (ART). HIV testing has moved from a voluntary, client-initiated intervention to one that is provider-initiated and a routine part of the diagnostic work-up. The efficacy and safety of CPT in HIV-infected patients is now well established, and this is an essential part of the package of HIV care. ART scale-up in Africa can substantially improve outcomes in co-infected patients. However, the clinical and programmatic challenges of combining ART with anti-tuberculosis treatment need to be resolved to realise the full potential of this benefit. These include the optimal time to start ART, how best to combine rifampicin-containing regimens with first-line and second-line ART regimens, management of immune reconstitution disease, the role of isoniazid preventive treatment with ART after TB treatment completion, and where and how to provide combined treatment to best suit the patient. Clinical and operational studies in the next few years should help to resolve some of these issues.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286371</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop8.pdf]]&gt;</url>
    <title>Pseudomonas selective agar (MSOP 8)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>345893</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/heat-resistant-vaccine-development.aspx]]&gt;</url>
    <title>Push for more stable vaccines</title>
    <publicationDate>2010-02-19T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Scientists at Oxford University have found a way of keeping vaccines stable without refrigeration,” the BBC website has reported.&lt;/P&gt;
&lt;P&gt;The news is based on research on using two special membranes to dry the viral particles used in vaccines in order to keep them stable when stored at warm temperatures. Normally these viral substances cannot stand warmer atmospheres for more than a few weeks, which means they need to be kept refrigerated. The new techniques tested were shown to increase the shelf life of viral substances by several months, meaning they could help reduce the practical problems faced by vaccination programmes in the developing world.&lt;/P&gt;
&lt;P&gt;This is potentially a very useful development as it offers the hope that doctors will be able to distribute vaccines more easily in the rural areas of developing countries where refrigerated storage for vaccines can be problematic and costly. This will be of particular importance for the distribution of any HIV and malaria vaccines that may be developed, as these illnesses are very common in some hot, remote parts of Africa.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a proof-of-concept study that showed that viral vector stability at warm temperatures could be increased by slowly drying vaccines suspended in sugar stabilisers onto special filter-like membranes.&lt;/P&gt;
&lt;P&gt;This study was performed with model viral vectors that can have DNA inserted into them to make them work as vaccines for specific diseases. Further work is needed to characterise the effect of the technique on the storage conditions needed for vaccines used for specific diseases.&lt;/P&gt;
&lt;P&gt;This development is potentially very useful as it may lead to improvements in the availability and effectiveness of vaccination programmes in areas of the world with fewer resources.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Alcock R, Cottingham MG, Rollier CS et al. &lt;A href="http://stm.sciencemag.org/content/2/19/19ra12.abstract?sid=" target="_blank"&gt;Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass&lt;/A&gt;. &lt;EM&gt;Science Translational Medicine&lt;/EM&gt;, February 17&amp;nbsp;2010: Vol. 2, Issue 19, p. 19ra12&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286373</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop28.pdf]]&gt;</url>
    <title>Qualifications, experience and duties/responsibilities of Food Examiners in the Health Protection Agency (QSOP 28)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>345446</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.plosone.org/article/fetchObjectAttachment.action;jsessionid=51435072F799CFD99DD15416CDD1DB10?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0007753&amp;representation=PDF]]&gt;</url>
    <title>Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards</title>
    <publicationDate>2009-11-13T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,MALARIA,HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,DIAGNOSIS,TRAVEL ASSOCIATED INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,PLASMODIUM,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MOSQUITO,PARASITES,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Poor methodological quality and reporting are known concerns with diagnostic accuracy studies. In 2003, the QUADAS tool and the STARD standards were published for evaluating the quality and improving the reporting of diagnostic studies, respectively. However, it is unclear whether these tools have been applied to diagnostic studies of infectious diseases. We performed a systematic review on the methodological and reporting quality of diagnostic studies in TB, malaria and HIV.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: We identified diagnostic accuracy studies of commercial tests for TB, malaria and HIV through a systematic search of the literature using PubMed and EMBASE (2004–2006). Original studies that reported sensitivity and specificity data were included. Two reviewers independently extracted data on study characteristics and diagnostic accuracy, and used QUADAS and STARD to evaluate the quality of methods and reporting, respectively.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Findings&lt;/STRONG&gt;: Ninety (38%) of 238 articles met inclusion criteria. All studies had design deficiencies. Study quality indicators that were met in less than 25% of the studies included adequate description of withdrawals (6%) and reference test execution (10%), absence of index test review bias (19%) and reference test review bias (24%), and report of uninterpretable results (22%). In terms of quality of reporting, 9 STARD indicators were reported in less than 25% of the studies: methods for calculation and estimates of reproducibility (0%), adverse effects of the diagnostic tests (1%), estimates of diagnostic accuracy between subgroups (10%), distribution of severity of disease/other diagnoses (11%), number of eligible patients who did not participate in the study (14%), blinding of the test readers (16%), and description of the team executing the test and management of indeterminate/outlier results (both 17%). The use of STARD was not explicitly mentioned in any study. Only 22% of 46 journals that published the studies included in this review required authors to use STARD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Recently published diagnostic accuracy studies on commercial tests for TB, malaria and HIV have moderate to low quality and are poorly reported. The more frequent use of tools such as QUADAS and STARD may be necessary to improve the methodological and reporting quality of future diagnostic accuracy studies in infectious diseases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286374</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop27.pdf]]&gt;</url>
    <title>Quality assurance in the diagnostic virology and serology laboratory (QSOP 27)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,VIRUSES,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In microbiology a quality product or service can be defined as “the right result on the right specimen from the right patient that is accurate, timely and properly interpreted”.
The objective of any test laboratory should therefore be to produce cost effective, accurate,
reproducible and timely results which are comparable with the results obtained in a similar
laboratory elsewhere which are promptly, effectively and appropriately communicated to the
users of the service. The results must be unchallengeable. In this way the quality of the
product or service can be guaranteed. The way laboratories achieve this quality service is through quality assurance which can be defined as “the total process whereby the quality of laboratory reports can be guaranteed”.

Basically it comprises all the different measures taken to ensure the reliability of
investigations. It seeks to minimise any variability in test results arising from such variables as
the quality and education of staff, the quality of reagents, apparatus and specimens and the
suitability of the techniques in use. Therefore, it is clear that quality assurance relates to the entire process of diagnosis of infection which starts and ends with the patient. It does not matter how well controlled the assay procedure in the laboratory is if an error has occurred at the pre or post examination phase which might have resulted in the wrong patient being identified, the wrong specimen taken, the specimen having been abused during transportation to the laboratory, a data entry error occurring at specimen reception, an incorrect interpretation of the results or the result having been sent to the wrong address. We generally focus the majority of our effort on the laboratory aspects of quality assurance, even though it is generally agreed that most errors occur during the pre and post examination phases.

This document concentrates on the laboratory aspects of quality assurance, specifically the
examination phase. However readers are urged to pay as much attention to ensuring that pre
and post examination phases are reviewed and control measures put in place to minimise the
risk of errors occurring. Quality assurance in the examination phase is the collective term for several distinct procedures used to monitor the performance of all aspects of work in the laboratory. A quality assurance scheme should be used to identify procedural and technical problems, check the adequacy of current techniques, calculate the frequency of errors and ultimately to increase confidence in the procedures and techniques used and in the reports issued.

A comprehensive quality assurance programme should be an integral part of the procedures
of a diagnostic microbiology laboratory and is necessary for compliance with the Clinical
Pathology Accreditation (UK) Ltd (CPA) standards and to maintain accreditation.]]&gt;</body>
  </document>
  <document>
    <id>330476</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/bsc/cchd/2009/00000035/00000004/art00002;jsessionid=j0cp2jms4r65.alexandra]]&gt;</url>
    <title>Quality of life measurement in paediatric and adolescent populations with HIV: A review of the literature</title>
    <publicationDate>2009-07-04T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,CHILDREN,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 09,ADOLESCENTS,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Purpose&lt;/STRONG&gt;: To review the quality and utility of currently available self-report generic quality of life (QOL) and health-related quality of life (HRQOL) measures for use with children and adolescents with human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: Literature searches were conducted to identify QOL and HRQOL measures developed for, adapted for, or otherwise used with paediatric and adolescent populations with HIV/AIDS. The quality of measures (i.e. item generation techniques, instrument properties including reliability, validity and responsiveness) were compared and critically evaluated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Nineteen QOL/HRQOL measures were identified. Item content was generated from the respondent (adult) population in only eight (42%) measures. Seventeen (90%) measures reported internal reliability in the accepted range between 0.70 and 0.90 and four (21%) reported reproducibility statistics in this range. Although validity was reported for 19 (100%) measures, only six (32%) showed evidence for three or more properties, with construct validity being the most commonly reported aspect. The authors of eight (42%) measures reported evidence for responsiveness. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: While almost all measures reviewed demonstrated adequate psychometric properties, only one-third demonstrated all aspects of validity, and less than half demonstrated responsiveness. None included paediatric or adolescent populations with HIV/AIDS in their development, neglecting to obtain input from target respondents in item generation to determine what health-related and daily functioning factors are of importance to them. Despite noted limitations, the AUQUEI or the SWED-QUAL appear the best currently available generic measure, and the MQOL-HIV the preferred disease-specific measure, at least for use with older adolescents/young adults.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286375</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/316/7135/906?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=316&amp;firstpage=906&amp;resourcetype=HWCIT,HWISS,HWFIG,HWDSUP,HWELTR]]&gt;</url>
    <title>Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults</title>
    <publicationDate>1998-03-21T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ 
Objectives: To assess whether antibiotic treatment for acute cough is effective and to measure the side effects of such treatment. 
Design: Quantitative systematic review of randomised placebo controlled trials. 
Data sources: Nine trials (8 published, 1 unpublished) retrieved from a systematic search (electronic databases, contact with authors, contact with drug manufacturers, reference lists); no restriction on language. 
Main outcome measures: Proportion of subjects with productive cough at follow up (7-11 days after consultation with general practitioner); proportion of subjects who had not improved clinically at follow up; proportion of subjects who reported side effects from taking antibiotic or placebo. 
Results: Eight trials contributed to the meta-analysis. Resolution of cough was not affected by antibiotic treatment (relative risk 0.85 (95% confidence interval 0.73 to 1.00)), neither was clinical improvement at re-examination (relative risk 0.62 (0.36 to 1.09)). The side effects of antibiotic were more common in the antibiotic group when compared to placebo (relative risk 1.51 (0.86 to 2.64)). 
Conclusions: Treatment with antibiotic does not affect the resolution of cough or alter the course of illness. The benefits of antibiotic treatment are marginal for most patients with acute cough and may be outweighed by the side effects of treatment. 

Key messages 
Acute cough, with or without sputum, is a common reason for consulting a general practitioner 
Although antibiotic treatment is common for this condition, its likely benefits and side effects have not been measured 
This systematic review reports the outcome of nine randomised controlled trials that compared antibiotic with placebo in patients with acute cough 
Resolution of cough and clinical improvement at follow up was no different in the two groups 
The benefits of antibiotic treatment seem to be marginal for most patients with acute cough and may be outweighed by the side effects of treatment 
]]&gt;</body>
  </document>
  <document>
    <id>320036</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/publications/quickwins/Commissioning_chlamydia_screening_06Oct08.pdf]]&gt;</url>
    <title>Quick wins and sustainable services: Hitting the target without missing the point</title>
    <publicationDate>2008-09-30T00:00:00</publicationDate>
    <publisher>National Chlamydia Screening Programme</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHLAMYDIA,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MICROORGANISM,CHLAMYDIA,BACTERIA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Commissioning chlamydia screening]]&gt;</body>
  </document>
  <document>
    <id>394471</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20808204]]&gt;</url>
    <title>Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome</title>
    <publicationDate>2010-09-24T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a frequent complication of antiretroviral therapy in resource-limited countries. We aimed to assess whether a 4-week course of prednisone would reduce morbidity in patients with paradoxical TB-IRIS without excess adverse events.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: A randomized, double-blind, placebo-controlled trial of prednisone (1.5 mg/kg per day for 2 weeks then 0.75 mg/kg per day for 2 weeks). Patients with immediately life-threatening TB-IRIS manifestations were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: The primary combined endpoint was days of hospitalization and outpatient therapeutic procedures, which were counted as one hospital day.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: One hundred and ten participants were enrolled (55 to each arm). The primary combined endpoint was more frequent in the placebo than the prednisone arm {median hospital days 3 [interquartile range (IQR) 0-9] and 0 (IQR 0-3), respectively; P = 0.04}. There were significantly greater improvements in symptoms, Karnofsky score, and quality of life (MOS-HIV) in the prednisone vs. the placebo arm at 2 and 4 weeks, but not at later time points. Chest radiographs improved significantly more in the prednisone arm at weeks 2 (P = 0.002) and 4 (P = 0.02). Infections on study medication occurred in more participants in prednisone than in placebo arm (27 vs. 17, respectively; P = 0.05), but there was no difference in severe infections (2 vs. 4, respectively; P = 0.40). Isolates from 10 participants were found to be resistant to rifampicin after enrolment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Prednisone reduced the need for hospitalization and therapeutic procedures and hastened improvements in symptoms, performance, and quality of life. It is important to investigate for drug-resistant tuberculosis and other causes for deterioration before administering glucocorticoids.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308623</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ajrccm.atsjournals.org/cgi/content/abstract/177/7/787]]&gt;</url>
    <title>Rapid Molecular Screening for Multidrug-Resistant Tuberculosis in a High-Volume Public Health Laboratory in South Africa.</title>
    <publicationDate>2008-01-07T00:00:00</publicationDate>
    <publisher>American Thoracic Society</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,DIAGNOSIS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Rationale&lt;/STRONG&gt;: The dual challenges to tuberculosis (TB) control of HIV infection and multidrug resistance are particularly pressing in South Africa. Conventional methods for detecting Mycobacterium tuberculosis drug resistance take weeks to months to produce results. Rapid molecular testing for drug resistance is available but has not been implemented in high-TB-burden settings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives&lt;/STRONG&gt;: To assess the performance and feasibility of implementation of a commercially available molecular line-probe assay for rapid detection of rifampicin and isoniazid resistance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: We performed the assay directly on 536 consecutive smear-positive sputum specimens from patients at increased risk of multidrug-resistant (MDR) TB in a busy routine diagnostic laboratory in Cape Town, South Africa. Results were compared with conventional liquid culture and drug susceptibility testing on solid medium.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Measurements and Main Results&lt;/STRONG&gt;: Overall, 97% of smear-positive specimens gave interpretable results within 1–2 days using the molecular assay. Sensitivity, specificity, and positive and negative predictive values were 98.9, 99.4, 97.9, and 99.7%, respectively, for detection of rifampicin resistance; 94.2, 99.7, 99.1, and 97.9%, respectively, for detection of isoniazid resistance; and 98.8, 100, 100, and 99.7%, respectively, for detection of multidrug resistance compared with conventional results. The assay also performed well on specimens that were contaminated on conventional culture and on smear-negative, culture-positive specimens.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: This molecular assay is a highly accurate screening tool for MDR TB, which achieves a substantial reduction in diagnostic delay. With overall performance characteristics that are superior to conventional culture and drug susceptibility testing and the possibility for high throughput with substantial cost savings, molecular testing has the potential to revolutionize MDR TB diagnosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315570</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19215]]&gt;</url>
    <title>Rapid spread of drug-resistant influenza A viruses in the Basque Country, northern Spain, 2000-1 to 2008-9</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>Eurosurveillance</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,ANTIVIRALS,ANTIMICROBIALS,TREATMENT,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,MAY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A worldwide increase of adamantane-resistant influenza A(H3N2) and oseltamivir-resistant influenza A(H1N1) viruses has been observed in recent years. The aim of this study was to analyse the prevalence of antiviral drug-resistant influenza A in a region of northern Spain. Resistance to adamantanes was detected in 45.3% (68/150) of influenza AH3 viruses analysed for the period from 2000-1 to 2008-9. Adamantane-resistance was absent in our region during the 2000-1 to 2002-3 influenza seasons. However, after the first adamantane-resistant virus (characterised as A/Fujian/411/2002) was detected in the 2003-4 season, a rapid increase in the proportion of resistant strains was observed (4.9% [2/41], 80% [8/10] and 100% [53/53] in the 2004-5, 2006-7 and 2008-9 seasons, respectively).&amp;nbsp; Four of the first five adamantane-resistant AH3 viruses detected were isolated from adult patients, but the subsequent spread was observed mainly among children. No resistance to adamantanes was detected among the 65 influenza AH1 viruses analysed throughout the study period. Among the 172 influenza A (76 AH1 and 96 AH3) viruses analysed, five strains (AH1 with mutation H274Y) showed oseltamivir resistance, and all were detected in the last season. Amantadine use was very scarce in our region, and oseltamivir was not used at all; therefore the increase of resistance was attributed to imported drug-resistant influenza viruses.]]&gt;</body>
  </document>
  <document>
    <id>330574</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/fm/whe/2009/00000005/00000001/art00010]]&gt;</url>
    <title>Rapid testing at labor and delivery to prevent mother-to-child HIV transmission in developing settings: issues and challenges</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,ADULTS,CHILDREN,POPULATION GROUPS,PREGNANT WOMEN,DIAGNOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Worldwide, approximately 2.5 million children (95% CI: 2.2-2.6) are living with HIV infection. In 2007 alone, approximately 420,000 children (95%CI: 350,000-540,000) were newly infected with HIV - a vast majority of these infections were acquired through maternal-fetal transmission. Many of these infections could have been reduced by timely diagnosis and the delivery of interventions aimed at preventing mother-to-child HIV transmission. This perspective examines the attitudes preventing women from accessing HIV testing early on during pregnancy and the issues and challenges that remain in the institutionalization of interventions to prevent mother-to-child HIV transmission at labor and delivery. Socio-cultural and economic factors prevent women from accessing testing at an opportune time during pregnancy. In addition, a lack of adequate infrastructure often prevents timely delivery of interventions to those who access testing at the last minute (i.e., during labor and delivery). In the wake of a pediatric HIV epidemic and the need for lifelong provision of antiretroviral therapy to infected children, a simple strategy for provision of round-the-clock rapid testing and counseling services in the labor rooms may be cost saving to the healthcare systems worldwide.]]&gt;</body>
  </document>
  <document>
    <id>286378</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TD4-4FJW177-1&amp;_user=910131&amp;_coverDate=01%2F09%2F2006&amp;_rdoc=14&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%235188%232006%23999759998%23612777%23FLA%23display%23Volume)&amp;_cdi=5188&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=14&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=b3c274719cf10bca4a3767309da7beb1]]&gt;</url>
    <title>Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children </title>
    <publicationDate>2006-12-09T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,RESPIRATORY INFECTIONS,BODY PART AFFECTED,AIRBORNE,TRANSMISSION MODE,INFLUENZA,INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ To inform the development of a national influenza immunisation programme and the potential role of antiviral drugs in young children, we studied 613 children aged 71 months or younger who attended Leicester Childrens’ Hospital during winter 2001–2002. During periods of respiratory syncytial virus (RSV), influenza, and human metapneumovirus activity, an estimated 12.2% (95% CI: 11.4–13.1), 7.1% (6.3–7.9), and 2.5% (2.1–2.9), respectively, of all medical cases assessed in the hospital were associated with these infections. The respective rates of hospital assessments for RSV, influenza, and human metapneumovirus (HMPV) were 1042 (95% CI: 967–1021), 394 (348–443), and 223 (189–262) per 100,000 children, and for admissions were 517 (465–574), 144 (117–175), and 126 (101–156) per 100,000. Few children with influenza had a prior risk factor. Children with influenza were admitted a median of 4 days after onset of illness and none was coded at discharge as influenza. We conclude that antivirals have little role in the hospital management of children with influenza. Our data provide health economists with information to evaluate the place of universal immunisation of young children against influenza. Hospitalisation rates decreased markedly with referral age, so vaccine would need to be given in early infancy for maximum benefit. ]]&gt;</body>
  </document>
  <document>
    <id>308986</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.informaworld.com/smpp/content~content=a792732395~db=all]]&gt;</url>
    <title>Rational design of novel antibacterial vaccines with an emphasis on tuberculosis</title>
    <publicationDate>2008-03-03T00:00:00</publicationDate>
    <publisher>Informa Pharmaceutical Science</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,MARCH 09,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Vaccines are available for some, but not all, bacterial pathogens. Accordingly, bacterial pathogens still cause major health problems. Novel insights into the basic immunological mechanisms involved in protection against bacteria will provide guidelines for the design of novel vaccines. In particular, these include broad-acting vaccines composed of protein antigens shared by all members of a given pathogen group but absent in the human host and vaccines which operate via T-cells.]]&gt;</body>
  </document>
  <document>
    <id>308987</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B7GW0-4PF6W36-2&amp;_user=855288&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000046143&amp;_version=1&amp;_urlVersion=0&amp;_userid=855288&amp;md5=ce9fc2a87b203ca4bfa21019f7868b9a]]&gt;</url>
    <title>Rational design of vaccines against tuberculosis directed by basic immunology</title>
    <publicationDate>2008-01-03T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,TUBERCULOSIS,MYCOBACTERIUM,MARCH 09,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis represents a serious problem for public health worldwide, and effective vaccines are urgently required. This represents a significant challenge as the causative bacterial agent, Mycobacterium tuberculosis, has developed strategies to persist in infected hosts despite the presence of potent T-cell-mediated immune responses. New advances in basic immunology are giving us improved understanding of what constitutes a protective immune response and ways this response is manipulated by the bacillus. Such insights should inform us how to design more effective vaccination strategies against intracellular pathogens.]]&gt;</body>
  </document>
  <document>
    <id>308978</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?author=Dockrell&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=5]]&gt;</url>
    <title>Real vaccines in the real world: tuberculosis vaccines move south.</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,VACCINES / IMMUNISATION,PREVENTION,INFECTIONS,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MARCH 09,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ No abstract available without a subscription.]]&gt;</body>
  </document>
  <document>
    <id>345955</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6TD4-4X3V4K0-3-1&amp;_cdi=5188&amp;_user=8810565&amp;_pii=S0264410X09012201&amp;_orig=search&amp;_coverDate=11%2F05%2F2009&amp;_sk=999729952&amp;view=c&amp;wchp=dGLzVzz-zSkWb&amp;md5=be26109f6d16e94a2b90f23ed6afeecd&amp;ie=/sdarticle.pdf]]&gt;</url>
    <title>Recombinant Mycobacterium bovis BCG</title>
    <publicationDate>2009-08-29T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,PREVENTION,TUBERCULOSIS,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,VACCINES / IMMUNISATION,BCG,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Bacillus Calmette–Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens and the adjuvanticity of BCG are the basis of the potential use of this attenuated mycobacterium as a recombinant vaccine. Over the years, a range of strategies has been developed to allow controlled and stable expression of viral, bacterial and parasite antigens in BCG. Herein, we review the strategies developed to express heterologous antigens in BCG and the immune response elicited by recombinant BCG constructs. In addition, the use of recombinant BCG as an immunomodulator and future perspectives of BCG as a recombinant vaccine vector are discussed.]]&gt;</body>
  </document>
  <document>
    <id>286381</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop53.pdf]]&gt;</url>
    <title>Recommendations for the screening of specimens for Corynebacterium species (QSOP 53)</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286382</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop18.pdf]]&gt;</url>
    <title>Recommended minimum internal quality control in food mcrobiology testing laboratories (QSOP 18)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>297224</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpch.ac.uk/doc.aspx?id_Resource=1917]]&gt;</url>
    <title>Reducing Mother to Child Transmission of HIV: Update Report of an Intercollegiate Working Party</title>
    <publicationDate>2006-07-03T00:00:00</publicationDate>
    <publisher>Royal College of Paediatrics and Child Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,POPULATION GROUPS,CHILDREN,PREGNANT WOMEN,ADULTS,NOV 08,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2008]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;At the time of publication of the first intercollegiate report in 1998, the proportion of pregnant women with HIV in the UK whose diagnosis was known before delivery was very low. This meant that an opportunity for reducing mother to child transmission of the virus was being missed. Since that time, enormous strides have been made in improving the uptake of testing in antenatal clinics, achieving the Department of Health target of 80% uptake by the end of 2002 and since surpassing it. The agencies and health professionals involved can feel justifiably proud of this outstanding achievement. &lt;/P&gt;
&lt;P&gt;This updated brief report details the progress made to date and then goes on to address some of the challenges in clinical management that health professionals are still facing. It is not meant to be a comprehensive treatise on the management of HIV in pregnancy as such publications are available elsewhere. Rather, this publication is meant to document the success that has been achieved, to act as a reminder that there is no room for complacency and to provide recommendations for addressing ongoing and future challenges in the field.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286383</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/jinf.2001.0898]]&gt;</url>
    <title>Reflections on Epstein-Barr Virus: Some Recently Resolved Old Uncertainties</title>
    <publicationDate>2001-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,EPSTEIN-BARR VIRUS (EBV),VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The change over recent decades in perceptions of the role of viruses in human cancer-causation is illustrated by the reception given to the discovery of Epstein–Barr virus (EBV) in 1964 compared to that of Kaposi's sarcoma herpesvirus (KSHV or HHV-8) in 1994. Very new data on EBV-like agents in New World monkeys is considered in relation to the antiquity of the association of proto-EBV with early anthropoids. Although the finding that individuals without B lymphocytes do not seem to be infected with EBV appears to have resolved the controversy regarding the permissive cell type producing infectious virus in the oropharynx, the presence of EBV in certain squamous and other epithelial cells raises continuing problems which are discussed. Among many recent successes of molecular biology applied to EBV, new information from such investigations on the genetic defect in X-linked lymphoproliferative syndrome now explains the cause of the disastrous pathological changes underlying the disease. Finally, current progress with vaccines against EBV is reviewed.]]&gt;</body>
  </document>
  <document>
    <id>286385</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/333/7563/321]]&gt;</url>
    <title>Research - A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice.</title>
    <publicationDate>2006-07-17T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TRANSMISSION MODE,CONTACT,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,CONJUNCTIVITIS,EYE INFECTIONS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This study aimed to assess different management strategies for acute infective conjunctivitis using an open, factorial, randomised controlled trial in 30 general practices in southern England. 307 adults and children with acute infective conjunctivitis were participants. One of three antibiotic prescribing strategies—immediate antibiotics (chloramphenicol eye drops; n = 104), no antibiotics (controls; n = 94), or delayed antibiotics (n = 109); a patient information leaflet or not; and an eye swab or not were used. Results showed that prescribing strategies did not affect the severity of symptoms but the duration of moderate symptoms was less with antibiotics. Compared with no initial offer of antibiotics, antibiotic use was higher in the immediate antibiotic group, as was belief in the effectiveness of antibiotics, and intention to reattend for eye infections. A patient information leaflet or eye swab had no effect on the main outcomes. Reattendance within two weeks was less in the delayed compared with immediate antibiotic group. Delayed prescribing of antibiotics is probably the most appropriate strategy for managing acute conjunctivitis in primary care. It reduces antibiotic use, shows no evidence of medicalisation, provides similar duration and severity of symptoms to immediate prescribing, and reduces reattendance for eye infections.]]&gt;</body>
  </document>
  <document>
    <id>330530</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/gtj5276774573478/]]&gt;</url>
    <title>Responding to her question: a review of the influence of pregnancy on HIV disease progression in the context of expanded access to HAART in sub-Saharan Africa</title>
    <publicationDate>2009-03-20T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,ANTIVIRALS,ANTIMICROBIALS,PREGNANT WOMEN,CHILDREN,ADULTS,TREATMENT,POPULATION GROUPS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In 2007, sub-Saharan Africa was home to over half of all women living with HIV. The vast majority of these women are of reproductive age, which raises concerns about the high incidence of pregnancy. As access to antiretroviral treatment is rapidly scaled up, two important questions must be answered: (1) Does pregnancy impact HIV disease progression?; (2) Does pregnancy modify the highly active antiretroviral therapy (HAART) response on HIV disease progression? A systematic review of the biomedical literature was conducted and seven relevant studies were identified. To date, it appears that there is no effect of pregnancy on HIV disease progression. Furthermore, initial studies in high-income countries suggest that pregnancy may positively modify the HAART response. These findings, however, must be interpreted with caution as it remains unclear how other factors, such as adherence, may influence the relationship between pregnancy, HIV disease progression, and HAART.]]&gt;</body>
  </document>
  <document>
    <id>393374</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-2458-10-401.pdf]]&gt;</url>
    <title>Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand</title>
    <publicationDate>2010-07-05T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,PREVENTION,INFECTIONS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Following universal access to antiretroviral therapy in Thailand, evidence from National AIDS Spending Assessment indicates a decreasing proportion of expenditure on prevention interventions. To prompt policymakers to revitalize HIV prevention, this study identifies a comprehensive list of HIV/AIDs preventive interventions that are likely to be effective and cost-effective in Thailand.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A systematic review of the national and international literature on HIV prevention strategies from 1997 to 2008 was undertaken. The outcomes used to consider the effectiveness of HIV prevention interventions were changes in HIV risk behaviour and HIV incidence. Economic evaluations that presented their results in terms of cost per HIV infection averted or cost per quality-adjusted life year (QALY) gained were also included. All studies were assessed against quality criteria.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: The findings demonstrated that school based-sex education plus life-skill programs, voluntary and routine HIV counselling and testing, male condoms, street outreach programs, needle and syringe programs, programs for the prevention of mother-to-child HIV transmission, male circumcision, screening blood products and donated organs for HIV, and increased alcohol tax were all effective in reducing HIV infection among target populations in a cost-effective manner.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: We found very limited local evidence regarding the effectiveness of HIV interventions amongst specific high risk populations. This underlines the urgent need to prioritise health research resources to assess the effectiveness and cost-effectiveness of HIV interventions aimed at reducing HIV infection among high risk groups in Thailand.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345461</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/download?pub=infobike%3a%2f%2fiuatld%2fijtld%2f2009%2f00000013%2f00000007%2fart00005&amp;mimetype=application%2fpdf]]&gt;</url>
    <title>Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review</title>
    <publicationDate>2009-07-13T00:00:00</publicationDate>
    <publisher>The Union</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,TREATMENT,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To evaluate the efficacy and safety of rifapentine (RPT) vs. rifampicin (RMP) for the treatment of pulmonary tuberculosis (PTB).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: Systematic review of randomised controlled trials (RCTs) that compared combination drug regimens containing RPT with those containing RMP for the treatment of drug-susceptible or previously untreated PTB.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Nine RCTs were identified. Statistically significant differences were not found in the cure rates, severe adverse effects, severe hepatotoxicity or bacteriological relapse rates between the regimens containing once- or twice-weekly RPT and those containing daily RMP for human immunodefi ciency virus (HIV) negative patients, but were found in the bacteriological relapse rates between regimens containing once-weekly or less frequent RPT and those containing twice- or thrice-weekly RMP: the pooled relative risks in the two subgroups were respectively 1.71 (95%CI 1.13–2.58, P = 0.01) and 2.44 (95%CI 1.15–5.18, P = 0.02). The trial for HIV-positive patients did not show significant differences in the sputum&lt;BR&gt;conversion rate, severe adverse effects or bacteriological relapse rate between the RPT- and RMP-containing regimens; four of the five relapses were associated with the RPT-containing regimen, but none of the three relapses with the RMP-containing regimen produced monoresistance to rifamycin (RIF).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Once- or twice-weekly RPT and daily RMP have similar efficacy and safety for the treatment of HIV-negative PTB, but once-weekly or less frequent use of RPT, in comparison with twice- or thrice-weekly RMP, increases the risk of bacteriological relapse. RPT might increase the risk of resistance to RIF in HIV-positive patients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347277</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Rise-in-mouth-cancer-linked-to-STI.aspx]]&gt;</url>
    <title>Rise in mouth cancer linked to STIs</title>
    <publicationDate>2010-03-26T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HERPES,INFECTIONS,HUMAN PAPILLOMAVIRUS (HPV),VIRUSES,MICROORGANISM,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Telegraph reported that a “rise in mouth cancer may be due to sexually transmitted infection”. The newspaper said that there has been a 50% increase in the number of mouth cancers in the last 20 years, and the increase appears to be in those cases related to the human papilloma virus (HPV).&lt;/P&gt;
&lt;P&gt;The story is based on an editorial in the British Medical Journal by cancer specialists, which highlighted an increase in the numbers of a specific type of throat cancer in the UK. The specialists also discussed studies from other countries that show an increase in the proportion of HPV-related throat cancers.&lt;/P&gt;
&lt;P&gt;The editorial reported on a very small number of studies, but it shows that there may be a need to investigate the incidence of HPV-related throat cancers in the UK, to track these cases and to see if HPV-related cancers should be treated differently to non-HPV-related throat cancers. There is insufficient evidence at the moment to suggest that the HPV vaccination, currently available for teenage girls, should also be given to boys.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The authors have highlighted the increasing incidence of oropharyngeal cancers in men in the UK. They have associated this with an increase in the proportion of HPV-related cancers based on studies in Sweden and the US.&lt;/P&gt;
&lt;P&gt;Further research is needed to assess whether the increase in oropharyngeal cancers in British men reflects an increase in HPV-related or non-HPV-related cancers. As HPV-related and non-HPV-related throat cancers have a different prognosis for survival, further research may look at whether different treatments can have different effects on these two throat cancer subtypes.&lt;/P&gt;
&lt;P&gt;There is insufficient evidence at present to suggest that the HPV vaccination currently given to teenage girls should also be given to boys.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Mehanna H, Jones TM, Gregoire V, Ang KK.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/extract/340/mar25_1/c1439" target="_blank"&gt;Oropharyngeal carcinoma related to human papillomavirus&lt;/A&gt;. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286392</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/ncidod/EID/vol9no12/03-0355.htm]]&gt;</url>
    <title>Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo</title>
    <publicationDate>2003-12-01T00:00:00</publicationDate>
    <publisher>Emerging Infectious Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,BLOOD AND BODY FLUIDS,INFECTIONS,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ ..."We conducted two antibody surveys to assess risk factors for Marburg hemorrhagic fever in an area of confirmed Marburg virus transmission in the Democratic Republic of the Congo. Questionnaires were administered and serum samples tested for Marburg-specific antibodies by enzyme-linked immunosorbent assay. Fifteen (2%) of 912 participants in a general village cross-sectional  antibody survey were positive for Marburg immunoglobulin G antibody. Thirteen (87%) of these 15 were men who worked in the local gold mines. Working as a miner (odds ratio [OR] 13.9, 95% confidence interval [CI] 3.1 to 62.1) and receiving injections (OR 7.4, 95% CI 1.6 to 33.2) were associated with a positive antibody result. All 103 participants in a targeted antibody survey of healthcare workers were antibody negative. Primary transmission of Marburg virus to humans likely occurred via exposure to a still unidentified reservoir in the local mines. Secondary transmission appears to be less common with Marburg virus than with Ebola virus, the other known filovirus."....]]&gt;</body>
  </document>
  <document>
    <id>286393</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://thorax.bmjjournals.com/cgi/content/abstract/thx.2005.045963v1]]&gt;</url>
    <title>Risk factors for multi-drug resistant tuberculosis in Europe: a systematic review </title>
    <publicationDate>2005-10-27T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONTACT,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background: The resurgence of tuberculosis (TB) in western countries has been attributed to the HIV epidemic, immigration and drug resistance. Multi-drug-resistant tuberculosis (MDR-TB) is due to the transmission of MDR Mycobacterium tuberculosis strains in new cases, or to selection of single-drug resistant strains induced by previous treatment. The aim of this report is to determine risk factors for MDR-TB in Europe. 
Methods: A systematic review was conducted of published reports of risk factors associated with MDR-TB in Europe. Meta-analysis, meta-regression and sub-grouping were used to pool risk estimates of MDR-TB and analyse associations with age, gender, immigrant status, HIV status, occurrence year, study design and area of Europe. 
Results: Twenty-nine papers were eligible for the review from 123 identified in the search. The pooled risk of MDR-TB was 10.23 times higher in previously treated than in never-treated cases, with wide heterogeneity between studies. Study design and geographical area were associated with MDR-TB risk estimates in previously treated patients, which in turn was higher in cohort studies carried-out in western Europe (RR=12.63; 95%CI=8.20-19.45) than in eastern Europe (RR=8.53;95%CI=6.57-11.06). National estimates were possible for 6 countries. MDR-TB cases were more likely to be foreign-born (OR=2.46;95%CI=1.86-3.24), younger than 65 years (OR=2.53;95%CI=1.74-4.83), male (OR=1.38;95%CI=1.16-1.65), and HIV-positive (OR=3.52; 95%CI=2.48-5.01). 
Conclusions: Previous treatment was the strongest determinant of MDR-TB in Europe. Detailed study of the reasons for inadequate treatment could improve control strategies. The risk of MDRTB in foreign-born people needs to be re-evaluated, taking into account any previous treatment.]]&gt;</body>
  </document>
  <document>
    <id>308935</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?title=Robert+Koch+and+the+discovery+of+the+tubercle+bacillus&amp;title_type=tka&amp;author=Harries&amp;year_from=1998&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>Robert Koch and the discovery of the tubercle bacillus: The challenge of HIV and tuberculosis 125 years later.</title>
    <publicationDate>2008-03-03T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ WHO was this great man? Born in 1843 in Germany into a poor mining family, Robert Koch astounded his parents at the age of 5 years by announcing that with the aid of newspapers he had taught himself to read, this feat foreshadowing the intelligence and perseverance that were to characterise his later life. He qualified as a medical doctor, worked as a district medical officer, was appointed Professor of Hygiene and 20 years later, in 1905, was awarded that exalted honour, the Nobel Prize in Physiology or Medicine. In 1910, at the age of 66, his great heart gave out and he died in Baden-Baden, Germany. We remember him because he was without doubt the father of that new generation of scientists known as ‘the microbe hunters’. Koch discovered the cause of anthrax, tuberculosis (TB) and cholera, and Koch’s postulates, the proof that a particular microbe causes a particular disease, are still taught to this day to every new generation of medical students.]]&gt;</body>
  </document>
  <document>
    <id>308958</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/abstract/337/jul10_1/a257]]&gt;</url>
    <title>Role of co-trimoxazole prophylaxis in reducing mortality in HIV-infected adults being treated for tuberculosis: randomised clinical trial.</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,TUBERCULOSIS,INFECTIONS,DIAGNOSIS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,VIRUSES,MYCOBACTERIUM TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: To assess the impact of prophylactic oral cotrimoxazole in reducing mortality in HIV positive Zambian adults being treated for pulmonary tuberculosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design&lt;/STRONG&gt;: Double blind placebo controlled randomised clinical trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants&lt;/STRONG&gt;: Two groups of antiretroviral treatment naive adults with HIV infection: patients newly diagnosed as having tuberculosis and receiving tuberculosis treatment either for the first time or for retreatment after relapse; previously treated patients not receiving treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention&lt;/STRONG&gt;:Oral co-trimoxazole or matching placebo daily.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Primary outcome measures&lt;/STRONG&gt;: Time to death and occurrence of serious adverse events related to study drug.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: 1003 patients were randomised: 835 (416 cotrimoxazole, 419 placebo) were receiving treatment for tuberculosis, 762 (376 co-trimoxazole, 386 placebo) of them newly diagnosed previously untreated patients and 73 (40 co-trimoxazole, 33 placebo) receiving a retreatment regimen;168 (84 co-trimoxazole, 84 placebo) were not on treatment but had received treatment in the past. Of 835 participants receiving tuberculosis treatment, follow-up information was available for 757, with a total of 1012.6 person years of follow-up. A total of 310 (147 co-trimoxazole, 163 placebo) participants died, corresponding to death rates of 27.3 and 34.4 per 100 person years. In the Cox regression analysis, the hazard ratio for death (co-trimoxazole:placebo) was 0.79 (95% confidence interval 0.63 to 0.99). The effect of cotrimoxazole waned with time, possibly owing to falling adherence levels; in a per protocol analysis based on patients who spent at least 90% of their time at risk supplied with study drug, the hazard ratio was 0.65 (0.45 to 0.93). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: Prophylaxis with co-trimoxazole reduces mortality in HIV infected adults with pulmonary tuberculosis. Co-trimoxazole was generally safe and well tolerated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330544</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nature.com/jp/journal/v29/n5/abs/jp2008187a.html]]&gt;</url>
    <title>Role of placenta in the vertical transmission of human immunodeficiency virus</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,ADULTS,CHILDREN,POPULATION GROUPS,PREGNANT WOMEN,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: Review the role and mechanism of in utero placental transmission of HIV-1. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study design&lt;/STRONG&gt;: A thorough review based on a literature search for publications relevant to this subject was performed using relevant search terms. Articles that describe the genetic and pathophysiology of vertical transmission have been acknowledged. The articles pertinent to the topic were selected to support the discussion. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Vertical transmission may occur through CD4+ endothelial tissues or CD4+ Hofbauer cells. Trophoblasts and villi have CD4 receptors, which make them potential candidates for HIV infection. Placental cytokines and chemokines influence HIV replication in trophoblasts. Genetic analysis of HIV-1 sequences verify the interaction of HIV-1 and placental tissue. The vertical transmission of HIV-1 characterized by selection of genotype variant that escape the mother's immune system. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Placental transmission of HIV-1 is a complex incompletely understood process which requires advanced studies. The available literature provides information with regards to the interactions of placental cells with HIV.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286395</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/507554]]&gt;</url>
    <title>Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics.</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>University of Chicago Press</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PANDEMIC INFLUENZA,SEASONAL INFLUENZA,VIRUSES,INFLUENZA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Laboratory diagnosis of influenza is critical to its treatment and surveillance. With the emergence of novel and highly pathogenic avian influenza viruses, the role of the laboratory has been further extended to include isolation and subtyping of the virus to monitor its appearance and facilitate appropriate vaccine development. Recent progress in enhancing testing for influenza promises to both improve the management of patients with influenza and decrease associated health care costs. The present review covers the technological characteristics and utilization features of currently available diagnostic tests, the factors that influence the selection of such tests, and the developments that are essential for pandemic preparedness.]]&gt;</body>
  </document>
  <document>
    <id>342757</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/MMR-vaccine-autism-scare-doctor.aspx]]&gt;</url>
    <title>Ruling on doctor in MMR scare</title>
    <publicationDate>2010-01-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MUMPS,MEASLES,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MEASLES,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,RUBELLA,VACCINES / IMMUNISATION,MICROORGANISM,VIRUSES,MUMPS VIRUS,MEASLES VIRUS,RUBELLA VIRUS,ADDED 2010,FEB 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The doctor who sparked the MMR controversy was “dishonest, irresponsible and showed callous disregard for the distress and pain” of children, the General Medical Council (GMC) has ruled. The ruling has been reported by many newspapers.&lt;/P&gt;
&lt;P&gt;The GMC said Dr Andrew Wakefield “abused his position of trust” when conducting research into a proposed link between the MMR vaccine, autism and bowel disorders. He carried out clinically unnecessary and invasive tests on children without ethical approval or appropriate qualifications. &lt;/P&gt;
&lt;P&gt;Wakefield also failed to disclose conflicts of interest to &lt;EM&gt;The Lancet&lt;/EM&gt; medical journal, which in 1998 published the research paper that sparked the MMR scare. The paper has since been withdrawn by &lt;EM&gt;The Lancet&lt;/EM&gt; and discredited. The scare nonetheless led to a dramatic drop in MMR vaccination rates and a rise in cases of measles.&lt;/P&gt;
&lt;P&gt;The ruling comes after a two-and-a-half-year investigation by the GMC.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.cochrane.org/reviews/en/ab004407.html" target="_blank"&gt;latest systematic review&lt;/A&gt;, conducted by the Cochrane Collaboration, analysed evidence from 31 studies and concluded that there was no evidence for a link between MMR and autism.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;In 2003, following an extensive review, the World Health Organization stated there was &lt;A href="http://www.who.int/vaccine_safety/topics/mmr/mmr_autism/en/" target="_blank"&gt;no evidence to suggest MMR caused autism&lt;/A&gt;.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;All results of published vaccine trials reaffirm the safety and efficacy of the MMR vaccine. Rates of autism have not increased since the MMR vaccination was introduced.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>342757</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/MMR-vaccine-autism-scare-doctor.aspx]]&gt;</url>
    <title>Ruling on doctor in MMR scare</title>
    <publicationDate>2010-01-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MUMPS,MEASLES,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MEASLES,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,RUBELLA,VACCINES / IMMUNISATION,MICROORGANISM,VIRUSES,MUMPS VIRUS,MEASLES VIRUS,RUBELLA VIRUS,ADDED 2010,FEB 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The doctor who sparked the MMR controversy was “dishonest, irresponsible and showed callous disregard for the distress and pain” of children, the General Medical Council (GMC) has ruled. The ruling has been reported by many newspapers.&lt;/P&gt;
&lt;P&gt;The GMC said Dr Andrew Wakefield “abused his position of trust” when conducting research into a proposed link between the MMR vaccine, autism and bowel disorders. He carried out clinically unnecessary and invasive tests on children without ethical approval or appropriate qualifications. &lt;/P&gt;
&lt;P&gt;Wakefield also failed to disclose conflicts of interest to &lt;EM&gt;The Lancet&lt;/EM&gt; medical journal, which in 1998 published the research paper that sparked the MMR scare. The paper has since been withdrawn by &lt;EM&gt;The Lancet&lt;/EM&gt; and discredited. The scare nonetheless led to a dramatic drop in MMR vaccination rates and a rise in cases of measles.&lt;/P&gt;
&lt;P&gt;The ruling comes after a two-and-a-half-year investigation by the GMC.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.cochrane.org/reviews/en/ab004407.html" target="_blank"&gt;latest systematic review&lt;/A&gt;, conducted by the Cochrane Collaboration, analysed evidence from 31 studies and concluded that there was no evidence for a link between MMR and autism.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;In 2003, following an extensive review, the World Health Organization stated there was &lt;A href="http://www.who.int/vaccine_safety/topics/mmr/mmr_autism/en/" target="_blank"&gt;no evidence to suggest MMR caused autism&lt;/A&gt;.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;All results of published vaccine trials reaffirm the safety and efficacy of the MMR vaccine. Rates of autism have not increased since the MMR vaccination was introduced.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345900</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/MMR-vaccine-autism-scare-doctor.aspx]]&gt;</url>
    <title>Ruling on doctor in MMR scare</title>
    <publicationDate>2010-01-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MUMPS,MEASLES,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINE PREVENTABLE DISEASES,RUBELLA,CHILDHOOD VACCINES,MEASLES,POPULATION GROUPS,CHILDREN,VIRUSES,RUBELLA VIRUS,MUMPS VIRUS,MEASLES VIRUS,MICROORGANISM,VACCINES / IMMUNISATION,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The doctor who sparked the MMR controversy was “dishonest, irresponsible and showed callous disregard for the distress and pain” of children, the General Medical Council (GMC) has ruled. The ruling has been reported by many newspapers.&lt;/P&gt;
&lt;P&gt;The GMC said Dr Andrew Wakefield “abused his position of trust” when conducting research into a proposed link between the MMR vaccine, autism and bowel disorders. He carried out clinically unnecessary and invasive tests on children without ethical approval or appropriate qualifications.&lt;/P&gt;
&lt;P&gt;Wakefield also failed to disclose conflicts of interest to The Lancet medical journal, which in 1998 published the research paper that sparked the MMR scare. The paper has since been withdrawn by The Lancet and discredited. The scare nonetheless led to a dramatic drop in MMR vaccination rates and a rise in cases of measles.&lt;/P&gt;
&lt;P&gt;The ruling comes after a two-and-a-half-year investigation by the GMC.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H3&gt;There are a number of evidence-based resources to help parents understand MMR and vaccination:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS Choices Health A-Z: &lt;A href="http://www.nhs.uk/conditions/mmr/Pages/Introduction.aspx" target="_blank"&gt;MMR vaccination&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS Choices Health A-Z: &lt;A href="http://www.nhs.uk/Conditions/Immunisations-childhood/Pages/Introduction.aspx?url=Pages/what-is-it.aspx" target="_blank"&gt;child vaccinations&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS Choices Birth to Five: &lt;A href="http://www.nhs.uk/Planners/birthtofive/Pages/vaccinationsexplained.aspx" target="_blank"&gt;child vaccinations explained&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS &lt;A href="http://www.immunisation.nhs.uk/" target="_blank"&gt;Immunisation Information&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Health Protection Agency: &lt;A href="http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/1204100449462/" target="_blank"&gt;vaccinations for measles, mumps and rubella&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The National Autistic Society: &lt;A href="http://www.nas.org.uk/nas/jsp/polopoly.jsp?d=459&amp;amp;a=17709" target="_blank"&gt;statement on MMR&lt;/A&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345900</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/MMR-vaccine-autism-scare-doctor.aspx]]&gt;</url>
    <title>Ruling on doctor in MMR scare</title>
    <publicationDate>2010-01-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MUMPS,MEASLES,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINE PREVENTABLE DISEASES,RUBELLA,CHILDHOOD VACCINES,MEASLES,POPULATION GROUPS,CHILDREN,VIRUSES,RUBELLA VIRUS,MUMPS VIRUS,MEASLES VIRUS,MICROORGANISM,VACCINES / IMMUNISATION,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The doctor who sparked the MMR controversy was “dishonest, irresponsible and showed callous disregard for the distress and pain” of children, the General Medical Council (GMC) has ruled. The ruling has been reported by many newspapers.&lt;/P&gt;
&lt;P&gt;The GMC said Dr Andrew Wakefield “abused his position of trust” when conducting research into a proposed link between the MMR vaccine, autism and bowel disorders. He carried out clinically unnecessary and invasive tests on children without ethical approval or appropriate qualifications.&lt;/P&gt;
&lt;P&gt;Wakefield also failed to disclose conflicts of interest to The Lancet medical journal, which in 1998 published the research paper that sparked the MMR scare. The paper has since been withdrawn by The Lancet and discredited. The scare nonetheless led to a dramatic drop in MMR vaccination rates and a rise in cases of measles.&lt;/P&gt;
&lt;P&gt;The ruling comes after a two-and-a-half-year investigation by the GMC.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H3&gt;There are a number of evidence-based resources to help parents understand MMR and vaccination:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS Choices Health A-Z: &lt;A href="http://www.nhs.uk/conditions/mmr/Pages/Introduction.aspx" target="_blank"&gt;MMR vaccination&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS Choices Health A-Z: &lt;A href="http://www.nhs.uk/Conditions/Immunisations-childhood/Pages/Introduction.aspx?url=Pages/what-is-it.aspx" target="_blank"&gt;child vaccinations&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS Choices Birth to Five: &lt;A href="http://www.nhs.uk/Planners/birthtofive/Pages/vaccinationsexplained.aspx" target="_blank"&gt;child vaccinations explained&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS &lt;A href="http://www.immunisation.nhs.uk/" target="_blank"&gt;Immunisation Information&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Health Protection Agency: &lt;A href="http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/1204100449462/" target="_blank"&gt;vaccinations for measles, mumps and rubella&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The National Autistic Society: &lt;A href="http://www.nas.org.uk/nas/jsp/polopoly.jsp?d=459&amp;amp;a=17709" target="_blank"&gt;statement on MMR&lt;/A&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286400</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop6.pdf]]&gt;</url>
    <title>Sabouraud Agar (MSOP 6)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,INFECTIONS,MICROORGANISM,CANDIDA ALBICANS,FUNGI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>371437</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1256639904173]]&gt;</url>
    <title>Safe Supplies: Testing the Nation</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HEPATITIS,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,MALARIA,INFECTIONS,HEPATITIS B,HEPATITIS C,PLASMODIUM,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,DIAGNOSIS,TRAVEL ASSOCIATED INFECTIONS,VIRUSES,HEPATITIS B VIRUS,HEPATITIS C VIRUS,HEPATITIS VIRUS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),PARASITES,MOSQUITO,MICROORGANISM,SEPT 10,ADDED 2010,WHAT'S NEW]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report presents data on infections in blood and tissue donors for the calendar year 2009 together with antenatal testing data. The role of the unit in horizon scanning for new infections is also discussed.&lt;/P&gt;
&lt;P&gt;Of note this year is the reporting of additional information on the testing of tissue and cord blood donors. Data are reported for hepatitis B anti-core testing and discretionary testing for malaria and Trypanosoma cruzi in these donors. Changes in the testing laboratories resulted in a new nucleic acid testing system being introduced with an additional test to detect hepatitis B virus DNA in blood donors. This test identified three individuals with early acute hepatitis B infections and in addition two donors with chronic infections which had not previously been detected by hepatitis B surface antigen screening.&lt;/P&gt;
&lt;P&gt;Read the report for 2008 &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1256639904173" target="_blank"&gt;here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286401</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop49.pdf]]&gt;</url>
    <title>Safe use of plastic bags for incubation of food samples (QSOP 49)</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document describes the use of twist seal plastic bags as a substitute for honey jars when
testing food samples.

At a meeting of the PHLS Safety Working Group in 2001 the current working arrangements for
the handling and isolation of E. coli O157 were reviewed. A recommendation was made to
substitute the use of honey jars with plastic bags that can be securely closed ie twist seal
plastic bags.

It is recommended that these plastic bags are used for all food sample enrichments.
The advantages associated with the use of twist seal plastic bags include:
• Minimisation of aerosol production
• There is no need to transfer liquids between homogeniser bags and jars, this further
minimises the risk of cross contamination between samples
• They can be used effectively for enrichment of Campylobacter species because the size
of the head space of the bags is easily controlled
• They can be space saving for the purpose of disposal
• They are safer than glass and less likely to break or explode when dropped
• They offer a cost saving if used as an alternative to plastic jars]]&gt;</body>
  </document>
  <document>
    <id>345551</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jrheum.org/content/36/5/914.abstract]]&gt;</url>
    <title>Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>The Journal of Rheumatology Publishing Company Ltd</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: The magnitude of the risk of reactivation of tuberculosis (TB) on use of etanercept, especially in patients with positive purified protein derivative (PPD) test, has not been assessed. We evaluated the risk of developing active TB among PPD-positive patients treated with etanercept.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; All patients with a positive PPD test, as defined by American Thoracic Society guidelines, who received etanercept at Cook County Hospital from 2001 to 2008 were retrospectively reviewed. The primary endpoint was the development of active TB either while receiving or after completing etanercept therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Four hundred eighty-seven patients received etanercept, of whom 84 were PPD-positive and constituted the primary cohort. The cohort was composed largely of patients who were at high risk for development of active TB: born in endemic area (80%), ethnic/racial minorities (51 Hispanic, 16 African American, and 8 Asian), and low socioeconomic status (66, 78.57%). Overall etanercept exposure was a mean of 24.6 months (range 3 to 60 mo), with 196 patient-years of etanercept exposure in PPD-positive individuals. Indications for etanercept use included rheumatoid arthritis 58 (69%), ankylosing spondylitis 11 (13%), psoriatic arthritis 13 (15.5%), juvenile inflammatory arthritis 1 (1.2%), and vasculitis 1 (1.2%). Of the 80 subjects, 74 received treatment for latent TB infection (LTBI) prior to initiating etanercept. A comprehensive review of these patients’ medical records failed to reveal any active TB infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; This systematic analysis suggests that the risk of reactivation of LTBI during etanercept therapy is low in appropriately treated individuals. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394233</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20081389]]&gt;</url>
    <title>Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To determine from the literature whether HIV-infected women who use hormonal or intrauterine contraception are at increased risk of HIV disease progression, other adverse health outcomes, or HIV transmission to uninfected sexual partners.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: A systematic review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We searched PubMed for articles published in peer-reviewed journals through August 2009 for evidence relevant to all hormonal and intrauterine contraceptive methods and HIV/AIDS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Eight observational studies reported no increased risk of HIV disease progression with hormonal or intrauterine contraceptive use, whereas one randomized controlled trial found increased risks of declining CD4 cell count and death for hormonal contraceptive users compared with intrauterine device users. Women with HIV who used hormonal contraception had increased risks of acquiring sexually transmitted infections compared with women not using hormonal contraception, similar to the risks reported among uninfected women. One study found no association between hormonal or intrauterine contraceptive use and increased risk of HIV transmission to uninfected partners, whereas findings from nine studies examining contraceptive use and viral shedding from the genital tract were inconsistent.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Evidence regarding the safety of hormonal and intrauterine contraceptive use among women with HIV remains limited, but generally reassuring regarding adverse health effects, disease transmission to uninfected partners, and disease progression; however, one randomized trial raised concerns about enhanced disease progression among women using hormonal contraception. Preventing unintended pregnancy among women with HIV remains a high priority in public health, both for the health of the woman as well as for the prevention of mother-to-child transmission of HIV.&lt;/P&gt;
&lt;P&gt;Read the &lt;A href="nelh:374693:1" name=internalLink&gt;structured abstract&lt;/A&gt; by the Centre of Reviews and Dissemination.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286402</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop51.pdf]]&gt;</url>
    <title>Screening for Meninogcocci (BSOP 51)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,MENINGOCOCCAL MENINGITIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,NEISSERIA MENINGITIDIS,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286403</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/507550]]&gt;</url>
    <title>Seasonal and pandemic influenza preparedness: science and countermeasures.</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>University of Chicago Press</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,BODY PART AFFECTED,AIRBORNE,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,TRANSMISSION MODE,INFLUENZA,INFECTIONS,ANTIMICROBIALS,ANTIVIRALS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,VACCINE PREVENTABLE DISEASES,INFLUENZA,SEASONAL INFLUENZA,PANDEMIC INFLUENZA,INFLUENZA VACCINE,TREATMENT,MICROORGANISM,VIRUSES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza has not been treated with the degree of medical attention that the disease warrants. As such, there is not an adequate baseline of preparedness in the United States to deal with the potential of pandemic influenza. The National Institute of Allergy and Infectious Diseases (NIAID) has been working to enact measures to deal more effectively with a potential influenza pandemic and also to assist in the management of seasonal influenza. The majority of the NIAID’s efforts have been dedicated to basic research aimed ultimately at developing and testing, in clinical trials, countermeasures in the form of antiviral drugs and vaccines. Some of the NIAID’s current and planned antiviral projects include the (1) assessment of oseltamivir therapy in infants, (2) conduct of clinical trials of higher doses of osteltamivir for avian influenza, (3) appraisal of combination therapies, and (4) evaluation of the next generation of neuraminidase inhibitors. In addition, the NIAID is screening potential new antiviral drugs and evaluating novel drug targets. Similarly, significant funding has been committed to vaccine preparedness, and numerous novel candidate influenza vaccines are in various stages of development. Importantly, there is an integral relationship between preparation for seasonal influenza and preparation for pandemic influenza. Until these approaches are firmly linked, the community will not have optimized its preparedness for a pandemic.]]&gt;</body>
  </document>
  <document>
    <id>286404</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.cambridge.org/action/displayAbstract?fromPage=online&amp;aid=1217604]]&gt;</url>
    <title>Seasonal influenza in the United States, France, and Australia: transmission and prospects for control</title>
    <publicationDate>2007-07-18T00:00:00</publicationDate>
    <publisher>Cambridge University Press</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,TRANSMISSION MODE,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,AIRBORNE,BODY PART AFFECTED,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,PREVENTION,INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Recurrent epidemics of influenza are observed seasonally around the world with considerable health and economic consequences. A key quantity for the control of infectious diseases is the reproduction number, which measures the transmissibility of a pathogen and determines the magnitude of public health interventions necessary to control epidemics. Here we applied a simple epidemic model to weekly indicators of influenza mortality to estimate the reproduction numbers of seasonal influenza epidemics spanning three decades in the United States, France, and Australia. We found similar distributions of reproduction number estimates in the three countries, with mean value 1.3 and important year-to-year variability (range 0.9–2.1). Estimates derived from two different mortality indicators (pneumonia and influenza excess deaths and influenza-specific deaths) were in close agreement for the United States (correlation=0.61, P&lt;0.001) and France (correlation=0.79, P&lt;0.001), but not Australia. Interestingly, high prevalence of A/H3N2 influenza viruses was associated with high transmission seasons (P=0.006), while B viruses were more prevalent in low transmission seasons (P=0.004). The current vaccination strategy targeted at people at highest risk of severe disease outcome is suboptimal because current vaccines are poorly immunogenic in these population groups. Our results suggest that interrupting transmission of seasonal influenza would require a relatively high vaccination coverage (&gt;60%) in healthy individuals who respond well to vaccine, in addition to periodic re-vaccination due to evolving viral antigens and waning population immunity. ]]&gt;</body>
  </document>
  <document>
    <id>327555</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Seasonal-jab-and-swine-flu.aspx]]&gt;</url>
    <title>Seasonal jab and swine flu</title>
    <publicationDate>2009-10-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,RESPIRATORY INFECTIONS,INFLUENZA VACCINE,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,OCT 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A study published recently in the British Medical Journal suggests that the 2008-9 seasonal flu vaccine may offer some level of cross-protection against the swine flu virus. This is an unexpected finding as it was widely assumed that the annual flu jab would offer no protection, particularly against the severe complications of flu.&lt;/P&gt;
&lt;P&gt;There are several limitations to this case-control study, which the researchers acknowledge. Among these are the facts that the study was in only a small number of patients, and there are no guarantees that the people given the vaccine were similar enough to the people who did not have it to make the results meaningful.&lt;/P&gt;
&lt;P&gt;People in high-risk groups should still receive the swine flu vaccine. Although this study appears to suggest that people who had last winter’s seasonal flu vaccine may have been given some small level of protection, the authors of the research note that this does not mean that the seasonal flu vaccine should replace a specific swine flu vaccine, which they say is “crucial”.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Many of the 60 people with swine flu (63%) were between 21 and 60 years of age. The controls were age matched to the cases.&lt;/P&gt;
&lt;P&gt;Controls were more likely than cases to have chronic conditions that conferred a higher risk of&lt;BR&gt;Influenza-related complications. This may have been because they were selected from a respiratory hospital population that had a high incidence of these long-term conditions.&lt;/P&gt;
&lt;P&gt;In the model, the risk of having influenza A/H1N1 was significantly reduced in people who received the 2008-9 seasonal trivalent inactivated vaccine (odds ratio 0.27, 95% CI 0.11 to 0.66). Vaccine effectiveness was 73% (95% confidence interval 34% to 89%). This means that the vaccine was linked to a reduction of 73% in the odds of developing swine flu.&lt;/P&gt;
&lt;P&gt;The model also showed that the chances of having swine flu were also lower for people with underlying conditions that could make them more susceptible to have complications from flu infection, independent of their vaccination status (odds ratio 0.15, 95% CI 0.08 to 0.30).&lt;/P&gt;
&lt;P&gt;None of the eight patients with swine flu who had received the seasonal flu vaccine died. Whereas 18 of the 52 unvaccinated people (35%) with swine flu died.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;DIV class="row pad-tl clear"&gt;
&lt;DIV class="col two"&gt;
&lt;DIV class=further-reading&gt;
&lt;P&gt;Garcia-Garcia L, Valdespino-Gómez JL, Lazcano-Ponce E, et al. Partial&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/abstract/339/oct06_2/b3928" target="_blank"&gt;protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City.&lt;/A&gt; BMJ 2009; 339: b3928&lt;/P&gt;
&lt;P&gt;de Jong M.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/full/339/oct06_2/b4014" target="_blank"&gt;The future of influenza vaccines.&lt;/A&gt; BMJ 2009; 339: b4014&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV class="bookmark-wrap clear"&gt;
&lt;DIV class=clear&gt;
&lt;HR&gt;
&lt;/DIV&gt;&lt;/DIV&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286405</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001441&amp;representation=PDF]]&gt;</url>
    <title>Sensitivity of IFN-gamma Release Assay to Detect Latent Tuberculosis Infection Is Retained in HIV-Infected Patients but Dependent on HIV/AIDS Progression.</title>
    <publicationDate>2008-01-16T00:00:00</publicationDate>
    <publisher>PLoS (Public Library of Science)</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,AIRBORNE,CONTACT,BLOOD AND BODY FLUIDS,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,INFECTIOUS DISEASES,MICROORGANISM,BACTERIA,VIRUSES,MYCOBACTERIUM TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV)]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Background
Detection and treatment of latent TB infection (LTBI) in HIV infected individuals is strongly recommended to decrease morbidity and mortality in countries with high levels of HIV.

Objective
To assess the validity of a newly developed in-house ELISPOT interferon-? release assay (IGRA) for the detection of LTBI amongst HIV infected individuals, in comparison with the Tuberculin Skin Test (TST).

Methodology/Principal Findings
ESAT6/CFP10 (EC) ELISPOT assays were performed, together with a TST, in 285 HIV infected individuals recruited in HIV clinics in Dakar, Senegal, who had no signs of active TB at time of enrolment. Thirty eight of the subjects (13.3%) failed to respond to PHA stimulation and were excluded from the analysis. In the 247 remaining patients, response to PHA did not vary according to CD4 cell count categories (p = 0.51). EC ELISPOT was positive in 125 (50.6%) subjects, while 53 (21.5%) had a positive TST. Concordance between EC ELISPOT and TST was observed in 151 patients (61.1%) (kappa = 0.23). The proportion of subjects with a positive response to the EC ELISPOT assay decreased with declining CD4 counts (p trend = 0.001), but were consistently higher than the proportion of TST responders. In multivariate analysis, the risk of being EC-ELISPOT positive in HIV infected individuals was associated with age, CD4 count and HIV-1 strain.

Conclusion
Our study indicates that IGRAs using M. tuberculosis specific antigens are likely to retain their validity for the diagnosis of LTBI among HIV positive individuals, but may be impaired by T-cell anergy in severely immuno-suppressed individuals.]]&gt;</body>
  </document>
  <document>
    <id>326867</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop44.pdf]]&gt;</url>
    <title>Serological Diagnosis of Syphilis (VSOP 44)</title>
    <publicationDate>2007-08-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ SYPHILIS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,TREPONEMA PALLIDUM,DIAGNOSIS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Syphilis has re-emerged as an increasing cause of outbreaks across England and Wales in recent years, following a period of rapid decline in numbers resulting in a period when very few cases were seen in the early 1990’s. The current approach to the serological diagnosis of syphilis was established during this period of low numbers of positive cases. Many laboratories only dealt with a few positive cases and lacked experience in interpretation of serological results and therefore these positive sera were referred to regional and/or reference laboratories for further testing and confirmation. &lt;/P&gt;
&lt;P&gt;In the current situation where syphilis does not appear to be in control there is some concern that referral of sera from patients with a positive screening test without further testing may incur a delay in providing the patient with a timely result. This can result from delays due to batching of sera before referral for confirmation, time spent at regional/reference centres and inherent delays in the generation and documentation of reports. &lt;/P&gt;
&lt;P&gt;The minimum testing algorithm attempts to readdress this problem and suggests a minimum of teststhat should be performed at the primary diagnostic laboratories (marked in red) before extended testing or confirmation which can be performed at a primary diagnostic laboratories with appropriate expertise or a regional/reference centre (marked in green). Discrepant samples or those with unusual profiles should always be referred to a regional/reference centre (marked in orange). &lt;/P&gt;
&lt;P&gt;In this algorithm the EIA detecting both IgG/IgM has been chosen as the screening test as it is highly sensitive but slightly less specific than the TPPA/TPHA. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286409</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.co-pulmonarymedicine.com/pt/re/copulmonary/abstract.00063198-200405000-00003.htm;jsessionid=AOQ8rKJLfH8q1aPpQjV1oQMoLPjDbU1hoTbr12lYtK4QjeomCsFg!1032750822!-949856031!9001!-1]]&gt;</url>
    <title>Severe acute respiratory syndrome: clinical features, diagnos is and management</title>
    <publicationDate>2004-05-01T00:00:00</publicationDate>
    <publisher>Current Opinion in Pulmonary Medicine</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,CONTACT,FOOD/WATER,AIRBORNE,BODY PART AFFECTED,INFECTIONS,SARS CORONA VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Purpose of review: In November 2003, a new, life-threatening, respiratory illness named severe acute respiratory syndrome (SARS) arose from Guangdong Province in China. The illness spread across the globe, caused many major outbreaks, and had an overall mortality rate of 11%. The purpose of this review is primarily to review the clinical features, diagnosis, and management of SARS, but also to comment briefly on the epidemiology and pathogen.]]&gt;</body>
  </document>
  <document>
    <id>319571</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1227515298225]]&gt;</url>
    <title>Sexually transmitted infections and men who have sex with men in the UK: 2008 report</title>
    <publicationDate>2008-11-28T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,LYMPHOGRANULOMA VENEREUM (LGV),SYPHILIS,GONORRHOEA,HERPES,CHLAMYDIA,INFECTIONS,TREPONEMA PALLIDUM,NOV 08,BACTERIA,CHLAMYDIA,MICROORGANISM,NEISSERIA GONORRHOEA,VIRUSES,HERPES SIMPLEX VIRUS (HSV),HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN PAPILLOMAVIRUS (HPV)]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Of all new HIV diagnoses in 2007, 41% (3,160 adjusted) were among men who have sex with men (MSM), and 82% of these infections were probably acquired in the UK.&lt;/LI&gt;
&lt;LI&gt;An estimated 32,000 MSM were living with HIV, with at least one in four of those&amp;nbsp; aged 15-59 unaware of their infection.&lt;/LI&gt;
&lt;LI&gt;A total of 23,990 HIV diagnosed MSM were seen for HIV-related care, more than double the number accessing services in 1998.&lt;/LI&gt;
&lt;LI&gt;Surveillance indicates that a high proportion of MSM with an acute STI were also infected with HIV, for example 32% of those diagnosed with gonorrhoea, 40%of those with syphilis,78% with lymphogranuloma venereum and 97% with hepatitis C.&lt;/LI&gt;
&lt;LI&gt;In genitourinary medicine (GUM) clinics the uptake of HIV testing among MSM continues to increase reaching 86%, compared to 84% in 2006.&lt;/LI&gt;
&lt;LI&gt;Despite increases in HIV testing, almost one in five MSM are still diagnosed after the point at which treatment would normally begin.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319577</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1225441603957]]&gt;</url>
    <title>Sexually transmitted infections in black African and black Caribbean communities in the UK: 2008 report</title>
    <publicationDate>2008-11-28T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHLAMYDIA,HERPES,GONORRHOEA,SYPHILIS,LYMPHOGRANULOMA VENEREUM (LGV),HIV/AIDS,GENITAL WARTS (HPV),SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,CHANCROID,CHLAMYDIA,CANDIDA,BACTERIAL VAGINOSIS,GENITAL HERPES,GENITAL WARTS (HPV),DONOVANOSIS,GONORRHOEA,HIV,CO-EXISTING DISEASE,PROVISION OF CARE,LGV,PEDICULOSIS PUBIS,PUBLIC HEALTH,TRICHOMONAS,SYPHILIS,PELVIC INFLAMMATORY DISEASE,SEXUAL HEALTH,WOMEN'S HEALTH,COMPLICATED PREGNANCY,INFECTIONS,NOV 08,TREPONEMA PALLIDUM,NEISSERIA GONORRHOEA,MICROORGANISM,CHLAMYDIA,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;The prevalence of diagnosed HIV in black African and black Caribbean communities in England is estimated to be 3.7% and 0.4% respectively, compared to 0.09% among the white population. 
&lt;LI&gt;In 2007 there were 2,691 new HIV diagnoses among black Africans, representing 40%o fall new diagnoses in the UK. The majority had acquired their infection heterosexually and in Africa. The number of new diagnoses among black Caribbeans remained low (189 in 2007), representing 3% of new diagnoses in 2007. 
&lt;LI&gt;The percentage of late diagnoses, that is after a point when treatment should have begun, among new diagnoses of HIV in 2007 was highest among black Africans (42%). Twenty-seven percent of HIV diagnoses among black Caribbeans were late. 
&lt;LI&gt;In 2007 black Caribbeans accounted for over a quarter (26%) of heterosexually acquired gonorrhoea diagnosed in a sample of genitourinary medicine clinics in England and Wales.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>327569</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Shingles-stroke-danger-research.aspx]]&gt;</url>
    <title>Shingles linked to stroke risk</title>
    <publicationDate>2009-10-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,MICROORGANISM,VIRUSES,VARICELLA ZOSTER VIRUS,OCT 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;People with shingles are almost a third more likely to have a stroke in the next year, according to &lt;EM&gt;The Daily Telegraph,&lt;/EM&gt; which reported research into stroke risk following shingles. The newspaper also says that people with a “rare” form of shingles affecting the eye were four times more likely to suffer from a stroke.&lt;/P&gt;
&lt;P&gt;The research behind this report followed groups of people with and without shingles, a condition caused by the varicella virus (chickenpox) earlier in life being reactivated years later. This research cannot prove whether or not shingles causes a stroke because it was a &lt;A href="http://www.nhs.uk/news/Pages/Newsglossary.aspx#Cohortstudy" target="_blank"&gt;cohort study&lt;/A&gt;, which cannot establish cause and effect. &lt;/P&gt;
&lt;P&gt;The researchers were also unable to take into account factors including general health, obesity, smoking and physical activity,&amp;nbsp;as these were not included in their original data source.&lt;/P&gt;
&lt;P&gt;A simple&amp;nbsp;explanation for the results&amp;nbsp;could be that both shingles and stroke are more common in people with poorer health and unhealthier lifestyles. &lt;/P&gt;
&lt;P&gt;There may be a link between adult shingles and stroke, but more robust research is needed to confirm the strength and nature of that link. There is not yet enough evidence to justify changing the way stroke is prevented or treated.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;According to the authors, previous infection with the varicella virus (chickenpox) is an important risk factor for stroke in children. In this study they set out to estimate how frequent stroke was in adults following herpes zoster attacks (shingles).&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.telegraph.co.uk/health/healthnews/6272401/Shingles-sufferers-almost-a-third-more-likely-to-have-a-stroke-in-the-next-year.html#" target="_blank"&gt;Shingles sufferers 'almost a third more likely to have a stroke in the next year'&lt;/A&gt;. &lt;EM&gt;The Daily Telegraph,&lt;/EM&gt; October 9 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.independent.co.uk/life-style/health-and-families/health-news/shingles-increases-risk-of-stroke-by-a-third-1799956.html" target="_blank"&gt;Shingles increases risk of stroke by a third&lt;/A&gt;. &lt;EM&gt;The Independent,&lt;/EM&gt; October 9 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345897</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/shingles-vaccinations-old-people.aspx]]&gt;</url>
    <title>Shingles vaccination proposed</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,CHICKENPOX,PREVENTION,INFECTIONS,CHICKENPOX VACCINE,SKIN AND NAIL INFECTIONS,SHINGLES,VACCINE PREVENTABLE DISEASES,VACCINES / IMMUNISATION,MICROORGANISM,VARICELLA ZOSTER VIRUS,VIRUSES,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Millions of people in their seventies could be vaccinated against shingles, according to several newspapers. The news is based on a recommendation from the government’s independent committee on immunisation. It says there may be benefits in vaccinating the elderly against the virus that causes the painful skin condition. The Daily Telegraph says a vaccination programme could be in place by late 2010 if it is proven to be cost-effective.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>325291</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/Showerheadsandlungdisease.aspx]]&gt;</url>
    <title>Shower heads and lung disease</title>
    <publicationDate>2009-09-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,PNEUMONIA,INFECTIONS,LEGIONNAIRE'S DISEASE,LEGIONELLA PNEUMOPHILA,RESPIRATORY INFECTIONS,MYCOBACTERIUM,MICROORGANISM,BACTERIA,ADDED 2009,SEPT 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Telegraph today reported that a “daily shower could be hazardous”. It said that US researchers have found that shower heads are “breeding grounds for bacteria and when water is passed through them, they blast out the bugs”. One of the main microbes identified was Mycobacterium avium, which can cause respiratory infections mainly in people with a weak immune system or chronic respiratory disease.&lt;/P&gt;
&lt;P&gt;This small study looked at the microbes in 45 shower heads from nine cities in the US. Although it did find the presence of mycobacteria and other bacteria, it did not look at whether using a shower actually increased the risk of mycobacterial or other infections. This research should not cause healthy individuals to be concerned about having showers, as the mycobacterium identified is unlikely to cause illness in people with a healthy immune system.&lt;/P&gt;
&lt;P&gt;Mycobacteria avium is common in the environment. Further research is needed to determine whether or not shower heads are an important source of mycobacterial infection in immunocompromised individuals.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These findings should not cause undue alarm as humans are constantly exposed to microbes. The authors of the study point out that indoor air usually has about a million bacteria per cubic metre, and tap water at least 10m bacteria per litre. &lt;EM&gt;Mycobacterium avium&lt;/EM&gt; is one of several largely unavoidable bacteria known to occur in water, particularly in hot water supplies and aerosolised water, such as fountains. Many of these bacteria are not harmful to humans and our bodies’ defences are capable of protecting us from those that are harmful.&lt;/P&gt;
&lt;P&gt;There is the possibility that the microbes identified could infect people whose immune systems are compromised but it is not clear from this study how common such shower-related infections might be. Further researcher will be needed to determine whether showers do increase the risk of non-tuberculous mycobacterial infection.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Feazel LM, Baumgartner LK, Peterson KL, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.pnas.org/content/early/2009/09/11/0908446106.abstract?sid=687c69e1-f58f-4014-91bc-c6a272e9ab88" target="_blank"&gt;Opportunistic pathogens enriched in showerhead biofilms.&lt;/A&gt; &lt;EM&gt;PNAS&lt;/EM&gt; 2009; Published online before print September 14 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>394415</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6V8X-50DNKKF-1-1&amp;_cdi=5882&amp;_user=8810565&amp;_pii=S0168851010001132&amp;_origin=search&amp;_coverDate=12%2F31%2F2010&amp;_sk=999019997&amp;view=c&amp;wchp=dGLzVtz-zSkWA&amp;md5=42c584b9fd900c2338763a303c7d232b&amp;ie=/sdarticle.pd]]&gt;</url>
    <title>Sibling caregiving among children orphaned by AIDS: Synthesis of recent studies for policy implications</title>
    <publicationDate>2010-11-30T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: The HIV/AIDS epidemic has increased the number of orphans who have to care for their younger siblings. However, their caregiving practices are poorly reported. This review aimed to explore and accumulate available evidences on sibling caregiving among children orphaned by AIDS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We conducted a systematic review of sibling caregiving among AIDS orphans in developing countries and identified 25 relevant articles. We analysed the compiled literature and extracted information on the prevalence of sibling caregiving, the framework of sibling caregiving, factors influencing caregiving, and the impact of sibling caregiving on caregivers and those cared for.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Sibling caregiving, which includes economic, physical, psychological, and educational care, was influenced by children's, familial, community, and policy factors. Unlike sibling caregiving that occurs under adequate adult supervision, sibling caregiving among AIDS orphans negatively impacts both the sibling caregivers and the cared for. However, the lack of studies about such sibling caregiving had prevented measurement of the level of burden and impact of sibling caregiving on orphans.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Policy makers need to be aware that older children caring for younger siblings risk physical and psychological ill health and information must be collected so that measures can be developed to mitigate this burden on orphans.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286418</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sign.ac.uk/pdf/qrg7update.pdf]]&gt;</url>
    <title>SIGN update Helicobacter pylori - Eradication Therapy in Dyspeptic Disease</title>
    <publicationDate>1999-10-01T00:00:00</publicationDate>
    <publisher>Scottish Intercollegiate Guidelines Network (SIGN)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA,HELICOBACTER PYLORI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This online guideline provides information about Helicobacter pylori, including background information, a review of the sign guideline, information about what has changed, and a quick reference guide.]]&gt;</body>
  </document>
  <document>
    <id>286419</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/08/39/64/04083964.pdf]]&gt;</url>
    <title>Smallpox vaccination of regional response groups</title>
    <publicationDate>2004-05-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,SMALLPOX,SMALLPOX VACCINE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The pack contains information and practical tools needed by vaccinators and vaccinees to carry out vaccinations and ensure optimal follow-up. Included are a tracking form for the vaccine, sample vaccination certificate, health diary and national registration form as well as information on the possible complications of the vaccination and their treatment. Also included are the consent form, information on indemnity and a patient information leaflet.]]&gt;</body>
  </document>
  <document>
    <id>321578</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Cervicalscreening.aspx]]&gt;</url>
    <title>Smear test 'no benefit' in early 20s</title>
    <publicationDate>2009-07-30T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GENITAL WARTS (HPV),INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,DIAGNOSIS,VIRUSES,HUMAN PAPILLOMAVIRUS (HPV),MICROORGANISM,JULY 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Medical Journal recently published &lt;A href="http://www.bmj.com/cgi/content/abstract/339/jul28_2/b2968" target="_blank"&gt;research &lt;/A&gt;looking at the effectiveness of smear tests across different age groups of women. This large and well-designed case-control study analysed the impact of cervical screening on the risk of cancer development in over 4,000 diagnosed cases and nearly 8,000 age-matched controls without cancer.&lt;/P&gt;
&lt;P&gt;It found that screening reduced the risk of developing cervical cancer in all age groups except the youngest. As women got older, the more their risk was reduced in the five years after screening. Screening women between the ages of 20 and 24 had no detectable impact on cervical cancer rates at ages 25 to 29. These are important findings, which support the NHS approach of only inviting women for cervical screening once they reach the age of 25.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286422</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/infect/commoneye/resources/merec_bulletin_vol17_no3_sore_throat.pdf]]&gt;</url>
    <title>Sore Throat: MeReC Bulletin</title>
    <publicationDate>2006-12-08T00:00:00</publicationDate>
    <publisher>NHS</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TRANSMISSION MODE,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,RESPIRATORY INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This bulletin looks at the management of common infections, such as a sore throat, in primary care. It considers which patients are likely to benefit from antibiotic treatment, either because their symptoms are probably due to bacterial infection rather than viral infection, or because they are at risk of complications from the infection. The evidence to support antibiotic treatment, symptomatic treatment and delayed prescriptions is discussed.]]&gt;</body>
  </document>
  <document>
    <id>286423</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop20.pdf]]&gt;</url>
    <title>Specification and standard comments for dairy products report forms (QSOP 20)</title>
    <publicationDate>2004-08-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286424</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop19.pdf]]&gt;</url>
    <title>Specification for food and dairy products request forms (QSOP 19)</title>
    <publicationDate>2004-08-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>380984</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ecdc.europa.eu/en/healthtopics/spotlight/spotlight_tickborne/Pages/home.aspx]]&gt;</url>
    <title>Spotlight: Tick-borne diseases</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,LYME DISEASE,ZOONOSES,TICKS,PARASITES,MICROORGANISM,ADDED 2010,JULY 10,TICK-BORNE ENCEPHALITIS,TICK-BORNE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Key messages&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;1. Ticks can carry disease&lt;/STRONG&gt;&lt;BR&gt;Ticks are abundant in woodlands all across Europe from early spring to late autumn. They live by sucking blood from animals and occasionally bite humans. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2. Tick-borne diseases are preventable&lt;/STRONG&gt; &lt;BR&gt;There are effective and safe vaccines against the TBE virus, and immunisation is recommended for people who live in TBE risk areas or who frequently visit forests and grasslands in TBE risk areas. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3. Tick-borne diseases are found only in certain geographical areas in Europe&lt;/STRONG&gt;&lt;BR&gt;The risk of contracting a tick-borne infection is determined by the overall number of ticks in the area (tick density), the proportion of ticks in the area that carry disease (tick infection rate), and human behaviour (exposure). People engaged in recreational or occupational outdoor activities in a risk area are at increased risk of tick bites. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This spotlight on tick-borne diseases also includes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;A communication toolkit 
&lt;LI&gt;Factsheets 
&lt;LI&gt;Country specific information on tick-borne encephalitis&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286425</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp39.pdf]]&gt;</url>
    <title>Staining Procedures (BSOP TP 39)</title>
    <publicationDate>2007-03-14T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ WOMEN'S HEALTH,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This test procedure contains the methods for the staining procedures commonly used in Clinical
Microbiology Laboratories for the identification of pathogens.

Many of the stains that are described in this National Standard Method (NSM) are commercially
available. Users should ensure that commercially prepared stains have been subject to stringent
quality control. When using commercial stains it is important for quality control purposes to keep
records of the batch numbers of the stains and the dates when they were used.
Stains prepared or diluted in house should be controlled to ensure that there is no contamination by environmental organisms. Positive and negative control slides should be used every time the staining procedure is performed except for Gram staining where positive controls may be enough unless a new batch of stain is made. If the control slides do not prove satisfactory, the staining procedure is not accepted. Positive and negative slides may be prepared using known or reference strains.]]&gt;</body>
  </document>
  <document>
    <id>286426</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop12.pdf]]&gt;</url>
    <title>Staph/Strep selective agar (MSOP 12)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,BACTERIA,MICROORGANISM,STREPTOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>325125</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.stoptb.org/resource_center/assets/documents/WHO-RA2008_web.pdf]]&gt;</url>
    <title>Stop TB Partnership Annual Report 2008</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,SEPT 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The evaluation’s major findings were that the Partnership had: expanded and strengthened the coalition of organizations involved in TB control and research; broadened the agenda for TB control and research and increased consensus; increased the reach and strength of global advocacy; coordinated and supported Partner activities in key areas, including technical assistance to countries; and improved TB control in countries, both directly (for example, through the Global Drug Facility) and indirectly (through advocacy and other activities).]]&gt;</body>
  </document>
  <document>
    <id>286433</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/S0163-4453(03)00012-4]]&gt;</url>
    <title>Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy</title>
    <publicationDate>2003-08-01T00:00:00</publicationDate>
    <publisher>Journal of Infection</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CARDIOVASCULAR,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION AND CONTROL,INFECTIONS,TREATMENT,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Treatment of resistant gram-positive endocarditis is difficult. We report a case of resistant Staphylococcus epidermidis endocarditis that failed to respond to conventional antibiotic therapy but was treated successfully with an oral regimen of a new antibiotic, linezolid as a single active agent. This case report demonstrates the use of linezolid as an effective alternative to conventional antibiotics in such cases. ]]&gt;</body>
  </document>
  <document>
    <id>316291</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1243581475043]]&gt;</url>
    <title>Summary of prescribing guidance for the treatment and prophylaxis of influenza-like illness: CONTAINMENT PHASE (Last updated 5th June)</title>
    <publicationDate>2009-05-05T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,ANTIMICROBIALS,ANTIVIRALS,INFECTIONS,RESPIRATORY INFECTIONS,TREATMENT,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,JUNE 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance is intended to enable health protection units (HPUs) to address local queries about the treatment and prophylaxis of influenza A(H1N1). It is not a substitute for the Summary of Product Characteristics (SPC) and the Patient Information Leaflet (PIL) which must accompany the drug package provided.&lt;/P&gt;
&lt;P&gt;Further information is also available on the HPA website: &lt;A href="http://www.hpa.org.uk/" target="_blank"&gt;www.hpa.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Current guidelines are based on the Department of Health document Use of antiviral drugs in an influenza pandemic - scientific evidence base. Available from: &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_077276" target="_blank"&gt;www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_077276&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Note: NICE guidance on triggering prescription of antiviral medications does not apply during a flu pandemic. This guidance will be regularly reviewed and updated. Please refer to the HPA or Department of Health website.&lt;/P&gt;
&lt;P&gt;Last updated 5th June&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286438</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop27.pdf]]&gt;</url>
    <title>Supplemented brain heart infusion broth (MSOP 27)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,CONTACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>391965</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ecdc.europa.eu/en/publications/Publications/101012_TER_HepBandC_survey.pdf]]&gt;</url>
    <title>Surveillance and prevention of hepatitis B and C in Europe</title>
    <publicationDate>2010-09-30T00:00:00</publicationDate>
    <publisher>European Centre for Disease Prevention and Control</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,OUTCOMES,MANAGEMENT &amp; INTERVENTIONS,ANALYSIS &amp; RESEARCH,SETTINGS,LIVER DISORDERS,HEPATITIS,METHODS,MEASUREMENT,GEOGRAPHY,EUROPEAN UNION,SERVICES,POPULATION BASED &amp; PREVENTATIVE SERVICES,INFECTION CONTROL,INFECTIONS,MONTHLY ADDITIONS,MICROORGANISM,VIRUSES,HEPATITIS VIRUS,HEPATITIS B VIRUS,HEPATITIS C VIRUS,INFECTIOUS DISEASES,HEPATITIS,HEPATITIS B,HEPATITIS C,ADDED 2010,WHAT'S NEW,OCT 10,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This survey was carried out to map existing national surveillance systems and prevention programmes for hepatitis B and C in the EU/EEA.]]&gt;</body>
  </document>
  <document>
    <id>286442</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop31.pdf]]&gt;</url>
    <title>Surveillance of polio in the UK (QSOP 31)</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,CONTACT,BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,INFECTIONS,PREVENTION AND CONTROL,PREVENTION,VACCINES / IMMUNISATION,MICROORGANISM,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286446</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop45.pdf]]&gt;</url>
    <title>Susceptibility testing (BSOP 45)</title>
    <publicationDate>2006-10-30T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,PREVENTION AND CONTROL,ANTIMICROBIALS,INFECTIONS,TREATMENT,ANTIMICROBIAL RESISTANCE,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ACINETOBACTER BAUMANII,E. COLI,KLEBSIELLA PNEUMONIAE,BACTERIA,MICROORGANISM,STREPTOCOCCUS,PSEUDOMONAS AERUGINOSA,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document describes routine antimicrobial susceptibility testing methods recommended for use with commonly isolated bacteria. Methods for Mycobacterium species, Brucella species and filamentous fungi are not included in this SOP. It is recommended that filamentous fungi, Brucella species and Mycobacterium species are referred to a reference laboratory for susceptibility testing.]]&gt;</body>
  </document>
  <document>
    <id>286445</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop49.pdf]]&gt;</url>
    <title>Susceptibility testing agar (MSOP 49)</title>
    <publicationDate>2005-05-31T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,ANTIMICROBIALS,PREVENTION AND CONTROL,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,MRSA INFECTION,ENTEROCOCCUS AND GRE/VRE,ANTIMICROBIAL RESISTANCE,TREATMENT,HAEMOPHILUS,NEISSERIA GONORRHOEA,STAPHYLOCOCCUS,PSEUDOMONAS AERUGINOSA,STAPHYLOCOCCUS AUREUS,MICROORGANISM,BACTERIA,HAEMOPHILUS INFLUENZAE,E. COLI,ENTEROCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The recommended medium for antimicrobial susceptibility testing using the disc diffusion method is iso-sensitest agar. This is a well-defined medium containing a stabilised mineral content to avoid antagonism to certain antimicrobials by metal ions. It is supplemented with defined growth factors and the nutrients are prepared such that trimethoprim and sulphonamide antagonists are at very low levels.&lt;/P&gt;
&lt;P&gt;Iso-sensitest is supplemented for fastidious organisms with 5% whole horse blood or 5% whole horse blood and 20mg/l ß-nicotinamide adenine dinucleotide (NAD).&lt;/P&gt;
&lt;P&gt;For testing staphylococci for sensitivity to methicillin/oxacillin Columbia agar with 2% sodium&lt;BR&gt;chloride is recommended.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325310</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/ReportingAntiviralSideEffects.aspx]]&gt;</url>
    <title>Suspected antiviral side effects</title>
    <publicationDate>2009-08-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,ANTIMICROBIALS,ANTIVIRALS,PANDEMIC INFLUENZA,SEASONAL INFLUENZA,RESPIRATORY INFECTIONS,TREATMENT,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,SWINE INFLUENZA,ADDED 2009,AUGUST 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A report on&amp;nbsp;side effects of&amp;nbsp;Tamiflu and Relenza has been published by the Medicines and Healthcare products Regulatory Agency (MHRA). This is the first weekly report, and is based on information gathered between April 1 and August 13 2009.&lt;/P&gt;
&lt;P&gt;The MHRA has stressed that the&amp;nbsp;&lt;A href="http://www.mhra.gov.uk/Safetyinformation/Swinefluinformation/Antiviralmedicines/index.htm" target="_blank"&gt;report on suspected adverse reactions to Tamiflu and Relenza&lt;/A&gt;&amp;nbsp;involves only suspected reactions to the antivirals, and the actual causes could be due to other illnesses or could&amp;nbsp;be purely coincidental rather than being caused by the drugs themselves. It also says the list cannot be used to determine how often these side effects occur or to make direct comparisons between the safety of Tamiflu and Relenza. Information about&amp;nbsp;known side effects of Tamiflu and Relenza is available in the product information (see &lt;A href="http://emc.medicines.org.uk/" target="_blank"&gt;http://emc.medicines.org.uk/&lt;/A&gt;) or at &lt;A href="http://www.mhra.gov.uk/swineflu" target="_blank"&gt;www.mhra.gov.uk/swineflu&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The information is submitted by healthcare professionals and members of the public via a special website for reporting adverse drug reactions (ADRs) and the&amp;nbsp;&lt;A href="http://yellowcard.mhra.gov.uk/the-yellow-card-scheme" target="_blank"&gt;Yellow Card Scheme&lt;/A&gt;. It also includes reports submitted by the manufacturers of the drugs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key points&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No new safety concerns have been identified for either Tamiflu or Relenza, and there is no change to the product information. Patients should continue to take the drugs as advised by their healthcare provider. &lt;/LI&gt;
&lt;LI&gt;The balance of risks and benefits for Tamiflu and Relenza remains positive. &lt;/LI&gt;
&lt;LI&gt;As of August 13&amp;nbsp;2009, the MHRA had received 533 reports about Tamiflu, mentioning 895 suspected adverse reactions (reports can list more than one suspected adverse reaction). &lt;/LI&gt;
&lt;LI&gt;For the same period there were 12 reports for Relenza (with 19 suspected adverse reactions). &lt;/LI&gt;
&lt;LI&gt;For both antivirals most of the reported suspected adverse reactions resemble already known mild side effects of the drugs and are listed as such. Many can also be caused by flu-like illness, so it is unclear whether they were caused by the drugs or by the illness. &lt;/LI&gt;
&lt;LI&gt;The MHRA will continue to monitor the situation. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>321489</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Swinefluandimmunosuppression.aspx]]&gt;</url>
    <title>Swine flu and immunosuppression</title>
    <publicationDate>2009-07-22T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,RESPIRATORY INFECTIONS,ADULTS,IMMUNOCOMPROMISED,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,JULY 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A review of research on how flu affects immunosuppressed people and the effects of vaccination on them has been published in &lt;A href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(09)70175-6/abstract" target="_blank"&gt;The Lancet Infectious Diseases&lt;/A&gt;. The authors specifically looked at susceptibility in people with HIV/AIDS, cancer, those who have had a solid organ transplant or bone-marrow transplant and patients on haemodialysis or steroids.&lt;/P&gt;
&lt;P&gt;Such groups are thought to be at higher risk of serious influenza-associated complications and as such are priority groups for immunisation.&lt;/P&gt;
&lt;P&gt;However, treatments for immune dysfunction may also limit the effectiveness of vaccination and there may be complications from the vaccination itself in these groups. The evidence behind these issues is discussed in this review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Key points from the review&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;There is little research on using vaccination to prevent influenza in immunosuppressed people. This review found just one randomised clinical trial. This trial of HIV-infected patients found high vaccine effectiveness.&lt;/LI&gt;
&lt;LI&gt;The same immune dysfunction that can increase the risk and consequences of influenza infection might also compromise vaccine responses and effectiveness.&lt;/LI&gt;
&lt;LI&gt;Most immunosuppressed populations are at higher risk of influenza-associated complications, have a general trend toward impaired antibody responses but can be safely vaccinated.&lt;/LI&gt;
&lt;LI&gt;The priority for control of influenza is focused on generating effective antibody responses with vaccines. Progress is being made at increasing the scale, duration, and breadth of vaccine responses to the two main surface proteins H and N (haemagglutinin and neuraminidase) in both healthy and immuno-compromised populations.&lt;/LI&gt;
&lt;LI&gt;There are two main types of influenza vaccine and both are being developed for the new H1N1 swine flu virus. One involves inactivated vaccines that contain viruses grown in eggs (mostly) and then killed. The other involves live weakened H1N1 vaccines.&amp;nbsp; The researchers say that previous concerns that these live attenuated vaccine would pose a risk to people that are immunocompromised have not been demonstrated by the studies in their review. Research into this area and into and other novel approaches to flu vaccine development are important. They ask that efficacy studies of attenuated vaccines in adults that are immunocompromised are also considered.&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;&amp;nbsp;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321485</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Swineflufactsheet.aspx]]&gt;</url>
    <title>Swine flu basics</title>
    <publicationDate>2009-07-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,ADDED 2009,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A &lt;A href="http://www.bmj.com/cgi/content/full/339/jul24_2/b3046?q=w_pandemic_flu_bmj" target="_blank"&gt;recent article &lt;/A&gt;in the British Medical Journal discusses the basics of the Pandemic (H1N1) 2009 virus, including how it differs from ordinary seasonal flu and how mutations lead to these new strains.&lt;/P&gt;
&lt;P&gt;Here we discuss these points in the context of other basic facts about the H1N1 strain that is causing the current global pandemic.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320575</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/SwineFluH1N1Behaviour.aspx]]&gt;</url>
    <title>Swine flu behaviour revealed</title>
    <publicationDate>2009-07-14T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have published &lt;A href="http://www.nature.com/nature/journal/vnfv/ncurrent/abs/nature08260.html" target="_blank"&gt;new research &lt;/A&gt;exploring the characteristics of the pandemic swine flu strain, including why it appears to affect younger people more severely. The study, which used both lab testing and animal models, suggests that the pandemic strain causes more lung damage and replicates deeper in the lungs than other human H1N1 infections. It is thought that these characteristics could be responsible for the viral pneumonia that seems to be contributing to hospitalisations and fatalities in people without existing health problems.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>333384</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/H1N1-swine-flu-virus-death-rate.aspx]]&gt;</url>
    <title>Swine flu deaths examined</title>
    <publicationDate>2009-12-11T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,VIRUSES,INFLUENZA VIRUS,MICROORGANISM,DEC 09,ADDED 2009,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Swine flu is less lethal than feared, according to reports on the BBC news. The website quotes research led by Sir Liam Donaldson, the chief medical officer, which found that only 0.026% of those infected with swine flu have died.&lt;/P&gt;
&lt;P&gt;This was a well conducted investigation into all deaths in England attributed to swine flu up to November 2009. It found that there were 138 deaths from an estimated 540,000 cases, or around 26 deaths per 100,000 people. Because of the nature of swine flu and the difficulties in identifying cases, there remains the unavoidable possibility that these mortality rates were slightly over- or underestimated. For example, some deaths associated with swine flu may not have been correctly identified, which would lead to an underestimation of the mortality rate. Equally, underestimations of the total number of swine flu cases could lead to overestimation of the mortality rates. However, the figures calculated in this study give the best estimate based on available information.&lt;/P&gt;
&lt;P&gt;This research also suggests that mortality rates are much lower than in twentieth-century flu pandemics. However, vigilance and the prompt use of antivirals when indicated, in addition to vaccination, remain highly important. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The researchers conclude that mortality levels in this pandemic compare favourably with rates of death in influenza pandemics of the twentieth century. However, they say that public health measures are still required even though mortality rates appear low, and that the vaccination of high-risk groups remains a priority. They also say that as a third of deaths occurred in previously healthy people there is a case for extending the vaccination programme and for continuing to make early antiviral treatment widely available.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Donaldson LJ, Rutter PD, Ellis BM et al. &lt;A href="http://www.bmj.com/cgi/content/full/339/dec10_1/b5213" target="_blank"&gt;Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study&lt;/A&gt;. BMJ 2009;339:b5213&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>321482</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/SwineFluPregnancyAntiviralTreatment.aspx]]&gt;</url>
    <title>Swine flu drugs for the pregnant</title>
    <publicationDate>2009-07-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,POPULATION GROUPS,PREGNANT WOMEN,ADULTS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,ADDED 2009,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Pregnant women who develop swine flu should be given antiviral treatment as soon as possible, say the authors of a new study. The &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61304-0/abstract" target="_blank"&gt;research &lt;/A&gt;gathered data from 13 US states between mid-April and mid-May 2009, and has shown that the rate of hospital admissions of pregnant women with flu was four times higher than among the general population.&lt;/P&gt;
&lt;P&gt;However, there is some suggestion that doctors may be more likely to admit women if they are pregnant, and that the pattern of cases seen in the early part of an epidemic may be different to the pattern of cases seen now. This study supports the current advice that pregnant women are a high-risk group that should be offered antiviral treatment early and given priority for vaccination when a jab becomes available.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Key points&lt;/STRONG&gt;&lt;BR&gt;Eleven (32%) of the 34 pregnant women with swine flu were admitted to hospital. This is four times the admission rate of the general population at the time.&lt;/LI&gt;
&lt;LI&gt;Amongst all the pregnant women, 24% were given antiviral medication within 48 hours of symptoms. However, when the researchers looked at those who died they found that they had been treated with antivirals between 8 and 15 days after symptoms, suggesting that there was some delay in starting treatment.&lt;/LI&gt;
&lt;LI&gt;The fact that doctors may be more likely to admit pregnant women with swine flu is one explanation for the higher rate of hospital admissions. However, the increased number of deaths among pregnant women also suggests that the disease is more serious in pregnancy.&lt;/LI&gt;
&lt;LI&gt;According to the researchers, vaccinating pregnant women should be a priority. They say that there is currently a low level of uptake of the seasonal flu vaccinations among pregnant women, with one 2004 study finding that uptake was as low as 14%.&lt;/LI&gt;
&lt;LI&gt;Most states changed how they reported data to the CDC from May 18, therefore the researchers were unable to calculate illness and admission rates after this date.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325314</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/WHOSwineFluVaccineSafety.aspx]]&gt;</url>
    <title>Swine flu jab safety checks</title>
    <publicationDate>2009-08-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,PREVENTION,INFECTIONS,INFLUENZA VACCINE,RESPIRATORY INFECTIONS,MICROORGANISM,VACCINES / IMMUNISATION,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,AUGUST 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The World Health Organization has&amp;nbsp;&lt;A href="http:///" target="_blank"&gt;issued a briefing&lt;/A&gt; on its website discussing the safety of new pandemic vaccines, a topic that has been the subject of much media speculation in recent weeks. It says that the public needs reassurance about the regulation procedures involved in the licensing of pandemic vaccines and assurance that, despite their large-scale production, the various steps in vaccine production are safe and meet stringent quality requirements.&lt;/P&gt;
&lt;P&gt;It also states that, with the widespread use of pandemic flu vaccine compared to seasonal vaccines, it is possible that some serious adverse effects will be reported, although these are likely to be rare occurrences and difficult to predict in advance. Unfortunately, full clinical data on the safety of the vaccine is unlikely to be available by the time the vaccine is distributed so monitoring of its safety and effectiveness will need to take place after administration of the vaccine has begun. &lt;/P&gt;
&lt;P&gt;The World Health Organization (WHO) advises that all countries administering pandemic vaccines conduct intensive checks for safety and effectiveness, and that sharing of this data will be needed to inform vaccine policies further. The WHO has also developed guidance to help countries formulate country-specific guidelines, as well as a standard set of protocols that should be used in data collection and reporting.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;As the WHO says, strategies to shorten the time between emergence of a flu pandemic and the availability of a safe and effective vaccine are of the greatest priority in global health security. Although seasonal influenza viruses are routinely produced, with the advent of a new influenza strain that has not previously circulated among humans, production is likely to be different, and the demand for the vaccine will possibly exceed the supply.&lt;/P&gt;
&lt;P&gt;As a result of this, various different technical solutions and manufacturing options are in development and investigation, and are the subject of WHO guidelines. The WHO has developed a Global Action Plan for pandemic flu vaccines in order to identify and prioritise practical solutions to meet the vaccine demand. To facilitate increased production it is likely that governments will turn to new vaccine manufacturers in addition to those used during current seasonal flu vaccine production.&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>320587</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/Swineflulatest.aspx]]&gt;</url>
    <title>Swine flu latest from the NHS</title>
    <publicationDate>2009-02-05T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,FEB 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;The National Pandemic Flu Service, set up to offer online and telephone assessments, has now closed. The decline in swine flu cases means the service is no longer needed, although it can be reinstated within seven days if a new wave of infections emerges.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;People showing swine flu symptoms are now advised to stay at home and contact their GP, who will be able to assess them. If appropriate patients will be offered antiviral medication and vaccination jabs.&lt;/P&gt;
&lt;P&gt;The service was designed to ease the extra pressure placed on GPs and the NHS during a pandemic, allowing members of the public to get advice and request antivirals from their own home.&lt;/P&gt;
&lt;P&gt;Discussing the move the Department of Health said "Our priority remains to vaccinate those most at risk from swine flu, as people are still in hospital from the virus and sadly some have died.&lt;/P&gt;
&lt;P&gt;“However, given the current welcome reduction in the number of cases, and the need to make sure our response to the pandemic remains proportionate, we have decided to close the National Pandemic Flu Service”&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>320590</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/Pages/Swinefluscienceoverview.aspx]]&gt;</url>
    <title>Swine flu science: overview</title>
    <publicationDate>2009-09-02T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,SEPT 09,ADDED 2009,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This page brings together the latest science and developments on the swine flu pandemic into a single accessible resource for both health professionals and the general public.&lt;/P&gt;
&lt;P&gt;You will find a range of regularly updated links to scientific resources on the Pandemic (H1N1) 2009 virus listed below. We will also be critically appraising&amp;nbsp;&lt;A href="http://www.nhs.uk/news/Pages/Swinefluscienceoverview.aspx#bazianswineflu" target="_blank"&gt;new research&lt;/A&gt; on swine flu as it is published.&lt;/P&gt;
&lt;P&gt;For the latest, more general news on swine flu in the UK, including prevalence, NHS policy and guidance, go to &lt;A href="http://www.nhs.uk/news/2009/04April/Pages/Swineflulatest.aspx" target="_blank"&gt;swine flu latest from the NHS&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;We encourage&amp;nbsp;&lt;A href="http://www.nhs.uk/news/Pages/Swinefluscienceoverview.aspx#bazianswineflu" target="_blank"&gt;comments and suggestions&lt;/A&gt; from the scientific community on the development of this page.&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>321488</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/SwineFluVaccineTest.aspx]]&gt;</url>
    <title>Swine flu vaccine being tested</title>
    <publicationDate>2009-07-23T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,RESPIRATORY INFECTIONS,INFLUENZA VACCINE,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,ADDED 2009,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Clinical trials of newly developed vaccines for swine flu have begun in the USA and Australia. These human studies will gather data on the safety and effectiveness of the vaccine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key points&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health in the USA, announced yesterday that a network of medical research institutions is about to begin a series of clinical trials to gather safety and efficacy data about some of the new influenza vaccines.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;At the same time, two vaccine manufacturers in Australia (CSL and Vaxine) have also begun testing their vaccine in healthy adult volunteers.&lt;/LI&gt;
&lt;LI&gt;&lt;BR&gt;The clinical trials will provide important early safety and efficacy data about the vaccines. In particular, the researchers will be monitoring adverse effects and immunogenicity (how well the vaccine provokes an immune response). They will also be assessing the dose required to be effective and whether the vaccine can be given alongside seasonal influenza vaccination.&lt;BR&gt;The American trials will be in healthy adult volunteers and in elderly volunteers who are also receiving the seasonal vaccine. If early results are positive, further studies may begin in healthy adolescents and children.&lt;/LI&gt;
&lt;LI&gt;The trials may take some months to complete, and the vaccination programmes are likely begin before the full results are available. However, there should be sufficient results by September or October to spot real safety concerns and to allow governments to begin planning for the use and distribution of the new vaccines. Safety will continue to be monitored through surveillance when vaccination programmes are introduced nationally.&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325292</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/SwineFluVaccinationPredictions.aspx]]&gt;</url>
    <title>Swine flu vaccine predictions</title>
    <publicationDate>2009-09-11T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,RESPIRATORY INFECTIONS,INFLUENZA VACCINE,MICROORGANISM,VACCINES / IMMUNISATION,VIRUSES,INFLUENZA VIRUS,SEPT 09,ADDED 2009,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have published research estimating how effective the swine flu vaccine will at reducing infection rates in the US this autumn. This research involves complex statistical modelling based on what is already known about swine flu and assumptions based on a range of flu vaccination strategies. The study suggests that strategies that aim to vaccinate everyone before the start of an autumn spread of the virus or of a phased vaccination at the onset of an autumn surge are likely to be effective as long as 70% of the population is vaccinated.&lt;/P&gt;
&lt;P&gt;This type of complex modelling study is important for estimating the effects of epidemics and pandemics, and the best ways of reducing their effects. The results of such models are dependent on what assumptions are fed into them, and this is why researchers looked at what happened if they varied a number of assumptions in their models. Whether these models accurately predict what will happen is dependent on how closely these assumptions match the real situation.&lt;/P&gt;
&lt;P&gt;This model aimed to estimate the effects of vaccination in the US, and therefore the underlying assumptions and results may not be representative of other countries, but its results will undoubtedly be of interest to policy makers planning vaccination strategies in both the US and other countries.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This type of complex modelling study is important for estimating the effects of epidemics and pandemics and the best ways of minimising their effects. The results of such models are dependent on what assumptions are made and this is why researchers look at a range of assumptions in their models. Whether these models accurately predict what will happen is dependent on how closely these assumptions match the real situation.&lt;/P&gt;
&lt;P&gt;This model aimed to estimate the effects of vaccination in the US, and therefore the underlying assumptions and results may not be representative of other countries. These results suggest that if a relatively high vaccination coverage in the population can be achieved this could reduce the impact of swine flu, and that slightly different strategies may still have similar effects. This study will undoubtedly be of interest to policy makers planning vaccination strategies in both the US and other countries. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yang Y, Sugimoto JD, Halloran ME &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.sciencemag.org/cgi/content/abstract/sci;1177373v1?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=swine+flu&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=date&amp;amp;resourcetype=HWCIT" target="_blank"&gt;The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus&lt;/A&gt;. &lt;EM&gt;Science&lt;/EM&gt;, September 10 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>333391</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Swine-flu-vaccine-uptake.aspx]]&gt;</url>
    <title>Swine flu vaccine uptake</title>
    <publicationDate>2009-11-18T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,PREVENTION,INFECTIONS,RESPIRATORY INFECTIONS,INFLUENZA VACCINE,MICROORGANISM,VACCINES / IMMUNISATION,INFLUENZA VIRUS,VIRUSES,SWINE INFLUENZA,SWINE FLU VACCINE,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Several newspapers have reported that pregnant women and other vulnerable people are refusing to have the swine flu vaccine. The Times reported that a poll of GPs found that only 46% of people who were offered the vaccine have accepted it, and one doctor estimated that only 5% of pregnant women have had it.&lt;/P&gt;
&lt;P&gt;The news reports are based on a “snapshot” survey of 107 GPs. The survey asked how likely they were to hit the government’s target of vaccinating at least half of their patients who are under 65 and in high-risk groups this winter. GPs were also asked to estimate how many of the people who were offered the vaccine in their practice had agreed to have it (the uptake).&lt;/P&gt;
&lt;P&gt;It is not clear if the experiences of this relatively small sample of GPs is representative of the 30,000 GPs in the UK. This picture of overall uptake is based purely on these 107 GPs’ estimates. It is possible that these GPs chose to take part in the survey themselves, and that GPs who chose not to take part may have a different experience of vaccine uptake.&lt;/P&gt;
&lt;P&gt;Based on this survey, it can’t be assumed that there is similar vaccine uptake nationwide, or that particular groups, such as pregnant women, are more likely to reject the vaccine.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Pregnant women are one of the groups that are more likely to have serious complications if they get swine flu, which could result in miscarriage and premature labour.&lt;/P&gt;
&lt;P&gt;There is evidence that pregnant women are at increased risk of severe disease and of being admitted to hospital with flu-related problems. The risk increases as the pregnancy progresses, and women in the third trimester of pregnancy are particularly at risk (WHO 2009; Jain &lt;EM&gt;et al&lt;/EM&gt;, 2009; Jamieson &lt;EM&gt;et al&lt;/EM&gt;, 2009).&lt;/P&gt;
&lt;P&gt;The World Health Organization has stated that 7–10% of all hospitalised patients with swine flu are pregnant women in their second or third trimester. Pregnant women are 10 times more likely to need care in an intensive care unit than the general population (WHO, 2009).&lt;/P&gt;
&lt;P&gt;Complications in pregnant women, based on information on seasonal flu, may include pneumonia and cardiorespiratory complications (Kort BA &lt;EM&gt;et al&lt;/EM&gt;, 1986; Neuzil KM &lt;EM&gt;et al&lt;/EM&gt;, 1998).&lt;/P&gt;
&lt;P&gt;Both swine flu vaccines have been licensed for use in pregnant women, but&amp;nbsp;it is recommended that&amp;nbsp;pregnant women are&amp;nbsp;given Pandemrix. This is because it appears to give adequate levels of antibodies after a single dose,&amp;nbsp;protecting the recipient&amp;nbsp;more&amp;nbsp;quickly than Celvapan, which&amp;nbsp;requires two doses given three weeks apart.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.pulsetoday.co.uk/story.asp?sectioncode=35&amp;amp;storycode=4124349&amp;amp;c=2" target="_blank"&gt;GPs braced to miss swine flu target.&lt;/A&gt;&amp;nbsp;&lt;EM&gt;Pulse&lt;/EM&gt;, November 16 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.pulsetoday.co.uk/story.asp?storycode=4124337" target="_blank"&gt;Pregnant women rejecting swine flu vaccine over safety fears.&lt;/A&gt;&amp;nbsp;&lt;EM&gt;Pulse&lt;/EM&gt;, November 16 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>320569</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Swinefluearlyepidemiology.aspx]]&gt;</url>
    <title>Swine flu: early epidemiology</title>
    <publicationDate>2009-07-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In the first months of its outbreak in the UK, H1N1 mostly affected young people, and was most commonly spread through contact at school, research by the HPA has shown.&lt;/P&gt;
&lt;P&gt;These findings are based on an analysis of the first 252 cases of swine flu diagnosed in the UK after news of the virus broke.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>320681</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Swinefluearlyhospitalizations.aspx]]&gt;</url>
    <title>Swine flu: early hospitalisations</title>
    <publicationDate>2009-07-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;On May 22 2009, the &lt;A href="http://www.cdc.gov/" target="_blank"&gt;Centre for Disease Control (CDC) &lt;/A&gt;published its &lt;A href="http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a6.htm" target="_blank"&gt;weekly report &lt;/A&gt;in which it discussed the characteristics of the first 30 patients with swine flu who had been hospitalised up to May 17 in California.&lt;/P&gt;
&lt;P&gt;This report provides a helpful snapshot of the nature of the illness in a sample of patients hospitalised with swine flu.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Key points&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The majority of the 30 swine flu patients hospitalised in California up to May 17 were discharged after 30 days. 
&lt;LI&gt;Those who experienced severe disease and prolonged hospitalisation commonly had underlying conditions that were probably contributing to the severity of their illness. 
&lt;LI&gt;The CDC says that more information is needed on which populations are at greatest risk of hospitalisation.&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320721</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1244763940872?p=1244763940872]]&gt;</url>
    <title>Swine flu: travel advice</title>
    <publicationDate>2009-07-20T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,TRAVELLERS,ADULTS,TRAVEL ASSOCIATED INFECTIONS,POPULATION GROUPS,RESPIRATORY INFECTIONS,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,JULY 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Check for the latest information before you travel. &lt;A href="http://www.fco.gov.uk/" target="_blank"&gt;The Foreign and Commonwealth Office (FCO)&lt;/A&gt; regularly updates its travel advice to all countries. Visit the FCO website&amp;nbsp; or call 0845 850 2829 for the latest alerts.&amp;nbsp; Although the UK has cases of swine flu, travel to the UK is not restricted. If you are a traveller planning to visit the UK read our &lt;A href="http://www.hpa.org.uk/web/HPAweb&amp;amp;HPAwebStandard/HPAweb_C/1247816512876" target="_blank"&gt;advice for travellers coming to the UK&lt;/A&gt;.]]&gt;</body>
  </document>
  <document>
    <id>316049</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1243322117077]]&gt;</url>
    <title>Swine-lineage Influenza A H1N1 - UK Update</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,RESPIRATORY INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MICROORGANISM,INFLUENZA VIRUS,VIRUSES,SWINE INFLUENZA,JUNE 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;As of 01/06/2009 255 cases have been confirmed in the UK since 27 April 2009: 234 in England, one in Northern Ireland, 19 in Scotland and one in Wales. No deaths have been reported from these cases.&lt;/P&gt;
&lt;P&gt;Last updated on 1st June 2009.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379593</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Swingers-greater-risk-of-STIs.aspx]]&gt;</url>
    <title>Swingers at greater risk of STIs</title>
    <publicationDate>2010-06-24T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,OLDER PEOPLE,ADULTS,JUNE 10,ADDED 2010,WHAT'S NEW]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Older ‘swingers’ seeking sexual thrills are to blame for soaring rates of sexually transmitted infections (STIs), the Daily Mail&amp;nbsp; has warned.&lt;/P&gt;
&lt;P&gt;The story is based on Dutch research, which found that the rates of STIs in swingers are comparable to other recognised high-risk groups such as young heterosexuals and men who have sex with men. The researchers conclude that swingers need to be identified and targeted as an ‘at-risk group’ in terms of STI prevention and treatment.&lt;/P&gt;
&lt;P&gt;The finding that people who swap partners and engage in group sex are also vulnerable to higher rates of STDs, is perhaps unsurprising. But the study’s conclusion that this group need recognition is important in the provision of STI services. It should be stressed that this study was carried out in the Netherlands and its findings may not apply to the UK. Nor it is clear how large the swinger population may be in either country.&lt;/P&gt;
&lt;P&gt;However, the message of this study is clear and cross-cultural: unprotected sex with multiple partners greatly increases the risk of STIs, regardless of age or gender.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The study draws attention to a group at high risk of STIs, yet who have previously been unrecognised as such. The STI infection rates of swingers would appear to be comparable to other risk groups such as men who have sex with men and young heterosexuals, at least in the Netherlands. However, the study’s finding that 55% of the STIs in older people were in swingers should be seen in context. Only 11.7% of people, just over 1,000 people, attending the clinic were over 45 years, so 55% of this group is a relatively small number (about 577).&lt;/P&gt;
&lt;P&gt;It should be highlighted that the study relies on self-reported sexual behaviour and so may be prone to error. Also, this is a study of the population from the Netherlands and its figures may not apply to other countries including the UK. It is also&amp;nbsp;unclear how the STI rates of infection in the Netherlands compare to the UK. However, the message of this study is clear and cross-cultural - unprotected sex with multiple partners greatly increases the risk of STIs, regardless of age or sex.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Dukers-Muijrers NHTM, Niekamp A-M, Brouwers EEHG, &lt;EM&gt;et al&lt;/EM&gt;. Older and swinging; need to identify hidden and emerging risk groups at STI clinics. &lt;EM&gt;Sexually Transmitted Infections&lt;/EM&gt; 2010 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319866</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245581513523]]&gt;</url>
    <title>Syphilis and Lymphogranuloma Venereum: Resurgent Sexually Transmitted Infections in the UK: 2009 report</title>
    <publicationDate>2009-06-29T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,LYMPHOGRANULOMA VENEREUM (LGV),SYPHILIS,WOMEN'S HEALTH,SEXUAL HEALTH,SYPHILIS,LGV,INFECTIONS,TREPONEMA PALLIDUM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,BACTERIA,CHLAMYDIA,JULY 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Epidemics of infectious syphilis and Lymphogranuloma venereum (LGV) are continuing especially among men who have sex with men (MSM) who are known to be HIV infected.&lt;/LI&gt;
&lt;LI&gt;3762 diagnoses of infectious syphilis were made in 2007, more than in any other year since 1950.&lt;/LI&gt;
&lt;LI&gt;849 cases of LGV were diagnosed between 2003 and 2008, the majority of whom had symptoms of proctitis (rectal pain, discharge, bloody stools and constipation).&lt;/LI&gt;
&lt;LI&gt;MSM account for 73% of infectious syphilis and 99% of LGV cases.&lt;BR&gt;HIV co-infection is common in those diagnosed with LGV (74%) and syphilis (27%) reflecting the close relationships between the epidemics.&lt;/LI&gt;
&lt;LI&gt;The increased number of syphilis cases in women of reproductive age has resulted in an increase in cases of congenital infection.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>394224</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/655681]]&gt;</url>
    <title>Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HEPATITIS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HEPATITIS VIRUS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: MEDLINE, EMBASE, Global Health, Scopus, Biosis Previews, Cochrane Library, Web of Science, and existing systematic reviews were searched. Prospective studies comparing TDF-containing with non-TDF containing ART regimens were selected for inclusion. We extracted data on study characteristics, participant characteristics, therapeutic interventions, renal function, bone density, and fracture rates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: A total of 17 studies (including 9 randomized, controlled trials) met the selection criteria. Median sample size was 517 participants. Constituent ART regimens were diverse. There was a significantly greater loss of kidney function among the TDF recipients, compared with control subjects (mean difference in calculated creatinine clearance, 3.92 mL/min; 95% confidence interval [CI], 2.13-5.70 mL/min), as well as a greater risk of acute renal failure (risk difference, 0.7%; 95% CI, 0.2-1.2). There was no evidence that TDF use led to increased risk of severe proteinuria, hypophosphatemia, or fractures.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Although TDF use was associated with a statistically significant loss of renal function, the clinical magnitude of this effect was modest. Our findings do not support the need to restrict TDF use in jurisdictions where regular monitoring of renal function and serum phosphate levels is impractical.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392342</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829175/pdf/CroatMedJ_51_0074.pdf]]&gt;</url>
    <title>Systematic review of interventions to prevent the spread of sexually transmitted infections, including HIV, among young people in Europe</title>
    <publicationDate>2010-01-07T00:00:00</publicationDate>
    <publisher>Croatian Medical Journal</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,PREVENTION,INFECTIONS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,OCT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim&lt;/STRONG&gt;: To examine the effectiveness of interventions seeking to prevent the spread of sexually transmitted infections (STI), including HIV, among young people in the European Union.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: For this systematic review, we examined interventions that aimed at STI risk reduction and health promotion conducted in schools, clinics, and in the community for reported effectiveness (in changing sexual behavior and/or knowledge) between 1995 and 2005. We also reviewed study design and intervention methodology to discover how these factors affected the results, and we compiled a list of characteristics associated with successful and unsuccessful programs. Studies were eligible if they employed a randomized control design or intervention-only design that examined change over time and measured behavioral, biologic, or certain psychosocial outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Of the 19 studies that satisfied our review criteria, 11 reported improvements in the sexual health knowledge and/or attitudes of young people. Ten of the 19 studies aimed to change sexual risk behavior and 3 studies reported a significant reduction in a specific aspect of sexual risk behavior. Two of the interventions that led to behavioral change were peer-led and the other was teacher-led. Only 1 of the 8 randomized controlled trials reported any statistically significant change in sexual behavior, and then only for young females.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: The young people studied were more accepting of peer-led than teacher-led interventions. Peer-led interventions were also more successful in improving sexual knowledge, though there was no clear difference in their effectiveness in changing behavior. The improvement in sexual health knowledge does not necessarily lead to behavioral change. While knowledge may help improve health-seeking behavior, additional interventions are needed to reduce STIs among young people.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>297244</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/118511329/abstract]]&gt;</url>
    <title>Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection</title>
    <publicationDate>2007-05-02T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,INFECTIONS,NOV 08,ADULTS,PREGNANT WOMEN,CHILDREN,POPULATION GROUPS,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2008]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The objective of this systematic review was to evaluate the efficacy of antiretroviral therapies in reducing the risk of mother-to-child transmission of HIV infection.&lt;/P&gt;
&lt;P&gt;Abstract only.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286447</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://adc.bmjjournals.com/cgi/content/full/archdischild;79/3/225?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=1&amp;searchid=1055761546721_544&amp;stored_search=&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;volume=79&amp;firstpage=225&amp;search_url=http%3A%2F%2Fadc.bmjjournals.com%2Fcgi%2]]&gt;</url>
    <title>Systematic review of the treatment of upper respiratory tract infection</title>
    <publicationDate>1998-09-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ OBJECTIVESTo assess the risks and benefits of antibiotic treatment in children with symptoms of upper respiratory tract infection (URTI).
DESIGNQuantitative systematic review of randomised trials that compare antibiotic treatment with placebo.
DATA SOURCESTwelve trials retrieved from a systematic search (electronic databases, contact with authors, contact with drug manufacturers, reference lists); no restriction on language.
MAIN OUTCOME MEASURESThe proportion of children in whom the clinical outcome was worse or unchanged; the proportion of children who suffered complications or progression of illness; the proportion of children who had side effects.
RESULTS1699 children were randomised in six trials that contributed to the meta-analysis. Six trials were not used in the meta-analysis because of different outcomes or incomplete data. Clinical outcome was not improved by antibiotic treatment (relative risk 1.01, 95% confidence interval (CI) 0.90 to 1.13), neither was the proportion of children suffering from complications or progression of illness (relative risk 0.71, 95% CI 0.45 to 1.12). Complications from URTI in the five trials that reported this outcome was low (range 2-15%). Antibiotic treatment was not associated with an increase in side effects compared with placebo (relative risk 0.8, 95% CI 0.54 to 1.21).
CONCLUSIONSIn view of the lack of efficacy and low complication rates, antibiotic treatment of children with URTI is not supported by current evidence from randomised trials.

Key messages 
Antibiotic treatment did not alter clinical outcome or reduce complication rates in children with upper respiratory tract infections 
Side effects were similar in antibiotic treatment and placebo groups 
Complications from upper respiratory tract infections are low (2-15%) 
Larger trials are needed to establish whether antibiotic treatment reduces complications in children with upper respiratory tract infections ]]&gt;</body>
  </document>
  <document>
    <id>345653</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Tuberculosis/TBSurvey2009/FINAL%20APPG%20report.pdf]]&gt;</url>
    <title>Tackling tuberculosis in England: the PCT response to the challenge</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>British Thoracic Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Tuberculosis (TB) in England has been increasing since the late 1980s. The Health Protection Agency provisionally reported that there were 7,998 cases in 2008 – a rise of 2% on the previous year. All parts of the country and most Primary Care Trusts (PCT) report active cases every year. Very different issues face high and low TB incidence areas, but all need to be prepared to treat TB patients and effectively manage any associated infection control and public health issues. TB is not only a medically complex disease but also one that requires flexible and reactive commissioning which encompasses primary, secondary and tertiary care services. PCTs have responsibility for commissioning health services for the local population that they serve. The PCT should be the local leader on health, and to commission locally appropriate, fully staffed TB services.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325313</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/TamifluForChildrenQuestioned.aspx]]&gt;</url>
    <title>Tamiflu for children questioned</title>
    <publicationDate>2009-08-11T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,ANTIVIRALS,ANTIMICROBIALS,PANDEMIC INFLUENZA,RESPIRATORY INFECTIONS,POPULATION GROUPS,TREATMENT,CHILDREN,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,ADDED 2009,AUGUST 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;It has been widely reported that Tamiflu may be of little benefit when given to children, with several news sources suggesting that the antiviral drugs Tamiflu and Relenza rarely prevent complications in children with seasonal flu, but still carry side effects. The news is based on a review of research on seasonal flu, which found that the antivirals could shorten the duration of seasonal flu in children by up to a day and a half, but had “little or no effect on asthma flare-ups, ear infections or the likelihood of children needing antibiotics”. The review did not look at swine flu.&lt;/P&gt;
&lt;P&gt;The authors of the review are reported to have said that these drugs “are unlikely to help” children who catch swine flu. However, they offer a more cautious interpretation within the research paper, saying that the effects of antivirals on the “incidence of serious complications, and on the current A/H1N1 influenza strain remain to be determined”.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has systematically identified and summarised the available research on the effects of the neuraminidase inhibitors oseltamivir and zanamivir for preventing and treating seasonal flu in children.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Shun-Shin M, Thompson M, Heneghan C &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.bmj.com/cgi/content/abstract/339/aug10_1/b3172" target="_blank"&gt;Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials&lt;/A&gt;. BMJ 2009;339:b3172&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>321838</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Tamiflusideeffects.aspx]]&gt;</url>
    <title>Tamiflu side effects in children</title>
    <publicationDate>2009-07-31T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,ANTIVIRALS,ANTIMICROBIALS,TREATMENT,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM,AUGUST 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;New research claims that “more than half of children taking Tamiflu to combat swine flu suffer side effects such as nausea, insomnia and nightmares,” said The Daily Telegraph. It also said the study suggests that one in five children who took part reported having a neuropsychiatric side effect, such as poor concentration, inability to think clearly, problems sleeping, and feeling dazed or confused.&lt;/P&gt;
&lt;P&gt;This online survey looked at schoolchildren’s adherence to Tamiflu and any side effects they experienced. It had a low response rate, and no control group against which to compare the symptoms. As such, it is not possible to say for sure that this frequency of side effects is precise. It is possible that the rate of symptoms in a school that closed down because of a new epidemic would have been quite high anyway, whether pupils were given the drug or not. No serious or long-term side effects of the drug were reported.&lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302211</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947325114]]&gt;</url>
    <title>TB &amp; Homelessness: Guidance for homelessness sector staff</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,JAN 09,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Knowledge Service along with the Homeless Link has developed the following information resources for officials of hostels, shelters and day centres. One of the leaflets is aimed at hostel 'Managers' and the other at 'Staff' working in the hostels. These leaflets were developed as it was perceived that there is a need for knowledge support among the Staff and Managers of hostels for the homeless, where the incidence of tuberculosis is high. These resources are currently being piloted by&amp;nbsp;&amp;nbsp; &lt;A href="http://www.homeless.org.uk/" target="_blank"&gt;http://www.homeless.org.uk&lt;/A&gt;&amp;nbsp; - nationally among members of the target groups.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;These information sheets are being evaluated, please click on this &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947355299" target="_blank"&gt;link &lt;/A&gt;to obtain the evaluation form.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398235</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/tb-tuberculosis-cases-rise-london-uk.aspx]]&gt;</url>
    <title>TB rises in UK and London</title>
    <publicationDate>2010-12-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES,TUBERCULOSIS,MYCOBACTERIUM,ADDED 2010,WHAT'S NEW,DEC 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;London is “the TB capital of Europe”, &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported. The newspaper says that Britain is now the only nation in Western Europe with rising levels of &lt;A href="http://www.nhs.uk/conditions/tuberculosis/pages/introduction.aspx" target="_blank"&gt;tuberculosis&lt;/A&gt;, with more than 9,000 cases diagnosed annually. In London, where 40% of UK cases are reportedly diagnosed, the number of cases has risen by almost 50% since 1999, up from 2,309 in 1999 to 3,450 in 2009.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The Guardian&lt;/EM&gt; has also discussed the rising prevalence of the disease, which was detailed in a report on the modern TB situation in London, as well as the UK as a whole. The report’s author, Professor Alimuddin Zumla of University College London, attributes the rise to people living under “Victorian” conditions, with poor housing, inadequate ventilation and overcrowding in certain deprived areas of London.&lt;/P&gt;
&lt;P&gt;Professor Zumla has also observed that the increase in TB cases has been predominantly among people born outside the UK, but who appear to have been infected here, rather than in their country of origin. He has called for the implementation of a London-wide strategy to help control the disease.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The author says that the current situation in London has similarities with previous outbreaks of drug-resistant TB in the US in the 1990s, where a large amount of financial investment and government support was required to regain control of the disease through the clear establishment of clinical policy and protocol.&lt;/P&gt;
&lt;P&gt;The author also says that there is now a need to implement the recommendations of a recent &lt;A href="http://www.csl.nhs.uk/News/Pages/LondonTuberculosisreviewhighlightsneedforaction.aspx" target="_blank"&gt;London tuberculosis service review&lt;/A&gt;, which has suggested steps such as standardising the various testing and treatment methods used in different areas.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962176-9/fulltext" target="_blank"&gt;The white plague returns to London with a vengeance&lt;/A&gt;. The Lancet, Early Online Publication, December 17 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>308972</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.tuberculosisjournal.com/article/S1472-9792(06)00022-9/abstract]]&gt;</url>
    <title>TB vaccine strategies – What is needed to solve a complex problem?</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,PREVENTION,INFECTIONS,VACCINES / IMMUNISATION,CHILDHOOD VACCINES,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MARCH 09,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ An estimated 2 billion people are latently infected with Mycobacterium tuberculosis, the majority of which are already BCG vaccinated and repeatedly sensitized to mycobacterial strains from the environment. To be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti-mycobacterial immune response. In this review we will discuss some of the most advanced attempts to address this challenge.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>330554</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/122383804/abstract]]&gt;</url>
    <title>Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: Is it time to move on from zidovudine?</title>
    <publicationDate>2009-05-12T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,ADULTS,CHILDREN,POPULATION GROUPS,PREGNANT WOMEN,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,NOV 09,ADDED 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objectives&lt;/STRONG&gt;: Zidovudine (ZDV) has been the cornerstone of antiretroviral (ARV) therapy for pregnant women infected with HIV-1 in the prevention of mother-to-child transmission (MTCT) and remains the only licensed ARV for use in pregnancy. We explored the current and future roles of tenofovir disoproxil fumarate (TDF) in the prevention of MTCT of HIV-1. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: We reviewed the published literature by conducting database searches of in vitro, animal and clinical studies, reported in journals and at conferences, using the search terms Tenofovir/gs4331/viread, pregnant/pregnancy, lactate, lactation, natal, reproduce/reproduction, placenta/placental, malformation, and teratogenicity/teratogenic. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: In a macaque model, perinatal exposure to very high dose tenofovir resulted in bone toxicity in some offspring. However, perinatal use of TDF, both single dose and as part of highly active antiretroviral therapy in women, has been well tolerated in the short term by mothers and their infants. Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: The addition of TDF to SD-NVP reduces NNRTI resistance. The role of TDF in this setting and during pregnancy for reducing rates of MTCT requires investigation. While short-term toxicity data are encouraging, long-term follow-up of exposed mothers and infants is required.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304162</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947387361]]&gt;</url>
    <title>Test and treat Helicobacter managment of dyspepsia: Cost comparison of serology to stoool antigen and breath test</title>
    <publicationDate>2007-05-15T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ GASTROINTESTINAL INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,TREATMENT,JAN 09,HELICOBACTER PYLORI,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Recently published dyspepsia guidelines suggest that all patients, irrespective of age, with uncomplicated dyspepsia unresponsive to lifestyle changes or PPIs should be considered for helicobacter testing and treated accordingly.]]&gt;</body>
  </document>
  <document>
    <id>319566</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1203496897276]]&gt;</url>
    <title>Testing Times - HIV and other Sexually Transmitted Infections in the United Kingdom: 2007</title>
    <publicationDate>2007-11-23T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GOOD PRACTICE,HERPES,CHLAMYDIA,GONORRHOEA,SYPHILIS,LYMPHOGRANULOMA VENEREUM (LGV),HIV/AIDS,GENITAL WARTS (HPV),SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,WOMEN'S HEALTH,SEXUAL HEALTH,PELVIC INFLAMMATORY DISEASE,SYPHILIS,TRICHOMONAS,PUBLIC HEALTH,PEDICULOSIS PUBIS,LGV,PROVISION OF CARE,HIV,GONORRHOEA,DONOVANOSIS,GENITAL WARTS (HPV),GENITAL HERPES,BACTERIAL VAGINOSIS,CANDIDA,CHLAMYDIA,CHANCROID,INFECTIONS,COMMISSIONING,NOV 08,TREPONEMA PALLIDUM,PUBIC LICE,HUMAN PAPILLOMAVIRUS (HPV),HUMAN IMMUNODEFICIENCY VIRUS (HIV),HERPES SIMPLEX VIRUS (HSV),VIRUSES,NEISSERIA GONORRHOEA,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report presents detailed information from HIV and STI surveillance and prevention monitoring systems to give a synthesis of the current state of these infections in the UK and to make recommendations. It is intended to be read by all those directly involved with sexual health promotion at local and national levels, by those engaged in HIV and STI treatment and care services, and by those setting local commissioning priorities.]]&gt;</body>
  </document>
  <document>
    <id>286450</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/tetanus/tetanus_health_professionals.pdf]]&gt;</url>
    <title>Tetanus information for health professionals </title>
    <publicationDate>2003-11-24T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CENTRAL NERVOUS SYSTEM,INSECT BITE,CONTACT,TRANSMISSION MODE,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document aims to assist in the diagnosis, treatment and public health management of cases of tetanus. It includes sections on the causative organism, epidemiology of tetanus in England and Wales, clinical features, diagnosis, clinical management, occupational health, preventative measures, reporting and public health management. Detailed information on tetanus vaccine, the management of tetatus prone wounds and the national vaccination programme are referenced but available elsewhere.  ]]&gt;</body>
  </document>
  <document>
    <id>381029</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable.pdf]]&gt;</url>
    <title>The ABCs of Hepatitis Factsheet</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Centers for Disease Control and Prevention</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,HEPATITIS,INFECTIONS,PREVENTION,ANTIVIRALS,ANTIMICROBIALS,TREATMENT,HEPATITIS B,HEPATITIS A,HEPATITIS C,HEPATITIS A VACCINE,HEPATITIS B VACCINE,HEPATITIS VIRUS,HEPATITIS B VIRUS,HEPATITIS A VIRUS,HEPATITIS C VIRUS,VIRUSES,MICROORGANISM,VACCINES / IMMUNISATION,TRAVEL VACCINES,JULY 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This updated factsheet by the CDC provides a summary of useful information about Hepatitis A, B and C.]]&gt;</body>
  </document>
  <document>
    <id>345542</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-2458-9-450.pdf]]&gt;</url>
    <title>The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review</title>
    <publicationDate>2009-12-05T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: In 2004, tuberculosis (TB) was responsible for 2.5% of global mortality (among men 3.1%; among women 1.8%) and 2.2% of global burden of disease (men 2.7%; women 1.7%). The present work portrays accumulated evidence on the association between alcohol consumption and TB with the aim to clarify the nature of the relationship.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: A systematic review of existing scientific data on the association between alcohol consumption and TB, and on studies relevant for clarification of causality was undertaken.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: There is a strong association between heavy alcohol use/alcohol use disorders (AUD) and TB. A meta-analysis on the risk of TB for these factors yielded a pooled relative risk of 2.94 (95% CI: 1.89-4.59). Numerous studies show pathogenic impact of alcohol on the immune system causing susceptibility to TB among heavy drinkers. In addition, there are potential social pathways linking AUD and TB. Heavy alcohol use strongly influences both the incidence and the outcome of the disease and was found to be linked to altered pharmacokinetics of medicines used in treatment of TB, social marginalization and drift, higher rate of re-infection, higher rate of treatment defaults and development of drug-resistant forms of TB. Based on the available data, about 10% of the TB cases globally were estimated to be attributable to alcohol.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: The epidemiological and other evidence presented indicates that heavy alcohol use/ AUD constitute a risk factor for incidence and re-infection of TB. Consequences for prevention and clinical interventions are discussed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286458</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/libra/cmro/2002/00000018/00000006/art00003]]&gt;</url>
    <title>The clinical diagnosis of influenza</title>
    <publicationDate>2002-10-01T00:00:00</publicationDate>
    <publisher>LibraPharm</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFLUENZA,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIONS,MICROORGANISM,VIRUSES,INFECTIOUS DISEASES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Effective management of influenza depends on early recognition of influenza in the community and on rapid diagnosis. Early recognition is achieved by integrated clinical and laboratory based surveillance programmes in representative populations. The recent introduction of 'near patient tests' for influenza provide increased opportunities for surveillance but diagnosis remains largely clinically based. The combination of cough and fever in conditons of known local influenza virus circulation provide a useful indicator of diagnosis to guide management. ]]&gt;</body>
  </document>
  <document>
    <id>286460</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHVol3/no1/resp.pdf#page=5]]&gt;</url>
    <title>The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter</title>
    <publicationDate>2000-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFLUENZA,TRANSMISSION MODE,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,RESPIRATORY INFECTIONS,INFLUENZA VIRUS,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The impact of influenza is assessed by comparing events during epidemics with those expected outside epidemic periods (defined from incidence data collected by the Weekly Returns Service of the Royal College of General Practitioners from 1989 to 1998 for influenza-like illness, acute otitis media, acute bronchitis, and all respiratory infections combined in the community and virus isolate data). Estimates of the consulting populations for each condition in England and Wales were derived by extrapolating the difference between observed and baseline incidence rates to the total population. Similar methods were applied to data on hospital admissions for cardiac and respiratory diseases and to deaths. Each year an average of 422,000 extra people consulted and were diagnosed with influenza-like illness during the epidemic period; among 1.1 million extra people who presented with acute respiratory infections. There were 3028 excess respiratory admissions (England only) in the age group 65 to 74 years and 6049 who were aged over 75 years, but no excess cardiac admissions. An average of 12,554 deaths occurred in England and Wales during influenza epidemic periods each year. Age specific national data are needed to interpret the economic impact of an illness in relation to the setting for health care delivery.]]&gt;</body>
  </document>
  <document>
    <id>286461</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6WJT-4P1273C-1&amp;_user=910131&amp;_coverDate=09%2F30%2F2007&amp;_rdoc=7&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%236887%232007%23999449996%23665964%23FLA%23display%23Volume)&amp;_cdi=6887&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=185&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=648722b3667e16def9b1c35be2cf24f5]]&gt;</url>
    <title>The contribution of respiratory pathogens to the seasonality of NHS Direct calls </title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFLUENZA,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,INFECTIONS,MICROORGANISM,VIRUSES,INFECTIOUS DISEASES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objectives: Primary care is thought to bear half the cost of treating infections in the UK. We describe the seasonal variation in NHS Direct respiratory calls (a new source of primary care data) and estimate the contribution of specific respiratory pathogens to this variation.

Methods: Linear regression models were used to estimate the weekly contribution of specific respiratory pathogens to the volume of NHS Direct respiratory calls (England and Wales, 2002–2004, all ages and 0–4 years).

Results: Annual peaks in NHS Direct cough and difficulty breathing calls occurred in late December, with peaks in ‘cold/flu’ and fever calls occurring between November and April. The main explanatory variables were influenza (estimated to account for 72.5 calls per 100,000/year; 22% of ‘cold/flu’ calls; 15% of cough; and 13% of fever) and Streptococcus pneumoniae (55.5 per 100,000; 33% of ‘cold/flu’ calls; 20% of cough; and 15% of fever (0–4 years)).

Conclusions: It is estimated that respiratory viruses, notably influenza and RSV, are responsible for at least 50% of the seasonal variation in NHS Direct respiratory calls. These results provide estimates of the burden of specific respiratory diseases reported to NHS Direct, and will help interpret syndromic surveillance data used to provide early warning of rises in community morbidity. ]]&gt;</body>
  </document>
  <document>
    <id>286462</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TD4-4H21FPK-3&amp;_user=910131&amp;_coverDate=02%2F13%2F2006&amp;_rdoc=25&amp;_fmt=summary&amp;_orig=browse&amp;_srch=doc-info(%23toc%235188%232006%23999759992%23616169%23FLA%23display%23Volume)&amp;_cdi=5188&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=25&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=e08666ee1d81a33e1607792a15096780]]&gt;</url>
    <title>The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age </title>
    <publicationDate>2006-02-13T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY INFECTIONS,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFLUENZA,TRANSMISSION MODE,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,INFLUENZA VIRUS,INFECTIOUS DISEASES,VIRUSES,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza can cause significant morbidity and mortality. Influenza vaccination is an effective and safe strategy in the prevention of influenza. Currently the National Health Service (NHS) vaccinates ‘at-risk’ individuals only. This definition includes everyone over 65 years of age but excludes individuals 50–64 years of age unless they have an additional risk factor, such as underlying heart disease or lung disease. In order to examine the cost-effectiveness of an extension of the vaccination policy to include this age group we constructed an economic model to estimate the costs and benefits of vaccination from both a health service and a societal perspective. Data to populate the model was obtained from the literature and the outcome measure used was the quality adjusted life year (QALY). Influenza vaccination prevented an estimated 4508 cases (95% CI: 2431–7606) per 100,000 vaccinees per influenza season for a net cost to the NHS of £653,221 (95% CI: 354,575–1,072,257). The net cost increased to £1,139,069 (95% CI 27,052–2,030,473) when non-NHS costs were included and the estimated cost-per-QALY were £6174 and £10,766 for NHS and all costs respectively. Extension of the current immunisation policy has the potential to generate a significant health benefit at a comparatively low cost. ]]&gt;</body>
  </document>
  <document>
    <id>307710</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.tuberculosisjournal.com/article/PIIS1472979208700386/abstract]]&gt;</url>
    <title>The early bactericidal activity of anti-tuberculosis drugs: a literature review</title>
    <publicationDate>2008-08-04T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Quantification of mycobacteria in sputum from pulmonary tuberculosis patients has been used to evaluate patient's response to treatment since the earliest days of anti-tuberculosis chemotherapy. More recently the early bactericidal activity (EBA) of anti-tuberculosis agents, measured as the fall in viable colony forming units of Myco-bacterium tuberculosis in sputum early in therapy, has been shown to be an objective, repeatable measure of the ability of an agent to kill the metabolically active bacilli found in the sputum of patients with sputum microscopy smear-positive pulmonary tuberculosis. EBA offers an opportunity to rapidly demonstrate that a new agent has a detectable anti-tuberculosis effect in a relatively small number of patients, what the most appropriate dose is to take forward to more extensive clinical trials and allows the study of the relationship between pharmacokinetics and bactericidal activity and toxicity of the relevant agent.]]&gt;</body>
  </document>
  <document>
    <id>286463</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/content/abstract/272/21/1661?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;searchid=1055764111969_674&amp;stored_search=&amp;FIRSTINDEX=0&amp;volume=272&amp;firstpage=1661&amp;journalcode=jama]]&gt;</url>
    <title>The efficacy of influenza vaccination in elderly individuals. A randomized double blind placebo-controlled trial</title>
    <publicationDate>1994-12-07T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,BODY PART AFFECTED,RESPIRATORY TRACT,RESPIRATORY INFECTIONS,VACCINES / IMMUNISATION,PREVENTION AND CONTROL,PREVENTION,INFECTIONS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ OBJECTIVE--To determine the efficacy of influenza vaccination in elderly people. DESIGN--Randomized double-blind placebo-controlled trial. SETTING--Fifteen family practices in the Netherlands during influenza season 1991-1992. PARTICIPANTS--A total of 1838 subjects aged 60 years or older, not known as belonging to those high-risk groups in which vaccination was previously given. INTERVENTION--Purified split-virion vaccine containing A/Singapore/6/86(H1N1), A/Beijing/353/89(H3N2), B/Beijing/1/87, and B/Panama/45/90 (n = 927) or intramuscular placebo containing physiological saline solution (n = 911). MAIN OUTCOME MEASURES--Patients presenting with influenzalike illness up to 5 months after vaccination; self-reported influenza in postal questionnaires 10 weeks and 5 months after vaccination; serological influenza (fourfold increase of antibody titer between 3 weeks and 5 months after vaccination). RESULTS--The incidence of serological influenza was 4% in the vaccine group and 9% in the placebo group (relative risk [RR], 0.50; 95% confidence interval [CI], 0.35 to 0.61). The incidences of clinical influenza were 2% and 3%, respectively (RR, 0.53; 95% CI, 0.39 to 0.73). The effect was strongest for the combination of serological and clinical influenza (RR, 0.42; 95% CI, 0.23 to 0.74). The effect was less pronounced for self-reported influenza. CONCLUSION--In the elderly, influenza vaccination may halve the incidence of serological and clinical influenza (in periods of antigenic drift). ]]&gt;</body>
  </document>
  <document>
    <id>308926</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://fieldresearch.msf.org/msf/bitstream/10144/41794/1/Murphy%20NY%20CID.pdf]]&gt;</url>
    <title>The emerging crisis of drug-resistant tuberculosis in South Africa: Lessons from New York City.</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Infectious Diseases Society of America</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis have emerged as important infections in South Africa among patients infected with human immunodeficiency virus (HIV). In the face of this new epidemic, South Africa must rededicate itself to the task of tuberculosis control and treatment with a rapid, multifaceted approach. Priorities include expansion of second-line treatment capacity, investment in clinical laboratories, a system to ensure supervised treatment for all patients, and enhancement of infection control procedures. In New York City, where drug-resistant tuberculosis emerged 2 decades ago—also in the context of a large HIV-infected population and an underfunded public health infrastructure—similar steps were successful in leading to the rapid decrease in rates of drug resistance among tuberculosis isolates. With refinements based on local resource constraints, urgent measures could potentially arrest the alarming increase in multidrugresistant and extensively drug-resistant tuberculosis cases in South Africa. Unlike many countries in sub-Saharan Africa, South Africa has the capacity to mount a rapid and large-scale response before drug-resistant tuberculosis envelops a much larger and far poorer region.]]&gt;</body>
  </document>
  <document>
    <id>394194</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://epirev.oxfordjournals.org/content/32/1/137.full.pdf+html]]&gt;</url>
    <title>The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency</title>
    <publicationDate>2010-04-19T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Men who have sex with men (MSM) have borne a disproportionate burden of human immunodeficiency virus (HIV) infection and remain a markedly underresourced population globally. To better describe HIV epidemics among MSM in low- and middle-income countries, the authors conducted a systematic review of published and unpublished literature available after January 1, 2000 (2000-2009). A total of 133 HIV prevalence studies from 50 countries met the search criteria. Data were used to develop an algorithmic approach to categorize these epidemics. The authors found that the HIV epidemic in low- and middle-income countries may be described using the following 4 scenarios: 1) settings where MSM are the predominant contributor to HIV cases; 2) settings where HIV transmission among MSM occurs in the context of epidemics driven by injection drug users; 3) settings where HIV transmission among MSM occurs in the context of well-established HIV transmission among heterosexuals; and 4) settings where both sexual and parenteral modes contribute significantly to HIV transmission. The authors focused on Peru, Ukraine, Kenya, and Thailand to describe the diversity across and similarities between proposed epidemic scenarios. This scenario-based categorization of HIV epidemics among MSM may assist public health agencies and civil societies to develop and implement better-targeted HIV prevention programs and interventions.]]&gt;</body>
  </document>
  <document>
    <id>345655</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.stoptb.org/assets/documents/global/plan/GlobalPlanFinal.pdf]]&gt;</url>
    <title>The Global Plan to Stop TB: 2006-2015</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Actions for life-towards a world free of tuberculosis</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Global Plan to Stop TB 2006 - 2015 is a comprehensive assessment of the action and resources needed to implement the Stop TB strategy and make an impact on the global TB burden.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View the full &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GlobalPlanFinal.pdf" target="_blank"&gt;Global Plan to Stop TB 2006 - 2015 [.pdf]&lt;/A&gt;&lt;BR&gt;&lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GPII_SPversion%20finale.pdf" target="_blank"&gt;Español [.pdf]&lt;/A&gt;, &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GPII_Arabic.pdf" target="_blank"&gt;Arabic [.pdf]&lt;/A&gt;, &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/StopTB_GlobalPlan_FR_web.pdf" target="_blank"&gt;Français [.pdf]&lt;/A&gt; 
&lt;LI&gt;The Executive Summary &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GP_ES_Eng.pdf" target="_blank"&gt;English [.pdf]&lt;/A&gt;, &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GP_ES_Fre.pdf" target="_blank"&gt;Français [.pdf]&lt;/A&gt;, &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GP_ES_Spa.pdf" target="_blank"&gt;Español [.pdf]&lt;/A&gt; 
&lt;LI&gt;The &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GP_Forward.pdf" target="_blank"&gt;Foreword&lt;/A&gt; to the plan by Irene Koek (Chair, Stop TB Partnership Coordinating Board) and Ernest Loevinsohn (Emeritus Chair, Stop TB Partnership Coordinating Board) 
&lt;LI&gt;The &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GP_Preface.pdf" target="_blank"&gt;Preface&lt;/A&gt; by Dr LEE Jong-wook, Director-General, World Health Organization 
&lt;LI&gt;The &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GP_Statements.pdf" target="_blank"&gt;Statements of Suppport&lt;/A&gt; by Emile Bongeli Yeikelo ya Ato, Minister of Health, Democratic Republic of Congo, Hilary Benn, United Kingdom Secretary of State for International Development and Andrew Natsios, Administrator, U.S. Agency for International Development 
&lt;LI&gt;The &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/GP_Introduction.pdf" target="_blank"&gt;Introduction&lt;/A&gt; explains the rationale for the Plan and outlines how the Plan is structured. 
&lt;LI&gt;The &lt;A href="http://www.stoptb.org/global/plan/main/plan_steering.asp" target="_blank"&gt;Steering Committee of the Global Plan to Stop TB 2006 - 2015&lt;/A&gt; 
&lt;LI&gt;Click &lt;A href="http://www.stoptb.org/global/plan/main/plan_development.asp" target="_blank"&gt;here&lt;/A&gt; to learn more about the development of the Global Plan 
&lt;LI&gt;Click &lt;A title="Opens in new window" href="http://www.stoptb.org/assets/documents/global/plan/Thanks%20to%20all%20Partners.pdf" target="_blank"&gt;here&lt;/A&gt; for the message of thanks from Partnership Executive Secretary to all partners&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394462</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf]]&gt;</url>
    <title>The Global Plan to Stop TB: 2011-2015</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Transforming the fight towards elimination of tuberculosis</description>
    <body>&lt;![CDATA[ &lt;P class="grid_8 level2"&gt;The Global Plan to Stop TB is a comprehensive assessment of the action and resources needed to implement the Stop TB strategy and make an impact on the global TB burden. &lt;/P&gt;
&lt;H2 class="grid_8 level2"&gt;
&lt;P&gt;&lt;/P&gt;&lt;/H2&gt;]]&gt;</body>
  </document>
  <document>
    <id>286469</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://thorax.bmj.com/content/62/8/672.abstract]]&gt;</url>
    <title>The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales 1999-2003.</title>
    <publicationDate>2007-02-20T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,TRANSMISSION MODE,HIV/AIDS,AIRBORNE,CONTACT,BODY PART AFFECTED,RESPIRATORY TRACT,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Previous studies have estimated the prevalence of tuberculosis and HIV infection in population subgroups in the UK. This study was undertaken to describe recent trends in the proportion of individuals with HIV infection among reported cases of tuberculosis in England and Wales, and to review the implications for clinical and public health care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: A population-based matching study using national surveillance databases was used to investigate all persons aged 15 years and over reported with a diagnosis of tuberculosis to the Health Protection Agency in England and Wales in 1999–2003. Record linkage was used to match the national tuberculosis and HIV/AIDS surveillance databases to identify all cases of tuberculosis and determine the proportion of patients with tuberculosis co-infected with HIV. The distribution and characteristics of the cases were determined and the trend examined by year.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Of 30 670 cases of tuberculosis reported in England and Wales between 1999 and 2003, an estimated 1743 (5.7%) were co-infected with HIV. There was a year on year increase in the proportion from 3.1% (169/5388) in 1999 to 8.3% (548/6584) in 2003 (p for trend &amp;lt;0.0001). Co-infected patients contributed to almost a third of the increase in the number of cases of tuberculosis during the 5 year period. Patients co-infected with HIV were predominantly those born abroad. 18.5% (n?=?323) of co-infected patients had not been reported as active cases of tuberculosis on the national tuberculosis database.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: The proportion of patients with tuberculosis co-infected with HIV in England and Wales is increasing, with the greatest impact on those born abroad regardless of their ethnic origin. With HIV infection contributing substantially to the increase in the number of cases of tuberculosis, close cooperation in the clinical management and accurate notification of patients is vital if appropriate care and public health action is to be achieved. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>391961</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.eurosurveillance.org/images/dynamic/EE/V15N39/art19671.pdf]]&gt;</url>
    <title>The Hajj: communicable and non-communicable health hazards and current guidance for pilgrims</title>
    <publicationDate>2010-09-30T00:00:00</publicationDate>
    <publisher>Eurosurveillance</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,GASTROINTESTINAL INFECTIONS,INFECTIONS,RESPIRATORY INFECTIONS,MENINGITIS,POPULATION GROUPS,BRAIN AND SPINAL CORD INFECTIONS,TRAVELLERS,ADULTS,OCT 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Hajj has become the epicenter of mass migration of millions of Muslims of enormous ethnic diversity. No other mass gathering can compare, either in scale or in regularity. Communicable disease outbreaks of various infectious diseases have been reported repeatedly, during and following the Hajj. The Hajj 2010 starts in the first week of November 2010 and this report is a timely reminder that many infectious diseases can be avoided or averted by adopting appropriate prophylactic measures.]]&gt;</body>
  </document>
  <document>
    <id>305152</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_093762?IdcService=GET_FILE&amp;dID=182901&amp;Rendition=Web]]&gt;</url>
    <title>The Health and Social Care Act 2008: Code of Practice for the NHS on the prevention and control of healthcare associated infections and related guidance</title>
    <publicationDate>2009-01-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,PREVENTION,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,INFECTION CONTROL,JAN 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Code, which comes into force on 1 April 2009, sets out how the Care Quality Commission will assess compliance with the requirements set out in the Regulations made under section 20(5) of the Health and Social Care Act 2008 and provides guidance on how providers can meet the registration requirements relating to healthcare associated infections set out in the Regulations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This document sets out the decisions reached after considering the responses to the recent consultation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The January 2008 version of the Code will remain in force until 1 April 2009.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394433</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861016/pdf/1478-7547-8-5.pdf]]&gt;</url>
    <title>The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study</title>
    <publicationDate></publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ dfsdf]]&gt;</body>
  </document>
  <document>
    <id>394433</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861016/pdf/1478-7547-8-5.pdf]]&gt;</url>
    <title>The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study</title>
    <publicationDate></publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ dfsdf]]&gt;</body>
  </document>
  <document>
    <id>394449</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861016/pdf/1478-7547-8-5.pdf]]&gt;</url>
    <title>The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>QUALITATIVE STUDY</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: While health outcomes of HIV/AIDS treatments in terms of increased longevity has been the subject of much research, there appears to be very limited research on the improved health related quality of life (HRQL) that can be applied in cost-utility analyses in Africa south of the Sahara (SSA). Most of the literature that does exist present HRQL measured by disease specific instruments, but such data is of little use as input to economic evaluations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A systematic review of the literature on HRQL weights for people living with HIV/AIDS in Africa was performed, and the findings are presented and interpreted. We also use focus group discussions in panels of clinical AIDS experts to test the preference based on a generic descriptive system EQ-5D. We contrast quality of life with and without antiretroviral treatment (ART), and with and without treatment failure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: In only four papers were the HRQL weights for HIV/AIDS in sub-Saharan Africa estimated with generic preference based methodologies that can be directly applied in economic evaluation. A total of eight studies were based on generic health profiles. While such 'health profiles' are not preference based, the scores could potentially be transformed into health state utilities. Most of the available literature (20 papers) utilized disease specific instrument, which are not applicable for economic evaluation.The focus group discussions revealed that HRQL weights are strongly correlated to disease stage. Furthermore, clinical experts consistently report that ART has a strong positive impact on the HRQL of patients, although this effect appears to rebound in cases of drug resistance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: EQ-5D appears to be an appropriate tool for measuring and valuing HRQL of HIV/AIDS in Africa. More empirical research is needed on various methodological aspects in order to obtain valid and reliable HRQL weights in economic evaluations of HIV/AIDS prevention and treatment interventions.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394449</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861016/pdf/1478-7547-8-5.pdf]]&gt;</url>
    <title>The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>QUALITATIVE STUDY</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: While health outcomes of HIV/AIDS treatments in terms of increased longevity has been the subject of much research, there appears to be very limited research on the improved health related quality of life (HRQL) that can be applied in cost-utility analyses in Africa south of the Sahara (SSA). Most of the literature that does exist present HRQL measured by disease specific instruments, but such data is of little use as input to economic evaluations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A systematic review of the literature on HRQL weights for people living with HIV/AIDS in Africa was performed, and the findings are presented and interpreted. We also use focus group discussions in panels of clinical AIDS experts to test the preference based on a generic descriptive system EQ-5D. We contrast quality of life with and without antiretroviral treatment (ART), and with and without treatment failure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: In only four papers were the HRQL weights for HIV/AIDS in sub-Saharan Africa estimated with generic preference based methodologies that can be directly applied in economic evaluation. A total of eight studies were based on generic health profiles. While such 'health profiles' are not preference based, the scores could potentially be transformed into health state utilities. Most of the available literature (20 papers) utilized disease specific instrument, which are not applicable for economic evaluation.The focus group discussions revealed that HRQL weights are strongly correlated to disease stage. Furthermore, clinical experts consistently report that ART has a strong positive impact on the HRQL of patients, although this effect appears to rebound in cases of drug resistance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: EQ-5D appears to be an appropriate tool for measuring and valuing HRQL of HIV/AIDS in Africa. More empirical research is needed on various methodological aspects in order to obtain valid and reliable HRQL weights in economic evaluations of HIV/AIDS prevention and treatment interventions.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321491</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/Swinefluhistory.aspx]]&gt;</url>
    <title>The history of swine flu</title>
    <publicationDate>2009-06-30T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLUENZA,INFECTIOUS DISEASES,INFECTIONS,RESPIRATORY INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,SWINE INFLUENZA,ADDED 2009,JUNE 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Independent says that “the swine flu pandemic might not have happened had it not been for the accidental release of the same strain of influenza virus from a research laboratory in the late 1970s.” The news comes from a medical article which analysed the history of the influenza A H1N1 virus, including the recent development of swine flu seen around the world.&lt;/P&gt;
&lt;P&gt;The reports say that the H1N1 influenza strain was responsible for a flu pandemic in 1977, but before this it had not been found in humans for more than 20 years. By looking at the genetic makeup of the 1977 virus, researchers have found that it was similar to a strain that was circulating in 1950. This 1950s strain would have been stored in labs and researchers have suggested that the re-emergence of the virus in 1977 “was probably an accidental release from a laboratory source”, possibly through laboratory workers becoming infected.&lt;/P&gt;
&lt;P&gt;Professor John Oxford of the Royal London Hospital is reported as saying that the theory is “plausible”, but that “it may have been a good thing as it would have given many older people alive today some measure of immunity to the current pandemic.” The newspapers have concentrated on the possibility of an accidental reintroduction of the H1N1 virus during the 1970s. However, this is only one aspect of the complex history of the current pandemic swine flu virus discussed in the article. The current swine flu virus has developed over time by natural exchange of genetic material between human, bird and pig strains of the influenza virus. This review does not suggest that the current form was created in or leaked from a laboratory. &lt;/P&gt;
&lt;P align=center&gt;----------------------------------------------------&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;A href="http://www.nhs.uk/News/Pages/NewsIndex.aspx" target="_blank"&gt;Behind the Headlines&lt;/A&gt;&lt;/EM&gt; provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296262</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1223534078963]]&gt;</url>
    <title>The Human Animal Infections and Risk Surveillance (HAIRS) Group First Report 2004-2007</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,OCT 08,ZOONOSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The HAIRS group carries out horizon scanning to identify emerging and potentially zoonotic infections which may pose a threat to UK public health. This is carried out by systematic examination of formal and informal reports on infectious incidents in animal and human populations globally. A wide range of sources of information are scanned, including informal news reports and bulletins, early warning communications, surveillance data and peer-reviewed scientific literature. The Secretariat and members of the group identify potential hazards, such as new or unusual syndromes or infections in animals, or increases in endemic disease, and these are then brought to the group for discussion and assessment. The multidisciplinary nature of the HAIRS group enables objective and scientific assessment of potential threats, and the group to assess these reports in an objective and scientific manner.]]&gt;</body>
  </document>
  <document>
    <id>345505</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/download?pub=infobike%3a%2f%2fiuatld%2fijtld%2f2009%2f00000013%2f00000005%2fart00020&amp;mimetype=application%2fpdf]]&gt;</url>
    <title>The impact of immigration on tuberculosis rates in the United Kingdom compared with other European countries</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>The Union</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ADULTS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,POPULATION GROUPS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,IMMIGRANTS,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To investigate whether trends in tuberculosis (TB) rates across Europe are linked to patterns of migration. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: Descriptive analysis of Organisation for Economic Co-operation and Development population statistics and EuroTB data for 21 European countries for 1996-2005. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: TB notification rates increased in only three of the 21 countries: the United Kingdom, Norway and Sweden. In all three countries, approximately three quarters of cases were foreign-born. The UK had the third highest number of foreign nationals overall, but the highest number from a country with a TB incidence &amp;gt; or =250 cases/100000 (219000, 13%). European countries with declining TB rates had varying patterns of migration, but did not generally receive migrants from very high-incidence countries and/or had a smaller proportion of their total TB cases in their migrant population. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: The increase in the rate of TB in the UK, which contrasts with most other European countries, may, at least in part, be due to the fact that a high proportion of UK cases occur in the foreign-born, coupled with a comparatively large number of foreign nationals from countries with a very high incidence of TB.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286471</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bjhm.co.uk/cgi-bin/go.pl/library/abstract.html?uid=1216]]&gt;</url>
    <title>The influenza virus</title>
    <publicationDate>1999-10-13T00:00:00</publicationDate>
    <publisher>British Journal of Hospital Medicine</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFLUENZA,AIRBORNE,BODY PART AFFECTED,RESPIRATORY INFECTIONS,RESPIRATORY TRACT,INFECTIONS,MICROORGANISM,VIRUSES,INFECTIOUS DISEASES,INFLUENZA VIRUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Influenza is a severe cause of morbidity and mortality throughout the world, resulting in annual outbreaks in all age ranges of the population. With an extensive animal reservoir the threat of emergence of a novel influenza virus, capable of causing a pandemic, has spurred research into novel therapies with which to fight the virus. ]]&gt;</body>
  </document>
  <document>
    <id>286473</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/S0163-4453(03)00003-3]]&gt;</url>
    <title>The microbial diagnosis of infective endocarditis</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,CARDIOVASCULAR,INFECTIONS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This review suggests an evidence-based algorithm for sequential testing in infective endocarditis. It discusses blood culture and the merits and drawbacks of serology in making the diagnosis. Newer techniques are briefly reviewed. The proposed algorithm will complement the Duke criteria in clinical practice.]]&gt;</body>
  </document>
  <document>
    <id>286474</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop57.pdf]]&gt;</url>
    <title>The Microbiological Examination of Water Samples (QSOP 57)</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>307711</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.resmedjournal.com/article/S0954-6111(08)00051-6/abstract]]&gt;</url>
    <title>The use of adjunctive corticosteroids in the treatment of pericardial, pleural and meningeal tuberculosis: Do they improve outcome?</title>
    <publicationDate>2008-06-02T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tuberculosis remains a major cause of mortality and morbidity on a global scale. Effective anti-tuberculous chemotherapy has improved outcomes for individuals suffering from tuberculosis, although the disease often results in significant and permanent damage to organs. The use of adjunctive corticosteroid treatment has been studied with a view to demonstrating a reduction in inflammatory events that may improve outcomes for both mortality and morbidity. Cochrane reviews have summarized the evidence for adjunctive corticosteroids in the treatment of tuberculous pericarditis, meningitis and pleural effusion. These reviews have shown improved mortality for pericarditis and meningitis, but inconclusive effects for pericardial constriction and ongoing neurological disability. Rapid improvements in clinical parameters for pleural effusion were not supported by any lasting improved outcomes for these patients.]]&gt;</body>
  </document>
  <document>
    <id>393933</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://ijsa.rsmjournals.com/cgi/content/abstract/21/5/305]]&gt;</url>
    <title>The utility of voluntary counselling and testing data as a source of information on HIV prevalence: a systematic review</title>
    <publicationDate>2010-05-21T00:00:00</publicationDate>
    <publisher>The Royal Society of Medicine Press Limited</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ We explored the utility of routine HIV testing data from clinical services for estimating HIV prevalence. A systematic review identified 28 eligible publications, covering concentrated epidemics (16 of 28) and generalized epidemics (12). Of the 16 papers from concentrated epidemics, five presented estimates by risk group and four by testing history with a median HIV prevalence of 1.8% in first-time testers compared with 3% in repeat testers. Two reports from generalized epidemics restricted estimates to asymptomatic clients and three included breakdowns by reason-for-test, with the median HIV prevalence higher in symptomatic clients (62%) than others (24%). Two papers from generalized epidemics showed prevalence estimates based on routine HIV testing data were slightly higher than estimates derived from other surveillance methods, but did not restrict estimates to asymptomatic patients. We conclude that routine HIV testing data may be a supplementary data source for HIV surveillance provided careful analyses are conducted.]]&gt;</body>
  </document>
  <document>
    <id>286484</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp34.pdf]]&gt;</url>
    <title>Thermonuclease activity test (BSOP TP 34)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,CARDIOVASCULAR,FOOD/WATER,INFECTIONS,MICROORGANISM,BACTERIA,STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286485</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop16.pdf]]&gt;</url>
    <title>Thiosulphate citrate bile salt sucrose (TCBS) agar (MSOP 16)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,FOOD/WATER,TRANSMISSION MODE,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,INFECTIOUS DISEASES,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286487</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/content/full/328/7443/791]]&gt;</url>
    <title>Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomized controlled trial</title>
    <publicationDate>2004-04-03T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY TRACT,BODY PART AFFECTED,INFECTIONS,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective To assess the efficacy of three days versus five days of treatment with oral amoxicillin for curing non-severe pneumonia in children. 
Design Randomised, double blind, placebo controlled multicentre trial. 
Setting Outpatient departments of seven referral hospitals in India. 
Participants 2188 children aged 2-59 months, 1095 given three days of treatment and 1093 given five days. 
Intervention Oral amoxicillin 31-54 mg/kg/day in three divided doses. 
Main outcome measures Treatment failure: defined as development of chest indrawing, convulsions, drowsiness, or inability to drink at any time; respiratory rate above age specific cut points on day 3 or later; or oxygen saturation by pulse oximetry &lt; 90% on day 3. 
Results The clinical cure rates with three days and five days of treatment were 89.5% and 89.9%, respectively (absolute difference 0.4 (95% confidence interval - 2.1 to 3.0)). Adherence to treatment regimen was 94% and 85% for three day and five day treatments, respectively. Loss to follow up was 5.4% by day 5. There were no deaths, 41 hospitalisations, and 36 minor adverse reactions. There were 225 (10.3%) clinical failures and 106 (5.3%) relapses, and rates were similar in both treatments. At enrolment, 513 (23.4%) children tested positive for respiratory syncytial virus, and Streptococcus pneumoniae and Haemophilus influenzae were isolated from the nasopharynx in 878 (40.4%) and 496 (22.8%) children, respectively. Clinical failure was associated with isolation of respiratory syncytial virus (adjusted odds ratio 1.95 (95% confidence interval 1.0 to 3.8)), excess respiratory rate of &gt; 10 breaths/minute (2.89 (1.83 to 4.55)), and non-adherence with treatment at day 5 (11.57 (7.4 to 18.0)). 
Conclusions Treatment with oral amoxicillin for three days was as effective as for five days in children with non-severe pneumonia]]&gt;</body>
  </document>
  <document>
    <id>286488</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TDC-4HGK23W-4&amp;_user=910131&amp;_handle=V-WA-A-W-VA-MsSWYVW-UUA-U-AACBBYEUYW-AACUEZEYYW-EVYWYAZCV-VA-U&amp;_fmt=summary&amp;_coverDate=11%2F30%2F2005&amp;_rdoc=4&amp;_orig=browse&amp;_srch=%23toc%235195%232005%23998819988%23609863!&amp;_cdi=5195&amp;view=c&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=3bae20279d096eb247383495ec2a81df]]&gt;</url>
    <title>Three days of antibiotics is enough for uncomplicated cystitis</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,URINARY TRACT,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Purpose: We performed a meta-analysis to ascertain the efficacy and safety of the currently practiced 3-day antibiotic therapy for cystitis versus prolonged therapy (5 days or longer) to relieve symptoms and to achieve bacteriological cure. 
Methods: The Cochrane Library, the Cochrane Renal Group’s Register of trials, EMBASE and MEDLINE were searched to identify all randomized controlled trials comparing 3-day oral antibiotic therapy with prolonged therapy (5 days and longer) for uncomplicated cystitis in adult non-pregnant women. Two reviewers independently applied selection criteria, performed quality assessment, and extracted data. Relative risks (RR) with their 95% confidence intervals (CI) were estimated; a fixed effect model was used. An intention-to-treat analysis was performed whenever possible. 
Results: Thirty-two trials and 9605 patients met inclusion criteria. For symptomatic failure rates no difference between 3-day and prolonged antibiotic regimens was found at short term (RR 1.16, 95% CI: 0.96-1.41) and long-term follow-up (RR 1.17, 95% CI: 0.99-1.38). Three-day treatment was less effective than prolonged therapy in preventing bacteriological failure, relative risk 1.37 (95% CI: 1.07-1.74) for short-term follow-up, and 1.47 (95% CI: 1.22-1.77) for long-term follow-up. Adverse effects were more common in the prolonged therapy group (RR 0.83, 95% CI: 0.79-0.91). The results were consistent for subgroup and sensitivity analyses. 
Conclusion: Antibiotic therapy for 3 days is similar to prolonged therapy in achieving symptomatic cure for cystitis, while the prolonged treatment is more effective in obtaining bacteriological cure. ]]&gt;</body>
  </document>
  <document>
    <id>286486</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jcm.asm.org/cgi/content/abstract/JCM.02089-07v1?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Three-year population-based evaluation of standardized Mycobacterial Interspersed Repetitive Unit-Variable Number of Tandem Repeat typing of Mycobacterium tuberculosis</title>
    <publicationDate>2008-01-30T00:00:00</publicationDate>
    <publisher>American Society of Microbiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,TUBERCULOSIS,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,INFECTIONS,MYCOBACTERIUM,MICROORGANISM,BACTERIA,INFECTIOUS DISEASES,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Standardized Mycobacterial Interspersed Repetitive Unit-Variable Number of Tandem Repeat (MIRU-VNTR) typing based on 15 and 24 loci has recently been proposed for Mycobacterium tuberculosis genotyping. So far, this optimized system has been assessed in a single, one-year population-based study performed in Germany. Here, we evaluated these optimized formats in a much larger population-based study conducted over 39 months in the Brussels-capital Region. Isolates from 807 patients were genotyped. Resolution power, cluster and lineage identification by the standardized MIRU-VNTR sets were compared with those obtained using standardized IS6110-RFLP, spoligotyping and a previous 12 MIRU-VNTR-locus set. On a subset representing 77 % of the cases over a 16-month period, a high concordance was observed between unique isolates or strain-clusters defined by standardized MIRU-VNTR and IS6110-RFLP (&gt;5 IS6110). When extended to the entire population-based collection, the discriminatory subset of 15 loci decreased the strain-clustering rate by almost two-fold as compared to the old 12-locus set. Addition of the 9 ancillary MIRU-VNTR loci and/or spoligotyping only slightly further decreased this strain-clustering rate. Familial, social or geographic proximity links were found in 48 % of clusters identified, and well-known risk factors for tuberculosis (TB) transmission were identified. Finally, excellent correspondence was determined between our MIRU-VNTR-spoligotyping strain identifications and external reference strain lineages included in the MIRU-VNTRplus database and identified e.g. by large sequence polymorphisms (LSPs). Our results reinforce the proposal of standardized MIRU-VNTR typing as a new reference genotyping method for epidemiological and phylogenetical screening of M. tuberculosis strains. ]]&gt;</body>
  </document>
  <document>
    <id>345431</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-2334-9-91.pdf]]&gt;</url>
    <title>Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature</title>
    <publicationDate>2009-06-11T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,DIAGNOSIS,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Delay in diagnosis of pulmonary tuberculosis results in increasing severity, mortality and transmission. Various investigators have reported about delays in diagnosis of tuberculosis. We aimed at summarizing the data on these delays in diagnosis of tuberculosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: A systematic review of literature was carried out. Literature search was done in Medline and EMBASE from 1990 to 2008. We used the following search terms: delay, tuberculosis, diagnosis, and help-seeking/health-seeking behavior without language restrictions. In addition, indices of four major tuberculosis journals were hand-searched. Subject experts in tuberculosis and authors of primary studies were contacted. Reference lists, review articles and text book chapters were also searched. All the studies were assessed for methodological quality. Only studies carried out on smear/culture-positive tuberculosis patients and reporting about total, patient and healthcare system delays were included.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: A total of 419 potential studies were identified by the search. Fifty two studies qualified for the review. The reported ranges of average (median or mean) total delay, patient delay, health system delay were 25–185 days, 4.9–162 days and 2–87 days respectively for both low and high income countries. Average patient delay was similar to health system delay (28.7 versus 25 days). Both patient delay and health system delay in low income countries (31.7 days and 28.5 days) were similar to those reported in high income countries (25.8 days and 21.5 days).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: The results of this review suggest that there is a need for revising case-finding strategies. The reported high treatment success rate of directly observed treatment may be supplemented by measures to shorten the delay in diagnosis. This may result in reduction of infectious cases and better tuberculosis control.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307655</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/fulltext/119417430/PDFSTART]]&gt;</url>
    <title>Timing of default from tuberculosis treatment: a systematic review</title>
    <publicationDate>2008-05-08T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TREATMENT,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objectives&lt;/STRONG&gt;: To provide a systematic assessment of the timing of default from tuberculosis (TB) treatment which could help to quantify the potential contribution of new shorter duration TB drugs to global TB control.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: We performed a systematic review following QUOROM guidelines. MEDLINE was searched from 1998 to the present using the terms TB and default or drop-out or compliance or adherence and therapy. A total of 840 articles were returned. A further detailed manual review selected 15 randomized trials and observational studies that reported timing of drop-out and focused on developing countries.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: The selected studies comprised randomized controlled trials, retrospective record reviews, and qualitative assessments and spanned 10 countries. Both directly observed treatment (DOT) and non-DOT programs were represented. Thus results were highly heterogeneous and not statistically aggregated. Data suggest, but do not conclude, that the majority of defaulters across the studies completed the 2-month intensive phase of treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: There is insufficient high-quality comparable information on the timing of default from TB treatment to permit any firm conclusions on trends in default. However, a substantial proportion of defaulters appear to leave treatment in the later stages of the current 6-month regimen, suggesting that new TB chemotherapeutic agents which can reduce the length of treatment have the potential to improve global TB treatment success rates.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394469</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905848]]&gt;</url>
    <title>Timing of initiation of antiretroviral drugs during tuberculosis therapy</title>
    <publicationDate>2010-06-03T00:00:00</publicationDate>
    <publisher>Massachusetts Medical Society</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: The rates of death are high among patients with coinfection with tuberculosis and the human immunodeficiency virus (HIV). The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: In an open-label, randomized, controlled trial in Durban, South Africa, we assigned 642 patients with both tuberculosis and HIV infection to start antiretroviral therapy either during tuberculosis therapy (in two integrated-therapy groups) or after the completion of such treatment (in one sequential-therapy group). The diagnosis of tuberculosis was based on a positive sputum smear for acid-fast bacilli. Only patients with HIV infection and a CD4+ cell count of less than 500 per cubic millimeter were included. All patients received standard tuberculosis therapy, prophylaxis with trimethoprim-sulfamethoxazole, and a once-daily antiretroviral regimen of didanosine, lamivudine, and efavirenz. The primary end point was death from any cause.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: This analysis compares data from the sequential-therapy group and the combined integrated-therapy groups up to September 1, 2008, when the data and safety monitoring committee recommended that all patients receive integrated antiretroviral therapy. There was a reduction in the rate of death among the 429 patients in the combined integrated-therapy groups (5.4 deaths per 100 person-years, or 25 deaths), as compared with the 213 patients in the sequential-therapy group (12.1 per 100 person-years, or 27 deaths); a relative reduction of 56% (hazard ratio in the combined integrated-therapy groups, 0.44; 95% confidence interval, 0.25 to 0.79; P=0.003). Mortality was lower in the combined integrated-therapy groups in all CD4+ count strata. Rates of adverse events during follow-up were similar in the two study groups.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: The initiation of antiretroviral therapy during tuberculosis therapy significantly improved survival and provides further impetus for the integration of tuberculosis and HIV services. (ClinicalTrials.gov number, NCT00398996.)&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286491</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/fungal_infections/pubs.htm]]&gt;</url>
    <title>Tinea capitis in the United Kingdom : A report on its diagnosis, management and prevention</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,TRANSMISSION MODE,INFECTIONS,ANTIMICROBIALS,ANTIFUNGALS,PREVENTION AND CONTROL,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Tinea capitis, or scalp ringworm, is an infection caused by dermatophyte fungi mainly found in pre-pubertal children. It is characterised by infection of the hair of the scalp and scalp skin associated with symptoms and signs of inflammation and hair loss. Tinea capitis is an exogenous infection caused by dermatophytes which originate from sources including other children or adults (anthropophilic), animals (zoophilic) or soil (geophilic). The main signs are scaling and hair loss but acute inflammation with erythema and pustule formation may also occur. The dermatophytes that cause tinea capitis can invade other parts of the body such as the nails and the body, but rarely the feet or groins. Children or adults who have neither signs nor symptoms of infection, but from whose scalps causative fungi can be grown, are described as “carriers”.

The epidemiology of tinea capitis is not static as movements of people provide the potential to introduce new species to different areas. For instance since the 1970’s there has been a progressive spread of infections caused by Trichophyton tonsurans through inner city areas of much of the USA and more recently in the UK and other European cities. By contrast Trichophyton schoenleinii, which causes a characteristic scalp infection, favus, is becoming less common, partly because its striking clinical appearances and the tendency to scar are recognised even in remote communities. Patients with favus, or their parents, are more likely to present for treatment.]]&gt;</body>
  </document>
  <document>
    <id>286495</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/cdph/issues/CDPHvol6/No4/6_4guideline1.pdf]]&gt;</url>
    <title>Towards error-free HIV diagnosis: guidelines on laboratory practice.</title>
    <publicationDate>2003-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,MALE SEXUALLY TRANSMITTED INFECTIONS,VIRAL,HIV,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Error can have multiple causes. These guidelines set out the most common reasons for inaccuracies in HIV testing and indicate how they can be avoided. Emphasis is placed on laboratory procedures as during over 15 years experience they, rather than the kits and regents, have proved to be the most frequent source of error.]]&gt;</body>
  </document>
  <document>
    <id>394455</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/hiv/pub/2010progressreport/report/en/index.html]]&gt;</url>
    <title>Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector</title>
    <publicationDate>2010-09-28T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report reviews the progress made in 2009 in scaling up access to selected health sector interventions for HIV prevention, treatment and care in low- and middle-income countries. It is the fourth in a series of annual progress reports published since 2006 by the World Health Organization (WHO), United Nations Children's Fund (UNICEF) and Joint United Nations Programme on HIV/AIDS (UNAIDS) in collaboration with international and national partners to monitor key components of the health sector response to the HIV epidemic worldwide. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/summary_en.pdf" target="_blank"&gt;Download executive summary [pdf 1.57Mb]&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;A href="http://whqlibdoc.who.int/publications/2010/9789241500395_eng.pdf" target="_blank"&gt;Download full report [pdf 2.77Mb]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/cover_en.pdf" target="_blank"&gt;Cover and table of contents [pdf 335kb]&lt;/A&gt; &lt;BR&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/ch1_en.pdf" target="_blank"&gt;Chapter 1: Introduction [pdf 171kb]&lt;/A&gt; &lt;BR&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/ch2_en.pdf" target="_blank"&gt;Chapter 2: HIV testing and counselling [pdf 543kb]&lt;/A&gt; &lt;BR&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/ch3_en.pdf" target="_blank"&gt;Chapter 3: Health sector interventions for HIV prevention [pdf 969kb]&lt;/A&gt; &lt;BR&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/ch4_en.pdf" target="_blank"&gt;Chapter 4: Treatment and care for people living with HIV [pdf 1.21Mb]&lt;/A&gt; &lt;BR&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/ch5_en.pdf" target="_blank"&gt;Chapter 5: Scaling up HIV services for women and children [pdf 774kb]&lt;/A&gt; &lt;BR&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/ch6_en.pdf" target="_blank"&gt;Chapter 6: Beyond 2010 [pdf 139kb]&lt;/A&gt; &lt;BR&gt;- &lt;A href="http://www.who.int/entity/hiv/pub/2010progressreport/annexes_en.pdf" target="_blank"&gt;Annexes 1-8 [pdf 684kb]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Read the progress report from 2009 &lt;A href="http://www.who.int/hiv/pub/tuapr_2009_en.pdf" target="_blank"&gt;here&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286496</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop10.pdf]]&gt;</url>
    <title>Toxin detection, isolation &amp; identification of Clostridium difficile from faeces (BSOP 10)</title>
    <publicationDate>2008-01-09T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,CLOSTRIDIUM,MICROORGANISM,BACTERIA,CLOSTRIDIUM DIFFICILE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document describes:
1. The use of toxin detection kits.
2. The isolation and identification of Clostridium difficile from faeces and is intended to
be followed in outbreak situations or as part of enhanced surveillance. A maximum of
10 isolates from each outbreak should be sufficient.
Reference to BSOP 30 – ‘Processing of faeces specimens for bacterial pathogens’ is recommended for additional background information]]&gt;</body>
  </document>
  <document>
    <id>286497</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop10.pdf]]&gt;</url>
    <title>Traceability of liquid-in-glass thermometers in UKAS accredited laboratories (QSOP 10)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>308533</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6WJT-4TMYJVK-1-C&amp;_cdi=6887&amp;_user=855288&amp;_orig=search&amp;_coverDate=03%2F31%2F2009&amp;_sk=999419996&amp;view=c&amp;wchp=dGLzVlz-zSkWA&amp;md5=27ea3f7e96a228191f9b03008f227b33&amp;ie=/sdarticle.pdf]]&gt;</url>
    <title>Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment.</title>
    <publicationDate>2008-10-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ANTIMICROBIALS,ANTIBIOTICS,TREATMENT,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Currently, there is no available test for monitoring the clinical effect of active tuberculosis (TB) disease treatment. Therefore, we studied the usefulness of two commercial IFN-gamma assays (QuantiFERON TB-2G (QFT-2G) and T-SPOT.TB tests) for monitoring clinical efficacy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: The subjects were 40 patients with active TB disease. These two commercial IFN-gamma assays were carried out every three months during active TB disease treatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: While the positive response rate of QFT-2G test significantly decreased from 83% at treatment initiation to 58% at treatment completion, that of T-SPOT.TB decreased&amp;nbsp;from 90% at treatment initiation to 63% at treatment completion. Although there was a significant decrease in patients with TB infection showing positive responses for ESAT-6 only or CFP-10 only antigens on both IFN-gamma assays, there was no significant decrease in patients showing positive responses for both ESAT-6 and CFP-10 antigens on both IFN-gamma assays. On both QFT-2G test and T-SPOT.TB test, the mean values of the IFN-gamma levels in the pre- and&lt;BR&gt;post-treatment responses showed significantly decreased responses to CFP-10. On the other hand, smear conversion results of clinical specimens were obtained in all patients at treatment completion. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Antituberculous treatment induced a significant decrease in T-cell responses to separate ESAT-6 and CFP-10 antigens as measured by both IFN-gamma assays. Although IFN-gamma assays might be later than smear conversion results of clinical specimens, the quantitative&lt;BR&gt;responses especially to CFP-10 may be one of the useful monitoring markers of clinical efficacy for active TB disease treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286498</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/reprint/355/2/118.pdf]]&gt;</url>
    <title>Transmission of Mycobacterium tuberculosis from Health Care Workers</title>
    <publicationDate>2006-07-13T00:00:00</publicationDate>
    <publisher>Massachusetts Medical Society</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ CONTACT,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,PREVENTION,VACCINES / IMMUNISATION,TREATMENT,MYCOBACTERIUM,BACTERIA,MICROORGANISM,INFECTIOUS DISEASES,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Centers for Disease Control and Prevention (CDC) recently reported the transmission
of Mycobacterium tuberculosis from a health care worker to patients in New York City. Several aspects of the episode were notable: the health care worker was foreignborn; latent uberculosis infection had previously been diagnosed by tuberculin skin testing, but the health care worker had declined treatment; and after active disease developed in the health care worker, 1500 persons were exposed, which necessitated a large-scale contact investigation to determine
the extent of transmission and prevent further spread.

Today, the incidence of tuberculosis in the United States is the lowest ever recorded. This  downward trend has been driven largely by steady decreases in incidence among persons born in this country. However, case rates have not decreased among foreign-born persons living in the United States, and tuberculosis in the foreignborn now accounts for most of the reported domestic cases. Latent tuberculosis infection is also more common among foreignborn persons: one third of the world’s population, but less than 10 percent of the U.S. population, has latent infection.]]&gt;</body>
  </document>
  <document>
    <id>394199</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/651686]]&gt;</url>
    <title>Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis</title>
    <publicationDate>2010-05-03T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,TUBERCULOSIS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Patients with human immunodeficiency virus (HIV) infection and tuberculosis have an increased risk of death, treatment failure, and relapse.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A systematic review and meta-analysis of randomized, controlled trials and cohort studies was conducted to evaluate the impact of duration and dosing schedule of rifamycin and use of antiretroviral therapy in the treatment of active tuberculosis in HIV-positive patients. In included studies, the initial tuberculosis diagnosis, failure, and/or relapse were microbiologically confirmed, and patients received standardized rifampin- or rifabutin-containing regimens. Pooled cumulative incidence of treatment failure, death during treatment, and relapse were calculated using random-effects models. Multivariable meta-regression was performed using negative binomial regression.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: After screening 5158 citations, 6 randomized trials and 21 cohort studies were included. Relapse was more common with regimens using 2 months rifamycin (adjusted risk ratio, 3.6; 95% confidence interval, 1.1-11.7) than with regimens using rifamycin for at least 8 months. Compared with daily therapy in the initial phase (n=3352 patients from 35 study arms), thrice-weekly therapy (n=211 patients from 5 study arms) was associated with higher rates of failure (adjusted risk ratio, 4.0; 95% confidence interval, 1.5-10.4) and relapse [adjusted risk ratio, 4.8; 95% confidence interval, 1.8-12.8). There were trends toward higher relapse rates if rifamycins were used for only 6 months, compared with &amp;gt; or =8 months, or if antiretroviral therapy was not used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: This review raises serious concerns regarding current recommendations for treatment of HIV-tuberculosis coinfection. The data suggest that at least 8 months duration of rifamycin therapy, initial daily dosing, and concurrent antiretroviral therapy might be associated with better outcomes, but adequately powered randomized trials are urgently needed to confirm this.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286502</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/reprint/279/21/1736]]&gt;</url>
    <title>Treatment of Acute Otitis Media with a Shortened Course of Antibiotics</title>
    <publicationDate>1998-06-03T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,PREVENTION AND CONTROL,TREATMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective.— To conduct a meta-analysis of randomized controlled trials of antibiotic treatment of acute otitis media in children to determine whether outcomes were comparable in children treated with antibiotics for less than 7 days or at least 7 days or more. 

Data Sources.— MEDLINE (1966-1997), EMBASE (1974-1997), Current Contents, and Science Citation Index searches were conducted to identify randomized controlled trials of the treatment of acute otitis media in children with antibiotics of different durations. 

Study Selection.— Studies were included if they met the following criteria: subjects aged 4 weeks to 18 years, clinical diagnosis of acute otitis media, no antimicrobial therapy at time of diagnosis, and randomization to less than 7 days of antibiotic treatment vs 7 days or more of antibiotic treatment. 

Data Extraction.— Trial methodological quality was assessed independently by 7 reviewers; outcomes were extracted as the number of treatment failures, relapses, or reinfections. 

Data Synthesis.— Included trials were grouped by antibiotic used in the short course: (1) 15 short-acting oral antibiotic trials (penicillin V potassium, amoxicillin [-clavulanate], cefaclor, cefixime, cefuroxime, cefpodoxime proxetil, cefprozil), (2) 4 intramuscular ceftriaxone sodium trials, and (3) 11 oral azithromycin trials. The summary odds ratio for treatment outcomes at 8 to 19 days in children treated with short-acting antibiotics for 5 days vs 8 to 10 days was 1.52 (95% confidence interval [CI], 1.17-1.98) but by 20 to 30 days outcomes between treatment groups were comparable (odds ratio, 1.22; 95% CI, 0.98 to 1.54). The risk difference (2.3%; 95% CI,-0.2% to 4.9%) at 20 to 30 days suggests that 44 children would need to be treated with the long course of short-acting antibiotics to avoid 1 treatment failure. This similarity in later outcomes was observed for up to 3 months following therapy (odds ratio, 1.16; 95% CI, 0.90-1.50). Comparable outcomes were shown between treatment with ceftriaxone or azithromycin, and at least 7 days of other antibiotics. 

Conclusion.— This meta-analysis suggests that 5 days of short-acting antibiotic use is effective treatment for uncomplicated acute otitis media in children. ]]&gt;</body>
  </document>
  <document>
    <id>308578</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61204-0/abstract]]&gt;</url>
    <title>Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study.</title>
    <publicationDate>2008-10-18T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,TREATMENT,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Mycobacterium tuberculosis strains that cause untreatable drug-resistant disease are a threat worldwide. We describe the treatment, management, and outcomes of patients with extensively drug-resistant tuberculosis in Tomsk, Russia. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We undertook a retrospective cohort study of 608 patients with multidrug resistant tuberculosis who had treatment in civilian or prison services, between Sept 10, 2000, and Nov 1, 2004, according to the treatment strategy recommended by WHO. Clinical characteristics, management practices, and treatment outcomes of patients with extensively drug-resistant (XDR) tuberculosis and non-extensively drug-resistant (non-XDR) tuberculosis are described. The main outcome was the frequency of poor and favourable outcomes at the end of treatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FINDINGS&lt;/STRONG&gt;: Of 608 patients with multidrug resistant tuberculosis, 29 (4.8%) patients had baseline XDR tuberculosis. Treatment failure was more common in patients with XDR tuberculosis than in those with non-XDR tuberculosis (31%vs 8.5%, p=0.0008). 48.3% of patients with XDR tuberculosis and 66.7% of patients with non-XDR tuberculosis had treatment cure or completion (p=0.04). The frequency and management of adverse events did not differ between patients with XDR and non-XDR tuberculosis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;INTERPRETATION&lt;/STRONG&gt;: The chronic features of tuberculosis in these patients suggest that extensively drug-resistant tuberculosis may be acquired through previous treatments that include second-line drugs. Aggressive management of this infectious disease is feasible and can prevent high mortality rates and further transmission of drug-resistant strains of Mycobacterium tuberculosis.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286503</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/reprint/297/20/2264]]&gt;</url>
    <title>Treatment of Malaria in the United States: A Systematic Review</title>
    <publicationDate>2007-05-23T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INSECT BITE,TRANSMISSION MODE,MALARIA,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIPARASITICS,PREVENTION,INFECTIONS,TREATMENT,TRAVEL ASSOCIATED INFECTIONS,MICROORGANISM,PARASITES,MOSQUITO,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Context: Many US clinicians and laboratory personnel are unfamiliar with the diagnosis
and treatment of malaria.

Objectives: To examine the evidence base for management of uncomplicated and
severe malaria and to provide clinicians with practical recommendations for the diagnosis
and treatment of malaria in the United States.

Evidence Acquisition: Systematic MEDLINE search from 1966 to 2006 using the search term malaria (with the subheadings congenital, diagnosis, drug therapy, epidemiology, and therapy). Additional references were obtained from searching the bibliographies of pertinent articles and by reviewing articles suggested by experts in the treatment of malaria in North America.

Evidence Synthesis: Important measures to reduce morbidity and mortality from malaria in the United States include the following: obtaining a travel history, considering malaria in the differential diagnosis of fever based on the travel history, and prompt and accurate diagnosis and treatment. Chloroquine remains the treatment of choice for Plasmodium falciparum acquired in areas without chloroquineresistant strains. In areas with chloroquine resistance, a combination of atovaquone and proguanil or quinine plus tetracycline or doxycycline or clindamycin are the best treatment options. Chloroquine remains the treatment of choice for all other malaria species, with the exception of P vivax acquired in Indonesia or Papua New Guinea, in which case atovaquone-proguanil is best, with mefloquine or quinine plus tetracycline or doxycycline as alternatives. Quinidine is currently the recommended treatment for severe malaria in the United States because the artemisinins are not yet available. Severe malaria occurs when a patient with asexual malaria parasitemia, and no other confirmed cause of symptoms, has 1 or more designated clinical or laboratory findings. The only adjunctive measure recommended in severe
malaria is exchange transfusion.

Conclusions: Malaria remains a diagnostic and treatment challenge for US clinicians as increasing numbers of persons travel to and emigrate from malarious areas. A strong evidence base exists to help clinicians rapidly initiate appropriate therapy and minimize the major mortality and morbidity burdens caused by this disease.]]&gt;</body>
  </document>
  <document>
    <id>345469</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=MImg&amp;_imagekey=B6W8X-4VP58TG-M-D&amp;_cdi=6666&amp;_user=8810565&amp;_pii=S1473309909700416&amp;_orig=search&amp;_coverDate=03%2F31%2F2009&amp;_sk=999909996&amp;view=c&amp;wchp=dGLbVtb-zSkzS&amp;md5=c815dda0be4280fd99a181511fb222e3&amp;ie=/sdarticle.pdf]]&gt;</url>
    <title>Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis</title>
    <publicationDate>2009-03-02T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,ANTIBIOTICS,ANTIMICROBIALS,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TREATMENT,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Multidrug-resistant (MDR) tuberculosis is a growing clinical and public-health concern. To evaluate existing evidence regarding treatment regimens for MDR tuberculosis, we used a Bayesian random-effects meta-analysis of the available therapeutic studies to assess how the reported proportion of patients treated successfully is influenced by differences in treatment regimen design, study methodology, and patient population. Successful treatment outcome was defined as cure or treatment completion. 34 clinical reports with a mean of 250 patients per report met the inclusion criteria. Our analysis shows that the proportion of patients treated successfully improved when treatment duration was at least 18 months, and if patients received directly observed therapy throughout treatment. Studies that combined both factors had significantly higher pooled success proportions (69%, 95% credible interval [CI] 64–73%) than other studies of treatment outcomes (58%, 95% CI 52–64%). Individualised treatment regimens had higher treatment success (64%, 95% CI 59–68%) than standardised regimens (54%, 95% CI 43–68%), although the difference was not significant. Treatment approaches and study methodologies were heterogeneous across studies. Many important variables, including patients' HIV status, were inconsistently reported between studies. These results underscore the importance of strong patient support and treatment follow-up systems to develop successful MDR tuberculosis treatment programmes.]]&gt;</body>
  </document>
  <document>
    <id>345458</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735675/pdf/pone.0006914.pdf]]&gt;</url>
    <title>Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis</title>
    <publicationDate>2009-09-09T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Treatment outcomes for multidrug-resistant Mycobacterium Tuberculosis (MDRTB) are generally poor compared to drug sensitive disease. We sought to estimate treatment outcomes and identify risk factors associated with poor outcomes in patients with MDRTB.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology/Principal Findings&lt;/STRONG&gt;: We performed a systematic search (to December 2008) to identify trials describing outcomes of patients treated for MDRTB. We pooled appropriate data to estimate WHO-defined outcomes at the end of treatment and follow-up. Where appropriate, pooled covariates were analyzed to identify factors associated with worse outcomes. Among articles identified, 36 met our inclusion criteria, representing 31 treatment programmes from 21 countries. In a pooled analysis, 62% [95% CI 57–67] of patients had successful outcomes, while 13% [9–17] defaulted, 11% [9–13] died, and 2% [1–4] were transferred out. Factors associated with worse outcome included male gender 0.61 (OR for successful outcome) [0.46–0.82], alcohol abuse 0.49 [0.39–0.63], low BMI 0.41[0.23–0.72], smear positivity at diagnosis 0.53 [0.31–0.91], fluoroquinolone resistance 0.45 [0.22–0.91] and the presence of an XDR resistance pattern 0.57 [0.41–0.80]. Factors associated with successful outcome were surgical intervention 1.91 [1.44–2.53], no previous treatment 1.42 [1.05–1.94], and fluoroquinolone use 2.20 [1.19–4.09].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions/Significance&lt;/STRONG&gt;: We have identified several factors associated with poor outcomes where interventions may be targeted. In addition, we have identified high rates of default, which likely contributes to the development and spread of MDRTB.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286504</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/publications/2006/antimicrobial_resistance/AMR_report_2004_2005.pdf]]&gt;</url>
    <title>Trends in Antimicrobial Resistance in England and Wales, 2004 - 2005</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,CLOSTRIDIUM,HAEMOPHILUS,MYCOBACTERIUM,CANDIDA ALBICANS,FUNGI,HEPATITIS C VIRUS,HEPATITIS B VIRUS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HERPES SIMPLEX VIRUS (HSV),CYTOMEGALOVIRUS (CMV),HEPATITIS VIRUS,INFLUENZA VIRUS,NEISSERIA MENINGITIDIS,NEISSERIA GONORRHOEA,STAPHYLOCOCCUS,SALMONELLA,MYCOBACTERIUM TUBERCULOSIS,STAPHYLOCOCCUS AUREUS,STREPTOCOCCUS,VIRUSES,MICROORGANISM,CLOSTRIDIUM DIFFICILE,CAMPYLOBACTER,ACINETOBACTER BAUMANII,ENTEROCOCCUS,HELICOBACTER PYLORI,E. COLI,HAEMOPHILUS INFLUENZAE,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This is the third Report from the Health Protection Agency (HPA) aimed at providing a detailed overview of antimicrobial resistance in a range of pathogens (bacteria, viruses, fungi and protozoa) of public health importance.
The majority of the data presented relate to England and Wales, although data from other European countries are included reflecting the participation of the Health Protection Agency in the European Antimicrobial Resistance Surveillance Scheme (EARSS), which is a pan-European surveillance programme.
Although this Report focuses on data collected during 2004 and 2005, where possible, trend data over a longer period of time are also presented in order to put the most recent data into context.]]&gt;</body>
  </document>
  <document>
    <id>298241</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ucl.ac.uk/paediatric-epidemiology/pdfs/BJOG_Trends_2008.pdf]]&gt;</url>
    <title>Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006</title>
    <publicationDate>2008-05-23T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,POPULATION GROUPS,NOV 08,ADULTS,PREGNANT WOMEN,MICROORGANISM,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,ADDED 2008]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt;: To describe the changing demographic profile of diagnosed HIV-infected pregnant women over time and trends in pregnancy outcome, uptake of interventions and mother-to-child transmission.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design&lt;/STRONG&gt;: National surveillance study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting&lt;/STRONG&gt;: UK and Ireland.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; Diagnosed HIV-infected pregnant women, 1990–2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Active surveillance of obstetric and paediatric HIV conducted through the National Study of HIV in Pregnancy and Childhood.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main outcome measures:&lt;/STRONG&gt; Maternal characteristics, pregnancy outcome, use of antiretroviral therapy, mode of delivery and mother-to-child transmission.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: A total of 8327 pregnancies were reported, increasing from 82 in 1990 to 1394 in 2006, with an increasing proportion from areas outside London. Injecting drug use as the reported risk factor for maternal HIV acquisition declined from 49.2% (185/376) in 1990–1993 to 3.1% (125/4009) in 2004–2006 (P &amp;lt; 0.001), while the proportion of women born in sub-Saharan Africa increased from 43.5% (93/214) in 1990–1993 to 78.6% (3076/3912) in 2004–2006 (P &amp;lt; 0.004). Reported pregnancy terminations decreased from 29.6% (111/376) in 1990–1993 to 3.4% (135/4009) in 2004–2006 (P &amp;lt; 0.001). Most (56.4%, 3717/6593) deliveries were by elective caesarean section, with rates highest in 1999 (66.4%, 144/217). Vaginal deliveries increased from 16.6% (36/217) in 1999 to 28.3% (321/1136) in 2006 (P &amp;lt; 0.001). Use of antiretroviral therapy in pregnancy increased over time, reaching 98.4% (1092/1110) in 2006, and the overall mother-to-child transmission rate declined from 18.5% (35/189) in 1990–1993 to 1.0% (29/2832) in 2004–2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;: The annual number of reported pregnancies increased dramatically between 1990 and 2006, with changing demographic and geographic profiles and substantial changes in pregnancy management and outcome.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286505</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop31.pdf]]&gt;</url>
    <title>Tryptone bile x-glucuronide (TBX) agar (MSOP 31)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,GASTROINTESTINAL INFECTIONS,GASTROENTERITIS,INFECTIONS,BACTERIA,MICROORGANISM,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>345034</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19445749]]&gt;</url>
    <title>Tuberculosis (HIV-negative people)</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;INTRODUCTION&lt;/STRONG&gt;: About a third of the world's population has latent tuberculosis. In 2004, over 14 million people had active tuberculosis. Approximately 1.7 million people died from the infection. Over 80% of new cases diagnosed in 2004 were in people in Africa, South-East Asia, and Western Pacific regions. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS AND OUTCOMES&lt;/STRONG&gt;: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent tuberculosis in people without HIV infection at high risk of developing tuberculosis? What are the effects of interventions to prevent tuberculosis in people without HIV infection at high risk of developing multidrug-resistant tuberculosis? What are the effects of different drug regimens in people with newly diagnosed pulmonary tuberculosis without HIV infection? What are the effects of different drug regimens in people with multidrug-resistant tuberculosis without HIV infection? What are the effects of low-level laser therapy in people with tuberculosis without HIV infection? Which interventions improve adherence to treatment in people with tuberculosis without HIV infection? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: We found 31 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months; adding rifampicin to isoniazid regimens; benefits of different regimens; chemotherapy for less than 6 months; daily chemotherapy; direct observation treatment; intermittent chemotherapy for 6 months or longer; isoniazid; low-level laser therapy for pulmonary tuberculosis; regimens containing quinolones; rifampicin plus isoniazid; substituting rifampicin with ethambutol in the continuous phase; and support mechanisms for directly observed treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394464</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19770622]]&gt;</url>
    <title>Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?</title>
    <publicationDate>2009-11-27T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>OBSERVATIONAL STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,PREVENTION,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To investigate the incidence of, and risk factors for, tuberculosis among HIV clinic attendees in the United Kingdom.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN AND METHODS&lt;/STRONG&gt;: Observational cohort study of 27 868 individuals in the United Kingdom Collaborative HIV Cohort collaboration, 1996-2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Among individuals not taking combination antiretroviral therapy (cART), tuberculosis incidence was considerably higher among individuals of black African vs. white or other ethnicities {incidence rates 9.9 [95% confidence intervals (CIs) 7.2, 12.6], 2.5 [95% CI 1.8, 3.0] and 4.4 [95% CI 2.7, 6.0] episodes per 1000 person-years, respectively}. Tuberculosis incidence decreased with time after starting cART; among black Africans, incidence was consistently higher and remained substantial (5.3 per 1000 person-years) at 24 months and longer after starting cART. The strongest independent risk factors for tuberculosis after cART start were most recent CD4 cell count: adjusted rate ratios (aRR) 10.65 (95% CI 6.11, 18.57), 3.40 (95% CI 2.05, 5.65), 1.77 (95% CI 1.06, 2.96) and 1.84 (95% CI 1.09, 3.12) for individuals with CD4 cell counts less than 50, 50-199, 200-349 and 350-499 cells/microl, respectively, compared with at least 500 cells/microl; and black African vs. white ethnicity [aRR 2.93 (95% CI 1.89, 4.54)]. HIV risk group, shorter time on cART, later calendar period and unsuppressed viral load were also independently associated with incident tuberculosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Tuberculosis incidence among people attending UK HIV clinics is substantial, particularly among those with non-white ethnicity and low CD4 cell counts, even after starting cART. Earlier HIV diagnosis is needed in order to implement interventions to prevent tuberculosis; tuberculosis preventive therapy should be considered in addition to cART.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286510</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://download.thelancet.com/pdfs/journals/0140-6736/PIIS0140673606683888.pdf]]&gt;</url>
    <title>Tuberculosis drug development pipeline: progress and hope.</title>
    <publicationDate>2006-03-18T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,RESPIRATORY TRACT,BODY PART AFFECTED,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,INFECTIONS,TREATMENT,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ More than 50 years after the introduction of effective chemotherapy for tuberculosis, the disease remains unconquered and in many resource-poor countries, especially those blighted by HIV, alarmingly unstable. Although multidrug regimens are available that cure 95% of patients with active, drug-sensitive pulmonary tuberculosis, newer and better drugs are needed because
of poor compliance with the 6 months of treatment, interactions with antiretroviral drugs, and the emerging issue of drug resistance.

Of these problems, the long duration of therapy is the most important to overcome, since shorter regimens would increase the proportion of patients who complete treatment, reduce the number who relapse, and improve the overall effectiveness of tuberculosis control programmes. Causes of non-compliance with complex treatment regimens include feeling well long before drugs can be safely set aside and the difficult conditions in most developing countries. In part because of these difficulties, WHO introduced their DOTS strategy in 1993. One of the crucial components of this strategy is the direct observation by trained personnel of patients taking their medications to ensure compliance and help prevent the emergence of drug resistance. Although important for
treatment success, this strategy greatly increases the cost of delivering care. That said, regimens to treat multidrugresistant tuberculosis (MDR-TB) are badly tolerated, expensive, relatively ineffective, and must be taken for up to 2 years.]]&gt;</body>
  </document>
  <document>
    <id>394467</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20386425]]&gt;</url>
    <title>Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>OBSERVATIONAL STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),BACTERIA,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To determine the baseline prevalence of tuberculosis (TB) in a cohort using a strategy of intensive pretreatment screening for TB and the subsequent incidence rate and temporal distribution of cases during the first year of antiretroviral therapy (ART).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: Prospective observational community-based ART cohort in South Africa.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Adults enrolling for ART and who did not have a current TB diagnosis were intensively screened for TB at baseline using culture of two sputum samples, chest radiography and investigations for extrapulmonary disease as required. Patients who developed symptoms consistent with incident TB during ART were similarly investigated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Two hundred forty-one patients had a median CD4 cell count of 125 cells/microl (interquartile range 70-186) and 200 (83%) started ART. TB was diagnosed in 87 (36%) patients, with 82% of pulmonary cases being culture-proven. Most TB cases (87%) were prevalent disease detectable at baseline, whereas just 11 (13%) were incident cases that presented during the first year of ART. The incidence rate during 0-4 months of ART was similar to the rate during months 5-12 of ART [10.9 (95% confidence interval [CI] 4.6-23.3) cases per 100 person-years versus 8.1 (95% CI 3.6-18.0) cases per 100 person-years].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Systematic culture-based screening detected a very high burden of prevalent TB present at baseline. This intensified screening strategy was associated with an approximately two-fold lower incidence rate in the first 4 months of ART than previously observed in this cohort. This suggests that many incident cases of symptomatic TB presenting during early ART can be detected as prevalent disease prior to ART initiation using sensitive diagnostic tests.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345547</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/122525895/abstract]]&gt;</url>
    <title>Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data</title>
    <publicationDate>2009-07-29T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Mycobacterium tuberculosis (MTB) causes substantial morbidity and mortality in liver transplant recipients. We examined the efficacy of isoniazid latent Mycobacterium tuberculosis infection (LTBI) treatment in liver transplant recipients and reviewed systematically all cases of active MTB infection in this population. We found 7 studies that evaluated LTBI treatment and 139 cases of active MTB infection in liver transplant recipients. Isoniazid LTBI treatment was associated with reduced MTB reactivation in transplant patients with latent MTB risk factors (0.0% versus 8.2%, P = 0.02), and isoniazid-related hepatotoxicity occurred in 6% of treated patients, with no reported deaths. The prevalence of active MTB infection in transplant recipients was 1.3%. Nearly half of all recipients with active MTB infection had an identifiable pretransplant MTB risk factor. Among recipients who developed active MTB infection, extrapulmonary involvement was common (67%), including multiorgan disease (27%). The short-term mortality rate was 31%. Surviving patients were more likely to have received 3 or more drugs for MTB induction therapy (P = 0.003) and to have been diagnosed within 1 month of symptom onset (P = 0.01) and were less likely to have multiorgan disease (P = 0.01) or to have experienced episodes of acute transplant rejection (P = 0.02). Compared with the general population, liver transplant recipients have an 18-fold increase in the prevalence of active MTB infection and a 4-fold increase in the case-fatality rate. For high-risk transplant candidates, isoniazid appears safe and is probably effective at reducing MTB reactivation. All liver transplant candidates should receive a tuberculin skin test, and isoniazid LTBI treatment should be given to patients with a positive skin test result or MTB pretransplant risk factors, barring a specific contraindication.]]&gt;</body>
  </document>
  <document>
    <id>332634</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1287143594275]]&gt;</url>
    <title>Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2010</title>
    <publicationDate>2010-11-03T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,OUTCOMES,ANALYSIS &amp; RESEARCH,COMMUNICABLE DISEASES,TUBERCULOSIS,EPIDEMIOLOGICAL MEASURES,INFECTIONS,MONTHLY ADDITIONS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,ADDED 2010,WHAT'S NEW,NOV 10,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The trend of a gradual rise in the number of tuberculosis cases observed over the last 20 years continued in 2009, with a 4.2% rise giving an overall rate of 15 cases per 100,000 population in the UK.&lt;/P&gt;
&lt;P&gt;A total of 9,040 cases of tuberculosis were reported in 2009 with the majority of disease concentrated in urban centres. All 19 primary care organisations with a rate of 40 per 100,000 or more were in major urban areas. London accounts for 38% of cases, with a rate of 44.4 per 100,000.&lt;/P&gt;
&lt;P&gt;Read the annual reports on tuberculosis surveillance from &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259152022594" target="_blank"&gt;2009 &lt;/A&gt;and &lt;A href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1225268885463" target="_blank"&gt;2008&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394468</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20622529]]&gt;</url>
    <title>Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa</title>
    <publicationDate>2010-07-31T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,HIV/AIDS,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MYCOBACTERIUM TUBERCULOSIS,NOV 10,WHAT'S NEW,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To determine important risk factors for and impact of tuberculosis on survival in HIV-infected patients starting antiretroviral therapy (ART) in South Africa.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: Prospective trial of 1771 HIV-infected patients with either CD4 cell count less than 200 cells/microl or a prior AIDS-defining illness, enrolled in randomized trial of four antiretroviral regimens.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Data collected from patient records.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: A history of tuberculosis at study entry was reported by 27% of patients and correlated with poor baseline health status. A history of tuberculosis at baseline was associated with subsequent tuberculosis and death during ART, but was not itself an independent risk factor for poor outcome. Tuberculosis was diagnosed during ART in 14% of patients and was more frequent during the first 3 months. Tuberculosis during therapy was independently associated with increased hazard of other AIDS-defining events and death, regardless of when during ART tuberculosis occurred. ART that consistently suppressed circulating viremia reduced but did not eliminate tuberculosis risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: In HIV-infected patients who started ART at low CD4 cell counts, tuberculosis at baseline was a predictor of death, but was not independent of other factors indicating poor baseline health status. Tuberculosis during follow-up was, in contrast, an independent predictor of death even after adjustments for baseline risk factors, including CD4 cell count and viral load. Virologic failure during ART was associated with a 55% increase in risk of tuberculosis. Thus, tuberculosis is a major marker for poor outcome both at baseline and during ART and is not completely eliminated by fully suppressive ART.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308977</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.informapharmascience.com/doi/abs/10.1517/14712598.7.10.1539]]&gt;</url>
    <title>Tuberculosis subunit vaccines: from basic science to clinical testing.</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Informa Pharmaceutical Science</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,MARCH 09,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MYCOBACTERIUM TUBERCULOSIS,BCG,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ More than 80 years after the introduction of Bacillus Calmette–GuÉrin, the first tuberculosis vaccine, new vaccines for tuberculosis are finally in clinical trials. The selection of antigens on which new subunit vaccines are based represent the first fulfilment of the promise of proteomics and genomics, and the delivery systems for these antigens are likewise the first fruits of the improved understanding of how the host immune system recognizes pathogens. However, clinical trials are still at Phase I and there remain formidable obstacles to the registration of the first new TB vaccines. Here the authors review the vaccines in clinical trials and discuss the different approaches they take to stimulating immunity to Mycobacterium tuberculosis infection, focusing on recombinant subunit vaccines. The challenges that confront these approaches and how they are being addressed are then discussed.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>308964</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61036-3/abstract]]&gt;</url>
    <title>Tuberculosis vaccine development: goals, immunological design, and evaluation</title>
    <publicationDate>2008-07-12T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,PREVENTION,INFECTIONS,VACCINES / IMMUNISATION,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,TUBERCULOSIS,MYCOBACTERIUM,BACTERIA,MICROORGANISM,BCG,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A third of the world's population is infected with Mycobacterium tuberculosis, and 2 million people die from tuberculosis every year even though the bacille Calmette Guérin (BCG) vaccine has been available for more than 75 years. In order to reduce the immense burden of tuberculosis, new vaccines or vaccination strategies, or both, are urgently needed. Why BCG vaccination has not reduced disease prevalence, especially in the developing world, is not yet understood. Important contributing factors might include background immunity induced by non-tuberculous environmental mycobacteria, diversity of BCG strains, and overattenuation of presently used strains. This review provides a summary of the immune responses thought to be important for protective tuberculosis immunity; various mycobacterial antigens that seem to be promising targets for vaccine-induced immunity; different vaccination approaches being developed for use in people; and the key issues involved in the selection of new vaccines for expanded phase II or III testing.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>345579</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6VS1-4WG7CBV-1&amp;_user=10&amp;_coverDate=06%2F30%2F2009&amp;_rdoc=1&amp;_fmt=high&amp;_orig=search&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1242294132&amp;_rerunOrigin=google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_us]]&gt;</url>
    <title>Tuberculosis vaccine research: the impact of immunology</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,VACCINES / IMMUNISATION,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A safe and effective vaccine to prevent tuberculosis is necessary to combat this ancient disease that kills millions worldwide. Recent advances in our understanding of the host immune response to Mycobacterium tuberculosis (Mtb) are facilitating the development of several novel vaccine approaches. New tools for measuring and characterizing cell-mediated immune responses to Mtb have furthered the assessment of these new vaccines in animal models and in human clinical studies including efficacy trials. Measurements of the relative contribution of CD4+ and CD8+ T cells, central and effector memory T cells, and regulatory T cells are being completed in these studies, as well as broad screening efforts utilizing bead array cytokine determination and microarray technology in an effort to determine the immunologic markers that predict vaccine-induced efficacy for different stages of TB infection and disease.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308981</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.expert-reviews.com/doi/abs/10.1586/14760584.7.5.635]]&gt;</url>
    <title>Tuberculosis: Vaccines in the pipeline.</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Expert Reviews Ltd</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,MARCH 09,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,CHILDHOOD VACCINES,MYCOBACTERIUM TUBERCULOSIS,BCG,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ TB is presenting new challenges as a global health problem, especially with new threats of HIV coinfection and multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis. The current TB vaccine, Mycobacterium bovis bacillus Calmette–Guerin (BCG), is the most widely used vaccine worldwide but its efficacy against pulmonary TB in adults in many high-burden countries is limited. Different vaccine strategies will probably be required for the various needs that exist within a population in which some individuals have been previously immunized with BCG, coinfected with HIV and/or latently infected with M. tuberculosis. In the last 15 years, new strategies to improve or replace BCG in the laboratory have led to several promising vaccine candidates that are actively being evaluated in human clinical trials. Some of these new vaccines may eventually be recommended for travelers to TB high-burden countries. This paper summarizes the progress of vaccine candidates in animal models to improve, replace or augment BCG vaccination.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>286507</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.aidsonline.com/pt/re/aids/fulltext.00002030-200701300-00007.htm;jsessionid=HQmLShzGk436CVG251qfLnxYL1yp2TFbNvJkwSFmH12LHL0dppTn!1253064403!181195628!8091!-1?index=1&amp;database=ppvovft&amp;results=1&amp;count=10&amp;searchid=1&amp;nav=search]]&gt;</url>
    <title>Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa</title>
    <publicationDate>2007-01-30T00:00:00</publicationDate>
    <publisher>Wolters Kluwer Health</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,TRANSMISSION MODE,RESPIRATORY TRACT,AIRBORNE,BLOOD AND BODY FLUIDS,CONTACT,BODY PART AFFECTED,PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,ANTIVIRALS,INFECTIONS,TREATMENT,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Objective: To determine the burden and impact of immune reconstitution disease (IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment (ART) in sub-Saharan Africa.

Design: Retrospective analysis of a study cohort enrolled over 3 years within a community-based ART service in South Africa.

Methods: Patients receiving treatment for TB at the time ART was initiated (n = 160) were studied. Cases of TB-associated IRD during the first 4 months of ART were ascertained.

Results: The median baseline CD4 cell count was 68 cells/µl [interquartile range (IQR), 29-133 cells/µl) and ART was initiated after a median of 105 days (IQR, 61-164 days) from TB diagnosis. Although IRD was diagnosed in just 12% (n = 19) of patients overall, IRD developed in 32% (n = 12) of those who started ART within 2 months of TB diagnosis. Pulmonary involvement was observed in 84% (n = 16) and intra-abdominal manifestations were also common (37%). Overall, 4% (n = 7) of the cohort required secondary level health-care for IRD and two (1%) patients died. In multivariate analysis, risk of IRD was strongly associated with early ART initiation and low baseline CD4 cell count. Of patients with CD4 counts &lt; 50 cells/µl, the proportions who developed IRD following initiation of ART within 0-30, 31-60, 61-90, 91-120 and &gt; 120 days of TB diagnosis were 100%, 33%, 14%, 7% and 0%, respectively.

Conclusions: The risk of TB-associated IRD in this setting is very high for those with low baseline CD4 cell counts initiating ART early in the course of antituberculosis treatment. However, most cases were self-limiting; overall secondary health-care utilization and mortality risk from IRD were low.]]&gt;</body>
  </document>
  <document>
    <id>345651</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.appg-tb.org.uk/documents/RCN_APPG_BTS_report_final.pdf]]&gt;</url>
    <title>Turning UK TB policy into action: the view from the frontline</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>All Party Parliamentary Group On Global Tuberculosis</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,MYCOBACTERIUM,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;TB rates in the UK continue to rise with the HPA reporting a 2% increase in incidence in 2008. Now that healthcare is devolved, somewhat different approaches to TB management are being employed within individual UK countries based on local circumstances. The common factor is that much clinical guidance and policy has been published aimed at both&amp;nbsp;commissioners of TB services and local service providers. Two&lt;BR&gt;surveys undertaken in the past three years by the BTS and APPG indicated that progress was needed in implementing policy and guideline.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Among the important policies that have been released on TB in England is the Chief Medical Officers Action Plan. This set out the actions that should be taken if TB is to be bought under control. It used the successful control of TB in the USA as the underlying philosophy of how success can be achieved. The CMO set out 10 recommended actions including increased awareness, an expert workforce and well coordinated patient services. The BTS and APPG surveys of 2007 were completed in order to see what was&lt;BR&gt;happening at the local level with regard to the CMO’s Action Plan.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This report sets out the results of two interconnected surveys of TB lead consultants and TB nursing staff. They were completed by BTS and RCN members between January and April 2009. The surveys sought to ascertain from frontline staff the degree to which central policy has been implemented and the outstanding barriers that prevent effective TB prevention and control.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The results of the surveys are encouraging and highlight that much progress has been made. However, they also indicate that there are areas where more effort is needed if effective services for TB are to be developed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286513</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/pancreatic.pdf]]&gt;</url>
    <title>UK guidelines for the management of acute pancreatitis</title>
    <publicationDate>1998-06-01T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,DIGESTIVE TRACT,GASTROENTERITIS,GASTROINTESTINAL INFECTIONS,INFECTIONS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Aims: During recent years there have been many changes in the management of patients with acute pancreatitis.  These have included the general availability of computed tomography (CT) scanning, interventional radiological procedures, refinements in ITU care, and a more aggressive surgical policy in those with infected necrosis.  Multicentre audits have revealed deficiencies in the management of the disease, with a lack of standardised protocols both within and between institutions.  It is hoped that these guidelines will provide a framework for clinicians to follow when treating patients with this difficult disease.
Intended audience: Healthcare professionals.
]]&gt;</body>
  </document>
  <document>
    <id>286514</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jpubhealth.oupjournals.org/cgi/reprint/24/3/200?ijkey=RYdtp2O55I0iU&amp;keytype=ref&amp;siteid=jphm]]&gt;</url>
    <title>UK Guidelines for use of erythromycin chemoprophylaxis in persons exposed to pertussis</title>
    <publicationDate>2002-02-22T00:00:00</publicationDate>
    <publisher>Journal of Public Health Medicine </publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BODY PART AFFECTED,AIRBORNE,CONTACT,RESPIRATORY TRACT,TRANSMISSION MODE,INFECTIONS,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Erythromycin chemoprophylaxis has been advocated for its use in contacts to prevent secondary cases of pertussis, but the evidence for its use is weak.  These guidelines are based on a review of the evidence and aim to help clinicians make more rational decisions on its usage.]]&gt;</body>
  </document>
  <document>
    <id>286516</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/malaria/pdf/mal_treat_JoI07.pdf]]&gt;</url>
    <title>UK malaria treatment guidelines</title>
    <publicationDate>2007-01-26T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INSECT BITE,MALARIA,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,TRAVEL ASSOCIATED INFECTIONS,MICROORGANISM,MOSQUITO,PARASITES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Malaria is the tropical disease most commonly imported into the UK, with 1500 - 2000 cases reported each year, and 10 - 20 deaths. Approximately three-quarters of reported malaria cases in the UK are caused by Plasmodium falciparum, which is capable of invading a high proportion of red blood cells and rapidly leading to severe or life-threatening multi-organ disease. 

Management of malaria depends on awareness of the diagnosis and on performing the
correct diagnostic tests: the diagnosis cannot be excluded until 3 blood specimens have been
examined by an experienced microscopist. 

The treatment of choice for non-falciparum malaria is a 3-day course of oral chloroquine, to which only a limited proportion of P. vivax strains have gained resistance.  ALL patients treated for P. falciparum malaria should be admitted to hospital for at least 24 h, since patients can deteriorate suddenly, especially early in the course of treatment.

Falciparum malaria in pregnancy is more likely to be severe and complicated: the placenta
contains high levels of parasites. Malaria in children (and sometimes in adults) may
present with misleading symptoms such as gastrointestinal features, sore throat or lower respiratory complaints; the diagnosis must always be sought in a feverish or very sick child who
has visited malaria-endemic areas. 

An acute attack of malaria does not confer protection from future attacks: individuals who have had malaria should take effective anti-mosquito precautions and chemoprophylaxis during future visits to endemic areas.]]&gt;</body>
  </document>
  <document>
    <id>286520</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop7.pdf]]&gt;</url>
    <title>UKAS requirements laboratories using ready-to-use media produced by outside suppliers (QSOP 7)</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>330547</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.lww.com/co-pediatrics/Abstract/2009/02000/Update_on_successes_and_challenges_regarding.14.aspx]]&gt;</url>
    <title>Update on successes and challenges regarding mother-to-child transmission of HIV</title>
    <publicationDate>2009-02-02T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,PREGNANT WOMEN,POPULATION GROUPS,CHILDREN,ADULTS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Purpose of review&lt;/STRONG&gt;: There is an unprecedented global commitment to reverse the pediatric HIV epidemic by making prevention of mother-to-child transmission (PMTCT) services accessible in all countries. This review outlines the successes made and the challenges that remain. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recent findings&lt;/STRONG&gt;: In resource-rich countries, mother-to-child transmission rates of HIV as low as 1% have been achieved. The efficacy of short-course antiretrovirals for PMTCT in Africa is estimated at 50%. Coinfections with herpes simplex virus type 2, other sexually transmitted infections resulting in genital ulcers, and endemic infectious diseases (e.g., malaria) may increase the risk of mother-to-child transmission of HIV. Vertical transmission of drug-resistant viruses has been reported; the prevalence and effect of transmitted resistant virus on treatment outcomes are under investigation. Obstacles facing PMTCT in resource-limited countries include the lack of healthcare infrastructure, limited manpower, and competing public health priorities with the limited healthcare budget. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: Although the birth of an HIV-infected child in a resource-rich country is now a sentinel health event, in most resource-limited countries the birth of an HIV-infected child continues to be the status quo. Comprehensive PMTCT, including antiretroviral treatment for HIV-infected women and children, should be paramount in resource-limited countries.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286530</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp36.pdf]]&gt;</url>
    <title>Urease test (BSOP TP36) UNDER REVIEW</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,MICROORGANISM,BACTERIA,HELICOBACTER PYLORI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Urease test is used to differentiate Urease-positive Proteus species from other members of the Enterobacteriaceae. Some strains of Enterobacter and Klebsiella speices are also Urease-positive. The test may be used to distinguish Physobacter phenylpyruvicus from Moraxella species. Corynebacterium diptheriae is Urease-negative which differentiates it from the Urease positive Corynebacterium ulcerans and Corynebacterium pseudotuberculosis. Helicobacter pylori also possesses the ability to split urea. Most Brucella species are Urease positive. Bacteroides ureolyticus splits urea rapidly,usually within a few minutes, and is a quick way of identifying this organism. The Urease test may aid in the identification of Cryptococcus species which produces a positive result after prolonged incubation.]]&gt;</body>
  </document>
  <document>
    <id>286534</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140673606685796/abstract]]&gt;</url>
    <title>Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study.</title>
    <publicationDate>2006-04-22T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CONTACT,AIRBORNE,BODY PART AFFECTED,RESPIRATORY TRACT,TRANSMISSION MODE,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,BACTERIA,MICROORGANISM,MYCOBACTERIUM TUBERCULOSIS,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Two commercial blood assays for the diagnosis of latent tuberculosis infection—T-SPOT.TB and QuantiFERON-TB Gold—have been separately compared with the tuberculin skin test. This study aimed  to compare the efficacy of all three tests in the same population sample.

This was done using a prospective study in 393 consecutively enrolled patients who were tested simultaneously with T-SPOT.TB and QuantiFERON-TB Gold because of suspected latent or active tuberculosis. 318 patients also had results available for a tuberculin skin test.

This study showed that T-SPOT.TB and QuantiFERON-TB Gold have higher specificity than the tuberculin skin test. Rates of indeterminate and positive results, however, differ between the blood tests, suggesting that they might provide different results in routine clinical practice.]]&gt;</body>
  </document>
  <document>
    <id>308658</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/v637774k0g13pq8n/?p=1e1a2849f7a0484595000235745037b3]]&gt;</url>
    <title>Use of the INNO LiPA Rif.TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility.</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,DIAGNOSIS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The INNO LiPA Rif.TB (Innogenetics, Ghent, Belgium) is a reverse hybridization test developed to detect genetic markers of resistance to rifampin in Mycobacterium tuberculosis complex. In the present study, this test was used directly on 3,763 clinical specimens by adopting a nested amplification of the target. The specificity of the system (98.4%) was optimal, but sensitivity (69.5%) was unsatisfactory. However, when use of the system was limited to smear-positive specimens, the sensitivity rose to 91.7%. As expected, the ability of the system to predict rifampin resistance was not influenced by its direct use on clinical specimens and confirmed the favorable results repeatedly reported in the literature.]]&gt;</body>
  </document>
  <document>
    <id>286536</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6WXK-4MJBTR3-1&amp;_user=910131&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000047819&amp;_version=1&amp;_urlVersion=0&amp;_userid=910131&amp;md5=fda418aa296708acf3c42c870cdfae13]]&gt;</url>
    <title>Utility of genotyping of Mycobacterium tuberculosis in the contact investigation: a decision analysis.</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,AIRBORNE,INFECTIONS,MYCOBACTERIUM,INFECTIOUS DISEASES,MYCOBACTERIUM TUBERCULOSIS,MICROORGANISM,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The objective of this study was to compare the traditional tuberculosis contact-tracing strategy with a two-stage strategy, in low prevalence countries. We compared the utility of contact tracing of pulmonary tuberculosis patients using a single interview (Strategy I) with that of two-stage strategies, namely traditional ‘stone-in the pond’ contact tracing (strategy II) and a strategy involving second interviews of patients whose Mycobacterium tuberculosis isolates are genotypically clustered (Strategy III). Factors affecting the utility and impact of each were explored using sensitivity analysis of probabilistic decision trees and a quantitative Markov simulation. Contact tracing using Strategy III demonstrated a higher utility and a 12% lower probability of secondary infection being missed compared with Strategy II. The threshold level, at which a change, from a traditional to a two-stage contact tracing strategy is indicated, is when the rate of clustering is 4% or more. The utility of Strategy III is optimal when the probability of detecting new epidemiological links is more than 10%. Strategy III allows detection of 58% of infected patients within 2 years after exposure compared with Strategy II and Strategy I which will detect 47% and 32% of infected contacts within 2 years, respectively. Strategy III allows detection of 58% of infected patients within 2 years after exposure, compared with 32% and 47% for Strategies I and II, respectively. There is a linear relationship between the rate of clustering of isolates and the probability of secondary cases being prevented by the use of Strategy III. A two-stage tuberculosis contact tracing strategy, based on clustering of genetically related M. tuberculosis isolates, should improve identification of epidemiologic links and prevent more cases of secondary infections in low prevalence settings and so augment traditional contact tracing. The main factors affecting utilities were the likelihood of new epidemiological links being identified after the second interview and the local rate of clustering of M. tuberculosis isolates. ]]&gt;</body>
  </document>
  <document>
    <id>286539</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/entity/bulletin/volumes/86/2/07-040089.pdf]]&gt;</url>
    <title>Vaccination greatly reduces disease, disability, death and inequity worldwide</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>World Health Organization (WHO)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,TRAVEL VACCINES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In low-income countries, infectious diseases still account for a large proportion of deaths, highlighting health inequities largely caused by economic differences. Vaccination can cut health-care costs and reduce these inequities. Disease control, elimination or eradication can save billions of US dollars for communities and countries. Vaccines have lowered the incidence of hepatocellular carcinoma and will control cervical cancer. Travellers can be protected against “exotic” diseases by appropriate vaccination. Vaccines are considered indispensable against bioterrorism. They can combat resistance to antibiotics in some pathogens. Noncommunicable diseases, such as ischaemic heart disease, could also be reduced by influenza vaccination.
Immunization programmes have improved the primary care infrastructure in developing countries, lowered mortality in childhood and empowered women to better plan their families, with consequent health, social and economic benefits.

Vaccination helps economic growth everywhere, because of lower morbidity and mortality. The annual return on investment in vaccination has been calculated to be between 12% and 18%. Vaccination leads to increased life expectancy. Long healthy lives are now recognized as a prerequisite for wealth, and wealth promotes health. Vaccines are thus efficient tools to reduce disparities in wealth and inequities in health.]]&gt;</body>
  </document>
  <document>
    <id>381207</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/vaccine-patch-replace-flu-jabs.aspx]]&gt;</url>
    <title>Vaccine patch could replace jabs</title>
    <publicationDate>2010-07-19T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,PREVENTION,INFECTIONS,VACCINES / IMMUNISATION,ADDED 2010,JULY 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The conventional flu jab could be replaced by a skin patch,” says The Guardian. The patch, which is coated in microscopic dissolving spikes, is designed to deliver the flu vaccine into the skin without a syringe.&lt;/P&gt;
&lt;P&gt;The news is based on important research, and the patch’s animal trial has been covered widely. Some papers have focused on the patch as a means of delivering the flu vaccination, while others have concentrated on the potential for the patch to eliminate all injections.&lt;/P&gt;
&lt;P&gt;While the technology worked in mice, the immune response and safety issues need to be tested in human trials before this will become an acceptable alternative to intramuscular injections for vaccinating humans. If testing is successful, the patch will be an attractive option because, as many of the newspapers report, it is easier to administer than a normal injection. It might also reduce some of the difficulties associated with traditional mass vaccination campaigns. This is a technology to watch, and more research will undoubtedly follow.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted and well-reported laboratory and animal study describes the early investigations into a new technology to deliver the influenza vaccine. Research in mice has produced good results, and the technique compares well with the traditional intramuscular approach to vaccination. The patch is also seen to penetrate pig skin (which researchers note is of similar thickness to human skin) to the required degree and to dissolve well.&lt;/P&gt;
&lt;P&gt;The technology may allow the simple administration of other vaccines and medicines to the skin without the need for hypodermic needles, although human studies will demonstrate its real value. Studies in humans look likely given the importance of this laboratory research and the potential this technology may hold.&lt;/P&gt;
&lt;P&gt;There are a few other points to note:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;This research only looked at vaccines against the influenza virus, which use deactivated or ‘dead’ viral particles to induce an immune response. Other types of vaccine, particularly ‘live vaccines’ that feature weakened versions of viruses may not be effective when delivered using this method. This question will also need to be addressed through further research. 
&lt;LI&gt;Newspaper reports suggest that future vaccinations using this method might not need medical supervision but, again, this will need testing if human trials eventually confirm that patches are effective. 
&lt;LI&gt;The costs involved in this method are unclear, and it may prove less cost-effective than intramuscular vaccination. However, it does appear to avoid some of the expensive practicalities that come with traditional vaccines, such as the need for constant refrigeration.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sullivan SP, Koutsonanos DG, del Pilar Martin M et al. &lt;A href="http://www.nature.com/nm/journal/vaop/ncurrent/abs/nm.2182.html" target="_blank"&gt;Dissolving polymer microneedle patches for influenza vaccination&lt;/A&gt;. &lt;EM&gt;Nature Medicine&lt;/EM&gt;, [Published online] 18 July 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286547</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/328/7451/1306]]&gt;</url>
    <title>Vaginal discharge - causes, diagnosis and treatment</title>
    <publicationDate>2004-05-29T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SYPHILIS,GONORRHOEA,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,TREPONEMA PALLIDUM,NEISSERIA GONORRHOEA,VIRUSES,FUNGI,CANDIDA ALBICANS,PUBIC LICE,LICE,PARASITES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HUMAN PAPILLOMAVIRUS (HPV),HERPES SIMPLEX VIRUS (HSV),MICROORGANISM,CHLAMYDIA,BACTERIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Vaginal discharge is a common presenting symptom seen by doctors in many services (primary care, gynaecology, family planning, and departments of genitourinary medicine). Vaginal discharge may be physiological or pathological. Although abnormal vaginal discharge often prompts women to seek screening for sexually transmitted infections (STIs), vaginal discharge is poorly predictive of the presence of an STI. This article focuses on the causes and diagnosis of vaginal discharge and treatment of the most common infective causes.]]&gt;</body>
  </document>
  <document>
    <id>308648</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/search/article?title=Validation+of+the+line-probe+assay&amp;title_type=title&amp;year_from=2004&amp;year_to=2009&amp;database=1&amp;pageSize=20&amp;index=1]]&gt;</url>
    <title>Validation of the line-probe assay for rapid detection of rifampicin-resistant Mycobacterium tuberculosis in Vietnam.</title>
    <publicationDate>2009-02-02T00:00:00</publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,DIAGNOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Delays in identifying multidrug-resistant tuberculosis (MDR-TB) contribute to higher TB morbidity and mortality, and ongoing transmission. The line-probe assay (LiPA) is a rapid, commercially available polymerase chain reaction based assay that detects most mutations in the rpoB gene for rifampicin (RMP) resistance. We validated and compared this assay with conventional drug susceptibility testing (DST).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: We re-cultured a random sample of stored isolates known to be either RMP-resistant or RMP-susceptible according to DST (proportion method). We performed a blinded comparison between LiPA and conventional DST. Genetic sequencing of the rpoB gene was performed on RMP-resistant isolates and discordant results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: We tested 79 RMP-resistant and 64 RMP-susceptible strains. Concordance of LiPA with DST was 94%. For detecting RMP resistance, LiPA sensitivity was 90% and specificity was 100%. Molecular analysis of possible false-negative isolates by LiPA revealed an absence of mutations in the rpoB gene. RMP resistance was a good proxy for MDR-TB, as 66 (93%) of 71 RMP-resistant isolates were also isoniazid-resistant.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: The LiPA provided rapid results that were highly predictive of RMP resistance and MDR-TB. False-negatives occurred, but only among isolates with mutations in regions not assessed by LiPA. Performance and cost-effectiveness should be evaluated in patients during routine program conditions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286548</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://jac.oxfordjournals.org/cgi/reprint/50/5/713]]&gt;</url>
    <title>Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for antibiotic assays questionnaire</title>
    <publicationDate>2002-10-08T00:00:00</publicationDate>
    <publisher>Journal of Antimicrobial Chemotherapy</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PREVENTION AND CONTROL,ANTIBIOTICS,ANTIMICROBIALS,INFECTIONS,TREATMENT,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper reports the results of a questionnaire distributed to 310 participants in the UK NEQAS for antibiotic assays, which sought to ascertain practice regarding the therapeutic drug monitoring (TDM) of vancomycin. The response rate of laboratories to the questionnaire was 57.4% (125 UK, 21 European, 7 non-European, and 25 where the location was not specified). Most (76%) provided an in-house assay service, and almost all performed assays using fluorescence polarisation immunoassy (FPIA), and expected same day results to be available.Most had guidelines for vancomycin use, and the majority recommended a twelve hourly dosage regimen as standard.There was a wide variety of recommendations for timing of collection and target levels for post-dose assay samples (23 different ranges quoted), but greater consensus on pre-dose assay sample collection (the majority recommended collection &lt; 10 minutes before the dose, and target levels of &lt; 10mg/L or 5-10 mg/L). Few laboratories recommended trough-only samples.There has long been debate over the value of routine vancomycin TDM. This paper confirms the apparent confusion over which approach is actually useful to ensure that therapeutic levels are maintained and potentially toxic serum levels are avoided, not least for post-dose monitoring.]]&gt;</body>
  </document>
  <document>
    <id>319257</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_100357]]&gt;</url>
    <title>vCJD risk assessment calculations for a patient with multiple routes of exposure</title>
    <publicationDate>2009-06-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CREUTZFELDT-JAKOB (CJD) DISEASE,INFECTIOUS DISEASES,INFECTIONS,PRION DISEASE,CONDITIONS,CREUTZFELDT-JAKOB DISEASE (CJD),BRAIN AND SPINAL CORD INFECTIONS,JUNE 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper was developed in response to a request from the CJD Incidents Panel following the finding of abnormal prion protein in the spleen of a patient with haemophilia. Assuming that the abnormal protein represents a marker of vCJD infection, the paper sets the various possible routes through which such infection could have occurred, and considers their relative likelihood in various scenarios. As well as dealing with this specific “incident”, the paper sets out a more general methodology for assessing multiple possible infection routes. The analysis was considered by the Panel at its meeting on 20th May 2009. The Panel concluded that there was no evidence to change its current advice to those patients treated with UK sourced pooled plasma products between 1980 and 2001 already notified as being “at risk of vCJD for public health purposes”, or to notify any new groups of patients. This version of the paper repeats the analysis presented to the Panel, while giving slightly more background information for other readers, and is placed here for public record.]]&gt;</body>
  </document>
  <document>
    <id>304733</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947348323]]&gt;</url>
    <title>Venous Leg Ulcers: Infection Diagnosis and Microbiology Investigation</title>
    <publicationDate>2006-08-30T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,JAN 09,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,BACTERAEMIA / SEPTICAEMIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To improve the diagnosis of infectious disease in primary care 
&lt;LI&gt;To improve use of the microbiology laboratory in primary care 
&lt;LI&gt;To target the use of antibiotics and anti-fungals in primary care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Production:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The templates have been produced in consultation with GPs and specialists in the field. 
&lt;LI&gt;They are in agreement with other guidance, including Prodigy, SIGN and NICE. 
&lt;LI&gt;The guidance is fully referenced and graded. 
&lt;LI&gt;The guidance is not all-encompassing, as it is meant to be quick reference. If more detail is required we suggest referral to the websites and references quoted. 
&lt;LI&gt;The guidance is updated annually. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Local adaptation:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The guidance will need to be taken forward in collaboration between laboratories, PCTs and secondary care providers. 
&lt;LI&gt;Recommendations can be changed to suit local service delivery and sampling protocols. 
&lt;LI&gt;Change in laboratory use may increase or decrease laboratory workload and have financial implications for laboratories and Primary Care Trusts (PCTs). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Your feedback:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;We welcome, in fact encourage, opinions on the advice given and future topics we should cover. 
&lt;LI&gt;Comments should be submitted to Dr Cliodna McNulty, Head, HPA Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN. Email: &lt;A href="mailto:jill.whiting@hpa.org.uk" target="_blank"&gt;jill.whiting@hpa.org.uk&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286549</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop8.pdf]]&gt;</url>
    <title>Vertical HCV transmission algorithm  VSOP 8</title>
    <publicationDate>2007-11-21T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,TRANSMISSION MODE,BLOOD AND BODY FLUIDS,INFECTIONS,MICROORGANISM,HEPATITIS C VIRUS,HEPATITIS VIRUS,VIRUSES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ ]]&gt;</body>
  </document>
  <document>
    <id>297895</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/r951h51413v65773/fulltext.pdf]]&gt;</url>
    <title>Vertical transmission of HIV in Belgium: a 1986–2002 retrospective analysis</title>
    <publicationDate>2008-03-06T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,PREGNANT WOMEN,CHILDREN,ADULTS,NOV 08,POPULATION GROUPS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2008,HIV,MALE UROGENITAL DISORDERS,VIRAL,MALE SEXUALLY TRANSMITTED INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Prophylactic interventions have lead to the reduction of the mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) to less than 2% in industrialized countries. The aim of this study was to evaluate the changes over time in vertical transmission according to the standard care of prophylaxis in the practice of a single large reference center and to identify the risk factors for failure. The rate of MTCT decreased progressively from 10% in 1986–1993 to 4.7% in 1999–2002, reflecting the progressive implementation of newly available means of prevention. During the last period evaluated (1999–2002), where highly active antiretroviral therapy (HAART) prophylaxis was the standard of care, 17% of women had a viral load between 400 and 20,000 copies/ml around delivery and 5% had a viral load above 20,000 copies/ml. High viral load and low CD4 lymphocyte count were strongly associated with vertical transmission. The rate of MTCT in women who received HAART for more than one month during pregnancy was 1.7%, compared to 13.3% in women treated with HAART for less than one month. The risk of vertical transmission in the absence of therapy was four times higher than before the era of antiretroviral therapy (ART; p=0.05). In conclusion, since the prevention of MTCT of HIV with HAART is the standard of care, a short duration or absence of ART during pregnancy linked to late or absent prenatal care is associated with a high risk of transmission. The early detection of HIV-1 infection in pregnant women, and close follow up and support during pregnancy are crucial to the success of the prevention of transmission.]]&gt;</body>
  </document>
  <document>
    <id>286550</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop45.pdf]]&gt;</url>
    <title>Violet red bile glucose agar (MSOP 45)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286551</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop46.pdf]]&gt;</url>
    <title>Violet red bile lactose agar (MSOP 46)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,FOOD/WATER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>393401</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2809%2970328-7/abstract]]&gt;</url>
    <title>Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Following large-scale roll-out of antiretroviral therapy in sub-Saharan Africa, the non-clinical efficacy of antiretroviral therapy has received little attention. We aimed to systematically review virological efficacy and drug-resistance outcomes of programmes of antiretroviral therapy in sub-Saharan Africa. 89 studies with heterogeneous design, definitions, and methods were identified. Overall, in on-treatment analysis, 10 351 (78%) of 13 288 patients showed virological suppression after 6 months of antiretroviral therapy, 7413 (76%) of 9794 after 12 months, and 3840 (67%) of 5690 after 24 months. Long-term virological data are scarce. Genotyping results were available for patients with virological failure (HIV-1 RNA greater than 1000 copies per mL). Most patients (839 of 849; 99%) were infected with a non-B HIV-1 subtype. However, drug-resistance patterns were largely similar to those in subtype B. Resistance profiles were associated with the antiretroviral drugs commonly used: the lamivudine-associated M184V mutation was most common, followed by K103N which is associated with non-nucleoside reverse transcriptase inhibitors. Thymidine-analogue mutations and the K65R mutation were less common. First-line antiretroviral therapy regimens used in sub-Saharan Africa are effective. Profiles of drug resistance suggest that a second-line treatment regimen based on protease inhibitors, with a backbone of nucleoside reverse transcriptase inhibitors, is a reasonable option for patients with HIV in sub-Saharan Africa who experience first-line treatment failure.]]&gt;</body>
  </document>
  <document>
    <id>286552</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/14651858.CD001479.pub2]]&gt;</url>
    <title>Vitamin A for treating measles in children</title>
    <publicationDate>2001-11-28T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MEASLES,INFECTIONS,VACCINE PREVENTABLE DISEASES,INFECTIOUS DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The editorial group responsible for this previously published document have withdrawn it from publication.
Reason For Withdrawal
The Cochrane Acute Respiratory Infections Group would like to acknowledge funding for its editorial base from the Medical Benefits Fund of Australia.
Sources of support
External sources of support 
China Medical Board of New York USA
Internal sources of support 
Chinese Cochrane Centre, Chinese Centre of Evidence-based Medicine, West China Hospital of Sichuan University CHINA ]]&gt;</body>
  </document>
  <document>
    <id>345889</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Vitamin-D-and-the-immune-system.aspx]]&gt;</url>
    <title>Vitamin D immune system boost?</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFECTIONS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Telegraph has reported that “vitamin D 'triggers and arms' the immune system”. It said that researchers believe that vitamin D plays a key role in boosting the immune system.&lt;/P&gt;
&lt;P&gt;The study looked at human T cells in the laboratory, and found that vitamin D was part of a complex process in which T cells become 'primed' and help to fight infection. While these findings suggest that people with vitamin D deficiency are more susceptible to infection or that vitamin D supplements might boost immunity, such theories need to be tested further before drawing any firm conclusions.&lt;/P&gt;
&lt;P&gt;It is important to have enough vitamin D to maintain a healthy body. Vitamin D forms in our skin in response to sunlight. However, care should be taken to avoid burning or over-exposure. Vitamin D is also found in foods such as oily fish, eggs, fortified margarines, some breakfast cereals and vitamin supplements.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research indicates that vitamin D is involved in the activation of the T cells of the immune system. It is important to note that this is a laboratory study, and it is useful in helping researchers to understand what happens in specific immune system cells when exposed to foreign entities such as bacteria or viruses. It does not tell us how variations in vitamin D levels might affect people’s susceptibility to infection, or what the ideal level of vitamin D is for supporting immune system responses to infection.&lt;/P&gt;
&lt;P&gt;Other studies will no doubt look into these questions. However, as with other vitamins, it is clearly important to have sufficient vitamin D to maintain a healthy body. Vitamin D forms in our skin in response to sunlight, but care should still be taken to avoid burning or over-exposure. Vitamin D is also found in foods such as oily fish, eggs, fortified margarines, some breakfast cereals and vitamin supplements.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Rode von Essen M, Kongsbak M, Schjerling P, &lt;I&gt;et al&lt;/I&gt;.&amp;nbsp;&lt;A href="http://www.nature.com/ni/journal/vaop/ncurrent/full/ni.1851.html" target="_blank"&gt;Vitamin D controls T cell antigen receptor signaling and activation of human T cells&lt;/A&gt;. &lt;I&gt;Nature Immunology&lt;/I&gt; 2010; published online March 7 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346442</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Vitamin-D-supplements-and-flu.aspx]]&gt;</url>
    <title>Vitamin D supplements and flu</title>
    <publicationDate>2010-03-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,INFLUENZA,INFECTIONS,RHINOVIRUS,COMMON COLD,RESPIRATORY INFECTIONS,TREATMENT,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Vitamin D is better than vaccines at preventing flu,” reported The Times. The newspaper said that children’s risk of getting flu could be halved if they take vitamin D, a finding that has implications for flu epidemics.&lt;/P&gt;
&lt;P&gt;This trial of 430 schoolchildren in Japan found that taking daily vitamin D supplements in winter decreased their risk of seasonal flu, compared to taking an inactive tablet. The news headline is misleading, as the vitamin D supplementation was only compared with this inactive placebo, not with flu vaccines.&lt;/P&gt;
&lt;P&gt;Vitamin D is produced through exposure to natural daylight and is also present in various food sources. Most people should therefore be able to gain all the vitamin D that they need without taking supplements. Exceptions to this include pregnant women, the elderly or people who cover up their skin or rarely go outdoors. These people are advised to take 10 micrograms (0.01mg) a day.&lt;/P&gt;
&lt;P&gt;It is important not to take above the recommended daily dose of any supplements. The FSA recommends that taking 25 micrograms (0.025 mg) or less of vitamin D supplements a day is unlikely to cause any harm.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This randomised controlled trial of 430 schoolchildren found that taking daily vitamin D supplements for the four winter months reduced children’s risk of being diagnosed with seasonal flu compared to taking an inactive tablet. There are a few important points:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The Times headline, “Vitamin D better than vaccines”, is misleading, as it implies that the vitamin has been trialled against vaccines. It has only been compared with an inactive placebo drug, so there is no evidence that the vitamin is more effective than seasonal flu vaccines or any other vaccine, including the swine flu vaccine. 
&lt;LI&gt;Subgroup analyses found that there were some differences in the effect of vitamin D depending on certain characteristics, such as if the child had never taken supplements before, or if they started school later than their peers. However, there were very small numbers of children with flu in each of these groups (eight in the treatment group who had never before taken supplements vs 22 in the placebo group). When calculating differences between such small numbers of cases there is a higher likelihood of chance findings. 
&lt;LI&gt;The trial did not last long enough to examine the long-term safety effects of taking vitamin D. In particular, the researchers say they did not measure the potentially adverse effects of vitamin D on calcium metabolism. People taking supplements should not take more than the recommended daily maximum. 
&lt;LI&gt;The sample was relatively small and the research needs to be replicated in larger numbers of people over a longer period to confirm these results. 
&lt;LI&gt;Although compliance was reportedly high in this study, this may be an issue in real-life situations. Few children are going to be happy taking three tablets twice a day on a regular basis.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Vitamin D is produced through our exposure to natural daylight and is also present in various food sources including oily fish, dairy and fortified cereals and margarine. Most people should therefore be able to gain all the vitamin D that they need through natural sources, without needing to take supplements. Exceptions to this include pregnant women, the elderly or people who cover up their skin or rarely go outdoors.&lt;/P&gt;
&lt;P&gt;It is important not to take more than the recommended daily dose of any supplement. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Urashima M, Segawa T, Okazaki M, et al.&amp;nbsp;&lt;A href="http://www.ajcn.org/cgi/content/abstract/ajcn.2009.29094v1" target="_blank"&gt;Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren.&lt;/A&gt; &lt;EM&gt;American&amp;nbsp;Journal of Clinical Nutrition 2010&lt;/EM&gt;; March 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>397903</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/vulnerable-urged-to-take-swine-flu-vaccine.aspx]]&gt;</url>
    <title>Vulnerable urged to have swine flu vaccine</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,PREVENTION,VACCINES / IMMUNISATION,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,INFECTIOUS DISEASES,INFLUENZA,RESPIRATORY INFECTIONS,INFLUENZA VACCINE,SWINE INFLUENZA,SWINE FLU VACCINE,ADDED 2010,WHAT'S NEW,DEC 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Swine flu has claimed the lives of 10 British adults in recent weeks, newspapers reported. &lt;EM&gt;The Independent&lt;/EM&gt; and the &lt;EM&gt;Daily Mail&lt;/EM&gt; said there are signs that the virus ‘is back’, raising fears of ‘a new epidemic’. Although most of the 10 fatalities had underlying health conditions, the newspapers&amp;nbsp;said 'a small proportion' had been healthy before the virus. Numbers of people hospitalised with severe flu have also risen, and there have been several outbreaks in schools and on a military base.&lt;/P&gt;
&lt;P&gt;The Health Protection Agency (HPA) has warned that although the overall number of cases of flu is not unusual for this time of year, the number of severe cases of&amp;nbsp;&lt;A href="http://www.nhs.uk/conditions/Pandemic-flu/Pages/Introduction.aspx" target="_blank"&gt;H1N1&lt;/A&gt; is higher than expected in England.&lt;/P&gt;
&lt;P&gt;For most people, H1N1 flu is a mild illness lasting seven to ten days. However, some groups of people are at greater risk of serious illness if they catch flu, such as people over 65, pregnant women and those with other long-term illnesses. These people should ask their GP to be given the&amp;nbsp;&lt;A href="http://www.nhs.uk/conditions/flu-jab/Pages/Introduction.aspx" target="_blank"&gt;vaccine&lt;/A&gt; as soon as possible. A detailed list of at-risk groups is given below.&lt;/P&gt;
&lt;P&gt;It is important that people at greater risk are vaccinated. However, the actual numbers of people visiting their GP with flu are low and there is no indication yet of another swine flu epidemic. The virus is not known to have mutated into a new strain or developed any new characteristics. As the H1N1 virus was widely circulating last year, it is not surprising that it is still present this winter.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;If you are in an at-risk group, you should seek medical advice if you are having flu symptoms. If you are not in one of these groups, stay at home, get plenty of rest and use over-the-counter painkillers to relieve symptoms. If the symptoms persist or get more severe, seek medical advice.&lt;/P&gt;
&lt;P&gt;Maintaining good cough and hand hygiene, should limit the spread of germs and reduce the chances of people you come into contact with getting flu:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;cover your nose and mouth with a tissue when you cough and sneeze &lt;/LI&gt;
&lt;LI&gt;dispose of the tissue as soon as possible &lt;/LI&gt;
&lt;LI&gt;clean your hands as soon you can &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>392345</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://journals.lww.com/aidsonline/Abstract/2010/03130/Weighing_the_gold_in_the_gold_standard__challenges.2.aspx]]&gt;</url>
    <title>Weighing the gold in the gold standard: challenges in HIV prevention research</title>
    <publicationDate>2010-03-13T00:00:00</publicationDate>
    <publisher>Wolters Kluwer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MANAGEMENT &amp; INTERVENTIONS,SEXUAL HEALTH,INDIVIDUAL BEHAVIOUR,OUTCOMES,DETERMINANTS,PUBLIC HEALTH,HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,MONTHLY ADDITIONS,PREVENTION,COMMUNICABLE DISEASES,HIV INFECTION,SERVICES,POPULATION BASED &amp; PREVENTATIVE SERVICES,INFECTION CONTROL,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2010,WHAT'S NEW,OCT 10,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objectives&lt;/STRONG&gt;: Few HIV prevention interventions have been evaluated in randomized controlled trials (RCTs). We examined design, implementation, and contextual considerations that may limit detection of a positive or adverse effect in HIV prevention trials.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design&lt;/STRONG&gt;: A systematic review of late phase RCTs for prevention of sexual transmission of HIV that randomly allocated intervention and comparison groups; evaluated interventions to prevent sexual transmission in nonpregnant populations; and reported HIV incidence as the primary or secondary outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: PubMed/MEDLINE, other electronic databases, and electronic conference proceedings of recent HIV/AIDS-related conferences were searched to identify published or unpublished trials meeting the inclusion criteria. Descriptive, methodological, and contextual factors were abstracted from each trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: The review included 37 HIV prevention RCTs reporting on 39 unique interventions. Only six RCTs, all evaluating biomedical interventions, demonstrated definitive effects on HIV incidence. Five of the six RCTs significantly reduced HIV infection: all three male circumcision trials, one trial of sexually transmitted infection treatment and care, and one vaccine trial. One microbicide trial of nonoxynol-9 gel produced adverse results. Lack of statistical power, poor adherence, and diluted versions of the intervention in comparison groups may have been important issues for the other trials that demonstrated ‘flat’ results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Almost 90% of HIV prevention trials had ‘flat’ results, which may be attributable to trial design and/or implementation. The HIV prevention community must not only examine evidence from significant RCTs, but must also examine flat trials and address design and implementation issues that limit detection of an effect.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330512</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.metapress.com/content/542v46134020g144/?p=da39fda3cb9e42ca87352b2840eae992&amp;pi=4]]&gt;</url>
    <title>Where is the evidence base? Mental health issues surrounding bereavement and HIV in children</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>MetaPress</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PUBLIC HEALTH,OUTCOMES,GROUPS,POPULATIONS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,MONTHLY ADDITIONS,CHILDREN,AGE GROUPS,PEOPLE WITH HIV OR AIDS,MENTAL &amp; BEHAVIOURAL DISORDERS,CHILDREN,POPULATION GROUPS,MICROORGANISM,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ADDED 2009,NOV 09,2009 DECEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Parental illness can affect child and adolescent psychosocial well-being. Mental health effects of parental bereavement generally and HIV-related bereavement specifically have been poorly explored in children. HIV-related illness has a number of specific features that may directly affect mental health considerations. Infection is clustered in families. Bereavement is often multiple. Death is often preceded by severe illness and multiple opportunistic infections. AIDS is stigmatised, which may impede disclosure, social support and adjustment. In low-income countries where HIV infection is concentrated, access to palliative care as well as medical care may be limited. This review systematically identifies studies on HIV and bereavement in children. Searches of electronic databases for relevant articles revealed 14 studies examining bereavement with sufficient measurement and controlled methodology providing standardised behavioural and emotional outcome measures. Scrutiny of the results revealed the majority (12: 86%) recorded an adverse behavioural or emotional impact on the child. A detailed analysis of the studies provides insights to risks as well as protective factors that may inform future interventions. Only one systematic intervention was identified whereby a coping skills intervention had positive and long-lasting effects. This paper examines urgent future needs and the requirement for evidence-based policy and provision.]]&gt;</body>
  </document>
  <document>
    <id>286554</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/csr/sars/discharge/en/]]&gt;</url>
    <title>WHO hospital discharge and follow-up policy for patients who have been diagnosed with Severe Acute Respiratory Syndrome (SARS)</title>
    <publicationDate>2003-03-28T00:00:00</publicationDate>
    <publisher>World Health Organization (WHO)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,BODY PART AFFECTED,CONTACT,AIRBORNE,RESPIRATORY TRACT,INFECTIONS,VIRUSES,SARS CORONA VIRUS,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This webpage provides advice on hospital discharge and follow up policy for patients who have been diagnoses with SARS]]&gt;</body>
  </document>
  <document>
    <id>286556</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/ith/]]&gt;</url>
    <title>WHO International Travel and Health 2005</title>
    <publicationDate>2005-09-01T00:00:00</publicationDate>
    <publisher>World Health Organization (WHO)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INSECT BITE,TRANSMISSION MODE,FOOD/WATER,CONTACT,BLOOD AND BODY FLUIDS,AIRBORNE,INFECTIONS,PREVENTION,PREVENTION AND CONTROL,VACCINES / IMMUNISATION,BACTERIA,TRAVEL VACCINES,MICROORGANISM,FUNGI,PARASITES,VIRUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ International travel and health is a WHO publication that offers guidance on the full range of health risks likely to be encountered at specific destinations and associated with different types of travel – from business, humanitarian and leisure travel to backpacking and adventure tours. 

The guidance is intended to help the medical profession to be fully aware of potential risks and to provide appropriate advice, whether this concerns recommended vaccinations, protection against insects and other disease vectors, or safety in different environmental settings. ]]&gt;</body>
  </document>
  <document>
    <id>345659</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2009/9789241598323_eng.pdf]]&gt;</url>
    <title>WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION,TUBERCULOSIS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,INFECTION CONTROL,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document is an evidence-based policy for the implementation of sound tuberculosis (TB) infection control by all stakeholders.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;TB infection control is a combination of measures aimed at minimizing the risk of TB transmission within populations. The foundation of infection control is early and rapid diagnosis, and proper management of TB patients.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;TB infection control requires and complements implementation of core activities in TB control, HIV control and health-systems strengthening. It should be part of national infection prevention and control policies because it complements such policies – in particular, those that target airborne infections.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The evidence base for the policy was established through a systematic literature review. The review highlighted some areas where evidence supports interventions that add value to TB infection control. A number of recommendations were developed, based on this evidence and on additional factors, such as feasibility, programmatic implementation and anticipated&lt;BR&gt;cost.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330444</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://pediatrics.aappublications.org/cgi/content/abstract/123/2/e199]]&gt;</url>
    <title>Who will speak for me? Improving end-of-life decision-making for adolescents with HIV and their families.</title>
    <publicationDate>2009-02-02T00:00:00</publicationDate>
    <publisher>American Academy of Pediatrics</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,HIV/AIDS,INFECTIONS,POPULATION GROUPS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MICROORGANISM,ADDED 2009,ADOLESCENTS,NOV 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objectives&lt;/STRONG&gt;:&lt;BR&gt;The purpose of this research was to test the effectiveness of a model of family/adolescent-centered advance care planning for adolescents living with HIV and their families for increasing congruence and quality of communication while decreasing decisional conflict.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients and Methods&lt;/STRONG&gt;:&lt;BR&gt;Ours was a 2-group, randomized, controlled trial in 2 hospital-based outpatient clinics in Washington and Memphis from 2006 to 2008. Participants (N = 38 dyads) included medically stable adolescents aged 14 to 21 years with HIV/AIDS and surrogates/families aged =21 years. Three 60- to 90-minute sessions were conducted 1 week apart via a semistructured family interview with a trained/certified interviewer. Each session encompassed, respectively: (1) Lyon Advance Care Planning Survey; (2) Respecting Choices interview; and (3) Five Wishes. Controls received (1) developmental history, (2) safety tips, and (3) future plans. Family congruence was measured by the Statement of Treatment Preferences and adolescent decisional conflict by the Decisional Conflict Scale, immediately after session 2. Communication was measured by the Quality of Participant-Interviewer Communication Scale after each session.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;:&lt;BR&gt;Adolescent demographics were as follows: mean age was 16 years; 40% were boys; 92% were black; HIV transmission rate was 68% perinatal and 32% sexually acquired; 42% were asymptomatic; 29% were symptomatic; and 29% had a diagnosis of AIDS. Significantly increased congruence for testing the difference of the 2 {kappa} values for the 2 conditions was observed for intervention versus control dyads. Intervention adolescents reported feeling significantly better informed about end-of-life decisions. Intervention adolescents and all of the surrogates were more likely to feel that their attitudes and wishes were known by the interviewer over time. Intervention families, significantly more so than controls, rated the overall quality of discussion as very good to excellent.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;:&lt;BR&gt;Family-centered advance care planning by trained facilitators increased congruence in adolescent/surrogate preferences for end-of-life care, decreased decisional conflict, and enhanced communication quality. Families acknowledged a life-threatening condition and were willing to initiate end-of-life conversations when their adolescents were medically stable.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345426</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795193/pdf/pone.0008517.pdf]]&gt;</url>
    <title>Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review</title>
    <publicationDate>2009-12-30T00:00:00</publicationDate>
    <publisher>Public Library of Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,VACCINE PREVENTABLE DISEASES,MYCOBACTERIUM,TUBERCULOSIS,DIAGNOSIS,MYCOBACTERIUM TUBERCULOSIS,BACTERIA,MICROORGANISM,ADDED 2010,MARCH 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;: Variability in interferon-gamma release assays (IGRAs) results for tuberculosis has implications for interpretation of results close to the cut-point, and for defining thresholds for test conversion and reversion. However, little is known about the within-subject variability (reproducibility) of IGRAs. Several national guidelines recommend a twostep testing procedure (tuberculin skin test [TST] followed by IGRA) for the diagnosis of LTBI. However, the effect of a preceding TST on subsequent IGRA results has been reported in studies with apparently conflicting results.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology/Findings&lt;/STRONG&gt;: We conducted a systematic review to synthesize evidence on within-subject variability of IGRA results and the potential boosting effect of TST. We searched several databases and reviewed citations of previous reviews on IGRAs. We included studies using commercial IGRAs, in addition to non-commercial versions of the ELISPOT assay. Four studies, fulfilling our predefined criteria, examined within-subject variability and 13 studies evaluated TST effects on subsequent IGRA responses. Meta-analysis was not considered appropriate because of heterogeneity in study methods, assays, and populations. Although based on limited data, within-subject variability was present in all studies but the magnitude varied (16-80%) across studies. A TST induced ‘‘boosting’’ of IGRA responses was demonstrated in several studies and although more pronounced in IGRA-positive (i.e. sensitized) individuals, also occurred in a smaller but not insignificant proportion of IGRA-negative subjects. The TST appeared to affect IGRA responses only after 3 days and may apparently persist for several months, but evidence for this is weak.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions/Significance&lt;/STRONG&gt;: Although reproducibility data are scarce, significant within person IGRA variability has been reported. If confirmed in more studies, this has implications for the interpretation of results close to the cut-point and for definition of conversions and reversions. Although the effect of TST on IGRA results is likely to be inconsequential in IGRA positive subjects, in IGRA-negative subjects, the interpretation of results may be confounded by a preceding TST if administered more than 3 days prior to an IGRA.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286558</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.journals.uchicago.edu/doi/pdf/10.1086/506443]]&gt;</url>
    <title>World Wide Web Resources on Antimicrobial Resistance</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,PREVENTION AND CONTROL,ANTIMICROBIALS,ANTIBIOTICS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,HEALTHCARE ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE,ANTIMICROBIAL RESISTANCE,ENTEROCOCCUS AND GRE/VRE,MRSA INFECTION,TREATMENT,MICROORGANISM,BACTERIA,ACINETOBACTER BAUMANII,ENTEROCOCCUS,VANCOMYCIN RESISTANT ENTEROCOCCUS,KLEBSIELLA PNEUMONIAE,STREPTOCOCCUS,STAPHYLOCOCCUS AUREUS,METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS,STAPHYLOCOCCUS,MYCOBACTERIUM TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Advances of modern technology, including the development of the Internet and the World Wide Web, have given clinicians and researches the opportunity to have immediate access to continuously updated information in various scientific fields. This article has compiled a list of World Wide Web resources of data from surveillance studies on antimicrobial resistance that may be useful to practitioners—especially infectious diseases specialists—as well as to scientists with a research interest in the field of antimicrobial resistance.]]&gt;</body>
  </document>
  <document>
    <id>286559</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsopTP/pdf/bsoptp38.pdf]]&gt;</url>
    <title>X and V factor test (BSOP TP38)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,RESPIRATORY TRACT,BODY PART AFFECTED,CONTACT,INFECTIONS,HAEMOPHILUS,HAEMOPHILUS INFLUENZAE,BACTERIA,MICROORGANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286560</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop14.pdf]]&gt;</url>
    <title>Xylose lysine desoxycholate (XLD) agar (MSOP 14)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ FOOD/WATER,BODY PART AFFECTED,DIGESTIVE TRACT,TRANSMISSION MODE,INFECTIONS,MICROORGANISM,BACTERIA,SALMONELLA,SHIGELLA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>286561</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/msop/pdf/msop47.pdf]]&gt;</url>
    <title>Yeast extract agar (MSOP 47)</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ TRANSMISSION MODE,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. National Standard Methods have been developed since 1996 by working groups of experienced laboratory-based medical and scientific microbiologists from throughout the HPA (previously the PHLS) and NHS. 

The development of National Standard Methods and algorithms is undertaken under the auspices of the HPA in conjunction with the NHS and the National Public Health Service for Wales and with professional societies including the Association of Medical Microbiologists, Association of Clinical Microbiologists, Institute of Biomedical Science, Clinical Virology Network and the Scottish Microbiology Association. 

Background information on National Standard Methods (http://www.hpa-standardmethods.org.uk/about_sops.asp)

Your attention is drawn to the Terms of Use (http://www.hpa.org.uk/hpa/terms.htm) of this Website, which you must read before accessing the documents. Whilst every care has been taken in the preparation of these publications, the Health Protection Agency Board cannot be responsible for the accuracy of any statement or representation made or the consequences arising from the use of or alteration to any information contained in it.]]&gt;</body>
  </document>
  <document>
    <id>345489</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2809%2970326-3/abstract]]&gt;</url>
    <title>Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TUBERCULOSIS,HIV/AIDS,INFECTIOUS DISEASES,SEXUALLY TRANSMITTED INFECTIONS,INFECTIONS,MYCOBACTERIUM,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS,MICROORGANISM,BACTERIA,MYCOBACTERIUM TUBERCULOSIS,VIRUSES,HUMAN IMMUNODEFICIENCY VIRUS (HIV),MARCH 10,ADDED 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Intensified case finding is the regular screening for evidence of tuberculosis in people infected with HIV, at high risk of HIV, or living in congregate settings. We systematically reviewed studies of intensified case finding published between January, 1994, and April, 2009. In 78 eligible studies, the number of people with tuberculosis detected during intensified case finding varied substantially between countries and target groups of patients. Median prevalence of newly diagnosed tuberculosis was 0·7% in population-based surveys, 2·2% in contact-tracing studies, 2·3% in mines, 2·3% in programmes preventing mother-to-child transmission of HIV, 2·5% in prisons, 8·2% in medical and antiretroviral treatment clinics, and 8·5% in voluntary counselling and testing services. Metaregression analysis of studies that included only people with HIV showed that for each increment in national prevalence of tuberculosis of 100 cases per 100 000 population, intensified case finding identified an additional one case per 100 screened individuals (p=0·03). Microbiological sputum examination of all individuals without prior selection by symptom screening yielded an additional four cases per 100 individuals screened (p=0·05). Data on the use of serial screening, treatment outcomes in actively identified cases of tuberculosis, and cost-effectiveness, however, were lacking. Concerted action is needed to develop intensified case finding as an important method for control of tuberculosis.]]&gt;</body>
  </document>
  <document>
    <id>394428</id>
    <name>&lt;![CDATA[ Infections]]&gt;</name>
    <rootDirectory>/infections</rootDirectory>
    <url>&lt;![CDATA[http://www.nepjol.info/index.php/KUMJ/article/view/2759]]&gt;</url>
    <title>Young people's knowledge, attitude, and behaviour on STI/HIV/AIDS in the context of Nepal: a systematic review</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>International Network for the Availability of Scientific Publications</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HIV/AIDS,SEXUALLY TRANSMITTED INFECTIONS,INFECTIOUS DISEASES,INFECTIONS,HUMAN IMMUNODEFICIENCY VIRUS (HIV),VIRUSES,MICROORGANISM,ADDED 2010,WHAT'S NEW,NOV 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Sexual and reproductive health of young people has become a major health problem in recent decades. Recent and rapidly increasing Human Immune Deficiency Virus (HIV) rates show an urgent need for Sexually Transmitted Infections (STIs) and HIV prevention interventions in Nepal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: This paper attempts to assess knowledge, attitude and behaviour on STIs/HIV/AIDS in the context of young peoples of Nepal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD AND MATERIAL&lt;/STRONG&gt;: A systematic review based on the available literature was carried out including both qualitative and quantitative studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Our findings indicate that the overall knowledge regarding STIs and HIV/AIDS is high although the level of knowledge seems to differ according to education, gender, and area of residence. Knowledge about condoms was also very high but practice of correct and consistent use in premarital and extramarital sexual relations with non-regular partners seems to be lower. The overall sexual behaviour among young people is unsafe.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: This suggests that young people's sexual and reproductive health issues need to be further addressed and explored in order to promote safer and responsible sexual behaviour.&lt;/P&gt;]]&gt;</body>
  </document>
</documents>